Compositions for the treatment of disease

ABSTRACT

The invention provides compositions and methods for the preparation, manufacture and therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral genomes encoding one or more antibodies or antibody fragments or antibody-like polypeptides, for the prevention and/or treatment of diseases and/or disorders.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent ApplicationNo. 62/329,468, filed on Apr. 29, 2016, entitled Compositions for theTreatment of Disease, and U.S. Provisional Patent Application No.62/329,479, filed on Apr. 29, 2016, entitled Compositions for theTreatment of Disease, the contents of each of which are hereinincorporated by reference in their entireties.

REFERENCE TO THE SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format. The Sequence Listing file, entitled20571302PCTSL.txt, was created on Apr. 28, 2017, and is 14,209,554 bytesin size. The information in electronic format of the Sequence Listing isincorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The invention relates to compositions and methods for vectored antibodydelivery (VAD).

BACKGROUND OF THE INVENTION

Antibody-based therapies have been developed for a wide variety ofdiseases, disorders and conditions, including infectious andnon-infectious diseases. The U.S. Food and Drug Administration (FDA) hasapproved antibodies for treatment of cancers, autoimmune and immunesystem disorders, ocular diseases, nervous system diseases,inflammations, and infections, amongst many others. Naturally,antibodies are components of the adaptive immune response and theyfunction by recognizing specific foreign antigens and stimulatinghumoral immunity responses. As a consequence, antibodies may be appliedto the treatment, prevention, management, diagnosis and research ofdiseases, disorders and/or conditions.

Antibodies have relatively short half-lives and this presents an ongoingand long-felt challenge for antibody-based therapies. In order toachieve a sufficiently high concentration of an antibody for longlasting therapeutic effects, antibody therapies are traditionallydelivered by repeated administration, e.g. by multiple injections. Thisdosing regimen results in an inconsistent level of antibody throughoutthe treatment period, limited efficiency per administration, high costof administration and consumption of the antibody. Hence, there remainsa need in the art for delivery of antibodies and antibody-basedtherapeutics through alternative routes or modalities of administration.

One such alternative route of administration is by expression vector(e.g. plasmid or viral vector), including but not limited to,adeno-associated viral vectors (AAVs). Adeno-associated viral vectorsare widely used in gene therapy approaches due to a number ofadvantageous features. As dependoparvoviruses, AAV are non-replicatingin infected cells and therefore not associated with any known disease.Further, AAVs may be introduced to a wide variety of host cells, do notintegrate into the genome of the host cell, and are capable of infectingboth quiescent and dividing cells. AAVs transduce non-replicating andlong-lived cells in vivo, resulting in long term expression of theprotein of interest. Further, AAVs can be manipulated with cellular andmolecular biology techniques to produce non-toxic particles carrying apayload encoded in the AAV viral genome that can be delivered to atarget tissue or set of cells with limited or no side-effects. Given theforegoing, the use of AAVs for vectored antibody delivery (VAD) wouldallow for longer lasting efficacy, fewer dose treatments, and moreconsistent levels of the antibody throughout the treatment period.

In vectored antibody delivery (VAD) an AAV is used as the deliverymodality for a nucleic acid sequence encoding the antibody, whichresults in in vivo expression of the encoded payload, e.g., functionalantibody.

The mechanism underlying VAD is thought to proceed through the followingsteps. First the AAV vector enters the cell via endocytosis, thenescapes from the endosomal compartment and is transported to the nucleuswherein the viral genome is released and converted into adouble-stranded episomal molecule of DNA by the host. Thetranscriptionally active episome results in the expression of encodedantibodies that may then be secreted from the cell into the circulation.VAD may therefore enable continuous, sustained and long-term delivery ofantibodies administered by a single injection of an AAV particle.

Previous studies of an AAV-mediated antibody technique known as vectoredimmunoprophylaxis (VIP) have focused on neutralization of humanimmunodeficiency virus (HIV) (see, e.g. Johnson et al., 2009, NatureMed., 15, 901-906, Saunders et al., 2015, J. Virol., 89(16), 8334-8345,Balasz et al., 2012, Nature 481, 81-84, the contents of which areincorporated herein by reference in their entirety). Balasz et al.reported a long-term, even lifelong, expression of monoclonal antibodyat high concentration from a single intramuscular administration in micethat resulted in full protection against HIV infection. AAV-mediated VIPhas also been demonstrated against influenza strains (see, e.g. Balaszet al. Nat. Biotechnol., 2013, 31(7):647-52) and Plasmodium falciparum,a sporozoite causing malaria infection (see, e.g. Deal at al., 2014,PNAS, 111 (34), 12528-12532), as well as cancer, RSV and drug addiction(see, e.g. review by Schnepp and Johnson, Microbiol. Spectrum 2(4),2014). Though promising, these studies emphasize efforts to merelyprevent disease. There still remains a need for improved methods ofprevention, and new antibody-mediated therapies for research, diagnosis,and treatment of disease.

The present invention addresses this need by providing novel AAVparticles having viral genomes engineered to encode antibodies andantibody-based compositions and methods of using these constructs (e.g.,VAD) for the treatment, prevention, diagnosis and research of diseases,disorders and/or conditions. The present invention further embracesoptimized AAV particles for delivery of nucleic acids (e.g., viralgenomes) encoding antibodies and antibody-based compositions to asubject in need thereof.

SUMMARY OF THE INVENTION

The invention provides AAV particles comprising a capsid and a viralgenome, said viral genome comprising at least one inverted terminalrepeat (ITR) region and a payload region, said payload region comprisinga regulatory sequence operably linked to at least a first nucleic acidsegment, said first nucleic acid segment encoding one or morepolypeptides given in Tables 3-42, variants and fragments thereof. Thecapsid of the AAV particle may be any of the serotypes described hereinand/or described in Table 1.

In one aspect, the first nucleic acid segment may encode one or morepolypeptides such as, but not limited to, an antibody heavy chain, anantibody light chain, a linker, and combinations thereof. The firstnucleic acid segment may encode one or more polypeptides which ishumanized. As a non-limiting example, the first nucleic acid segmentencodes from 5′ to 3′, an antibody heavy chain, a linker, and anantibody light chain. As another non-limiting example, the first nucleicacid segment encodes from 5′ to 3′, an antibody light chain, a linker,and an antibody heavy chain. As yet another non-limiting example, thefirst nucleic acid segment encodes one or more antibody heavy chains. Asyet another non-limiting example, the first nucleic acid segment encodesone or more antibody light chains.

In one aspect, the first nucleic acid segment encodes an antibody,having at least 95% identity to any of the sequences of Tables 3-42 (SEQID NO: 2948-9220).

In one aspect, the regulatory sequence may comprise a promoter such asbut not limited to, human elongation factor 1α-subunit (EF1α),cytomegalovirus (CMV) immediate-early enhancer and/or promoter, chickenβ-actin (CBA) and its derivative CAG, 1(glucuronidase (GUSB), orubiquitin C (UBC). Tissue-specific expression elements can be used torestrict expression to certain cell types such as, but not limited to,muscle specific promoters, B cell promoters, monocyte promoters,leukocyte promoters, macrophage promoters, pancreatic acinar cellpromoters, endothelial cell promoters, lung tissue promoters, astrocytepromoters, or nervous system promoters which can be used to restrictexpression to neurons, astrocytes, or oligodendrocytes.

In one aspect, the linker in the viral genome is selected from one ormore of the linkers given in Table 2.

In one aspect, the AAV particles described herein may comprise a viralgenome which is single stranded.

In one aspect, the AAV particles described herein may comprise a viralgenome which is self-complementary.

In one aspect, the AAV particles described herein may comprise a viralgenome comprising at least one intron sequence.

In one aspect, the AAV particles described herein may comprise a viralgenome comprising at least one stuffer sequence to adjust the length ofthe viral genome to increase efficacy and/or efficiency.

In one aspect, the AAV particles described herein may comprise at leastone region which has been codon optimized. As a non-limiting example,the viral genome may be codon optimized. As another non-limitingexample, the first nucleic acid segment is codon-optimized.

In one aspect, the AAV particles described herein may comprise a viralgenome with 2 ITR regions. At least one of the ITR regions may bederived from the same or different parental serotype of the capsid. As anon-limiting example, at least one ITR region is derived from AAV2.

In one aspect, the AAV particles comprise a viral genome which comprisesa second nucleic acid segment. The second nucleic acid segment mayencode an aptamer, siRNA, saRNA, ribozyme, microRNA, mRNA or combinationthereof.

In one aspect, the AAV particles comprise a viral genome which comprisesa second nucleic acid segment encoding an siRNA designed to target themRNA that encodes the target of the antibody encoded by the firstnucleic acid segment.

In one aspect, the AAV particles comprise a viral genome which comprisesa second nucleic acid segment encoding a microRNA, the microRNA isselected to target the mRNA that encodes the target of the antibodyencoded by the first nucleic acid segment.

In one aspect, the AAV particles comprise a viral genome which comprisesa second nucleic acid segment encoding an mRNA, the mRNA encodes one ormore peptides inhibitors of the same target of the antibody encoded bythe first nucleic acid segment.

In one aspect, the AAV particles comprise a viral genome which comprisesa third nucleic acid segment. The third nucleic acid segment may encodea nuclear export signal, a polynucleotide or polypeptide which acts as aregulator of expression of the viral genome in which it is encoded, apolynucleotide or polypeptide which acts as a regulator of expression ofthe payload region of the viral genome in which it is encoded and/or apolynucleotide or polypeptide which acts as a regulator of expression ofthe first nucleic acid segment of the payload region of the viral genomein which it is encoded.

The invention provides AAV particles comprising a capsid and a viralgenome, said viral genome comprising at least one inverted terminalrepeat (ITR) region and a payload region comprising a regulatorysequence operably linked to at least a first nucleic acid segment, thefirst nucleic acid segment encoding a bispecific antibody derived fromany of the sequences listed in Tables 3-42 or portions or fragmentsthereof.

The invention provides methods of producing a functional antibody in asubject in need thereof, comprising administering to a subject the AAVparticles described herein. The level or amount of the functionalantibody in the target cell or tissue after administration to thesubject may be from about 0.001 ug/mL to 100 mg/mL. The functionalantibody may be encoded by a single first nucleic acid segment of aviral genome within the AAV particle. The functional antibody may beencoded by two different viral genomes, the two different viral genomesmay be packaged in separate capsids.

The invention provides a pharmaceutical composition comprising an AAVparticle described herein in a pharmaceutically acceptable excipient. Asa non-limiting example, the pharmaceutically acceptable excipient issaline. As a non-limiting example, the pharmaceutically acceptableexcipient is 0.001% pluronic in saline.

The invention provides methods of producing a functional antibody in asubject in need thereof, comprising administering to a subject the AAVparticles described herein by a delivery route such as, but not limitedto, enteral (into the intestine), gastroenteral, epidural (into the duramater), oral (by way of the mouth), transdermal, intracerebral (into thecerebrum), intracerebroventricular (into the cerebral ventricles),epicutaneous (application onto the skin), intradermal, (into the skinitself), subcutaneous (under the skin), nasal administration (throughthe nose), intravenous (into a vein), intravenous bolus, intravenousdrip, intra-arterial (into an arter.), intramuscular (into a muscle),intracardiac (into the heart), intraosseous infusion (into the bonemarrow), intrathecal (into the spinal canal), intraparenchymal (intobrain tissue), intraperitoneal, (infusion or injection into theperitoneum), intravesical infusion, intravitreal. (through the eye),intracavernous injection (into a pathologic cavity) intracavitary (intothe base of the penis), intravaginal administration, intrauterine,extra-amniotic administration, transdermal (diffusion through the intactskin for systemic distribution), transmucosal (diffusion through amucous membrane), transvaginal, insufflation (snorting), sublingual,sublabial, enema, eye drops (onto the conjunctiva), or in ear drops,auricular (in or by way of the ear), buccal (directed toward the cheek),conjunctival, cutaneous, dental (to a tooth or teeth), electro-osmosis,endocervical, endosinusial, endotracheal, extracorporeal, hemodialysis,infiltration, interstitial, intra-abdominal, intra-amniotic,intra-articular, intrabiliar, intrabronchial, intrabursal,intracartilaginous (within a cartilage), intracaudal (within the caudaequine), intracisternal (within the cisterna magna cerebellomedularis),intracorneal (within the cornea), dental intracoronal, intracoronary(within the coronary arteries), intracorporus cavernosum (within thedilatable spaces of the corporus cavernosa of the penis), intradiscal(within a disc), intraductal (within a duct of a gland), intraduodenal(within the duodenum), intradural (within or beneath the dura),intraepidermal (to the epidermis), intraesophageal (to the esophagus),intragastric (within the stomach), intragingival (within the gingivae),intraileal (within the distal portion of the small intestine),intralesional (within or introduced directly to a localized lesion),intraluminal (within a lumen of a tube), intralymphatic (within thelymph), intramedullary (within the marrow cavity of a bone),intrameningeal (within the meninges), intramyocardial (within themyocardium), intraocular (within the eye), intraovarian (within theovary), intrapericardial (within the pericardium), intrapleural (withinthe pleura), intraprostatic (within the prostate gland), intrapulmonary(within the lungs or its bronchi), intrasmal (within the nasal orperiorbital sinuses), intraspinal (within the vertebral column),intrasynovial (within the synovial cavity of a joint), intratendinous(within a tendon), intratesticular (within the testicle), intrathecal(within the cerebrospinal fluid at any level of the cerebrospinal axis),intrathoracic (within the thorax), intratubular (within the tubules ofan organ), intraturnor (within a tumor), intratympanic (within the aurusmedia), intravascular (within a vessel or vessels), intraventricular(within a ventricle), iontophoresis (by means of electric current whereions of soluble salts migrate into the tissues of the body), irrigation(to bathe or flush open wounds or body cavities), laryngeal (directlyupon the larynx), nasogastric (through the nose and into the stomach),occlusive dressing technique (topical route administration which is thencovered by a dressing which occludes the area), ophthalmic (to theexternal eye), oropharyngeal (directly to the mouth and pharynx),parenteral, percutaneous, periarticular, pendural, perineural,penodontal, rectal, respiratory (within the respiratory tract byinhaling orally or nasally for local or systemic effect), retrobulbar(behind the pons or behind the eyeball), soft tissue, subarachnoid,subconjunctival, submucosal, topical, transplacental (through or acrossthe placenta), transtracheal (through the wall of the trachea),transtympanic (across or through the tympanic cavity), ureteral (to theureter), urethral (to the urethra), vaginal, caudal block, diagnostic,nerve block, biliary perfusion, cardiac perfusion, photophoresis andspinal.

The invention provides methods of treating and/or preventing a diseaseor disorder in a subject comprising administering to the subject an AAVparticle described herein. The administration may be at aprophylactically effective dose such as, but not limited to, from about1 ug/mL to about 500 ug/mL of expressed polypeptide or 1×10e4 to 1×10e16VG/mL from the pharmaceutical composition. The pharmaceuticalcomposition may be administered at least once. The pharmaceuticalcomposition may be administered daily, weekly, monthly or yearly. Thepharmaceutical composition may be co-administered as part of acombination therapy.

The invention provides methods of producing an antibody in a subject byadministering the AAV particles described herein, where the antibody isnot a virus neutralizing antibody.

The invention provides methods of producing an antibody in a subject byadministering the AAV particles described herein, where the antibody isnot an HIV or HCV virus neutralizing antibody.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages will beapparent from the following description of particular embodiments of theinvention, as illustrated in the accompanying drawings. The drawings arenot necessarily to scale, emphasis instead being placed uponillustrating the principles of various embodiments of the invention.

FIG. 1 is a schematic of vectored antibody delivery.

FIG. 2 is a schematic of a viral genome of the invention.

FIG. 3 is a schematic of payload regions FIG. 3 discloses SEQ ID NO:9221.

DETAILED DESCRIPTION OF THE INVENTION I. Compositions of the Invention

According to the present invention, compositions for deliveringfunctional antibodies and/or antibody-based compositions byadeno-associated viruses (AAVs) are provided. AAV particles of theinvention may be provided via any of several routes of administration,to a cell, tissue, organ, or organism min vivo, ex vivo or in vitro.

As used herein, an “AAV particle” is a virus which comprises a viralgenome with at least one payload region and at least one invertedterminal repeat (ITR) region.

As used herein. “viral genome” or “vector genome” refers to the nucleicacid sequence(s) encapsulated in an AAV particle. Viral genomes compriseat least one payload region encoding polypeptides of the invention,e.g., antibodies, antibody-based compositions or fragments thereof.

As used herein, a “payload” or “payload region” is any nucleic acidmolecule which encodes one or more polypeptides of the invention. At aminimum, a payload region comprises nucleic acid sequences that encodean antibody, an antibody-based composition, or a fragment thereof, butmay also optionally comprise one or more functional or regulatoryelements to facilitate transcriptional expression and/or polypeptidetranslation.

The nucleic acid sequences and polypeptides disclosed herein may beengineered to contain modular elements and/or sequence motifs assembledto enable expression of the antibodies or antibody-based compositions ofthe invention. In some embodiments, the nucleic acid sequence comprisingthe payload region may comprise one or more of a promoter region, anintron, a Kozak sequence, an enhancer or a poly adenylation sequence.Payload regions of the invention typically encode antibodies or antibodybased compositions, which may include an antibody heavy chain domain, anantibody light chain domain, both antibody heavy and light chaindomains, or fragments of the foregoing in combination with each other orin combination with other polypeptide moieties. In some cases, payloadregions may also encode one or more linkers or joining regions betweenantibody heavy and light chain domains or fragments. The order ofexpression, structural position, or concatemer count (heavy chain, lightchain, or linker) may be different within or among different payloadregions. The identity, position and number of linkers expressed bypayload regions may also vary.

The payload regions of the invention may be delivered to one or moretarget cells, tissues, organs or organisms within the viral genome of anAAV particle.

Adeno-Associated Viruses (AAVs) and AAV Particles

Viruses of the Parvoviridae family are small non-enveloped icosahedralcapsid viruses characterized by a single stranded DNA genome.Parvovindae family viruses consist of two subfamilies: Parovirinae,which infect vertebrates, and Densovinnae, which infect invertebrates.Due to its relatively simple structure, easily manipulated usingstandard molecular biology techniques, this virus family is useful as abiological tool. The genome of the virus may be modified to contain aminimum of components for the assembly of a functional recombinantvirus, or viral particle, which is loaded with or engineered to expressor deliver a desired payload, which may be delivered to a target cell,tissue, organ, or organism.

The parvoviruses and other members of the Parvoviridae family aregenerally described in Kenneth I. Berns, “Parvoviridae: The Viruses andTheir Replication,” Chapter 69 in FIELDS VIROLOGY (3d Ed. 1996), thecontents of which are incorporated by reference in their entirety.

The Parvoviridae family comprises the Dependovirus genus which includesadeno-associated viruses (AAV) capable of replication in vertebratehosts including, but not limited to, human, primate, bovine, canine,equine, and ovine species.

The AAV vector genome is a linear, single-stranded DNA (ssDNA) moleculeapproximately 5,000 nucleotides (nt) in length. The AAV viral genome cancomprise a payload region and at least one inverted terminal repeat(ITR) or ITR region. ITRs traditionally flank the coding nucleotidesequences for the non-structural proteins (encoded by Rep genes) and thestructural proteins (encoded by capsid genes or Cap genes). While notwishing to be bound by theory, an AAV viral genome typically comprisestwo ITR sequences. The AAV vector genome comprises a characteristicT-shaped hairpin structure defined by the self-complementary terminal145 nt of the 5′ and 3′ ends of the ssDNA which form an energeticallystable double stranded region. The double stranded hairpin structurescomprise multiple functions including, but not limited to, acting as anorigin for DNA replication by functioning as primers for the endogenousDNA polymerase complex of the host viral replication cell.

In addition to the encoded heterologous payload, AAV vectors maycomprise the viral genome, in whole or in part, of any naturallyoccurring and/or recombinant AAV serotype nucleotide sequence orvariant. AAV variants may have sequences of significant homology at thenucleic acid (genome or capsid) and amino acid levels (capsids), toproduce constructs which are generally physical and functionalequivalents, replicate by similar mechanisms, and assemble by similarmechanisms. Chiorini et al., J. Vir. 71: 6823-33(1997); Srivastava etal., J. Vir. 45:555-64 (1983), Chiorini et al., J. Vir. 73:1309-1319(1999); Rutledge et al., J. Vir. 72:309-319 (1998); and Wu et al., J.Vir. 74: 8635-47 (2000), the contents of each of which are incorporatedherein by reference in their entirety.

In one embodiment, AAV particles of the present invention arerecombinant AAV viral vectors which are replication defective, lackingsequences encoding functional Rep and Cap proteins within their viralgenome. These defective AAV vectors may lack most or all parental codingsequences and essentially carry only one or two AAV ITR sequences andthe nucleic acid of interest for delivery to a cell, a tissue, an organor an organism.

In one embodiment, the viral genome of the AAV particles of the presentinvention comprise at least one control element which provides for thereplication, transcription and translation of a coding sequence encodedtherein. Not all of the control elements need always be present as longas the coding sequence is capable of being replicated, transcribedand/or translated in an appropriate host cell. Non-limiting examples ofexpression control elements include sequences for transcriptioninitiation and/or termination, promoter and/or enhancer sequences,efficient RNA processing signals such as splicing and polyadenylationsignals, sequences that stabilize cytoplasmic mRNA, sequences thatenhance translation efficacy (e.g., Kozak consensus sequence), sequencesthat enhance protein stability, and/or sequences that enhance proteinprocessing and/or secretion.

According to the present invention. AAV particles for use intherapeutics and/or diagnostics comprise a virus that has been distilledor reduced to the minimum components necessary for transduction of anucleic acid payload or cargo of interest. In this manner, AAV particlesare engineered as vehicles for specific delivery while lacking thedeleterious replication and/or integration features found in wild-typeviruses.

AAV vectors of the present invention may be produced recombinantly andmay be based on adeno-associated virus (AAV) parent or referencesequences. As used herein, a “vector” is any molecule or moiety whichtransports, transduces or otherwise acts as a carrier of a heterologousmolecule such as the nucleic acids described herein.

In addition to single stranded AAV viral genomes (e.g., ssAAVs), thepresent invention also provides for self-complementary AAV (scAAVs)viral genomes scAAV vector genomes contain DNA strands which annealtogether to form double stranded DNA. By skipping second strandsynthesis, scAAVs allow for rapid expression in the cell.

In one embodiment, the AAV particle of the present invention is anscAAV.

In one embodiment, the AAV particle of the present invention is anssAAV.

Methods for producing and/or modifying AAV particles are disclosed inthe art such as pseudotyped AAV vectors (PCT Patent Publication Nos.WO200028004; WO200123001; WO2004112727; WO 2005005610 and WO2005072364,the content of each of which is incorporated herein by reference in itsentirety).

AAV particles may be modified to enhance the efficiency of delivery.Such modified AAV particles can be packaged efficiently and be used tosuccessfully infect the target cells at high frequency and with minimaltoxicity. In some embodiments, the capsids of the AAV particles areengineered according to the methods described in US Publication NumberUS 20130195801, the contents of which are incorporated herein byreference in their entirety.

In one embodiment, the AAV particles comprising a payload regionencoding the polypeptides of the invention may be introduced intomammalian cells.

AAV Serotypes

AAV particles of the present invention may comprise or be derived fromany natural or recombinant AAV serotype. According to the presentinvention, the AAV particles may utilize or be based on a serotypeselected from any of the following AAV1, AAV2, AAV2G9, AAV3, AAV3a,AAV3b, AAV3-3, AAV4, AAV4-4, AAV5, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7,AAV7.2, AAV8, AAV9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45,AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV12,AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42-1b, AAV42-2, AAV42-3a,AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, AAV42-8, AAV42-10,AAV42-11, AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12,AAV43-20, AAV43-21, AAV43-23, AAV43-25, AAV43-5, AAV44.1, AAV44.2,AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7,AAV1-7/rh.48, AAV1-8/rh.49, AAV2-15/rh.62, AAV2-3/rh.61, AAV2-4/rh.50,AAV2-5/rh.51, AAV3.1/hu.6, AAV3.1/hu.9, AAV3-9/rh.52, AAV3-11/rh.53,AAV4-8/r11.64, AAV4-9/rh.54, AAV4-19/rh.55, AAV5-3/rh.57, AAV5-22/rh.58,AAV7.3/hu.7, AAV16.8/hu.10, AAV16.12/hu.11, AAV29.3/bb.1, AAV29.5/bb.2,AAV106.1/hu.37, AAV114.3/hu.40, AAV127.2/hu.41, AAV127.5/hu.42,AAV128.3/hu.44, AAV130.4/hu.48, AAV145.1/hu.53, AAV145.5/hu.54,AAV145.6/hu.55, AAV161.10/hu.60, AAV161.6/hu.61, AAV33.12/hu.17,AAV33.4/hu.15, AAV33.8/hu.16, AAV52/hu.19, AAV52.1/hu.20, AAV58.2/hu.25,AAVA3.3, AAVA3.4, AAVA3.5, AAVA3.7, AAVC1, AAVC2, AAVC5, AAV-DJ,AAV-DJ8, AAVF3, AAVF5, AAVH2, AAVrh.72, AAVhu.8, AAVrh.68, AAVrh.70,AAVpi.1, AAVpi.3, AAVpi.2, AAVrh.60, AAVrh.44, AAVrh.65, AAVrh.55,AAVrh.47, AAVrh.69, AAVrh.45, AAVrh.59, AAVhu.12, AAVH6, AAVLK03,AAVH-1/hu.1, AAVH-5/hu.3, AAVLG-10/rh.40, AAVLG-4/rh.38, AAVLG-9/hu.39,AAVN721-8/rh.43, AAVCh.5, AAVCh.5Ra, AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5,AAVCy.5R1, AAVCy.5R2, AAVCy.5R3, AAVCy.5R4, AAVcy.6, AAVhu.1, AAVhu.2,AAVhu.3, AAVhu.4, AAVhu.5, AAVhu.6, AAVhu.7, AAVhu.9, AAVhu.10,AAVhu.11, AAVhu.13, AAVhu.15, AAVhu.16, AAVhu.17, AAVhu.18, AAVhu.20,AAVhu.21, AAVhu.22, AAVhu.23.2, AAVhu.24, AAVhu.25, AAVhu.27, AAVhu.28,AAVhu.29, AAVhu.29R, AAVhu.31, AAVhu.32, AAVhu.34, AAVhu.35, AAVhu.37,AAVhu.39, AAVhu.40, AAVhu.41, AAVhu.42, AAVhu.43, AAVhu.44, AAVhu.44R1,AAVhu44R2, AAVhu.44R3, AAVhu.45, AAVhu.46, AAVhu.47, AAVhu.48,AAVhu.48R1, AAVhu.48R2, AAVhu.48R3, AAVhu.49, AAVhu.51, AAVhu.52,AAVhu.54, AAVhu.55, AAVhu.56, AAVhu.57, AAVhu.58, AAVhu.60, AAVhu.61,AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14/9, AAVhu.t 19, AAVrh.2,AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.12, AAVrh.13, AAVrh.13R,AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.20, AAVrh.21, AAVrh.22,AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34,AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40,AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49,AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54. AAVrh.56, AAVrh.57, AAVrh.58,AAVrh.61, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73,AAVrh.74, AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV,BAAV, caprine AAV, bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14,AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36,AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36,AAVhER1.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-1LK03,AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV-LK10,AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV-LK17,AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7,AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-mniRNA-101, AAV-8h, AAV-8b,AAV-h, AAV-b, AAV SM 10-2, AAV Shuffle 100-1, AAV Shuffle 100-3, AAVShuffle 100-7, AAV Shuffle 10-2, AAV Shuffle 10-6, AAV Shuffle 10-8, AAVShuffle 100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10,BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48,AAVhu.19, AAVhu.11, AAVhu.53, AAV4-8/rh.64, AAVLG-9/hu.39,AAV54.5/hu.23, AAV54.2/hu.22, AAV54.7/hu.24, AAV54.1/hu.21,AAV54.4R/hu.27, AAV46.2/hu.28, AAV46.6/hu.29, AAV128.1/hu.43, true typeAAV (ttAAV), UPENN AAV10, Japanese AAV10 serotypes, AAV CBr-7.1, AAVCBr-7.10, AAV CBr-7.2, AAV CBr-7.3, AAV CBr-7.4, AAV CBr-7.5, AAVCBr-7.7, AAV CBr-7.8, AAV CBr-B7.3, AAV CBr-B7.4, AAV CBr-E1, AAVCBr-E2, AAV CBr-E3, AAV CBr-E4, AAV CBr-E5, AAV CBr-e5, AAV CBr-E6, AAVCBr-E7, AAV CBr-E8, AAV CHt-1, AAV CHt-2, AAV CHt-3, AAV CHt-6.1, AAVCHt-6.10, AAV CHt-6.5, AAV CHt-6.6, AAV CHt-6.7, AAV CHt-6.8, AAVCHt-P1, AAV CHt-P2, AAV CHt-P5, AAV CHt-P6, AAV CHt-P8, AAV CHt-P9, AAVCKd-1, AAV CKd-10, AAV CKd-2, AAV CKd-3, AAV CKd-4, AAV CKd-6, AAVCKd-7, AAV CKd-8, AAV CKd-B1, AAV CKd-B2, AAV CKd-B3, AAV CKd-B4, AAVCKd-B5, AAV CKd-B6, AAV Ckd-B7, AAV Ckd-B8, AAV CKd-H1, AAV CKd-H2, AAVCKd-H3, AAV CKd-H4, AAV CKd-H5, AAV CKd-H6, AAV CKd-N3, AAV CKd-N4, AAVCKd-N9, AAV CLg-F1, AAV CLg-F2, AAV CLg-F3, AAV CLg-F4, AAV CLg-F5, AAVCLg-F6, AAV CLg-F7, AAV CLg-F8, AAV CLv-1, AAV CLv1-1, AAV Clv1-10, AAVCLv1-2, AAV CLv-12, AAV CLv1-3, AAV CLv-13, AAV CLv1-4, AAV Clv1-7, AAVClv1-8, AAV Clv1-9, AAV CLv-2, AAV CLv-3, AAV CLv-4, AAV CLv-6, AAVCLv-8, AAV CLv-D1, AAV CLv-D2, AAV CLv-D3, AAV CLv-D4, AAV Clv-D5, AAVCLv-D6, AAV CLv-D7, AAV CLv-D8, AAV CL-E1, AAV CL-K1, AAV CLv-K3, AAVCLv-K6, AAV CLv-L4, AAV CLv-L5, AAV CLv-L6, AAV CLv-M1, AAV CLv-M11, AAVCLv-M2, AAV CLv-M5, AAV CLv-M6, AAV CLv-M7, AAV CLv-M8, AAV CLv-M9, AAVCLv-R1, AAV CLv-R2, AAV CLv-R3, AAV CLv-R4, AAV CLv-R5, AAV CLv-R6, AAVCLv-R7, AAV CLv-R8, AAV CLv-R9, AAV CSp-1, AAV CSp-10, AAV CSp-1, AAVCSp-2, AAV CSp-3, AAV CSp-4, AAV CSp-6, AAV CSp-7, AAV CSp-8, AAVCSp-8.10, AAV CSp-8.2, AAV CSp-8.4, AAV CSp-8.5, AAV CSp-8.6, AAVCSp-8.7, AAV CSp-8.8, AAV CSp-8.9, AAV CSp-9, AAV.hu.48R3, AAV.VR-355,AAV3B, AAV4, AAV5, AAVF1/HSC1, AAVF11/HSC11, AAVF12/HSC12, AAVF13/HSC13,AAVF14/HSC14, AAVF15/HSC15, AAVF16/HSC16, AAVF17/HSC17, AAVF2/HSC2,AAVF3/HSC3, AAVF4/HSC4, AAVF5/HSC5, AAVF6/HSC6, AAVF7/HSC7, AAVF8/HSC8,AAVF9/HSC9, PHP.B. PHP.A, G2B-26, G2B-13, TH1.1-32 and/or TH1.1-35 andvariants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in United States Publication No. US20030138772, the contentsof which are herein incorporated by reference in their entirety, suchas, but not limited to, AAV1 (SEQ ID NO: 6 and 64 of US20030138772),AAV2 (SEQ ID NO: 7 and 70 of US20030138772), AAV3 (SEQ ID NO: 8 and 71of US20030138772), AAV4 (SEQ ID NO: 63 of US20030138772), AAV5 (SEQ IDNO-114 of US20030138772), AAV6 (SEQ ID NO: 65 of US20030138772), AAV7(SEQ ID NO: 1-3 of US20030138772), AAV8 (SEQ ID NO: 4 and 95 ofUS20030138772), AAV9 (SEQ ID NO: 5 and 100 of US20030138772), AAV10 (SEQID NO: 117 of US20030138772), AAV11 (SEQ ID NO-118 of US20030138772),AAV12 (SEQ ID NO: 119 of US20030138772), AAVrh10 (amino acids 1 to 738of SEQ ID NO: 81 of US20030138772), AAV16.3 (US20030138772 SEQ ID NO.10), AAV29.3/bb.1 (US20030138772 SEQ ID NO: 11), AAV29.4 (US20030138772SEQ ID NO:12), AAV29.5/bb.2 (US20030138772 SEQ ID NO: 13), AAV1.3(US20030138772 SEQ ID NO: 14), AAV13.3 (US20030138772 SEQ ID NO: 15),AAV24.1 (US20030138772 SEQ ID NO: 16), AAV27.3 (US20030138772 SEQ ID NO:17), AAV7.2 (US20030138772 SEQ ID NO: 18), AAVC1 (US20030138772 SEQ IDNO: 19), AAVC3 (US20030138772 SEQ ID NO: 20), AAVC5 (US20030138772 SEQID NO: 21), AAVF1 (US20030138772 SEQ ID NO: 22), AAVF3 (US20030138772SEQ ID NO: 23), AAV F5 (US20030138772 SEQ ID NO: 24), AAVH6(US20030138772 SEQ ID NO: 25), AAVH2 (US20030138772 SEQ ID NO: 26),AAV42-8 (US20030138772 SEQ ID NO: 27), AAV42-15 (US20030138772 SEQ IDNO: 28), AAV42-5b (US20030138772 SEQ ID NO: 29), AAV42-1b (US20030138772SEQ ID NO: 30), AAV42-13 (US20030138772 SEQ ID NO: 31), AAV42-3a(US20030138772 SEQ ID NO: 32), AAV42-4 (US20013138772 SEQ ID NO: 33),AAV42-5a (US20030138772 SEQ ID NO: 34), AAV42-10 (US20030138772 SEQ IDNO: 35), AAV42-3b (US20030138772 SEQ ID NO: 36), AAV42-11 (US20030138772SEQ ID NO: 37), AAV42-6b (US20030138772 SEQ ID NO: 38), AAV43-1(US20030138772 SEQ ID NO: 39), AAV43-5 (US20030138772 SEQ ID NO: 40),AAV43-12 (US20030138772 SEQ ID NO: 41), AAV43-20 (US20030138772 SEQ IDNO: 42), AAV43-21 (US20030138772 SEQ ID NO: 43), AAV43-23 (US20030138772SEQ ID NO: 44), AAV43-25 (US20030138772 SEQ ID NO: 45), AAV44.1(US20030138772 SEQ ID NO: 46), AAV44.5 (US20030138772 SEQ ID NO: 47),AAV223.1 (US20030138772 SEQ ID NO: 48), AAV223.2 (US20030138772 SEQ IDNO: 49), AAV223.4 (US20030138772 SEQ ID NO: 50), AAV223.5 (US20030138772SEQ ID NO: 51), AAV223.6 (US20030138772 SEQ ID NO: 52), AAV223.7(US20030138772 SEQ ID NO: 53), AAVA3.4 (US20030138772 SEQ ID NO: 54),AAVA3.5 (US20030138772 SEQ ID NO: 55), AAVA3.7 (US20030138772 SEQ ID NO:56), AAVA3.3 (US20030138772 SEQ ID NO: 57), AAV42.12 (US20030138772 SEQID NO: 58), AAV44.2 (US20030138772 SEQ ID NO: 59), AAV42-2(US20030138772 SEQ ID NO: 9), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in United States Publication No. US20150159173, the contentsof which are herein incorporated by reference in their entirety, suchas, but not limited to, AAV2 (SEQ ID NO: 7 and 23 of US20150159173),rh20 (SEQ ID NO: 1 of US20150159173), rh32/33 (SEQ ID NO: 2 ofUS20150159173), rh39 (SEQ ID NO: 3, 20 and 36 of US20150159173), rh46(SEQ ID NO: 4 and 22 of US20150159173), rh73 (SEQ ID NO: 5 ofUS20150159173), rh74 (SEQ ID NO: 6 of US20150159173), AAV6.1 (SEQ IDNO:29 of US20150159173), rh.8 (SEQ ID NO: 41 of US20150159173), rh.48.1(SEQ ID NO: 44 of US20150159173), hu.44 (SEQ ID NO: 45 ofUS20150159173), hu.29 (SEQ ID NO: 42 of US20150159173), hu.48 (SEQ IDNO: 38 of US20150159173), rh54 (SEQ ID NO:49 of US20150159173), AAV2(SEQ ID NO: 7 of US20150159173), cy.5 (SEQ ID NO: 8 and 24 ofUS20150159173), rh.10 (SEQ ID NO: 9 and 25 of US20150159173), rh.13 (SEQID NO: 10 and 26 of US20150159173), AAV1 (SEQ ID NO: 11 and 27 ofUS20150159173), AAV3 (SEQ ID NO: 12 and 28 of US20150159173), AAV6 (SEQID NO: 13 and 29 of US20150159173), AAV7 (SEQ ID NO: 14 and 30 ofUS20150159173), AAV8 (SEQ ID NO: 15 and 31 of US20150159173), hu.13 (SEQID NO: 16 and 32 of US20150159173), hu.26 (SEQ ID NO: 17 and 33 ofUS20150159173), hu.37 (SEQ ID NO: 18 and 34 of US20150159173), hu.53(SEQ ID NO: 19 and 35 of US20150159173), rh.43 (SEQ ID NO: 21 and 37 ofUS20150159173), rh2 (SEQ ID NO: 39 of US20150159173), rh.37 (SEQ ID NO:40 of US20150159173), rh.64 (SEQ ID NO: 43 of US20150159173), rh.48 (SEQID NO: 44 of US20150159173), ch 5 (SEQ ID NO: 46 of US20150159173),rh.67 (SEQ ID NO: 47 of US20150159173), rh.58 (SEQ ID NO: 48 ofUS20150159173), or variants thereof including, but not limited to Cy5R1,Cy5R2, Cy5R3, Cy5R4, rh.13R, rh.37R2, rh.2R, rh.8R, rh.48.1, rh.48.2,rh.48.12, hu.44R1, hu.44R2, hu.44R3, hu.29R, ch.5R1, rh64R1, rh64R2,AAV6.2, AAV6.1, AAV6.12, hu.48R1, hu.48R2, and hu.48R3.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in U.S. Pat. No. 7,198,951, the contents of which are hereinincorporated by reference in their entirety, such as, but not limitedto, AAV9 (SEQ ID NO: 1-3 of U.S. Pat. No. 7,198,951), AAV2 (SEQ ID NO: 4of U.S. Pat. No. 7,198,951), AAV1 (SEQ ID NO: 5 of U.S. Pat. No.7,198,951), AAV3 (SEQ ID NO: 6 of U.S. Pat. No. 7,198,951), and AAV8(SEQ ID NO: 7 of U.S. Pat. No. 7,198,951).

In some embodiments, the AAV serotype may be, or have, a mutation in theAAV9 sequence as described by N Pulicherla et al. (Molecular Therapy19(6): 1070-1078 (2011), herein incorporated by reference in itsentirety), such as but not limited to, AAV9.9, AAV9.11, AAV9.13,AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in U.S. Pat. No. 6,156,303, the contents of which are hereinincorporated by reference in their entirety, such as, but not limitedto, AAV3B (SEQ ID NO: 1 and 10 of U.S. Pat. No. 6,156,303), AAV6 (SEQ IDNO: 2, 7 and 11 of U.S. Pat. No. 6,156,303), AAV2 (SEQ ID NO: 3 and 8 ofU.S. Pat. No. 6,156,303), AAV3A (SEQ ID NO: 4 and 9, of U.S. Pat. No.6,156,303), or derivatives thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in United States Publication No US20140359799, the contents ofwhich are herein incorporated by reference in their entirety, such as,but not limited to, AAV8 (SEQ ID NO:1 of US20140359799), AAVDJ (SEQ IDNO: 2 and 3 of US20140359799), or variants thereof.

In some embodiments, the serotype may be AAVDJ or a variant thereof,such as AAVDJ8 (or AAV-DJ8), as described by Grimm et al. (Journal ofVirology 82(12): 5887-5911 (2008), herein incorporated by reference inits entirety). The amino acid sequence of AAVDJ8 may comprise two ormore mutations in order to remove the heparin binding domain (HBD). As anon-limiting example, the AAV-DJ sequence described as SEQ ID NO: 1 inU.S. Pat. No. 7,588,772, the contents of which are herein incorporatedby reference in their entirety, may comprise two mutations: (1) R587Qwhere arginine (R; Arg) at amino acid 587 is changed to glutamine (Q;Gin) and (2) R590T where arginine (R; Arg) at amino acid 590 is changedto threonine (T; Thr). As another non-limiting example, may comprisethree mutations: (1) K406R where lysine (K; Lys) at amino acid 406 ischanged to arginine (R; Arg), (2) R587Q where arginine (R; Arg) at aminoacid 587 is changed to glutamine (Q; Gln) and (3) R590T where arginine(R; Arg) at amino acid 590 is changed to threonine (T; Thr).

In some embodiments, the AAV serotype may be, or have, a sequence ofAAV4 as described in International Publication No. WO1998011244, thecontents of which are herein incorporated by reference in theirentirety, such as, but not limited to AAV4 (SEQ ID NO: 1-20 ofWO1998011244).

In some embodiments, the AAV serotype may be, or have, a mutation in theAAV2 sequence to generate AAV2C9 as described in InternationalPublication No. WO2014144229 and herein incorporated by reference in itsentirety.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in International Publication No. WO2005033321, the contents ofwhich are herein incorporated by reference in their entirety, such as,but not limited to AAV3-3 (SEQ ID NO:217 of WO2005033321), AAV1 (SEQ IDNO: 219 and 202 of WO2005033321), AAV106.1/hu.37 (SEQ ID No: 10 ofWO2005033321), AAV114.3/hu.40 (SEQ ID No: 11 of WO2005033321),AAV127.2/hu.41 (SEQ ID NO:6 and 8 of WO2005033321), AAV128.3/hu.44 (SEQID No. 81 of WO2005033321), AAV130.4/hu.48 (SEQ ID NO: 78 ofWO2005033321), AAV145.1/hu.53 (SEQ ID No: 176 and 177 of WO2005033321),AAV145.6/hu.56 (SEQ ID NO: 168 and 192 of WO2005033321), AAV16.12hu.11(SEQ ID NO: 153 and 57 of WO2005033321), AAV16.8/hu.10 (SEQ ID NO: 156and 56 of WO2005033321), AAV61.10hu.60 (SEQ ID No-170 of WO2005033321),AAV161.6/hu.61 (SEQ ID No: 174 of WO2005033321), AAV1-7/rh.48 (SEQ IDNO: 32 of WO2005033321), AAV1-8/rh.49 (SEQ ID NOs: 103 and 25 ofWO2005033321), AAV2 (SEQ ID NO: 211 and 221 of WO2005033321),AAV2-15rh.62 (SEQ ID No: 33 and 114 of WO2005033321), AAV2-3/rh.61 (SEQID NO: 21 of WO2005033321), AAV2-4/rh.50 (SEQ ID No: 23 and 108 ofWO2005033321), AAV2-5/rh.51 (SEQ ID NO: 104 and 22 of WO02005033321),AAV3.1/hu.6 (SEQ ID NO: 5 and 84 of WO20 (5033321), AAV3.4/hu.9 (SEQ IDNO: 155 and 58 of WO2005033321), AAV3-11/rh.53 (SEQ ID NO: 186 and 176of WO2005033321), AAV3-3 (SEQ ID NO: 200 of WO2005033321),AAV33.12/hu.17 (SEQ ID NO:4 of WO2005033321), AAV33.4/hu.15 (SEQ ID No:50 of WO2005033321), AAV33.8/hu.16 (SEQ ID No: 51 of WO2005033321),AAV3-9/rh.52 (SEQ ID NO: 96 and 18 of WO2005033321), AAV4-19/rh.55 (SEQID NO: 117 of WO2005033321), AAV4-4 (SEQ ID NO: 201 and 218 ofWO2005033321), AAV4-9/rh.54 (SEQ ID NO: 116 of WO2005033321), AAV5 (SEQID NO: 199 and 216 of WO2005033321), AAV52.1/hu.20 (SEQ ID NO: 63 ofWO2005033321), AAV52hu.19 (SEQ ID NO:133 of WO2005033321), AAV5-22/rh.58(SEQ ID No: 27 of WO2005033321), AAV5-3/rh.57 (SEQ ID NO: 105 ofWO2005033321), AAV5-3/rh.57 (SEQ ID No. 26 of WO2005033321),AAV58.2hu.25 (SEQ ID No: 49 of WO2005033321), AAV6 (SEQ ID NO: 203 and220 of WO2005033321), AAV7 (SEQ ID NO: 222 and 213 of WO20050333321),AAV7.3/hu.7 (SEQ ID No: 55 of WO2005033321), AAV8 (SEQ ID NO: 223 and214 of WO02005033321), AAVH-1/hu.1 (SEQ ID No: 46 of WO2005033321),AAVH-5/hu.3 (SEQ ID No:44 of WO2005033321), AAVhu.11 (SEQ ID NO: 144 ofWO2005033321), AAVhu.10 (SEQ ID NO: 156 of WO2005033321), AAVhu.1 (SEQID NO: 153 of WO20050333321), AAVhu.12 (WO2005033321 SEQ ID NO: 59),AAVhu.13 (SEQ ID NO: 129 of WO2005033321), AAVhu.14AAV9 (SEQ ID NO: 123and 3 of WO2005033321), AAVhu.15 (SEQ ID NO: 147 of WO2005033321),AAVhu.16 (SEQ ID NO: 148 of WO02005033321), AAVhu.17 (SEQ ID NO: 83 ofWO02005033321), AAVhu.18 (SEQ ID NO: 149 of WO2005033321), AAVhu.19 (SEQID NO: 133 of WO205033321), AAVhu.2 (SEQ ID NO:143 of WO2005033321),AAVhu.20 (SEQ ID NO:134 of WO2005033321), AAVhu.21 (SEQ ID NO: 135 ofWO2005033321), AAVhu.22 (SEQ ID NO: 138 of WO2005033321), AAVhu.23.2(SEQ ID NO: 137 of WO20050333321), AAVhu.24 (SEQ ID NO: 136 ofWO2005033321), AAVhu.25 (SEQ ID NO: 146 of WO2005033321), AAVhu.27 (SEQID NO: 140 of WO2005033321), AAVhu.29 (SEQ ID NO: 132 of WO2005033321),AAVhu.3 (SEQ ID NO: 145 of WO20050333321), AAVhu.31 (SEQ ID NO: 121 ofWO2005033321), AAVhu.32 (SEQ ID NO: 122 of WO2005033321), AAVhu.34 (SEQID NO. 125 of WO2005033321), AAVhu.35 (SEQ ID NO: 164 of WO2005033321),AAVhu.37 (SEQ ID NO: 88 of WO2005033321), AAVhu.39 (SEQ ID NO: 102 ofWO2005033321), AAVhu.4 (SEQ ID NO: 141 of WO2005033321), AAVhu.40 (SEQID NO: 87 of WO2005033321), AAVhu.41 (SEQ ID NO: 91 of WO2005033321),AAVhu.42 (SEQ ID NO: 85 of WO2005033321), AAVhu.43 (SEQ ID NO:160 ofWO2005033321), AAVhu.44 (SEQ ID NO-144 of WO2005033321), AAVhu.45 (SEQID NO: 127 of WO2005033321), AAVhu.46 (SEQ ID NO. 159 of WO2005033321),AAVhu.47 (SEQ ID NO: 128 of WO2005033321), AAVhu.48 (SEQ ID NO:157 ofWO2005033321), AAVhu.49 (SEQ ID NO:189 of WO2005033321), AAVhu.51 (SEQID NO: 190 of WO2005033321), AAVhu.52 (SEQ ID NO: 191 of WO2005033321),AAVhu.53 (SEQ ID NO: 186 of WO2005033321), AAVhu.54 (SEQ ID NO: 188 ofWO205033321), AAVhu.55 (SEQ ID NO: 187 of WO2005033321), AAVhu.56 (SEQID NO-192 of WO2005033321), AAVhu.57 (SEQ ID NO:193 of WO2005033321),AAVhu.58 (SEQ ID NO: 194 of WO2005033321), AAVhu.6 (SEQ ID NO: 84 ofWO2005033321), AAVhu.60 (SEQ ID NO: 184 of WO2005033321), AAVhu.61 (SEQID NO: 185 of WO2005033321), AAVhu.63 (SEQ ID NO: 195 of WO2005033321),AAVhu.64 (SEQ ID NO: 196 of WO2005033321), AAVhu.66 (SEQ ID NO: 197 ofWO2005033321), AAVhu.67 (SEQ ID NO: 198 of WO2005033321), AAVhu.7 (SEQID NO: 150 of WO2005033321), AAVhu.8 (WO2005033321 SEQ ID NO: 12),AAVhu.9 (SEQ ID NO: 155 of WO2005033321), AAVLG-10/rh.40 (SEQ ID No: 14of WO2005033321), AAVLG-4/rh.38 (SEQ ID NO: 86 of WO2005033321),AAVLG-4/rh.38 (SEQ ID No: 7 of WO2005033321), AAVN721-8/rh.43 (SEQ IDNO:163 of WO2005033321), AAVN721-8/rh.43 (SEQ ID No: 43 ofWO2005033321), AAVpi.1 (WO2005033321 SEQ ID NO: 28), AAVpi.2(WO2005033321 SEQ ID NO: 30), AAVpi.3 (WO2005033321 SEQ ID NO: 29),AAVrh.38 (SEQ ID NO: 86 of WO2005033321), AAVrh.40 (SEQ ID NO: 92 ofWO2005033321), AAVrh.43 (SEQ ID NO: 163 of WO2005033321), AAVrh.44(WO2005033321 SEQ ID NO: 34), AAVrh.45 (WO2005033321 SEQ ID NO: 41),AAVrh.47 (WO2005033321 SEQ ID NO: 38), AAVrh.48 (SEQ ID NO: 115 ofWO2005033321), AAVrh.49 (SEQ ID NO: 103 of WO2005033321), AAVrh.50 (SEQID NO: 108 of WO2005033321), AAVrh.51 (SEQ ID NO: 104 of WO2005033321),AAVrh.52 (SEQ ID NO: 96 of WO2005033321), AAVrh.53 (SEQ ID NO: 97 ofWO2005033321), AAVrh.55 (WO2005033321 SEQ ID NO: 37), AAVrh.56 (SEQ IDNO: 152 of WO20050333321), AAVrh.57 (SEQ ID NO: 105 of WO2005033321),AAVrh.58 (SEQ ID NO: 106 of WO2005033321), AAVrh.59 (WO2005033321 SEQ IDNO: 42), AAVrh.60 (WO2005033321 SEQ ID NO: 31), AAVrh.61 (SEQ ID NO: 107of WO2005033321), AAVrh.62 (SEQ ID NO: 114 of WO2005033321), AAVrh.64(SEQ ID NO: 99 of WO2005033321), AAVrh.65 (WO2005033321 SEQ ID NO: 35),AAVrh.68 (WO2005033321 SEQ ID NO: 16), AAVrh.69 (WO2005033321 SEQ ID NO:39), AAVrh.70 (WO2005033321 SEQ ID NO: 20), AAVrh.72 (WO2005033321 SEQID NO: 9), or variants thereof including, but not limited to, AAVcy.2,AAVcy.3, AAVcy.4, AAVcy.5, AAVcy.6, AAVrh.12, AAVrh.17, AAVrh.18,AAVrh.19, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.25/4215, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36,AAVrh.37, AAVrh.14. Non-limiting examples of variants include SEQ ID NO:13, 15, 17, 19, 24, 36, 40, 45, 47, 48, 51-54, 60-62, 64-77, 79, 80, 82,89, 90, 93-95, 98, 100, 101, 109-113, 118-120, 124, 126, 131, 139, 142,151, 154, 158, 161, 162, 165-183, 202, 204-212, 215, 219, 224-236, ofWO2005033321, the contents of which are herein incorporated by referencein their entirety.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in International Publication No. WO2015168666, the contents ofwhich are herein incorporated by reference in their entirety, such as,but not limited to, AAVrh8R (SEQ ID NO: 9 of WO2015168666), AAVrh8RA586R mutant (SEQ ID NO: 10 of WO2015168666), AAVrh8R R533A mutant (SEQID NO: 11 of WO2015168666), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in U.S. Pat. No. 9,233,131, the contents of which are hereinincorporated by reference in their entirety, such as, but not limitedto, AAVhE1.1 (SEQ ID NO:44 of U.S. Pat. No. 9,233,131), AAVhEr1.5 (SEQID NO:45 of U.S. Pat. No. 9,233,131), AAVhER1.14 (SEQ ID NO:46 of U.S.Pat. No. 9,233,131), AAVhEr1.8 (SEQ ID NO:47 of U.S. Pat. No.9,233,131), AAVhEr1.16 (SEQ ID NO:48 of U.S. Pat. No. 9,233,131),AAVhEr1.18 (SEQ ID NO:49 of U.S. Pat. No. 9,233,131), AAVhEr1.35 (SEQ IDNO:50 of U.S. Pat. No. 9,233,131), AAVhEr1.7 (SEQ ID NO:51 of U.S. Pat.No. 9,233,131), AAVhEr1.36 (SEQ ID NO:52 of U.S. Pat. No. 9,233,131),AAVhEr2.29 (SEQ ID NO:53 of U.S. Pat. No. 9,233,131), AAVhEr2.4 (SEQ IDNO:54 of U.S. Pat. No. 9,233,131), AAVhEr2.16 (SEQ ID NO:55 of U.S. Pat.No. 9,233,131), AAVhEr2.30 (SEQ ID NO:56 of U.S. Pat. No. 9,233,131),AAVhEr2.31 (SEQ ID NO:58 of U.S. Pat. No. 9,233,131), AAVhEr2.36 (SEQ IDNO:57 of U.S. Pat. No. 9,233,131), AAVhER1.23 (SEQ ID NO:53 of U.S. Pat.No. 9,233,131), AAVhEr3.1 (SEQ ID NO:59 of U.S. Pat. No. 9,233,131),AAV2.5T (SEQ ID NO:42 of U.S. Pat. No. 9,233,131), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in United States Patent Publication No. US20150376607, thecontents of which are herein incorporated by reference in theirentirety, such as, but not limited to, AAV-PAEC (SEQ ID NO: 1 ofUS20150376607), AAV-LK01 (SEQ ID NO:2 of US20150376607), AAV-LK02 (SEQID NO:3 of US20150376607), AAV-LK03 (SEQ ID NO:4 of US20150376607),AAV-LK04 (SEQ ID NO:5 of US20150376607), AAV-LK05 (SEQ ID NO:6 ofUS20150376607), AAV-LK06 (SEQ ID NO:7 of US20150376607), AAV-LK07 (SEQID NO:8 of US20150376607), AAV-LK08 (SEQ ID NO:9 of US20150376607),AAV-LK09 (SEQ ID NO:10 of US20150376607), AAV-LK10 (SEQ ID NO: 11 ofUS20150376607), AAV-LK11 (SEQ ID NO: 12 of US20150376607), AAV-LK12 (SEQID NO: 13 of US20150376607), AAV-LK13 (SEQ ID NO:14 of US20150376607),AAV-LK14 (SEQ ID NO:15 of US20150376607), AAV-LK15 (SEQ ID NO:16 ofUS20150376607), AAV-LK16 (SEQ ID NO:17 of US20150376607), AAV-LK17 (SEQID NO:18 of US20150376607), AAV-LK8 (SEQ ID NO:19 of US20150376607),AAV-LK19 (SEQ ID NO:20 of US20150376607), AAV-PAEC2 (SEQ ID NO:21 ofUS20150376607), AAV-PAEC4 (SEQ ID NO:22 of US20150376607), AAV-PAEC6(SEQ ID NO:23 of US20150376607), AAV-PAEC7 (SEQ ID NO:24 ofUS20150376607), AAV-PAEC8 (SEQ ID NO:25 of US20150376607), AAV-PAEC11(SEQ ID NO:26 of US20150376607), AAV-PAEC12 (SEQ ID NO:27, ofUS20150376607), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in U.S. Pat. No. 9,163,261, the contents of which are hereinincorporated by reference in their entirety, such as, but not limitedto, AAV-2-pre-miRNA-101 (SEQ ID NO: 1 U.S. Pat. No. 9,163,261), orvariants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in United States Patent Publication No. US20150376240, thecontents of which are herein incorporated by reference in theirentirety, such as, but not limited to, AAV-8h (SEQ ID NO: 6 ofUS20150376240), AAV-8b (SEQ ID NO: 5 of US20150376240), AAV-h (SEQ IDNO: 2 of US20150376240), AAV-b (SEQ ID NO: 1 of US20150376240), orvariants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in United States Patent Publication No. US20160017295, thecontents of which are herein incorporated by reference in theirentirety, such as, but not limited to, AAV SM 10-2 (SEQ ID NO: 22 ofUS20160017295), AAV Shuffle 100-1 (SEQ ID NO: 23 of US2016017295), AAVShuffle 100-3 (SEQ ID NO: 24 of US20160017295), AAV Shuffle 100-7 (SEQID NO: 25 of US20160017295), AAV Shuffle 10-2 (SEQ ID NO: 34 ofUS20160017295), AAV Shuffle 10-6 (SEQ ID NO: 35 of US20160017295), AAVShuffle 10-8 (SEQ ID NO: 36 of US20160017295), AAV Shuffle 100-2 (SEQ IDNO: 37 of US20160017295), AAV SM 10-1 (SEQ ID NO: 38 of US20160017295),AAV SM 10-8 (SEQ ID NO: 39 of US20160017295), AAV SM 100-3 (SEQ ID NO:40 of US20160017295), AAV SM 100-10) (SEQ ID NO: 41 of US20160017295),or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in United States Patent Publication No. US20150238550, thecontents of which are herein incorporated by reference in theirentirety, such as, but not limited to, BNP61 AAV (SEQ ID NO: 1 ofUS20150238550), BNP62 AAV (SEQ ID NO: 3 of US20150238550), BNP63 AAV(SEQ ID NO: 4 of US20150238550), or variants thereof.

In some embodiments, the AAV serotype may be or may have a sequence asdescribed in United States Patent Publication No. US20150315612, thecontents of which are herein incorporated by reference in theirentirety, such as, but not limited to, AAVrh.50 (SEQ ID NO: 108 ofUS20150315612), AAVrh.43 (SEQ ID NO: 163 of US20150315612), AAVrh.62(SEQ ID NO. 114 of US20150315612), AAVrh.48 (SEQ ID NO: 115 ofUS20150315612), AAVhu.19 (SEQ ID NO:133 of US20150315612), AAVhu.11 (SEQID NO: 153 of US20150315612), AAVhu.53 (SEQ ID NO: 186 ofUS20150315612), AAV4-8/rh.64 (SEQ ID No: 15 of US20150315612),AAVLG-9/hu.39 (SEQ ID No: 24 of US20150315612), AAV54.5/hu.23 (SEQ IDNo: 60 of US20150315612), AAV54.2/hu.22 (SEQ ID No. 67 ofUS20150315612), AAV54.7/hu.24 (SEQ ID No: 66 of US20150315612),AAV54.1/hu.21 (SEQ ID No:65 of US20150315612), AAV54.4R/hu.27 (SEQ IDNo: 64 of US20150315612), AAV46.2/hu.28 (SEQ ID No: 68 ofUS20150315612), AAV46.6hu.29 (SEQ ID No: 69 of US20150315612),AAV128.1/hu.43 (SEQ ID No:80 of US20150315612), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in International Publication No. WO2015121501, the contents ofwhich are herein incorporated by reference in their entirety, such as,but not limited to, true type AAV (ttAAV) (SEQ ID NO: 2 of WO2015121501.“UPenn AAV10” (SEQ ID NO: 8 of WO2015121501), “Japanese AAV10” (SEQ IDNO: 9 of WO2015121501), or variants thereof.

According to the present invention, AAV capsid serotype selection or usemay be from a variety of species. In one embodiment, the AAV may be anavian AAV (AAAV). The AAAV serotype may be, or have, a sequence asdescribed in U.S. Pat. No. 9,238,800, the contents of which are hereinincorporated by reference in their entirety, such as, but not limitedto, AAAV (SEQ ID NO: 1, 2, 4, 6, 8, 10, 12, and 14 of U.S. Pat. No.9,238,800), or variants thereof.

In one embodiment, the AAV may be a bovine AAV (BAAV). The BAAV serotypemay be, or have, a sequence as described in U.S. Pat. No. 9,193,769, thecontents of which are herein incorporated by reference in theirentirety, such as, but not limited to, BAAV (SEQ ID NO: 1 and 6 of U.S.Pat. No. 9,193,769), or variants thereof. The BAAV serotype may be orhave a sequence as described in U.S. Pat. No. 7,427,396, the contents ofwhich are herein incorporated by reference in their entirety, such as,but not limited to, BAAV (SEQ ID NO: 5 and 6 of U.S. Pat. No.7,427,396), or variants thereof.

In one embodiment, the AAV may be a caprine AAV. The caprine AAVserotype may be, or have, a sequence as described in U.S. Pat. No.7,427,396, the contents of which are herein incorporated by reference intheir entirety, such as, but not limited to, caprine AAV (SEQ ID NO: 3of U.S. Pat. No. 7,427,396), or variants thereof.

In other embodiments, the AAV may be engineered as a hybrid AAV from twoor more parental serotypes. In one embodiment, the AAV may be AAV2G9which comprises sequences from AAV2 and AAV9. The AAV2G9 AAV serotypemay be, or have, a sequence as described in United States PatentPublication No. US2016017005, the contents of which are hereinincorporated by reference in its entirety.

In one embodiment, the AAV may be a serotype generated by the AAV9capsid library with mutations in amino acids 390-627 (VP1 numbering) asdescribed by Pulicherla et al. (Molecular Therapy 19(6):1070-1078(2011), the contents of which are herein incorporated by reference intheir entirety. The serotype and corresponding nucleotide and amino acidsubstitutions may be, but is not limited to, AAV9.1 (G1594C; D5321HI),AAV6.2 (T1418A and T1436X; V473D and 1479K), AAV9.3 (T1238A; F413Y),AAV9.4 (T1250C and A1617T; F417S), AAV9.5 (A1235G, A1314T, A1642G,C1760T; Q412R, T548A, A587V), AAV9.6 (T1231A; F4111), AAV9.9 (G1203A,G1785T; W595C), AAV9.10 (A1500G, T1676C; M559T), AAV9.11 (A1425T,A1702C, A1769T; T568P, Q590L), AAV9.13 (A1369C, A1720T; N457H, T574S),AAV9.14 (T1340A, T1362C, T1560C, G1713A; L447H), AAV9.16 (A1775T;Q592L), AAV9.24 (T1507C, T1521G; W503R), AAV9.26 (A1337G, A1769C; Y446C,Q590P), AAV9.33 (A1667C; D556A), AAV9.34 (A1534G, C1794T; N512D),AAV9.35 (A1289T, TI 450, C1494T, A1515T, C1794A, G1816A; Q430L, Y484N,N98K, V6061), AAV9.40 (A1694T, E565V), AAV9.41 (A1348T, T1362C; T450S),AAV9.44 (A1684C, A1701T, A1737G; N562H, K567N), AAV9.45 (A1492T, C804T;N498Y, L602F), AAV9.46 (G1441C, T1525C, T1549G; G481R, W509R, L517V),9.47 (G1241A, G1358A, A1669G, C1745T; S414N, G453D, K557E, T582I),AAV9.48 (C1445T, A1736T; P482L, Q579L), AAV9.50 (A1638T, C1683T, T1805A;Q546H, L602H), AAV9.53 (G1301A, A1405C, C1664T, G1811T; R134Q, S469R,A555V, G604V), AAV9.54 (C1531A, T1609A; L511I, L537M), AAV9.55 (T1605A;F535L), AAV9.58 (C1475T, C1579A; T492I, H527N), AAV.59 (T1336C; Y446H),AAV9.61 (A1493T; N4981), AAV9.64 (C1531A, A1617T; L511I), AAV9.65(C1335T, T1530C, C1568A; A523D), AAV9.68 (C1510A; P504T), AAV9.80(G1441A, G481R), AAV9.83 (C1402A, A1500T; P468T, E500D), AAV9.87(T1464C, T1468C; S49(P), AAV9.90 (A1196T; Y399F), AAV9.91 (T1316G,A1583T, C1782G, T1806C; L439R, K5281), AAV9.93 (A1273G, A1421G, A1638C,C1712T, G1732A, A1744T, A1832T; S425G, Q474R, Q546H, P571L, G578R,T582S, D611V), AAV9.94 (A1675T; M559L) and AAV9.95 (T1605A; F535L).

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in International Publication No. WO2016049230, the contents ofwhich are herein incorporated by reference in their entirety, such as,but not limited to AAVF1/HSC1 (SEQ ID NO: 2 and 20 of WO2016049230),AAVF2/HSC2 (SEQ ID NO: 3 and 21 of WO2016049230), AAVF3/HSC3 (SEQ ID NO:5 and 22 of WO20160(49230), AAVF4/HSC4 (SEQ ID NO: 6 and 23 ofWO2016049230), AAVF5/HSC5 (SEQ ID NO: 11 and 25 of WO2016049230),AAVF6/HSC6 (SEQ ID NO: 7 and 24 of WO2016049230), AAVF7/HSC7 (SEQ ID NO:8 and 27 of WO2016049230), AAVF8/HSC8 (SEQ ID NO: 9 and 28 ofWO20160(49230), AAVF9/HSC9 (SEQ ID NO: 10 and 29 of WO2016049230),AAVF11/HSC11 (SEQ ID NO: 4 and 26 of WO2016049230), AAVF12/HSC12 (SEQ IDNO: 12 and 30) of WO2016049230), AAVF13/HSC13 (SEQ ID NO: 14 and 31 ofWO2016049230), AAVF14/HSC14 (SEQ ID NO: 15 and 32 of WO2016049230),AAVF15/HSC15 (SEQ ID NO: 16 and 33 of WO2016049230), AAVF16/HSC16 (SEQID NO: 17 and 34 of WO2016049230), AAVF177/HSC17 (SEQ ID NO. 13 and 35of WO2016049230), or variants or derivatives thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in U.S. Pat. No. 8,734,809, the contents of which are hereinincorporated by reference in their entirety, such as, but not limitedto, AAV CBr-E1 (SEQ ID NO: 13 and 87 of U.S. Pat. No. 8,734,809), AAVCBr-E2 (SEQ ID NO: 14 and 88 of U.S. Pat. No. 8,734,809), AAV CBr-E3(SEQ ID NO: 15 and 89 of U.S. Pat. No. 8,734,809), AAV CBr-E4 (SEQ IDNO: 16 and 90 of U.S. Pat. No. 8,734,809), AAV CBr-E5 (SEQ ID NO: 17 and91 of U.S. Pat. No. 8,734,809), AAV CBr-e5 (SEQ ID NO: 18 and 92 of U.S.Pat. No. 8,734,809), AAV CBr-E6 (SEQ ID NO:19 and 93 of U.S. Pat. No.8,734,809), AAV CBr-E7 (SEQ ID NO: 20 and 94 of U.S. Pat. No.8,734,809), AAV CBr-E8 (SEQ ID NO: 21 and 95 of U.S. Pat. No.8,734,809), AAV CLv-D1 (SEQ ID NO: 22 and 96 of U.S. Pat. No.8,734,809), AAV CLv-D2 (SEQ ID NO: 23 and 97 of U.S. Pat. No.8,734,809), AAV CLv-D3 (SEQ ID NO: 24 and 98 of U.S. Pat. No.8,734,809), AAV CLv-D4 (SEQ ID NO: 25 and 99 of U.S. Pat. No.8,734,809), AAV CLv-D5 (SEQ ID NO: 26 and 100 of U.S. Pat. No.8,734,809), AAV CLv-D6 (SEQ ID NO: 27 and 101 of U.S. Pat. No.8,734,809), AAV CLv-D7 (SEQ ID NO: 28 and 102 of U.S. Pat. No.8,734,809), AAV CLv-D8 (SEQ ID NO: 29 and 103 of U.S. Pat. No.8,734,809, AAV CLv-E1 (SEQ ID NO: 13 and 87 of U.S. Pat. No. 8,734,809),AAV CLv-R1 (SEQ ID NO: 30 and 104 of U.S. Pat. No. 8,734,809), AAVCLv-R2 (SEQ ID NO: 31 and 105 of U.S. Pat. No. 8,734,809), AAV CLv-R3(SEQ ID NO: 32 and 106 of U.S. Pat. No. 8,734,809), AAV CLv-R4 (SEQ IDNO: 33 and 107 of U.S. Pat. No. 8,734,809), AAV CLv-R5 (SEQ ID NO: 34and 108 of U.S. Pat. No. 8,734,809), AAV CLv-R6 (SEQ ID NO: 35 and 109of U.S. Pat. No. 8,734,809), AAV CLv-R7 (SEQ ID NO: 36 and 110 of U.S.Pat. No. 8,734,809), AAV CLv-R8 (SEQ ID NO: 37 and 111 of U.S. Pat. No.8,734,809), AAV CL-R9 (SEQ ID NO: 38 and 112 of U.S. Pat. No.8,734,809), AAV CLg-F1 (SEQ ID NO: 39 and 113 of U.S. Pat. No.8,734,809), AAV CLg-F2 (SEQ ID NO: 40 and 114 of U.S. Pat. No.8,734,809), AAV CLg-F3 (SEQ ID NO: 41 and 115 of U.S. Pat. No.8,734,809), AAV CLg-F4 (SEQ ID NO: 42 and 116 of U.S. Pat. No.8,734,809), AAV CLg-F5 (SEQ ID NO: 43 and 117 of U.S. Pat. No.8,734,809), AAV CLg-F6 (SEQ ID NO: 43 and 117 of U.S. Pat. No.8,734,809), AAV CLg-F7 (SEQ ID NO: 44 and 118 of U.S. Pat. No.8,734,809), AAV CLg-F8 (SEQ ID NO: 43 and 117 of U.S. Pat. No.8,734,809), AAV CSp-1 (SEQ ID NO: 45 and 119 of U.S. Pat. No.8,734,809), AAV CSp-10 (SEQ ID NO: 46 and 120 of U.S. Pat. No.8,734,809), AAV CSp-11 (SEQ ID NO: 47 and 121 of U.S. Pat. No.8,734,809), AAV CSp-2 (SEQ ID NO: 48 and 122 of U.S. Pat. No.8,734,809), AAV CSp-3 (SEQ ID NO: 49 and 123 of U.S. Pat. No.8,734,809), AAV CSp-4 (SEQ ID NO: 50 and 124 of U.S. Pat. No.8,734,809), AAV CSp-6 (SEQ ID NO: 51 and 125 of U.S. Pat. No. 734,809),AAV CSp-7 (SEQ ID NO-52 and 126 of U.S. Pat. No. 8,734,809), AAV CSp-8(SEQ ID NO: 53 and 127 of U.S. Pat. No. 8,734,809), AAV CSp-9 (SEQ IDNO: 54 and 128 of U.S. Pat. No. 8,734,809), AAV CHt-2 (SEQ ID NO: 55 and129 of U.S. Pat. No. 8,734,809), AAV CHt-3 (SEQ ID NO: 56 and 130 ofU.S. Pat. No. 8,734,809), AAV CKd-1 (SEQ ID NO: 57 and 131 of U.S. Pat.No. 8,734,809), AAV CKd-10 (SEQ ID NO: 58 and 132 of U.S. Pat. No.8,734,809), AAV CKd-2 (SEQ ID NO: 59 and 133 of U.S. Pat. No.8,734,809), AAV CKd-3 (SEQ ID NO: 60 and 134 of U.S. Pat. No.8,734,809), AAV CKd-4 (SEQ ID NO: 61 and 135 of U.S. Pat. No.8,734,809), AAV CKd-6 (SEQ ID NO: 62 and 136 of U.S. Pat. No.8,734,809), AAV CKd-7 (SEQ ID NO: 63 and 137 of U.S. Pat. No.8,734,809), AAV CKd-8 (SEQ ID NO: 64 and 138 of U.S. Pat. No.8,734,809), AAV CLv-1 (SEQ ID NO: 35 and 139 of U.S. Pat. No.8,734,809), AAV CLv-12 (SEQ ID NO: 66 and 140 of U.S. Pat. No.8,734,809), AAV CLv-13 (SEQ ID NO: 67 and 141 of U.S. Pat. No.8,734,809), AAV CLv-2 (SEQ ID NO: 68 and 142 of U.S. Pat. No.8,734,809), AAV CLv-3 (SEQ ID NO: 69 and 143 of U.S. Pat. No.8,734,809), AAV CLv-4 (SEQ ID NO: 70 and 144 of U.S. Pat. No.8,734,809), AAV CLv-6 (SEQ ID NO: 71 and 145 of U.S. Pat. No.8,734,809), AAV CLv-8 (SEQ ID NO: 72 and 146 of U.S. Pat. No.8,734,809), AAV CKd-B1 (SEQ ID NO: 73 and 147 of U.S. Pat. No.8,734,809), AAV CKd-B2 (SEQ ID NO: 74 and 148 of U.S. Pat. No.8,734,809), AAV CKd-B3 (SEQ ID NO: 75 and 149 of U.S. Pat. No.8,734,809), AAV CKd-B4 (SEQ ID NO: 76 and 150) of U.S. Pat. No.8,734,809), AAV CKd-B5 (SEQ ID NO: 77 and 151 of U.S. Pat. No.8,734,809), AAV CKd-B6 (SEQ ID NO: 78 and 152 of U.S. Pat. No.8,734,809), AAV CKd-B7 (SEQ ID NO: 79 and 153 of U.S. Pat. No.8,734,809), AAV CKd-B8 (SEQ ID NO: 80 and 154 of U.S. Pat. No.8,734,809), AAV CKd-H1 (SEQ ID NO: 81 and 155 of U.S. Pat. No.8,734,809), AAV CKd-H2 (SEQ ID NO: 82 and 156 of U.S. Pat. No.8,734,809), AAV CKd-H3 (SEQ ID NO: 83 and 157 of U.S. Pat. No.8,734,809), AAV CKd-H4 (SEQ ID NO: 84 and 158 of U.S. Pat. No.8,734,809), AAV CKd-H5 (SEQ ID NO: 85 and 159 of U.S. Pat. No.8,734,809), AAV CKd-H6 (SEQ ID NO: 77 and 151 of U.S. Pat. No.8,734,809), AAV CHt-1 (SEQ ID NO: 86 and 160 of 8734809), AAV CLv1-1(SEQ ID NO: 171 of U.S. Pat. No. 8,734,809), AAV CLv1-2 (SEQ ID NO: 172of U.S. Pat. No. 8,734,809), AAV CLv1-3 (SEQ ID NO: 173 of U.S. Pat. No.734,809), AAV CLv1-4 (SEQ ID NO: 174 of U.S. Pat. No. 8,734,809), AAVClv1-7 (SEQ ID NO: 175 of U.S. Pat. No. 8,734,809), AAV Clv1-8 (SEQ IDNO: 176 of U.S. Pat. No. 8,734,809), AAV Clv1-9 (SEQ ID NO: 177 of U.S.Pat. No. 8,734,809), AAV Clv-10 (SEQ ID NO: 178 of U.S. Pat. No.8,734,809), AAV.VR-355 (SEQ ID NO: 181 of U.S. Pat. No. 8,734,809),AAV.hu.48R3 (SEQ ID NO: 183 of U.S. Pat. No. 8,734,809), or variants orderivatives thereof.

In some embodiments, the AAV serotype may be, or have, a sequence asdescribed in International Publication No. WO02016065001, the contentsof which are herein incorporated by reference in their entirety, suchas, but not limited to AAV CHt-P2 (SEQ ID NO: 1 and 51 of WO2016065001),AAV CHt-P5 (SEQ ID NO: 2 and 52 of WO2016065001), AAV CHt-P9 (SEQ ID NO:3 and 53 of WO2016065001), AAV CBr-7.1 (SEQ ID NO: 4 and 54 ofWO2016065001), AAV CBr-7.2 (SEQ ID NO: 5 and 55 of WO2016065001), AAVCBr-7.3 (SEQ ID NO: 6 and 56 of WO2016065001), AAV CBr-7.4 (SEQ ID NO: 7and 57 of WO2016065001), AAV CBr-7.5 (SEQ ID NO: 8 and 58 ofWO2016065001), AAV CBr-7.7 (SEQ ID NO: 9 and 59 of WO2016065001), AAVCBr-7.8 (SEQ ID NO: 10 and 60 of WO2016065001), AAV CBr-7.10 (SEQ ID NO:11 and 61 of WO2016065001), AAV CKd-N3 (SEQ ID NO: 12 and 62 ofWO2016065001), AAV CKd-N4 (SEQ ID NO: 13 and 63 of WO2016065001), AAVCKd-N9 (SEQ ID NO: 14 and 64 of WO2016065001), AAV CLv-L4 (SEQ ID NO: 15and 65 of WO2016065001), AAV CLv-L5 (SEQ ID NO: 16 and 66 ofWO2016065001), AAV CLv-L6 (SEQ ID NO: 17 and 67 of WO2016065001), AAVCLv-K1 (SEQ ID NO: 18 and 68 of WO2016065001), AAV CLv-K3 (SEQ ID NO: 19and 69 of WO2016065001), AAV CLv-K6 (SEQ ID NO: 20 and 70 ofWO2016065001), AAV CLv-M (SEQ ID NO: 21 and 71 of WO2016065001), AAVCLv-M11 (SEQ ID NO: 22 and 72 of WO2016065001), AAV CLv-M2 (SEQ ID NO:23 and 73 of WO2016065001), AAV CLv-M5 (SEQ ID NO: 24 and 74 ofWO2016065001), AAV CLv-M6 (SEQ ID NO: 25 and 75 of WO2016065001), AAVCLv-M7 (SEQ ID NO: 26 and 76 of WO2016065001), AAV CLv-M8 (SEQ ID NO: 27and 77 of WO2016065001), AAV CLv-M9 (SEQ ID NO: 28 and 78 ofWO2016065001), AAV CHt-P1 (SEQ ID NO: 29 and 79 of WO2016065001), AAVCHt-P6 (SEQ ID NO: 30 and 80 of WO2016065001), AAV CHt-P8 (SEQ ID NO: 31and 81 of WO2016065001), AAV CHt-6.1 (SEQ ID NO: 32 and 82 ofWO2016065001), AAV CHt-6.10 (SEQ ID NO: 33 and 83 of WO2016065001), AAVCHt-6.5 (SEQ ID NO: 34 and 84 of WO2016065001), AAV CHt-6.6 (SEQ ID NO:35 and 85 of WO2016065001), AAV CHt-6.7 (SEQ ID NO: 36 and 86 ofWO2016065001), AAV CHt-6.8 (SEQ ID NO: 37 and 87 of WO2016065001), AAVCSp-8.10 (SEQ ID NO: 38 and 88 of WO2016065001), AAV CSp-8.2 (SEQ ID NO:39 and 89 of WO2016065001), AAV CSp-8.4 (SEQ ID NO: 40 and 90 ofWO2016065001), AAV CSp-8.5 (SEQ ID NO: 41 and 91 of WO2016065001), AAVCSp-8.6 (SEQ ID NO: 42 and 92 of WO2016065001), AAV CSp-8.7 (SEQ ID NO:43 and 93 of WO2016065001), AAV CSp-8.8 (SEQ ID NO: 44 and 94 ofWO2016065001), AAV CSp-8.9 (SEQ ID NO: 45 and 95 of WO2016065001), AAVCBr-B7.3 (SEQ ID NO: 46 and 96 of WO2016065001), AAV CBr-B7.4 (SEQ IDNO: 47 and 97 of WO2016065001), AAV3B (SEQ ID NO: 48 and 98 ofWO2016065001), AAV4 (SEQ ID NO: 49 and 99 of WO2016065001), AAV5 (SEQ IDNO: 50 and 100 of WO2016065001), or variants or derivatives thereof.

In one embodiment, the AAV may be a serotype selected from any of thosefound in Table 1.

In one embodiment, the AAV may comprise a sequence, fragment or variantthereof, of the sequences in Table 1.

In one embodiment, the AAV may be encoded by a sequence, fragment orvariant as described in Table 1.

TABLE 1 AAV Serotypes Serotype SEQ ID NO Reference Information AAV1 1US20150159173 SEQ ID NO: 11, US2015 315612 SEQ ID NO: 202 AAV1 2US20160017295 SEQ ID NO: 1US20030138772 SEQ ID NO: 64, US20150159173 SEQID NO: 27, US20150315612 SEQ ID NO: 219, US7198951 SEQ ID NO: 5 AAV1 3US20030138772 SEQ ID NO: 6 AAV1.3 4 US20030138772 SEQ ID NO: 14 AAV10 5US20030 38772 SEQ ID NO: 117 AAV10 6 WO20151501 SEQ ID NO: 9 AAV10 7WO2015121501 SEQ ID NO: 8 AAV11 8 US20030138772 SEQ ID NO: 118 AAV12 9US20030138772 SEQ ID NO: 119 AAV2 10 US20150159173 SEQ ID NO: 7,US20150315612 SEQ ID NO: 211 AAV2 11 US20030138772 SEQ ID NO: 70,US20150159173 SEQ ID NO: 23, US20150315612 SEQ ID NO: 221, US20160017295SEQ ID NO: 2, US6156303 SEQ ID NO: 4, US7198951 SEQ ID NO: 4,WO2015121501 SEQ ID NO: 1 AAV2 12 US6156303 SEQ ID NO: 8 AAV2 13US20030138772 SEQ ID NO: 7 AAV2 14 US6156303 SEQ ID NO: 3 AAV2.5T 15US9233131 SEQ ID NO: 42 AAV223.10 16 US20030138772 SEQ ID NO: 75AAV223.2 17 US20030138772 SEQ ID NO: 49 AAV223.2 18 US20030138772 SEQ IDNO: 76 AAV223.4 19 US20030138772 SEQ ID NO: 50 AAV223.4 20 US20030138772SEQ ID NO: 73 AAV223.5 21 US20030138772 SEQ ID NO: 51 AAV223.5 22US20030138772 SEQ ID NO: 74 AAV223.6 23 US20030138772 SEQ ID NO: 52AAV223.6 24 US20030138772 SEQ ID NO: 78 AAV223.7 25 US20030138772 SEQ IDNO: 53 AAV223.7 26 US20030138772 SEQ ID NO: 77 AAV29.3 27 US20030138772SEQ ID NO: 82 AAV29.4 28 US20030138772 SEQ ID NO: 12 AAV29.5 29US20030138772 SEQ ID NO: 83 AAV29.5 30 US20030138772 SEQ ID NO: 13(AAVbb.2) AAV3 31 US20150159173 SEQ ID NO: 12 AAV3 32 US20030138772 SEQID NO: 71, US2015019173 SEQ ID NO: 28, US20160017295 SEQ ID NO: 3,US7198951 SEQ ID NO: 6 AAV3 33 US20030138772 SEQ ID NO: 8 AAV3.3b 34US20030138772 SEQ ID NO: 72 AAV3-3 35 US20150315612 SEQ ID NO: 200AAV3-3 36 US20150315612 SEQ ID NO: 217 AAV3a 37 US6156303 SEQ ID NO: 5AAV3a 38 US6156303 SEQ ID NO: 9 AAV3b 39 US6156303 SEQ ID NO: 6 AAV3b 40US6156303 SEQ ID NO: 10 AAV3b 41 US6156303 SEQ ID NO: 1 AAV4 42US20140348794 SEQ ID NO: 17 AAV4 43 US20140348794 SEQ ID NO: 5 AAV4 44US20140348794 SEQ ID NO: 3 AAV4 45 US20140348794 SEQ ID NO: 14 AAV4 46US20140348794 SEQ ID NO: 15 AAV4 47 US20140348794 SEQ ID NO: 19 AAV4 48US20140348794 SEQ ID NO: 12 AAV4 49 US20140348794 SEQ ID NO: 13 AAV4 50US20140348794 SEQ ID NO: 7 AAV4 51 US20140348794 SEQ ID NO: 8 AAV4 52US20140348794 SEQ ID NO: 9 AAV4 53 US20140348794 SEQ ID NO: 2 AAV4 54US20140348794 SEQ ID NO: 10 AAV4 55 US20140348794 SEQ ID NO: 11 AAV4 56US20140348794 SEQ ID NO: 18 AAV4 57 US20030138772 SEQ ID NO: 63,US20160017295 SEQ ID NO: 4, US20140348794 SEQ ID NO: 4 AAV4 58US20140348794 SEQ ID NO: 16 AAV4 59 US20140348794 SEQ ID NO: 20 AAV4 60US20140348794 SEQ ID NO: 6 AAV4 61 US20140348794 SEQ ID NO: 1 AAV42.2 62US20030138772 SEQ ID NO: 9 AAV42.2 63 US20030138772 SEQ ID NO: 102AAV42.3b 64 US20030138772 SEQ ID NO: 36 AAV42.3B 65 US20030138772 SEQ IDNO: 107 AAV42.4 66 US20030138772 SEQ ID NO: 33 AAV42.4 67 US20030138772SEQ ID NO: 88 AAV42.8 68 US20030138772 SEQ ID NO: 27 AAV42.8 69US20030138772 SEQ ID NO: 85 AAV43.1 70 US20030138772 SEQ ID NO: 39AAV43.1 71 US20030138772 SEQ ID NO: 92 AAV43.12 72 US20030138772 SEQ IDNO: 41 AAV43.12 73 US20030138772 SEQ ID NO: 93 AAV43.20 74 US20030138772SEQ ID NO: 42 AAV43.20 75 US20030138772 SEQ ID NO: 99 AAV43.21 76US20030138772 SEQ ID NO: 43 AAV43.21 77 US20030138772 SEQ ID NO: 96AAV43.23 78 US20030138772 SEQ ID NO: 44 AAV43.23 79 US20030138772 SEQ IDNO: 98 AAV43.25 80 US20030138772 SEQ ID NO: 45 AAV43.25 81 US20030138772SEQ ID NO: 97 AAV43.5 82 US20030138772 SEQ ID NO: 40 AAV43.5 83US20030138772 SEQ ID NO: 94 AAV4-4 84 US20150315612 SEQ ID NO: 201AAV4-4 85 US20150315612 SEQ ID NO: 218 AAV44.1 86 US20030138772 SEQ IDNO: 46 AAV44.1 87 US20030138772 SEQ ID NO: 79 AAV44.5 88 US20030138772SEQ ID NO: 47 AAV44.5 89 US20030138772 SEQ ID NO: 80 AAV4407 90US20150315612 SEQ ID NO: 90 AAV5 91 US7427396 SEQ ID NO: 1 AAV5 92US20030138772 SEQ ID NO: 114 AAV5 93 US20160017295 SEQ ID NO: 5,US7427396 SEQ ID NO: 2, US2015035612 SEQ ID NO: 216 AAV5 94US20150315612 SEQ ID NO: 199 AAV6 95 US20150159173 SEQ ID NO: 13 AAV6 96US20030138772 SEQ ID NO: 65, US20150159173 SEQ ID NO: 29, US20160017295SEQ ID NO: 6, US6156303 SEQ ID NO: 7 AAV6 97 US6156303 SEQ ID NO: 11AAV6 98 US6156303 SEQ ID NO: 2 AAV6 99 US20150315612 SEQ ID NO: 203 AAV6100 US20150315612 SEQ ID NO: 220 AAV6.1 101 US20150159173 AAV6.12 102US20150159173 AAV6.2 103 US20150159173 AAV7 104 US20150159173 SEQ ID NO:14 AAV7 105 US20150315612 SEQ ID NO: 183 AAV7 106 US20030138772 SEQ IDNO: 2, US20150159173 SEQ ID NO: 30, US20150315612 SEQ ID NO: 181,US20160017295 SEQ ID NO:7 AAV7 107 US20030138772 SEQ ID NO: 3 AAV7 108US20030138772 SEQ ID NO: 1, US20150315612 SEQ ID NO: 180 AAV7 109US20150315612 SEQ ID NO: 213 AAV7 110 US20150315612 SEQ ID NO: 222 AAV8111 US20150159173 SEQ ID NO: 15 AAV8 112 US20150376240 SEQ ID NO: 7 AAV8113 US20030138772 SEQ ID NO: 4, US20150315612 SEQ ID NO: 182 AAV8 114US20030138772 SEQ ID NO: 95, US20140359799 SEQ ID NO: 1, US20150159173SEQ ID NO: 31, US20160017295 SEQ ID NO: 8, US7198951 SEQ ID NO: 7,US20150315612 SEQ ID NO: 223 AAV8 115 US20150376240 SEQ ID NO: 8 AAV8116 US20150315612 SEQ ID NO: 214 AAV-8b 117 US20150376240 SEQ ID NO: 5AAV-8b 118 US20150376240 SEQ ID NO: 3 AAV-8h 119 US20150376240 SEQ IDNO: 6 AAV-8h 120 US20150376240 SEQ ID NO: 4 AAV9 121 US20030138772 SEQID NO: 5 AAV9 122 US7198951 SEQ ID NO: 1 AAV9 123 US20160017295 SEQ IDNO: 9 AAV9 124 US20030138772 SEQ ID NO: 100, US7198951 SEQ ID NO: 2 AAV9125 US7198951 SEQ ID NO: 3 AAV9 126 US7906111 SEQ ID NO: 3; WO2015038958SEQ ID NO: 11 (AAVhu.14) AAV9 127 US7906111 SEQ ID NO: 123; WO2015038958SEQ ID NO: 2 (AAVhu.14) AAVA3.1 128 US20030138772 SEQ ID NO: 120 AAVA3.3129 US20030138772 SEQ ID NO: 57 AAVA3.3 130 US20030138772 SEQ ID NO: 66AAVA3.4 131 US20030138772 SEQ ID NO: 54 AAVA3.4 132 US20030138772 SEQ IDNO: 68 AAVA3.5 133 US20030138772 SEQ ID NO: 55 AAVA3.5 134 US20030138772SEQ. ID NO: 69 AAVA3.7 135 US20030138772 SEQ ID NO: 56 AAVA3.7 136US20030138772 SEQ ID NO: 67 AAV29.3 137 US20030138772 SEQ ID NO: 11(AA.Vbb.1) AAVC2 138 US20030138772 SEQ ID NO: 61 AAVCh.5 139US20150159173 SEQ ID NO: 46, US20150315612 SEQ ID NO: 234 AAVcy.2 140US20030138772 SEQ ID NO: 15 (AAV13.3) AAV24.1 141 US20030138772 SEQ IDNO: 101 AAVcy.3 142 US20030138772 SEQ ID NO: 16 (AAV24.1) AAV27.3 143US20030138772 SEQ ID NO: 104 AAVcy.4 144 US20030138772 SEQ ID NO: 17(AAV27.3) AAVcy.5 145 US20150115612 SEQ ID NO: 227 AAV7.2 146US20030138772 SEQ ID NO: 103 AAVcy.5 147 US20030138772 SEQ ID NO: 18(AAV7.2) AAV16.3 148 US20030138772 SEQ ID NO: 105 AAVcy.6 149US20030138772 SEQ ID NO: 10 (AAV16.3) AAVcy.5 150 US20150159173 SEQ IDNO: 8 AAVcy.5 151 US20150159173 SEQ ID NO: 24 AAVCy.5R1 152US20150159173 AAVCy.5R2 153 US20150159173 AAVCy.5R3 154 US20150159173AAVCy.5R4 155 US20150159173 AAVDJ 156 US20140359799 SEQ ID NO: 3,US7588772 SEQ ID NO: 2 AAVDJ 157 US20140359799 SEQ ID NO: 2, US7588772SEQ ID NO: 1 AAVDJ-8 158 US7588772; Grimm et al 2008 AAVDJ-8 159US7588772; Grimm et al 2008 AAVF5 160 US20030138772 SEQ ID NO: 110 AAVH2161 US20030138772 SEQ ID NO: 26 AAVH6 162 US20030138772 SEQ ID NO: 25AAVhE1.1 163 US9233131 SEQ ID NO: 44 AAVhEr1.14 164 US9233131 SEQ ID NO:46 AAVhEr1.16 165 US9233131 SEQ ID NO: 48 AAVhEr1.18 166 US9233131 SEQID NO: 49 AAVhEr1.23 167 US9233131 SEQ ID NO: 53 (AAVhEr2.29) AAVhEr1.35168 US9233131 SEQ ID NO: 50 AAVhEr1.36 169 US9233131 SEQ ID NO: 52AAVhEr1.5 170 US9233131 SEQ ID NO: 45 AAVhEr1.7 171 US9233131 SEQ ID NO:51 AAVhEr1.8 172 US9233131 SEQ ID NO: 47 AAVhEr2.16 173 US9233131 SEQ IDNO: 55 AAVhEr2.30 174 US9233131 SEQ ID NO. 56 AAVhEr2.31 175 US9233131SEQ ID NO: 58 AAVhEr2.36 176 US9233131 SEQ ID NO: 57 AAVhEr2.4 177US9233131 SEQ ID NO: 54 AAVhEr3.1 178 US9233131 SEQ ID NO: 59 AAVhu.1179 US20150315612 SEQ ID NO: 46 AAVhu.1 180 US20150315612 SEQ ID NO: 144AAVhu.10 181 US20150315612 SEQ ID NO: 56 (AAV16.8) AAVhu.10 182US20150315612 SEQ ID NO: 156 (AAV16.8) AAVhu.11 183 US20150315612 SEQ IDNO: 57 (AAV16.12) AAVhu.11 184 US20150315612 SEQ ID NO: 153 (AAV16.12)AAVhu.12 185 US20150315612 SEQ ID NO: 59 AAVhu.12 186 US20150315612 SEQID NO: 154 AAVhu.13 187 US20150159173 SEQ ID NO: 16, US20150315612 SEQID NO: 71 AAVhu.13 188 US20150159173 SEQ ID NO: 32, US20150315612 SEQ IDNO: 129 AAVhu.136.1 189 US20150315612 SEQ ID NO: 165 AAVhu.140.1 190US20150315612 SEQ ID NO: 166 AAVhu.140.2 191 US20150315612 SEQ ID NO:167 AAVhu.145.6 192 US20150315612 SEQ ID No: 178 AAVhu.15 193US20150315612 SEQ ID NO: 147 AAVhu.15 194 US20150315612 SEQ ID NO: 50(AAV33.4) AAVhu.156.1 195 US20150315612 SEQ ID No: 179 AAVhu.16 196US20150315612 SEQ ID NO: 148 AAVhu.16 197 US20150315612 SEQ ID NO: 51(AAV33.8) AAVhu.17 198 US20150315612 SEQ ID NO: 83 AAVhu.17 199US20150315612 SEQ ID NO: 4 (AAV33.12) AAVhu.172.1 200 US20150315612 SEQID NO: 171 AAVhu.172.2 201 US20150315612 SEQ ID NO: 172 AAVhu.173.4 202US20150315612 SEQ ID NO: 173 AAVhu.173.8 203 US20150315612 SEQ ID NO:175 AAVhu.18 204 US20150315612 SEQ ID NO: 52 AAVhu.18 205 US20150315612SEQ ID NO: 149 AAVhu.19 206 US20150315612 SEQ ID NO: 62 AAVhu.19 207US20150315612 SEQ ID NO: 133 AAVhu.2 208 US20150315612 SEQ ID NO: 48AAVhu.2 209 US20150315612 SEQ ID NO: 143 AAVhu.20 210 US20150315612 SEQID NO: 63 AAVhu.20 211 US20150315612 SEQ ID NO: 134 AAVhu.21 212US20150315612 SEQ ID NO: 65 AAVhu.21 213 US20150315612 SEQ ID NO: 135AAVhu.22 214 US20150315612 SEQ ID NO: 67 AAVhu.22 215 US20150315612 SEQID NO: 138 AAVhu.23 216 US20150315612 SEQ ID NO: 60 AAVhu.23.2 217US20150315612 SEQ ID NO: 137 AAVhu.24 218 US20150315612 SEQ ID NO: 66AAVhu.24 219 US20150315612 SEQ ID NO: 136 AAVhu.25 220 US20150315612 SEQID NO: 49 AAVhu.25 221 US20150315612 SEQ ID NO: 146 AAVhu.26 222US20150159173 SEQ ID NO: 17, US20150315612 SEQ ID NO: 61 AAVhu.26 223US20150159173 SEQ ID NO: 33, US20150315612 SEQ ID NO: 139 AAVhu.27 224US20150315612 SEQ ID NO: 64 AAVhu.27 225 US20150315612 SEQ ID NO: 140AAVhu.28 226 US20150315612 SEQ ID NO: 68 AAVhu.28 227 US20150315612 SEQID NO: 130 AAVhu.29 228 US20150315612 SEQ ID NO: 69 AAVhu.29 229US20150159173 SEQ ID NO: 42, US20150315612 SEQ ID NO: 132 AAVhu.29 230US20150315612 SEQ ID NO: 225 AAVhu.29R 231 US20150159173 AAVhu.3 232US20150315612 SEQ ID NO: 44 AAVhu.3 233 US20150315612 SEQ ID NO: 145AAVhu.30 234 US20150315612 SEQ ID NO: 70 AAVhu.30 235 US20150315612 SEQID NO: 131 AAVhu.31 236 US20150315612 SEQ ID NO: 1 AAVhu.31 237US20150315612 SEQ ID NO: 121 AAVhu.32 238 US20150315612 SEQ ID NO: 2AAVhu.32 239 US20150315612 SEQ ID NO: 122 AAVhu.33 240 US20150315612 SEQID NO: 75 AAVhu.33 241 US20150315612 SEQ ID NO: 124 AAVhu.34 242US20150315612 SEQ ID NO: 72 AAVhu.34 243 US20150315612 SEQ ID NO: 125AAVhu.35 244 US20150315612 SEQ ID NO: 73 AAVhu.35 245 US20150315612 SEQID NO: 164 AAVhu.36 246 US20150315612 SEQ ID NO: 74 AAVhu.36 247US20150315612 SEQ ID NO: 126 AAVhu.37 248 US20150159173 SEQ ID NO: 34,US20150315612 SEQ ID NO: 88 AAVhu.37 249 US20150315612 SEQ ID NO: 10,US20150159173 SEQ ID NO: 18 (AAV106.1) AAVhu.38 250 US20150315612 SEQ IDNO: 161 AAVhu.39 251 US20150315612 SEQ ID NO: 102 AAVhu.39 252US20150315612 SEQ ID NO: 24 (AAVLG-9) AAVhu.4 253 US20150315612 SEQ IDNO: 47 AAVhu.4 254 US20150315612 SEQ ID NO: 141 AAVhu.40 255US20150315612 SEQ ID NO: 87 AAVhu.40 256 US20150315612 SEQ ID No: 11(AAV114.3) AAVhu.41 257 US20150315612 SEQ ID NO: 91 AAVhu.41 258US20150315612 SEQ ID NO: 6 (AAV127.2) AAVhu.42 259 US20150315612 SEQ IDNO: 85 AAVhu.42 260 US20150315612 SEQ ID NO: 8 (AAV127.5) AAVhu.43 261US20150315612 SEQ ID NO: 160 AAVhu.43 262 US20150315612 SEQ ID NO: 236AAVhu.43 263 US20150315612 SEQ ID NO: 80 (AAV128.1) AAVhu.44 264US20150159173 SEQ ID NO: 45, US20150315612 SEQ ID NO: 158 AAVhu.44 265US20150315612 SEQ ID NO: 81 (AAV128.3) AAVhu.44R1 266 US20150159173AAVhu.44R2 267 US20150159173 AAVhu.44R3 268 US20150159173 AAVhu.45 269US20150315612 SEQ ID NO: 76 AAVhu.45 270 US20150315612 SEQ ID NO: 127AAVhu.46 271 US20150315612 SEQ ID NO: 82 AAVhu.46 272 US20150315612 SEQID NO: 159 AAVhu.46 273 US20150315612 SEQ ID NO: 224 AAVhu.47 274US20150315612 SEQ ID NO: 77 AAVhu.47 275 US20150315612 SEQ ID NO: 128AAVhu.48 276 US20150159173 SEQ ID NO: 38 AAVhu.48 277 US20150315612 SEQID NO: 157 AAVhu.48 278 US20150315612 SEQ ID NO: 78 (AAV130.4)AAVhu.48R1 279 US20150159173 AAVhu.48R2 280 US20150159173 AAVhu.48R3 281US20150159173 AAVhu.49 282 US20150315612 SEQ ID NO: 209 AAVhu.49 283US20150315612 SEQ ID NO: 189 AAVhu.5 284 US20150315612 SEQ ID NO: 45AAVhu.5 285 US20150315612 SEQ ID NO: 142 AAVhu.51 286 US20150315612 SEQID NO: 208 AAVhu.51 287 US20150315612 SEQ ID NO: 190 AAVhu.52 288US20150315612 SEQ ID NO: 210 AAVhu.52 289 US20150315612 SEQ ID NO: 191AAVhu.53 290 US20150159173 SEQ ID NO: 19 AAVhu.53 291 US20150159173 SEQID NO: 35 AAVhu.53 292 US20150315612 SEQ ID NO: 176 (AAV145.1) AAVhu.54293 US20150315612 SEQ ID NO: 188 AAVhu.54 294 US20150315612 SEQ ID No:177 (AAV145.5) AAVhu.55 295 US20150315612 SEQ ID NO: 187 AAVhu.56 296US20150315612 SEQ ID NO: 205 AAVhu.56 297 US20150315612 SEQ ID NO: 168(AAV145.6) AAVhu.56 298 US20150315612 SEQ ID NO: 192 (AAV145.6) AAVhu.57299 US20150315612 SEQ ID NO: 206 AAVhu.57 300 US20150315612 SEQ ID NO:169 AAVhu.57 301 US20150315612 SEQ ID NO: 193 AAVhu.58 302 US20150315612SEQ ID NO: 207 AAVhu.58 303 US20150315612 SEQ ID NO: 194 AAVhu.6 304US20150315612 SEQ ID NO: 5 (AAV3.1) AAVhu.6 305 US20150315612 SEQ ID NO:84 (AAV3.1) AAVhu.60 306 US20150315612 SEQ ID NO: 184 AAVhu.60 307US20150315612 SEQ ID NO: 170 (AAV161.10) AAVhu.61 308 US20150315612 SEQID NO: 185 AAVhu.61 309 US20150315612 SEQ ID NO: 174 (AAV161.6) AAVhu.63310 US20150315612 SEQ ID NO: 204 AAVhu.63 311 US20150315612 SEQ ID NO:195 AAVhu.64 312 US20150315612 SEQ ID NO: 212 AAVhu.64 313 US20150315612SEQ ID NO: 196 AAVhu.66 314 US20150315612 SEQ ID NO: 197 AAVhu.67 315US20150315612 SEQ ID NO: 215 AAVhu.67 316 US20150315612 SEQ ID NO: 198AAVhu.7 317 US20150315612 SEQ ID NO: 226 AAVhu.7 318 US20150315612 SEQID NO: 150 AAVhu.7 319 US20150315612 SEQ ID NO: 55 (AAV7.3) AAVhu.71 320US20150315612 SEQ ID NO: 79 AAVhu.8 321 US20150315612 SEQ ID NO: 53AAVhu.8 322 US20150315612 SEQ ID NO: 12 AAVhu.8 323 US20150315612 SEQ IDNO: 151 AAVhu.9 324 US20150315612 SEQ ID NO: 58 (AAV3.1) AAVhu.9 325US20150315612 SEQ ID NO: 155 (AAV3.1) AAV-LK01 326 US20150376607 SEQ IDNO: 2 AAV-LK01 327 US20150376607 SEQ ID NO: 29 AAV-LK02 328US20150376607 SEQ ID NO: 3 AAV-LK02 329 US20150376607 SEQ ID NO: 30AAV-LK03 330 US20150376607 SEQ ID NO: 4 AAV-LK03 331 WO2015121501 SEQ IDNO: 12, US20150376607 SEQ ID NO: 31 AAV-LK04 332 US20150376607 SEQ IDNO: 5 AAV-LK04 333 US20150376607 SEQ ID NO: 32 AAV-LK05 334US20150376607 SEQ ID NO: 6 AAV-LK05 335 US20150376607 SEQ ID NO: 33AAV-LK06 336 US20150376607 SEQ ID NO: 7 AAV-LK06 337 US20150376607 SEQID NO: 34 AAV-LK07 338 US20150376607 SEQ ID NO: 8 AAV-LK07 339US20150376607 SEQ ID NO: 35 AAV-LK08 340 US20150376607 SEQ ID NO: 9AAV-LK08 341 US20150376607 SEQ ID NO: 36 AAV-LK09 342 US20150376607 SEQID NO: 10 AAV-LK09 343 US20150376607 SEQ ID NO: 37 AAV-LK10 344US20150376607 SEQ ID NO: 11 AAV-LK10 345 US20150376607 SEQ ID NO: 38AAV-LK11 346 US20150376607 SEQ ID NO: 12 AAV-LK11 347 US20150376607 SEQID NO: 39 AAV-LK12 348 US20150376607 SEQ ID NO: 13 AAV-LK12 349US20150376607 SEQ ID NO: 40 AAV-LK13 350 US20150376607 SEQ ID NO: 14AAV-LK13 351 US20150376607 SEQ ID NO: 41 AAV-LK14 352 US20150376607 SEQID NO: 15 AAV-LK14 353 US20150376607 SEQ ID NO: 42 AAV-LK15 354US20150376607 SEQ ID NO: 16 AAV-LK15 355 US20150376607 SEQ ID NO: 43AAV-LK16 356 US20150376607 SEQ ID NO: 17 AAV-LK16 357 US20150376607 SEQID NO: 44 AAV-LKI7 358 US20150376607 SEQ ID NO: 18 AAV-LK17 359US20150376607 SEQ ID NO: 45 AAV-LK18 360 US20150376607 SEQ ID NO: 19AAV-LK18 361 US20150376607 SEQ ID NO: 46 AAV-LK19 362 US20150376607 SEQID NO: 20 AAV-LK19 363 US20150376607 SEQ ID NO: 47 AAV-PAEC 364US20150376607 SEQ ID NO: 1 AAV-PAEC 365 US20150376607 SEQ ID NO: 48AAV-PAEC11 366 US20150376607 SEQ ID NO: 26 AAV-PAEC11 367 US20150376607SEQ ID NO: 54 AAV-PAEC12 368 US20150376607 SEQ ID NO: 27 AAV-PAEC12 369US20150376607 SEQ ID NO: 51 AAV-PAEC13 370 US20150376607 SEQ ID NO: 28AAV-PAEC13 371 US20150376607 SEQ ID NO: 49 AAV-PAEC2 372 US20150376607SEQ ID NO: 21 AAV-PAEC2 373 US20150376607 SEQ ID NO: 56 AAV-PAEC4 374US20150376607 SEQ ID NO: 22 AAV-PAEC4 375 US20150376607 SEQ ID NO: 55AAV-PAEC6 376 US20150376607 SEQ ID NO: 23 AAV-PAEC6 377 US20150376607SEQ ID NO: 52 AAV-PAEC7 378 US20150376607 SEQ ID NO: 24 AAV-PAEC7 379US20150376607 SEQ ID NO: 53 AAV-PAEC8 380 US20150376607 SEQ ID NO: 25AAV-PAEC8 381 US20150376607 SEQ ID NO: 50 AAVpi.1 382 US20150315612 SEQID NO: 28 AAVpi.1 383 US20150315612 SEQ ID NO: 93 AAVpi.2 384US20150315612 SEQ ID NO: 30 AAVpi.2 385 US20150315612 SEQ ID NO: 95AAVpi.3 386 US20150315612 SEQ ID NO: 29 AAVpi.3 387 US20150315612 SEQ IDNO: 94 AAVrh.10 388 US20150159173 SEQ ID NO: 9 AAVrh.10 389US20150159173 SEQ ID NO: 25 AAV44.2 390 US20030138772 SEQ ID NO: 59AAVrh.10 391 US20030138772 SEQ ID NO: 81 (AAV44.2) AAV42.1B 392US20030138772 SEQ ID NO: 90 AAVrh.12 393 US20030138772 SEQ ID NO: 30(AAV42.1b) AAVrh.13 394 US20150159173 SEQ ID NO: 10 AAVrh.13 395US20150159173 SEQ ID NO: 26 AAVrh.13 396 US20150315612 SEQ ID NO: 228AAVrh.13R 397 US20150159173 AAV42.3A 398 US20030138772 SEQ ID NO: 87AAVrh.14 399 US20030138772 SEQ ID NO: 32 (AAV42.3a) AAV42.5A 400US20030138772 SEQ ID NO: 89 AAVrh.17 401 US20030138772 SEQ ID NO: 34(AAV42.5a) AAV42.5B 402 US20030138772 SEQ ID NO: 91 AAVrh.18 403US20030138772 SEQ ID NO: 29 (AAV42.5b) AAV42.6B 404 US20030138772 SEQ IDNO: 112 AAVrh.19 405 US20030138772 SEQ ID NO: 38 (AAV42.6b) AAVrh.2 406US20150159173 SEQ ID NO: 39 AAVrh.2 407 US20150315612 SEQ ID NO: 231AAVrh.20 408 US20150159173 SEQ ID NO: 1 AAV42.10 409 US20030138772 SEQID NO: 106 AAVrh.21 410 US20030138772 SEQ ID NO: 35 (AAV42.10) AAV42.11411 US20030138772 SEQ ID NO: 108 AAVrh.22 412 US20030138772 SEQ ID NO:37 (AAV42.11) AAV42.12 413 US20030138772 SEQ ID NO: 113 AAVrh.23 414US20030138772 SEQ ID NO: 58 (AAV42.12) AAV42.13 415 US20030138772 SEQ IDNO: 86 AAVrh..24 416 US20030138772 SEQ ID NO: 31 (AAV42.13) AAV42.15 417US20030138772 SEQ ID NO: 84 AAVrh.25 418 US20030138772 SEQ ID NO: 28(AAV42.15) AAVrh.2R 419 US20150159173 AAVrh.31 420 US20030138772 SEQ IDNO: 48 (AAV223.1) AAVC1 421 US20030138772 SEQ ID NO: 60 AAVrh.32 422US20030138772 SEQ ID NO: 19 (AAVC1) AAVrh.32/33 423 US20150159173 SEQ IDNO: 2 AAVrh.33 424 US20030138772 SEQ ID NO: 20 (AAVC3) AAVC5 425US20030138772 SEQ ID NO: 62 AAVrh.34 426 US20030138772 SEQ ID NO: 21(AAVC5) AAVF1 427 US20030138772 SEQ ID NO: 109 AAVrh.35 428US20030138772 SEQ ID NO: 22 (AAVF1) AAVF3 429 US20030138772 SEQ ID NO:111 AAVrh.36 430 US20030138772 SEQ ID NO: 23 (AAVF3) AAVrh.37 431US20030138772 SEQ ID NO: 24 AAVrh.37 432 US20150159173 SEQ ID NO: 40AAVrh.37 433 US20150315612 SEQ ID NO: 229 AAVrh.37R2 434 US20150159173AAVrh.38 435 US20150315612 SEQ ID NO: 7 (AAVLG-4) AAVrh.38 436US20150315612 SEQ ID NO: 86 (AAVLG-4) AAVrh.39 437 US20150159173 SEQ IDNO: 20, US20150315612 SEQ ID NO: 13 AAVrh.39 438 US20150159173 SEQ IDNO: 3, US20150159173 SEQ ID NO: 36, US20150315612 SEQ ID NO: 89 AAVrh.40439 US20150315612 SEQ ID NO: 92 AAVrh.40 440 US20150315612 SEQ ID No: 14(AAVLG-10) AAVrh.43 441 US20150315612 SEQ ID NO: 43, US20150159173 SEQID NO: 21 (AAVN721-8) AAVrh.43 442 US20150315612 SEQ ID NO: 163,US20150159173 SEQ ID NO: 37 (AAVN721-8) AAVrh.44 443 US20150315612 SEQID NO: 34 AAVrh.44 444 US20150315612 SEQ ID NO: 111 AAVrh.45 445US20150315612 SEQ ID NO: 41 AAVrh.45 446 US20150315612 SEQ ID NO: 109AAVrh.46 447 US20150159173 SEQ ID NO: 22, US20150315612SEQ ID NO: 19AAVrh.46 448 US20150159173 SEQ ID NO: 4, US20150315612 SEQ ID NO: 101AAVrh.47 449 US20150315612 SEQ ID NO: 38 AAVrh.47 450 US20150315612 SEQID NO: 118 AAVrh.48 451 US20150159173 SEQ ID NO: 44, US20150315612 SEQID NO: 115 AAVrh.48.1 452 US20150159173 AAVrh.48.1.2 453 US20150159173AAVrh.48.2 454 US20150159173 AAVrh.48 455 US20150315612 SEQ ID NO: 32(AAV1-7) AAVrh.49 456 US20150315612 SEQ ID NO: 25 (AAV1-8) AAVrh.49 457US20150315612 SEQ ID NO: 103 (AAV1-8) AAVrh.50 458 US20150315612 SEQ IDNO: 23 (AAV2-4) AAVrh.50 459 US20150315612 SEQ ID NO: 108 (AAV2-4)AAVrh.51 460 US20150315612 SEQ ID NO: 22 (AAV2-5) AAVrh.51 461US20150315612 SEQ ID NO: 104 (AAV2-5) AAVrh.52 462 US20150315612 SEQ IDNO: 18 (AAV3-9) AAVrh.52 463 US20150315612 SEQ ID NO: 96 (AAV3-9)AAVrh.53 464 US20150315612 SEQ ID NO: 97 AAVrh.53 465 US20150315612 SEQID NO: 17 (AAV3-11) AAVrh.53 466 US20150315612 SEQ ID NO: 186 (AAV3-11)AAVrh.54 467 US20150315612 SEQ ID NO: 40 AAVrh.54 468 US20150159173 SEQID NO: 49, US20150315612 SEQ ID NO: 116 AAVrh.55 469 US20150315612 SEQID NO: 37 AAVrh.55 470 US20150315612 SEQ ID NO: 117 (AAV4-19) AAVrh.56471 US20150315612 SEQ ID NO: 54 AAVrh.56 472 US20150315612 SEQ ID NO:152 AAVrh.57 473 US20150315612 SEQ ID NO: 26 AAVrh.57 474 US20150315612SEQ ID NO: 105 AAVrh.58 475 US20150315612 SEQ ID NO: 27 AAVrh.58 476US20150159173 SEQ ID NO: 48, US20150315612 SEQ ID NO: 106 AAVrh.58 477US20150315612 SEQ ID NO: 232 AAVrh.59 478 US20150315612 SEQ ID NO: 42AAVrh.59 479 US20150315612 SEQ ID NO: 110 AAVrh.60 480 US20150315612 SEQID NO: 31 AAVrh.60 481 US20150315612 SEQ ID NO: 120 AAVrh.61 482US20150315612 SEQ ID NO: 107 AAVrh.61 483 US20150315612 SEQ ID NO: 21(AAV2-3) AAVrh.62 484 US20150315612 SEQ ID NO: 33 (AAV2-15) AAVrh.62 485US20150315612 SEQ ID NO: 114 (AAV2-15) AAVrh.64 486 US20150315612 SEQ IDNo: 15 AAVrh.64 487 US20150159173 SEQ ID NO: 43, US20150315612 SEQ IDNO: 99 AAVrh.64 488 US20150315612 SEQ ID NO: 233 AAVRh.64R1 489US20150159173 AAVRh.64R2 490 US20150159173 AAVrh.65 491 US20150315612SEQ ID NO: 35 AAVrh.65 492 US20150315612 SEQ ID NO: 112 AAVrh.67 493US20150315612 SEQ ID NO: 36 AAVrh.67 494 US20150315612 SEQ ID NO: 230AAVrh.67 495 US20150159173 SEQ ID NO: 47, US20150315612 SEQ ID NO: 113AAVrh.68 496 US20150315612 SEQ ID NO: 16 AAVrh.68 497 US20150315612 SEQID NO: 100 AAVrh.69 498 US20150315612 SEQ ID NO: 39 AAVrh.69 499US20150315612 SEQ ID NO: 119 AAVrh.70 500 US20150315612 SEQ ID NO: 20AAVrh.70 501 US20150315612 SEQ ID NO: 98 AAVrh.71 502 US20150315612 SEQID NO: 162 AAVrh.72 503 US20150315612 SEQ ID NO: 9 AAVrh.73 504US20150159173 SEQ ID NO: 5 AAVrh.74 505 US20150159173 SEQ ID NO: 6AAVrh.8 506 US20150159173 SEQ ID NO: 41 AAVrh.8 507 US20150315612 SEQ IDNO: 235 AAVrh.8R 508 US20150159173, WO2015168666 SEQ ID NO: 9 AAVrh.8R509 WO2015168666 SEQ ID NO: 10 A586R mutant AAVrh.8R 510 WO2015168666SEQ ID NO: 11 R533A mutant BAAV 511 US9193769 SEQ ID NO: 8 (bovine AAV)BAAV 512 US9193769 SEQ ID NO: 10 (bovine AAV) BAAV 513 US9193769 SEQ IDNO: 4 (bovine AAV) BAAV 514 US9193769 SEQ ID NO: 2 (bovine AAV) BAAV 515US9193769 SEQ ID NO: 6 (bovine AAV) BAAV 516 US9193769 SEQ ID NO: 1(bovine AAV) BAAV 517 US9193769 SEQ ID NO: 5 (bovine AAV) BAAV 518US9193769 SEQ ID NO: 3 (bovine AAV) BAAV 519 US9193769 SEQ ID NO: 11(bovine AAV) BAAV 520 US7427396 SEQ ID NO: 5 (bovine AAV) BAAV 521US7427396 SEC ID NO: 6 (bovine AAV) BAAV 522 US9193769 SEQ ID NO: 7(bovine AAV) BAAV 523 US9193769 SEQ ID NO: 9 (bovine AAV) BNP61 AAV 524US20150238550 SEQ ID NO: 1 BNP61 AAV 525 US20150238550 SEQ ID NO: 2BNP62 AAV 526 US20150238550 SEQ ID NO: 3 BNP63 AAV 527 US20150238550 SEQID NO: 4 caprine AAV 528 US7427396 SEQ ID NO: 3 caprine AAV 529US7427396 SEQ ID NO: 4 true type 530 WO2015121501 SEQ ID NO: 2 AAV(ttAAV) AAAV 531 US9238800 SEQ ID NO: 12 (Avian AAV) AAAV 532 US9238800SEQ ID NO: 2 (Avian AAV) AAAV 533 US9238800 SEQ ID NO: 6 (Avian AAV)AAAV 534 US9238800 SEQ ID NO: 4 (Avian AAV) AAAV 535 US9238800 SEQ IDNO: 8 (Avian AAV) AAAV 536 US9238800 SEQ ID NO: 14 (Avian AAV) AAAV 537US9238800 SEQ ID NO: 10 (Avian AAV) AAAV 538 US9238800 SEQ ID NO: 15(Avian AAV) AAAV 539 US9238800 SEQ ID NO: 5 (Avian AAV) AAAV 540US9238800 SEQ ID NO: 9 (Avian AAV) AAAV 541 US9238800 SEQ ID NO: 3(Avian AAV) AAAV 542 US9238800 SEQ ID NO: 7 (Avian AAV) AAAV 543US9238800 SEQ ID NO: 11 (Avian AAV) AAAV 544 US9238800 SEQ ID NO: 13(Avian AAV) AAAV 545 US9238800 SEQ ID NO: 1 (Avian AAV) AAV Shuffle 546US20160017295 SEQ ID NO: 23 100-1 AAV Shuffle 547 US20160017295 SEQ IDNO: 11 100-1 AAV Shuffle 548 US20160017295 SEQ ID NO: 37 100-2 AAVShuffle 549 US20160017295 SEQ ID NO: 29 100-2 AAV Shuffle 550US20160017295 SEQ ID NO: 24 100-3 AAV Shuffle 551 US20160017295 SEQ IDNO: 12 100-3 AAV Shuffle 552 US20160017295 SEQ ID NO: 25 100-7 AAVShuffle 553 US20160017295 SEQ ID NO: 13 100-7 AAV Shuffle 554US20160017295 SEQ ID NO: 34 10-2 AAV Shuffle 555 US20160017295 SEQ IDNO: 26 10-2 AAV Shuffle 556 US20160017295 SEQ ID NO: 35 10-6 AAV Shuffle557 US20160017295 SEQ ID NO: 27 10-6 AAV Shuffle 558 US20160017295 SEQID NO: 36 10-8 AAV Shuffle 559 US20160017295 SEQ ID NO: 28 10-8 AAV SM560 US20160017295 SEQ ID NO: 41 100-10 AAV SM 561 US20160017295 SEQ IDNO: 33 100-10 AAV SM 562 US20160017295 SEQ ID NO: 40 100-3 AAV SM 563US20160017295 SEQ ID NO: 32 100-3 AAV SM 10-1 564 US20160017295 SEQ IDNO: 38 AAV SM 10-1 565 US20160017295 SEQ ID NO: 30 AAV SM 10-2 566US20160017295 SEQ ID NO: 10 AAV SM 10-2 567 US20160017295 SEQ ID NO: 22AAV SM 10-8 568 US20160017295 SEQ ID NO: 39 AAV SM 10-8 569US20160017295 SEQ ID NO: 31 AAVF1/HSC1 570 WO2016049230 SEQ ID NO: 20AAVF2/HSC2 571 WO2016049230 SEQ ID NO: 21 AAVF3/HSC3 572 WO2016019230SEQ ID NO: 22 AAVF4/HSC4 573 WO2016049230 SEQ ID NO: 23 AAVF5/HSC5 574WO2016049230 SEQ ID NO: 25 AAVF6/HSC6 575 WO2016049230 SEQ ID NO: 24AAVF7/HSC7 576 WO2016049130 SEQ ID NO: 27 AAVF8/HSC8 577 WO2016049230SEQ ID NO: 28 AAVF9/HSC9 578 WO2016049130 SEQ ID NO: 29 AAVF11/HSC11 579WO2016049230 SEQ ID NO: 26 AAVF12/HSC12 580 WO2016049230 SEQ ID NO: 30AAVF13/HSC13 581 WO2016049230 SEQ ID NO: 31 AAVF14/HSC14 582WO2016049230 SEQ ID NO: 32 AAVF15/HSC15 583 WO2016049230 SEQ ID NO: 33AAVF16/HSC16 584 WO2016049230 SEQ ID NO: 34 AAVF17/HSC17 585WO2016049230 SEQ ID NO: 35 AAVF1/HSC1 586 WO2016049230 SEQ ID NO: 2AAVF2/HSC2 587 WO2016049230 SEQ ID NO: 3 AAVF3/HSC3 588 WO2016049230 SEQID NO: 5 AAVF4/HSC4 589 WO2016049230 SEQ ID NO: 6 AAVF5/HSC5 590WO2016049230 SEQ ID NO: 11 AAVF6/HSC6 591 WO2016049230 SEQ ID NO: 7AAVF7/HSC7 592 WO2016049230 SEQ ID NO: 8 AAVF8/HSC8 593 WO2016049230 SEQID NO: 9 AAVF9/HSC9 594 WO2016049230 SEQ ID NO: 10 AAVF11/HSC11 595WO2016049230 SEQ ID NO: 4 AAVF12/HSC12 596 WO2016049230 SEQ ID NO: 12AAVF13/HSC13 597 WO2016049230 SEQ ID NO: 14 AAVF14/HSC14 598WO2016049230 SEQ ID NO: 15 AAVF15/HSC15 599 WO2016049230 SEQ ID NO: 16AAVF16/HSC16 600 WO2016049230 SEQ ID NO: 17 AAVF17/HSC17 601WO2016049230 SEQ ID NO: 13 AAV CBr-E1 602 US8734809 SEQ ID NO: 13 AAVCBr-E2 603 US8734809 SEQ ID NO: 14 AAV CBr-E3 604 US8734809 SEQ ID NO:15 AAV CBr-E4 605 US8734809 SEQ ID NO: 16 AAV CBr-E5 606 US8734809 SEQID NO: 17 AAV CBr-e5 607 US8734809 SEQ ID NO: 18 AAV CBr-E6 608US8734809 SEQ ID NO: 19 AAV CBr-E7 609 US8734809 SEQ ID NO: 20 AAVCBr-E8 610 US8734809 SEQ ID NO: 21 AAV CLv-D1 611 US8734809 SEQ ID NO:22 AAV CLv-D2 612 US8734809 SEQ ID NO: 23 AAV CLv-D3 613 US8734809 SEQID NO: 24 AAV CLv-D4 614 US8734809 SEQ ID NO: 25 AAV CLv-D5 615US8734809 SEQ ID NO: 26 AAV CLv-D6 616 US8734809 SEQ ID NO: 27 AAVCLv-D7 617 US8734809 SEQ ID NO: 28 AAV CLv-D8 618 US8734809 SEQ ID NO:29 AAV CLv-E1 619 US8734809 SEQ ID NO: 13 AAV CLv-R1 620 US8734809 SEQID NO: 30 AAV CLv-R2 621 US8734809 SEQ ID NO: 31 AAV CLv-R3 622US8734809 SEQ ID NO: 32 AAV CLv-R4 623 US8734809 SEQ ID NO: 33 AAVCLv-R5 624 US8734809 SEQ ID NO: 34 AAV CLv-R6 625 US8734809 SEQ ID NO:35 AAV CLv-R7 626 US8734809 SEQ ID NO: 36 AAV CLv-R8 627 US8734809 SEQID NO: 37 AAV CLv-R9 628 US8734809 SEQ ID NO: 38 AAV CLg-F1 629US8734809 SEQ ID NO: 39 AAV CLg-F2 630 US8734809 SEQ ID NO: 40 AAVCLg-F3 631 US8734809 SEQ ID NO: 41 AAV CLg-F4 632 US8734809 SEQ ID NO:42 AAV CLg-F5 633 US8734809 SEQ ID NO: 43 AAV CLg-F6 634 US8734809 SEQID NO: 43 AAV CLg-F7 635 US8734809 SEQ ID NO: 44 AAV CLg-F8 636US8734809 SEQ ID NO: 43 AAV CSp-1 637 US8734809 SEQ ID NO: 45 AAV CSp-10638 US8734809 SEQ ID NO: 46 AAV CSp-11 639 US8734809 SEQ ID NO: 47 AAVCSp-2 640 US8734809 SEQ ID NO: 48 AAV CSp-3 641 US8734809 SEQ ID NO: 49AAV CSp-4 642 US8734809 SEQ ID NO: 50 AAV CSp-6 643 US8734809 SEQ ID NO:51 AAV CSp-7 644 US8734809 SEQ ID NO: 52 AAV CSp-8 645 US8734809 SEQ IDNO: 53 AAV CSp-9 646 US8734809 SEQ ID NO: 54 AAV CHt-2 647 US8734809 SEQID NO: 55 AAV CHt-3 648 US8734809 SEQ ID NO: 56 AAV CKd-1 649 US8734809SEQ ID NO: 57 AAV CKd-10 650 US8734809 SEQ ID NO: 58 AAV CKd-2 651US8734809 SEQ ID NO: 59 AAV CKd-3 652 US8734809 SEQ ID NO: 60 AAV CKd-4653 US8734809 SEQ ID NO: 61 AAV CKd-6 654 US8734809 SEQ ID NO: 62 AAVCKd-7 655 US8734809 SEQ ID NO: 63 AAV CKd-8 656 US8734809 SEQ ID NO: 64AAV CLv-1 657 US8734809 SEQ ID NO: 65 AAV CLv-12 658 US8734809 SEQ IDNO: 66 AAV CLv-13 659 US8734809 SEQ ID NO: 67 AAV CLv-2 660 US8734809SEQ ID NO: 68 AAV CLv-3 661 US8734809 SEQ ID NO: 69 AAV CLv-4 662US8734809 SEQ ID NO: 70 AAV CLv-6 663 US8734809 SEQ ID NO: 71 AAV CLv-8664 US8734809 SEQ ID NO: 72 AAV CKd-B1 665 US8734809 SEQ ID NO: 73 AAVCKd-B2 666 US8734809 SEQ ID NO: 74 AAV CKd-B3 667 US8734809 SEQ ID NO:75 AAV CKd-B4 668 US8734809 SEQ ID NO: 76 AAV CKd-B5 669 US8734809 SEQID NO: 77 AAV CKd-B6 670 US8734809 SEQ ID NO: 78 AAV CKd-B7 671US8734809 SEQ ID NO: 79 AAV CKd-B8 672 US8734809 SEQ ID NO: 80 AAVCKd-H1 673 US8734809 SEQ ID NO: 81 AAV CKd-H2 674 US8734809 SEQ ID NO:82 AAV CKd-H3 675 US8734809 SEQ ID NO: 83 AAV CKd-H4 676 US8734809 SEQID NO: 84 AAV CKd-H5 677 US8734809 SEQ ID NO: 85 AAV CKd-H6 678US8734809 SEQ ID NO: 77 AAV CHt-1 679 US8734809 SEQ ID NO: 86 AAV CLv1-1680 US8734809 SEQ ID NO: 171 AAV CLv1-2 681 US8734809 SEQ ID NO: 172 AAVCLv1-3 682 US8734809 SEQ ID NO: 173 AAV CLv1-4 683 US8734809 SEQ ID NO:174 AAV Clv1-7 684 US8734809 SEQ ID NO: 175 AAV Clv1-8 685 US8734809 SEQID NO: 176 AAV Clv1-9 686 US8734809 SEQ ID NO: 177 AAV Clv1-10 687US8734809 SEQ ID NO: 178 AAV.VR-355 688 US8734809 SEQ ID NO: 181AAV.hu.48R3 689 US8734809 SEQ ID NO: 183 AAV CBr-E1 690 US8734809 SEQ IDNO: 87 AAV CBr-E2 691 US8734809 SEQ ID NO: 88 AAV CBr-E3 692 US8734809SEQ ID NO: 89 AAV CBr-E4 693 US8734809 SEQ ID NO: 90 AAV CBr-E5 694US8734809 SEQ ID NO: 91 AAV CBr-e5 695 US8734809 SEQ ID NO: 92 AAVCBr-E6 696 US8734809 SEQ ID NO: 93 AAV CBr-E7 697 US8734809 SEQ ID NO:94 AAV CBr-E8 698 US8734809 SEQ ID NO: 95 AAV CLv-D1 699 US8734809 SEQID NO: 96 AAV CLv-D2 700 US8734809 SEQ ID NO: 97 AAV CLv-D3 701US8734809 SEQ ID NO: 98 AAV CLv-D4 702 US8734809 SEQ ID NO: 99 AAVCLv-D5 703 US8734809 SEQ ID NO: 100 AAV CLv-D6 704 US8734809 SEQ ID NO:101 AAV CLv-D7 705 US8734809 SEQ ID NO: 102 AAV CLv-D8 706 US8734809 SEQID NO: 103 AAV CLv-E1 707 US8734809 SEQ ID NO: 87 AAV CLv-R1 708US8734809 SEQ ID NO: 104 AAV CLv-R2 709 US8734809 SEQ ID NO: 105 AAVCLv-R3 710 US8734809 SEQ ID NO: 106 AAV CLv-R4 711 US8734809 SEQ ID NO:107 AAV CLv-R5 712 US8734809 SEQ ID NO: 108 AAV CLv-R6 713 US8734809 SEQID NO: 109 AAV CLv-R7 714 US8734809 SEQ ID NO: 110 AAV CLv-R8 715US8734809 SEQ ID NO: 111 AAV CLv-R9 716 US8734809 SEQ ID NO: 112 AAVCLg-F1 717 US8734809 SEQ ID NO: 113 AAV CLg-F2 718 US8734809 SEQ ID NO:114 AAV CLg-F3 719 US8734809 SEQ ID NO: 115 AAV CLg-F4 720 US8734809 SEQID NO: 116 AAV CLg-F5 721 US8734809 SEQ ID NO: 117 AAV CLg-F6 722US8734809 SEQ ID NO: 117 AAV CLg-F7 723 US8734809 SEQ ID NO: 118 AAVCLg-F8 724 US8734809 SEQ ID NO: 117 AAV CSp-1 725 US8734809 SEQ ID NO:119 AAV CSp-10 726 US8734809 SEQ ID NO: 120 AAV CSp-11 727 US8734809 SEQID NO: 121 AAV CSp-2 728 US8734809 SEQ ID NO: 122 AAV CSp-3 729US8734809 SEQ ID NO: 123 AAV CSp-4 730 US8734809 SEQ ID NO: 124 AAVCSp-6 731 US8734809 SEQ ID NO: 125 AAV CSp-7 732 US8734809 SEQ ID NO:126 AAV CSp-8 733 US8734809 SEQ ID NO: 127 AAV CSp-9 734 US8734809 SEQID NO: 128 AAV CHt-2 735 US8734809 SEQ ID NO: 129 AAV CHt-3 736US8734809 SEQ ID NO: 130 AAV CKd-1 737 US8734809 SEQ ID NO: 131 AAVCKd-10 738 US8734809 SEQ ID NO: 132 AAV CKd-2 739 US8734809 SEQ ID NO:133 AAV CKd-3 740 US8734809 SEQ ID NO: 134 AAV CKd-4 741 US8734809 SEQID NO: 135 AAV CKd-6 742 US8734809 SEQ ID NO: 136 AAV CKd-7 743US8734809 SEQ ID NO: 137 AAV CKd-8 744 US8734809 SEQ ID NO: 138 AAVCLv-1 745 US8734809 SEQ ID NO: 139 AAV CLv-12 746 US8734809 SEQ ID NO:140 AAV CLv-13 747 US8734809 SEQ ID NO: 141 AAV CLv-2 748 US8734809 SEQID NO: 142 AAV CLv-3 749 US8734809 SEQ ID NO: 143 AAV CLv-4 750US8734809 SEQ ID NO: 144 AAV CLv-6 751 US8734809 SEQ ID NO: 145 AAVCLv-8 752 US8734809 SEQ ID NO: 146 AAV CKd-B1 753 US8734809 SEQ ID NO:147 AAV CKd-B2 754 US8734809 SEQ ID NO: 148 AAV CKd-B3 755 US8734809 SEQID NO: 149 AAV CKd-B4 756 US8734809 SEQ ID NO: 150 AAV CKd-B5 757US8734809 SEQ ID NO: 151 AAV CKd-B6 758 US8734809 SEQ ID NO: 152 AAVCKd-B7 759 US8734809 SEQ ID NO: 153 AAV CKd-B8 760 US8734809 SEQ ID NO:154 AAV CKd-H1 761 US8734809 SEQ ID NO: 155 AAV CKd-H2 762 US8734809 SEQID NO: 156 AAV CKd-H3 763 US8734809 SEQ ID NO: 157 AAV CKd-H4 764US8734809 SEQ ID NO: 158 AAV CKd-H5 765 US8734809 SEQ ID NO: 159 AAVCKd-H6 766 US8734809 SEQ ID NO: 151 AAV CHt-1 767 US8734809 SEQ ID NO:160 AAV CHt-P2 768 WO2016065001 SEQ ID NO: 1 AAV CHt-P5 769 WO2016065001SEQ ID NO: 2 AAV CHt-P9 770 WO2016065001 SEQ ID NO: 3 AAV CBr-7.1 771WO2016065001 SEQ ID NO: 4 AAV CBr-7.2 772 WO2016065001 SEQ ID NO: 5 AAVCBr-7.3 773 WO2016065001 SEQ ID NO: 6 AAV CBr-7.4 774 WO2016065001 SEQID NO: 7 AAV CBr-7.5 775 WO2016065001 SEQ ID NO: 8 AAV CBr-7.7 776WO2016065001 SEQ ID NO: 9 AAV CBr-7.8 777 WO2016065001 SEQ ID NO: 10 AAVCBr-7.10 778 WO2016065001 SEQ ID NO: 11 AAV CKd-N3 779 WO2016065001 SEQID NO: 12 AAV CKd-N4 780 WO2016065001 SEQ ID NO: 13 AAV CKd-N9 781WO2016065001 SEQ ID NO: 14 AAV CLv-L4 782 WO2016065001 SEQ ID NO: 15 AAVCLv-L5 783 WO2016065001 SEQ ID NO: 16 AAV CLv-L6 784 WO2016065001 SEQ IDNO: 17 AAV CLv-K1 785 WO2016065001 SEQ ID NO: 18 AAV CLv-K3 786WO2016065001 SEQ ID NO: 19 AAV CLv-K6 787 WO2016065001 SEQ ID NO: 20 AAVCLv-M1 788 WO2016065001 SEQ ID NO: 21 AAV CLv-M11 789 WO2016065001 SEQID NO: 22 AAV CLv-M2 790 WO2016065001 SEQ ID NO: 23 AAV CLv-M5 791WO2016065001 SEQ ID NO: 24 AAV CLv-M6 792 WO2016065001 SEQ ID NO: 25 AAVCLv-M7 793 WO2016065001 SEQ ID NO: 26 AAV CLv-M8 794 WO2016065001 SEQ IDNO: 27 AAV CLv-M9 795 WO2016065001 SEQ ID NO: 28 AAV CHt-P1 796WO2016065001 SEQ ID NO: 29 AAV CHt-P6 797 WO2016065001 SEQ ID NO: 30 AAVCHt-P8 798 WO2016065001 SEQ ID NO: 31 AAV CHt-6.1 799 WO2016065001 SEQID NO: 32 AAV CHt-6.10 800 WO2016065001 SEQ ID NO: 33 AAV CHt-6.5 801WO2016065001 SEQ ID NO: 34 AAV CHt-6.6 802 WO2016065001 SEQ ID NO: 35AAV CHt-6.7 803 WO2016065001 SEQ ID NO: 36 AAV CHt-6.8 804 WO2016065001SEQ ID NO: 37 AAV CSp-8.10 805 WO2016065001 SEQ ID NO: 38 AAV CSp-8.2806 WO2016065001 SEQ ID NO: 39 AAV CSp-8.4 807 WO2016065001 SEQ ID NO:40 AAV CSp-8.5 808 WO2016065001 SEQ ID NO: 41 AAV CSp-8.6 809WO2016065001 SEQ ID NO: 42 AAV CSp-8.7 810 WO2016065001 SEQ ID NO: 43AAV CSp-8.8 811 WO2016065001 SEQ ID NO: 44 AAV CSp-8.9 812 WO2016065001SEQ ID NO: 45 AAV CBr-B7.3 813 WO2016065001 SEQ ID NO: 46 AAV CBr-B7.4814 WO2016065001 SEQ ID NO: 47 AAV3B 815 WO2016065001 SEQ ID NO: 48 AAV4816 WO2016065001 SEQ ID NO: 49 AAV5 817 WO2016065001 SEQ ID NO: 50 AAVCHt-P2 818 WO2016065001 SEQ ID NO: 51 AAV CHt-P5 819 WO2016065001 SEQ IDNO: 52 AAV CHt-P9 820 WO2016065001 SEQ ID NO: 53 AAV CBr-7.1 821WO2016065001 SEQ ID NO: 54 AAV CBr-7.2 822 WO2016065001 SEQ ID NO: 55AAV CBr-7.3 823 WO2016065001 SEQ ID NO: 56 AAV CBr-7.4 824 WO2016065001SEQ ID NO: 57 AAV CBr-7.5 825 WO2016065001 SEQ ID NO: 58 AAV CBr-7.7 826WO2016065001 SEQ ID NO: 59 AAV CBr-7.8 827 WO2016065001 SEQ ID NO: 60AAV CBr-7.10 828 WO2016065001 SEQ ID NO: 61 AAV CKd-N3 829 WO2016065001SEQ ID NO: 62 AAV CKd-N4 830 WO2016065001 SEQ ID NO: 63 AAV CKd-N9 831WO2016065001 SEQ ID NO: 64 AAV CLv-L4 832 WO2016065001 SEQ ID NO: 65 AAVCLv-L5 833 WO2016065001 SEQ ID NO: 66 AAV CLv-L6 834 WO2016065001 SEQ IDNO: 67 AAV CLv-K1 835 WO2016065001 SEQ ID NO: 68 AAV CLv-K3 836WO2016065001 SEQ ID NO: 69 AAV CLv-K6 837 WO2016065001 SEQ ID NO: 70 AAVCLv-M1 838 WO2016065001 SEQ ID NO: 71 AAV CLv-M11 839 WO2016065001 SEQID NO: 72 AAV CLv-M2 840 WO2016065001 SEQ ID NO: 73 AAV CLv-M5 841WO2016065001 SEQ ID NO: 74 AAV CLv-M6 842 WO2016065001 SEQ ID NO: 75 AAVCLv-M7 843 WO2016065001 SEQ ID NO: 76 AAV CLv-M8 844 WO2016065001 SEQ IDNO: 77 AAV CLv-M9 845 WO2016065001 SEQ ID NO: 78 AAV CHt-P1 846WO2016065001 SEQ ID NO: 79 AAV CHt-P6 847 WO2016065001 SEQ ID NO: 80 AAVCHt-P8 848 WO2016065001 SEQ ID NO: 81 AAV CHt-6.1 849 WO2016065001 SEQID NO: 82 AAV CHt-6.10 850 WO2016065001 SEQ ID NO: 83 AAV CHt-6.5 851WO2016065001 SEQ ID NO: 84 AAV CHt-6.6 852 WO2016065001 SEQ ID NO: 85AAV CHt-6.7 853 WO2016065001 SEQ ID NO: 86 AAV CHt-6.8 854 WO2016065001SEQ ID NO: 87 AAV CSp-8.10 855 WO2016065001 SEQ ID NO: 88 AAV CSp-8.2856 WO2016065001 SEQ ID NO: 89 AAV CSp-8.4 857 WO2016065001 SEQ ID NO:90 AAV CSp-8.5 858 WO2016065001 SEQ ID NO: 91 AAV CSp-8.6 859WO2016065001 SEQ ID NO: 92 AAV CSp-8.7 860 WO2016065001 SEQ ID NO: 93AAV CSp-8.8 861 WO2016065001 SEQ ID NO: 94 AAV CSp-8.9 862 WO2016065001SEQ ID NO: 95 AAV CBr-B7.3 863 WO2016065001 SEQ ID NO: 96 AAV CBr-B7.4864 WO2016065001 SEQ ID NO: 97 AAV3B 865 WO2016065001 SEQ ID NO: 98 AAV4866 WO2016065001 SEQ ID NO: 99 AAV5 867 WO2016065001 SEQ ID NO: 100AAVPHP.B 868 WO2015038958 SEQ ID NO: 8 and 13; GenBankALU85156.1 orG2B-26 AAVPHP.B 869 WO2015038958 SEQ ID NO: 9 AAVG2B-13 870 WO2015038958SEQ ID NO: 12 AAVTH1.1-32 871 WO2015038958 SEQ ID NO: 14 AAVTH1.1-35 872WO2015038958 SEQ ID NO: 15

Each of the patents, applications and/or publications listed in Table 1are hereby incorporated by reference in their entirety.

In one embodiment, the AAV serotype may be, or may have a sequence asdescribed in International Patent Publication WO2015038958, the contentsof which are herein incorporated by reference in their entirety, suchas, but not limited to, AAV9 (SEQ ID NO: 2 and 11 of WO2015038958 or SEQID NO: 127 and 126 respectively herein), PHP.B (SEQ ID NO: 8 and 9 ofWO2015038958, herein SEQ ID NO: 868 and 869), G2B-13 (SEQ ID NO: 12 ofWO2015038958, herein SEQ ID NO: 870), G2B-26 (SEQ ID NO: 13 ofWO2015038958, herein SEQ ID NO: 868 and 869), TH1.1-32 (SEQ ID NO: 14 ofWO2015038958, herein SEQ ID NO: 871), TH1.1-35 (SEQ ID NO: 15 ofWO2015038958, herein SEQ ID NO: 872) or variants thereof. Further, anyof the targeting peptides or amino acid inserts described inWO2015038958, may be inserted into any parent AAV serotype, such as, butnot limited to, AAV9 (SEQ ID NO: 126 for the DNA sequence and SEQ ID NO:127 for the amino acid sequence). In one embodiment, the amino acidinsert is inserted between amino acids 586-592 of the parent AAV (e.g.,AAV9). In another embodiment, the amino acid insert is inserted betweenamino acids 588-589 of the parent AAV sequence. The amino acid insertmay be, but is not limited to, any of the following amino acidsequences, TLAVPFK (SEQ ID NO: 1 of WO2015038958; herein SEQ ID NO:873), KFPVALT (SEQ ID NO: 3 of WO2015038958, herein SEQ ID NO: 874),LAVPFK (SEQ ID NO: 31 of WO2015038958; herein SEQ ID NO: 875), AVPFK(SEQ ID NO: 32 of WO2015038958; herein SEQ ID NO: 876), VPFK (SEQ ID NO:33 of WO02015038958; herein SEQ ID NO: 877), TLAVPF (SEQ ID NO: 34 ofWO2015038958; herein SEQ ID NO: 878), TLAVP (SEQ ID NO: 35 ofWO2015038958; herein SEQ ID NO: 879), TLAV (SEQ ID NO: 36 ofWO2015038958; herein SEQ ID NO: 880), SVSKPFL (SEQ ID NO: 28 ofWO2015038958; herein SEQ ID NO: 881), FTLTTPK (SEQ ID NO: 29 ofWO2015038958; herein SEQ ID NO: 882), MNATKNV (SEQ ID NO: 30 ofWO2015038958; herein SEQ ID NO: 883), QSSQTPR (SEQ ID NO: 54 ofWO2015038958; herein SEQ ID NO: 884), ILGTGTS (SEQ ID NO: 55 ofWO2015038958; herein SEQ ID NO: 885), TRTNPEA (SEQ ID NO: 56 ofWO2015038958; herein SEQ ID NO: 886), NGGTSSS (SEQ ID NO:58 ofWO2015038958; herein SEQ ID NO:887), or YTLSQGW (SEQ ID NO: 60 ofWO2015038958; herein SEQ ID NO: 888). Non-limiting examples ofnucleotide sequences that may encode the amino acid inserts include thefollowing, AAGTITCCTGTGGKCGTTGACT (for SEQ ID NO: 3 of WO2015038958;herein SEQ ID NO: 889), ACYTTGGCGGTGCCTITYAAG (SEQ ID NO: 24 and 49 ofWO2015038958; herein SEQ ID NO: 890), AGTGTGAGTAAGCCITIITG (SEQ ID NO:25 of WO2015038958; herein SEQ ID NO. 891), TTACGTTGACGACGCCTAAG (SEQ IDNO: 26 of WO2015038958; herein SEQ ID NO:892), ATGAATGCTACGAAGAATGTG(SEQ ID NO: 27 of WO2015038958; herein SEQ ID NO: 893),CAGTCGTCGCAGACGCCTAGG (SEQ ID NO: 48 of WO2015038958; herein SEQ ID NO:894), ATTCTGGGGACTCGGTACTTCG (SEQ ID NO: 50) and 52 of WO2015038958;herein SEQ ID NO: 895), ACGCGGACTAATCCTGAGGCT (SEQ ID NO-51 ofWO2015038958; herein SEQ ID NO:896), AATGCiGGGGACTAGTAGTTCT (SEQ ID NO:53 of WO2015038958; herein SEQ ID NO: 897), or TATACTTTGTCGCAGGGTTGG(SEQ ID NO: 59 of WO2015038958, herein SEQ ID NO: 898).

Viral Genome Component: Inverted Terminal Repeats (ITRs)

The AAV particles of the present invention comprise a viral genome withat least one ITR region and a payload region. In one embodiment, theviral genome has two ITRs. These two ITRs flank the payload region atthe 5′ and 3′ ends. The ITRs function as origins of replicationcomprising recognition sites for replication. ITRs comprise sequenceregions which can be complementary and symmetrically arranged. ITRsincorporated into viral genomes of the invention may be comprised ofnaturally occurring polynucleotide sequences or recombinantly derivedpolynucleotide sequences.

The ITRs may be derived from the same serotype as the capsid, selectedfrom any of the serotypes listed in Table 1, or a derivative thereof.The ITR may be of a different serotype than the capsid. In oneembodiment, the AAV particle has more than one ITR, In a non-limitingexample, the AAV particle has a viral genome comprising two ITRs. In oneembodiment, the ITRs are of the same serotype as one another. In anotherembodiment, the ITRs are of different serotypes. Non-limiting examplesinclude zero, one or both of the ITRs having the same serotype as thecapsid. In one embodiment both ITRs of the viral genome of the AAVparticle are AAV2 ITRs.

Independently, each ITR may be about 100 to about 150 nucleotides inlength. An ITR may be about 100-105 nucleotides in length, 106-110nucleotides in length, 111-115 nucleotides in length, 116-120nucleotides in length, 121-125 nucleotides in length, 126-130nucleotides in length, 131-135 nucleotides in length, 136-140nucleotides in length, 141-145 nucleotides in length or 146-150nucleotides in length. In one embodiment, the ITRs are 140-142nucleotides in length. Non-limiting examples of ITR length are 102, 140,141, 142, 145 nucleotides in length, and those having at least 95%identity thereto

Viral Genome Component: Promoters

In one embodiment, the payload region of the viral genome comprises atleast one element to enhance the transgene target specificity andexpression (See e.g., Powell et al. Viral Expression Cassette Elementsto Enhance Transgene Target Specificity and Expression in Gene Therapy,2015; the contents of which are herein incorporated by reference in itsentirety). Non-limiting examples of elements to enhance the transgenetarget specificity and expression include promoters, endogenous miRNAs,post-transcriptional regulatory elements (PREs, polyadenylation (PolyA)signal sequences and upstream enhancers (USEs), CMV enhancers andintrons.

A person skilled in the art may recognize that expression of thepolypeptides of the invention in a target cell may require a specificpromoter, including but not limited to, a promoter that is speciesspecific, inducible, tissue-specific, or cell cycle-specific (Parr etal., Nat. Med. 3:1145-9 (1997) the contents of which are hereinincorporated by reference in their entirety).

In one embodiment, the promoter is deemed to be efficient when it drivesexpression of the polypeptide(s) encoded in the payload region of theviral genome of the AAV particle.

In one embodiment, the promoter is a promoter deemed to be efficientwhen it drives expression in the cell being targeted.

In one embodiment, the promoter drives expression of the polypeptides ofthe invention (e.g., a functional antibody) for a period of time intargeted tissues. Expression driven by a promoter may be for a period of1 hour, 2, hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours,9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 8 days, 9days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 15 days, 16 days, 17days, 18 days, 19 days, 20 days, 3 weeks, 22 days, 23 days, 24 days, 25days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 1 month, 2months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months,16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22months, 23 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years,8 years, 9 years, 10 years or more than 10 years. Expression may be for1-5 hours, 1-12 hours, 1-2 days, 1-5 days, 1-2 weeks, 1-3 weeks, 1-4weeks, 1-2 months, 1-4 months, 1-6 months, 2-6 months, 3-6 months, 3-9months, 4-8 months, 6-12 months, 1-2 years, 1-5 years, 2-5 years, 3-6years, 3-8 years, 4-8 years or 5-10 years.

In one embodiment, the promoter drives expression of the polypeptides ofthe invention (e.g., a functional antibody) for at least 1 month, 2months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9months, 10 months, 11 months, 1 year, 2 years, 3 years 4 years, 5 years,6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20years, 21 years, 22 years, 23 years, 24 years, 25 years, 26 years, 27years, 28 years, 29 years, 30 years, 31 years, 32 years, 33 years, 34years, 35 years, 36 years, 37 years, 38 years, 39 years, 40 years, 41years, 42 years, 43 years, 44 years, 45 years, 46 years, 47 years, 48years, 49 years, 50 years, 55 years, 60 years, 65 years, or more than 65years.

Promoters may be naturally occurring or non-naturally occurring.Non-limiting examples of promoters include viral promoters, plantpromoters and mammalian promoters. In some embodiments, the promotersmay be human promoters. In some embodiments, the promoter may betruncated.

Promoters which drive or promote expression in most tissues include, butare not limited to, human elongation factor 1α-subunit (EF1α),cytomegalovirus (CMV) immediate-early enhancer and/or promoter, chickenβ-actin (CBA) and its derivative CAG, β glucuronidase (GUSB), orubiquitin C (UBC). Tissue-specific expression elements can be used torestrict expression to certain cell types such as, but not limited to,muscle specific promoters, B cell promoters, monocyte promoters,leukocyte promoters, macrophage promoters, pancreatic acinar cellpromoters, endothelial cell promoters, lung tissue promoters, astrocytepromoters, or nervous system promoters which can be used to restrictexpression to neurons, astrocytes, or oligodendrocytes.

Non-limiting examples of muscle-specific promoters include mammalianmuscle creatine kinase (MCK) promoter, mammalian desmin (DES) promoter,mammalian troponin I (TNNI2) promoter, and mammalian skeletalalpha-actin (ASKA) promoter (see, e.g. U.S. Patent Publication US20110212529, the contents of which are herein incorporated by referencein their entirety).

Non-limiting examples of tissue-specific expression elements for neuronsinclude neuron-specific enolase (NSE), platelet-derived growth factor(PDGF), platelet-derived growth factor B-chain (PDGF-β), synapsin (Syn),methyl-CpG binding protein 2 (MeCP2), Ca²⁺/calmodulin-dependent proteinkinase II (CaM KII), metabotropic glutamate receptor 2 (mGluR2),neurofilament light (NFL) or heavy (NFH), β-globin minigene nβ2,preproenkephalin (PPE), enkephalin (Enk) and excitatory amino acidtransporter 2 (EAAT2) promoters. Non-limiting examples oftissue-specific expression elements for astrocytes include glialfibrillary acidic protein (GFAP) and EAAT2 promoters. A non-limitingexample of a tissue-specific expression element for oligodendrocytesincludes the myelin basic protein (MBP) promoter.

In one embodiment, the promoter may be less than 1 kb. The promoter mayhave a length of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300,310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440,450, 460, 470, 480, 490, 501), 510, 520, 530, 540, 550, 560, 570, 580,590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720,730, 740, 750, 760, 770, 780, 790, 800 or more than 800 nucleotides. Thepromoter may have a length between 200-300, 200-400, 200-500, 200-60,200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500,400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800or 700-800.

In one embodiment, the promoter may be a combination of two or morecomponents of the same or different starting or parental promoters suchas, but not limited to, CMV and CBA, Each component may have a length of200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330,340, 350, 360, 370, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389,390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520,530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660,670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 ormore than 800. Each component may have a length between 200-300,200-400, 200-500, 200-600, 200-700), 200-800, 300-400, 300-500, 300-600,300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700,500-800, 600-700, 600-800 or 700-800. In one embodiment, the promoter isa combination of a 382 nucleotide CMV-enhancer sequence and a 260nucleotide CBA-promoter sequence.

In one embodiment, the viral genome comprises a ubiquitous promoter.Non-limiting examples of ubiquitous promoters include CMV, CBA(including derivatives CAG, CBh, etc.), EF-1α, PGK, UBC, GUSB (hGBp),and UCOE (promoter of HNRPA2B1-CBX3). Yu et al. (Molecular Pain 2011,7-63, the contents of which are herein incorporated by reference intheir entirety) evaluated the expression of eGFP under the CAG, EF1α,PGK and UBC promoters in rat DRG cells and primary DRG cells usinglentiviral vectors and found that UBC showed weaker expression than theother 3 promoters and only 10-12% glial expression was seen for allpromoters Soderblom et al. (E. Neuro 2015; the contents of which areherein incorporated by reference in its entirety) evaluated theexpression of eGFP in AAV8 with CMV and UBC promoters and AAV2 with theCMV promoter after injection in the motor cortex. Intranasaladministration of a plasmid containing a UBC or EF1a promoter showed asustained airway expression greater than the expression with the CMVpromoter (See e.g., Gill et al., Gene Therapy 2001, Vol. 8, 1539-1546;the contents of which are herein incorporated by reference in theirentirety). Husain et al. (Gene Therapy 2009 the contents of which areherein incorporated by reference in its entirety) evaluated an HβHconstruct with a hGUSB promoter, a HSV-1LAT promoter and an NSE promoterand found that the HβH construct showed weaker expression than NSE inmouse brain. Passini and Wolfe (J. Virol. 2001, 12382-12392, thecontents of which are herein incorporated by reference in its entirety)evaluated the long term effects of the HβH vector following anintraventricular injection in neonatal mice and found that there wassustained expression for at least 1 year. Low expression in all brainregions was found by Xu et al. (Gene Therapy 2001, 8, 1323-1332; thecontents of which are herein incorporated by reference in theirentirety) when NFL and NFH promoters were used as compared to theCMV-lacZ, CMV-luc, EF, GFAP, hENK, nAChR, PPE, PPE+wpre, NSE (0.3 kb),NSE (1.8 kb) and NSE (1.8 kb 4 wpre). Xu et al. found that the promoteractivity in descending order was NSE (1.8 kb), EF, NSE (0.3 kb), GFAP,CMV, hENK, PPE, NFL and NFH. NFL is a 650 nucleotide promoter and NFH isa 920 nucleotide promoter which are both absent in the liver but NFH isabundant in the sensory proprioceptive neurons, brain and spinal cordand NFH is present in the heart. Scn8a is a 470 nucleotide promoterwhich expresses throughout the DRG, spinal cord and brain withparticularly high expression seen in the hippocampal neurons andcerebellar Purkinje cells, cortex, thalamus and hypothalamus (See e.g.,Drews et al. Identification of evolutionary conserved functionalnoncoding elements in the promoter region of the sodium channel geneSCN8A, Mamm Genome (2007) 18:723-731; and Raymond et al Expression ofAlternatively Spliced Sodium Channel α-subunit genes, Journal ofBiological Chemistry (2004) 279(44) 46234-46241; the contents of each ofwhich are herein incorporated by reference in their entireties).

Any of promoters taught by the aforementioned Yu, Soderblom. Gill,Husamin, Passini, Xu, Drews or Raymond may be used in the presentinventions.

In one embodiment, the promoter is not cell specific.

In one embodiment, the promoter is a ubiquitin c (UBC) promoter. The UBCpromoter may have a size of 300-350 nucleotides. As a non-limitingexample, the UBC promoter is 332 nucleotides.

In one embodiment, the promoter is a β-glucuronidase (GUSB) promoter.The CrUSB promoter may have a size of 350-400 nucleotides. As anon-limiting example, the GUSB promoter is 378 nucleotides.

In one embodiment, the promoter is a neurofilament light (NFL) promoter.The NFL promoter may have a size of 600-700 nucleotides. As anon-limiting example, the NFL promoter is 650 nucleotides.

In one embodiment, the promoter is a neurofilament heavy (NFH) promoter.The NFL promoter may have a size of 900-950 nucleotides. As anon-limiting example, the NFH promoter is 920 nucleotides.

In one embodiment, the promoter is a scn8a promoter. The scn8a promotermay have a size of 450-500 nucleotides. As a non-limiting example, thescn8a promoter is 470 nucleotides.

In one embodiment, the promoter is a phosphoglycerate kinase 1 (PGK)promoter.

In one embodiment, the promoter is a chicken β-actin (CBA) promoter.

In one embodiment, the promoter is a cytomegalovirus (CMV) promoter.

In one embodiment, the promoter is a liver or a skeletal musclepromoter. Non-limiting examples of liver promoters include humanα-1-antitrypsin (hAAT) and thyroxine binding globulin (TBG).Non-limiting examples of skeletal muscle promoters include Desmin. MCKor synthetic C5-12.

In one embodiment, the promoter is a RNA pol III promoter. As anon-limiting example, the RNA pol III promoter is U6. As a non-limitingexample, the RNA pol III promoter is H1.

In one embodiment, the viral genome comprises two promoters. As anon-limiting example, the promoters are an EF1α promoter and a CMVpromoter.

In one embodiment, the viral genome comprises an enhancer element, apromoter and/or a 5′UTR intron. The enhancer element, also referred toherein as an “enhancer,” may be, but is not limited to, a CMV enhancer,the promoter may be, but is not limited to, a CMV. CBA. UBC, GUSB, NSE,Synapsin, MeCP2, and GFAP promoter and the 5′UTR/intron may be, but isnot limited to, SV40, and CBA-MVM. As a non-limiting example, theenhancer, promoter and/or intron used in combination may be: (1) CMVenhancer. CMV promoter. SV40 5′UTR intron, (2) CMV enhancer, CBApromoter, SV 40 5′UTR intron, (3) CMV enhancer, CBA promoter, CBA-MVM5′UTR intron; (4) UBC promoter; (5) GUSB promoter; (6) NSF promoter; (7)Synapsin promoter; (8) MeCP2 promoter and (9) GFAP promoter.

In one embodiment, the viral genome comprises an engineered promoter.

In another embodiment, the viral genome comprises a promoter from anaturally expressed protein.

Viral Genome Component: Untranslated Regions (UTRs)

By definition, wild type untranslated regions (UTRs) of a gene aretranscribed but not translated. Generally, the 5′ UTR starts at thetranscription start site and ends at the start codon and the 3′ UTRstarts immediately following the stop codon and continues until thetermination signal for transcription.

Features typically found in abundantly expressed genes of specifictarget organs may be engineered into UTRs to enhance the stability andprotein production. As a non-limiting example, a 5′ UTR from mRNAnormally expressed in the liver (e.g., albumin, serum amyloid A,Apolipoprotein A/B/E, transferrin, alpha fetoprotein, erythropoietin, orFactor VIII) may be used in the viral genomes of the AAV particles ofthe invention to enhance expression in hepatic cell lines or liver.

While not wishing to be bound by theory, wild-type 5′ untranslatedregions (UTRs) include features which play roles in translationinitiation. Kozak sequences, which are commonly known to be involved inthe process by which the ribosome initiates translation of many genes,are usually included in 5′ UTRs. Kozak sequences have the consensusCCR(A/G)CCAUGG, where R is a purine (adenine or guanine) three basesupstream of the start codon (ATG), which is followed by another ‘G’.

In one embodiment, the 5′UTR in the viral genome includes a Kozaksequence.

In one embodiment, the 5′UTR in the viral genome does not include aKozak sequence.

While not wishing to be bound by theory, wild-type 3′ UTRs are known tohave stretches of Adenosines and Uridines embedded therein. These AUrich signatures are particularly prevalent in genes with high rates ofturnover. Based on their sequence features and functional properties,the AU rich elements (AREs) can be separated into three classes (Chen etal, 1995, the contents of which are herein incorporated by reference inits entirety); Class I AREs, such as, but not limited to, c-Myc andMyoD, contain several dispersed copies of an AUUUA motif within U-richregions. Class II AREs, such as, but not limited to, GM-CSF and TNF-a,possess two or more overlapping UUAUUUA(U/AXU/A) nonamers. Class IIIARES, such as, but not limited to, c-Jun and Myogenin, are less welldefined. These U rich regions do not contain an AUUUA motif. Mostproteins binding to the AREs are known to destabilize the messenger,whereas members of the ELAV family, most notably HuR, have beendocumented to increase the stability of mRNA. HuR binds to AREs of allthe three classes. Engineering the HuR specific binding sites into the3′ UTR of nucleic acid molecules will lead to HuR binding and thus,stabilization of the message in vivo.

Introduction, removal or modification of 3′ UTR AU rich elements (AREs)can be used to modulate the stability of polynucleotides. Whenengineering specific polynucleotides, e.g., payload regions of viralgenomes, one or more copies of an ARE can be introduced to makepolynucleotides less stable and thereby curtail translation and decreaseproduction of the resultant protein. Likewise, AREs can be identifiedand removed or mutated to increase the intracellular stability and thusincrease translation and production of the resultant protein.

In one embodiment, the 3′ UTR of the viral genome may include anoligo(dT) sequence for templated addition of a poly-A tail.

In one embodiment, the viral genome may include at least one miRNA seed,binding site or full sequence, microRNAs (or miRNA or miR) are 19-25nucleotide noncoding RNAs that bind to the sites of nucleic acid targetsand down-regulate gene expression either by reducing nucleic acidmolecule stability or by inhibiting translation. A microRNA sequencecomprises a “seed” region, i.e., a sequence in the region of positions2-8 of the mature microRNA, which sequence has perfect Watson-Crickcomplementarity to the miRNA target sequence of the nucleic acid.

In one embodiment, the viral genome may be engineered to include, alteror remove at least one miRNA binding site, sequence or seed region.

Any UTR from any gene known in the art may be incorporated into theviral genome of the AAV particle. These UTRs, or portions thereof, maybe placed in the same orientation as in the gene from which they wereselected or they may be altered in orientation or location. In oneembodiment, the UTR used in the viral genome of the AAV particle may beinverted, shortened, lengthened, made with one or more other 5′ UTRs or3′ UTRs known in the art. As used herein, the term “altered” as itrelates to a UTR, means that the UTR has been changed in some way inrelation to a reference sequence. For example, a 3′ or 5′ UTR may bealtered relative to a wild type or native UTR by the change inorientation or location as taught above or may be altered by theinclusion of additional nucleotides, deletion of nucleotides, swappingor transposition of nucleotides.

In one embodiment, the viral genome of the AAV particle comprises atleast one artificial UTRs which is not a variant of a wild type UTR.

In one embodiment, the viral genome of the AAV particle comprises UTRswhich have been selected from a family of transcripts whose proteinsshare a common function, structure, feature or property.

Viral Genome Component: Polyadenylation Sequence

In one embodiment, the viral genome of the AAV particles of the presentinvention comprise at least one polyadenylation sequence. The viralgenome of the AAV particle may comprise a poly adenylation sequencebetween the 3′ end of the payload coding sequence and the 5′ end of the3′ITR

In one embodiment, the polyadenylation sequence or “polyA sequence” mayrange from absent to about 500 nucleotides in length. Thepolyadenylation sequence may be, but is not limited to, 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42,43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111,112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125,126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139,140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153,154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167,168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181,182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195,196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223,224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237,238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251,252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265,266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279,280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293,294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307,308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321,322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335,336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349,350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363,364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377,378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391,392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405,406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419,420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433,434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447,448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461,462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475,476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489,490, 491, 492, 493, 494, 495, 496, 497, 498, 499, and 500) nucleotidesin length.

In one embodiment, the polyadenylation sequence is 50-100 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 50-150 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 50-160 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 50-200 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 60-100 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 60-150 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 60-160 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 60-200) nucleotidesin length.

In one embodiment, the polyadenylation sequence is 70-100 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 70-150 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 70-160 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 70-200 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 80-100 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 80-150 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 80-160 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 80-200 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 90-100 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 90-150 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 90-160 nucleotides inlength.

In one embodiment, the polyadenylation sequence is 90-200 nucleotides inlength.

Viral Genome Component: Linkers

Viral genomes of the invention may be engineered with one or more spaceror linker regions to separate coding or non-coding regions.

In one embodiment, the payload region of the AAV particle may optionallyencode one or more linker sequences. In some cases, the linker may be apeptide linker that may be used to connect the polypeptides encoded bythe payload region (i.e., light and heavy antibody chains duringexpression). Some peptide linkers may be cleaved after expression toseparate heavy and light chain domains, allowing assembly of matureantibodies or antibody fragments. Linker cleavage may be enzymatic. Insome cases, linkers comprise an enzymatic cleavage site to facilitateintracellular or extracellular cleavage. Some payload regions encodelinkers that interrupt polypeptide synthesis during translation of thelinker sequence from an mRNA transcript. Such linkers may facilitate thetranslation of separate protein domains (e.g., heavy and light chainantibody domains) from a single transcript. In some cases, two or morelinkers are encoded by a payload region of the viral genome.Non-limiting examples of linkers that may be encoded by the payloadregion of an AAV particle viral genome are given in Table 2.

TABLE 2 Linkers Linker No. Description SEQ ID NO L1 Internal ribosomeentry site (IRES)  899 L2 Foot and month disease vims 2A (F2A)  900 L3Porcine teschovirus-1 virus 2A (P2A)  901 L4 Furin cleavage site (F) 902 L5 5xG4S (SEQ ID NO: 9221)  903 L6 1,4-alpha-glucan-branchingenzyme CHP L7 1,4-alpha-glucan-branching enzyme  904 L81,4-beta-N-acetylmuramidase FKK L9 1,4-beta-N-acetylmuramidase  905 L101,4-beta-N-acetylmuramidase  906 L11 1,4-beta-N-acetylmuramidase  907L12 1,4-beta-N-acetylmuramidase  908 L13 1,4-beta-N-acetylmuramidase 909 L14 1,4-beta-N-acetylmuramidase  910 L151,4-beta-N-acetylmuramidase  911 L16 1,4-beta-N-acetylmuramidase  912L17 1,4-beta-N-acetylmuramidase  913 L18 1,4-beta-N-acetylmuramidase 914 L19 150aa long hypothetical transcriptional regulator  915 L20150aa long hypothetical transcriptional regulator  916 L211-deoxy-D-xylulose 5-phosphate reductoisomerase  917 L221-deoxy-D-xylulose 5-phosphate reductoisomerase  918 L231-deoxy-D-xylulose 5-phosphate reductoisomerase  919 L241-deoxy-D-xylulose 5-phosphate reductoisomerase  920 L25 235aa longhypothetical biotin-[acetyl-CoA-carboxylase] ligase  921 L26 235aa longhypothetical biotin-[acetyl-CoA-carboxylase] ligase  922 L27 235aa longhypothetical biotin-[acetyl-CoA-carboxylase] ligase  923 L282-dehydropantoate 2-reductase  924 L29 2-dehydropantoate 2-reductase 925 L30 2-dehydropantoate 2-reductase  926 L31 2-dehydropantoate2-reductase  927 L32 2-dehydropantoate 2-reductase  928 L332-dehydropantoate 2-reductase  929 L34 2-dehydropantoate 2-reductase,putative  930 L35 2-dehydropantoate 2-reductase, putative  931 L364-alpha-glucanotransferase  932 L37 4-alpha-glucanotransferase  933 L384-alpha-glucanotransferase  934 L394-diphosphocytidyl-2C-methyl-D-erythritol kinase HAA L404-diphosphocytidyl-2C-methyl-D-erythritol kinase  935 L414-diphosphocytidyl-2C-methyl-D-erythritol kinase  936 L424-diphosphocytidyl-2C-methyl-D-erythritol kinase  937 L434-diphosphocytidyl-2C-methyl-D-erythritol kinase  938 L444-hydroxyphenylpyruvate dioxygenase  939 L45 5-13 amino acids from the Ntermini of human Ck and CH1 domains linker  940 L46 5-13 amino acidsfrom the N termini of human Ck and CH1 domains linker ERK L47 5-13 aminoacids from the N termini of human Ck and CH1 domains linker  941 L485-13 amino acids from the N termini of human Ck and CH1 domains linker 942 L49 5-13 amino acids from the N termini of human Ck and CH1 domainslinker  943 L50 5-13 amino acids from the N termini of human Ck and CH1domains linker  944 L51 5′-exonuclease  945 L525-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase ARLL53 5-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase 946 L545-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase 947 L555-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase 948 L565-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase 949 L57 5′-nucleotidase  950 L58 5′-nucleotidase  951 L595′-nucleotidase  952 L60 5′-nucleotidase  953 L61 704aa longhypothetical glycosyltransferase  954 L62 704aa long hypotheticalglycosyltransferase  955 L63 80 kDa nuclear cap binding protein  956 L6480 kDa nuclear cap binding protein  957 L65 80 kDa nuclear cap bindingprotein  958 L66 80 kDa nuclear cap binding protein  959 L67Acetaldehyde dehydrogenase (acylating)  960 L68 Acetaldehydedehydrogenase (acylating)  961 L69 Acetolactate synthase isozyme IIIsmall subunit  962 L70 Acetylcholine receptor protein, alpha chain  963L71 Acetylcholine receptor protein, beta chain  964 L72 Aconitatehydratase 2  965 L73 Aconitate hydratase 2  966 L74 Aconitate hydratase2  967 L75 Aconitate hydratase 2  968 L76 Aconitate hydratase 2  969 L77Acriflavine resistance protein B DWY L78 Acriflavine resistance proteinB GGS L79 Acriflavine resistance protein B IDQ L80 Acriflavineresistance protein B NKV L81 Acriflavine resistance protein B SEA L82Acriflavine resistance protein B  970 L83 Acriflavine resistance proteinB  971 L84 Acriflavine resistance protein B  972 L85 Acriflavineresistance protein B  973 L86 Acriflavine resistance protein B  974 L87Acriflavine resistance protein B  975 L88 Acriflavine resistance proteinB  976 L89 Acriflavine resistance protein B  977 L90 Acriflavineresistance protein B  978 L91 Acriflavine resistance protein B  979 L92Acriflavine resistance protein B  980 L93 Acriflavine resistance proteinB  981 L94 Acriflavine resistance protein B  982 L95 Acriflavineresistance protein B  983 L96 Acriflavine resistance protein B  984 L97Acriflavine resistance protein B  985 L98 Acriflavine resistance proteinB  986 L99 Acriflavine resistance protein B  987 L100 Acriflavineresistance protein B  988 L101 Acriflavine resistance protein B  989L102 Acriflavine resistance protein B  990 L103 Acriflavine resistanceprotein B  991 L104 Acriflavine resistance protein B  992 L105Acriflavine resistance protein B  993 L106 Acyl-CoA thioesterase II  994L107 Acyl-CoA thioesterase II  995 L108 Acyl-CoA thioesterase II  996L109 Acyl-CoA thioesterase II  997 L110 Acyl-CoA thioesterase II  998L111 Acyl-coenzyme A thioesterase 4  999 L112 Acyl-coenzyme Athioesterase 4 1000 L113 Acyl-coenzyme A thioesterase 4 1001 L114Acyl-coenzyme A thioesterase 4 1002 L115 Acyl-coenzyme A thioesterase 41003 L116 Adenine glycosylase 1004 L117 Adenylate cyclase 1005 L118Aerolysin 1006 L119 Aerolysin 1007 L120 Agglutinin DWK L121 Agglutininisolectin 1 1008 L122 Agglutinin isolectin 1 1009 L123 Aldehydeferredoxin oxidoreductase 1010 L124 Aldehyde oxidoreductase 1011 L125Aldehyde oxidoreductase 1012 L126 Aldehyde oxidoreductase 1013 L127Aldehyde oxidoreductase 1014 L128 Aldehyde oxidoreductase 1015 L129Alkyl hydroperoxide reductase subunit F 1016 L130 Alkyl hydroperoxidereductase subunit F 1017 L131 Alkyl hydroperoxide reductase subunit F1018 L132 Alkyl hydroperoxide reductase subunit F 1019 L133 Alkylhydroperoxide reductase subunit F 1020 L134 Alkyl hydroperoxidereductase subunit F 1021 L135 Alkyl hydroperoxide reductase subunit F1022 L136 Alkyl hydroperoxide reductase subunit F 1023 L137 Alkylhydroperoxide reductase subunit F 1024 L138 Alkyl hydroperoxidereductase subunit F 1025 L139 Allantoicase 1026 L140 Allantoicase 1027L141 Alliin lyase 1 SAV L142 Alliin lyase 1 1028 L143 Alliin lyase 11029 L144 Alliin lyase 1 1030 L145 Alliin lyase 1 1031 L146 Alphaamylase 1032 L147 Alpha amylase 1033 L148 Alpha-actinin 1 1034 L149Alpha-actinin 1 1035 L150 Alpha-adaptin C 1036 L151 Alpha-amylase 1037L152 Alpha-glucuronidase LSD L153 Alpha-glucuronidase 1038 L154Alpha-glucuronidase 1039 L155 Alpha-glucuronidase 1040 L156Alpha-glucuronidase 1041 L157 Alpha-glucuronidase 1042 L158Alpha-glucuronidase 1043 L159 Alpha-glucuronidase 1044 L160Alpha-glucuronidase 1045 L161 Alpha-glucuronidase 1046 L162Alpha-glucuronidase 1047 L163 Alpha-glucuronidase 1048 L164Alpha-glucuronidase 1049 L165 Alpha-glucuronidase 1050 L166Alpha-glucuronidase 1051 L167 Alpha-glucuronidase 1052 L168Alpha-glucuronidase 1053 L169 Alpha-glucuronidase 1054 L170Alpha-glucuronidase 1055 L171 Alpha-glucuronidase 1056 L172Alpha-glucuronidase 1057 L173 Alpha-glucuronidase 1058 L174Alpha-L-arabinofuranosidase B 1059 L175 Alpha-mannosidase 1060 L176Alr2269 protein 1061 L177 AMP nucleosidase 1062 L178 AMP nucleosidase1063 L179 AMP nucleosidase 1064 L180 Angiopoietin-1 receptor DAG L181Angiopoietin-1 receptor NSG L182 Angiopoietin-1 receptor TSA L183Angiopoietin-1 receptor VPR L184 Angiopoietin-1 receptor 1065 L185Angiopoietin-1 receptor 1066 L186 Angiopoietin-1 receptor 1067 L187Angiopoietin-1 receptor 1068 L188 Angiopoietin-1 receptor 1069 L189Angiopoietin-1 receptor 1070 L190 Angiopoietin-1 receptor 1071 L191Angiopoietin-1 receptor 1072 L192 Angiopoietin-1 receptor 1073 L193Angiopoietin-1 receptor 1074 L194 Angiopoietin-1 receptor 1075 L195Angiopoietin-1 receptor 1076 L196 Angiopoietin-1 receptor 1077 L197Angiopoietin-1 receptor 1078 L198 Angiopoietin-1 receptor 1079 L199Angiopoietin-1 receptor 1080 L200 Angiopoietin-1 receptor 1081 L201Angiopoietin-1 receptor 1082 L202 Angiopoietin-1 receptor 1083 L203Angiopoietin-1 receptor 1084 L204 Angiopoietin-1 receptor 1085 L205Annexin A2 QNK L206 Annexin A2 1086 L207 Annexin A2 1087 L208Anthranilate phosphoribosyltransferase 1088 L209 AP-2 complex subunitbeta-2 1089 L210 Archaeosine tRNA-guanine transglycosylase LGI L211Archaeosine tRNA-guanine transglycosylase 1090 L212 ArchaeosinetRNA-guanine transglycosylase 1091 L213 Archaeosine tRNA-guaninetransglycosylase 1092 L214 Archaeosine tRNA-guanine transglycosylase1093 L215 Archaeosine tRNA-guanine transglycosylase 1094 L216Archaeosine tRNA-guanine transglycosylase 1095 L217 ArchaeosinetRNA-guanine transglycosylase 1096 L218 Archeal exosome RNA bindingprotein rrp4 1097 L219 Archeal exosome RNA binding protein rrp4 1098L220 Archeal exosome RNA binding protein rrp4 1099 L221 Arginyl-tRNAsynthetase IDY L222 Arginyl-tRNA synthetase 1100 L223 Arginyl-tRNAsynthetase 1101 L224 Arginyl-tRNA synthetase 1102 L225 Arrestin 1103L226 Arrestin 1104 L227 Arsenite oxidase 1105 L228 Artificial linker PGSL229 Artificial linker ATK L230 Artificial linker ASK L231 Artificiallinker 1106 L232 Artificial tinker 1107 L233 Artificial linker 1108 L234Artificial linker 1109 L235 Artificial tinker 1110 L236 Artificiallinker 1111 L237 ATP phosphoribosyltransferase ANR L238 ATP-dependentDNA helicase YDP L239 ATP-dependent DNA helicase 1112 L240 ATP-dependentDNA helicase 1113 L241 ATP-dependent DNA helicase 1114 L242ATP-dependent DNA helicase 1115 L243 ATP-dependent DNA helicase 1116L244 ATP-dependent DNA helicase 1117 L245 ATP-dependent DNA helicase1118 L246 ATP-dependent DNA helicase 1119 L247 AT-rich DNA-bindingprotein 1120 L248 AT-rich DNA-binding protein 1121 L249 Axonin-1 DEGL250 Axonin-1 ECF L251 Axonin-1 1122 L252 Axonin-1 1123 L253 Axonin-11124 L254 Axonin-1 1125 L255 Axonin-1 1126 L256 Axonin-1 1127 L257Axonin-1 1128 L258 Bacilysin biosynthesis protein BacB 1129 L259Bacilysin biosynthesis protein BacB 1130 L260 Bacilysin biosynthesisprotein BacB 1131 L261 Bacilysin biosynthesis protein BacB 1132 L262Bacilysin biosynthesis protein BacB 1133 L263 Bacteriophage Mutransposase 1134 L264 Bacteriophage Mu transposase 1135 L265Benzoyl-CoA-dihydrodiol lyase 1136 L266 Benzoyl-CoA-dihydrodiol lyase1137 L267 Benzoyl-CoA-dihydrodiol lyase 1138 L268Benzoyl-CoA-dihydrodiol lyase 1139 L269 Benzoyl-CoA-dihydrodiol lyase1140 L270 Benzoylformate decarboxylase 1141 L271 Benzoylformatedecarboxylase 1142 L272 Benzoylformate decarboxylase 1143 L273Beta-amylase 1144 L274 Beta-galactosidase AIS L275 Beta-galactosidase1145 L276 Beta-galactosidase 1146 L277 Beta-galactosidase 1147 L278Beta-galactosidase 1148 L279 Beta-galactosidase 1149 L280Beta-galactosidase 1150 L281 Beta-galactosidase 1151 L282Beta-galactosidase 1152 L283 Beta-galactosidase 1153 L284Beta-galactosidase 1154 L285 Beta-galactosidase 1155 L286Beta-galactosidase 1156 L287 Beta-galactosidase 1157 L288Beta-galactosidase 1158 L289 Beta-galactosidase 1159 L290Beta-galactosidase 1160 L291 Beta-galactosidase 1161 L292Beta-galactosidase 1162 L293 Beta-galactosidase 1163 L294Beta-galactosidase 1164 L295 Beta-galactosidase 1165 L296Beta-galactosidase 1166 L297 Beta-N-acetylhexosaminidase QRE L298Beta-N-acetylhexosaminidase 1167 L299 Beta-N-acetylhexosaminidase 1168L300 Beta-N-acetylhexosaminidase 1169 L301 Bifunctional NMNadenylyltransferase/Nudix hydrolase 1170 L302 Bifunctional purinebiosynthesis protein PURH 1171 L303 Biliverdin reductase A EHV L304Biliverdin reductase A LME L305 Biliverdin reductase A 1172 L306Biliverdin reductase A 1173 L307 Biodegradative arginine decarboxylaseTVQ L308 Biodegradative arginine decarboxylase 1174 L309 Biodegradativearginine decarboxylase 1175 L310 Biodegradative arginine decarboxylase1176 L311 Biodegradative arginine decarboxylase 1177 L312 Biodegradativearginine decarboxylase 1178 L313 Biodegradative arginine decarboxylase1179 L314 Biodegradative arginine decarboxylase 1180 L315 Biodegradativearginine decarboxylase 1181 L316 Biodegradative arginine decarboxylase1182 L317 Biodegradative arginine decarboxylase 1183 L318 Biodegradativearginine decarboxylase 1184 L319 Biodegradative arginine decarboxylase1185 L320 Biotin carboxylase 1186 L321 Bowman-Birk trypsin inhibitor1187 L322 Bpt4 gene 59 helicase assembly protein KQI L323BRCA1-associated RING domain protein 1 1188 L324 BRCA1-associated RINGdomain protein 1 1189 L325 BRCA1-associated RING domain protein 1 1190L326 Breast cancer 2 1191 L327 Breast cancer 2 1192 L328 Breast cancer 21193 L329 Breast cancer 2 1194 L330 Breast cancer 2 1195 L331 Breastcancer 2 1196 L332 Butyrate response factor 2 1197 L333 C4b-bindingprotein YKR L334 C4b-binding protein 1198 L335 C5a peptidase 1199 L336C5a peptidase 1200 L337 C5a peptidase 1201 L338 C5a peptidase 1202 L339C5a peptidase 1203 L340 C5a peptidase 1204 L341 C5a peptidase 1205 L342C5a peptidase 1206 L343 C5a peptidase 1207 L344 C5a peptidase 1208 L345C5a peptidase 1209 L346 C5a peptidase 1210 L347 C5a peptidase 1211 L348Calcium-binding protein 1212 L349 CarA 1213 L350 CarA 1214 L351Carbamoyl phosphate synthetase (small chain) 1215 L352 Carbamoylphosphate synthetase (small chain) 1216 L353 Carbamoyl phosphatesynthetase (small chain) 1217 L354 Carbamoyl phosphate synthetase (smallchain) 1218 L355 Carbamoyl phosphate synthetase (small chain) 1219 L356Carbon monoxide dehydrogenase/acetyl-CoA synthase subunitalpha 1220 L357Carboxypeptidase Gp180 residues 503-882 HRG L358 Cataboliteactivation-like protein 1221 L359 Catabolite activation-like protein1222 L360 Catechol 2,3-dioxygenase 1223 L361 Cation-independent mannose6-phosphate receptor 1224 L362 CD3 epsilon and gamma ectodomain fragmentcomplex 1225 L363 CD3 epsilon and gamma ectodomain fragment complex 1226L364 Cell filamentation protein SNP L365 Cell filamentation protein 1227L366 Cell filamentation protein 1228 L367 Cellular coagulation factorXIII zymogen DIT L368 Cellular coagulation factor XIII zymogen NSD L369Cellular coagulation factor XIII zymogen TDT L370 Cellular coagulationfactor XIII zymogen 1229 L371 Cellular coagulation factor XIII zymogen1230 L372 Cellular coagulation factor XIII zymogen 1231 L373 Cellularcoagulation factor XIII zymogen 1232 L374 Cellular coagulation factorXIII zymogen 1233 L375 Cellular coagulation factor XIII zymogen 1234L376 Cellular coagulation factor XIII zymogen 1235 L377 Cellularcoagulation factor XIII zymogen 1236 L378 Cellular coagulation factorXIII zymogen 1237 L379 Cellular coagulation factor XIII zymogen 1238L380 Cellular coagulation factor XIII zymogen 1239 L381 Cellularcoagulation factor XIII zymogen 1240 L382 Cellular coagulation factorXIII zymogen 1241 L383 Cellular coagulation factor XIII zymogen 1242L384 Cellular coagulation factor XIII zymogen 1243 L385 Cellularcoagulation factor XIII zymogen 1244 L386 Cellular coagulation factorXIII zymogen 1245 L387 Cellular coagulation factor XIII zymogen 1246L388 Cellular coagulation factor XIII zymogen 1247 L389 Cellulase 1248L390 Cellulase 1249 L391 Cellulase 1250 L392 Cellulase 1251 L393Cellulase 1252 L394 Cellulase 1253 L395 Cellulase 1254 L396 Cellulase1255 L397 Cellulase 1256 L398 Cellulase linker 1257 L399 Cellulaselinker 1258 L400 Cellulase linker 1259 L401 Cellulase linker 1260 L402Chaperone protein FimC KLR L403 Chaperone protein FimC QAA L404Chaperone protein FimC 1261 L405 Chaperone protein FimC 1262 L406Chaperone protein HscB RHP L407 Chaperone protein HscB 1263 L408 CheBmethylesterase 1264 L409 CheB methylesterase 1265 L410 CheBmethylesterase 1266 L411 Chelatase, putative 1267 L412 Chemotaxisreceptor methyltransferase cheR 1268 L413 Chemotaxis receptormethyltransferase cheR 1269 L414 Chemotaxis receptor methyltransferasecheR 1270 L415 Cholesterol oxidase 1271 L416 Cholesterol oxidase 1272L417 Cholesterol oxidase 1273 L418 Cholesterol oxidase 1274 L419Cholesterol oxidase 1275 L420 Cholesterol oxidase 1276 L421 Cholesteroloxidase 1277 L422 Cholesterol oxidase 1278 L423 Cholesterol oxidase 1279L424 Cholesterol oxidase 1280 L425 Cholesterol oxidase 1281 L426Cholesterol oxidase 1282 L427 Chromatin structure-remodeling complexprotein RSC4 KNL L428 Chromatin structure-remodeling complex proteinRSC4 1283 L429 Chromatin structure-remodeling complex protein RSC4 1284L430 Chromatin structure-remodeling complex protein RSC4 1285 L431Chromodomain-helicase-DNA-binding protein 1 1286 L432Chromodomain-helicase-DNA-binding protein 1 1287 L433 Cleavabledisulfide 1288 L434 Cleavable disulfide 1289 L435 Cleavable disulfide1290 L436 Cleavable disulfide 1291 L437 Cleavable disulfide 1292 L438Cleavable disulfide 1293 L439 Cleavable disulfide 1294 L440 Cleavabledisulfide 1295 L441 Cleavable disulfide 1296 L442 Cleavable disulfide1297 L443 Cleavable disulfide 1298 L444 Colicin Ia 1299 L445 Collagenadhesin 1300 L446 Complement C3 beta chain 1301 L447 Complement C3 betacliain 1302 L448 Complement C3 beta chain 1303 L449 Complement C3 betacliain 1304 L450 Complement decay-accelerating factor EIY L451Complement factor H KRP L452 Complement receptor type 2 1305 L453Conserved hypothetical protein 1306 L454 Conserved hypothetical proteinMTH1747 DIR L455 Conserved hypothetical protein MTH1747 1307 L456Conserved hypothetical protein MTH1747 1308 L457 Conserved hypotheticalprotein MTH1747 1309 L458 Conserved hypothetical protein MTH1747 1310L459 Conserved hypothetical protein MTH1747 1311 L460 Conservedhypothetical protein MTH1747 1312 L461 Conserved hypothetical proteinMTH1747 1313 L462 Conserved protein (MTH177) 1314 L463 Creatineamidinohydrolase 1315 L464 Cruciferin 1316 L465 Cruciferin 1317 L466Cruciferin 1318 L467 Cruciferin 1319 L468 Cruciferin 1320 L469Cruciferin 1321 L470 Cruciferin 1322 L471 CSL3 1323 L472 CSL3 1324 L473CTP synthase 1325 L474 CTP synthase 1326 L475 Cullin homolog HKN L476Cullin homolog 1327 L477 Cullin homolog 1328 L478 Cullin homolog 1329L479 Cullin homolog 1330 L480 Cullin homolog 1331 L481 Cyclin A2 1332L482 Cysteine-rich secretory protein 1333 L483 Cytidine deaminase 1334L484 Cytidine deaminase 1335 L485 Cytidine deaminase 1336 L486Cytochrome b-c1 complex subunit Rieske, mitochondrial 1337 L487Cytochrome c oxidase subunit 2 QAV L488 Cytochrome c oxidase subunit 21338 L489 Cytochrome c oxidase subunit 2 1339 L490 Cytochrome c oxidasesubunit 2 1340 L491 Cytochrome c oxidase subunit 2 1341 L492 Cytochromec4 GGK L493 Cytochrome c4 QGM L494 D-aminopeptidase 1342 L495 DDMC 1343L496 DDMC 1344 L497 Deltex protein 1345 L498 Deoxyuridine5′-triphosphate nucleotidohydrolase 1346 L499 Diaminopimelate epimerase1347 L500 Diaminopimelate epimerase 1348 L501 Diaminopimelate epimerase1349 L502 Di-heme peroxidase SGC L503 Di-heme peroxidase 1350 L504Dihydropyrimidine dehydrogenase 1351 L505 Dihydropyrimidinedehydrogenase 1352 L506 Dihydropyrimidine dehydrogenase 1353 L507Dihydropyrimidine dehydrogenase 1354 L508 Dihydropyrimidinedehydrogenase 1355 L509 Dihydropyrimidine dehydrogenase 1356 L510Dihydropyrimidine dehydrogenase 1357 L511 Dihydropyrimidinedehydrogenase 1358 L512 Dihydropyrimidine dehydrogenase 1359 L513Dihydropyrimidine dehydrogenase 1360 L514 Dihydropyrimidinedehydrogenase 1361 L515 Dihydropyrimidine dehydrogenase 1362 L516Dihydropyrimidine dehydrogenase 1363 L517 Dihydropyrimidinedehydrogenase 1364 L518 Dihydropyrimidine dehydrogenase 1365 L519Dihydropyrimidine dehydrogenase 1366 L520 Dihydropyrimidinedehydrogenase 1367 L521 Dihydropyrimidine dehydrogenase 1368 L522Dihydropyrimidine dehydrogenase 1369 L523 Dihydropyrimidinedehydrogenase 1370 L524 Dihydropyrimidine dehydrogenase 1371 L525Dihydropyrimidine dehydrogenase 1372 L526 Dihydropyrimidinedehydrogenase 1373 L527 Dihydropyrimidine dehydrogenase 1374 L528Dihydropyrimidine dehydrogenase 1375 L529 Dihydropyrimidinedehydrogenase 1376 L530 Dihydropyrimidine dehydrogenase 1377 L531Dihydropyrimidine dehydrogenase 1378 L532 Dihydropyrimidinedehydrogenase 1379 L533 Dihydropyrimidine dehydrogenase 1380 L534Dihydropyrimidine dehydrogenase 1381 L535 Discoidin-1 subunit A 1382L536 Discoidin-1 subunit A 1383 L537 Discoidin-1 subunit A 1384 L538Dissimilatory copper-containing nitritereductase 1385 L539 D-lactatedehydrogenase DTF L540 D-lactate dehydrogenase 1386 L541 D-lactatedehydrogenase 1387 L542 D-lactate dehydrogenase 1388 L543 D-lactatedehydrogenase 1389 L544 D-lactate dehydrogenase 1390 L545 D-lactatedehydrogenase 1391 L546 DNA damage-binding protein 1 LCA L547 DNAdamage-binding protein 1 1392 L548 DNA damage-binding protein 1 1393L549 DNA damage-binding protein 1 1394 L550 DNA damage-binding protein 11395 L551 DNA damage-binding protein 1 1396 L552 DNA damage-bindingprotein 1 1397 L553 DNA damage-binding protein 1 1398 L554 DNAdamage-binding protein 1 1399 L555 DNA damage-binding protein 1 1400L556 DNA damage-binding protein 1 1401 L557 DNA damage-binding protein 11402 L558 DNA damage-binding protein 1 1403 L559 DNA damage-bindingprotein 1 1404 L560 DNA damage-binding protein 1 1405 L561 DNAdamage-binding protein 1 1406 L562 DNA damage-binding protein 1 1407L563 DNA damage-binding protein 1 1408 L564 DNA damage-binding protein 11409 L565 DNA damage-binding protein 1 1410 L566 DNA damage-bindingprotein 1 1411 L567 DNA damage-binding protein 1 1412 L568 DNAdamage-binding protein 1 1413 L569 DNA gyrase B ALS L570 DNA gyrase B1414 L571 DNA gyrase B 1415 L572 DNA gyrase B 1416 L573 DNA gyrase B1417 L574 DNA gyrase B 1418 L575 DNA gyrase B 1419 L576 DNA gyrase B1420 L577 DNA gyrase B 1421 L578 DNA gyrase B 1422 L579 DNA gyrase B1423 L580 DNA gyrase B 1424 L581 DNA ligase 1425 L582 DNA ligase 1426L583 DNA ligase 1427 L584 DNA ligase 1428 L585 DNA ligase 1429 L586 DNAmismatch repair protein MutS MDA L587 DNA mismatch repair protein MutSSII L588 DNA mismatch repair protein MutS 1430 L589 DNA mismatch repairprotein MutS 1431 L590 DNA mismatch repair protein MutS 1432 L591 DNAmismatch repair protein MutS 1433 L592 DNA mismatch repair protein MutS1434 L593 DNA polymerase FSP L594 DNA polymerase RQF L595 DNA polymerase1435 L596 DNA polymerase 1436 L597 DNA polymerase 1437 L598 DNApolymerase 1438 L599 DNA polymerase 1439 L600 DNA polymerase 1440 L601DNA polymerase 1441 L602 DNA polymerase 1442 L603 DNA polymerase alphasubunit B 1443 L604 DNA polymerase alpha subunit B 1444 L605 DNApolymerase alpha subunit B 1445 L606 DNA polymerase alpha subunit B 1446L607 DNA polymerase alpha subunit B 1447 L608 DNA polymerase alphasubunit B 1448 L609 DNA polymerase alpha subunit B 1449 L610 DNApolymerase alpha subunit B 1450 L611 DNA polymerase alpha subunit B 1451L612 DNA polymerase alpha subunit B 1452 L613 DNA polymerase eta ALSL614 DNA polymerase eta 1453 L615 DNA polymerase eta 1454 L616 DNApolymerase eta 1455 L617 DNA polymerase eta 1456 L618 DNA polymerase eta1457 L619 DNA polymerase I AGV L620 DNA polymerase I ELE L621 DNApolymerase I 1458 L622 DNA primase DHK L623 DNA primase 1459 L624 DNAprimase 1460 L625 DNA primase 1461 L626 DNA primase 1462 L627 DNAprimase 1463 L628 DNA primase 1464 L629 DNA primase 1465 L630 DNAprimase/helicase AGY L631 DNA primase/helicase 1466 L632 DNAprimase/helicase 1467 L633 DNA primase/helicase 1468 L634 DNAprimase/helicase 1469 L635 DNA primase/helicase 1470 L630 DNAprimase/helicase 1471 L637 DNA primase/helicase 1472 L638 DNAprimase/helicase 1473 L639 DNA primase/helicase 1474 L640 DNAprimase/helicase 1475 L641 DNA topoisomerase 2 EES L642 DNAtopoisomerase 2 IPI L643 DNA topoisomerase 2 KEL L644 DNA topoisomerase2 1476 L645 DNA topoisomerase 2 1477 L646 DNA topoisomerase 2 1478 L647DNA topoisomerase 2 1479 L648 DNA topoisomerase 2 1480 L649 DNAtopoisomerase 2 1481 L650 DNA topoisomerase 2 1482 L651 DNAtopoisomerase 2 1483 L652 DNA topoisomerase 2 1484 L653 DNAtopoisomerase I 1485 L654 DNA topoisomerase I 1486 L655 DNAtopoisomerase I 1487 L656 DNA topoisomerase II, alpha isozyme PDL L657DNA topoisomerase II, alpha isozyme 1488 L658 DNA topoisomerase II,alpha isozyme 1489 L659 DNA topoisomerase II, alpha isozyme 1490 L660DNA topoisomerase II, alpha isozyme 1491 L661 DNA topoisomerase II,alpha isozyme 1492 L662 DNA topoisomerase II, alpha isozyme 1493 L663DNA topoisomerase II, alpha isozyme 1494 L664 DNA topoisomerase II,alpha isozyme 1495 L665 DNA topoisomerase VI A subunit 1496 L666 DNAtopoisomerase VI A subunit 1497 L667 DNA topoisomerase VI A subunit 1498L668 DNA topoisomerase VI A subunit 1499 L669 DNA topoisomerase VI Asubunit 1500 L670 DNA topoisomerase VI A subunit 1501 L671DNA-3-methyladenine glycosylase 2 1502 L672 DNA-binding responseregulator MtrA 1503 L673 DNA-directed RNA polymerase beta chain 1504L674 DNA-directed RNA polymerase beta chain 1505 L675 DNA-directed RNApolymerase beta chain 1506 L676 DNA-directed RNA polymerase beta chain1507 L677 DNA-directed RNA polymerase beta chain 1508 L678 DNA-directedRNA polymerase beta chain 1509 L679 DNA-directed RNA polymerase betachain 1510 L680 DNA-directed RNA polymerase beta chain 1511 L681DNA-directed RNA polymerase II 14.2 kDa polypeptide 1512 L682DNA-directed RNA polymerase II 14.2 kDa polypeptide 1513 L683DNA-directed RNA polymerase, subunit E′ (rpoe1) 1514 L684 DNA-directedRNA polymerase, subunit E′ (rpoe1) 1515 L685 DNA-directed RNApolymerases I, II, and III 27 kDa polypeptide IIP L686 DNA-directed RNApolymerases I, II, and III 27 kDa polypeptide 1516 L687 DNA-directed RNApolymerases I, II, and III 27 kDa polypeptide 1517 L688 DNA-directed RNApolymerases I, II, and III 27 kDa polypeptide 1518 L689 DNA-directed RNApolymerases I, II, and III 27 kDa polypeptide 1519 L690 Drosophilaneuroglian 1520 L691 Dystroglycan 1521 L692 Dystrophin 1522 L693Dystrophin 1523 L694 Dystrophin 1524 L695 Dystrophin 1525 L696Dystrophin 1526 L697 Dystrophin 1527 L698 Dystrophin 1528 L699 E2ADNA-binding protein 1529 L700 E2A DNA-binding protein 1530 L701 E3sumo-protein ligase SIZ1 1531 L702 E3 sumo-protein ligase SIZ1 1532 L703E3 sumo-protein ligase SIZ1 1533 L704 Early switch protein xol-l 2.2ksplice form 1534 L705 EGF-like module containing mucin-likehormonereceptor-like 2 precursor 1535 L706 EGF-like module containingmucin-like hormonereceptor-like 2 precursor 1536 L707 Elongation factor1-gamma 1 1537 L708 Elongation factor 1-gamma 1 1538 L709 Elongationfactor g 1539 L710 Elongation factor G 1540 L711 Elongation factor G1541 L712 Elongation factor G 1542 L713 Elongation factor G 1543 L714Elongation factor G 1544 L715 Elongation factor G 1545 L716 Elongationfactor G 1546 L717 Elongation factor G 1547 L718 Elongation factor G1548 L719 Elongation factor P 1549 L720 Elongation factor Ts 1550 L721Elongation factor Ts 1551 L722 Elongation factor Ts 1552 L723 Elongationfactor Tu (ef-Tu) 1553 L724 Endoglucanase 1554 L725 Endonuclease PI-SceI1555 L726 Endonuclease PI-SceI 1556 L727 Endonuclease PI-SceI 1557 L728Endonuclease PI-SceI 1558 L729 Endonuclease PI-SceI 1559 L730Endonuclease PI-SceI 1560 L731 Endonuclease PI-SceI 1561 L732Endonuclease PI-SceI 1562 L733 Endonuclease PI-SceI 1563 L734Enterobactin synthetase component F 1564 L735 Enterobactin synthetasecomponent F 1565 L736 Enterobactin synthetase component F 1566 L737Enterobactin synthetase component F 1567 L738 Enterobactin synthetasecomponent F 1568 L739 Enterobactin synthetase component F 1569 L740Enterobactin synthetase component F 1570 L741 Enterobactin synthetasecomponent F 1571 L742 Enterobactin synthetase component F 1572 L743Enterochelin esterase 1573 L744 Epo receptor EVV L745 Epo receptor 1574L746 Erythrocyte binding antigen region II 1575 L747 Erythrocyte bindingantigen region II 1576 L748 Erythrocyte binding antigen region II 1577L749 Erythrocyte binding antigen region II 1578 L750 Erythrocyte bindingantigen region II 1579 L751 E-selectin 1580 L752 Esterase EstA SAP L753Esterase EstA 1581 L754 Esterase EstA 1582 L755 Eukaryotic peptide chainrelease factor GTP-binding subunit 1583 L756 Exonuclease I RQP L757Exonuclease I 1584 L758 FascIclIn I SDP L759 FascIclIn I 1585 L760Fibrillin-1 1586 L761 Fibrillin-1 1587 L762 Fibrillin-1 1588 L763Fibrillin-1 1589 L764 Fibrillin-1 1590 L765 Fibronectin 1591 L766Fibronectin 1592 L767 Fibronectin 1593 L768 Flagellar hook protein FlgE1594 L769 Flagellar hook protein FlgE 1595 L770 Flagellar hook proteinFlgE 1596 L771 Flagellar hook protein FlgE 1597 L772 Flagellar hookprotein FlgE 1598 L773 Flagellar hook protein FlgE 1599 L774 Flagellarhook protein FlgE 1600 L775 Flavohemoprotein 1601 L776 Flexible G/S richlinker G L777 Flexible G/S rich linker S L778 Flexible G/S rich linkerGG L779 Flexible G/S rich linker GS L780 Flexible G/S rich linker GGSL781 Flexible G/S rich linker GGG L782 Flexible G/S rich linker 1602L783 Flexible G/S rich linker 1603 L784 Flexible G/S rich linker 1604L785 Flexible G/S rich linker 1605 L786 Flexible G/S rich linker 1606L787 Flexible G/S rich linker 1607 L788 Flexible G/S rich linker 1608L789 Flexible G/S rich linker 1609 L790 Flexible G/S rich linker 1610L791 Flexible G/S rich linker 1611 L792 Flexible G/S rich linker 1612L793 Flexible G/S rich linker 1613 L794 Flexible G/S rich linker 1614L795 Flexible G/S rich linker 1615 L796 Focal adhesion kinase 1 1616L797 FolC bifunctional protein 1617 L798 FolC bifunctional protein 1618L799 FolC bifunctional protein 1619 L800 FolC bifunctional protein 1620L801 FolC bifunctional protein 1621 L802 FolC bifunctioiial protein 1622L803 FolC bifunctional protein 1623 L804 FolC bifunctional protein 1624L805 Follistatin 1625 L806 Formate dehydrogenase (large subunit) YDKL807 Formate dehydrogenase (large subunit) 1626 L808 Formatedehydrogenase (large subunit) 1627 L809 Formate dehydrogenase (largesubunit) 1628 L810 Formate dehydrogenase (large subunit) 1629 L811Formate dehydrogenase (large subunit) 1630 L812 Formate dehydrogenase(large subunit) 1631 L813 Formate dehydrogenase (large subunit) 1632L814 Formate dehydrogenase (large subunit) 1633 L815 Formatedehydrogenase (large subunit) 1634 L816 Formate dehydrogenase (largesubunit) 1635 L817 Formate dehydrogenase (large subunit) 1636 L818Formate dehydrogenase(large subunit) 1637 L819 Formate dehydrogenase,nitrate-inducible major subunit 1638 L820 Formate dehydrogenase,nitrate-inducible, major subunit 1639 L821 Formate dehydrogenase,nitrate-inducible, major subunit 1640 L822 Formate dehydrogenase,nitrate-inducible, major subunit 1641 L823 Formate dehydrogenase,nitrate-inducible, major subunit 1642 L824 Formate dehydrogenase,nitrate-inducible, major subunit 1643 L825 Formate dehydrogenase,nitrate-inducible, major subunit 1644 L826 Formate dehydrogenase,nitrate-inducible, major subunit 1645 L827 Formate dehydrogenase,nitrate-inducible, major subunit 1646 L828 Formate dehydrogenase,nitrate-inducible, major subunit 1647 L829 Formate dehydrogenase,nitrate-inducible, major subunit 1648 L830 Formate dehydrogenase,nitrate-inducible, major subunit 1649 L831 Formate dehydrogenase,nitrate-inducible, major subunit 1650 L832 Formate dehydrogenase,nitrate-inducible, major subunit 1651 L833 Fumarylacetoacetate hydrolase1652 L834 Galactose oxidase GSV L835 Galactose oxidase GWK L836Galactose oxidase IAE L837 Galactose oxidase KRQ L838 Galactose oxidaseQDT L839 Galactose oxidase TPN L840 Galactose oxidase 1653 L841Galactose oxidase 1654 L842 Galactose oxidase 1655 L843 Galactoseoxidase 1656 L844 Galactose oxidase 1657 L845 Galactose oxidase 1658L846 Galactose oxidase 1659 L847 Galactose oxidase 1660 L848 Galactoseoxidase 1661 L849 Galactose oxidase 1662 L850 Galactose oxidase 1663L851 Galactose oxidase 1664 L852 Galactose oxidase 1665 L853 Galactoseoxidase 1666 L854 Galactose oxidase 1667 L855 Galactose oxidase 1668L856 Galactose oxidase 1669 L857 Galactose oxidase 1670 L858 Galactoseoxidase 1671 L859 Galactose oxidase 1672 L860 Galactose oxidase 1673L861 Galactose oxidase 1674 L862 Galactose oxidase 1675 L863 Galactoseoxidase 1676 L864 Gamma B-crystallin 1677 L865 Gamma-delta T-cellreceptor 1678 L866 Gelation factor DSS L867 Gelation factor 1679 L868Gelation factor 1680 L869 Gelation factor 1681 L870 Gene activator alpha1682 L871 Gingipain R 1683 L872 Glucodextranase 1684 L873Glucodextranase 1685 L874 Glucodextranase 1686 L875Glucosamine-fructose-6-phosphate aminotransferase YEQ L876Glucosamine-fructose-6-phosphate aminotransferase 1687 L877Glucosamine-fructose-6-phosphate aminotransferase 1688 L878Glucosamine-fructose-6-phosphate aminotransferase 1689 L879Glucosamine-fructose-6-phosphate aminotransferase 1690 L880Glucosamine-fructose-6-phosphate aminotransferase 1691 L881Glucosamine-fructose-6-phosphate aminotransferase 1692 L882Glucosamine-fructose-6-phosphate aminotransferase 1693 L883Glucosamine-fructose-6-phosphate aminotransferase 1694 L884Glucosamine-fructose-6-phosphate aminotransferase 1695 L885Glucosamine-fructose-6-phosphate aminotransferase 1696 L886Glucose-1-phosphate adenylyltransferase small subunit 1697 L887Glucose-1-phosphate adenylyltransferase small subunit 1698 L888Glucose-6-phosphate isomerase KNA L889 Glucose-6-phosphate isomerase VGFL890 Glucose-6-phosphate isomerase 1699 L891 Glucose-6-phosphateisomerase 1700 L892 Glucose-6-phosphate isomerase, conjectural 1701 L893Glutamate dehydrogenase 1702 L894 Glutamate dehydrogenase 1703 L895Glutamate receptor interacting protein 1704 L896 Glutamate synthase[NADPH] large chain 1705 L897 Glutamate synthase [NADPH] large chain1706 L898 Glutamate synthase [NADPH] large chain 1707 L899 Glutamatesynthase [NADPH] large chain 1708 L900 Glutamate synthase [NADPH] largechain 1709 L901 Glutamate synthase [NADPH] large chain 1710 L902Glutamate synthase [NADPH] large chain 1711 L903 Glutamine synthetase1712 L904 Glutamine synthetase 1713 L905 Glutamyl-tRNA synthetase 1714L906 Glutamyl-tRNA synthetase 1715 L907 Glutamyl-tRNA synthetase 1716L908 Glutamyl-tRNA synthetase 1717 L909 Glutamyl-tRNA synthetase 1718L910 Glutamyl-tRNA synthetase 1719 L911 Glutamyl-tRNA synthetase 1720L912 Glutamyl-tRNA synthetase 1721 L913 Glutaredoxin 2 1722 L914Glutathione S-transferase 1723 L915 Glutathione S-transferase 1724 L916Glutathione S-transferase 1725 L917 Glutathione S-transferase 1-6 1726L918 Glutathione S-transferase A1 1727 L919 Glutathione S-transferase INKP L920 Glutathione S-transferase I 1728 L921 Glutathione synthetase1729 L922 Glutathione transferase GST1-4 1730 L923 Glutathionetransferase GST1-4 1731 L924 Glutathione transferase sigma class 1732L925 Glvcerol-3-phosphate dehydrogenase [NAD(P)+] 1733 L926 Glycinecleavage system transcriptional repressor, putative 1734 L927Glycolipid-anchored surface protein 2 1735 L928 Glycolipid-anchoredsurface protein 2 1736 L929 Glycyl-tRNA synthetase KFA L930 Glycyl-tRNAsynthetase 1737 L931 Glycyl-tRNA synthetase 1738 L932 Glycyl-tRNAsynthetase 1739 L933 Glycyl-tRNA synthetase 1740 L934 Glycyl-tRNAsynthetase 1741 L935 Glycyl-tRNA synthetase 1742 L936 Glycyl-tRNAsynthetase 1743 L937 Glycyl-tRNA synthetase 1744 L938 Glycyl-tRNAsynthetase 1745 L939 Growth hormone receptor 1746 L940 Growth hormonereceptor 1747 L941 Harmonin 1748 L942 HasR protein 1749 L943 HasRprotein 1750 L944 Hemin transport protein HemS 1751 L945 Hemin transportprotein HemS 1752 L946 Hemin transport protein HemS 1753 L947 Hemoglobin1754 L948 Hemolytic lectin CEL-iii 1755 L949 Hepatocyte nuclear factor 61756 L950 Histidyl-tRNA synthetase 1757 L951 HNH homing endonuclease1758 L952 HNH homing endonuclease 1759 L953 HNH homing endonuclease 1760L954 Homoserine dehydrogenase 1761 L955 Homoserine kinase 1762 L956Homoserine kinase 1763 L957 Homoserine kinase 1764 L958 Homoserinekinase 1765 L959 HTH-type transcriptional regulator MqsA (Ygit/B3021)1766 L960 HTH-type transcriptional repressor 1767 L961 HTH-typetranscriptional repressor YvoA 1768 L962 Human IgG1 middle hinge linker1769 L963 Human IgG1 upper hinge linker 1770 L964 Human IgG3 middlehinge linker 1771 L965 Human IgG3m15 middle hinge linker 1772 L966 HumanIgG4 lower hinge linker 1773 L967 Human IgG4 middle hinge linker 1774L968 Human IgG4 upper hinge linker 1775 L969 Hybrid cluster protein 1776L970 Hybrid cluster protein 1777 L971 Hybrid cluster protein 1778 L972Hybrid cluster protein 1779 L973 Hybrid cluster protein 1780 L974Hypothetical conserved protein, GK1056 1781 L975 Hypothetical membranespanning protein 1782 L976 Hypothetical methylmalonyl-CoA decarboxylasealpha subunit 1783 L977 Hypothetical methylmalonyl-CoA decarboxylasealpha subunit 1784 L978 Hypothetical methylmalonyl-CoA decarboxylasealpha subunit 1785 L979 Hypothetical methylmalonyl-CoA decarboxylasealpha subunit 1786 L980 Hypothetical methylmalonyl-CoA decarboxylasealpha subunit 1787 L981 Hypothetical methylmalonyl-CoA decarboxylasealpha subunit 1788 L982 Hypothetical methylmalonyl-CoA decarboxylasealpha subunit 1789 L983 Hypothetical protein AEP L984 Hypotheticalprotein 1790 L985 Hypothetical protein APE0525 PTL L986 Hypotheticalprotein APE0525 1791 L987 Hypothetical protein LOC449832 1792 L988Hypothetical protein LOC449832 1793 L989 Hypothetical protein PA43881794 L990 Hypothetical protein PA5201 ASE L991 Hypothetical proteinPA5201 QDP L992 Hypothetical protein PA5201 VKL L993 Hypotheticalprotein PA5201 1795 L994 Hypothetical protein PA5201 1796 L995Hypothetical protein PA5201 1797 L996 Hypothetical protein PA5201 1798L997 Hypothetical protein PA5201 1799 L998 Hypothetical protein PA52011800 L999 Hypothetical protein PA5201 1801 L1000 Hypothetical proteinPA5201 1802 L1001 Hypothetical protein PA5201 1803 L1002 Hypotheticalprotein PA5201 1804 L1003 Hypothetical protein PA5201 1805 L1004Hypothetical protein PA5201 1806 L1005 Hypothetical protein PA5201 1807L1006 Hypothetical protein PA5201 1808 L1007 Hypothetical protein PA52011809 L1008 Hypothetical protein PA5201 1810 L1009 Hypothetical proteinPA5201 1811 L1010 Hypothetical protein PA5201 1812 L1011 Hypotheticalprotein PA5201 1813 L1012 Hypothetical protein PA5201 1814 L1013Hypothetical protein PH0495 ASN L1014 Hypothetical protein PH0495 1815L1015 Hypothetical protein PH0495 1816 L1016 Hypothetical protein PH04951817 L1017 Hypothetical protein PH0495 1818 L1018 Hypothetical proteinPH0510 1819 L1019 Hypothetical protein PH0510 1820 L1020 Hypotheticalprotein PH1313 1821 L1021 Hypothetical protein PH1313 1822 L1022Hypothetical protein SLR0953 1823 L1023 Hypothetical protein SLR09531824 L1024 Hypothetical protein SLR0953 1825 L1025 Hypothetical proteinSLR0953 1826 L1026 Hypothetical protein SLR0953 1827 L1027 Hypotheticalprotein YIGZ 1828 L1028 Hypothetical protein YIGZ 1829 L1029Hypothetical protein YJIA 1830 L1030 Hypothetical protein YJIA 1831L1031 Hypothetical protein YJIA 1832 L1032 Hypothetical protein YJIA1833 L1033 Hypothetical protein YJIA 1834 L1034 Hypothetical tRNA/rRNAmethyltransferase YJFH 1835 L1035 Hypothetical tRNA/rRNAmethyltransferase YJFH 1836 L1036 IclR transcriptional regulator 1837L1037 IclR transcriptional regulator 1838 L1038 IclR transcriptionalregulator 1839 L1039 IclR transcriptional regulator 1840 L1040 Integrase1841 L1041 Interferon, alpha-inducible protein (clone IFI-15k) 1842L1042 Interleukin-1 receptor, type I AIF L1043 Interleukin-1 receptor,type I 1843 L1044 Interleukin-1 receptor, type I 1844 L1045Interleukin-1 receptor, type I 1845 L1046 Interleukin-12 subunit p40 FFIL1047 Interleukin-12 subunit p40 1846 L1048 Interleukin-12 subunit p401847 L1049 Interleukin-12 subunit p40 1848 L1050 Interleukin-12 subunitp40 1849 L1051 Interleukin-12 subunit p40 1850 L1052 Interleukin-12subunit p40 1851 L1053 Interleukin-12 subunit p40 1852 L1054Interletiktn-2 receptor alpha chain 1853 L1055 Interleukin-2 receptoralpha chain 1854 L1056 Internalin B VTQ L1057 Internalin B 1855 L1058Internalin B 1856 L1059 Internalin B 1857 L1060 Internalin B 1858 L1061Internalin B 1859 L1062 Internalin B 1860 L1063 Internalin B 1861 L1064Internalin B 1862 L1065 Internalin B 1863 L1066 Internalin B 1864 L1067Internalin B 1865 L1068 Internalin B 1866 L1069 Intimin SLV L1070Intimin 1867 L1071 Intimin 1868 L1072 Intimin 1869 L1073 Intron-encodedDNA endonuclease I-anil 1870 L1074 Intron-encoded DNA endonucleaseI-anil 1871 L1075 Invasin KST L1076 Invasin 1872 L1077 Invasin 1873L1078 Invasin 1874 L1079 Invasin 1875 L1080 Invasin 1876 L1081 Invasin1877 L1082 Invasin 1878 L1083 Invasin 1879 L1084 Invasin 1880 L1085Invasin 1881 L1086 Invasin 1882 L1087 Invasin 1883 L1088 Ironhydrogenase 1 GAE L1089 Iron hydrogenase 1 1884 L1090 Iron hydrogenase 11885 L1091 Iron hydrogenase 1 1886 L1092 Iron hydrogenase 1 1887 L1093Iron hydrogenase 1 1888 L1094 Iron hydrogenase 1 1889 L1095 Ironhydrogenase 1 1890 L1096 Iron hydrogenase 1 1891 L1097 Iron hydrogenase1 1892 L1098 Iron hydrogenase 1 1893 L1099 Iron hydrogenase 1 1894 L1100Iron hydrogenase 1 1895 L1101 Iron hydrogenase 1 1896 L1102 Irontransport protein 1897 L1103 Isoflavanone 4′-O-methyltransferase 1898L1104 Isoflavanone 4′-O-methyltransferase 1899 L1105 Junctional adhesionmolecule 1 1900 L1106 Junctional adhesion molecule 1 1901 L1107Junctional adhesion molecule 1 1902 L1108 Kanamycinnucleotidyltransferase 1903 L1109 Kanamycin nucleotidyltransferase 1904L1110 Kanamycin nucleotidyltransferase 1905 L1111 Kanamycinnucleotidyltransferase 1906 L1112 Kelch-like protein 11 1907 L1113 KexinISE L1114 Kexin 1908 L1115 Kexin 1909 L1116 Kexin 1910 L1117 Kexin 1911L1118 Kexin 1912 L1119 Kexin 1913 L1120 Kexin 1914 L1121 Ku70 1915 L1122Ku70 1916 L1123 Ku70 1917 L1124 Ku70 1918 L1125 Ku80 1919 L1126Laccase-1 1920 L1127 Laccase-1 1921 L1128 Laccase-1 1922 L1129 Laccase-11923 L1130 Laminin DKC L1131 L-aspartate dehydrogenase SAS L1132L-aspartate dehydrogenase 1924 L1133 L-aspartate dehydrogenase 1925L1134 Leucine dehydrogenase 1926 L1135 Leucine dehydrogenase 1927 L1136Light chain of HyHel10 antibody fragment (fab) 1928 L1137 Lin2111protein 1929 L1138 Lin2111 protein 1930 L1139Lipopolysaccharide-responsive and beige-like anchor protein 1931 L1140Lipopolysaccharide-responsive and beige-like anchor protein 1932 L1141Lipovitellin (LV-1N, LV-1C) 1933 L1142 Lipovitellin (LV-1N, LV-1C) 1934L1143 Lipovitellin (LV-1N, LV-1C) 1935 L1144 Lipovitellin (LV-1N, LV-1C)1936 L1145 Lipovitellin (LV-1N, LV-1C) 1937 L1146 Lipoxygenase-1 1938L1147 Lipoxygenase-1 1939 L1148 Low affinity immunoglobulin gamma Fcregion receptor II-A 1940 L1149 Luciferase 1941 L1150 LysR-typeregulatory protein 1942 L1151 Macrolide-specific efflux protein MacA ATEL1152 Macrolide-specific efflux protein MacA 1943 L1153Macrolide-specific efflux protein MacA 1944 L1154 Magnesium transporter,putative 1945 L1155 Main hemagglutinin component 1946 L1156 Majorcentromere autoantigen B 1947 L1157 Major surface antigen p30 1948 L1158Major surface antigen p30 1949 L1159 Major vault protein 1950 L1160Major vault protein 1951 L1161 Maltose phosphorylase 1952 L1162 Maltosephosphorylase 1953 L1163 Maltose phosphorylase 1954 L1164 Maltosephosphorylase 1955 L1165 Maltose phosphorylase 1956 L1166Manganese-dependent inorganic pyrophosphatase 1957 L1167Manganese-dependent inorganic pyrophosphatase 1958 L1168 Mannan-bindinglectin 1959 L1169 Mannan-binding lectin 1960 L1170 Mannan-binding lectin1961 L1171 Mannitol dehydrogenase HNA L1172 Mannitol dehydrogenase 1962L1173 Membrane cofactor protein RET L1174 Membrane cofactor protein 1963L1175 Membrane-associated prostaglandin E synthase-2 1964 L1176Membrane-associated prostaglandin E synthase-2 1965 L1177Membrane-associated prostaglandin E synthase-2 1966 L1178Membrane-associated prostaglandin E synthase-2 1967 L1179Membrane-associated prostaglandin E synthase-2 1968 L1180 Membrane-boundlytic murein transglycosylase A 1969 L1181 Methionyl-tRNA synthetase1970 L1182 Methyl-accepting chemotaxis protein VRP L1183Methyl-accepting chemotaxis protein 1971 L1184 Methyl-acceptingchemotaxis protein 1972 L1185 Methyl-accepting chemotaxis protein 1973L1186 Methyl-coenzyme M reductase 1974 L1187 Methyl-coenzyme M reductase1975 L1188 Methyl-coenzyme M reductase 1976 L1189 Methyl-coenzyme Mreductase 1977 L1190 Methylene tetrahydromethanopterin dehydrogenase1978 L1191 Methylene tetrahydromethanopterin dehydrogenase 1979 L1192Mg2+ transporter MgtE 1980 L1193 Mg2+ transporter MgtE 1981 L1194 Mg2+transporter MgtE 1982 L1195 Mitochondrial aconitase 1983 L1196Mitochondrial aconitase 1984 L1197 Modification methylase TaqI EGK L1198Modification methylase TaqI PAT L1199 Modification methylase TaqI 1985L1200 Modification methylase TaqI 1986 L1201 Modification methylase TaqI1987 L1202 Modification methylase TaqI 1988 L1203 Modification methylaseTaqI 1989 L1204 Modification methylase TaqI 1990 L1205 Modificationmethylase TaqI 1991 L1206 Modification methylase TaqI 1992 L1207Multidrag-efflux transporter 1 regulator 1993 L1208Muramoyl-pentapeptide carboxypeptidase 1994 L1209 MutL 1995 L1210 MutL1996 L1211 MutL 1997 L1212 MutL 1998 L1213 MutL 1999 L1214 MutL 2000L1215 MutL 2001 L1216 MutL 2002 L1217 MutL 2003 L1218 MutM (Fpg) protein2004 L1219 MutM (Fpg) protein 2005 L1220 MutM (Fpg) protein 2006 L1221MutM (Fpg) protein 2007 L1222 Myotubularin-related protein 2 THW L1223Myotubularin-related protein 2 2008 L1224 Myotubularin-related protein 22009 L1225 Myotubularin-related protein 2 2010 L1226Myotubularin-related protein 2 2011 L1227 Myotubularin-related protein 22012 L1228 N utilization substance protein A EIP L1229 N utilizationsubstance protein A 2013 L1230 N utilization substance protein A 2014L1231 N utilization substance protein A 2015 L1232 N-acetylglucosaminekinase CAY L1233 N-acetylglucosamine kinase ISP L1234N-acetylglucosamine kinase 2016 L1235 N-acyl-D-glutamate deacylase 2017L1236 N-acyl-D-glutamate deacylase 2018 L1237 N-acyl-D-glutamatedeacylase 2019 L1238 N-acyl-D-glutamate deacylase 2020 L1239N-acyl-D-glutamate deacylase 2021 L1240 N-acyl-D-glutamate deacylase2022 L1241 N-acyl-D-glutamate deacylase 2023 L1242 NAD-dependent malicenzyme 2024 L1243 NAD-dependent malic enzyme 2025 L1244 NADH peroxidaseADT L1245 NADH peroxidase AVG L1246 NADH peroxidase TLI L1247 NADHperoxidase 2026 L1248 NADH peroxidase 2027 L1249 NADH peroxidase 2028L1250 NADH peroxidase 2029 L1251 NADH peroxidase 2030 L1252 NADHperoxidase 2031 L1253 NADH pyrophosphatase 2032 L1254 Naphthalene1,2-dioxygenase alpha subunit 2033 L1255 Naphthalene 1,2-dioxygenasealpha subunit 2034 L1256 NEDD8-activating enzyme E1 catalytic subunit2035 L1257 NEDD8-activating enzyme E1 regulatory subunit 2036 L1258NEDD8-activating enzyme E1 regulatory subunit 2037 L1259NEDD8-activating enzyme E1 regulatory subunit 2038 L1260 Neiendonuclease VIII-Like 1 2039 L1261 Nei endonuclease VIII-Like 1 2040L1262 Nei endonuclease VIII-Like 1 2041 L1263 Nei endonuclease VIII-Like1 2042 L1264 Neural cell adhesion molecule 2 2043 L1265 Neural celladhesion molecule 2 2044 L1266 Neural cell adhesion molecule 2 2045L1267 Neural cell adhesion molecule 2 2046 L1268 Neural cell adhesionmolecule 2 2047 L1269 Neuroplastin 2048 L1270 Neuroplastin 2049 L1271Neuroplastin 2050 L1272 Neutrophil cytosol factor 1 2051 L1273 Nickelresponsive regulator 2052 L1274 NifU-like protein 2, chloroplast 2053L1275 Nitric oxide reductase ILM L1276 Nitric oxide reductase 2054 L1277Nitric oxide reductase 2055 L1278 Nitric oxide reductase 2056 L1279Nitric oxide reductase 2057 L1280 Nitric oxide reductase 2058 L1281 NKreceptor 2059 L1282 Nuclear factor of activated t-cells, cytoplasmic22060 L1283 Nucleolin RED12 2061 L1284 O-GlcNAcase NagJ 2062 L1285 Orangecarotenoid protein EGV L1286 Orange carotenoid protein 2063 L1287 Orangecarotenoid protein 2064 L1288 Orn/Lys/Arg decarboxylase family proteinLEL L1289 Orn/Lys/Arg decarboxylase family protein 2065 L1290Orn/Lys/Arg decarboxylase family protein 2066 L1291 Orn/Lys/Argdecarboxylase family protein 2067 L1292 Orn/Lys/Arg decarboxylase familyprotein 2068 L1293 Orn/Lys/Arg decarboxylase family protein 2069 L1294Orn/Lys/Arg decarboxylase family protein 2070 L1295 Orn/Lys/Argdecarboxylase family protein 2071 L1296 Osteoclast-stimulating factor 12072 L1297 Oxygen-independent coproporphyrinogen III oxidase 2073 L1298Oxygen-independent coproporphyrinogen III oxidase 2074 L1299Oxygen-independent coproporphyrinogen III oxidase 2075 L1300Oxygen-independent coproporphyrinogen III oxidase 2076 L1301Oxygen-independent coproporphyrinogen III oxidase 2077 L1302Oxygen-independent coproporphyrinogen III oxidase 2078 L1303Oxygen-independent coproporphyrinogen III oxidase 2079 L1304Oxygen-independent coproporphyrinogen III oxidase 2080 L1305Oxygen-independent coproporphyrinogen III oxidase 2081 L1306Oxygen-independent coproporphyrinogen III oxidase 2082 L1307Paraneoplastic encephalomyelitis antigen HuD 2083 L1308 Paraneoplasticencephalomyelitis antigen HuD 2084 L1309 Penicillin binding protein 42085 L1310 Penicillin binding protein 4 2086 L1311 Penicillin bindingprotein 4 2087 L1312 Penicillin binding protein 4 2088 L1313 Penicillinbinding protein 4 2089 L1314 Penicillin binding protein 4 2090 L1315Penicillin binding protein 4 2091 L1316Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F DGVL1317 Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F2092 L1318 Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidaseF 2093 L1319 Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagineamidase F 2094 L1320 Peroxisomal primary amine oxidase 2095 L1321Peroxisomal primary amine oxidase 2096 L1322 Peroxisome biogenesisfactor 1 2097 L1323 Pesticidial crystal protein Cry2Aa 2098 L1324Pesticidial crystal protein Cry2Aa 2099 L1325 Pesticidial crystalprotein Cry2Aa 2100 L1326 Phase 1 flagellin DLT L1327 Phase 1 flagellin2101 L1328 Phase 1 flagellin 2102 L1329 Phase 1 flagellin 2103 L1330Phase 1 flagellin 2104 L1331 Phase 1 flagellin 2105 L1332 Phase 1flagellin 2106 L1333 Phase 1 flagellin 2107 L1334 Phase 1 flagellin 2108L1335 Phase 1 flagellin 2109 L1336 Phase 1 flagellin 2110 L1337 Phase 1flagellin 2111 L1338 Phase 1 flagellin 2112 L1339 Phenylalanyl-tRNAsynthetase beta chain LGL L1340 Phenylalanyl-tRNA synthetase beta chain2113 L1341 Phenylalanyl-tRNA synthetase beta chain 2114 L1342Phenylalanyl-tRNA synthetase beta chain 2115 L1343 Phenylalanyl-tRNAsynthetase beta chain 2116 L1344 Phenylalanyl-tRNA synthetase beta chain2117 L1345 Phenylalanyl-tRNA synthetase beta chain 2118 L1346Phenylalanyl-tRNA synthetase beta chain 2119 L1347 Phenylalanyl-tRNAsynthetase beta chain 2120 L1348 Phenylalanyl-tRNA synthetase beta chain2121 L1349 Phenylalanyl-tRNA synthetase beta chain 2122 L1350Phenylalanyl-tRNA synthetase beta chain 2123 L1351 Phenylalanyl-tRNAsynthetase beta chain 2124 L1352 Phenylalanyl-tRNA synthetase beta chain2125 L1353 Phosphatase 2126 L1354 Phosphatase 2127 L1355 Phosphatase2128 L1356 Phosphatidylinositol transfer protein Sec14p YGT L1357Phosphatidylinositol transfer protein Sec14p 2129 L1358Phosphatidylinositol transfer protein Sec14p 2130 L1359Phosphatidylserine synthase 2131 L1360 Phosphatidylserine synthase 2132L1361 Phosphatidylserine synthase 2133 L1362 Phosphoglycolatephosphatase 2134 L1363 Phosphoglycolate phosphatase 2135 L1364Phosphoglycolate phosphatase 2136 L1365 Phosphoglycolate phosphatase2137 L1366 Phospholipase D 2138 L1367 Phospholipase D 2139 L1368Phospholipase D 2140 L1369 Phosphoribosylamine-glycine ligase 2141 L1370Phosphoribosylamine-glycine ligase 2142 L1371 Phosphotransferase system,enzyme I 2143 L1372 Photosystem II d1 protease 2144 L1373 Photosystem IId1 protease 2145 L1374 Photosystem II d1 protease 2146 L1375 PhotosystemII d1 protease 2147 L1376 Photosystem II d1 protease 2148 L1377Phthalate dioxygenase reductase 2149 L1378 P-hydroxybenzoate hydroxylaseDGL L1379 P-hydroxybenzoate hydroxylase IDL L1380 P-hydroxybenzoatehydroxylase RLK L1381 P-hydroxybenzoate hydroxylase 2150 L1382P-hydroxybenzoate hydroxylase 2151 L1383 P-hydroxybenzoate hydroxylase2152 L1384 P-hydroxybenzoate hydroxylase 2153 L1385 P-hydroxybenzoatehydroxylase 2154 L1386 P-hydroxybenzoate hydroxylase 2155 L1387P-hydroxybenzoate hydroxylase 2156 L1388 P-hydroxybenzoate hydroxylase2157 L1389 P-hydroxybenzoate hydroxylase 2158 L1390 P-hydroxybenzoatehydroxylase 2159 L1391 P-hydroxybenzoate hydroxylase 2160 L1392P-hydroxybenzoate hydroxylase 2161 L1393 P-hydroxybenzoate hydroxylase2162 L1394 P-hydroxybenzoate hydroxylase 2163 L1395 P-hydroxybenzoatehydroxylase 2164 L1396 P-hydroxybenzoate hydroxylase 2165 L1397P-hydroxybenzoate hydroxylase 2166 L1398 Phytase LNF L1399 Phytase QSNL1400 Phytase 2167 L1401 Phytase 2168 L1402 Phytase 2169 L1403 Phytase2170 L1404 Phytase 2171 L1405 Phytase 2172 L1406 Phytase 2173 L1407Phytase 2174 L1408 Pirin LKS L1409 Pirin SGE L1410 Pirin 2175 L1411Pirin 2176 L1412 Pirin 2177 L1413 Pirin 2178 L1414 Pirin 2179 L1415Pirin 2180 L1416 Poly(A) polymerase 2181 L1417 Poly(A) polymerase 2182L1418 Poly(A) polymerase 2183 L1419 Poly(A) polymerase 2184 L1420Poly(A) polymerase 2185 L1421 Poly(A) polymerase 2186 L1422 Poly(A)polymerase 2187 L1423 Poly(A) polymerase 2188 L1424 Poly(A) polymerase2189 L1425 Poly(A) polymerase 2190 L1426 Poly(A) polymerase 2191 L1427Poly(A) polymerase 2192 L1428 Poly(rC)-binding protein 2 2193 L1429Polymerase x 2194 L1430 Polymerase x 2195 L1431 PolypeptideN-acetylgalactosaminyltransferase 2 2196 L1432 PolypeptideN-acetylgalactosaminyltransferase 2 2197 L1433 Polyphosphate kinase 2198L1434 Polyphosphate kinase 2199 L1435 Polyphosphate kinase 2200 L1436Polypyrimidine tract-binding protein 2201 L1437 Porcine pancreaticspasmolytic polypeptide 2202 L1438 Possible 3-mercaptopyruvatesulfurtransferase LFR L1439 Possible 3-mercaptopyruvatesulfurtransferase YGM L1440 Possible 3-mercaptopyruvatesulfurtransferase 2203 L1441 Possible 3-mercaptopyruvatesulfurtransferase 2204 L1442 Possible 3-mercaptopyruvatesulfurtransferase 2205 L1443 Postsynaptic density protein 95 2206 L1444Postsynaptic density protein 95 2207 L1445 Predicted sugar phosphatasesof the HAD superfamily IAI L1446 Predicted sugar phosphatases of the HADsuperfamily 2208 L1447 Predicted sugar phosphatases of the HADsuperfamily 2209 L1448 Predicted sugar phosphatases of the HADsuperfamily 2210 L1449 Predicted sugar phosphatases of the HADsuperfamily 2211 L1450 Predicted sugar phosphatases of the HADsuperfamily 2212 L1451 Predicted sugar phosphatases of the HADsuperfamily 2213 L1452 Predicted sugar phosphatases of the HADsuperfamily 2214 L1453 Predicted sugar phosphatases of the HADsuperfamily 2215 L1454 Preprotein translocase SecA ITF L1455 Preproteintranslocase SecA LID L1456 Preprotein translocase SecA 2216 L1457Preprotein translocase SecA 2217 L1458 Preprotein translocase SecA 2218L1459 Preprotein translocase SecA 2219 L1460 Preprotein translocase SecA2220 L1461 Preprotein translocase SecA 2221 L1462 Preprotein translocaseSecA 2222 L1463 Preprotein translocase SecA 2223 L1464 Preproteintranslocase SecA 2224 L1465 Preprotein translocase SecA 2225 L1466Preprotein translocase SecA 2226 L1467 Preprotein translocase SecA 2227L1468 Preprotein translocase SecA 2228 L1469 Preprotein translocase SecA2229 L1470 Preprotein translocase SecA 2230 L1471 Preprotein translocaseSecA 2231 L1472 Preprotein translocase SecA 2232 L1473 PrfA ING L1474Probable 16s rRNA-processing protein RimM 2233 L1475 Probablebiphenyl-2,3-diol 1,2-dioxygenase BphC 2234 L1476 Probable chorismatemutase LLA L1477 Probable chorismate mutase 2235 L1478 Probablechorismate mutase 2236 L1479 Probable ferredoxin-dependent nitritereductase NirA VPL L1480 Probable ferredoxin-dependent nitrite reductaseNirA WGI L1481 Probable ferredoxin-dependent nitrite reductase NirA 2237L1482 Probable ferredoxin-dependent nitrite reductase NirA 2238 L1483Probable ferredoxin-dependent nitrite reductase NirA 2239 L1484 Probableferredoxin-dependent nitrite reductase NirA 2240 L1485 Probableferredoxin-dependent nitrite reductase NirA 2241 L1486 Probableferredoxin-dependent nitrite reductase NirA 2242 L1487 Probableferredoxin-dependent nitrite reductase NirA 2243 L1488 Probableferredoxin-dependent nitrite reductase NirA 2244 L1489 Probableferredoxin-dependent nitrite reductase NirA 2245 L1490 Probableferredoxin-dependent nitrite reductase NirA 2246 L1491 Probableferredoxin-dependent nitrite reductase NirA 2247 L1492 Probableferredoxin-dependent nitrite reductase NirA 2248 L1493 Probablegalactokinase 2249 L1494 Probable galactokinase 2250 L1495 Probablegalactokinase 2251 L1496 Probable galactokinase 2252 L1497 Probablegalactokinase 2253 L1498 Probable galactokinase 2254 L1499 Probablegalactokinase 2255 L1500 Probable galactokinase 2256 L1501 Probablegalactokinase 2257 L1502 Probable galactokinase 2258 L1503 Probablegalactokinase 2259 L1504 Probable galactokinase 2260 L1505 Probableglutathione S-transferase 2261 L1506 Probable GST-related protein 2262L1507 Probable HPr(Ser) kinase/phosphatase 2263 L1508 Probablethiosulfate sulfur transferase 2264 L1509 Probable thiosulfate sulfurtransferase 2265 L1510 Probable thiosulfate sulfur transferase 2266L1511 Probable thiosulfate sulfur transferase 2267 L1512 Probablethiosulfate sulfur transferase 2268 L1513 Probable thiosulfate sulfurtransferase 2269 L1514 Probable thiosulfate sulfur transferase 2270L1515 Probable thiosulfate sulfur transferase 2271 L1516 Probable tRNApseudouridine synthase D 2272 L1517 Probable tRNA pseudouridine synthaseD 2273 L1518 Probable tRNA pseudouridine synthase D 2274 L1519 ProbabletRNA pseudouridine synthase D 2275 L1520 Probable tRNA pseudouridinesynthase D 2276 L1521 Probable tRNA pseudouridine synthase D 2277 L1522Programed cell death protein 8 SKE L1523 Programed cell death protein 8TLQ L1524 Programed cell death protein 8 2278 L1525 Programed cell deathprotein 8 2279 L1526 Programed cell death protein 8 2280 L1527 Programedcell death protein 8 2281 L1528 Programed cell death protein 8 2282L1529 Programed cell death protein 8 2283 L1530 Programed cell deathprotein 8 2284 L1531 Programed cell death protein 8 2285 L1532 Programedcell death protein 8 2286 L1533 Programed cell death protein 8 2287L1534 Programed cell death protein 8 2288 L1535 Programed cell deathprotein 8 2289 L1536 Programed cell death protein 8 2290 L1537 Programedcell death protein 8 2291 L1538 Programed cell death protein 8 2292L1539 Programed cell death protein 8 2293 L1540 Programed cell deathprotein 8 2294 L1541 Programed cell death protein 8 2295 L1542 Prolineoxidase 2296 L1543 Prolyl-tRNA synthetase 2297 L1544 Prostaglandin G/Hsynthase 1 PEI L1545 Prostaglandin G/H synthase 1 2298 L1546 Protease2299 L1547 Protease 2300 L1548 Protease 2301 L1549 Protease DegS 2302L1550 Protease DegS 2303 L1551 Protease DegS 2304 L1552 Protease DegS2305 L1553 Protease III NAR L1554 Protease III RNP L1555 Protease III2306 L1556 Protease III 2307 L1557 Protease III 2308 L1558 Protease III2309 L1559 Protease III 2310 L1560 Protease III 2311 L1561 Protease III2312 L1562 Protease III 2313 L1563 Protease III 2314 L1564 Protease III2315 L1565 Protease III 2316 L1566 Protease III 2317 L1567 Protease III2318 L1568 Protease III 2319 L1569 Protease III 2320 L1570 Protease III2321 L1571 Protease III 2322 L1572 Protease III 2323 L1573 Protease III2324 L1574 Protease III 2325 L1575 Protection of telomeres 1 2326 L1576Protection of telomeres 1 2327 L1577 Protein (CD58) 2328 L1578 Protein(CRP1) 2329 L1579 Protein (DNA polymerase) 2330 L1580 Protein (DNApolymerase) 2331 L1581 Protein (DNA polymerase) 2332 L1582 Protein(electron transfer flavoprotein) 2333 L1583 Protein (electron transferflavoprotein) 2334 L1584 Protein (Ffh) 2335 L1585 Protein (Ffh) 2336L1586 Protein (Ffh) 2337 L1587 Protein (Ffh) 2338 L1588 Protein (Ffh)2339 L1589 Protein (FokI restriction endonuclease) 2340 L1590 Protein(FokI restriction endonuclease) 2341 L1591 Protein (FokI restrictionendonuclease) 2342 L1592 Protein (FokI restriction endonuclease) 2343L1593 Protein (FokI restriction endonuclease) 2344 L1594 Protein (FokIrestriction endonuclease) 2345 L1595 Protein (FokI restrictionendonuclease) 2346 L1596 Protein (FokI restriction endonuclease) 2347L1597 Protein (FokI restriction endonuclease) 2348 L1598 Protein (neuralcell adhesion molecule) 2349 L1599 Protein (neural cell adhesionmolecule) 2350 L1600 Protein (neural cell adhesion molecule) 2351 L1601Protein (nine-haem cytochrome c) FTH L1602 Protein (nine-haem cytochromec) 2352 L1603 Protein (nine-haem cytochrome c) 2353 L1604 Protein(nine-haem cytochrome c) 2354 L1605 Protein (nine-haem cytochrome c)2355 L1606 Protein (nine-haem cytochrome c) 2356 L1607 Protein(nine-haem cytochrome c) 2357 L1608 Protein (nine-haem cytochrome c)2358 L1609 Protein (nine-haem cytochrome c) 2359 L1610 Protein(protease/helicase NS3) 2360 L1611 Protein (protease/helicase NS3) 2361L1612 Protein (protease/helicase NS3) 2362 L1613 Protein(protease/helicase NS3) 2363 L1614 Protein disulfide oxidoreductase 2364L1615 Protein disulfide oxidoreductase 2365 L1616 Proteindisulfide-isomerase A4 2366 L1617 Protein kinase PKR 2367 L1618 Proteinkinase PKR 2368 L1619 Protein TolB VNK L1620 Protein TolB 2369 L1621Protein TolB 2370 L1622 Protein TolB 2371 L1623 Protein TolB 2372 L1624Protein TolB 2373 L1625 Protein TolB 2374 L1626 Protein translationelongation factor 1A 2375 L1627 Protein transport protein Sec24 DRNL1628 Protein transport protein Sec24 2376 L1629 Protein transportprotein Sec24 2377 L1630 Protein transport protein Sec24 2378 L1631Protein transport protein Sec24 2379 L1632 Protein transport proteinSec24 2380 L1633 Protein transport protein Sec24 2381 L1634 Proteintransport protein Sec24 2382 L1635 Protein transport protein Sec24 2383L1636 Pseudouridine synthase CBF5 AIQ L1637 Pseudouridine synthase CBF52384 L1638 Pseudouridine synthase CBF5 2385 L1639 Putativeacetylglutamate synthase 2386 L1640 Putative acetylglutamate synthase2387 L1641 Putative acetylglutamate synthase 2388 L1642 Putative family31 glucosidase Yicl 2389 L1643 Putative family 31 glucosidase Yicl 2390L1644 Putative family 31 glucosidase Yicl 2391 L1645 Putativeglutathione transferase 2392 L1646 Putative glutathione transferase 2393L1647 Putative glutathione transferase 2394 L1648 Putative GNTR-familytranscriptional regulator 2395 L1649 Putative GNTR-familytranscriptional regulator 2396 L1650 Putative GNTR-familytranscriptional regulator 2397 L1651 Putative HTH-type transcriptionalregulator PH0061 2398 L1652 Putative HTH-type transcriptional regulatorPH1519 2399 L1653 Putative HTH-type transcriptional regulator PH15192400 L1654 Putative metallopeptidase 2401 L1655 PutativeN-acetylmannosamine kinase 2402 L1656 Putative N-acetylmannosaminekinase 2403 L1657 Putative N-acetylmannosamine kinase 2404 L1658Putative NADP oxidoreductase BF3122 2405 L1659 Putative NADPoxidoreductase BF3122 2406 L1660 Putative NADP oxidoreductase BF31222407 L1661 Putative NADP oxidoreductase BF3122 2408 L1662 Putativeoxidoreductase 2409 L1663 Putative secreted alpha-galactosidase PLPL1664 Putative secreted alpha-galactosidase TNG L1665 Putative secretedalpha-galactosidase 2410 L1666 Putative secreted alpha-galactosidase2411 L1667 Putative secreted alpha-galactosidase 2412 L1668 Putativetagatose-6-phosphate ketose/aldose isomerase DKA L1669 Putativetagatose-6-phosphate ketose/aldose isomerase 2413 L1670 Putativetagatose-6-phosphate ketose/aldose isomerase 2414 L1671 Putativetagatose-6-phosphate ketose/aldose isomerase 2415 L1672 Putativetranscriptional regulator GntR 2416 L1673 Putative transcriptionalrepressor (TetR/AcrR family) KFR L1674 Putative transcriptionalrepressor (TetR/AcrR family) 2417 L1675 Putative uncharacterized protein2418 L1676 Putative uncharacterized protein 2419 L1677 Putativeuncharacterized protein 2420 L1678 Putative uncharacterized protein 2421L1679 Putative uncharacterized protein 2422 L1680 Putativeuncharacterized protein 2423 L1681 Putative uncharacterized protein 2424L1682 Putative uncharacterized protein 2425 L1683 Putativeuncharacterized protein 2426 L1684 Pyruvate decarboxylase CAA L1685Pyruvate decarboxylase 2427 L1686 Pyruvate decarboxylase 2428 L1687Pyruvate decarboxylase 2429 L1688 Pyruvate decarboxylase 2430 L1689Pyruvate decarboxylase 2431 L1690 Pyruvate dehydrogenase [lipoamide]kinase isozyme 2, mitochondrial YVP L1691 Pyruvate dehydrogenase[lipoamide] kinase isozyme 2, mitochondrial 2432 L1692 Pyruvatedehydrogenase [lipoamide] kinase isozyme 2, mitochondrial 2433 L1693Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 2434L1694 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial2435 L1695 Pyruvate dehydrogenase E1 component subunit beta,mitochondrial 2436 L1696 Pyruvate phosphate dikinase FNP L1697 Pyruvatephosphate dikinase SAL L1698 Pyruvate phosphate dikinase 2437 L1699Pyruvate phosphate dikinase 2438 L1700 Pyruvate phosphate dikinase 2439L1701 Pyruvate phosphate dikinase 2440 L1702 Pyruvate phosphate dikinase2441 L1703 Pyruvate phosphate dikinase 2442 L1704 Pyruvate phosphatedikinase 2443 L1705 Pyruvate phosphate dikinase 2444 L1706 Pyruvatephosphate dikinase 2445 L1707 Pyruvate phosphate dikinase 2446 L1708Pyruvate-ferredoxin oxidoreductase VRL L1709 Pyruvate-ferredoxinoxidoreductase 2447 L1710 Pyruvate-ferredoxin oxidoreductase 2448 L1711Pyruvate-ferredoxin oxidoreductase 2449 L1712 Pyruvate-ferredoxinoxidoreductase 2450 L1713 Pyruvate-ferredoxin oxidoreductase 2451 L1714Pyruvate-ferredoxin oxidoreductase 2452 L1715 Pyruvate-ferredoxinoxidoreductase 2453 L1716 Pyruvate-ferredoxin oxidoreductase 2454 L1717Pyruvate-ferredoxin oxidoreductase 2455 L1718 Pyruvate-ferredoxinoxidoreductase 2456 L1719 Pyruvate-ferredoxin oxidoreductase 2457 L1720Pyruvate-ferredoxin oxidoreductase 2458 L1721 Pyruvate-ferredoxinoxidoreductase 2459 L1722 Pyruvate-ferredoxin oxidoreductase 2460 L1723Pyruvate-ferredoxin oxidoreductase 2461 L1724 Pyruvate-ferredoxinoxidoreductase 2462 L1725 Pyruvate-ferredoxin oxidoreductase 2463 L1726Pyruvate-ferredoxin oxidoreductase 2464 L1727 Pyruvate-ferredoxinoxidoreductase 2465 L1728 Quinohemoprotein amine dehydrogenase 60 kDasubunit 2466 L1729 Quinohemoprotein amine dehydrogenase 60 kDa subunit2467 L1730 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2468L1731 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2469 L1732Quinohemoprotein amine dehydrogenase 60 kDa subunit 2470 L1733Quinohemoprotein amine dehydrogenase 60 kDa subunit 2471 L1734Quinohemoprotein amine dehydrogenase 60 kDa subunit 2472 L1735Quinohemoprotein amine dehydrogenase 60 kDa subunit 2473 L1736Quinohemoprotein amine dehydrogenase 60 kDa subunit 2474 L1737Quinohemoprotein amine dehydrogenase 60 kDa subunit 2475 L1738 Rag1 2476L1739 Rag1 2477 L1740 Receptor-type tyrosine-protein phosphatase Mu 2478L1741 Receptor-type tyrosine-protein phosphatase Mu 2479 L1742 RecG 2480L1743 RecG 2481 L1744 RecG 2482 L1745 RecG 2483 L1746 RecG 2484 L1747RecG 2485 L1748 RecG 2486 L1749 RecG 2487 L1750 RecG 2488 L1751 RecG2489 L1752 RecG 2490 L1753 RecG 2491 L1754 Recombination endonucleaseVII 2492 L1755 Recombining binding protein suppressor of hairless 2493L1756 Restriction endonuclease ERV L1757 Restriction endonuclease 2494L1758 Restriction endonuclease 2495 L1759 Restriction endonuclease 2496L1760 Retinaldehyde-binding protein 1 QYP L1761 Retinaldehyde-bindingprotein 1 2497 L1762 Retinaldehyde-binding protein 1 2498 L1763Retinoblastoma pocket 2499 L1764 RfcS ITD L1765 RfcS LTE L1766 RfcS 2500L1767 RfcS 2501 L1768 RfcS 2502 L1769 RfcS 2503 L1770 RfcS 2504 L1771Rhamnogalacturonase B 2505 L1772 Rhamnogalacturonase B 2506 L1773Rhamnogalacturonase B 2507 L1774 Rhamnogalacturonase B 2508 L1775Rhamnogalacturonase B 2509 L1776 Rhodniin 2510 L1777 Rhodniin 2511 L1778Riboflavin synthase 2512 L1779 Ribonuclease D 2513 L1780 Ribonuclease D2514 L1781 Ribonuclease D 2515 L1782 Ribonuclease TTHA0252 2516 L1783Ribonuclease TTHA0252 2517 L1784 Ribonuclease TTHA0252 2518 L1785Ribonuclease THHA0252 2519 L1786 Ribonuclease TTHA0252 2520 L1787Ribonuclease TTHA0252 2521 L1788 Ribonucleotide reductase r1 protein2522 L1789 Ribonucleotide reductase r1 protein 2523 L1790 Ribonucleotidereductase r1 protein 2524 L1791 Ribonucleotide reductase r1 protein 2525L1792 Ribonucleotide reductase r1 protein 2526 L1793 Ribonucleotidereductase r1 protein 2527 L1794 Ribosome maturation factor RimM 2528L1795 Ribulose-1,5 bisphosphate carboxylase/oxygenase RHA large subunitN-methyltransferase L1796 Ribulose-1,5 bisphosphatecarboxylase/oxygenase 2529 large subunit N-methyltransferase L1797 Rigidextended P-rich 2530 L1798 Rigid extended P-rich 2531 L1799 Rigidextended P-rich 2532 L1800 Rigid extended P-rich 2533 L1801 Rigidextended P-rich 2534 L1802 Rigid extended P-rich 2535 L1803 Rigidextended P-rich 2536 L1804 Rigid extended P-rich 2537 L1805 Rigidextended P-rich 2538 L1806 Rigid extended P-rich 2539 L1807 Rigidextended P-rich 2540 L1808 Rigid extended P-rich 2541 L1809 Rigidextended P-rich 2542 L1810 Rigid extended P-rich 2543 L1811 Rigidextended P-rich 2544 L1812 Rigid helical 2545 L1813 Rigid helical 2546L1814 Rigid helical 2547 L1815 Rigid helical 2548 L1816 Rigid helical2549 L1817 Rigid helical 2550 L1818 Rigid helical 2551 L1819 Rigidhelical 2552 L1820 RNA binding domain of rho transcription terminationfactor 2553 L1821 RNA binding protein ZFa 2554 L1822 Rob transcriptionfactor 2555 L1823 Rob transcription factor 2556 L1824 RP2 lipase 2557L1825 Rubreiythrin 2558 L1826 S-adenosylmethionine synthetase 2559 L1827Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 QFD L1828Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2560 L1829Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2561 L1830Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2562 L1831Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2563 L1832Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2564 L1833Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2565 L1834Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2566 L1835Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2567 L1836Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2568 L1837Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2569 L1838Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2570 L1839Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2571 L1840Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2572 L1841Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2573 L1842Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2574 L1843Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2575 L1844Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2576 L1845Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2577 L1846Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2578 L1847Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2579 L1848Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2580 L1849Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2581 L1850Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2582 L1851Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2583 L1852Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2584 L1853 ScavengermRNA-decapping enzyme DcpS ETC L1854 Scavenger mRNA-decapping enzymeDcpS NIT L1855 Scavenger mRNA-decapping enzyme DcpS 2585 L1856 ScavengermRNA-decapping enzyme DcpS 2586 L1857 Sec18p (residues 22-210) 2587L1858 Sec18p (residues 22-210) 2588 L1859 Sensor protein 2589 L1860Sensor protein 2590 L1861 Septum site-determining protein MinC 2591L1862 Serine acetyltransferase 2592 L1863 Serineprotease/NTPase/helicase NS3 2593 L1864 Serine protease/NTPase/helicaseNS3 2594 L1865 Serine protease/NTPase/helicase NS3 2595 L1866 Serinerich linker 2596 L1867 Serine rich linker 2597 L1868 Serine rich linker2598 L1869 Serine rich linker 2599 L1870 Serine rich linker 2600 L1871Serine rich linker 2601 L1872 Serine rich linker 2602 L1873 Seryl-tRNAsynthetase 2603 L1874 Sialidase 2604 L1875 Sialidase B SLT L1876Sialidase B VRE L1877 Sialidase B 2605 L1878 Sialidase B 2606 L1879Sialidase B 2607 L1880 Sialidase B 2608 L1881 Sialidase B 2609 L1882Sialidase B 2610 L1883 SIgnal peptIdase I SRR L1884 SIgnal peptIdase I2611 L1885 SIgnal peptIdase I 2612 L1886 SIgnal peptIdase I 2613 L1887SIgnal peptIdase I 2614 L1888 SIgnal peptIdase I 2615 L1889 SIgnalpeptIdase I 2616 L1890 SIgnal peptIdase I 2617 L1891 SIgnal peptIdase I2618 L1892 SIgnal peptIdase I 2619 L1893 SIgnal peptIdase I 2620 L1894Signal recognition particle protein 2621 L1895 Signal transducer andactivator of transcription1-alpha/beta NDE L1896 Signal transducer andactivator of transcription1-alpha/beta SSF L1897 Signal transducer andactivator of transcription1-alpha/beta 2622 L1898 Signal transducer andactivator of transcription1-alpha/beta 2623 L1899 Signal transducer andactivator of transcription1-alpha/beta 2624 L1900 Signal transducer andactivator of transcription1-alpha/beta 2625 L1901 Signal transductionprotein CBL 2626 L1902 Signal transduction protein CBL 2627 L1903Similar to RAD54-like AKP L1904 Similar to RAD54-like EYF L1905 Similarto RAD54-like RFE L1906 Similar to RAD54-like 2628 L1907 Similar toRAD54-like 2629 L1908 Similar to RAD54-like 2630 L1909 Similar toRAD54-like 2631 L1910 Similar to RAD54-like 2632 L1911 Similar toRAD54-like 2633 L1912 Similar to RAD54-like 2634 L1913 Similar toRAD54-like 2635 L1914 Similar to RAD54-like 2636 L1915 Similar toRAD54-like 2637 L1916 SKD1 protein LMQ L1917 SKD1 protein 2638 L1918SKD1 protein 2639 L1919 SKD1 protein 2640 L1920 SKD1 protein 2641 L1921SKD1 protein 2642 L1922 Sll1358 protein 2643 L1923 Sll1358 protein 2644L1924 Sll1358 protein 2645 L1925 Sll1358 protein 2646 L1926 Soluble IFNalpba/beta receptor 2647 L1927 Soluble IFN alpha/beta receptor 2648L1928 Sporozoite-specific SAG protein 2649 L1929 Staphylococcalaccessory regulator a homologue 2650 L1930 Staphylococcal nucleasedomain-containing protein 1 2651 L1931 Staphylococcal nucleasedomain-containing protein 1 2652 L1932 Staphylococcal nucleasedomain-containing protein 1 2653 L1933 Staphylococcal nucleasedomain-containing protein 1 2654 L1934 Staphylococcal nucleasedomain-containing protein 1 2655 L1935 Staphylococcal nucleasedomain-containing protein 1 2656 L1936 Stat protein 2657 L1937 Statprotein 2658 L1938 Stat protein 2659 L1939 Stat protein 2660 L1940 Statprotein 2661 L1941 Stat protein 2662 L1942 Stat protein 2663 L1943 Statprotein 2664 L1944 Stat protein 2665 L1945 Stat protein 2666 L1946 Statprotein 2667 L1947 Stat protein 2668 L1948 Stat protein 2669 L1949 Statprotein 2670 L1950 Stat protein 2671 L1951 Subtilisin-like protease 2672L1952 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2673L1953 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2674L1954 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2675L1955 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2676L1956 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2677L1957 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2678L1958 Succinyl-CoA synthetase beta chain ADG L1959 Succinyl-CoAsynthetase beta chain RQP L1960 Succinyl-CoA synthetase beta chain 2679L1961 Succinyl-CoA synthetase beta chain 2680 L1962 Succinyl-CoAsynthetase beta chain 2681 L1963 Succinyl-CoA synthetase beta chain 2682L1964 Succinyl-CoA synthetase beta chain 2683 L1965 Succinyl-CoAsynthetase beta chain 2684 L1966 Succinyl-CoA: 3-ketoacid-coenzyme Atransferase 2685 L1967 Sulfurtransferase 2686 L1968 Superantigen SMEZ-22687 L1969 Superoxide dismutase 1 copper chaperone 2688 L1970 Surfacelayer protein 2689 L1971 Surface layer protein 2690 L1972 Surface layerprotein 2691 L1973 Surface layer protein 2692 L1974 Surface layerprotein 2693 L1975 Surface layer protein 2694 L1976 Surface layerprotein 2695 L1977 Surface layer protein 2696 L1978 T lymphocyteactivation antigen 2697 L1979 T lymphocyte activation antigen 2698 L1980T-cell receptor alpha chain C region 2699 L1981 Terminal oxygenasecomponent of carbazole 2700 L1982 Tetanus neurotoxin 2701 L1983Tetracycline repressor protein class D 2702 L1984 The GTP-bindingprotein Obg 2703 L1985 The GTP-binding protein Obg 2704 L1986 TheGTP-binding protein Obg 2705 L1987 The GTP-binding protein Obg 2706L1988 Thioredoxin domain-containing protein 4 2707 L1989 Thioredoxindomain-containing protein 4 2708 L1990 Thiosulfate sulfurtransferase IDPL1991 Thiosulfate sulfurtransferase 2709 L1992 Thiosulfatesulfurtransferase 2710 L1993 Thiosulfate sulfurtransferase 2711 L1994Thiosulfate sulfurtransferase 2712 L1995 Threonyl-tRNA synthetase 2713L1996 Threonyl-tRNA synthetase 2714 L1997 Threonyl-tRNA synthetase 2715L1998 Threonyl-tRNA synthetase 2716 L1999 Threonyl-tRNA synthetase 2717L2000 Threonyl-tRNA synthetase 2718 L2001 Threonyl-tRNA synthetase 2719L2002 Threonyl-tRNA synthetase 2720 L2003 Threonyl-tRNA synthetase 2721L2004 Threonyl-tRNA synthetase 1 2722 L2005 Threonyl-tRNA synthetase 12723 L2006 Threonyl-tRNA synthetase 1 2724 L2007 Threonyl-tRNAsynthetase 1 2725 L2008 Threonyl-tRNA synthetase 1 2726 L2009Threonyl-tRNA synthetase 1 2727 L2010 Threonyl-tRNA synthetase 1 2728L2011 Threonyl-tRNA synthetase 1 2729 L2012 Thrombospondin 1 2730 L2013Tick-borne encephalitis virus glycoprotein 2731 L2014 Titin 2732 L2015Titin 2733 L2016 TLR1789 protein 2734 L2017 TLR1789 protein 2735 L2018Topoisomerase I 2736 L2019 Topoisomerase I 2737 L2020 Toxic shocksyndrome toxin-1 2738 L2021 Toxic shock syndrome toxin-1 2739 L2022Toxic shock syndrome toxin-1 2740 L2023 Toxic shock syndrome toxin-12741 L2024 T-plasminogen activator F1-G VPV L2025 T-plasminogenactivator F1-G 2742 L2026 TpsB transporter FhaC 2743 L2027 TpsBtransporter FhaC 2744 L2028 TpsB transporter FhaC 2745 L2029Transcarbamylase 2746 L2030 Transcarbamylase 2747 L2031 Transcriptionantiterminator LicT 2748 L2032 Transcription elongation factor GreB 2749L2033 Transcription initiation factor IIa gamma chain 2750 L2034Transcription initiation factor IIb 2751 L2035 Transcription initiationfactor IIb 2752 L2036 Transcriptional regulator (NtrC family) 2753 L2037Transcriptional regulator AefR 2754 L2038 Transcriptional regulator AefR2755 L2039 Transcriptional regulator AefR 2756 L2040 Transcriptionalregulator AefR 2757 L2041 Transcriptional regulator AefR 2758 L2042Transcriptional regulator, AsnC family 2759 L2043 Transcriptionalregulator, AsnC family 2760 L2044 Transcriptional regulator, AsnC family2761 L2045 Transcriptional regulator, biotin repressor family 2762 L2046Transcriptional regulator, Crp/Fnr family 2763 L2047 Transcriptionalregulator, GntR family 2764 L2048 Transcriptional regulator, HTH_3family 2765 L2049 Transcriptional regulator, HTH_3 family 2766 L2050Transcriptional regulator, HTH_3 family 2767 L2051 Transcriptionalregulator, HTH_3 family 2768 L2052 Transcriptional regulator, HTH_3family 2769 L2053 Transcriptional regulator, laci family 2770 L2054Transcriptional regulatory protein ZraR 2771 L2055 Transcriptionalregulatory protein ZraR 2772 L2056 Transcriptional regulatory proteinZraR 2773 L2057 Transcriptional regulatory protein ZraR 2774 L2058Transcriptional regulatory protein ZraR 2775 L2059 Transcriptionalregulatory protein ZraR 2776 L2060 Transcriptional regulatory proteinZraR 2777 L2061 Transferrin receptor protein VSN L2062 Transferrinreceptor protein 2778 L2063 Transferrin receptor protein 2779 L2064Transferrin receptor protein 2780 L2065 Transferrin receptor protein2781 L2066 Translation initiation factor 5A 2782 L2067 Translationinitiation factor 5A 2783 L2068 Translation initiation factor 5A 2784L2069 Translation initiation factor IF2/eIF5b 2785 L2070 Translationinitiation factor IF2/eIF5b 2786 L2071 Transposable element mariner,complete CDS 2787 L2072 Tricorn protease 2788 L2073 Tricorn protease2789 L2074 Tricorn protease 2790 L2075 Trigger factor 2791 L2076 Triggerfactor 2792 L2077 Trigger factor 2793 L2078 TRNA CCA-adding enzyme RRIL2079 TRNA CCA-adding enzyme 2794 L2080 TRNA CCA-adding enzyme 2795L2081 TRNA CCA-adding enzyme 2796 L2082 TRNA CCA-adding enzyme 2797L2083 TRNA nucleotidyltransferase 2798 L2084 TRNA-splicing endonuclease2799 L2085 Tt1467 protein LEA L2086 Tt1467 protein 2800 L2087 Tumorsuppressor p53-binding protein 1 2801 L2088 Tumor suppressor p53-bindingprotein 1 2802 L2089 Tumor suppressor p53-binding protein 1 2803 L2090Tumor suppressor p53-binding protein 1 2804 L2091 Type A flavoproteinFprA 2805 L2092 Type A flavoprotein FprA 2806 L2093 Type A flavoproteinFprA 2807 L2094 Type A flavoprotein FprA 2808 L2095 Type A flavoproteinFprA 2809 L2096 Type I restriction enzyme specificity protein MG438 QMHL2097 Type I restriction enzyme specificity protein MG438 2810 L2098Type I restriction enzyme specificity protein MG438 2811 L2099 Type Irestriction-modification enzyme, S subunit 2812 L2100 Type Irestriction-modification enzyme, S subunit 2813 L2101 Type Isite-specific restriction-modification system, R (restriction) subunit2814 L2102 Type I site-specific restriction-modification system, R(restriction) subunit 2815 L2103 Type I site-specificrestriction-modification system, R (restriction) subunit 2816 L2104 TypeII DNA topoisomerase VI subunit B 2817 L2105 Type II DNA topoisomeraseVI subunit B 2818 L2106 Type II DNA topoisomerase VI subunit B 2819L2107 Type II DNA topoisomerase VI subunit B 2820 L2108 Type II DNAtopoisomerase VI subunit B 2821 L2109 Type II DNA topoisomerase VIsubunit B 2822 L2110 Type II DNA topoisomerase VI subunit B 2823 L2111Type II DNA topoisomerase VI subunit B 2824 L2112 Type II DNAtopoisomerase VI subunit B 2825 L2113 Type II DNA topoisomerase VIsubunit B 2826 L2114 Type II DNA topoisomerase VI subunit B 2827 L2115Type VI secretion system component 2828 L2116 Type VI secretion systemcomponent 2829 L2117 Type VI secretion system component 2830 L2118Tyrosine-protein kinase receptor UFO 2831 L2119 Tyrosine-protein kinasereceptor UFO 2832 L2120 Tyrosine-protein kinase ZAP-70 2833 L2121Tyrosine-protein kinase ZAP-70 2834 L2122 Tyrosyl-DNA phosphodiesterase2835 L2123 Tyrosyl-DNA phosphodiesterase 2836 L2124 Ubiquitincarboxyl-terminal hydrolase 7 2837 L2125 UDP-galactopyranose mutase 2838L2126 UDP-galactopyranose mutase 2839 L2127 UDP-galactopyranose mutase2840 L2128 UDP-galactopyranose mutase 2841 L2129 UDP-galactopyranosemutase 2842 L2130 UDP-glucose dehydrogenase 2843 L2131UDP-N-acetylmuramate-L-alanine ligase 2844 L2132UDP-N-acetylmuramate-L-alanine ligase 2845 L2133UDP-N-acetylmuramoylalanine--D-glutamate ligase 2846 L2134UDP-N-acetylmuramoylalanine--D-glutamate ligase 2847 L2135UDP-N-acetylmuramoylalanine-D-glutamyl-lysine-D-alanyl-D-alanine 2848ligase, MurF protein L2136UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2849L2137 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase2850 L2138 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelateligase 2851 L2139UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2852L2140 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase2853 L2141 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelateligase 2854 L2142UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2855L2143 Uncharacterized conserved protein 2856 L2144 Uncharacterizedconserved protein 2857 L2145 Uncharacterized GST-like protein yfcF 2858L2146 Uncharacterized GST-like proteinprotein 2859 L2147 UncharacterizedGST-like proteinprotein 2860 L2148 Uncharacterized GST-likeproteinprotein 2861 L2149 Uncharacterized protein 2862 L2150Uncharacterized protein 2863 L2151 Uncharacterized protein BT_1490 2864L2152 Uncharacterized protein ypfl TLR L2153 Uncharacterized proteinypfl VHP L2154 Uncharacterized protein ypfl 2865 L2155 Uncharacterizedprotein ypfl 2866 L2156 Uncharacterized protein ypfl 2867 L2157Uncharacterized protein ypfl 2868 L2158 Uncharacterized protein ypfl2869 L2159 Uncharacterized protein ypfl 2870 L2160 Uncharacterizedprotein ypfl 2871 L2161 Uncharacterized protein ypfl 2872 L2162Uncharacterized protein ypfl 2873 L2163 Uncharacterized protein ypfl2874 L2164 Uncharacterized protein ypfl 2875 L2165 Uncharacterizedprotein ypfl 2876 L2166 Uncharacterized protein ypfl 2877 L2167Uncharacterized protein ypfl 2878 L2168 Uncharacterized protein ypfl2879 L2169 Unknown protein 2880 L2170 Unknown protein 2881 L2171 UPF0131protein ykqA 2882 L2172 UPF0131 protein ykqA 2883 L2173 UPF0131 proteinykqA 2884 L2174 UPF0348 protein MJ0951 2885 L2175 UPF0348 protein MJ09512886 L2176 UPF0348 protein MJ0951 2887 L2177 UPF0348 protein MJ0951 2888L2178 UPF0348 protein MJ0951 2889 L2179 UPF0348 protein MJ0951 2890L2180 UPF0348 protein MJ0951 2891 L2181 UPF0348 protein MJ0951 2892L2182 URE2 protein 2893 L2183 Uridinediphospho-N-acetylenolpyruvylglucosaminereductase TAK L2184 Uridinediphospho-N-acetylenolpyruvylglucosaminereductase 2894 L2185 Uridinediphospho-N-acetylenolpyruvylglucosaminereductase 2895 L2186 Uridinediphospho-N-acetylenolpyruvylglucosaminereductase 2896 L2187 Uridinediphospho-N-acetylenolpyruvylglucosaminereductase 2897 L2188 Urokinaseplasminogen activator surface receptor 2898 L2189 Urokinase plasminogenactivator surface receptor 2899 L2190 Vascular cell adhesion molecule-12900 L2191 VCP-like ATPase 2901 L2192 VCP-like ATPase 2902 L2193 ViralCASP8 and FADD-like apoptosis regulator 2903 L2194 Vitamin K-dependentprotein Z 2904 L2195 VP1 protein 2905 L2196 V-type ATP synthase alphachain 2906 L2197 Xaa-Pro aminopeptidase 2907 L2198 Xaa-Proaminopeptidase 2908 L2199 Xaa-Pro aminopeptidase 2909 L2200 Xaa-Proaminopeptidase 2910 L2201 Xanthine dehydrogenase 2911 L2202 Xanthinedehydrogenase 2912 L2203 Xanthine dehydrogenase 2913 L2204 Xanthinedehydrogenase 2914 L2205 X-prolyl dipeptidyl aminopeptidase KSY L2206X-prolyl dipeptidyl aminopeptidase LDG L2207 X-prolyl dipeptidylaminopeptidase LLE L2208 X-prolyl dipeptidyl aminopeptidase TVS L2209X-prolyl dipeptidyl aminopeptidase 2915 L2210 X-prolyl dipeptidylaminopeptidase 2916 L2211 X-prolyl dipeptidyl aminopeptidase 2917 L2212X-prolyl dipeptidyl aminopeptidase 2918 L2213 X-prolyl dipeptidylaminopeptidase 2919 L2214 X-prolyl dipeptidyl aminopeptidase 2920 L2215X-prolyl dipeptidyl aminopeptidase 2921 L2216 X-prolyl dipeptidylaminopeptidase 2922 L2217 X-prolyl dipeptidyl aminopeptidase 2923 L2218X-prolyl dipeptidyl aminopeptidase 2924 L2219 X-prolyl dipeptidylaminopeptidase 2925 L2220 X-prolyl dipeptidyl aminopeptidase 2926 L2221X-prolyl dipeptidyl aminopeptidase 2927 L2222 X-prolyl dipeptidylaminopeptidase 2928 L2223 X-prolyl dipeptidyl aminopeptidase 2929 L2224X-prolyl dipeptidyl aminopeptidase 2930 L2225 X-prolyl dipeptidylaminopeptidase 2931 L2226 X-prolyl dipeptidyl aminopeptidase 2932 L2227X-prolyl dipeptidyl aminopeptidase 2933 L2228 X-prolyl dipeptidylaminopeptidase 2934 L2229 X-prolyl dipeptidyl aminopeptidase 2935 L2230X-prolyl dipeptidyl aminopeptidase 2936 L2231 X-prolyl dipeptidylaminopeptidase 2937 L2232 X-prolyl dipeptidyl aminopeptidase 2938 L2233Xylosidase/arabinosidase 2939 L2234 Xylosidase/arabinosidase 2940 L2235Xylosidase/arabinosidase 2941 L2236 Xylosidase/arabinosidase 2942 L2237Xylosidase/arabinosidase 2943 L2238 Xylosidase/arabinosidase 2944 L2239Xylosidase/arabinosidase 2945 L2240 YkoF 2946 L2241 YkuI protein 2947

Internal ribosomal entry site (IRES) is a nucleotide sequence (>500nucleotides) that allows for initiation of translation in the middle ofan mRNA sequence (Kim. J. H. et al., 2011 PLoS One (4): e18556; thecontents of which are herein incorporated by reference in its entirety).Use of an IRES sequence ensures co-expression of genes before and afterthe IRES, though the sequence following the IRES may be transcribed andtranslated at lower levels than the sequence preceding the IRESsequence.

2A peptides are small “self-cleaving” peptides (18-22 amino acids)derived from viruses such as foot-and-mouth disease virus (F2A), porcineteschovirus-1 (P2A). Thoseaasigna virus (T2A), or equine rhinitis Avirus (E2A). The 2A designation refers specifically to a region ofpicornavirus polyproteins that lead to a ribosomal skip at theglycyl-prolyl bond in the C-terminus of the 2A peptide (Kim. J. H. etal., 2011. PLoS One 6(4): e18556; the contents of which are hereinincorporated by reference in its entirety). This skip results in acleavage between the 2A peptide and its immediate downstream peptide. Asopposed to IRES linkers, 2A peptides generate stoichiometric expressionof proteins flanking the 2A peptide and their shorter length can beadvantageous in generating viral expression vectors.

Some payload regions encode linkers comprising furin cleavage sites.Furin is a calcium dependent serine endoprotease that cleaves proteinsjust downstream of a basic amino acid target sequence(Arg-X-(Arg,Lys)-Arg) (Thomas. G., 2002. Nature Reviews Molecular CellBiology 3(10); 753-66; the contents of which are herein incorporated byreference in its entirety). Furin is enriched in the trans-golgi networkwhere it is involved in processing cellular precursor proteins. Furinalso plays a role in activating a number of pathogens. This activity canbe taken advantage of for expression of polypeptides of the invention.

In some embodiments, the payload region may encode one or more linkerscomprising cathepsin, matrix metalloproteinases or legumain cleavagesites. Such linkers are described e.g. by Cizeau and Macdonald inInternational Publication No. WO2008052322, the contents of which areherein incorporated in their entirety. Cathepsins are a family ofproteases with unique mechanisms to cleave specific proteins Cathepsin Bis a cysteine protease and cathepsin D is an aspartyl protease. Matrixmetalloproteinases are a family of calcium-dependent and zinc-containingendopeptidases. Legumain is an enzyme catalyzing the hydrolysis of(-Asn-Xaa-) bonds of proteins and small molecule substrates.

In some embodiments, payload regions may encode linkers that are notcleaved. Such linkers may include a simple amino acid sequence, such asa glycine rich sequence. In some cases, linkers may comprise flexiblepeptide linkers comprising glycine and serine residues. The linker maycomprise flexible peptide linkers of different lengths, e.g. nxG4S,where n=1-10 (SEQ ID NO:9222) and the length of the encoded linkervaries between 5 and 50 amino acids. In a non-limiting example, thelinker may be 5xG4S (SEQ ID NO: 9221) encoded by SEQ ID NO: 903. Theseflexible linkers are small and without side chains so they tend not toinfluence secondary protein structure while providing a flexible linkerbetween antibody segments (George. R. A., et al., 2002. ProteinEngineering 15(11): 871-9; Huston, J. S. et al., 1988. PNAS 85:5879-83,and Shan. D. et al., 1999. Journal of Immunology, 162(11):6589-95; thecontents of each of which are herein incorporated by reference in theirentirety). Furthermore, the polarity of the serine residues improvessolubility and prevents aggregation problems.

In some embodiments, payload regions of the invention may encode smalland unbranched serine-rich peptide linkers, such as those described byHuston et al, in U.S. Pat. No. 5,525,491, the contents of which areherein incorporated in their entirety Polypeptides encoded by thepayload region of the invention, linked by serine-rich linkers, haveincreased solubility.

In some embodiments, payload regions of the invention may encodeartificial linkers, such as those described by Whitlow and Filpula inU.S. Pat. No. 5,856,456 and Ladner et al, in U.S. Pat. No. 4,946,778,the contents of each of which are herein incorporated by their entirety.

Viral Genome Component: Introns

In one embodiment, the payload region comprises at least one element toenhance the expression such as one or more introns or portions thereof.Non-limiting examples of introns include, MVM (67-97 bps), F.IXtruncated intron 1 (300 bps), β-globin SD/immunoglobulin heavy chainsplice acceptor (250 bps), adenovirus splice donor/immunoglobin spliceacceptor (500 bps), SV40 late splice donor/splice acceptor (19S/16S)(180 bps) and hybrid adenovirus splice donor/IgG splice acceptor (230bps).

In one embodiment, the intron or intron portion may be 100-500nucleotides in length. The intron may have a length of 80, 90, 100, 110,120, 130, 140, 150, 160, 170, 171, 172, 173, 174, 175, 176, 177, 178,179, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300,310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440,450, 460, 470, 480, 490 or 500, The intron may have a length between80-100, 80-120, 80-140, 80-160, 80-180, 80-200, 80-250, 80-300, 80-350,80-400, 80-450, 80-500, 200-300, 200-400, 200-500, 300-400, 300-500, or400-500.

Payloads of the Invention

The AAV particles of the present disclosure comprise at least onepayload region. As used herein. “payload” or “payload region” refers toone or more polynucleotides or polynucleotide regions encoded by orwithin a viral genome or an expression product of such polynucleotide orpolynucleotide region, e.g., a transgene, a polynucleotide encoding apolypeptide or multi-polypeptide or a modulatory nucleic acid orregulatory nucleic acid Payloads of the present invention typicallyencode polypeptides (e.g., antibodies or antibody-based compositions) orfragments or variants thereof.

The payload region may be constructed in such a way as to reflect aregion similar to or mirroring the natural organization of an mRNA.

The payload region may comprise a combination of coding and non-codingnucleic acid sequences.

In some embodiments, the AAV payload region may encode a coding ornon-coding RNA.

In one embodiment, the AAV particle comprises a viral genome with apayload region comprising nucleic acid sequences encoding more than onepolypeptide of interest (e.g., an antibody). In such an embodiment, aviral genome encoding more than one polypeptide may be replicated andpackaged into a viral particle. A target cell transduced with a viralparticle comprising more than one polypeptide may express each of thepolypeptides in a single cell.

In one embodiment, as shown in FIG. 1, an AAV particle comprises a viralgenome with a payload region comprising a nucleic acid sequence encodinga heavy chain and a light chain of an antibody. The heavy chain andlight chain are expressed and assembled to form the antibody which issecreted.

In one embodiment, the payload region may comprise the components asshown in FIG. 2. The payload region 110 is located within the viralgenome 100. At the 5′ and/or the 3′ end of the payload region 110 theremay be at least one inverted terminal repeat (ITR) 120. Within thepayload region, there is a promoter region 130, an intron region 140 anda coding region 150. When the coding region 150 comprises a heavy chainregion 151 and light chain region 152 of an antibody, the two chains maybe separated by a linker region 155.

In one embodiment, the coding region may comprise a heavy and lightchain sequence and a linker. As shown in FIG. 3, the payload region maycomprise a heavy chain and light chain sequence separated by a linkerand/or a cleavage site. In one embodiment, the heavy and light chainsequence is sequence separated by an IRES sequence (1 and 2) In oneembodiment, the heavy and light chain sequence is separated by a footand mouth virus sequence (3 and 4). In one embodiment, the heavy andlight chain sequence is separated by a foot and mouth virus sequence anda furin cleavage site (5 and 6) In one embodiment, the heavy and lightchain sequence is separated by a porcine teschovirus-1 virus sequence (7and 8) In one embodiment, the heavy and light chain sequence isseparated by a porcine teschovirus-1 virus and a furin cleavage site (9and 10). In one embodiment, the heavy and light chain sequence isseparated by a 5xG4S (SEQ ID NO: 9221) sequence (11).

Where the AAV particle payload region encodes a polypeptide, thepolypeptide may be a peptide or protein. A protein encoded by the AAVparticle payload region may comprise an antibody, an antibody relatedcomposition, a secreted protein, an intracellular protein, anextracellular protein, and/or a membrane protein. The encoded proteinsmay be structural or functional. In addition to the antibodies orantibody-based composition, proteins encoded by the payload region mayinclude, in combination, certain mammalian proteins involved in immunesystem regulation. The AAV viral genomes encoding polypeptides describedherein may be useful in the fields of human disease, viruses, infectionsveterinary applications and a variety of in vivo and in vitro settings.

In some embodiments, the AAV particles are useful in the field ofmedicine for the treatment, prophylaxis, palliation or amelioration ofneurological diseases and/or disorders.

Antibodies and Antibody-Based Compositions

Payload regions of the AAV particles of the invention may encodepolypeptides that form one or more functional antibodies orantibody-based compositions. As used herein, the term “antibody” isreferred to in the broadest sense and specifically covers variousembodiments including, but not limited to monoclonal antibodies,polyclonal antibodies, multispecific antibodies (e.g. bispecificantibodies formed from at least two intact antibodies), and antibodyfragments (e.g., diabodies) so long as they exhibit a desired biologicalactivity (e.g., “functional”). Antibodies are primarily amino-acid basedmolecules but may also comprise one or more modifications (including,but not limited to the addition of sugar moieties, fluorescent moieties,chemical tags, etc.)

As used herein, “antibody-based” or “antibody-derived” compositions aremonomeric or multi-meric polypeptides which comprise at least oneamino-acid region derived from a known or parental antibody sequence andat least one amino acid region derived from a non-antibody sequence,e.g., mammalian protein.

Payload regions may encode polypeptides that form or function as anyantibody, including antibodies that are known in the art and/orantibodies that are commercially available. The encoded antibodies maybe therapeutic, diagnostic, or for research purposes. Further,polypeptides of the invention may include fragments of such antibodiesor antibodies that have been developed to comprise one or more of suchfragments (e.g., variable domains or complementarity determining regions(CDRs)).

In one embodiment, the viral genome of the AAV particles may comprisenucleic acids which have been engineered to enable expression ofantibodies, antibody fragments, or components of any of those describedin U.S. Pat. No. 7,041,807 related to YYX epitope; US20090175884,US20110305630, US20130330275 related to misfolded proteins in cancer;US20040175775 related to PrP in eye fluid, US20030114360 related tocopolymers and methods of treating prion-related diseases: WO2009121176insulin-induced gene peptide compositions, US20030022243, WO2003000853related to protein aggregation assays; WO200078344 related to prionprotein peptides and uses thereof. Each of these publications areincorporated by reference in their entireties.

Antibody Generation

In some embodiments, viral genomes of the AAV particles of the inventionmay encode antibodies or antibody-based compositions produced usingmethods known in the art. Such methods may include, but are not limitedto immunization and display technologies (e.g., phage display, yeastdisplay, and ribosomal display). Antibodies may be developed, forexample, using any naturally occurring or synthetic antigen. As usedherein, an “antigen” is an entity which induces or evokes an immuneresponse in an organism. An immune response is characterized by thereaction of the cells, tissues and/or organs of an organism to thepresence of a foreign entity. Such an immune response typically leads tothe production by the organism of one or more antibodies against theforeign entity, e.g., antigen or a portion of the antigen. As usedherein. “antigens” also refer to binding partners for specificantibodies or binding agents in a display library.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be derived from antibodiesproduced using hybridoma technology. Host animals (e.g. mice, rabbits,goats, and llamas) may be immunized by an injection with an antigenicprotein to elicit lymphocytes that specifically bind to the antigen.Lymphocytes may be collected and fused with immortalized cell lines togenerate hybridomas which can be cultured in a suitable culture mediumto promote growth. The antibodies produced by the cultured hybridomasmay be subjected to analysis to determine binding specificity of theantibodies for the target antigen. Once antibodies with desirablecharacteristics are identified, corresponding hybridomas may besubcloned through limiting dilution procedures and grown by standardmethods. The antibodies produced by these cells may be isolated andpurified using standard immunoglobulin purification procedures.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be produced using heavy and lightchain variable region cDNA sequences selected from hybridomas or fromother sources. Sequences encoding antibody variable domains expressed byhybridomas may be determined by extracting RNA molecules fromantibody-producing hybridoma cells and producing cDNA by reversetranscriptase polymerase chain reaction (PCR). PCR may be used toamplify cDNA using primers specific for heavy and light chain sequences.PCR products may then be subcloned into plasmids for sequence analysis.Antibodies may be produced by insertion of resulting variable domainsequences into expression vectors.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be generated using displaytechnologies. Display technologies used to generate polypeptides of theinvention may include any of the display techniques (e.g display libraryscreening techniques) disclosed in International Patent Application No.WO2014074532, the contents of which are herein incorporated by referencein their entirety. In some embodiments, synthetic antibodies may bedesigned, selected or optimized by screening target antigens usingdisplay technologies (e.g. phage display technologies). Phage displaylibraries may comprise millions to billions of phage particles, eachexpressing unique antibody fragments on their viral coats. Suchlibraries may provide richly diverse resources that may be used toselect potentially hundreds of antibody fragments with diverse levels ofaffinity for one or more antigens of interest (McCafferty, et al., 1990.Nature, 348:552-4; Edwards. B. M. et al., 2003. JMB, 334: 103-18;Schofield, D. et al., 2007. Genome Biol. 8. R254 and Pershad, K. et al.,2010 Protein Engineering Design and Selection, 23.279-88; the contentsof each of which are herein incorporated by reference in theirentirety). Often, the antibody fragments present in such librariescomprise scFv antibody fragments, comprising a fusion protein of V_(H)and V_(L) antibody domains joined by a flexible linker. In some cases,scFvs may contain the same sequence with the exception of uniquesequences encoding variable loops of the CDRs. In some cases, scFvs areexpressed as fusion proteins, linked to viral coat proteins (e.g. theN-terminus of the viral pIII coat protein) V_(L) chains may be expressedseparately for assembly with V_(H) chains in the periplasm prior tocomplex incorporation into viral coats. Precipitated library members maybe sequenced from the bound phage to obtain cDNA encoding desired scFvs.Antibody variable domains or CDRs from such sequences may be directlyincorporated into antibody sequences for recombinant antibodyproduction, or mutated and utilized for further optimization through invitro affinity maturation.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be produced using yeast surfacedisplay technology, wherein antibody variable domain sequences may beexpressed on the cell surface of Saccharomyces cerevisiae. Recombinantantibodies may be developed by displaying the antibody fragment ofinterest as a fusion to e.g. Aga2p protein on the surface of the yeast,where the protein interacts with proteins and small molecules in asolution, scFvs with affinity towards desired receptors may be isolatedfrom the yeast surface using magnetic separation and flow cytometry.Several cycles of yeast surface display and isolation may be done toattain scFvs with desired properties through directed evolution.

In one embodiment, the sequence of the polypeptides to be encoded in theviral genomes of the invention (e.g., antibodies) may be designed byVERSITOPE™ Antibody Generation and other methods used by BIOATLA® anddescribed in United States Patent Publication No. US20130281303, thecontents of which are herein incorporated by reference in theirentirety. In brief, recombinant monoclonal antibodies are derived fromB-cells of a host immuno-challenged with one or more target antigens.These methods of antibody generation do not rely on immortalized celllines, such as hybridoma, thereby avoiding some of the associatedchallenges i.e., genetic instability and low production capacity,producing high affinity and high diversity recombinant monoclonalantibodies. In one embodiment, the method is a natural diversityapproach. In another embodiment, the method is a high diversityapproach.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be generated using BIOATLA®natural diversity approach. In the natural diversity approach ofgenerating recombinant monoclonal antibodies described in United StatesPatent Publication No. US20130281303, the original pairings of variableheavy (V_(H)) and variable light (V_(L)) domains are retained from thehost, yielding recombinant monoclonal antibodies that are naturallypaired. These may be advantageous due to a higher likelihood offunctionality as compared to non-natural pairings of V_(H) and V_(L). Toproduce the recombinant monoclonal antibodies, first a non-human host(i.e., rabbit, mouse, hamster, guinea pig, camel or goat) isimmuno-challenged with an antigen of interest. In some embodiments, thehost may be a previously challenged human patient. In other embodiments,the host may not have been immuno-challenged. B-cells are harvested fromthe host and screened by fluorescence activated cell sorting (FACS), orother method, to create a library of B-cells enriched in B-cells capableof binding the target antigen. The cDNA obtained from the mRNA of asingle B-cell is then amplified to generate an immunoglobulin library ofV_(H) and V_(L) domains. This library of immunoglobulins is then clonedinto expression vectors capable of expressing the V_(H) and V_(L)domains, wherein the V_(H) and V_(L) domains remain naturally paired.The library of expression vectors is then used in an expression systemto express the V_(H) and V_(L) domains in order to create an antibodylibrary. Screening of the antibody library yields antibodies able tobind the target antigen, and these antibodies can be furthercharacterized. Characterization may include one or more of thefollowing: isoelectric point, thermal stability, sedimentation rate,folding rate, neutralization or antigen activity, antagonist oragonistic activity, expression level, specific and non-specific binding,inhibition of enzymatic activity, rigidity/flexibility, shape, charge,stability across pH, in solvents, under UV radiation, in mechanicalstress conditions, or in sonic conditions, half-life and glycosylation.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be generated using BIOATLA® highdiversity approach. In the high diversity approach of generatingrecombinant monoclonal antibodies described in United States PatentPublication No. US20130281303, additional pairings of variable heavy(V_(H)) and variable light (V_(L)) domains are attained. To produce therecombinant monoclonal antibodies, B-cells harvested from the host arescreened by fluorescence activated cell sorting (FACS), panning, orother method, to create a library of B-cells enriched in B-cells capableof binding the target antigen. The cDNA obtained from the mRNA of thepooled B-cells is then amplified to generate an immunoglobulihn libraryof V_(H) and V_(L) domains. This library of immunoglobulins is then usedin a biological display system (mammalian, yeast or bacterial cellsurface display systems) to generate a population of cells displayingantibodies, fragments or derivatives comprising the V_(H) and V_(L)domains wherein, the antibodies, fragments or derivatives comprise V_(H)and V_(L) domain combinations that were not present in the B-cells invivo. Screening of the cell population by FACS, with the target antigen,yields a subset of cells capable of binding the target antigen and theantibodies displayed on these cells can be further characterized. In analternate embodiment of the high diversity approach, the immunoglobulinlibrary comprises only V_(H) domains obtained from the B-cells of theimmuno-challenged host, while the V_(L) domain(s) are obtained fromanother source.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be evolved using BIOATLA®comprehensive approaches. The methods of generating recombinantmonoclonal antibodies as described in United States Patent PublicationNo. US20130281303, further comprises evolving the recombinant antibodyby comprehensive positional evolution (CPE™), CPE™ followed bycomprehensive protein synthesis (CPS™), PCR shuffling, or other method.

In one embodiment, the sequence of the polypeptides to be encoded in theviral genomes of the invention (e.g., antibodies) may be derived fromany of the BIOATLA® protein evolution methods described in InternationalPublication WO2012009026, the contents of which are herein incorporatedby reference in their entirety. In this method, mutations aresystematically performed throughout the polypeptide or molecule ofinterest, a map is created providing useful informatics to guide thesubsequent evolutionary steps. Not wishing to be bound by theory, theseevolutionary methods typically start with a template polypeptide and amutant is derived therefrom, which has desirable properties orcharacteristics. Non-limiting examples of evolutionary techniquesinclude polymerase chain reaction (PCR), error prone PCR,oligonucleotide-directed mutagenesis, cassette mutagenesis, shuffling,assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, site-specificmutagenesis, gene reassembly, gene site saturated mutagenesis, in vitromutagenesis, ligase chain reaction, oligonucleotide synthesis or anycombination thereof.

In one embodiment, the BIOATLA® evolution method is ComprehensivePositional Evolution (CPE™). In CPE, naturally occurring amino acidvariants are generated for each of the codons of the templatepolypeptide, wherein 63 different codon options exist for each aminoacid variant. A set of polypeptides with single amino acid mutations aregenerated and the mutations are then confirmed by sequencing or othermethod known in the art and each amino acid change screened for improvedfunction, neutral mutations, inhibitory mutations, expression andcompatibility with the host system. An EvoMap™ is created that describesin detail the effects of each amino acid mutation on the properties andcharacteristics of that polypeptide. The data from the EvoMap™ may beutilized to produce polypeptides with more than one amino acid mutation,wherein the resultant multi-site mutant polypeptides can be screened fordesirable characteristics.

In one embodiment, the BIOATLA® evolution method is Synergy Evolution,wherein an EvoMap™ is used to identify amino acid positions to introduce2-20 mutations simultaneously to produce a combinatorial effect. Theresulting multi-site mutant polypeptides may be screened on one or morepre-determined characteristics to identify “upmutants” wherein thefunction of the mutant is improved as compared to the parentpolypeptide. In one embodiment, Synergy Evolution is used to enhancebinding affinity of an antibody.

In one embodiment, the BIOATLA® evolution method is Flex Evolution,wherein an EvoMap™ is used to identify fully mutable sites within apolypeptide that may then be targeted for alteration, such asintroduction of glycosylation sites or chemical conjugation.

In one embodiment, the BIOATLA® evolution method is ComprehensivePositional Insertion Evolution (CPI™), wherein an amino acid is insertedafter each amino acid of a template polypeptide to generate a set oflengthened poly peptides. CPI may be used to insert 1, 2, 3, 4, or 5amino acids at each new position. The resultant lengthened polypeptidesare sequenced and assayed for one or more pre-determined properties andevaluated in comparison to its template or parent molecule. In oneembodiment, the binding affinity and immunogenicity of the resultantpoly peptides are assayed. In one embodiment, the lengthened polypeptides are further mutated and mapped to identify polypeptides withdesirable characteristics.

In one embodiment, the BIOATLA® evolution approach is ComprehensivePositional Deletion Evolution (CPD™), wherein each amino acid of thetemplate polypeptide is individually and systematically deleted one at atime. The resultant shortened polypeptides are then sequenced andevaluated by assay for at least one pre-determined feature. In oneembodiment, the shortened polypeptides are further mutated and mapped toidentify polypeptides with desirable characteristics.

In one embodiment, the BIOATLA® evolution approach is CombinatorialProtein Synthesis (CPS™), wherein mutants identified in CPE, CPI, CPD orother evolutionary technique are combined for polypeptide synthesis.These combined mutant polypeptides are then screened for enhancedproperties and characteristics. In one embodiment CPS is combined withany of the aforementioned evolutionary or polypeptide synthesis methods.

In one embodiment, the sequence of the polypeptides to be encoded in theviral genomes of the invention (e.g., antibodies) may be derived fromthe BIOATLA® Comprehensive Integrated Antibody Optimization (CIAO!™)described in U.S. Pat. No. 8,859,467, the contents of which are hereinincorporated by reference in their entirety. The CIAO!™ method allowsfor simultaneous evolution of polypeptide performance and expressionoptimization, within a eukaryotic cell host (i.e., mammalian or yeastcell host). First, an antibody library is generated in a mammalian cellproduction host by antibody cell surface display, wherein the generatedantibody library targets a particular antigen of interest. The antibodylibrary is then screened by any method known in the art, for one or moreproperties or characteristics. One or more antibodies of the library,with desirable properties or characteristics are chosen for further polypeptide evolution by any of the methods known in the art, to produce alibrary of mutant antibodies by antibody cell surface display in amammalian cell production host. The generated mutant antibodies arescreened for one or more predetermined properties or characteristics,whereby an upmutant is selected, wherein the upmutant has enhanced orimproved characteristics as compared to the parent template polypeptide.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be humanized by the methods ofBIOATLA® as described in United States Patent Publication US20130303399,the contents of which are herein incorporated by reference in theirentirety. In this method, for generating enhanced full length humanizedantibodies in mammalian cells, no back-mutations are required to retainaffinity to the antigen and no CDR grafting or phage-display isnecessary. The generated humanized antibody has reduced immunogenicityand equal or greater affinity for the target antigen as compared to theparent antibody. The variable regions or CDRs of the generated humanizedantibody are derived from the parent or template, whereas the frameworkand constant regions are derived from one or more human antibodies. Tostart, the parent, or template antibody is selected, cloned and each CDRsequence identified and synthesized into a CDR fragment library. Doublestranded DNA fragment libraries for V_(H) and V_(L) are synthesized fromthe CDR fragment encoding libraries, wherein at least one CDR fragmentlibrary is derived from the template antibody and framework (FW)fragment encoding libraries, wherein the FW fragment library is derivedfrom a pool of human frameworks obtained from natively expressed andfunctional human antibodies. Stepwise liquid phase ligation of FW andCDR encoding fragments is then used to generate both V_(H) and V_(L)fragment libraries. The V_(H) and V_(L) fragment libraries are thencloned into expression vectors to create a humanization library, whichis further transfected into cells for expression of full lengthhumanized antibodies, and used to create a humanized antibody library.The humanized antibody library is then screened to determine expressionlevel of the humanized antibodies, affinity or binding ability for theantigen, and additional improved or enhanced characteristics, ascompared to the template or parent antibody. Non-limiting examples ofcharacteristics that may be screened include equilibrium dissociationconstant (K_(D)), stability, melting temperature (T_(m)), pI,solubility, expression level, reduced immunogenicity and improvedeffector function.

In one embodiment, the sequences of the polypeptides to be encoded inthe viral genomes of the invention may be generated by the BIOATLA®method for preparing conditionally active antibodies as described inInternational Publications WO02016033331 and WO2016036916, the contentsof which are herein incorporated by reference in their entirety. As usedherein, the term “conditionally active” refers to a molecule that isactive at an aberrant condition. Further, the conditionally activemolecule may be virtually inactive at normal physiological conditions.Aberrant conditions may result from changes in pH, temperature, osmoticpressure, osmolality, oxidative stress, electrolyte concentration,and/or chemical or proteolytic resistance, as non-limiting examples.

The method of preparing a conditionally active antibody is described inInternational Publications WO2016033331 and WO2016036916 and summarizedherewithin. Briefly, a wild-type polypeptide is selected and the DNA isevolved to create mutant DNAs. Non-limiting examples of evolutionarytechniques that may be used to evolve the DNA include polymerase chainreaction (PCR), error prone PCR, shuffling, oligonucleotide-directedmutagenesis, assembly PCR sexual PCR mutagenesis, in vivo mutagenesis,site-specific mutagenesis, gene reassembly, gene site saturatedmutagenesis, in vitro mutagenesis, ligase chain reaction,oligonucleotide synthesis or any combination thereof. Once mutant DNAsare created, they are expressed in a eukaryotic cell production host(i.e., fungal, insect, mammalian, adenoviral, plant), wherein a mutantpolypeptide is produced. The mutant poly peptide and the correspondingwild-type polypeptide are then subjected to assays under both normalphysiological conditions and aberrant conditions in order to identifymutants that exhibit a decrease in activity in the assay at normalphysiological conditions as compared to the wild-type polypeptide and/oran increase in activity in the assay under aberrant conditions, ascompared to the corresponding wild-type polypeptide. The desiredconditionally active mutant may then be produced in the aforementionedeukaryotic cell production host.

In one embodiment, the conditionally active antibody is a “miracprotein” as described by BIOATLA® in U.S. Pat. No. 8,709,755, thecontents of which are herein incorporated by reference in theirentirety. As used herein “mirac protein” refers to a conditionallyactive antibody that is virtually inactive at body temperature butactive at lower temperatures.

In one embodiment, the sequence of the polypeptides to be encoded in theviral genomes of the invention (e.g., antibodies) may be derived basedon any of the BIOATLA™ methods including, but not limited to, VERSITOPE™Antibody Generation, natural diversity approaches and high diversityapproaches for generating monoclonal antibodies, methods for generationof conditionally active polypeptides, humanized antibodies, miracproteins, multi-specific antibodies or cross-species active mutantpolypeptides. Comprehensive Integrated Antibody Optimization (CIAO!®),Comprehensive Positional Evolution (CPE™). Synergy Evolution, FlexEvolution, Comprehensive Positional Insertion Evolution (CPI™).Comprehensive Positional Deletion Evolution (CPD™), CombinatorialProtein Synthesis (CPS®), or any combination thereof. These methods aredescribed in U.S. Pat. Nos. 8,859,467 and 8,709,755 and United StatesPublication Nos US20130281303, US20130303399, US20150065690,US20150252119, US20150086562 and US20100138945, and InternationalPublication Nos. WO201505888, WO2012009026, WO2011109726, WO2016036916,and WO2016033331, the contents of each of which are herein incorporatedby reference in their entirety.

Antibody Fragments and Variants

In some embodiments, antibody fragments encoded by payloads of theinvention comprise antigen binding regions from intact antibodies.Examples of antibody fragments may include, but are not limited to Fab,Fab′, F(ab′)₂, and Fv fragments; diabodies; linear antibodies;single-chain antibody molecules; and multispecific antibodies formedfrom antibody fragments. Papain digestion of antibodies produces twoidentical antigen-binding fragments, called “Fab” fragments, each with asingle antigen-binding site. Also produced is a residual “Fc” fragment,whose name reflects its ability to crystallize readily. Pepsin treatmentyields an F(ab′)₂ fragment that has two antigen-binding sites and isstill capable of cross-linking antigen. Compounds and/or compositions ofthe present invention may comprise one or more of these fragments. Forthe purposes herein, an “antibody” may comprise a heavy and lightvariable domain as well as an Fc region.

In one embodiment, the Fc region may be a modified Fc region, asdescribed in US Patent Publication US20150065690, wherein the Fc regionmay have a single amino acid substitution as compared to thecorresponding sequence for the wild-type Fc region, wherein the singleamino acid substitution yields an Fc region with preferred properties tothose of the wild-type Fc region. Non-limiting examples of Fc propertiesthat may be altered by the single amino acid substitution include bindproperties or response to pH conditions

As used herein, the term “native antibody” refers to a usuallyheterotetrameric glycoprotein of about 150,000 Daltons, composed of twoidentical light (L) chains and two identical heavy (H) chains. Genesencoding antibody heavy and light chains are known and segments makingup each have been well characterized and described (Matsuda, F. et al.,1998. The Journal of Experimental Medicine, 188(11); 2151-62 and Li. A.et al., 2004. Blood, 103(12, 4602-9, the content of each of which areherein incorporated by reference in their entirety). Each light chain islinked to a heavy chain by one covalent disulfide bond, while the numberof disulfide linkages varies among the heavy chains of differentimmunoglobulin isotypes. Each heavy and light chain also has regularlyspaced intrachain disulfide bridges. Each heavy chain has at one end avariable domain (V_(H)) followed by a number of constant domains. Eachlight chain has a variable domain at one end (V_(L)) and a constantdomain at its other end; the constant domain of the light chain isaligned with the first constant domain of the heavy chain, and the lightchain variable domain is aligned with the variable domain of the heavychain.

As used herein, the term “variable domain” refers to specific antibodydomains found on both the antibody heavy and light chains that differextensively in sequence among antibodies and are used in the binding andspecificity of each particular antibody for its particular antigen.Variable domains comprise hypervariable regions. As used herein, theterm “hypervariable region” refers to a region within a variable domaincomprising amino acid residues responsible for antigen binding. Theamino acids present within the hypervariable regions determine thestructure of the complementarity determining regions (CDRs) that becomepart of the antigen-binding site of the antibody. As used herein, theterm “CDR” refers to a region of an antibody comprising a structure thatis complimentary to its target antigen or epitope Other portions of thevariable domain, not interacting with the antigen, are referred to asframework (FW) regions. The antigen-binding site (also known as theantigen combining site or paratope) comprises the amino acid residuesnecessary to interact with a particular antigen. The exact residuesmaking up the antigen-binding site are typically elucidated byco-crystallography with bound antigen, however computational assessmentscan also be used based on comparisons with other antibodies (Strohl, W.R. Therapeutic Antibody Engineering. Woodhead Publishing, PhiladelphiaPa. 2012 Ch. 3, p 47-54, the contents of which are herein incorporatedby reference in their entirety). Determining residues making up CDRs mayinclude the use of numbering schemes including, but not limited to,those taught by Kabat [Wu. T. T. et al., 1970, JEM, 132(2):211-50 andJohnson, G. et al., 2000, Nucleic Acids Res. 28(1): 214-8, the contentsof each of which are herein incorporated by reference in theirentirety], Chothia [Chothia and Lesk. J. Mol Biol 196, 901 (1987),Chothia et al., Nature 342, 877 (1989) and Al-Lazikani, B. et al., 1997,J. Mol. Biol. 273(4):927-48, the contents of each of which are hereinincorporated by reference in their entirety], Lefranc (Lefranc, M. P. etal., 2005, Immunome Res 1:3) and Honegger (Honegger, A. and Pluckthun,A. 2001. J. Mol. Biol. 309(3):657-70, the contents of which are hereinincorporated by reference in their entirety).

V_(H) and V_(L) domains have three CDRs each. V_(L) CDRs are referred toherein as CDR-L1, CDR-L2 and CDR-L3, in order of occurrence when movingfrom N- to C-terminus along the variable domain polypeptide. V_(H) CDRsare referred to herein as CDR-H1, CDR-H2 and CDR-H3, in order ofoccurrence when moving from N- to C-terminus along the variable domainpolypeptide. Each of CDRs have favored canonical structures with theexception of the CDR-H3, which comprises amino acid sequences that maybe highly variable in sequence and length between antibodies resultingin a variety of three-dimensional structures in antigen-binding domains(Nikoloudis, D. et al., 2014 Peer J 2:e456; the contents of which areherein incorporated by reference in their entirety). In some cases.CDR-H3s may be analyzed among a panel of related antibodies to assessanti body, diversity. Various methods of determining CDR sequences areknown in the art and may be applied to known antibody sequences (Strohl.W. R. Therapeutic Antibody Engineering. Woodhead Publishing,Philadelphia Pa. 2012. Ch. 3, p 47-54, the contents of which are hereinincorporated by reference in their entirety).

As used herein, the term “Fv” refers to an antibody fragment comprisingthe minimum fragment on an antibody needed to form a completeantigen-binding site. These regions consist of a dimer of one heavychain and one light chain variable domain in tight, non-covalentassociation. Fv fragments can be generated by proteolytic cleavage, butare largely unstable. Recombinant methods are known in the art forgenerating stable Fv fragments, typically through insertion of aflexible linker between the light chain variable domain and the heavychain variable domain [to form a single chain F, (scFv)] or through theintroduction of a disulfide bridge between heavy and light chainvariable domains (Strohl, W. R. Therapeutic Antibody EngineeringWoodhead Publishing. Philadelphia Pa. 2012 Ch. 3, p 46-47, the contentsof which are herein incorporated by reference in their entirety).

As used herein, the term “light chain” refers to a component of anantibody from any vertebrate species assigned to one of two clearlydistinct types, called kappa and lambda based on amino acid sequences ofconstant domains. Depending on the amino acid sequence of the constantdomain of their heavy chains, antibodies can be assigned to differentclasses. There are five major classes of intact antibodies: IgA, IgD,IgE, IgG, and IgM, and several of these may be further divided intosubclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

As used herein, the term “single chain Fv” or “scFv” refers to a fusionprotein of V_(H) and V_(L) antibody domains, wherein these domains arelinked together into a single polypeptide chain by a flexible peptidelinker. In some embodiments, the Fv polypeptide linker enables the scFvto form the desired structure for antigen binding. In some embodiments,scFvs are utilized in conjunction with phage display, yeast display orother display methods where they may be expressed in association with asurface member (e.g. phage coat protein) and used in the identificationof high affinity peptides for a given antigen.

As used herein, the term “bispecific antibody” refers to an antibodycapable of binding two different antigens. Such antibodies typicallycomprise regions from at least two different antibodies. Bispecificantibodies may include any of those described in Riethmuller, G, 2012.Cancer Immunity, 12:12-18, Marvin, J. S. et al., 2005. ActaPharmacologica Sinuca, 26(6).649-58 and Schaefer, W. et al., 2011. PNAS.108(27) 11187-92, the contents of each of which are herein incorporatedby reference in their entirety.

As used herein, the term “diabody” refers to a small antibody fragmentwith two antigen-binding sites. Diabodies comprise a heavy chainvariable domain V_(H) connected to a light chain variable domain V_(L)in the same polypeptide chain. By using a linker that is too short toallow pairing between the two domains on the same chain, the domains areforced to pair with the complementary domains of another chain andcreate two antigen-binding sites. Diabodies are described more fully in,for example EP 404,097; WO 93/11161; and Hollinger et al. (Hollinger, P.et al., “Diabodies” Small bivalent and bispecific antibody fragments.PNAS. 1993, 90:6444-8) the contents of each of which are incorporatedherein by reference in their entirety.

The term “intrabody” refers to a form of antibody that is not secretedfrom a cell in which it is produced, but instead targets one or moreintracellular proteins. Intrabodies may be used to affect a multitude ofcellular processes including, but not limited to intracellulartrafficking, transcription, translation, metabolic processes,proliferative signaling and cell division. In some embodiments, methodsof the present invention may include intrabody-based therapies. In somesuch embodiments, variable domain sequences and/or CDR sequencesdisclosed herein may be incorporated into one or more constructs forintrabody-based therapy.

As used herein, the term “monoclonal antibody” refers to an antibodyobtained from a population of substantially homogeneous cells (orclones), i.e., the individual antibodies comprising the population areidentical and/or bind the same epitope, except for possible variantsthat may arise during production of the monoclonal antibodies, suchvariants generally being present in minor amounts. In contrast topolyclonal antibody preparations that typically include differentantibodies directed against different determinants (epitopes), eachmonoclonal antibody is directed against a single determinant on theantigen

The modifier “monoclonal” indicates the character of the antibody asbeing obtained from a substantially homogeneous population ofantibodies, and is not to be construed as requiring production of theantibody by any particular method. The monoclonal antibodies hereininclude “chimeric” antibodies (immunoglobulins) in which a portion ofthe heavy and/or light chain is identical with or homologous tocorresponding sequences in antibodies derived from a particular speciesor belonging to a particular antibody class or subclass, while theremainder of the chain(s) is identical with or homologous tocorresponding sequences in antibodies derived from another species orbelonging to another antibody class or subclass, as well as fragments ofsuch antibodies.

As used herein, the term “humanized antibody” refers to a chimericantibody comprising a minimal portion from one or more non-human (e.g.,murine) antibody source(s) with the remainder derived from one or morehuman immunoglobulin sources. For the most part, humanized antibodiesare human immunoglobulins (recipient antibody) in which residues fromthe hypervariable region from an antibody of the recipient are replacedby residues from the hypervariable region from an antibody of anon-human species (donor antibody) such as mouse, rat, rabbit ornonhuman primate having the desired specificity, affinity, and/orcapacity.

In some embodiments, viral genomes of the present invention may encodeantibody, mimetics. As used herein, the term “antibody mimetic” refersto any molecule which mimics the function or effect of an antibody andwhich binds specifically and with high affinity to their moleculartargets. In some embodiments, antibody mimetics may be monobodies,designed to incorporate the fibronectin type III domain (Fn3) as aprotein scaffold (U.S. Pat. Nos. 6,673,901; 6,348,584). In someembodiments, antibody mimetics may be those known in the art including,but are not limited to affibody molecules, affilins, affitins,anticalins, avimers, Centyrins, DARPINS™, Fynomers and Kunitz and domainpeptides. In other embodiments, antibody mimetics may include one ormore non-peptide regions.

As used herein, the term “antibody variant” refers to a modifiedantibody (in relation to a native or starting antibody) or a biomoleculeresembling a native or starting antibody in structure and/or function(e.g., an antibody mimetic). Antibody variants may be altered in theiramino acid sequence, composition or structure as compared to a nativeantibody. Antibody variants may include, but are not limited to,antibodies with altered isotypes (e.g., IgA, IgD, IgE, IgG₁, IgG₂, IgG₃,IgG₄, or IgM), humanized variants, optimized variants, multispecificantibody variants (e.g., bispecific variants), and antibody fragments.

The preparation of antibodies, whether monoclonal or polyclonal, isknown in the art. Techniques for the production of antibodies are wellknown in the art and described, e.g. in Harlow and Lane “Antibodies. ALaboratory Manual”, Cold Spring Harbor Laboratory Press, 1988, Harlowand Lane “Using Antibodies: A Laboratory Manual” Cold Spring HarborLaboratory Press, 1999 and “Therapeutic Antibody Engineering: Currentand Future Advances Driving the Strongest Growth Area in thePharmaceutical Industry” Woodhead Publishing, 2012.

Multispecific Antibodies

In some embodiments, payloads of the invention may encode antibodiesthat bind more than one epitope. As used herein, the terms “multibody”or “multispecific antibody” refer to an antibody wherein two or morevariable regions bind to different epitopes. The epitopes may be on thesame or different targets. In certain embodiments, a multi-specificantibody is a “bispecific antibody,” which recognizes two differentepitopes on the same or different antigens.

In one embodiment, multi-specific antibodies may be prepared by themethods used by BIOATLA® and described in International Patentpublication WO201109726, the contents of which are herein incorporatedby reference in their entirety. First a library of homologous, naturallyoccurring antibodies is generated by any method known in the art (i.e.,mammalian cell surface display), then screened by FACSAria or otherscreening method, for multi-specific antibodies that specifically bindto two or more target antigens. In one embodiment, the identifiedmulti-specific antibodies are further evolved by any method known in theart, to produce a set of modified multi-specific antibodies. Thesemodified multi-specific antibodies are screened for binding to thetarget antigens. In one embodiment, the multi-specific antibody may befurther optimized by screening the evolved modified multi-specificantibodies for optimized or desired characteristics.

In one embodiment, multi-specific antibodies may be prepared by themethods used by BIOATLA® and described in Unites States Publication No.US20150252119, the contents of which are herein incorporated byreference in their entirety. In one approach, the variable domains oftwo parent antibodies, wherein the parent antibodies are monoclonalantibodies are evolved using any method known in the art in a mannerthat allows a single light chain to functionally complement heavy chainsof two different parent antibodies. Another approach requires evolvingthe heavy chain of a single parent antibody to recognize a second targetantigen. A third approach involves evolving the light chain of a parentantibody so as to recognize a second target antigen. Methods forpolypeptide evolution are described in International PublicationWO2012009026, the contents of which are herein incorporated by referencein their entirety, and include as non-limiting examples. ComprehensivePositional Evolution (CPE), Combinatorial Protein Synthesis (CPS).Comprehensive Positional Insertion (CPI), Comprehensive PositionalDeletion (CPD), or any combination thereof. The Fc region of themulti-specific antibodies described in United States Publication No.US20150252119 may be created using a knob-in-hole approach, or any othermethod that allows the Fc domain to form heterodimers. The resultantmulti-specific antibodies may be further evolved for improvedcharacteristics or properties such as binding affinity for the targetantigen.

Bispecific Antibodies

In some embodiments, payloads of the invention may encode bispecificantibodies. Bispecific antibodies are capable of binding two differentantigens. Such antibodies typically comprise antigen-binding regionsfrom at least two different antibodies. For example, a bispecificmonoclonal antibody (BsMAb, BsAb) is an artificial protein composed offragments of two different monoclonal antibodies, thus allowing the BsAbto bind to two different types of antigen.

In some cases, payloads encode bispecific antibodies comprisingantigen-binding regions from two different anti-tau antibodies. Forexample, such bispecific antibodies may comprise binding regions fromtwo different antibodies selected from Tables 3-42. Bispecific antibodyframeworks may include any of those described in Riethmuller, G., 2012.Cancer Immunity, 12:12-18; Marvin, J. S. et al., 2005. ActaPharmacologica Sinica, 26(6):649-58, and Schaefer, W. et al., 2011.PNAS. 108(27); 11187-92, the contents of each of which are hereinincorporated by reference in their entirety.

New generations of BsMAb, called “trifunctional bispecific” antibodies,have been developed. These consist of two heavy and two light chains,one each from two different antibodies, where the two Fab regions (thearms) are directed against two antigens, and the Fc region (the foot)comprises the two heavy chains and forms the third binding site.

Of the two paratopes that form the tops of the variable domains of abispecific antibody, one can be directed against a target antigen andthe other against a T-lymphocytes antigen like CD3. In the case oftrifunctional antibodies, the Fc region may additionally bind to a cellthat expresses Fc receptors, like a macrophage, a natural killer (NK)cell or a dendritic cell. In sum, the targeted cell is connected to oneor two cells of the immune system, which subsequently destroy it.

Other types of bispecific antibodies have been designed to overcomecertain problems, such as short half-life, immunogenicity andside-effects caused by cytokine liberation. They include chemicallylinked Fabs, consisting only of the Fab regions, and various types ofbivalent and trivalent single-chain variable fragments (scFvs), fusionproteins mimicking the variable domains of two antibodies. The furthestdeveloped of these newer formats are the bi-specific T-cell engagers(BuTEs) and mAb2's, antibodies engineered to contain an Fcabantigen-binding fragment instead of the Fe constant region.

Using molecular genetics, two scFvs can be engineered in tandem into asingle polypeptide, separated by a linker domain, called a “tandem scFv”(tascFv). TascFvs have been found to be poorly soluble and requirerefolding when produced in bacteria, or they may be manufactured inmammalian cell culture systems, which avoids refolding requirements butmay result in poor yields. Construction of a tascFv with genes for twodifferent scFvs yields a “bispecific single-chain variable fragments”(bis-scFvs). Only two tascFvs have been developed clinically bycommercial firms, both are bispecific agents in active early phasedevelopment by Micromet for oncologic indications, and are described as“Bispecific T-cell Engagers (BiTE).” Blinatumomab is ananti-CD19/anti-CD3 bispecific tascFv that potentiates T-cell responsesto B-cell non-Hodgkin lymphoma in Phase 2. MT110 is ananti-EP-CAM/anti-CD3 bispecific tascFv that potentiates T-cell responsesto solid tumors in Phase 1. Bispecific, tetravalent “TandAbs” are alsobeing researched by Affimed (Nelson, A. L., MAbs. 2010.January-February, 2(1):77-83).

In some embodiments, payloads may encode antibodies comprising a singleantigen-binding domain. These molecules are extremely small, withmolecular weights approximately one-tenth of those observed forfull-sized mAbs. Further antibodies may include “nanobodies” derivedfrom the antigen-binding variable heavy chain regions (V_(HHS)) of heavychain antibodies found in camels and llamas, which lack light chains(Nelson. A. L., MAbs. 2010 January-February; 2(1):77-83).

Disclosed and claimed in PCT Publication WO02014144573 to MemorialSloan-Kettering Cancer Center are multimerization technologies formaking dimeric multispecific binding agents (e.g., fusion proteinscomprising antibody components) with improved properties overmultispecific binding agents without the capability of dimerization.

In some cases, payloads of the invention may encode tetravalentbispecific antibodies (TetBiAbs as disclosed and claimed in PCTPublication WO2014144357) TetBiAbs feature a second pair of Fabfragments with a second antigen specificity attached to the C-terminusof an antibody, thus providing a molecule that is bivalent for each ofthe two antigen specificities. The tetravalent antibody is produced bygenetic engineering methods, by linking an antibody heavy chaincovalently to a Fab light chain, which associates with its cognate,co-expressed Fab heavy chain.

In some aspects, payloads of the invention may encode biosyntheticantibodies as described in U.S. Pat. No. 5,091,513, the contents ofwhich are herein incorporated by reference in their entirety. Suchantibody may include one or more sequences of amino acids constituting aregion which behaves as a biosynthetic antibody binding site (BABS). Thesites comprise 1) non-covalently associated or disulfide bondedsynthetic V_(H) and V_(L) dimers, 2) V_(H)-V_(L) or V_(L)-V_(H) singlechains wherein the V_(H) and V_(L) are attached by a polypeptide linker,or 3) individuals V_(H) or V_(L) domains. The binding domains compriselinked CDR and FR regions, which may be derived from separateimmunoglobulins. The biosynthetic antibodies may also include otherpolypeptide sequences which function, e.g., as an enzyme, toxin, bindingsite, or site of attachment to an immobilization media or radioactiveatom. Methods are disclosed for producing the biosynthetic antibodies,for designing BABS having any specificity that can be elicited by invivo generation of antibody, and for producing analogs thereof.

In some embodiments, payloads may encode antibodies with antibodyacceptor frameworks taught in U.S. Pat. No. 8,399,625. Such antibodyacceptor frameworks may be particularly well suited accepting CDRs froman antibody of interest. In some cases. CDRs from anti-tau antibodiesknown in the art or developed according to the methods presented hereinmay be used.

Miniaturized Antibody

In one embodiment, the antibody encoded by the payloads of the inventionmay be a “miniaturized” antibody. Among the best examples of mAbminiaturization are the small modular immunopharmaceuticals (SMIPs) fromTrubion Pharmaceuticals. These molecules, which can be monovalent orbivalent, are recombinant single-chain molecules containing one V_(L),one V_(H) antigen-binding domain, and one or two constant “effector”domains, all connected by linker domains. Presumably, such a moleculemight offer the advantages of increased tissue or tumor penetrationclaimed by fragments while retaining the immune effector functionsconferred by constant domains. At least three “miniaturized” SMIPs haveentered clinical development. TRU-015, an anti-CD20 SMIP developed incollaboration with Wyeth, is the most advanced project, havingprogressed to Phase 2 for rheumatoid arthritis (RA). Earlier attempts insystemic lupus erythrematosus (SLE) and B cell lymphomas were ultimatelydiscontinued. Trubion and Facet Biotechnology are collaborating in thedevelopment of TRU-016, an anti-CD37 SMIP, for the treatment of CLL andother lymphoid neoplasias, a project that has reached Phase 2. Wyeth haslicensed the anti-CD20 SMIP SBI-087 for the treatment of autoimmunediseases, including RA, SLE and possibly multiple sclerosis, althoughthese projects remain in the earliest stages of clinical testing.(Nelson, A. L., MAbs. 2010. January-February; 2(1):77-83).

Diabodies

In some embodiments, payloads of the invention may encode diabodies.Diabodies are functional bispecific single-chain antibodies (bscAb).These bivalent antigen-binding molecules are composed of non-covalentdimers of scFvs, and can be produced in mammalian cells usingrecombinant methods. (See, e.g., Mack et al. Proc. Natl. Acad. Sci., 92,7021-7025, 1995). Few diabodies have entered clinical development. Aniodine-123-labeled diabody version of the anti-CEA chimeric antibodycT84.66 has been evaluated for pre-surgical immunoscintigraphicdetection of colorectal cancer in a study sponsored by the BeckmanResearch Institute of the City of Hope (Clinicaltrials.gov NCT00647153)(Nelson, A. L., MAbs 2010. January-February; 2(1):77-83)

Unibody

In some embodiments, payloads may encode a “unibody,” in which the hingeregion has been removed from IgG4 molecules. While IgG4 molecules areunstable and can exchange light-heavy chain heterodimers with oneanother, deletion of the hinge region prevents heavy chain-heavy chainpairing entirely, leaving highly specific monovalent light-heavyheterodimers, while retaining the Fc region to ensure stability andhalf-life in vivo. This configuration may minimize the risk of immuneactivation or oncogenic growth, as IgG4 interacts poorly with FcRs andmonovalent unibodies fail to promote intracellular signaling complexformation. These contentions are, however, largely supported bylaboratory, rather than clinical, evidence. Other antibodies may be“miniaturized” antibodies, which are compacted 100 kDa antibodies (see,e.g., Nelson, A. L., MAbs. 2010. January-February; 2(1):77-83).

Intrabodies

In some embodiments, payloads of the invention may encode intrabodies.Intrabodies are a form of antibody that is not secreted from a cell inwhich it is produced, but instead targets one or more intracellularproteins. Intrabodies are expressed and function intracellularly, andmay be used to affect a multitude of cellular processes including, butnot limited to intracellular trafficking, transcription, translation,metabolic processes, proliferative signaling and cell division. In someembodiments, methods described herein include intrabody-based therapies.In some such embodiments, variable domain sequences and/or CDR sequencesdisclosed herein are incorporated into one or more constructs forintrabody-based therapy. For example, intrabodies may target one or moreglycated intracellular proteins or may modulate the interaction betweenone or more glycated intracellular proteins and an alternative protein.

More than two decades ago, intracellular antibodies againstintracellular targets were first described (Biocca, Neuberger andCattaneo EMBO J. 9: 101-108, 1990). The intracellular expression ofintrabodies in different compartments of mammalian cells allows blockingor modulation of the function of endogenous molecules (Biocca, et al.,EMBO J 9: 101-108, 1990; Colby et al., Proc. Natl. Acad. Sci. U.S.A.101: 17616-21, 2004) Intrabodies can alter protein folding,protein-protein, protein-DNA, protein-RNA interactions and proteinmodification. They can induce a phenotypic knockout and work asneutralizing agents by direct binding to the target antigen, bydiverting its intracellular trafficking or by inhibiting its associationwith binding partners. They have been largely employed as research toolsand are emerging as therapeutic molecules for the treatment of humandiseases such as viral pathologies, cancer and misfolding diseases. Thefast growing bio-market of recombinant antibodies provides intrabodieswith enhanced binding specificity, stability and solubility, togetherwith lower immunogenicity, for their use in therapy (Biocca, abstract inAntibody Expression and Production Cell Engineering Volume 7, 2011, pp.179-195).

In some embodiments, intrabodies have advantages over interfering RNA(iRNA); for example, iRNA has been shown to exert multiple non-specificeffects, whereas intrabodies have been shown to have high specificityand affinity to target antigens. Furthermore, as proteins, intrabodiespossess a much longer active half-life than iRNA. Thus, when the activehalf-life of the intracellular target molecule is long, gene silencingthrough iRNA may be slow to yield an effect, whereas the effects ofintrabody expression can be almost instantaneous. Lastly, it is possibleto design intrabodies to block certain binding interactions of aparticular target molecule, while sparing others.

Intrabodies are often single chain variable fragments (scFvs) expressedfrom a recombinant nucleic acid molecule and engineered to be retainedintracellularly (e.g., retained in the cytoplasm, endoplasmic reticulum,or periplasm). Intrabodies may be used, for example, to ablate thefunction of a protein to which the intrabody binds. The expression ofintrabodies may also be regulated through the use of inducible promotersin the nucleic acid expression vector comprising the intrabody.Intrabodies may be produced for use in the viral genomes of theinvention using methods known in the art, such as those disclosed andreviewed in. (Marasco et al., 1993 Proc. Natl. Acal. Sci. USA, 90;7889-7893; Chen et al., 1994, Hum. Gene Ther. 5:595-601; Chen et al.,1994, Proc. Natl. Acad. Sci. USA, 91: 5932-5936; Macieiewski et al,1995, Nature Med., 1: 667-673; Marasco, 1995, Immunotech, 1: 1-19;Mhashilkar, et al., 1995, EMBO J. 14: 1542-51; Chen et al., 1996, Hum.Gene Therap., 7: 1515-1525, Marasco, Gene Ther. 4:11-15, 1997, Rondonand Marasco, 1997, Annu. Rev. Microbiol. 51: 257-283; Cohen, et al.,1998, Oncogene 17:2445-56; Proba et al., 1998, J. Mol. Biol.275:245-253; Cohen et al., 1998, Oncogene 17:2445-2456; Hassanzadeh, etal., 1998, FEBS Lett. 437:81-6; Richardson et al., 1998, Gene Ther5:635-44; Ohage and Steipe, 1999, J. Mol. Biol 291:1119-1128; Ohage etal., 1999, J. Mol. Biol. 291:1129-1134; Wirtz and Steipe, 1999, ProteinSci. 8:2245-2250; Zhu et al., 1999, J. Immunol Methods 231:207-222;Arafat et al., 2000, Cancer Gene Ther. 7:1250-6; der Maur et al., 2002,J. Biol. Chem. 277:45075-85, Mhashilkar et al., 2002, Gene Ther.9:307-19; and Wheeler et al., 2003, FASEB J. 17: 1733-5, and referencescited therein). In particular, a CCR5 intrabody has been produced bySteinberger et al., 2000), Proc. Natl. Acad. Sci. USA 97:805-810). Seegenerally Marasco. W A. 1998, “Intrabodies: Basic Research and ClinicalGene Therapy Applications” Springer: New York, and for a review ofscFvs, see Pluckthun in “The Pharmacology of Monoclonal Antibodies,”1994, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp.269-315.

Sequences from donor antibodies may be used to develop intrabodies.Intrabodies are often recombinantly expressed as single domain fragmentssuch as isolated V_(H) and V_(L) domains or as a single chain variablefragment (scFv) antibody within the cell. For example, intrabodies areoften expressed as a single polypeptide to form a single chain antibodycomprising the variable domains of the heavy and light chains joined bya flexible linker polypeptide. Intrabodies typically lack disulfidebonds and are capable of modulating the expression or activity of targetgenes through their specific binding activity. Single chain antibodiescan also be expressed as a single chain variable region fragment joinedto the light chain constant region.

As is known in the art, an intrabody can be engineered into recombinantpolynucleotide vectors to encode sub-cellular trafficking signals at itsN or C terminus to allow expression at high concentrations in thesub-cellular compartments where a target protein is located. Forexample, intrabodies targeted to the endoplasmic reticulum (ER) areengineered to incorporate a leader peptide and, optionally, a C-terminalER retention signal, such as the KDEL amino acid motif (SEQ ID NO:9223). Intrabodies intended to exert activity in the nucleus areengineered to include a nuclear localization signal. Lipid moieties arejoined to intrabodies in order to tether the intrabody to the cytosolicside of the plasma membrane. Intrabodies can also be targeted to exertfunction in the cytosol. For example, cytosolic intrabodies are used tosequester factors within the cytosol, thereby preventing them from beingtransported to their natural cellular destination.

There are certain technical challenges with intrabody expression. Inparticular, protein conformational folding and structural stability ofthe newly-synthesized intrabody within the cell is affected by reducingconditions of the intracellular environment.

Intrabodies of the invention may be promising therapeutic agents for thetreatment of misfolding diseases, including Alzheimer's, Parkinson's,Huntington's and prion diseases, because of their virtually infiniteability to specifically recognize the different conformations of aprotein, including pathological isoforms, and because they can betargeted to the potential sites of aggregation (both intra- andextracellular sites). These molecules can work as neutralizing agentsagainst anmyloidogenic proteins by preventing their aggregation, and/oras molecular shunters of intracellular traffic by rerouting the proteinfrom its potential aggregation site (Cardinale, and Biocca, Curr Mol.Med 2008, 8:2-11)

Maxibodies

In one embodiment, the payloads of the invention encode a maxibody(bivalent scFV fused to the amino terminus of the Fc (CH2-CH3 domains)of IgG,

Chimeric Antigen Receptors

In some embodiments, the polypeptides encoded by the viral genomes ofthe invention (e.g., antibodies) may be used to generate chimericantigen receptors (CARs) as described by BIOATLA® in InternationalPublications WO2016033331 and WO2016036916, the contents of which areherein incorporated by reference in their entirety. As used herein, a“chimeric antigen receptor (CAR)” refers to an artificial chimericprotein comprising at least one antigen specific targeting region(ASTR), wherein the antigen specific targeting region comprises afull-length antibody or a fragment thereof that specifically binds to atarget antigen. The ASTR may comprise any of the following; a fulllength heavy or light chain, an Fab fragment, a single chain Fvfragment, a divalent single chain antibody, or a diabody. As anon-limiting example the ASTR of a CAR may be any of the antibodieslisted in Tables 3-42, antibody-based compositions or fragments thereof.Any molecule that is capable of binding a target antigen with highaffinity can be used in the ASTR of a CAR. In one embodiment, the CARmay have more than one ASTR. These ASTRs may target two or more antigensor two or more epitopes of the same antigen. In one embodiment, the CARis conditionally active. In one embodiment, the CAR is used to produce agenetically engineered cytotoxic cell carrying the CAR and capable oftargeting the antigen bound by the ASTR.

Chimeric antigen receptors (CARs) are particularly useful in thetreatment of cancers, though also therapeutically effective in treatmentof a wide variety of other diseases and disorders. Non-limiting examplesof disease categories that may be treated with CARs or CAR-basedtherapeutics include autoimmune disorders, B-cell mediated diseases,inflammatory diseases, neuronal disorders, cardiovascular disease andcirculatory disorders, or infectious diseases. Not wishing to be boundby theory, CARs traditionally work by targeting antigens presented onthe surface of or on the inside of cells to be destroyed e.g., cancertumor cells, by the cytotoxic cell of the CAR.

Senescent Cell Surface Protein Antibodies

In some embodiments, the AAV particles may comprise nucleic acids whichhave been engineered to express of antibodies that selectively bind tosurface marker proteins of senescent cells. For example, the antibodiesmay selectively bind to proteins that are in misfolded conformation. Thebinding antibodies may reduce the number of senescent cells and be usedto treat age-related conditions, such as, but not limited to.Alzheimer's disease, cardiovascular disease, emphysema, sarcopenia, andtumorigenesis as well as conditions more cosmetic in nature such assigns of skin aging including wrinkling, sagging, discoloration,age-related tissue dysfunction, tumor formation, and other age-relatedconditions.

In one embodiment, the expressed antibodies binding to epitopes ofsenescent cell surface proteins may be, but are not limited to, such asprion epitopes presented by SEQ ID NOs: 1-14 of InternationalPublication No. WO2014186878, CD44 epitopes presented by SEQ ID NOs:47-51 of International Publication No. WO2014186878; TNFR epitopespresented by SEQ ID NOs: 52-56 of International Publication No.WO2014186878; NOTCH1 epitope presented by SEQ ID NOs: 57-61 ofInternational Publication No. WO2014186878; FasR epitopes presented bySEQ ID NOs: 62-66 of International Publication No. WO2014186878;epidermal growth factor epitopes presented by SEQ ID NOs: 67-81 ofInternational Publication No. WO2014186878; CD38 epitopes presented bySEQ ID NOs: 82-86 of International Publication No. WO2014186878, thecontents of each of which are herein incorporated by reference in theirentirety.

In one embodiment, the expressed antibodies may comprise peptidesbinding to senescent cell surface prion proteins, such as, but notlimited to, those presented by SEQ ID NOs: 15-36 of InternationalPublication No. WO2014186878, the contents of which are hereinincorporated by reference in their entirety.

In one embodiment, the expressed antibody may be AMF-3a-118 or AMF 3d-19(SEQ ID NO: 89-92 and 103-106 of International publication WO2014186878,respectively, the contents of which are herein incorporated by referencein their entirety) targeting senescent cell surface protein FasR, In oneembodiment, the expressed antibody may be Ab c-120 (SEQ ID NO: 37-40 ofInternational publication WO2014186878, the contents of which are hereinincorporated by reference in their entirety) targeting senescent cellsurface protein PrP.

Payload Antibodies of the Invention

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Tables 3-42.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences listed in Tables 3-42.

In some embodiments, the payload region of the AAV particle comprises anucleic acid sequence encoding a payload antibody with at least 50%identity to one or more payload antibody polypeptides listed in Tables3-42. The encoded antibody polypeptide may have 50%, 51%, 52%, 53%, 54%,55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%,69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99%, or 100% identity to one or more of the payload antibodypolypeptides listed in Tables 3-42.

In one embodiment, the full sequence of the encoded antibody polypeptidemay have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%,62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%,76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toone or more of the payload antibody polypeptides listed in Tables 3-42.

In one embodiment, the variable region sequence(s) of the encodedantibody polypeptide may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%,58%, 59%, 60%, 61%, 62%, 63%, 064%, 65%, 66%, 67%, 68%, 69%, 70%, 71%,72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or100% identity to one or more of the pay load antibody polypeptideslisted in Tables 3-42.

In one embodiment, the heavy chain of the encoded antibody polypeptidemay have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%,62%, 63%, 64%, 65% 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%,76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toone or more of the payload heavy chain antibody polypeptides listed inTables 3-42.

In one embodiment, the light chain of the encoded antibody polypeptidemay have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%,62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%,76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toone or more of the payload light chain antibody polypeptides listed inTables 3-42.

In one embodiment, the CDR region of the encoded antibody polypeptidemay have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%,62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%,76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity tothe CDRs of one or more of the payload antibody polypeptides listed inTables 3-42.

In one embodiment, the payload antibody has 90% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 91% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 92% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 93% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 94% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 95% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 96% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 97% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 98% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 99% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 100% identity to one or moreof the antibody polypeptides listed in Tables 3-42.

In some embodiments, the payload region of the AAV particle comprises anucleic acid sequence with at least 50% identity to one or more nucleicacid sequences listed in Tables 3-42. The payload nucleic acid sequencemay have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%,62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%,76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toone or more nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 90% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 91% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 92% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 93% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 94% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 95% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 96% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 97% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 98% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 99% identity toone or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 100% identityto one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload region of the AAV particle comprises anucleic acid sequence encoding a polypeptide which is an antibody, anantibody-based composition, or a fragment thereof. As a non-limitingexample, the antibody may be one or more of the polypeptides listed inTables 3-42. As another non-limiting example, the antibody may be one ormore of the heavy chain sequences listed in Tables 3-42. As anon-limiting example, the antibody may be one or more of the light chainsequences listed in Tables 3-42.

In one embodiment, the payload region of the AAV particle comprises anucleic acid sequence encoding a polypeptide comprising a heavy chainand a light chain sequence listed in Tables 3-42. The payload region mayalso comprise a linker between the heavy and light chain sequences. Thelinker may be a sequence known in the art or described in Table 2.

In one embodiment, the payload region of the AAV particle comprises anucleic acid sequence encoding a polypeptide comprising a heavy chainand a light chain sequence listed in Tables 3-42, where the heavy chainsequence is from a different antibody than the light chain sequence. Thepayload region may also comprise a linker between the heavy and lightchain sequences. The linker may be a sequence known in the art ordescribed in Table 2.

In one embodiment, the payload region comprises, in the 5′ to 3′direction, an antibody light chain sequence, a linker and a heavy chainsequence.

In one embodiment, the payload region comprises a nucleic acid sequenceencoding, in the 5′ to 3′ direction, an antibody light chain sequencefrom Tables 3-42, a linker from Table 2 and a heavy chain sequence fromTables 3-42.

In one embodiment, the payload region comprises, in the 5′ to 3′direction, an antibody heavy chain sequence, a linker and a light chainsequence.

In one embodiment, the payload region comprises a nucleic acid sequenceencoding, in the 5′ to 3′ direction, an antibody heavy chain sequencefrom Tables 3-42, a linker from Table 2 and a light chain sequence fromTables 3-42.

In one embodiment, the payload region comprises a nucleic acid sequenceencoding a single heavy chain. As a non-limiting example, the heavychain is an amino acid sequence or fragment thereof described in Tables3-42.

Shown in Tables 3-42 are a listing of antibodies and theirpolynucleotides and/or polypeptides sequences. These sequences may beencoded by or included in the AAV particles of the present invention.Variants or fragments of the antibody sequences described in Tables 3-42may be utilized in the AAV particles of the present invention.

In some embodiments, the AAV particles may comprise codon-optimizedversions of the nucleic acids encoding the polypeptides listed in Tables3-42. In some cases, the payload region of the AAV particles of theinvention may encode one or more isoforms or variants of these heavy andlight chain antibody domains. Such variants may be humanized oroptimized antibody domains comprising one or more complementaritydetermining regions (CDRs) from the heavy and light chains listed inTables 3-42. Methods of determining CDRs are well known in the art andare described herein Payload regions may encode antibody variants withone or more heavy chain variable domain (V_(H)) or light chain variabledomain (V_(L)) derived from the antibody sequences in Tables 3-42. Insome cases, such variants may include bispecific antibodies. Bispecificantibodies encoded by payload regions of the invention may comprisevariable domain pairs from two different antibodies.

In one embodiment, the AAV particles may comprise a heavy and a lightchain of an antibody described herein and two promoters. As anon-limiting example, the AAV particles may comprise a nucleic acidsequence of a genome as described in FIG. 1 or FIG. 2 of US PatentPublication No. US20030219733, the contents of which are hereinincorporated by reference in its entirety. As another non-limitingexample, the AAV particles may be a dual-promoter AAV for antibodyexpression as described by Lewis et al. (J. of Virology, September 2002,Vol. 76(17), p 8769-8775; the contents of which are herein incorporatedby reference in its entirety).

Foodborne Illness and Gastroenteritis Related Antibodies

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of thegastrointestinal and food illness related payload antibody polypeptideslisted in Tables 3-9.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 3 against Clostridium difficiletoxins

TABLE 3 Antibodies against Clostridium Difficile toxins SEQ AntibodyAntibody Reference ID No. Description Name Information NO CD1 Camelidheavy chain only, WO2015100409 2948 Toxin A and B, SEQ ID NO: 164 CD2Camelid heavy chain only, WO2015100409 2949 Toxin A and B, SEQ ID NO:165 CD3 Camelid heavy chain only, WO2015100409 2950 Toxin A and B, SEQID NO: 166 CD4 Camelid heavy chain only, WO2015100409 2951 Toxin A andB, SEQ ID NO: 167 CD5 Heavy chain variable region, PA-39 U.S. Pat. No.2952 toxin A 8,986,697 SEQ ID NO: 1 CD6 Heavy chain variable region,PA-39 U.S. Pat. No. 2953 toxin A 8,986,697 SEQ ID NO: 2 CD7 Heavy chainvariable region, PA-50 U.S. Pat. No. 2954 toxin A 8,986,697 SEQ ID NO: 5CD8 Heavy chain variable region, PA-50 U.S. Pat. No. 2955 toxin A8,986,697 SEQ ID NO: 6 CD9 Heavy chain variable region, US201302026182956 toxin A SEQ ID NO: 1 CD10 Heavy chain variable region,US20130202618 2957 toxin A SEQ ID NO: 2 CD11 Heavy chain variableregion, US20130202618 2958 toxin A SEQ ID NO: 5 CD12 Heavy chainvariable region, US20130202618 2959 toxin A SEQ ID NO: 6 CD13 Heavychain variable region, H1H3067N US20130230531 2960 toxin A and/or toxinB SEQ ID NO: 34 CD14 Heavy chain variable region, H1H3134N US201302305312961 toxin A and/or toxin B SEQ ID NO: 18 CD15 Heavy chain variableregion, H1H3117N US20130230531 2962 toxin A and/or toxin B SEQ ID NO: 2CD16 Heavy chain variable region, H1H3123N US20130230531 2963 toxin Aand/or toxin B SEQ ID NO: 66 CD17 Heavy chain variable region, H1H3121NUS20130230531 2964 toxin A and/or toxin B SEQ ID NO: 50 CD18 Heavy chainvariable region, H1H3124N US20130230531 2965 toxin A and/or toxin B SEQID NO: 82 CD19 Heavy chain variable region, H1H3328P US20130230531 2966toxin A and/or toxin B SEQ ID NO: 130 CD20 Heavy chain variable region,H1H3324P US20130230531 2967 toxin A and/or toxin B SEQ ID NO: 98 CD21Heavy chain variable region, H1H3325P US20130230531 2968 toxin A and/ortoxin B SEQ ID NO: 114 CD22 Heavy chain variable region, H1H3330PUS20130230531 2969 toxin A and/or toxin B SEQ ID NO: 146 CD23 Heavychain variable region, H1H3350P US20130230531 2970 toxin A and/or toxinB SEQ ID NO: 162 CD24 Heavy chain variable region, H1H3347PUS20130230531 2971 toxin A and/or toxin B SEQ ID NO: 274 CD25 Heavychain variable region, H1H3335P US20130230531 2972 toxin A and/or toxinB SEQ ID NO: 194 CD26 Heavy chain variable region, H1H3344PUS20130230531 2973 toxin A and/or toxin B SEQ ID NO: 258 CD27 Heavychain variable region, H1H3339P US20130230531 2974 toxin A and/or toxinB SEQ ID NO: 226 CD28 Heavy chain variable region, H1H3337PUS20130230531 2975 toxin A and/or toxin B SEQ ID NO: 210 CD29 Heavychain variable region, H1H3343P US20130230531 2976 toxin A and/or toxinB SEQ ID NO: 242 CD30 Heavy chain variable region, H1H3411PUS20130230531 2977 toxin A and/or toxin B SEQ ID NO: 354 CD31 Heavychain variable region, H1H3354P US20130230531 2978 toxin A and/or toxinB SEQ ID NO: 290 CD32 Heavy chain variable region, H1H3317PUS20130230531 2979 toxin A and/or toxin B SEQ ID NO: 178 CD33 Heavychain variable region, H1H3355P US20130230531 2980 toxin A and/or toxinB SEQ ID NO: 306 CD34 Heavy chain variable region, H1H3394PUS20130230531 2981 toxin A and/or toxin B SEQ ID NO. 322 CD35 Heavychain variable region, H1H3401P US20130230531 2982 toxin A and/or toxinB SEQ ID NO: 338 CD36 Heavy chain variable region, PA-41 U.S. Pat. No.2983 toxin B 8,986,697 SEQ ID NO: 8 CD37 Heavy chain variable region,PA-41 U.S. Pat. No. 2984 toxin B 8,986,697 SEQ ID NO: 9 CD38 Heavy chainvariable region, US20130202618 2985 toxin B SEQ ID NO: 8 CD39 Heavychain variable region, US20130202618 2986 toxin B SEQ ID NO: 9 CD40Heavy chain, toxin A 3D8 U.S. Pat. No. 2987 8,609,111 SEQ ID NO: 1 CD41Heavy chain, toxin A 1B11 U.S. Pat. No. 2988 8,609,111 SEQ ID NO: 2 CD42Heavy chain, toxin A 33.3H2 U.S. Pat. No. 2989 8,609,111 SEQ ID NO: 3CD43 Heavy chain, toxin A US20140004118 2990 SEQ ID NO: 89 CD44 Heavychain, toxin A US20140004118 2991 SEQ ID NO: 93 CD45 Heavy chain, toxinB US20130058962 2992 SEQ ID NO: 65 CD46 Heavy chain, toxin BBezlotoxumab 2993 CD47 Heavy-chain-only, toxin A US20130058962 2994 SEQID NO: 59 CD48 Heavy-chain-only, toxin A US20130058962 2995 SEQ ID NO:60 CD49 Heavy-chain-only, toxin A US20130058962 2996 SEQ ID NO: 61 CD50Heavy-chain-only, toxin A US20130058962 2997 SEQ ID NO: 62 CD51Heavy-chain-only, toxin A US20130058962 2998 SEQ ID NO: 63 CD52Heavy-chain-only, toxin A US20130058962 2999 SEQ ID NO: 64 CD53Heavy-chain-only, toxin A US20130058962 3000 SEQ ID NO: 87 CD54Heavy-chain-only, toxin A US20130058962 3001 SEQ ID NO: 95 CD55Heavy-chain-only, toxin B 124-152 U.S. Pat. No. 3002 8,609,111 SEQ IDNO: 54 CD56 Heavy-chain-only, toxin B US20130058962 3003 SEQ ID NO: 66CD57 Heavy-chain-only, toxin B US20130058962 3004 SEQ ID NO: 67 CD58Heavy-chain-only, toxin B US20130058962 3005 SEQ ID NO: 68 CD59Heavy-chain-only, toxin B US20130058962 3006 SEQ ID NO: 69 CD60Heavy-chain-only, toxin B US20130058962 3007 SEQ ID NO: 70 CD61Heavy-chain-only, toxin B US20130058962 3008 SEQ ID NO: 71 CD62Heavy-chain-only, toxin B US20130058962 3009 SEQ ID NO: 72 CD63Heavy-chain-only, toxin B US20130058962 3010 SEQ ID NO: 73 CD64Heavy-chain-only, toxin B US20130058962 3011 SEQ ID NO: 74 CD65Heavy-chain-only, toxin B US20130058962 3012 SEQ ID NO: 75 CD66Heavy-chain-only, toxin B US20130058962 3013 SEQ ID NO: 76; SEQ ID NO:87; SEQ ID NO: 95 CD67 Light chain variable region, toxin PA-39 U.S.Pat. No. 3014 A 8,986,697 SEQ ID NO: 3 CD68 Light chain variable region,toxin PA-39 U.S. Pat. No. 3015 A 8,986,697 SEQ ID NO: 4 CD69 Light chainvariable region, toxin PA-50 U.S. Pat. No. 3016 A 8,986,697 SEQ ID NO: 7CD70 Light chain variable region, toxin US20130202618 3017 A SEQ ID NO:3 CD71 Light chain variable region, toxin US20130202618 3018 A SEQ IDNO: 4 CD72 Light chain variable region, toxin US20130202618 3019 A SEQID NO: 7 CD73 Light chain variable region, toxin H1H3067N US201302305313020 A and/or toxin B SEQ ID NO: 42 CD74 Light chain variable region,toxin H1H3134N US20130230531 3021 A and/or toxin B SEQ ID NO: 26 CD75Light chain variable region, toxin H1H3117N US20130230531 3022 A and/ortoxin B SEQ ID NO: 10 CD76 Light chain variable region, toxin H1H3123NUS20130230531 3023 A and/or toxin B SEQ ID NO: 74 CD77 Light chainvariable region, toxin H1H3121N US20130230531 3024 A and/or toxin B SEQID NO: 58 CD78 Light chain variable region, toxin H1H3124N US201302305313025 A and/or toxin B SEQ ID NO: 90 CD79 Light chain variable region,toxin H1H3328P US20130230531 3026 A and/or toxin B SEQ ID NO: 138 CD80Light chain variable region, toxin H1H3324P US20130230531 3027 A and/ortoxin B SEQ ID NO: 106 CD81 Light chain variable region, toxin H1H3325PUS20130230531 3028 A and/or toxin B SEQ ID NO: 122 CD82 Light chainvariable region, toxin H1H3330P US20130230531 3029 A and/or toxin B SEQID NO: 154 CD83 Light chain variable region, toxin H1H3350PUS20130230531 3030 A and/or toxin B SEQ ID NO: 170 CD84 Light chainvariable region, toxin H1H3347P US20130230531 3031 A and/or toxin B SEQID NO: 282 CD85 Light chain variable region, toxin H1H3335PUS20130230531 3032 A and/or toxin B SEQ ID NO: 202 CD86 Light chainvariable region, toxin H1H3344P US20130230531 3033 A and/or toxin B SEQID NO: 266 CD87 Light chain variable region, toxin H1H3339PUS20130230531 3034 A and/or toxin B SEQ ID NO: 234 CD88 Light chainvariable region, toxin H1H3337P US20130230531 3035 A and/or toxin B SEQID NO: 218 CD89 Light chain variable region, toxin H1H3343PUS20130230531 3036 A and/or toxin B SEQ ID NO: 250 CD90 Light chainvariable region, toxin H1H3411P US20130230531 3037 A and/or toxin B SEQID NO: 362 CD91 Light chain variable region, toxin H1H3354PUS20130230531 3038 A and/or toxin B SEQ ID NO: 298 CD92 Light chainvariable region, toxin H1H3317P US20130230531 3039 A and/or toxin B SEQID NO: 186 CD93 Light chain variable region, toxin H1H3355PUS20130230531 3040 A and/or toxin B SEQ ID NO: 314 CD94 Light chainvariable region, toxin H1H3394P US20130230531 3041 A and/or toxin B SEQID NO: 330 CD95 Light chain variable region, toxin H1H3401PUS20130230531 3042 A and/or toxin B SEQ ID NO: 346 CD96 Light chainvariable region, toxin PA-41 U.S. Pat. No. 3043 B 8,986,697 SEQ ID NO:10 CD97 Light chain variable region, toxin US20130202618 3044 B SEQ IDNO: 10 CD98 Light chain, toxin A 3D8 U.S. Pat. No. 3045 8,609,111 SEQ IDNO: 4 CD99 Light chain, toxin A 1B11 U.S. Pat. No. 3046 8,609,111 SEQ IDNO: 5 CD100 Light chain, toxin A 33.3H2 U.S. Pat. No. 3047 8,609,111 SEQID NO: 6 CD101 Light chain, toxin A US20140004118 3048 SEQ ID NO: 91CD102 Light chain, toxin A US20140004118 3049 SEQ ID NO: 95 CD103 Lightchain, toxin B 124-152 U.S. Pat. No. 3050 8,609,111 SEQ ID NO: 58 CD104Light chain, toxin B Bezlotoxumab 3051 CD105 Recombinant camelid heavyWO2015100409 3052 chain only, Toxin A and B SEQ ID NO: 87 CD106Recombinant camelid heavy WO2015100409 3053 chain only, Toxin A and BSEQ ID NO: 95 CD107 Recombinant camelid heavy- WO2015100409 3054chain-only, toxin A SEQ ID NO: 59 CD108 Recombinant camelid heavy-WO2015100409 3055 chain-only, toxin A SEQ ID NO: 60 CD109 Recombinantcamelid heavy- WO2015100409 3056 chain-only, toxin A SEQ ID NO: 61 CD110Recombinant camelid heavy- WO2015100409 3057 chain-only, toxin A SEQ IDNO: 62 CD111 Recombinant camelid heavy- WO2015100409 3058 chain-only,toxin A SEQ ID NO: 63 CD112 Recombinant camelid heavy- WO2015100409 3059chain-only, toxin A SEQ ID NO: 64 CD113 Recombinant camelid heavy-WO2015100409 3060 chain-only, toxin B SEQ ID NO: 65 CD114 Recombinantcamelid heavy- WO2015100409 3061 chain-only, toxin B SEQ ID NO: 66 CD115Recombinant camelid heavy- WO2015100409 3062 chain-only, toxin B SEQ IDNO: 67 CD116 Recombinant camelid heavy- WO2015100409 3063 chain-only,toxin B SEQ ID NO: 68 CD117 Recombinant camelid heavy- WO2015100409 3064chain-only, toxin B SEQ ID NO: 69 CD118 Recombinant camelid heavy-WO2015100409 3065 chain-only, toxin B SEQ ID NO: 70 CD119 Recombinantcamelid heavy- WO2015100409 3066 chain-only, toxin B SEQ ID NO: 71 CD120Recombinant camelid heavy- WO2015100409 3067 chain-only, toxin B SEQ IDNO: 72 CD121 Recombinant camelid heavy- WO2015100409 3068 chain-only,toxin B SEQ ID NO: 73 CD122 Recombinant camelid heavy- WO2015100409 3069chain-only, toxin B SEQ ID NO: 74 CD123 Recombinant camelid heavy-WO2015100409 3070 chain-only, toxin B SEQ ID NO: 75 CD124 Recombinantcamelid heavy- WO2015100409 3071 chain-only, toxin B SEQ ID NO: 76 CD125Toxin A Actoxumab 3072 CD126 Toxin A Actoxumab 3073 CD127 Toxin AMK3415A U.S. Pat. No. 3074 (Actoxumab + 7,625,559 bezlotoxumab) SEQ IDNO: 1 CD128 Toxin A MK3415A U.S. Pat. No. 3075 (Actoxumab + 7,625,559bezlotoxumab) SEQ ID NO: 4 CD129 Toxin A MK3415A U.S. Pat. No. 3076(Actoxumab + 7,625,559 bezlotoxumab) SEQ ID NO: 54 CD130 Toxin A MK3415AU.S. Pat. No. 3077 (Actoxumab + 7,625,559 bezlotoxumab) SEQ ID NO: 58CD131 Toxin A A4.2 US20130230537 3078 SEQ ID NO: 34 CD132 Toxin A A5.1US20130230537 3079 SEQ ID NO: 35 CD133 Toxin A A19.2 US20130230537 3080SEQ ID NO: 36 CD134 Toxin A A20.1 US20130230537 3081 SEQ ID NO: 37 CD135Toxin A A24.1 US20130230537 3082 SEQ ID NO: 38 CD136 Toxin A A26.8US20130230537 3083 SEQ ID NO: 39 CD137 Toxin B B5.2 US20130230537 3084SEQ ID NO: 40 CD138 Toxin B B7.3 US20130230537 3085 SEQ ID NO: 41 CD139Toxin B B13.6 US20130230537 3086 SEQ ID NO: 42 CD140 Toxin B B15.3US20130230537 3087 SEQ ID NO: 43 CD141 Toxin B B15.5 US20130230537 3088SEQ ID NO: 44

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 4 against Campylobacter jejuni

TABLE 4 Antibodies against Campylobacter jejuni SEQ Antibody ReferenceID No. Description Antibody Name Information NO CAMP1 Consensus FlagV1WO2014063253 3089 SEQ ID NO: 7 CAMP2 — FlagV1M WO2014063253 3090 SEQ IDNO: 8 CAMP3 — F1agV1F23M WO2014063253 3091 SEQ ID NO: 9 CAMP4 —FlagV1MDSB WO2014063253 3092 SEQ ID NO: 10 CAMP5 — FlagV1MDSBWO2014063253 3093 SEQ ID NO: 11 CAMP6 Consensus FlagV6 WO2014063253 3094SEQ ID NO: 12 CAMP7 — FlagV6M WO2014063253 3095 SEQ ID NO: 13 CAMP8 —F1agV6F23M WO2014063253 3096 SEQ ID NO: 14 CAMP9 — FlagV6MDSBWO2014063253 3097 SEQ ID NO: 15 CAMP10 — FlagV6F23MDSB WO2014063253 3098SEQ ID NO: 16

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 5 against bacterial infections ofthe intestine.

TABLE 5 Antibodies against bacterial infections of the intestine SEQAntibody Antibody Reference ID No. Description Name Information NO BACG1Antibody against Listeria monocytogenes Antibody CN103497252 3099 fromSEQ ID NO: 1 CN103497252 BACG2 Bivalent monovalent antibody againstPseudomonas, anti- U.S. Pat. No. 3100 Clostridium, Staphylococcus,Pasteurella, Yersinia, LYS3- 7,655,759 Bacillus anthracis, Neisseria,Vibrio, enterotoxic E. coli, long SEQ ID NO: 22 Salmonella, Shigella,and Listeria, Clostridium, hinge/Cys- Staphylococcus, Pseudomonas,Pasteurella, Yersinia, Tag Bacillus anthracis, Neisseria, Vibrio,enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria BACG3Heavy chain only, Antibody against Pseudomonas, LYS2 U.S. Pat. No. 3101Clostridium, Staphylococcus, Pasteurella, Yersinia, VHH 7,655,759Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO:18 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus,Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria,Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteriaBACG4 Heavy chain only, Antibody against Pseudomonas, LYS3 U.S. Pat. No.3102 Clostridium, Staphylococcus, Pasteurella, Yersinia, VHH 7,655,759Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO:24 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus,Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria,Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteriaBACG5 Heavy chain segment including variable region, F10 U.S. Pat. No.3103 Starhylococcus enterotoxin B 8,895,704 SEQ ID NO: 30 BACG6 Heavychain variable region. Antibody against, P. mAb 741 U.S. Pat. No. 3104aeruginosa, Proteus Vulgaris, non-pathogenic E. coli, 8,263,078Citrobacter freundii, Serratia marcenscens, Enterobacter SEQ ID NO: 1cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonellatyphimurium, Salmonella muenchen, Proteus mirabilis and EnteropathogenicE. coli, BACG7 Heavy chain variable region, Antibody against, P. mAb 763U.S. Pat. No. 3105 aeruginosa, Proteus Vulgaris, non-pathogenic E. Coli,8,263,078 Citrobacter freundii, Serratia marcenscens, Enterobacter SEQID NO: 2 cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonellatyphimurium, Salmonella muenchen, Proteus mirabilis and EnteropathogenicE. coli., BACG8 Heavy chain variable region, antibody against flagellinU.S. Pat. No. 3106 from Salmonella or Pseudomonas 8,173,130 SEQ ID NO: 1BACG9 Heavy chain variable region, Antibody against Gram INO 743US20100239583 3107 negative (E. coli, Salmonella, Serratia, Proteus, SEQID NO: 1 Enterobacter, Citrobacter, Campylobacter and Pseudomonas)BACG10 Heavy chain variable region, Antibody against Abba3 U.S. Pat. No.3108 Helicobacter pyroli 8,025,880 SEQ ID NO: 18 BACG11 Heavy chainvariable region, Antibody against IgHV3-48*3 U.S. Pat. No. 3109Helicobacter pyroli 8,025,880 SEQ ID NO: 20 BACG12 Heavy chain variableregion, Antibody against clone 5 U.S. Pat. No. 3110 Helicobacter pyroli8,025,880 SEQ. ID NO: 21 BACG13 Heavy chain variable region, Antibodyagainst C4 U.S. Pat. No. 3111 Helicobacter pyroli 8,025,880 SEQ ID NO:22 BACG14 Heavy chain variable region, Antibody against IgHV1-18*01 U.S.Pat. No. 3112 Helicobacter pyroli 8,025,880 SEQ ID NO: 23 BACG15 Heavychain variable region, Antibody against C5 U.S. Pat. No. 3113Helicobacter pyroli 8,025,880 SEQ ID NO: 24 BACG16 Heavy chain variableregion, antibody against many SWLA3 WO2003007989 3114 pathogens, SEQ IDNO: 4 BACG17 Heavy chain variable region, antibody against SWLA3US20040052814 3115 Streptococcus mutans, Escherichia coli, Shigella SEQID NO: 4 dysenteriae, Salmonella typhimurium, Streptococcus pneumoniae,Staphylococcus aureus, and Pseudomonas aeruginosa BACG18 Heavy chainvariable region, antibody against SWLA3 US20040052814 3116 Streptococcusmutans, Escherichia coli, Shigella SEQ ID NO: 8 dysenteriae, Salmonellatyphimurium, Streptococcus pneumoniae, Staphylococcus aureus, andPseudomonas aeruginosa BACG19 Heavy chain, antibody against E coli,Shigella, Ab1 WO2012162253 3117 Entaamoeba histolytica, Salmonella,Campylobacter, or SEQ ID NO: 4 Clostridium difficile, rotavirus, RSV,HIV, norvovirus, adenovirus, and astrovirus, other diseases causingdiarrhea, BACG20 Heavy chain, antibody against E coli, Shigella, Ab2WO2012162253 3118 Entaamoeba histolytica, Salmonella, Campylobacter, orSEQ. ID NO: 14 Clostridium difficile, rotavirus, RSV, HIV, norvovirus,adenovirus, and astrovirus, other diseases causing diarrhea, BACG21Heavy chain, antibody against E coli, Shigella, Ab3 WO2012162253 3119Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 24Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, andastrovirus, other diseases causing diarrhea, BACG22 Heavy chain,antibody against E coli, Shigella, Ab4 WO2012162253 3120 Entaamoebahistolytica, Salmonella, Campylobacter, or SEQ ID NO: 34 Clostridiumdifficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus,other diseases causing diarrhea, BACG23 Heavy chain, antibody against Ecoli, Shigella, Ab5 WO2012162253 3121 Entaamoeba histolytica,Salmonella, Campylobacter, or SEQ ID NO: 44 Clostridium difficile,rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, otherdiseases causing diarrhea, BACG24 Heavy chain, antibody against E coli,Shigella, Ab6 WO2012162253 3122 Entaamoeba histolytica, Salmonella,Campylobacter, or SEQ ID NO: 54 Clostridium difficile, iotavirus, RSV,HIV, nomoyirus, adenovirus, and astrovirus, other diseases causingdiarrhea, BACG25 Heavy chain, antibody against E coli, Shigella, Ab7WO2012162253 3123 Entaamoeba histolytica, Salmonella, Campylobacter, orSEQ ID NO: 64 Clostridium difficile, rotavirus, RSV, HIV, norvovirus,adenovirus, and astrovirus, other diseases causing diarrhea, BACG26Heavy chain, antibody against E coli, Shigella, Ab8 WO2012162253 3124Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 74Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, andastrovirus, other diseases causing diarrhea, BACG27 Heavy chain,antibody against E coli, Shigella, Ab9 WO2012162253 3125 Entaamoebahistolytica, Salmonella, Campylobacter, or SEQ ID NO: 84 Clostridiumdifficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus,other diseases causing diarrhea, BACG28 Heavy chain, antibody against Ecoli, Shigella, Ab10 WO2012162253 3126 Entaamoeba histolytica,Salmonella, Campylobacter, or SEQ ID NO: 94 Clostridium difficile,rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, otherdiseases causing diarrhea, BACG29 Heavy chain, antibody against E coli,Shigella, Ab11 WO2012162253 3127 Entaamoeba histolytica, Salmonella,Campylobacter, or SEQ ID NO: 104 Clostridium difficile, rotavirus, RSV,HIV, norvovirus, adenovirus, and astrovirus, other diseases causingdiarrhea, BACG30 Heavy chain, antibody against E coli, Shigella, Ab12WO2012162253 3128 Entaamoeba histolytica, Salmonella, Campylobacter, orSEQ ID NO: 114 Clostridium difficile, rotavirus, RSV, HIV, norvovirus,adenovirus, and astrovirus, other diseases causing diarrhea, BACG31Heavy chain, antibody against E coli, Shigella, Ab13 WO2012162253 3129Entaamoeba histolytica, Salmonella. Campylobacter, or SEQ ID NO: 124Clostridium difficile, iotavirus, RSV, HIV, nomoyirus, adenovirus, andastrovirus, other diseases causing diarrhea, BACG32 Heavy chain,antibody against E coli, Shigella, Ab14 WO2012162253 3130 Entaamoebahistolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile,rotavirus, RSV, HIV, norvovirus, NO: 134 adenovirus, and astrovirus,other diseases causing diarrhea, BACG33 Heavy chain, Antibody againstEscherichia coli WO2014070117 3131 infection, Staphylococcus infectionSEQ ID NO: 3 BACG34 Heavy chain, Antibody against Listeria 6H8 U.S. Pat.No. 3132 monocytogenes or WR-tubercle bacillus 8,445,643 SEQ ID NO: 5BACG35 Heavy chain, Antibody against Pseudomonas, U.S. Pat. No. 3133Clostridium, Staphylococcus, Pasteurella, Yersinia, 7,655,759 Bacillusanthracis, Neisseria, Vibrio, enterotoxic E. coli. SEQ ID NO: 25Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus,Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria,Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteriaBACG36 Heavy chain, Antibody against Pseudomonas, U.S. Pat. No. 3134Clostridium, Staphylococcus, Pasteurella, Yersinia, 7,655,759 Bacillusanthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO: 26Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus,Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria,Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteriaBACG37 Heavy chain, Starhylococcus enterotoxin B 100C9 U.S. Pat. No.3135 8,895,704 SEQ ID NO: 34 BACG38 Heavy chain, Starhylococcusenterotoxin B 79G9+ U.S. Pat. No. 3136 8,895,704 SEQ ID NO: 38 BACG39Heavy chain, Starhylococcus enterotoxin B 79G9 U.S. Pat. No. 31378,895,704 SEQ ID NO: 126 BACG40 Heavy chain, Starhylococcus enterotoxinB 154G12 U.S. Pat. No. 3138 8,895,704 SEQ ID NO: 142 BACG41 Light chainvariable region, Antibody against, P. mAb 741 U.S. Pat. No. 3139aeruginosa, Proteus Vulgaris, non-pathogenic E. coli, 8,263,078Citrobacter freundii, Serratia marcenscens, Enterobacter SEQ ID NO: 3cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonellatyphimurium, Salmonella muenchen, Proteus mirabilis and EnteropathogenicE. coli BACG42 Light chain variable region, Antibody against, P. mAb 763U.S. Pat. No. 3140 aeruginosa, Proteus Vulgaris, non-pathogenic E. coli,8,263,078 Citrobacter freundii, Serratia marcenscens, Enterobacter SEQID NO: 4 cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonellatyphimurium, Salmonella muenchen, Proteus mirabilis and EnteropathogenicE. coli BACG43 Light chain variable region, Antibody against E coli, Ab1WO2012162253 3141 Shigella, Entaamoeba histolytica, Salmonella, SEQ IDNO: 1 Campylobacter, or Clostridium difficile, rotavirus, RSV, HIV,norvovirus, adenovirus, and astrovirus, other diseases causing diarrheaBACG44 Light chain variable region, antibody against flagellin U.S. Pat.No. 3142 from Salmonella or Pseudomonas 8,173,130 SEQ ID NO: 3 BACG45Light chain variable region, Antibody against Gram INO 743 US201002395833143 negative (E. coli, Salmonella, Serratia, Proteus, SEQ ID NO: 2Enterobacter, Citrobacter, Campylobacter and Pseudomonas) BACG46 Lightchain variable region, Antibody against Abba3 U.S. Pat. No. 3144Helicobacter pyroli 8,025,880 SEQ ID NO: 19 BACG47 Light chain variableregion, Antibody against many SWLA3 WO2003007989 3145 pathogens SEQ IDNO: 7 BACG48 Light chain, Antibody against E. coli, Shigaella, Ab 1US201200294822 3146 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID NO: 2 or Clostridium difficile or a virus selected fromrotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus BACG49 Lightchain, Antibody against E. coli, Shigaella, Ab 1 US201200294822 3147Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID NO: 4 orClostridium difficile or a virus selected from rotavirus, RSV, HIV,norvovirus, adenovirus, and astrovirus BACG50 Light chain, Antibodyagainst E. coli, Shigaella, Ab 2 US201200294822 3148 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 12 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG51 Light chain, Antibody against E. coli,Shigaella, Ab 2 US201200294822 3149 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 14 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG52 Light chain, Antibody against E. coli, Shigaella, Ab 3US201200294822 3150 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO:22 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG53 Light chain,Antibody against E. coli, Shigaella, Ab 3 US201200294822 3151 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 24 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG54 Light chain, Antibody against E. coli,Shigaella, Ab 4 US201200294822 3152 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 32 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG55 Light chain, Antibody against E. coli, Shigaella, Ab 4US201200294822 3153 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO:34 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG56 Light chain,Antibody against E. coli, Shigaella, Ab 5 US201200294822 3154 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 42 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG57 Light chain, Antibody against E. coli,Shigaella, Ab 5 US201200294822 3155 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 44 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG58 Light chain, Antibody against E. coli, Shigaella, Ab 6US201200294822 3156 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO:52 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG59 Light chain,Antibody against E. coli, Shigaella, Ab 6 US201200294822 3157 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 54 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG60 Light chain, Antibody against E. coli,Shigaella, Ab 7 US201200294822 3158 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 62 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG61 Light chain, Antibody against E. coli, Shigaella, Ab 7US201200294822 3159 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO:64 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG62 Light chain,Antibody against E. coli, Shigaella, Ab 8 US201200294822 3160 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 72 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG63 Light chain, Antibody against E. coli,Shigaella, Ab 8 US201200294822 3161 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 74 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG64 Light chain, Antibody against E. coli, Shigaella, Ab 9US201200294822 3162 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected front rotavirus, NO:82 RSV, HIV, norvovirus, adenovirus, and astrovirus BAC065 Light chain,Antibody against E coli, Shigaella, Ab 9 US201200294822 3163 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 84 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG66 Light chain, Antibody against E. coli,Shigaella, Ab 10 US201200294822 3164 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 92 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG67 Light chain, Antibody against E. coli, Shigaella, Ab 10US201200294822 3165 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO:94 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG68 Light chain,Antibody against E. coli, Shigaella, Ab 11 US201200294822 3166Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridiumdifficile or a virus selected from rotavirus, NO: 102 RSV, HIV,norvovirus, adenovirus, and astrovirus BACG69 Light chain, Antibodyagainst E. coli, Shigaella, Ab 11 US201200294822 3167 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 104 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG70 Light chain, Antibody against E. coli,Shigaella, Ab 12 US201200294822 3168 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 112 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG71 Light chain, Antibody against E. coli, Shigaella, Ab 12US201200294822 3169 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO:114 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG72 Light chain,Antibody against E. coli, Shigaella, Ab 13 US201200294822 3170Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridiumdifficile or a virus selected from rotavirus, NO: 122 RSV, HIV,norvovirus, adenovirus, and astrovirus BACG73 Light chain, Antibodyagainst E. coli, Shigaella, Ab 13 US201200294822 3171 Entaamoebahistolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficileor a virus selected from rotavirus, NO: 124 RSV, HIV, norvovirus,adenovirus, and astrovirus BACG74 Light chain, Antibody against E. coli,Shigaella, Ab 14 US201200294822 3172 Entaamoeba histolvtica, Salmonella,Campylobacter, SEQ ID or Clostridium difficile or a virus selected fromrotavirus, NO: 132 RSV, HIV, norvovirus, adenovirus, and astrovirusBACG75 Light chain, Antibody against E. coli, Shigaella, Ab 14US201200294822 3173 Entaamoeba histolvtica, Salmonella, Campylobacter,SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO:134 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG76 Light chain,Antibody against E coli, Shigella, Ab2 WO2012162253 3174 Entaamoebahistolvtica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile,rotavirus, RSV, HIV, norvovirus, NO: 11 adenovirus, and astrovirus,other diseases causing diarrhea BACG77 Light chain, Antibody against Ecoli, Shigella, Ab3 WO2012162253 3175 Entaamoeba histolytica,Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus,RSV, HIV, norvovirus, NO: 22 adenovirus, and astrovirus, other diseasescausing diarrhea BACG78 Light chain, Antibody against E coli, Shigella,Ab4 WO2012162253 3176 Entaamoeba histolytica, Salmonella, Campylobacter,or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 31adenovirus, and astrovirus, other diseases causing diarrhea BACG79 Lightchain, Antibody against E coli, Shigella, Ab5 WO2012162253 3177Entaamoeba histolytica, Salmonella. Campylobacter, or SEQ ID Clostridiumdifficile, rotavirus, RSV, HIV, norvovirus, NO: 42 adenovirus, andastrovirus, other diseases causing diarrhea BACG80 Light chain, Antibodyagainst E coli, Shigella, Ab6 WO2012162253 3178 Entaamoeba histolytica,Salmonella, Campylobacter, or SEQ ID Clostidium difficile, rotavirus,RSV, HIV, norvovirus, NO: 52 adenovirus, and astrovirus, other diseasescausing diarrhea BACG81 Light chain, Antibody against E coli, Shigella,Ab7 WO2012162253 3179 Entaamoeba histolytica, Salmonella, Campylobacter,or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 61adenovirus, and astrovirus, other diseases causing diarrhea BACG82 Lightchain, Antibody against E coli, Shigella, Ab8 WO2012162253 3180Entaamoeba histolytica, Salmonella. Campylobacter, or SEQ ID Clostridiumdifficile, rotavirus, RSV, HIV, norvovirus, NO: 71 adenovirus, andastrovirus, other diseases causing diarrhea BACG83 Light chain, Antibodyagainst E coli, Shigella, Ab9 WO2012162253 3181 Entaamoeba histolytica,Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus,RSV, HIV, norvovirus, NO: 82 adenovirus, and astrovirus, other diseasescausing diarrhea BACG84 Light chain, Antibody against E coli, Shigella,Ab10 WO2012162253 3182 Entaamoeba histolytica, Salmonella,Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV,norvovirus, NO: 91 adenovirus, and astrovirus, other diseases causingdiarrhea BACG85 Light chain, Antibody against E coli, Shigella, Ab11WO2012162253 3183 Entaamoeba histolytica, Salmonella, Campylobacter, orSEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 102adenovirus, and astrovirus, other diseases causing diarrhea BACG86 Lightchain, Antibody against E coli, Shigella, Ab12 WO2012162253 3184Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridiumdifficile, rotavirus, RSV, HIV, norvovirus, NO: 112 adenovirus, andastrovirus, other diseases causing diarrhea BACG87 Light chain, Antibodyagainst E coli, Shigella, Ab13 WO2012162253 3185 Entaamoeba histolytica,Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus,RSV, HIV, notvovirus, NO: 122 adenovirus, and astrovirus, other diseasescausing diarrhea BACG88 Light chain, Antibody against E coli, Shigella,Ab14 WO2012162253 3186 Entaamoeba histolytica, Salmonella,Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV,norvovirus, NO: 132 adenovirus, and astrovirus, other diseases causingdiarrhea BACG89 Light chain, Antibody against Escherichia coliinfection, WO2014070117 3187 Staphylococcus infection SEQ ID NO: 4BACG90 Light chain, Antibody against Listeria monocytogenes or 6H8 U.S.Pat. No. 3188 WR-tubercle bacillus 8,445,643 SEQ ID NO: 6 BACG91 Lightchain, Staphylococcus enterotoxin B F10 U.S. Pat. No. 3189 8,895,704 SEQID NO: 28 BACG92 Light chain, Staphylococcus enterotoxin B 100C9 U.S.Pat. No. 3190 8,895,704 SEQ ID NO: 32 BACG93 Light chain, Staphylococcusenterotoxin B 79G9 U.S. Pat. No. 3191 8,895,704 SEQ ID NO: 36 BACG94Light chain, Staphylococcus enterotoxin B 154G12 U.S. Pat. No. 31928,895,704 SEQ ID NO: 134 BACG95 ScFv, Antibody against Clostridiumperfringens, anti- ScFv-1A8 Zhao, B. and 3193 alpha toxin 1A8 Xu, C.“Cloning and sequencing of the ScFv-2E3 gene anti- alpha toxin ofclostridium perfringens type A”, Chin. J. Vet. Sci. 20, 246-248 (2000),CNBI Accession # AAU11282 BACG96 ScFv, Antibody against Clostridiumperfringens, anti- ScFv-2E3 Zhao, B. and 3194 alpha toxin 2E3 Xu, C.“Cloning and sequencing of the ScFv-2E3 gene anti- alpha toxin ofclostridium perfringens type A”, Chin. J. Vet. Sci. 20, 246-248 (2000),NCBI Accession # AAU11283 BACG97 Variable fragment, Antibody againstPseudomonas, αTT2 U.S. Pat. No. 3195 Clostridium, Staphylococcus,Pasteurella, Yersinia, 7,655,759 Bacillus anthracis, Neisseria, Vibrio,enterotoxic E. coli, SEQ ID NO: 8 Salmonella, Shigella, and Listeria,Clostridium, Staphylococcus, Pseudomonas, Pasteurella, Yersinia,Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella,Shigella, and Listeria bacteria BACG98 Variable fragment, antibodyagainst Pseudomonas, αTT1 U.S. Pat. No. 3196 Clostridium,Staphylococcus, Pasteurella, Yersinia, 7,655,759 Bacillus anthracis,Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO: 7 Salmonella,Shigella, and Listeria, Clostridium, Staphylococcus, Pseudomonas,Pasteurella, Yersinia, Bacillus anthracis, Neisseria, Vibrio,enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria,

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 6 against Hepatitis A and/orHepatitis E.

TABLE 6 Antibodies against Hepatitis A and Hepatitis E Antibody SEQ No.Description Antibody Name Reference Information ID NO HEPAE1 Heavy chainvariable region, HEV-Fab-216 CN1486990A; CN100497391C 3197 HEV Ab, ahumanized neutralizing genetically engineered antibody HEPAE2 Heavychain variable region, HEV-Fab-315 CN1486990A; CN100497391C 3198 HEV Ab,a humanized neutralizing genetically engineered antibody HEPAE3 Heavychain variable region, HEV-Fab-319 CN1486990A; CN100497391C 3199 HEV Ab,a humanized neutralizing genetically engineered antibody HEPAE4 Heavychain variable region, HEV-Fab-328 CN1486990A; CN100497391C 3200 HEV Ab,a humanized neutralizing genetically engineered antibody HEPAE5 Heavychain variable region, HEV-Fab-404 CN1486990A; CN100497391C 3201 HEV Ab,a humanized neutralizing genetically engineered antibody HEPAE6 Heavychain variable region, 13D8 US7786264 SEQ ID NO. 8; 3202 HEV monoclonalantibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE7 Heavychain variable region, 16D7 US7786264 SEQ ID NO. 20; 3203 HEV monoclonalantibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE8 Heavychain variable region, 8C11 US7786264 SEQ ID NO. 12; 3204 HEV monoclonalantibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE9 Heavychain variable region, 8H3 US7786264 SEQ ID NO. 16; 3205 HEV monoclonalantibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE10Heavy chain variable region, HEV # 31 US7148323 SEQ ID NO: 3; 3206 HEVneutralizing antibody US20050233316; US6930176; WO2001040270 HEPAE11Heavy chain variable region, HEV # 4 US7786264 SEQ ID NO: 1; 3207 HEVneutralizing antibody US20050233316; US6930176; WO2001040270 HEPAE12Heavy chain variable region, anti-HAV Kim S. J., et al., Neutralizing3208 partial, HAV capsid human monoclonal antibodies to hepatitis Avirus recovered by phage display; Virology 318 (2), 598-607 (2004), NCBIAccession # AAO86899.1(124aa) HEPAE13 Heavy chain variable region,anti-HAV Kim S. J., et al., Neutralizing 3209 partial. HAV capsid humanmonoclonal antibodies to hepatitis A virus recovered by phage display;Virology 318 (2), 598-607 (2004), NCBI Accession # AAO86898.1(129aa)HEPAE14 Heavy chain variable region, anti-HAV Kim S. J., et al.,Neutralizing 3210 partial, HAV capsid human monoclonal antibodies tohepatitis A virus recovered by phage display; Virology 318 (2), 598-607(2004), NCBI Accession # AAO86897.1(129aa) HEPAE15 Heavy chain variableregion, anti-HA V Kim S. J., et al., Neutralizing 3211 partial, HAVcapsid human monoclonal antibodies to hepatitis A virus recovered byphage display; Virology 318 (2), 598-607 (2004), NCBI Accession #AAO86896.1(129aa) HEPAE16 Heavy chain, HEV antibody 8g12 Gu Y., et al.,Structural basis for 3212 (mouse monoclonal antibody), tireneutralization of hepatitis E E2 glycoprotein virus by a cross-genotypeantibody; Cell Res. 25 (5), 604-620 (2015); NCBI Accession # 4PLJ_H(229aa) HEPAE17 Heavy chain, HEV antibody Tang X., et al., Proc. Natl.Acad. 3213 (mouse monoclonal antibody), E2 Sci. U.S.A. 108 (25), 10266-glycoprotein 10271 (2011); NCBI Accession # 3RKD_H(230aa) HEPAE18 Lightchain variable region, HAV # 14 US7635476 SEQ ID NO: 4; 3214 gamma1,HAV, US7282205; US20040260067; US20070287667; WO2003040341 HEPAE19 Lightchain variable region, HAV # 4 US7635476 SEQ ID NO: 1; 3215 gamma1, HAV,US7282205; US20040260067; US20070287667; WO2003040341 HEPAE20 Lightchain variable region, HAV # 5 US7635476 SEQ ID NO: 2; 3216 gamma1, HAV,US7282205; US20040260067; US20070287667; WO2003040341 HEPAE21 Lightchain variable region, HAV # 6 US7635476 SEQ ID NO: 3; 3217 gamma1, HAV,US7282205; US20040260067; US20070287667; WO2003040341 HEPAE22 Lightchain variable region, HEV HEV-Fab-216 CN1486990A; CN100497391C 3218 Ab,a humanized neutralizing genetically engineered antibody HEPAE23 Lightchain variable region, HEV HEV-Fab-315 CN1486990A; CN100497391C 3219 Ab,a humanized neutralizing genetically engineered antibody HEPAE24 Lightchain variable region, HEV HEV-Fab-319 CN1486990A; CN100497391C 3220 Ab,a humanized neutralizing genetically engineered antibody HEPAE25 Lightchain variable region, HEV HEV-Fab-328 CN1486990A; CN100497391C 3221 Ab,a humanized neutralizing genetically engineered antibody HEPAE26 Lightchain variable region, HEV HEV-Fab-404 CN1486990A; CN100497391C 3222 Ab,a humanized neutralizing genetically engineered antibody HEPAE27 Lightchain variable region, WO2011114353 SEQ ID NO: 25 3223 monovalent, HAVHEPAE28 Light chain variable region, anti-HAV Kim S. J., et al.,Neutralizing 3224 partial, HAV capsid human monoclonal antibodies tohepatitis A virus recovered by phage display; Virology 318 (2), 598-607(2004), NCB1 Accession # AAO86903.1(107aa) HEPAE29 Light chain variableregion, anti-HAV Kim S. J., el al., Neutralizing 3225 partial, HAVcapsid human monoclonal antibodies to hepatitis A virus recovered byphage display; Virology 318 (2), 598-607 (2004), NCBI Accession #AAO86902.1(107aa) HEPAE30 Light cliain variable region, anti-HAV Kim S.J., el al., Neutralizing partial, HAV capsid human monoclonal antibodiesto hepatitis A virus recovered by phage display; Virology 318 (2),598-607 (2004), NCBI Accession # AAO86901.1(107aa) HEPAE31 Light chainvariable region, anti-HAV Kim S. J., et al., Neutralizing partial, HAVcapsid human monoclonal antibodies to hepatitis A virus recovered byphage display; Virology 318 (2), 598-607 (2004). NCB I Accession #AAO86900.1(107aa) HEPAE32 Light chain variable, HEV 13D8 US7786264 SEQID NO. 6; 3228 monoclonal antibody US20060233822; US20100003281;EP1452541; EP2322625 HEPAE33 Light chain variable, HEV 16D7 US7786264SEQ ID NO. 18; 3229 monoclonal antibody US20060233822; US20100003281;EP1452541; EP2322625 HEPAE34 Light chain variable, HEV 8C11 US7786264SEQ ID NO: 10; 3230 monoclonal antibody US20060233822; US20100003281;EP1452541; EP2322625 HEPAE35 Light chain variable, HEV 8H3 US7786264 SEQID NO. 14; 3231 monoclonal antibody US20060233822; US20100003281;EP1452541; EP2322625 HEPAE36 Light chain variable, HEV HEV # 31US7148323 SEQ ID NO: 4; 3232 monoclonal antibody US20050233316;US6930176; WO2001040270 HEPAE37 Light chain variable, HEV HEV # 4US7148323 SEQ ID NO: 2; 3233 monoclonal antibody US20050233316;US6930176; WO2001040270 HEPAE38 Light chain, E2 glycoprotein, 8g12 GuY., et al., Structural basis for 3234 HEV antibody (mouse theneutralization of hepatitis E monoclonal antibody) virus by across-genotype antibody; Cell Res. 25 (5), 604- 620 (2015); NCBIAccession # 4PLJ_L (212aa) HEPAE39 Light chain, E2 glycoprotein, TangX., et al., Proc. Natl. Acad. 3235 HEV antibody (mouse Sci. U.S.A.108(25), 10266- monoclonal antibody) 10271 (2011), NCBI Accession #3RKD_C (214aa) HEPAE40 Monovalent Heavy chain variable WO2011114353 SEQID NO: 24 3236 region, HAV HEPAE41 ScFv, HAV, Monovalent humanWO2011114353 SEQ ID NO: 27 3237 antibody

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inChinese Pub. No. CN103923881, CN103923882, CN1605628, CN1318565,CN1163512, the contents of each of which are herein incorporated byreference in their entirety, against HAV.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 7 against Norwalk virus.

TABLE 7 Antibodies against Norwalk virus Antibody Antibody SEQ No.Description Name Reference Information ID NO NORV1 Heavy chain variableregion, B7 WO2014126921 SEQ ID NO: 8 3238 Norwalk virus NORV2 Lightchain variable region, B7 WO2014126921 SEQ ID NO: 16 3239 Norwalk virusNORV3 Heavy chain variable region, B72 WO2014126921 SEQ ID NO: 120 3240Norwalk virus NORV4 Light chain variable region, B72 WO2014126921 SEQ IDNO: 128 3241 Norwalk virus NORV5 Heavy chain variable region, C9WO2014126921 SEQ ID NO: 88 3242 Norwalk virus NORV6 Light chain variableregion, C9 WO2014126921 SEQ ID NO: 96 3243 Norwalk virus NORV7 Heavychain variable region, D4 WO2014126921 SEQ ID NO: 136 3244 Norwalk virusNORV8 Light chain variable region, D4 WO2014126921 SEQ ID NO: 144 3245Norwalk virus NORV9 Heavy chain variable region, D8 WO2014126921 SEQ IDNO: 24 3246 Norwalk virus NORV10 Light chain variable region, D8WO2014126921 SEQ ID NO: 32 3247 Norwalk virus NORV1 Heavy chain variableregion, E5 WO2014126921 SEQ ID NO: 40 3248 Norwalk virus NORV12 Lightchain variable region, E5 WO2014126921 SEQ ID NO: 48 3249 Norwalk virusNORV13 Heavy chain variable region, FI1 WO2014126921 SEQ ID NO: 72 3250Norwalk virus NORV14 Light chain variable region, FI1 WO2014126921 SEQID NO: 80 3251 Norwalk virus NORV15 Heavy chain variable region, G3WO2014126921 SEQ ID NO: 104 3252 Norwalk virus NORV16 Light chainvariable region, G3 WO2014126921 SEQ ID NO: 112 3253 Norwalk virusNORV17 Heavy chain variable region, G4 WO2014126921 SEQ ID NO: 56 3254Norwalk virus NORV18 Light chain variable region, G4 WO2014126921 SEQ IDNO: 64 3255 Norwalk virus NORV19 Heavy chain variable region,WO2014183052 SEQ ID NO: 1 3256 Norwalk or MD2004 virus NORV20 Heavychain variable region, WO2014183052 SEQ ID NO: 2 3257 Norwalk or MD2004virus NORV21 Heavy chain variable region, WO2014183052 SEQ ID NO: 3 3258Norwalk or MD2004 virus NORV22 Heavy chain variable region, WO2014183052SEQ ID NO: 4 3259 Norwalk or MD2004 virus NORV23 Heavy chain variableregion, WO2014183052 SEQ ID NO: 5 3260 Norwalk or MD2004 virus NORV24Heavy chain variable region, WO2014183052 SEQ ID NO: 6 3261 Norwalk orMD2004 virus NORV25 Heavy chain variable region, WO2014183052 SEQ ID NO:7 3262 Norwalk or MD2004 virus NORV26 Heavy chain variable region,WO2014183052 SEQ ID NO: 8 3263 Norwalk or MD2004 virus NORV27 Heavychain variable region, WO2014183052 SEQ ID NO: 9 3264 Norwalk or MD2004virus NORV28 Heavy chain variable region, WO2014183052 SEQ ID NO: 103265 Norwalk or MD2004 virus NORV29 Heavy chain variable region,WO2014183052 SEQ ID NO: 11 3266 Norwalk or MD2004 virus NORV30 Heavychain variable region, WO2014183052 SEQ ID NO: 12 3267 Norwalk or MD2004virus NORV31 Heavy chain variable region, WO2014183052 SEQ ID NO: 133268 Norwalk or MD2004 virus NORV32 Heavy chain variable region,WO2014183052 SEQ ID NO: 14 3269 Norwalk or MD2004 virus NORV33 Heavychain variable region, WO2014183052 SEQ ID NO: 15 3270 Norwalk or MD2004virus NORV34 Heavy chain variable region, WO2014183052 SEQ ID NO: 163271 Norwalk or MD2004 virus NORV35 Heavy chain variable region,WO2014183052 SEQ ID NO: 17 3272 Norwalk or MD2004 virus NORV36 Heavychain variable region, WO2014183052 SEQ ID NO: 18 3273 Norwalk or MD2004virus NORV37 Heavy chain variable region, WO2014183052 SEQ ID NO: 193274 Norwalk or MD2004 virus NORV38 Heavy chain variable region,WO2014183052 SEQ ID NO: 20 3275 Norwalk or MD2004 virus NORV39 Heavychain variable region, WO2014183052 SEQ ID NO: 21 3276 Norwalk or MD2004virus NORV40 Heavy chain variable region, WO2014183052 SEQ ID NO: 223277 Norwalk or MD2004 virus NORV41 Heavy chain variable region,WO2014183052 SEQ ID NO: 23 3278 Norwalk or MD2004 virus NORV42 Heavychain variable region, WO2014183052 SEQ ID NO: 24 3279 Norwalk or MD2004virus NORV43 Heavy chain variable region, WO2014183052 SEQ ID NO: 253280 Norwalk or MD2004 virus NORV44 Heavy chain variable region,WO2014183052 SEQ ID NO: 26 3281 Norwalk or MD2004 virus NORV45 Heavychain variable region, WO2014183052 SEQ ID NO: 27 3282 Norwalk or MD2004virus NORV46 Heavy chain variable region, WO2014183052 SEQ ID NO: 283283 Norwalk or MD2004 virus NORV47 Heavy chain variable region,WO2014183052 SEQ ID NO: 29 3284 Norwalk or MD2004 virus NORV48 Heavychain variable region, WO2014183052 SEQ ID NO: 30 3285 Norwalk or MD2004virus

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 8 against Rotavirus.

TABLE 8 Antibodies against rotavirus Antibody SEQ No. DescriptionReference Information ID NO ROTV1 Heavy chain single domain US8105592;US20090226418 SEQ ID NO: 1 3286 ROTV2 Heavy chain single domainUS8105592; US20090226418 SEQ ID NO: 2 3287 ROTV3 Heavy chain singledomain US8105592; US20090226418 SEQ ID NO: 3 3288 R0TV4 Heavy chainsingle domain US8105592; US20090226418 SEQ ID NO: 4 3289 ROTV5 Heavychain single domain US8105592; US20090226418 SEQ ID NO: 5 3290 ROTV6Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 6 3291ROTV7 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 73292 ROTV8 Heavy chain single domain US8105592; US20090226418 SEQ ID NO:8 3293 ROTV9 Heavy chain single domain US8105592; US20090226418 SEQ IDNO: 9 3294 ROTV10 Heavy chain single domain US8105592; US20090226418 SEQID NO: 10 3295 ROTV11 Heavy chain single domain US8105592; US20090226418SEQ ID NO: 11 3296 ROTV12 Heavy chain single domain US8105592;US20090226418 SEQ ID NO: 12 3297 ROTV13 Heavy chain single domainUS8105592; US20090226418 SEQ ID NO: 13 3298 ROTV14 Heavy chain singledomain US8105592; US20090226418 SEQ ID NO: 14 3299 ROTV15 Heavy chainsingle domain US8105592; US20090226418 SEQ ID NO: 15 3300 ROTV16 Heavychain single domain US8105592; US20090226418 SEQ ID NO: 16 3301 ROTV17Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 17 3302ROTV18 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 183303 ROTV19 Heavy chain single domain US8105592; US20090226418 SEQ IDNO: 19 3304 ROTV20 Heavy chain single domain US8105592; US20090226418SEQ ID NO: 20 3305 ROTV21 Heavy chain single domain US8105592;US20090226418 SEQ ID NO: 21 3306 ROTV22 Human VP6 polypeptideUS20030166139 SEQ ID NO: 2 3307 ROTV23 Human VP6 polypeptideUS20030166139 SEQ ID NO: 4 3308 ROTV24 Aiyegbo, M. S., et al ″HumanRotavirUSVp6- 3309 Specific Antibodies Mediate intracellularNeutralization By Binding To A Quater Structure in The TranscriptionalPore″, Plos One 8, 61101 (2013), NCBI Accession # 4HFW_B ROTV25 Aiyegbo,M. S., et al ″Human RotavirUSVp6- 3310 Specific Antibodies Mediateintracellular Neutralization By Binding To A Quater Structure in TheTranscriptional Pore″, Plos One 8, 61101 (2013), NCBI Accession # 4HFW_B

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 9 against Entamoeba histolytica.

TABLE 9 Antibodies against Entainoeba Histolytica Antibody No.; SEQAntibody Name Description Reference Information ID NO ENTH1 Heavy chain(partial sequence) gamma., Cheng, X. J. et al., Exp. Parasitol. 96 3311Entamoeba histolytica antibody (1), 52-56 (2000), NCBI Accession #BAA97670.1 (220aa) ENTH2 Heavy chain (partial sequence) gamma,Tachibana, H. et al., Clin. Diagn. Lab. 3312 Entamoeba histolyticaAntibody Immunol. 6 (3), 383-387 (1999), NCBI Accession # BAA82104.1(222aa) ENTH3 Heavy chain (partial sequence) gamma, Tachibana, H. etal., Clin. Diagn. Lab. 3313 Entamoeba histolytica Antibody Immunol. 6(3), 383-387 (1999), NCBI Accession # BAA82101.1 (226aa) ENTH4 Heavychain (partial sequence) IgG, Tachibana, H., et al., Infect. Immun. 773314 Entamoeba histolytica Intermediate (1), 549-556 (2009), NCBIAccession # Subunit Lectin-Specific Human BAH03695.1 (220aa) MonoclonalAntibodies ENTH5 Heavy chain (partial sequence) IgG, Tachibana, H., elal., Infect. Immun. 77 3315 Entamoeba histolytica Intermediate (1),549-556 (2009), NCBI Accession # Subunit Lectin-Specific HumanBAH03694.1 (226aa) Monoclonal Antibodies ENTH6 Heavy chain (partialsequence) IgG, Tachibana, H., et al., Infect. Immun. 77 3316 Entamoebahistolytica Intermediate (1), 549-556(2009), NCBI Accession # SubunitLectin-Specific Human BAH03693.1 (221aa) Monoclonal Antibodies ENTH7Heavy chain (partial sequence) IgG, Tachibana. H., et al., Infect.Immun. 77 3317 Entamoeba histolytica Intermediate (1), 549-556 (2009),NCBI Accession # Subunit Lectin-Specific Human BAH03692.1 (223aa)Monoclonal Anybodies ENTH8 Light chain (partial sequence) IgG,Tachibana, H., et al., Infect. Immun. 77 3318 Entamoeba histolyticaintermediate (1), 549-556 (2009), NCBI Accession # SubunitLectin-Specific Human BAH03699.1 (219aa) Monoclonal Antibodies ENTH9Light chain (partial sequence) IgG, Tachibana. H., et al., Infect.Immun. 77 3319 Entamoeba histolytica Intermediate (1), 549-556 (2009),NCBI Accession # Subunit Lectin-Specific Human BAH03698.1 (220aa)Monoclonal Antibodies ENTH10 Light chain (partial sequence) IgG,Tachibana, H., et al., Infect. Immun. 77 3320 Entamoeba histolyticaIntermediate (1), 549-556 (2009), NCBI Accession # SubunitLectin-Specific Human BAH03697.1 (214aa) Monoclonal Antibodies ENTH11Light chain (partial sequence) IgG, Tachibana, H., et al., Infect.Immun. 77 3321 Entamoeba histolytica Intermediate (1), 549-556 (2009),NCBI Accession # Subunit Lectin-Specific Human BAH03696.1 (214aa)Monoclonal Antibodies ENTH12 Light chain (partial sequence) kappa,Cheng, X. J. et al., Exp. Parasitol. 96 (1), 3322 Entamoeba histolyticaantibody 52-56 (2000), NCBI Accession # BAA97671.1 (214aa) ENTH13 Lightchain (partial sequence) kappa, Tachibana, H. et al., Clin. Diagn. Lab.3323 Entamoeba histolytica antibody Immunol. 6 (3), 383-387 (1999), NCBIAccession # BAA821051 (215aa) ENTH14 Light chain (partial sequence)kappa, Tachibana, H. et al., Clin. Diagn. Lab. 3324 Entamoebahistolytica antibody Immunol. 6 (3), 383-387 (1999), NCBI Accession #BAA82100.1 (214aa) ENTH15/ Single chain Fv Antibody 350-E2 NCBIAccession # AEY80059.1 (274aa) 3325 350-E2 against Entamoeba histolyticaENTH16/ Single chain Fv Antibody JR4A11 NCBI Accession # AEY80058.1(287aa) 3326 JR4A11 Entamoeba histolytica

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides, fragments or variants thereof described inInternational Pub. No. WO2001012646, the contents of which are hereinincorporated by reference in their entirety, against listenamonocytogenes, salmonella and/or leishmania.

Neglected Tropical Diseases

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the neglectedtropical disease related payload antibody polypeptides listed in Tables10-13.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 10 against Dengue Fever Virus.

TABLE 10 Antibodies against Dengue Fever Virus Antibody Antibody SEQ No.Description Name Reference Information ID NO DENG1 Bispecific, DENVserotype 1, m366 US20150218255 SEQ ID NO: 96 3327 DENV serotype 2, DENVserotype 3, and DENV serotype 4 DENG2 Fab Fragment Fab 14c10 Teoh, E.P., el al., Sci Transl Med 4 3328 (139), 139RA83 (2012), NCBI Accession# 4CAU_E(230 aa) DENG3 Heavy chain 5j7 Fab Fibriansah, G., el al., Ahighly 3329 potent human antibody neutralizes dengue virus serotype 3 bybinding across three surface proteins; Nat Commun 6, 6341 (2015), NCBIAccession # 3J6U_H (135aa) DENG4 Heavy Chain Ede1 C8 Dejnirattisai, W.,et al., A new 3330 class of highly potent, broadly neutralizingantibodies isolated from viremic patients infected with dengue virus;Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UTA_H (272 aa)DENG5 Heavy Chain Fab 2h12 Midgley, C.M., et al., J, Immunol. 3331 188(1), 4971-4979 (2012), NCBI Accession # 4AL8_H (217 aa) DENG6 HeavyChain Fab Fragment Of 1f4 Fab Fibriansah. G., et al., A potent anti-3332 Antibodv 1f4 dengue human antibody preferentially recognizes theconformation of E protein monomers assembled on the virus surface; EMBOMol Med 6 (3), 358-371 (2014), NCBI Accession # 4C2I_H (232 aa) DENG7Heavy chain variable region 9F12 WO2010093335 SEQ ID NO: 4 3333 DENG8Heavy chain variable region, 9F12 US20150218255 SEQ ID NO: 83 3334 DENVserotype l, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG9Heavy chain variable region, m366 US20150218255 SEQ ID NO: 4 3335 DENVserotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG10Heavy chain variable region, m366.6 US20150218255 SEQ ID NO: 24 3336DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4DENG11 Heavy chain variable region, m360.6 US20150218255 SEQ ID NO: 443337 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENVserotype 4 DENG12 Heavy chain variable region, HMB-DV-1 US9073981 SEQ IDNO: 13 3338 DENV-I, DENV-2, DENV-3, DENV-4 DENG13 Heavy chain variableregion, HMB-DV-2 US9073981 SEQ ID NO: 29 3339 DENV-I, DENV-2, DENV-3,DENV-4 DENG14 Heavy chain variable region, HMB-DV-3 US9073981 SEQ ID NO:45 3340 DENV-I, DENV-2, DENV-3, DENV-4 DENG15 Heavy chain variableregion, HMB-DV-4 US9073981 SEQ ID NO: 61 3341 DENV-I, DENV-2, DENV-3,DENV-4 DENG16 Heavy chain variable region, HMB-DV-4 US9073981 SEQ ID NO:65 3342 DENV-I, DENV-2, DENV-3, DENV-4 DENG17 Heavy chain variableregion, HMB-DV-5 US9073981 SEQ ID NO: 79 3343 DENV-I, DENV-2, DEN V-3,DENV-4 DENG18 Heavy chain variable region, HMB-DV-6, US9073981 SEQ IDNO: 95 3344 DENV-I, DENV-2, DENV-3, HMB-DV-7 DENV-4 DENG19 Heavy chainvariable region, HMB-DV-8 US9073981 SEQ ID NO: 117 3345 DENV-I, DENV-2,DENV-3, DENV-4 DENG20 Heavy chain variable region, HMB-DV-9 US9073981SEQ ID NO: 131 3346 DENV-I, DENV-2, DENV-3, DENV-4 DENG21 Heavy chainvariable region, HMB-DV-10 US9073981 SEQ ID NO: 145 3347 DENV-I, DENV-2,DENV-3, DENV-4 DENG22 Heavy chain variable region, HMB-DV-11 US9073981SEQ ID NO: 151 3348 DENV-I, DENV-2, DENV-3, DENV-4 DENG23 Heavy chainvariable region, HMB-DV-12 US9073981 SEQ ID NO: 165 3349 DENV-I, DENV-2,DENV-3, DENV-4 DENG24 Heavy chain variable region, HMB-DV-13 US9073981SEQ ID NO: 181 3350 DENV-I, DENV-2, DENV-3, DENV-4 DENG25 Heavy chainvariable region, HMB-DV-14 US9073981 SEQ ID NO: 195 3351 DENV-I, DENV-2,DENV-3, DENV-4 DENG26 Heavy chain variable region, DV- A68 US20150225474SEQ ID NO: 19 3352 1, DV-2, DV-3, and DV-10 DENG27 Heavy chain variableregion, DV- A100 US20150225474 SEQ ID NO: 20 3353 1, DV-2, DV-3, andDV-11 DENG28 Heavy chain variable region, DV- C58 US20150225474 SEQ IDNO: 21 3354 1, DV-2, DV-3, and DV-12 DENG29 Heavy chain variable region,DV- C98 US20150225474 SEQ ID NO: 32 3355 1, DV-2, DV-3, and DV-13 DENG30Heavy chain variable region, DV- A11 US20150225474 SEQ ID NO: 33 3356 1,DV-2, DV-3, and DV-14 DENG31 Heavy chain variable region, DV- B11US20150225474 SEQ ID NO: 36 3357 1, DV-2, DV-3, and DV-15 DENG32 Heavychain variable region, DV- D88 US20150225474 SEQ ID NO: 1 3358 1, DV-2,DV-3, and PV-4 DENG33 Heavy chain variable region, DV- mAb11WO2014144061 SEQ ID NO: 1 3359 1, DV-2, PV-3, and DV-1 DENG34 Heavychain variable region, DV- F38 US20150225474 SEQ ID NO: 80 3360 1, DV-2,DV-3, and PV-5 DENG35 Heavy chain variable region, DV- A48 US20150225474SEQ ID NO: 16 3361 1, DV-2, PV-3. and DV-6 DENG36 Heavy drain variableregion, DV- C8S US20150225474 SEQ ID NO: 17 3362 1, DV-2, PV-3, and DV-7DENG37 Heavy chain variable region, DV- F108 US20150225474 SEQ ID NO: 183363 1, DV-2, DV-3, and PV-8 DENG38 Heavy chain variable region, DV- B48US20150225474 SEQ ID NO: 18 3364 1, DV-2, PV-3, and PV-9 DENG39 Heavychain, Antigen-binding 2d22 Fibriansah, G., et al., DENGUE 3365 FragmentOf Human Antibody VIRUS. Cryo-EM structure of an 2d22 antibody thatneutralizes dengue virus type 2 by locking E protein dimers; Science 349(6243), 88-91 (2015), NCBI Accession # 5A1Z_K (128 aa) DENG40 Heavychain, Dengue virus NS-1 US7473424; US20040209244; 3366 proteinWO2004067567; EP1592712 SEQ ID NO: 3 DENG41 Heavy chain, Dengue virusDB32-6 US8637035 SEQ ID NO: 1 3367 serotype 2 DENG42 Heavy chain, Denguevirus DB2-3 US8637035 SEQ ID NO: 13 3368 serotype 2 DENG43 Heavy chain,Dengue virus DB13-19 US8637035 SEQ ID NO: 14 3369 serotype 2 DENG44Heavy chain, Dengue virus DB23-3 US8637035 SEQ ID NO: 15 3370 serotype 2DENG45 Heavy chain. Dengue virus DB25-2 US8637035 SEQ ID NO: 16 3371serotype 2 DENG46 Heavy chain, Dengue virus DB42-3 US8637035 SEQ ID NO:17 3372 serotype 2 DENG47 Heavy chain, Dengue virus type 1A5 US8337853SEQ ID NO: 97 3373 10 DENG48 Heavy chain. Dengue virus type 2H7US8337853 SEQ ID NO: 113 3374 11 DENG49 Heavy chain, Dengue virus type2H5 US8337853 SEQ ID NO: 129 3375 12 DENG50 Heavy chain, Dengue virustype 3A2 US20130089543 SEQ ID NO: 145 3376 13 DENG51 Heavy chain, Denguevirus type 1B2 US20130089543 SEQ ID NO: 161 3377 14 DENG52 Heavy chain.Dengue virus type 1A10 US20130089543 SEQ ID NO: 177 3378 13 DENG53 Heavychain, Dengue virus type 4 5H2 US7622113 SEQ ID NO: 1 3379 DENG54 Heavychain, Dengue virus type 5 5H7 US7622113 SEQ ID NO: 17 3380 DENG55 Heavychain, Dengue vires type 6 3Cl US7622113 SEQ ID NO: 33 3381 DENG56 Heavychain, Dengue virus type 7 3E4 US7622113 SEQ ID NO: 49 3382 DENG57 Heavychain, Dengue virus type 8 7G4 US7622113 SEQ ID NO: 65 3383 DENG58 Heavychain, Dengue virus type 9 5D9 US7622113 SEQ ID NO: 81 3384 DENG59 Heavychain, DV 1 14c10 clone US20130259871 Fig 4b 3385 8 DENG60 Heavy chain,DV-1, DV-2, DV-3, Antibody US20140056913 SEQ ID NO: 1 3386 and DV-4 4e11DENG61 Heavy chain, DV-1, DV-2, DV-3, Variant of US20140056913 SEQ IDNO: 21 3387 and DV-4 4E11 DENG62 Heavy chain, DV-1, DV-2, DV-3, 4E5AWO20155123362 SEQ ID NO: 29 3388 and DV-4 DENG63 Light Chain 5j7 FabFibriansah, G., et al., A highly 3389 potent human antibody neutralizesdengue virus serotype 3 by binding across three surface proteins; NatCommun 6, 6341 (2015), NCBI Accession # 3J6U_L (118aa) DENG64 LightChain Ede1 C8 Dejnirattisai, W., et al., A new 3390 class of highlypotent, broadly neutralizing antibodies isolated from viremic patientsinfected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBIAccession # 4UTA_L (217 aa) DENG65 Light Chain Fab 2h12 Midgley, C. M.,et al., J, Immunol. 3391 188 (10), 4971-4979 (2012), NCBI Accession #4AL8_L (213 aa) DENG66 Light Chain Fab Fragment Of 1f4 Fab Fibriansah,G., et al., A potent anti- 3392 Antibody 1f4 dengue human antibodypreferentially recognizes the conformation of E protein monomersassembled on the virus surface; EMBO Mol Med 6 (3), 358-371 (2014), NCBIAccession # 4C2I_N (239 aa) DENG67 Light chain variable region 9F12WO2010093335 SEQ ID NO: 6 DENG68 Light chain variable region, 9F12US20150218255 SEQ ID NO: 84 3393 DENV serotype 1, DENV serotype 2, DENVserotype 3, and DENV serotype 4 DENG69 Light chain variable region, m366US20150218255 SEQ ID NO: 6 3394 DENV serotype 1, DENV serotype 2, DENVserotype 3, and DENV serotype 4 DENG70 Light chain variable region,m366.6 US20150218255 SEQ ID NO: 26 3395 DENV serotype 1, DENV serotype2, DENV serotype 3, and DENV serotype 4 DENG71 Light chain variableregion, m360.6 US20150218255 SEQ ID NO: 46 3396 DENV serotype 1, DENVserotype 2, DENV serotype 3, and DENV serotype 4 HMB-DV-1 US9073981 SEQID NO: 14 3397 DENG72 Light chain variable region, DENV-I, DENV-2,DENV-3, DENV-4 DENG73 Light chain variable region, HMB-DV-2 US9073981SEQ ID NO: 30 3398 DENV-I, DENV-2, DENV-3, DENV-4 DENG74 Light chainvariable region, HMB-DV-3 US9073981 SEQ ID NO: 46 3399 DENV-I, DENV-2,DENV-3, DENV-4 DENG75 Light chain variable region, HMB-DV-4 US9073981SEQ ID NO: 62 3401 DENV-I, DENV-2, DENV-3, DENV-4 DENG76 Light chainvariable region, HMB-DV-5 US9073981 SEQ ID NO: 80 3402 DENV-I, DENV-2,DENV-3, DENV-4 DENG77 Light chain variable region, HMB-DV-6 US9073981SEQ ID NO: 96 3403 DENV-I, DENV-2, DENV-3, DENV-4 DENG78 Light chainvariable region, HMB-DV-7 US9073981 SEQ ID NO: 103 3404 DENV-I, DENV-2,DENV-3, DENV-4 DENG79 Light chain variable region, HNfB-DV-8 US9073981SEQ ID NO: 118 3405 DENV-I, DENV-2, DENV-3, DENV-4 DENG80 Light chainvariable region, HMB-DV-9 US9073981 SEQ ID NO: 132 3406 DENV-I, DENV-2,DENV-3, DENV-4 DENG81 Light chain variable region, HMB-DV-10, US9073981SEQ ID NO: 146 3407 DENV-I, DENV-2, DENV-3, HMB-DV-11 DENV-4 DENG82Light chain variable region, HMB-DV-12 US9073981 SEQ ID NO: 166 3408DENV-I, DENV-2, DENV-3, DENV-4 DENG83 Light chain variable region,HMB-DV-13 US9073981 SEQ ID NO: 182 3409 DENV-I, DENV-2, DENV-3, DENV-4DENG84 Light chain variable region, HMB-DV-14 US9073981 SEQ ID NO: 1963410 DENV-I, DENV-2, DENV-3, DENV-4 DENG85 Light chain variable region,DV-1, D88, F38, US20150225474 SEQ ID NO: 2 3411 DV-2, DV-3, and DV-4A48, C88, F108, B48, A68, A100, C58, C78, C68, D98, D188, C128, C98DENG86 Light chain variable region, DV-1, C78 US20S50225474 SEQ ID NO:23 3412 DV-2, DV-3, and DV-4 DENG87 Light chain variable region, DV-1,C68 US20150225474 SEQ ID NO: 25 3413 DV-2, DV-3, and DV-4 DENG88 Lightchain variable region, DV-1, D98 US20150225474 SEQ ID NO: 27 3414 DV-2,DV-3, and DV-4 DENG89 Light chain variable region, DV-1, D188US20150225474 SEQ ID NO: 29 3415 DV-2, DV-3, and DV-4 DENG90 Light chainvariable region, DV-1, C128 US20150225474 SEQ ID NO: 31 3416 DV-2, DV-3,and DV-4 DENG91 Light chain variable region, DV-1, A11, B11US20150225474 SEQ ID NO: 34 3417 DV-2, DV-3, and DV-4 DENG92 Light chainvariable region, DV-1, mAb11 WO2014144061 SEQ ID NO: 3 3418 DV-2, DV-3,and DV-4 DENG93 Light chain, Antigen-binding 2d22 Fibriansah, G., elal., DENGUE 3419 Fragment Of Human Antibody VIRUS. Cryo-EM structure ofan 2d22 antibody that neutralizes dengue virus type 2 by locking Eprotein dimers; Science 349 (6243), 88-91 (2015), NCBI Accession #5A1Z_L (115 aa) DENG94 Light cliain, Dengue virus NS-1 US7473424;US20040209244; 3420 protein WO2004067567; EP1592712 SEQ ID NO: 4 DENG95Light chain, Dengue virus DB32-6 US8637035 SEQ ID NO: 5 3421 serotype 2DENG96 Light chain, Dengue virus DB2-3, US8637035 SEQ ID NO: 19 3422serotype 2 DB-19 DENG97 Light chain, Dengue virus DB23-3 US8637035 SEQID NO: 20 3423 serotype 2 DENG98 Light chain, Dengue virus DB25-2US8637035 SEQ ID NO: 21 3424 serotype 2 DENG99 Light chain, Dengue virusDB42-3 US8637035 SEQ ID NO: 22 3425 serotype 2 DENG100 Light chain,Dengue virus 5H2 US7622113 SEQ ID NO: 9 3426 serotype 4 DENG101 Lightchain, Dengue virus 5A7 US7622113 SEQ ID NO: 25 3427 serotype 4 DENG102Light chain, Dengue virus 3C1 US7622113 SEQ ID NO: 41 3428 serotype 4DENG103 Light chain, Dengue virus 3E4 US7622113 SEQ ID NO: 57 3429serotype 4 DENG104 Light chain, Dengue virus 7G4 US7622113 SEQ ID NO: 733430 serotype 4 DENG105 Light chain, Dengue virus 5D9 US7622153 SEQ II)NO: 89 3431 serotype 4 DENG106 Light chain, Dengue virus 1A5 US8337853SEQ ID NO: 105 3432 serotype 4 DENG107 Light chain, Dengue virus 2H7US8337853 SEQ ID NO: 121 3433 serotype 4 DENG108 Light chain, Denguevirus 2H5 US8337853 SEQ ID NO: 137 3434 serotype 4 DENG109 Light chain,Dengue virus 3A2 US20130089543 SEQ ID NO: 153 3435 serotype 4 DENG110Light chain, Dengue virus 1B2 US20130089543 SEQ ID NO: 169 3436 serotype4 DENG111 Light chain, Dengue virus 1A10 US20130089543 SEQ ID NO: 1853437 serotype 4 DENG112 Light chain, DV 1 14c10 clone US20130259871 Fig4b 3438 8 DENG113 Light chain, DV-l, DV-2, DV-3, Antibody US20140056913SEQ ID NO: 2 3439 and DV-4 4e11 DENG114 Light chain, DV-l, DV-2, DV-3,Variant of US20140056913 SEQ ID NO: 22 3440 and DV-4 4E11 DENG115 Lightchain, DV-l, DV-2, DV-3, 4E5A WO20155123362 SEQ ID NO: 30 3441 and DV-4DENG116 scFv 9F12 WO2010093335 SEQ ID NO: 8 3442 DENG117 Scfv FragmentEde211 Dejnirattisai, W., et al., A new 3443 class of highly potent,broadly neutralizing antibodies isolated from viremic patients infectedwith dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession# 4UT7_L(153 aa) DENG118 Scfv Fragment Ede2 A11 Dejnirattisai, W., etal, A new 3444 class of highly potent, broadly neutralizing antibodiesisolated from viremic patients infected with dengue virus; Nat. Immunol.16 (2), 170-177 (2015), NCBI Accession # 4UT7_H (150 aa) DENG119 Ede2A11Dejnirattisai, W., et al., A new 3445 class of lightly potent, broadlyneutralizing antibodies isolated from viremic patients infected withdengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession #4UTB_L (218 aa) 3446 DENG120 Ede1 C10 Dejnirattisai, W., et al., A newclass of highly potent, broadly neutralizing antibodies isolated fromviremic patients infected with dengue virus; Nat. Immunol. 16 (2),170-177 (2015), NCBI Accession # 4UT9_L (154aa) DENG121 Ede1 C10Dejnirattisai, W., et al., A new 3447 class of highly potent, broadlyneutralizing antibodies isolated from viremic patients infected withdengue virus; Nat. Immunol 16 (2), 170-177 (2015), NCBI Accession #4UT9_H (144 aa) DENG122 Ede2 B7 Dejnirattisai. W. et al., A new 3448class of highly potent, broadly neutralizing antibodies isolated fromviremic patients infected with dengue virus; Nat. Immunol. 16 (2),170-177 (2015), NCBI Accession # 4UT6_L (218 aa) DENG123 Ede2 B7Dejnirattisai, W., et al., A new 3449 class of highly potent, broadlyneutralizing antibodies isolated from viremic patients injected withdengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession #4UT6_H (283 aa)

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides, fragments or variants thereof described inInternational Pub. No. WO2013089647 and WO2013035345, U.S. Pat. Nos.8,637,035 and 887,187, US Publication No. US20050123900, and ChinesePatent Publication No. CN102757480, the contents of which are hereinincorporated by reference in their entirety, against Listeriamonocytogenes, salmonella and/or leishmania.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 11 against Rabies Virus

TABLE 11 Antibodies against Rabies Virus Antibody SEQ No. DescriptionAntibody Name Reference Information ID NO RABV1 Fab Heavy Chain Fdregion CN101696242 SEQ ID NO: 9 3450 RABV2 Fab Light chain CN101696242SEQ ID NO: 10 3451 RABV3 Heavy chain US6890532 SEQ ID NO: 3 3452 RABV4Heavy chain Mab JB.1 US7071319 SEQ ID NO: 10 3453 RABV5 Heavy chain Mab57 US7071319 SEQ ID NO: 14 3454 RABV6 Heavy chain CR04-098 US9005624 SEQID NO: 335 3455 RABV7 Heavy chain CR57, US9005624 SEQ ID NO: 123 3456Rafivirumab RABV8 Heavy chain CR57, Rafivirumab RABV9 Heavy chain CRJBUS9005624 SEQ ID NO: 127 3458 RABV10 Heavy chain Foravirumab 3459 RABV11Heavy chain, Anti-rabies SOJB Presniak, M. et al. 3460 immunoglobulin″Development of a cocktail of recombinant-expressed human rabiesvirus-neutralizing monoclonal antibodies for postexposure prophylaxis ofrabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession #AA017822.1 RABV12 Heavy chain variable region CN101696242 SEQ ID NO: 43461 RABV13 Heavy chain variable region SC04-001 US9005624 SEQ ID NO: 263462 RABV14 Heavy chain variable region SC04-004 US9005624 SEQ ID NO: 273463 RABV15 Heavy chain variable region SC04-008 US9005624 SEQ ID NO: 283464 RABV16 Heavy chain variable region SC04-010 US9003624 SEQ ID NO: 293465 RABV17 Heavy chain variable region SC04-018 US9005624 SEQ ID NO: 303466 RABV18 Heavy chain variable region SC04-021 US9005624 SEQ ID NO: 313467 RABV19 Heavy chain variable region SC04-026 US9005624 SEQ ID NO: 323468 RABV20 Heavy chain variable region SC04-031 US9005624 SEQ ID NO: 333469 RABV21 Heavy chain variable region SC04-038 US9005624 SEQ ID NO: 443470 RABV22 Heavy chain variable region SC04-040 US9005624 SEQ ID NO: 353471 RABV23 Heavy chain variable region SC04-060 US9005624 SEQ ID NO: 363472 RABV24 Heavy chain variable region SC04-073 US9005624 SEQ ID NO: 373473 RABV25 Heavy chain variable region SC04-097 US9005624 SEQ ID NO: 383474 RABV26 Heavy chain variable region SC04-098 US9005624 SEQ ID NO: 393475 RABV27 Heavy chain variable region SC04-103 US9005624 SEQ ID NO: 403476 RABV28 Heavy chain variable region SC04-104 US9005624 SEQ ID NO: 413477 RABV29 Heavy chain variable region SC04-108 US9005624 SEQ ID NO: 423478 RABV30 Heavy chain variable region SC04-120 US9005624 SEQ ID NO: 433479 RABV31 Heavy chain variable region SC04-125 US9005624 SEQ ID NO: 443480 RABV32 Heavy chain variable region SC04-126 US9005624 SEQ ID NO: 453481 RABV33 Heavy chain variable region SC04-140 US9005624 SEQ ID NO: 463482 RABV34 Heavy chain variable region SC04-144 US9005624 SEQ ID NO: 473483 RABV35 Heavy chain variable region SC04-146 US9005624 SEQ ID NO: 483484 RABV36 Heavy chain variable region SC04-164 US9005624 SEQ ID NO: 493485 RABV37 Heavy chain variable region RVFab5 WO201113757 SEQ ID NO: 23486 RABV38 Heavy chain variable region RVFab8 WO2011137570 SEQ ID NO: 23487 RABV39 Heavy chain variable region CN101337990 SEQ ID NO: 2 3488RABV40 Heavy chain variable region CN101337990 SEQ ID NO: 8 3489 RABV41Heavy chain variable region R8 VH CN104193823 SEQ ID NO: 1 3490 RABV42Heavy chain variable region R5 VH CN104193823 SEQ ID NO: 2 3491 RABV43Heavy chain variable region R7 VH, R9 VH CN104193823 SEQ ID NO: 3 3492RABV44 Heavy chain variable region CN101235086 SEQ ID NO: 38 3493 RABV45Heavy chain, Anti-rabies Prosniak, M. et al. 3494 SOJA immunoglobulin″Development of a cocktail of recombinant-expressed human rabiesvirus-neutralizing monoclonal antibodies for postexposnre prophylaxis ofrabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession #AAO17823.1 RABV46 Light chain US6890532 SEQ ID NO: 4 3495 RABV47 Lightchain Mab JB.1 US7071319 SEQ ID NO: 12 3496 RABV48 Light chain Mab 57US7071319 SEQ ID NO: 16 3497 RABV49 Light chain CR04-098 US9005624 SEQID NO: 337 3498 RABV50 Light chain CR57, US9005624 SEQ ID NO: 125 3499Rafivirumab RABV51 Light chain CR57, 3500 Rafivirumab RABV52 Light chainCRJB US9005624 SEQ ID NO: 129 3501 RABV53 Light chain Foravirumab 3502RABV54 Light chain Kappa, Anti-rabies Prosniak, M. et al. 3503 SOJAimmunoglobulin ″Development of a cocktail of recombinant-expressed humanrabies virus-neutralizing monoclonal antibodies for postexposnreprophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBIAccession # AAO17825.1 RABV55 Light chain kappa, Anti-rabies Prosniak,M. et al. 3504 SOJA immunoglobulin [Homo ″Development of a cocktail ofsapiens] recombinant-expressed human rabies virus-neutralizingmonoclonal antibodies for postexposnre prophylaxis of rabies″, J.Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession # AAO17821.1 RABV56Light chain Lambda, Anti-rabies Prosniak, M. et al. 3505 S057immunoglobulin ″Development of a cocktail of recombinant-expressed humanrabies virus-neutralizing monoclonal antibodies for postexposnreprophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBIAccession # AAO17824.1 RABV57 Light cliain lambda, Anti-rabies Prosniak,M. et al. 3506 SOJB immunoglobulin ″Development of a cocktail ofrecombinant-expressed human rabies virus-neutralizing monoclonalantibodies for postexposnre prophylaxis of rabies″, J. Infect. Dis. 188(1), 53-56 (2003), NCBI Accession # AAO17826.1 RABV58 Light chainvariable region SC04-001 US9005624 SEQ ID NO: 50 3507 RABV59 Light chainvariable region SC04-00-1 US9005624 SEQ ID NO: 51 3508 RABV60 Lightchain variable region SC04-008 US9005624 SEQ ID NO: 52 3509 RABV61 Lightchain variable region SC04-010 US9005624 SEQ ID NO: 55 3510 RABV62 Lightchain variable region SC04-018 US9005624 SEQ ID NO: 54 3511 RABV63 Lightchain variable region SC04-021 US9005624 SEQ ID NO: 55 3512 RABV64 Lightchain variable region SC04-026 US9005624 SEQ ID NO: 56 3513 RABV65 Lightchain variable region SC04-031 US9005624 SEQ ID NO: 57 3514 RABV66 Lightchain variable region SC04-038 US9005624 SEQ ID NO: 58 3515 RABV67 Lightchain variable region SC04-040 US9005624 SEQ ID NO: 59 3516 RABV68 Lightchain variable region SC04-060 US9005624 SEQ ID NO: 60 3517 RABV69 Lightchain variable region SC04-073 US9005624 SEQ ID NO: 61 3518 RABV70 Lightchain variable region SC04-097 US9005624 SEQ ID NO: 62 3519 RABV71 Lightchain variable region SC04-098 US9005624 SEQ ID NO: 63 3520 RABV72 Lightchain variable region SC04-103 US9005624 SEQ ID NO: 64 3521 RABV73 Lightchain variable region SC04-104 US9005624 SEQ ID NO: 65 3522 RABV74 Lightchain variable region SC04-108 US9005624 SEQ ID NO: 66 3523 RABV75 Lightchain variable region SC04-120 US9005624 SEQ ID NO: 67 3524 RABV76 Lightchain variable region SC04-125 US9005624 SEQ ID NO: 68 3525 RABV77 Lightchain variable region SC04-126 US9005624 SEQ ID NO: 69 3526 RABV78 Lightchain variable region SC04-140 US9005624 SEQ ID NO: 70 3527 RABV79 Lightchain variable region SC04-144 US9005624 SEQ ID NO: 71 3528 RABV80 Lightchain variable region SC04-146 US9005624 SEQ ID NO: 72 3529 RABV81 Lightchain variable region SC04-164 US9005624 SEQ ID NO: 73 3530 RABV82 Lightchain variable region RVFab5 WO201113757 SEQ ID NO: 1 3531 RABV83 Lightchain variable region RVFab8 WO2011137570 SEQ ID NO: 1 3432 RABV84 Lightchain variable region CN101337990 SEQ ID NO: 4 3433 RABV85 Light chainvariable region CN101337990 SEQ ID NO: 10 3434 RABV86 Light chainvariable region R8 VL CN104193823 SEQ ID NO: 4 3435 RABV87 Light chainvariable region R5 VL CN104193823 SEQ ID NO: 5 3436 RABV88 Light chainvariable region R7 VL CN104193823 SEQ ID NO: 6 3437 RABV89 Light chainvariable region R9 VL CN104193823 SEQ ID NO: 7 3438 RABV90 Light chainvariable region CN101696242 SEQ ID NO: 8 3439 RABV91 Light chainvariable region CN101235086 SEQ ID NO: 39 3440

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 12 against Chagas Virus.

TABLE 12 Antibodies against Chagas Virus Antibody SEQ No. DescriptionReference Information ID NO CHAG1 Heavy Chain Of The Fab Fragment,Buschiazzo et al., PLoS Pathol. 8 (1), E1002474 3541 Trypanosoma cruzitrans-sialidase (2012), NCBI Accession # 3OPZ_J (222aa) CHAG2 Lightchain of Fab fragment, Buschiazzo et al., PLoS Pathog. 8 (1), E10024743542 Trypanosoma cmzi trans-sialidase (2012), NCBI Accession # 3OPZ_N(213aa)

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 13 against Chikungunya Virus.

TABLE 13 Antibodies against Chikungunya Virus Antibody Antibody SEQ No.Description Name Reference Information ID NO CHIK1 Heavy chain Fab 9.8bSun, S. et al., Structural analyses at pseudo 3543 fragment atomicresolution of Chikungunya virus and antibodies show mechanisms ofneutralization, Elife 2, E00435 (2013), NCBI Accession # 4GO9_H (218 aa)CHIK2 Heavy chain 5F101717E2 US20130189279 SEQ ID NO: 6 3544 variableCHIK3 Heavy chain 8B10F8 US20130189279 SEQ ID NO: 26 3545 variable CHIK4Light chain Fab 9.8b Sun, S. et al., Structural analyses at pseudo 3546fragment atomic resolution of Chikungunya virus and antibodies showmechanisms of neutralization, Elife 2, E00435 (2013), NCBI Accession #4GO9_L (212 aa) CHIK5 Light chain 5F10F175E2 US20130189279 SEQ ID NO: 83547 variable CHIK6 Light chain 8B10F8 US20130189279 SEQ ID NO 3548variable

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof encodingantibodies described International Pub No. WO1983001785 and U.S. Pat.No. 5,827,671, the contents of each of which are herein incorporated byreference in their entirety, against the protozoan parasite Leishmania.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof encodingantibodies against the Buruli ulcer (Mycobacterium ulcerans),Leprosy/Hansen's disease (Mycobacterium leprae), Leishmaniasis,Cysticercosis, Dracunculiasis (Guinea Worm Disease), Echinococcosis,Fascioliasis, Human African Trypanosomiasis (African Sleeping Sickness),Lymphatic filariasis, Onchocerciasis, Schistosomiasis, Soil-transmittedHelminths (STH).

Toxins

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the toxin relatedpayload antibody polypeptides listed in Tables 14-17.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 14 against Ricin Toxin.

TABLE 14 Antibodies against Ricin Toxin Antibody Antibody SEQ No.Description Name Reference Information ID NO RICN1 Candid heavy-chainonly RTA:JIV-F5 WO2015100409 SEQ ID NO: 124 3549 RICN2 Candidheavy-chain only JIV-F6 WO2015100409 SEQ ID NO: 126 3550 RICN3 Candidheavy-chain only JIV-G 12 WO2015100409 SEQ ID NO: 128 3551 RICN4 Candidheavy-chain only JIY-A7 WO2015100409 SEQ ID NO: 130 3552 RICN5 Candidheavy-chain only JIY-D9 WO2015100409 SEQ ID NO: 132 3553 RICN6 Candidheavy-chain only JIY-D10 WO2015100409 SEQ ID NO: 134 3554 RICN7 Candidheavy-chain only JIY-E1 WO2015100409 SEQ ID NO: 136 3555 RICN8 Candidheavy-chain only JIY-E3 WO2015100409 SEQ ID NO: 138 3556 RICN9 Candidheavy-chain only JIY-E5 WO2015100409 SEQ ID NO: 140 3557 RICN10 Candidheavy-chain only JIY-F10 WO2015100409 SEQ ID NO: 142 3558 RICN11 Candidheavy-chain only JIY-G11 WO2015100409 SEQ ID NO: 144 3559 RICN12 Candidheavy-chain only RTB:JIW-B1 WO2015100409 SEQ ID NO: 146 3560 RICN13Candid heavy-chain only JIW-C12 WO2015100409 SEQ ID NO: 148 3561 RICN14Candid heavy-chain only JIW-D12 WO2015100409 SEQ ID NO: 150 3562 RICN15Candid heavy-chain only JIW-G5 WO2015100409 SEQ ID NO: 152 3563 RICN16Candid heavy-chain only JIW-G 10 WO2015100409 SEQ ID NO: 154 3564 RICN17Candid heavy-chain only JIZ-B7 WO2015100409 SEQ ID NO: 156 3565 RICN18Candid heavy-chain only JIZ-B9 WO2015100409 SEQ ID NO: 158 3566 RICN19Candid heavy-chain only JIZ-D8 WO2015100409 SEQ ID NO: 160 3567 RICN20Candid heavy-chain only JIZ-G4 WO2015100409 SEQ ID NO: 162 3568

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 15 against Anthrax.

TABLE 15 Antibodies against Anthrax Antibody Antibody SEQ No.Description Name Reference Information ID NO ANTH1 Camelid heavy-chainonly JHD-B6 WO2015100409 SEQ ID NO: 100 3569 ANTH2 Camelid heavy-chainonly JHE-D9 WO2015100409 SEQ ID NO: 102 3570 ANTH3 Camelid heavy-chainonly JIJ-A12 WO2015100409 SEQ ID NO: 104 3571 ANTH4 Camelid heavy-chainonly JIJ-B8 WO2015100409 SEQ ID NO: 106 3572 ANTH5 Camelid heavy-chainonly JIJ-C11 WO2015100409 SEQ ID NO: 108 3573 ANTH6 Camelid heavy-chainonly JIJ-D3 WO2015100409 SEQ ID NO: 110 3574 ANTH7 Camelid heavy-chainonly JIJ-E9 WO2015100409 SEQ ID NO: 112 3575 ANTH8 Camelid heavy-chainonly JIJ-F11 WO2015100409 SEQ ID NO: 114 3576 ANTH9 Camelid heavy-chainonly JIK-B8 WO2015100409 SEQ ID NO: 116 3577 ANTH10 Camelid heavy-chainonly JI-B 10 WO2015100409 SEQ ID NO: 118 3578 ANTH11 Camelid heavy-chainonly JIK-B 12 WO2015100409 SEQ ID NO: 120 3579 ANTH12 Camelidheavy-chain only JIK-F4 WO2015100409 SEQ ID NO: 122 3580 ANTH13 CDRWO2003063768 SEQ ID NO: 1 3581 ANTH14 CDR WO2003063768 SEQ ID NO: 2 3582ANTH15 CDR WO2003063768 SEQ ID NO: 3 3583 ANTH16 Heavy chain US8617548SEC ID NO: 2 3584 ANTH17 Heavy chain IQNPA Lambda US7658925 SEQ ID NO: 23585 ANTH18 Heavy chain IQNLF Lambda US7658925 SEQ ID NO: 6 3586 ANTH19Heavy chain 1A5 US20090022736 SEQ ID NO: 1 3587 ANTH20 Heavy chain 4A12US20090022736 SEQ ID NO: 3 3588 ANTH21 Heavy chain 24B1 US20090022736SEQ ID NO: 5 3589 ANTH22 Heavy chain 24G4 US20090022736 SEQ ID NO: 73590 ANTH23 Heavy chain 32E12 US20090022736 SEQ ID NO: 9 3591 ANTH24Heavy chain 33F4 US20090022736 SEQ ID NO: 11 3592 ANTH25 Heavy chainscfv 2LF EP2778173 SEQ ID NO: 9 3593 ANTH26 Heavy chain US20040258699SEQ ID NO: 78 3594 ANTH27 Heavy chain US20040258699 SEQ ID NO: 79 3595ANTH28 Heavy chain US20040258699 SEQ ID NO: 80 3596 ANTH29 Heavy chainUS20040258699 SEQ ID NO: 81 3597 ANTH30 Heavy chain US20040258699 SEQ IDNO: 82 3598 ANTH31 Heavy chain US20040258699 SEQ ID NO: 83 3599 ANTH32Heavy chain US20040258699 SEQ ID NO: 84 3600 ANTH33 Heavy chainUS20040258699 SEQ ID NO: 85 3601 ANTH34 Heavy chain US20040258699 SEQ IDNO: 86 3602 ANTH35 Heavy chain US20040258699 SEQ ID NO: 87 3603 ANTH36Heavy chain US20040258699 SEQ ID NO: 88 3604 ANTH37 Heavy chainUS20040258699 SEQ ID NO: 89 3605 ANTH38 Heavy chain US20040258699 SEQ IDNO: 90 3606 ANTH39 Heavy chain US20040258699 SEQ ID NO: 91 3607 ANTH40Heavy chain US20040258699 SEQ ID NO: 92 3608 ANTH41 Heavy chainUS20040258699 SEQ ID NO: 93 3609 ANTH42 Heavy chain US20040258699 SEQ IDNO: 94 3610 ANTH43 Heavy chain US20040258699 SEQ ID NO: 95 3611 ANTH44Heavy chain US20040258699 SEQ ID NO: 96 3612 ANTH45 Heavy chainUS20040258699 SEQ ID NO: 97 3613 ANTH46 Heavy chain US20040258699 SEQ IDNO: 98 3614 ANTH47 Heavy chain US20040258699 SEQ ID NO: 99 3615 ANTH48Heavy chain US20040258699 SEQ ID NO: 100 3616 ANTH49 Heavy chainUS20040258699 SEQ ID NO: 101 3617 ANTH50 Heavy chain US20040258699 SEQID NO: 102 3618 ANTH51 Heavy chain US20040258699 SEQ ID NO: 103 3619ANTH52 Heavy chain US20040258699 SEQ ID NO: 104 3620 ANTH53 Heavy chainUS20040258699 SEQ ID NO: 105 3621 ANTH54 Heavy chain US20040258699 SEQID NO: 106 3622 ANTH55 Heavy chain US20040258699 SEQ ID NO: 107 3623ANTH56 Heavy chain US20040258699 SEQ ID NO: 108 3624 ANTH57 Heavy chainUS20040258699 SEQ ID NO: 109 3625 ANTH58 Heavy chain US20040258699 SEQID NO: 110 3626 ANTH59 Heavy chain US20040258699 SEQ ID NO: 111 3627ANTH60 Heavy chain US20040258699 SEQ ID NO: 112 3628 ANTH61 Heavy chainUS20040258699 SEQ ID NO: 113 3629 ANTH62 Heavy chain US20040258699 SEQID NO: 114 3630 ANTH63 Heavy chain US20040258699 SEQ ID NO: 115 3631ANTH64 Heavy chain US20040258699 SEQ ID NO: 116 3632 ANTH65 Heavy chainUS20040258699 SEQ ID NO: 117 3633 ANTH66 Heavy chain US20040258699 SEQID NO: 118 3634 ANTH67 Heavy chain and light chain 14B7 scFV US7902344;US6916474 SEQ ID 3635 variable region NO: 21 ANTH68 Heavy chain fdregion W1 US8685396 SEQ ID NO: 1 3636 ANTH69 Heavy chain fd region W2US8685396 SEQ ID NO: 17 3637 ANTH70 Heavy chain W5 US8685396 SEQ ID NO:33 3638 ANTH71 Heavy chain A63-6 US8685396 SEQ ID NO: 34 3639 ANTH72Heavy chain F3-6 US8685396 SEQ ID NO: 35 3640 ANTH73 Heavy chain F5-1US8685396 SEQ ID NO: 36 3641 ANTH74 Heavy chain variable region ETI-204US2010156196 SEQ ID NO: 1 3642 ANTH75 Heavy chain variable region 6.20WO2015107307 SEQ ID NO: 1 3643 ANTH76 Heavy chain variable region 33PA83WO2009071860 SEQ ID NO: 1 3644 ANTH77 Heavy chain variable regionanti-γDPGA US8501182 SEQ ID NO: 1 3645 antibody ANTH78 Heavy chainvariable region 4C US8501182 SEQ ID NO: 3 3646 ANTH79 Heavy chainvariable region 11D US8501182 SEQ ID NO: 5 3647 ANTH80 Heavy chainvariable region F20G75 WO2007131363 SEQ ID NO: 16 3648 ANTH81 Heavychain variable region F20G76 WO2007131363 SEQ ID NO: 18 3649 ANTH82Heavy chain variable region F20G77 WO2007131363 SEQ ID NO: 20 3650ANTH83 Heavy chain variable region V2 variant US8507655 SEQ ID NO: 73651 ANTH84 Heavy chain variable region 6.20 variant US8507655 SEQ IDNO: 9 3652 ANTH85 Heavy chain variable region J24.15 variant US8507653SEQ ID NO: 11 3653 ANTH86 Heavy chain variable region J24.7 variantUS8507655 SEQ ID NO: 13 3654 ANTH87 Heavy chain variable region V2variant human US85076S5 SEQ ID NO: 15 3655 ANTH88 Heavy chain variableregion 6.20 variant US8S07655 SEQ ID NO: 17 3656 human ANTH89 Heavychain variable region J24.15 variant US8507655 SEQ ID NO: 19 3657 humanANTH90 Heavy chain variable region J24.7 variant US8507655 SEQ ID NO: 213658 human ANTH91 Heavy chain variable region HuMab 5E8 US8404820 SEQ IDNO: 2 3659 ANTH92 Heavy chain variable region HnMab 2D5 US8404820 SEQ IDNO: 8 3660 ANTH93 Heavy chain variable region HuMab 2H4 US8404820 SEQ IDNO: 12 3661 ANTH94 Heavy chain variable region HuMab 5D5- US8404820 SEQID NO: 16 3662 2E10 ANTH95 Heavy chain variable region 13E3 US8309P9PSEQ ID NO: 2 3663 ANTH96 Heavy chain variable region 3E1 US8309090 SEQID NO: 6 3667 ANTH97 Heavy chain variable region KCTC 10756BP US8268316SEQ ID NO: 2 3665 ANTH98 Heavy chain variable region M18 scFv US7902344;US69I6474 SEQ ID 3666 NO: 23 ANTH99 Heavy chain variable region 21D9 MAbUS7442373 SEQ ID NO: 2 3667 ANTH100 Heavy chain variable region 1C6 MabUS7442373 SEQ ID NO: 6 3668 ANTH101 Heavy chain variable region 4H7 MabUS7442373 SEQ ID NO: 10 3669 ANTH102 Heavy chain variable region 22G12Mab US7442373 SEQ ID NO: 14 3670 ANTH103 Heavy chain variable regionmonoclonal WO1999055842 SEQ ID NO: 20 3671 antibody 9-1 ANTH104 Heavychain variable region monoclonal WO1999055842 SEQ ID NO: 21 3672antibody 7-1 ANTH105 Heavy chain variable region monoclonal WO1999055842SEQ ID NO: 22 3673 antibody 24-2 ANTH106 Heavy chain variable regionmonoclonal WO1999055842 SEQ ID NO: 23 3674 antibody 21-4 ANTH107 Heavychain variable region monoclonal WO1999055842 SEQ ID NO: 24 3675antibody 10-2 ANTH108 Heavy chain variable region monoclonalWO1999055842 SEQ ID NO: 25 3676 antibody 22-1 ANTH109 Heavy chainvariable region monoclonal WO1999055842 SEQ ID NO: 26 3677 antibody 13-3ANTH110 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO:27 3678 antibody 8-3 ANTH111 Heavy chain variable region monoclonalWO1999055842 SEQ ID NO 29 3679 antibody 6-1 ANTH112 Heavy chain variableregion monoclonal WO1999055842 SEQ ID NO: 30 3680 antibody 3-1 ANTH113Heavy chain variable region, EF12A US8961975 SEQ ID NO: 51 3681 Edemafactor binding ANTH114 Heavy chain variable region, EF13D US8961975 SEQID NO: 33 3682 Edema factor binding ANTH115 Heavy chain variable region,EF14H US8961975 SEQ ID NO: 52 3683 Edema factor binding ANTH116 Heavychain variable region, EF15A US8961975 SEQ ID NO: 53 3684 Edema factorbinding ANTH117 Heavy chain variable region, LF9D US8961975 SEQ ID NO:49 3685 Lethal factor ANTH118 Heavy chain variable region, LF10EUS8961975 SEQ ID NO: 1 3686 Lethal factor ANTH119 Heavy chain, AntibodyObiltoxaximab 3687 against inhalational anthrax ANTH120 Kappa lightchain US20040258699 SEQ ID NO: 19 3688 ANTH121 Kappa light chainUS20040258699 SEQ ID NO: 20 3689 ANTH122 Kappa light chain US20040258699SEQ ID NO: 21 3690 ANTH123 Kappa tight chain US20040258699 SEQ ID NO: 223691 ANTH124 Kappa light chain US20040258699 SEQ ID NO: 23 3692 ANTH125Kappa light chain US20040258699 SEQ ID NO: 24 3693 ANTH126 Kappa lightchain US20040258699 SEQ ID NO: 25 3694 ANTH127 Kappa light chainUS20040258699 SEQ ID NO: 26 3695 ANTH128 Kappa tight chain US20040258699SEQ ID NO: 39 3696 ANTH129 Kappa light chain US20040258699 SEQ ID NO: 403697 ANTH130 Kappa light chain US20040258699 SEQ ID NO: 41 3698 ANTH131Kappa light chain US20040258699 SEQ ID NO: 42 3699 ANTH132 Kappa lightchain US20040258699 SEQ ID NO: 43 3700 ANTH133 Kappa light chainUS20040258699 SEQ ID NO: 44 3701 ANTH134 Kappa light chain US20040258699SEQ ID NO: 45 3702 ANTH135 Kappa light chain US20040258699 SEQ ID NO: 463703 ANTH136 Kappa light chain US20040258699 SEQ ID NO: 47 3704 ANTH137Kappa light chain US20040258699 SEQ ID NO: 48 3705 ANTH138 Kappa lightchain US20040258699 SEQ ID NO: 49 3706 ANTH139 Kappa light chainUS20040258699 SEQ ID NO: 50 3707 ANTH140 Kappa light chain US20040258699SEQ ID NO: 51 3708 ANTH141 Kappa light chain US20040258699 SEQ ID NO: 523709 ANTH142 Kappa light chain US20040258699 SEQ ID NO: 53 3710 ANTH143Kappa light chain US20040258699 SEQ ID NO: 54 3711 ANTH144 Kappa lightchain US20040258699 SEQ ID NO: 55 3712 ANTH145 Kappa light chainUS20040258699 SEQ ID NO: 56 3713 ANTH146 Kappa light chain US20040258699SEQ ID NO: 57 3714 ANTH147 Kappa light chain US20040258699 SEQ ID NO: 583715 ANTH148 Kappa light chain US20040258699 SEQ ID NO: 59 3716 ANTH149Kappa light chain US20040258699 SEQ ID NO: 60 3717 ANTH150 Kappa lightchain US20040258699 SEQ ID NO: 61 3718 ANTH151 Lambda light chainUS20040258699 SEQ ID NO: 27 3719 ANTH152 Lambda light chainUS20040258699 SEQ ID NO: 28 3720 ANTH153 Lambda light chainUS20040258699 SEQ ID NO: 29 3721 ANTH154 Lambda light chainUS20040258699 SEQ ID NO: 30 3722 ANTH155 Lambda light chainUS20040258699 SEQ ID NO: 31 3723 ANTH156 Lambda light chainUS20040258699 SEQ ID NO: 32 3724 ANTH157 Lambda light chainUS20040258699 SEQ ID NO: 33 3725 ANTH158 Lambda light chainUS20040258699 SEQ ID NO: 34 3726 ANTH159 Lambda light chainUS20040258699 SEQ ID NO: 35 3727 ANTH160 Lambda tight chainUS20040258699 SEQ ID NO: 36 3728 ANTH161 Lambda light chainUS20040258699 SEQ ID NO: 37 3729 ANTH162 Lambda light chainUS20040258699 SEQ ID NO: 38 3730 ANTH163 Lambda light chainUS20040258699 SEQ ID NO: 62 3731 ANTH164 Lambda light chainUS20040258699 SEQ ID NO: 63 3732 ANTH165 Lambda light chainUS20040258699 SEQ ID NO: 64 3733 ANTH166 Lambda light chainUS20040258699 SEQ ID NO: 65 3734 ANTH167 Lambda light chainUS20040258699 SEQ ID NO: 66 3735 ANTH168 Lambda light chainUS20040258699 SEQ ID NO: 67 3736 ANTH169 Lambda light chainUS20040258699 SEQ ID NO: 68 3737 ANTH170 Lambda light chainUS20040258699 SEQ ID NO: 69 3738 ANTH171 Lambda light chainUS20040258699 SEQ ID NO: 70 3739 ANTH172 Lambda light chainUS20040258699 SEQ ID NO: 71 3740 ANTH173 Lambda light chainUS20040258699 SEQ ID NO: 72 3741 ANTH174 Lambda light chainUS20040258699 SEQ ID NO: 73 3742 ANTH175 Lambda light chainUS20040258699 SEQ ID NO: 74 3743 ANTH178 Lambda light chainUS20040258699 SEQ ID NO: 75 3744 ANTH177 Lambda light chainUS20040258699 SEQ ID NO: 76 3745 ANTH178 Lambda light chainUS20040258699 SEQ ID NO: 77 3746 ANTH179 Light chain US8617548 SEQ IDNO: 1 3747 ANTH180 Light chain IQNPA Lkappa US7658925 SEQ ID NO: 4 3748ANTH181 Light chain IQNPA Lkappa US7658925 SEQ ID NO: 8 3749 ANTH182Light chain 1A5 US20090022736 SEQ ID NO: 2 3750 ANTH183 Light chain 4A12US20090022736 SEQ ID NO: 4 3751 ANTH184 Light chain 24B1 US20090022736SEQ ID NO: 6 3752 ANTH185 Light chain 24G4 US20090022736 SEQ ID NO: 83753 ANTH186 Light chain ′32E12 US20090022736 SEQ ID NO: 10 3754 ANTH187Light chain 33F4 US20090022736 SEQ ID NO: 12 3755 ANTH188 Light chainscFv 2LF EP2778173 SEQ ID NO: 6 3756 ANTH189 Light chain Obiltoxaximab3757 ANTH190 Light chain region W1 US8685396 SEQ ID NO: 9 3758 ANTH191Light chain region W2 US8685396 SEQ ID NO: 25 3759 ANTH192 Light chainregion W5 USX685396 SEQ ID NO: 37 3760 ANTH193 Light chain region A63-6US8685396 SEQ ID NO: 38 3761 ANTH194 Light chain region F3-6 US8685396SEQ ID NO: 39 3762 ANTH195 Light chain region F5-1 US8685396 SEQ ID NO:40 3763 ANTH196 Light chain variable region LF11H US8961975 SEQ ID NO:25 3764 ANTH197 Light chain variable region LF9D US8961975 SEQ ID NO: 173765 ANTH198 Light chain variable region LF10E US8961975 SEQ ID NO: 93766 ANTH199 Light chain variable region 6.20 WO2015107307 SEQ ID NO: 23767 ANTH200 Light chain variable region 35PA83 WO200907186USEQ ID NO: 23768 ANTH201 Light chain variable region anti-γDPGA US8501182 SEQ ID NO:2 3769 antibody ANTH202 Light chain variable region 4C US8501182 SEQ IDNO: 4 3770 ANTH203 Light chain variable region 11D US8501182 SEQ ID NO:6 3771 ANTH204 Light chain variable region F20G75 WO2007131363 SEQ IDNO: 10 3772 ANTH205 Light chain variable region F20G76 WO2007131363 SEQID NO: 12 3773 ANTH206 Light chain variable region F20G77 WO2007131363SEQ ID NO: 14 3774 ANTH207 Light chain variable region V2 variantUS8507655 SEQ ID NO: 8 3775 ANTH208 Light chain variable region 6.20variant US8507655 SEQ ID NO: 10 3776 ANTH209 Light chain variable regionJ24.15 variant US8507655 SEQ ID NO: 12 3777 ANTH210 Light chain variableregion J24.7 variant US8507655 SEQ ID NO: 14 3778 ANTH211 Light chainvariable region V2 variant human US8507655 SEQ ID NO: 16 3779 ANTH212Light chain variable region 6.20 vaiiant US8507655 SEQ ID NO: 18 3780human ANTH213 Light chain variable region J24.15 variant US8507655 SEQID NO: 20 3781 human ANTH214 Light chain variable region J24.7 variantUS8507655 SEQ ID NO: 22 3782 human ANTH215 Light chain variable regionHuMab 5E8 US8401820 SEQ ID NO: 4 3783 (Major) ANTH216 Light chainvariable region HuMab 5E8 US8404820 SEQ ID NO: 6 3784 (Minor) ANTH217Light chain variable region HuMab 2P5 US8404820 SEQ ID NO: 10 3785ANTH218 Light chain variable region HuMab 2H4 US8404820 SEQ ID NO: 143786 ANTH219 Light chain variable region HuMab 5D5- US8404820 SEQ ID NO:18 3787 2E10 ANTH220 Light chain variable region 13E3 US8309090 SEQ IDNO: 4 3788 ANTH221 Light chain variable region 3E1 US8309090 SEQ ID NO:8 3789 ANTH222 Light chain variable region KCTC 10756BP US8268316 SEQ IDNO: 7 3790 ANTH223 Light chain variable region modified M18 US7902344;US6916474 SEQ ID 3791 sequence NO: 25 ANTH224 Light chain variableregion 21D9 MAb US7442373 SEQ ID NO: 4 3792 ANTH225 Light chain variableregion 1C6 Mab US7442373 SEQ ID NO: 8 3793 ANTH226 Light chain variableregion 4H7 Mab US7442373 SEQ ID NO: 12 3794 ANTH227 Light chain variableregion 22G12 Mab US7442373 SEQ ID NO: 16 3795 ANTH228 Light chainvariable region ETI-204 US20120156196 SEQ ID NO: 2 3796 antibody againstanthrax toxin, ANTH229 Light chain variable region, EF12A US8961975 SEQID NO: 54 3797 Edema factor ANTH230 Light chain variable region, EF13DUS8961975 SEQ ID NO: 41 3798 Edema factor ANTH231 Light chain variableregion, EF14H US8961973 SEQ ID NO: 55 3799 Edema factor ANTH232 Lightchain variable region, EP15A US8961975 SEQ ID NO: 56 3800 Edema factorANTH233 Scfv PWB2447 scFv US7601351; US7906119; 3801 US20110189197 SEQID NO 48 ANTH234 Scfv PWC2004 scFv US7601351; US7906119; 3802US20110189197 SEQ ID NO: 49 ANTH235 Scfv PWD0283 scFv US7601351;US7906119; 3803 US20110189197 SEQ ID NO 50 ANTH236 Scfv PWP0323 scFvUS7601351; US7906119; 3804 US20110189197 SEQ ID NO: 51 ANTH237 ScfvPWD0422 scFv US7601351; US7906119; 3805 US20110189197 SEQ ID NO: 52ANTH238 Scfv PWD0587 scFv US7601351; US7906119; 3806 US20110189197 SEQID NO: 53 ANTH239 Scfv PWD0791 scFv US7601351; US7906119; 3807US20110189197 SEQ ID NO: 54 ANTH240 Scfv PHP2222 scFv US7601351;US7906119; 3808 US20110189197 SEQ ID NO: 55 ANTH241 Scfv PHD2581 scFvUS7601351; US7906119; 3809 US20110189197 SEQ ID NO: 56 ANTH242 AbthraxUS20120136196 SEQ ID NO: 48 3810 ANTH243 Abthrax US20120156196 SEQ IDNO: 49 3811 ANTH244 WO2003063768 SEQ ID NO: 4 3812 ANTH245 WO2003063768SEQ ID NO: 5 3813

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 16 against Botulinum Toxin.

TABLE 16 Antibodies against Botulinum Toxin SEQ Antibody Antibody ID No.Description Name Reference Information NO BOTT1 Heavy-chain-onlyUS20130058962 SEQ ID NO: 56 3814 BOTT2 Heavy-chain-only US20130058962SEQ ID NO: 57 3815 BOTT3 Heavy-chain-only US20130058962 SEQ ID NO: 583816 BOTT4 Heavy-chain only binding JDA-D12 WO2015100409 SEQ ID NO: 203817 agents specific to BoNT/A holotoxin BOTT5 Heavy-chain only bindingJDQ-A5 WO2015100409 SEQ ID NO: 22 3818 agents specific to BoNT/Aholotoxin BOTT6 Heavy-chain only binding JDQ-B5 WO2015100409 SEQ ID NO:24 3819 agents specific to BoNT/A holotoxin BOTT7 Heavy-chain onlybinding JDQ-C2 WO2015100409 SEQ ID NO: 26 3820 agents specific to BoNT/Aholotoxin BOTT8 Heavy-chain only binding JDQ-F 12 WO2015100409 SEQ IDNO: 28 3821 agents specific to BoNT/A holotoxin BOTT9 Heavy-chain onlybinding JDQ-G5 WO2015100409 SEQ ID NO: 30 3822 agents specific to BoNT/Aholotoxin BOTT10 Heavy-chain only binding JDQ-H7 WO2015100409 SEQ ID NO:32 3823 agents specific to BoNT/A holotoxin BOTT11 Heavy-chain onlybinding JEQ-A5 WO2015100409 SEQ ID NO: 34 3824 agents specific to BoNT/Aholotoxin BOTT12 Heavy-chain only binding JEQ-H11 WO2015100409 SEQ IDNO: 36 3825 agents specific to BoNT/A holotoxin BOTT13 Heavy-chain onlybinding agent E-9 WO2015100409 SEQ ID NO: 38 3826 BOTT14 Heavy-chainonly binding agent B2 WO2015100409 SEQ ID NO: 40 3827 BOTT15 Heavy-chainonly binding agent C5 WO2015100409 SEQ ID NO: 42 3828 BOTT16 Heavy-chainonly binding agent F9 WO2015100409 SEQ ID NO: 44 3829 BOTT17 Heavy-chainonly binding agent heavy-chain only WO2015100409 SEQ ID NO: 46 3830binding agent BOTT18 Heavy-chain only binding agent heavy-chain onlyWO2015100409 SEQ ID NO: 48 3831 with tag binding agent with tag BOTT19Heavy-chain only binding agent heavy-chain only WO2015100409 SEQ ID NO:50 3832 with tag binding agent with tag BOTT20 Heavy-chain only dimerheavy-chain only WO2015100409 SEQ ID NO: 52 3833 binding agent with twotags dimer binding agent with two tags BOTT21 Recombinant camelid heavy-H7 WO2015100409 SEQ ID NO: 56 3834 chain-only antibody BOTT22Recombinant camelid heavy- B5 WO2015100409 SEQ ID NO: 57 3835 chain-onlyantibody BOTT23 Recombinant camelid heavy- WO2015100409 SEQ ID NO: 583836 chain-only antibody BOTT24 Scfv scFv#2 WO2015100409 SEQ ID NO: 23837 BOTT25 Scfv scFv#3 WO2015100409 SEQ ID NO: 4 3838 BOTT26 ScfvscFv#7 WO2015100409 SEQ ID NO: 6 3839 BOTT27 Scfv scFv#8 WO2015100409SEQ ID NO: 8 3840 BOTT28 Scfv scFv#21 WO2015100409 SEQ ID NO: 10 3841BOTT29 Scfv scFv#E WO2015100409 SEQ ID NO: 12 3842 BOTT30 Scfv scFv#7-2EWO2015100409 SEQ ID NO: 14 3843

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 17 against Shiga Toxin.

TABLE 17 Antibodies against Shiga Toxin SEQ Antibody Antibody ID No.Description Name Reference Information NO SHIG1 Camelid heavy-chain onlyJET-H12 WO2015100409 SEQ ID NO: 96 3844 SHIG2 Camelid heavy-chain onlyJFG-H6 WO2015100409 SEQ ID NO: 98 3845 SHIG3 Heavy chain US2014013548SEQ ID NO: 44 3846 SHIG4 Heavy chain US2014013548 SEQ ID NO: 21 3847SHIG5 Heavy chain of cαstx1 Shigamab US20120195891 SEQ ID NO: 1 3848SHIG6 Heavy chain of cαstx1 Shigamab US20120195891 SEQ ID NO: 2 3849SHIG7 Heavy chain of cαstx2 Shigamab US20120195891 SEQ ID NO: 3 3850SHIG8 Heavy chain of cαstx2 Shigamab US20120195891 SEQ ID NO: 4 3851SHIG9 Heavy chain single domain WO2014191904 SEQ ID NO: 7 3852 SHIG10Heavy chain single domain WO2014191904 SEQ ID NO: 8 3853 SHIG11 Heavychain single domain WO2014191904 SEQ ID NO: 9 3854 SHIG12 Heavy chainsingle domain WO2014191904 SEQ ID NO: 10 3855 SHIG13 Heavy chain singledomain WO2014191904 SEQ ID NO: 11 3856 SHIG14 Heavy chain single domainWO2014191904 SEQ ID NO: 12 3857 SHIG15 Heavy chain single domainWO2014191904 SEQ ID NO: 13 3858 SHIG16 Heavy chain single domainWO2014191904 SEQ ID NO: 14 3859 SHIG17 Heavy chain single domainWO2014191904 SEQ ID NO: 15 3860 SHIG18 Heavy chain single domainWO2014191904 SEQ ID NO: 16 3861 SHIG19 Heavy chain single domainWO2014191904 SEQ ID NO: 17 3862 SHIG20 Heavy chain single domainWO2014191904 SEQ ID NO: 18 3863 SHIG21 Heavy chain single domainWO2014191904 SEQ ID NO: 19 3864 SHIG22 Heavy chain single domainWO2014191904 SEQ ID NO: 20 3865 SHIG23 Heavy chain single domainWO2014191904 SEQ ID NO: 21 3866 SHIG24 Heavy chain single domainWO2014191904 SEQ ID NO: 22 3867 SHIG25 Heavy chain single domainWO2014191904 SEQ ID NO: 23 3868 SHIG26 Heavy chain single domainWO2014191904 SEQ ID NO: 24 3869 SHIG27 Heavy chain single domainWO2014191904 SEQ ID NO: 25 3870 SHIG28 Heavy chain single domainWO2014191904 SEQ ID NO: 26 3871 SHIG29 Heavy chain single domainWO2014191904 SEQ ID NO: 27 3872 SHIG30 Heavy chain single domainWO2014191904 SEQ ID NO: 28 3873 SHIG31 Heavy chain single domainWO2014191904 SEQ ID NO: 29 3874 SHIG32 Heavy chain single domainWO2014191904 SEQ ID NO: 30 3875 SHIG33 Heavy chain single domainWO2014191904 SEQ ID NO: 31 3876 SHIG34 Heavy chain single domainWO2014191904 SEQ ID NO: 32 3877 SHIG35 Heavy chain single domainWO2014191904 SEQ ID NO: 33 3878 SHIG36 Heavy chain single domainWO2014191904 SEQ ID NO: 34 3879 SHIG37 Heavy chain single domainWO2014191904 SEQ ID NO: 35 3880 SHIG38 Heavy chain single domainWO2014191904 SEQ ID NO: 36 3881 SHIG39 Heavy chain single domainWO2014191904 SEQ ID NO: 37 3882 SHIG40 Heavy chain single domainWO2014191904 SEQ ID NO: 38 3883 SHIG41 Heavy chain single domainWO2014191904 SEQ ID NO: 39 3884 SHIG42 Heavy chain single domainWO2014191904 SEQ ID NO: 40 3885 SHIG43 Heavy chain single domainWO2014191904 SEQ ID NO: 41 3886 SHIG44 Heavy chain single domainWO2014191904 SEQ ID NO: 42 3887 SHIG45 Heavy chain single domainWO2014191904 SEQ ID NO: 43 3888 SHIG46 Heavy chain single domainWO2014191904 SEQ ID NO: 44 3889 SHIG47 Heavy chain single domainWO2014191904 SEQ ID NO: 45 3890 SHIG48 Heavy chain single domainWO2014191904 SEQ ID NO: 46 3891 SHIG49 Heavy chain single domainWO2014191904 SEQ ID NO: 47 3892 SHIG50 Heavy-chain-only US20130058962SEQ ID NO: 77 3893 SHIG51 Heavy-chain-only US20130058962 SEQ ID NO: 783894 SHIG52 Heavy-chain-only US20130058962 SEQ ID NO: 79 3895 SHIG53Heavy-chain-only US20130058962 SEQ ID NO: 80 3896 SHIG54Heavy-chain-only US20130058962 SEQ ID NO: 81 3897 SHIG55Heavy-chain-only US20130058962 SEQ ID NO: 82 3898 SHIG56Heavy-chain-only US20130058962 SEQ ID NO: 83 3899 SHIG57Heavy-chain-only US20130058962 SEQ ID NO: 84 3900 SHIG58Heavy-chain-only US20130058962 SEQ ID NO: 85 3901 SHIG59Heavy-chain-only US20130058962 SEQ ID NO: 86 3902 SHIG60 Light chainUS2014013548 SEQ ID NO: 42 3903 SHIG61 Light chain US2014013548 SEQ IDNO: 19 3904 SHIG62 Recombinant camelid heavy- JET-A9 WO2015100409 SEQ IDNO: 77 3905 chain-only antibody, STX1 SHIG63 Recombinant camelid heavy-JGG-D4 WO2015100409 SEQ ID NO: 78 3906 chain-only antibody, STX1 SHIG64Recombinant camelid heavy- JFD-A4 WO2015100409 SEQ ID NO: 84 3907chain-only antibody, STX1, STX2 SHIG65 Recombinant camelid heavy- JFD-A5WO2015100409 SEQ ID NO: 85 3908 chain-only antibody, STX1, STX2 SHIG66Recombinant camelid heavy- JGG-G6 WO2015100409 SEQ ID NO: 86 3909chain-only antibody, STX1, STX2 SHIG67 Recombinant camelid heavy-JEN-D10 WO2015100409 SEQ ID NO: 79 3910 chain-only antibody, STX2 SHIG68Recombinant camelid heavy- JGH-G1 WO2015100409 SEQ ID NO: 80 3911chain-only antibody, STX2 SHIG69 Recombinant camelid heavy- JEU-A6WO2015100409 SEQ ID NO: 81 3912 chain-only antibody, STX2 SHIG70Recombinant camelid heavy- JEU-D2 WO2015100409 SEQ ID NO: 82 3913chain-only antibody, STX2 SHIG71 Recombinant camelid heavy- JGH-G9WO2015100409 SEQ ID NO: 83 3914 chain-only antibody, STX2

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described in USPub. No. US20090280104, the contents of each of which are hereinincorporated by reference in their entirety, against Shiga toxin

Tropical Diseases

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the tropicaldisease related payload antibody polypeptides listed in Tables 18-20.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 18 against Plasmodium falciparumcausing Malaria.

TABLE 18 Antibodies against Plasmodium Falciparum causing Malaria SEQAntibody Antibody ID No. Description Name Reference Information NO MALA1Heavy chain immunoglobulin Wajanarogana, S. et al., Construction of a3915 heavy chain human functional single-chain variable fragmentvariable region, (scFv) antibody recognizing the malaria parasitepartial Plasmodium falciparum, Biotechnol. Appl. Biochem. 44 (PT 1),55-61 (2006), NCBI Accession # AAX76832.1 (129aa) MALA2 Heavy chainanti-MSP1 Sowa, K. M. et al., Isolation of a monoclonal 3916 MAD20block2 antibody from a malaria patient-derived phage ScFv Ig heavydisplay library recognizing the Block 2 region chain variable ofPlasmodium falciparum merozoite surface region, partial protein-1, Mol.Biochem. Parasitol. 112 (1), 143-147 (2001), NCBI Accession #AAK08696.1(119aa) MALA3 Heavy chain immunoglobulin Lundquist, R. et al., Humanrecombinant 3917 heavy chain antibodies against Plasmodium falciparumvariable region, merozoite surface protein 3 cloned from partialperipheral blood leukocytes of individuals with immunity to malariademonstrate antiparasitic properties, Infect. Immun. 74 (6), 3222-3231,(2006), NCBI Accession # AAT09786.1 (113aa) MALA4 Heavy chain 2A10 anti-NCBI Accession # BAK41504.1 (118aa) 3918 variable region malariaantibody MALA5 Heavy chain U.S. Pat. No. 7,811,569 to Dziegiel; SEQ IDNO: 1 3919 MALA6 Heavy chain, U.S. Pat. No. 7,811,569 to Dziegiel; SEQID NO: 3 3920 Anti-ang-2 antibody MALA7 Heavy chain U.S. Pat. No.7,811,569 to Dziegiel; SEQ ID NO: 5 3921 MALA8 Heavy chain US20150197562SEQ ID NO: 14 3922 variable region MALA9 Heavy chain mAh 5D5US20150158941 SEQ ID NO: 16 3923 variable region MALA10 Heavy chainUS20140112930 SEQ ID NO: 18 3924 variable region MALA11 Heavy chainM071Xi0199 WO2014087007; SEQ ID NO: 182 3925 variable region MALA12Heavy chain M071Xi2204 WO2014087007; SEQ ID NO: 186 3926 variable regionMALA13 Heavy chain M071Xi0237 WO2014087007; SEQ ID NO: 190 3927 variableregion MALA14 Heavy chain M071Xi2127 WO2014087007; SEQ ID NO: 194 3928variable region MALA15 Heavy chain M071Xi0092 WO2014087007; SEQ ID NO:198 3929 variable region MALA16 Heavy chain M071Xi2057 WO2014087007; SEQID NO: 202 3930 variable region MALA17 Heavy chain M070Xi3010WO2014087007; SEQ ID NO: 206 3931 variable region MALA18 Heavy chainM071Xi0227 WO2014087007; SEQ ID NO: 210 3932 variable region MALA19Heavy chain M071Xi0081 WO2014087007; SEQ ID NO: 214 3933 variable regionMALA20 Heavy chain M071Xi0124 WO2014087007; SEQ ID NO: 218 3934 variableregion MALA21 Heavy chain M036Xi0326 WO2014087007; SEQ ID NO: 222 3935variable region MALA22 Heavy chain M070Xi3195 WO2014087007; SEQ ID NO:226 3936 variable region MALA23 Heavy chain M070Xi3062 WO2014087007; SEQID NO: 230 3937 variable region MALA24 Heavy chain M071Xi2217WO2014087007; SEQ ID NO: 234 3938 variable region MALA25 Heavy chainM036Xi0003 WO2014087007; SEQ ID NO: 238 3939 variable region MALA26Heavy chain, Eba- R217 Chen et al., PLoS Pathol. 9 (5), E1003390 3940175 (2013), NCBI Accession # 4QEX_I (215aa) MALA27 Heavy chain, Eba-R218 Chen et al., PLoS Pathol. 9 (5), E1003390 3941 175 (2013), NCBIAccession # 4K2U_I (233aa) MALA28 Light chain anti-MSP1 Sowa, K. M. etal., Isolation of a monoclonal 3942 MAD20 block2 antibody from a malariapatient-derived phage ScFv Ig heavy display library recognizing theBlock 2 region chain variable of Plasmodium falciparum merozoite surfaceregion, partial protein-1, Mol. Biochem. Parasitol. 112 (1), 143-147(2001), NCBI Accession #AAK08697.1 (119aa) MALA29 Light chain anti-MSP1Sowa, K. M. et al., Isolation of a monoclonal 3943 MAD20 block2 antibodyfrom a malaria patient-derived phage ScFv Ig light display libraryrecognizing the Block 2 region chain variable of Plasmodium falciparummerozoite surface region, partial protein-1, Mol. Biochem. Parasitol.112 (1), 143-147 (2001), NCBI Accession #AAK08698.1 (110aa) MALA30 Lightchain immunoglobulin Wajanarogana, S. et al., Construction of a 3944light chain human functional single-chain variable fragment variableregion, (scFv) antibody recognizing the malaria parasite partialPlasmodium falciparum, Biotechnol. Appl. Biochem. 44 (PT 1), 55-61(2006) AAX76833.1 (107aa) MALA31 Kappa light chain immunoglobulinLundquist, R. et al., Human recombinant 3945 kappa light antibodiesagainst Plasmodium falciparum chain variable merozoite surface protein 3cloned from region, partial peripheral blood leukocytes of individualswith immunity to malaria demonstrate antiparasitic properties, Infect.Immun. 74 (6), 3222-3231, (2006), NCBI Accession # AAT09787.1 (113aa)MALA32 Light chain 2A10 anti- NCBI Accession # BAK41503.1 (108aa) 3946variable region malaria antibody MALA33 Light chain U.S. Pat. No.7,811,569 to Dziegiel; SEQ ID NO: 2 3947 MALA34 Light chain, Anti- U.S.Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 4 3948 ang-2 antibody MALA35Light chain U.S. Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 6 3949MALA36 Light chain US20150197562 SEQ ID NO: 15 3950 variable regionMALA37 Light chain US20150197562 SEQ ID NO: 19 3951 variable regionMALA38 Light chain mAb 5D5 US20150158941 SEQ ID NO: 14 3952 variableregion MALA39 Light chain US20140112930 SEQ ID NO: 20 3953 variableregion MALA40 Light chain M071Xi0199 WO2014087007; SEQ ID NO: 184 3954variable region MALA41 Light chain M071Xi2204 WO2014087007; SEQ ID NO:188 3955 variable region MALA42 Light chain M071Xi0237 WO2014087007; SEQID NO: 192 3956 variable region MALA43 Light chain M071Xi2127WO2014087007; SEQ ID NO: 196 3957 variable region MALA44 Light chainM071Xi0092 WO2014087007; SEQ ID NO: 200 3958 variable region MALA45Light chain M071Xi2057 WO2014087007; SEQ ID NO: 204 3959 variable regionMALA46 Light chain M070Xi3010 WO2014087007; SEQ ID NO: 208 3960 variableregion MALA47 Light chain M071Xi0227 WO2014087007; SEQ ID NO: 212 3961variable region MALA48 Light chain M071Xi0081 WO2014087007; SEQ ID NO:216 3962 variable region MALA49 Light chain M071Xi0124 WO2014087007; SEQID NO: 220 3963 variable region MALA50 Light chain M036Xi0326WO2014087007; SEQ ID NO: 224 3964 variable region MALA51 Light chainM070Xi3195 WO2014087007; SEQ ID NO: 228 3965 variable region MALA52Light chain M070Xi3062 WO2014087007; SEQ ID NO: 232 3966 variable regionMALA53 Light chain M071Xi2217 WO2014087007; SEQ ID NO: 236 3967 variableregion MALA54 Light chain M036Xi0003 WO2014087007; SEQ ID NO: 240 3968variable region MALA55 Light chain, Eba- R217 Chen et al., PLoS Pathol.9 (5), E1003390 3969 175 (2013), NCBI Accession # 4QEX_M (214aa) MALA56Light chain, Eba- R218 Chen et al., PLoS Pathol. 9 (5), E1003390 3970175 (2013), NCBI Accession # 4K2U_M (234aa) MALA57 Vivax apical F8.12.19NCBI Accession # 2J4W_L (213aa) 3971 membrane antigen 1 monoclonalantibody, seqres

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 19 against Ebola and/or MargburgViruses.

TABLE 19 Antibodies against Ebola and Marburg viruses SEQ AntibodyAntibody ID No. Description Name Reference Information NO EBOL1 Chain A,Sudan Ebolavirus 16f6 Bale et al., Structural basis for 3972Glycoprotein (Strain Boniface) differential neutralization ofebolaviruses; Viruses 4 (4), 447-470 (2012), NCBI Accession # 3VE0_B(212aa) EBOL2 Chain B, Sudan Ebolavirus 16f6 Bale et al., Structuralbasis for 3973 Glycoprotein (Strain Boniface) differentialneutralization of ebolaviruses; Viruses 4 (4), 447-470 (2012), NCBIAccession # 3VE0_A (220aa) EBOL3 Ebola Virus Glycoprotein 13f6-1-2 LeeJ. E. et al., Complex of a protective 3974 Fab antibody with its Ebolavirus GP peptide epitope: unusual features of a V lambda x light chain;J. Mol. Biol. 375 (1), 202-216 (2008), NCBI Accession # 2QHR_L (218aa)EBOL4 Ebola Virus Glycoprotein 13f6-1-2 Lee J. E. et al., Complex of aprotective 3975 Fab antibody with its Ebola virus GP peptide epitope:unusual features of a V lambda x light chain; J. Mol. Biol. 375 (1),202-216 (2008), NCBI Accession # 2QHR_H (222aa) EBOL5 Fab heavy chainEnvelope Mr78 Hashiguchi, T., et al., Cell 160 (5), 3976 GlycoproteinGp1 904-912 (2015), NCBI Accession # 3X2D_P (226aa) EBOL6 Fab lightchain, Envelope Mr78 Hashiguchi, T., et al., Cell 160 (5), 3977Glycoprotein Gp1 904-912 (2015), NCBI Accession # 3X2D_O (213aa) EBOL7Fusion protein, Zaire Ebola virus, US20140356354 SEQ ID NO: 2 3978Mayinga strain glycoprotein EBOL8 Heavy chain Ebolavirus-ProtectiveOlal, D., et al., Structure of an 3979 Antibody Antibody in Complex withIts Mucin Domain Linear Epitope That Is Protective against Ebola Virus;J. Virol. 86 (5), 2809-2816 (2012), NCBI Accession # 2Y6S_H (213aa)EBOL9 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO: 6 3980Marburg) EBOL10 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO:7 3981 Marburg) EBOL11 Heavy chain Filovirus (Ebola or US20140356354 SEQID NO: 8 3982 Marburg) EBOL12 Heavy chain Filovirus (Ebola orUS20140356354 SEQ ID NO: 9 3983 Marburg) EBOL13 Heavy chain Filovirus(Ebola or US20140356354 SEQ ID NO: 10 3984 Marburg) EBOL14 Heavy chainFilovirus (Ebola or US20140356354 SEQ ID NO: 11 3985 Marburg) EBOL15Heavy chain variable region, Zaire WO2015127136 SEQ ID NO: 71 3986ebolavirus (ZEBOV) glycoprotein EBOL16 Heavy chain variable region,Zaire WO2015127136 SEQ ID NO: 47 3987 ebolavirus (ZEBOV) glycoproteinEBOL17 Heavy chain variable region, Zaire WO2015127136 SEQ ID NO: 233988 ebolavirus (ZEBOV) glycoprotein EBOL18 Heavy chain variable region,Ebola 16H11 U.S. Pat. No. 9,097,713 SEQ ID NO: 2 3989 Sudan Bonifacevirus (ESB) glycoprotein (GP) EBOL19 Heavy chain variable region, Ebola19B3 U.S. Pat. No. 9,097,713 SEQ ID NO: 4 3990 Sudan Boniface virus(ESB) glycoprotein (GP) EBOL20 Heavy chain variable region, Ebola 17F6U.S. Pat. No. 9,097,713 SEQ ID NO: 6 3991 Sudan Boniface virus (ESB)glycoprotein (GP) EBOL21 Heavy chain variable region, Ebola 16F6 U.S.Pat. No. 9,097,713 SEQ ID NO: 8 3992 Sudan Boniface virus (ESB)glycoprotein (GP) EBOL22 Heavy chain variable region, Ebola EGP 6D8 U.S.Pat. No. 7,335,356 SEQ ID NO: 22 3993 virus GP 1-2 EBOL23 Heavy chainvariable region, Ebola EGP13F6-1-2 U.S. Pat. No. 7,335,356 SEQ ID NO: 323994 virus GP EBOL24 Heavy chain variable region, Ebola EGP13C6-1-1 U.S.Pat. No. 7,335,356 SEQ ID NO: 12 3995 virus GP EBOL25 Heavy chainvariable region, WO2015127140 SEQ ID NO: 14 3996 Marburg virus, Ebolavirus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virusglycoprotein EBOL26 Heavy chain variable region, WO2015127140 SEQ ID NO:38 3997 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, TaiForest virus or Reston virus glycoprotein EBOL27 Heavy chain variableregion, WO2015127140 SEQ ID NO: 62 3998 Marburg virus, Ebola virus,Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virusglycoprotein EBOL28 Heavy chain variable region, WO2015127140 SEQ ID NO:86 3999 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, TaiForest virus or Reston virus glycoprotein EBOL29 Heavy chain variableregion, WO2015127140 SEQ ID NO: 110 4000 Marburg virus, Ebola virus,Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virusglycoprotein EBOL30 Heavy chain variable region, WO2015127140 SEQ ID NO:134 4001 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, TaiForest virus or Reston virus glycoprotein EBOL31 Heavy chain variableregion, WO2015127140 SEQ ID NO: 158 4002 Marburg virus, Ebola virus,Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virusglycoprotein EBOL32 Heavy chain, Ebola virus Fab Kz52 Lee J. E. et al.,Structure of the Ebola 4003 glycoprotein, virus glycoprotein bound to anantibody from a human survivor; Nature 454 (7201), 177-182 (2008), NCBIAccession # 3CSY_G (226aa) EBOL33 Light chain variable region, Ebola16F6 U.S. Pat. No. 9,097,713 SEQ ID NO: 10 4004 Sudan Boniface virus(ESB) glycoprotein (GP) EBOL34 Light chain variable region, Ebola EGP6D8 U.S. Pat. No. 7,335,356 SEQ ID NO: 27 4005 virus GP 1-2 EBOL35 Lightchain variable region, Ebola EGP13F6-1-2 U.S. Pat. No. 7,335,356 SEQ IDNO: 37 4006 virus GP EBOL36 Light chain variable region, EbolaEGP13C6-1-1 U.S. Pat. No. 7,335,356 SEQ ID NO: 16 4007 virus GP EBOL37Light chain variable region, WO2015127140 SEQ ID NO: 2 4008 Marburgvirus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus orReston virus glycoprotein EBOL38 Light chain variable region,WO2015127140 SEQ ID NO: 26 4009 Marburg virus, Ebola virus, Sudan virus,Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL39Light chain variable region, WO2015127140 SEQ ID NO: 50 4010 Marburgvirus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest vires orReston virus glycoprotein EBOL40 Light chain variable region,WO2015127140 SEQ ID NO: 74 4011 Marburg virus, Ebola virus, Sudan virus,Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL41Light chain variable region, WO2015127140 SEQ ID NO: 98 4012 Marburgvirus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus orReston virus glycoprotein EBOL42 Light chain variable region,WO2015127140 SEQ ID NO: 122 4013 Marburg virus, Ebola virus, Sudanvirus, Bundibugyo virus, Tai Forest virus or Reston virus glycoproteinEBOL43 Light chain variable region, WO2015127140 SEQ ID NO: 146 4014Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forestvirus or Reston virus glycoprotein EBOL44 Light chain variable region,Zaire WO2015127136 SEQ ID NO: 59 4015 ebolavirus (ZEBOV) glycoproteinEBOL45 Light chain variable region, Zaire WO2015127136 SEQ ID NO: 354016 ebolavirus (ZEBOV) glycoprotein EBOL46 Light chain variable region,Zaire WO2015127136 SEQ ID NO: 11 4017 ebolavirus (ZEBOV) glycoproteinEBOL47 light chain, Ebola virus Fab Kz52 Lee J. E. et al., Structure ofthe Ebola 4018 glycoprotein virus glycoprotein bound to an antibody froma human survivor; Nature 454 (7201), 177-182 (2008), NCBI Accession #3CSY_H (217aa) EBOL48 Light chain, Ebolavirus-Protective Olal, D., etal., Structure of an 4019 Antibody Antibody in Complex with Its MucinDomain Linear Epitope That Is Protective against Ebola Virus; J. Virol.86 (5), 2809-2816 (2012), NCBI Accession # 2Y6S_L (217aa) EBOL49 Lightchain, Filovirus (Ebola or US20140356354 SEQ ID NO: 12 4020 Marburg)EBOL50 Light chain, Filovirus (Ebola or US20140356354 SEQ ID NO: 13 4021Marburg) EBOL51 Light chain, Filovirus (Ebola or US20140356354 SEQ IDNO: 14 4022 Marburg) EBOL52 Light chain, Filovirus (Ebola orUS20140356354 SEQ ID NO: 15 4023 Marburg) EBOL53 Light chain, Filovirus(Ebola or US20140356354 SEQ ID NO: 16 4024 Marburg)

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inU.S. Pat. No. 7,335,356 and EP Pub. No. EP1539238, the contents of eachof which are herein incorporated by reference in their entirety, againstEbola.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 20 against Mosquito-borne disease.

TABLE 20 Antibodies against Mosquito-borne diseases SEQ AntibodyAntibody ID No. Description Name Reference Information NO MOSQ1 Gammaheavy chain, Thibodeaux, B. A. “Development of a human- 4025 partial,anti-Saint Louis murine chimeric immunoglobulin M antibody encephalitisvirus for use in the serological detection of human envelopeglycoprotein flavivirus antibodies”, Clin. Vaccine immunoglobulinImmunol. 16 (5), 679-685, 2009), NCBI Accession # ACI62179 MOSQ2 Gammaheavy chain, Thibodeaux, B. A. “Development of a human- 4026 partial,anti-Saint Louis murine chimeric immunoglobulin M antibody encephalitisvirus for use in the serological detection of human envelopeglycoprotein flavivirus antibodies”, Clin. Vaccine immunoglobulinImmunol. 16 (5), 679-685, 2009), NCBI Accession # ACI62180 MOSQ3 Heavychain variable anti- US20080292644 SEQ ID NO: 69 4027 region, JapaneseDLVR1/CLEC5A encephalitis virus MOSQ4 Heavy chain variable anti-US20080292644 SEQ ID NO: 70 4028 region, Japanese DLVR1/CLEC5Aencephalitis virus MOSQ5 Heavy chain variable anti- US20080292644 SEQ IDNO: 71 4029 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ6 Heavychain variable CN103864925 SEQ ID NO: 2 4030 region, Japaneseencephalitis virus MOSQ7 Heavy chain variable Throsby, M. “Isolation andcharacterization 4031 region, partial sequence, of human monoclonalantibodies from WNV individuals infected with west nile virus” J. Virol.80 (14), 6982-6992 (2006), NCBI Accession # ABF20480.1 MOSQ8 Heavy chainvariable Throsby, M. “Isolation and characterization 4032 region,partial sequence, of human monoclonal antibodies from WNV individualsinfected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBIAccession # ABF20479.1 MOSQ9 Heavy chain variable Throsby, M. “Isolationand characterization 4033 region, partial sequence, of human monoclonalantibodies from WNV individuals infected with west nile virus” J. Virol.80 (14), 6982-6992 (2006), NCBI Accession # ABF20478.1 MOSQ10 Heavychain variable Throsby, M. “Isolation and characterization 4034 region,partial sequence, of human monoclonal antibodies from WNV individualsinfected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBIAccession # ABF20477.1 MOSQ11 Heavy chain variable Throsby, M.“Isolation and characterization 4035 region, partial sequence, of humanmonoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20476.1MOSQ12 Heavy chain variable Throsby, M. “Isolation and characterization4036 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20475.1 MOSQ13 Heavy chain variable Throsby,M. “Isolation and characterization 4037 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20474.1MOSQ14 Heavy chain variable Throsby, M. “Isolation and characterization4038 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20473.1 MOSQ15 Heavy chain variable Throsby,M. “Isolation and characterization 4039 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20472.1MOSQ16 Heavy chain variable Throsby, M. “Isolation and characterization4040 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006). NCBI Accession # ABF20471.1 MOSQ17 Heavy chain variable mAbl 1WO2014144061 SEQ ID NO: 1 3359 region, WNV, Dengue, St. Louisencephalitis, yellow fever virus, Japanese encephalitis virus, MurrayValley encephalitis virus MOSQ18 Heavy chain, WNV CR4348 U.S. Pat. No.8,911,738 SEQ ID NO: 30 4041 MOSQ19 Heavy chain, WNV CR4354 U.S. Pat.No. 8,911,738 SEQ ID NO: 32 4042 MOSQ20 Heavy chain, WNV CR4261 U.S.Pat. No. 8,911,738 SEQ ID NO: 60 4043 MOSQ21 Heavy chain, WNV CR4267U.S. Pat. No. 8,911,738 SEQ ID NO: 62 4044 MOSQ22 Heavy chain, WNVCR4328 U.S. Pat. No. 8,911,738 SEQ ID NO: 64 4045 MOSQ23 Heavy chain,WNV CR4335 U.S. Pat. No. 8,911,738 SEQ ID NO: 66 4046 MOSQ24 Heavychain, WNV CR4383 U.S. Pat. No. 8,911,738 SEQ ID NO: 68 4047 MOSQ25Heavy chain, WNV CRM4354 U.S. Pat. No. 8,911,738 SEQ ID NO: 148 4048MOSQ26 Heavy chain variable Antibody from U.S. Pat. No. 8,911,738 SEQ IDNO: 20 4049 region, WNV U.S. Pat. No. 8,911,738 MOSQ27 Heavy chainvariable E16 heavy chain U.S. Pat. No. 7,572,456 SEQ ID NO: 21 4050region, WNV version 1 MOSQ28 Heavy chain variable E16 heavy chain U.S.Pat. No. 7,572,456 SEQ ID NO: 22 4051 region, WNV version 2 MOSQ29 Heavychain variable E16 heavy chain U.S. Pat. No. 7,572,456 SEQ ID NO: 234052 region, WNV version 3 MOSQ30 Heavy chain variable Antibody fromU.S. Pat. No. 8,911,738 SEQ ID NO: 18 4053 region, WNV U.S. Pat. No.8,911,738 MOSQ31 Heavy chain variable hu-E16/E16p U.S. Pat. No.8,663,950 SEQ ID NO: 2 4054 region, WNV MOSQ32 Heavy chain variablehu-E16/E16p U.S. Pat. No. 8,663,950 SEQ ID NO: 3 4055 region, WNV MOSQ33Heavy chain variable E16 U.S. Pat. No. 7,527,973 SEQ ID NO: 4 4056region, WNV MOSQ34 Heavy chain variable E24 U.S. Pat. No. 7,527,973 SEQID NO: 8 4057 region, WNV MOSQ35 Heavy chain variable E34 U.S. Pat. No.7,527,973 SEQ ID NO: 12 4058 region, WNV MOSQ36 Heavy chain variable 11US20090130123 SEQ ID NO: 23 4059 region, WNV MOSQ37 Heavy chain variable71 US20090130123 SEQ ID NO: 24 4060 region, WNV MOSQ38 Heavy chainvariable 73 US20090130123 SEQ ID NO: 25 4061 region, WNV MOSQ39 Heavychain variable 85 US20090130123 SEQ ID NO: 26 4062 region, WNV MOSQ40Heavy chain variable 15 US20090130123 SEQ ID NO: 27 4063 region, WNVMOSQ41 Heavy chain variable 95 US20090130123 SEQ ID NO: 28 4064 region,WNV MOSQ42 Heavy chain variable 84 US20090130123 SEQ ID NO: 29 4065region, WNV MOSQ43 Heavy chain variable 10 US20090130123 SEQ ID NO: 304066 region, WNV MOSQ44 Heavy chain variable 69 US20090130123 SEQ ID NO:31 4067 region, WNV MOSQ45 Heavy chain variable 79 US20090130123 SEQ IDNO: 32 4068 region, WNV MOSQ46 Heavy chain variable 94 US20090130123 SEQID NO: 33 4069 region, WNV MOSQ47 Heavy chain variable 9FI2 WO2010093335SEQ ID NO: 4 3333 region, WNV MOSQ48 Heavy chain variable Throsby, M.“Isolation and characterization 4070 region, partial sequence, of humanmonoclonal antibodies from WMV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20481.1MOSQ49 Heavy chain translation, hu-E16/E16p U.S. Pat. No. 8,663,950 SEQID NO: 5 4071 WNV MOSQ50 Heavy chain variable anti-yellow feverThibodeaux, B. A. “A humanized IgG but not 4072 region, Yellow fevervirus vaccine IgM antibody is effective in prophylaxis and virus strain17D E therapy of yellow fever infection in an glycoprotein AG129/17D-204peripheral challenge mouse model” Antiviral Res. 94 (1), 1-8 (2012),NCBI Accession # ADO17683 MOSQ51 Light chain variable anti-US20080292644 SEQ ID NO: 66 4073 region, Japanese DLVR1/CLEC5Aencephalitis virus MOSQ52 Light chain variable anti- US20080292644 SEQID NO: 67 4074 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ53Light chain variable anti- US20080292644 SEQ ID NO: 68 4075 region,Japanese DLVR1/CLEC5A encephalitis virus MOSQ54 Light chain variableCN103864925 SEQ ID NO: 1 4076 region, Japanese encephalitis virus MOSQ55Light chain variable mAbl 1 WO2014144061 SEQ ID NO: 3 3418 region, WNV,Dengue, St. Louis encephalitis, yellow fever virus, Japaneseencephalitis virus, Murray Valley encephalitis virus MOSQ56 Light chain,WNV CR4348 U.S. Pat. No. 8,911,738 SEQ ID NO: 34 4077 MOSQ57 Lightchain, WNV CR4354 U.S. Pat. No. 8,911,738 SEQ ID NO: 36 4078 MOSQ58Light chain, WNV CR4261 U.S. Pat. No. 8,911,738 SEQ ID NO: 70 4079MOSQ59 Light chain, WNV CR4267 U.S. Pat. No. 8,911,738 SEQ ID NO: 724080 MOSQ60 Light chain, WNV CR4328 U.S. Pat. No. 8,911,738 SEQ ID NO:74 4081 MOSQ61 Light chain, WNV CR4335 U.S. Pat. No. 8,911,738 SEQ IDNO: 76 4082 MOSQ62 Light chain, WNV CR4383 U.S. Pat. No. 8,911,738 SEQID NO: 78 4083 MOSQ63 Light chain variable Antibody from U.S. Pat. No.8,911,738 SEQ ID NO: 22 4084 region, WNV U.S. Pat. No. 8,911,738 MOSQ64Light chain variable Antibody from U.S. Pat. No. 8,911,738 SEQ ID NO: 244085 region, WNV U.S. Pat. No. 8,911,738 MOSQ65 Light chain variable E16U.S. Pat. No. 7,527,973 SEQ ID NO: 2 4086 region, WNV MOSQ66 Light chainvariable E24 U.S. Pat. No. 7,527,973 SEQ ID NO: 6 4087 region, WNVMOSQ67 Light chain variable E34 U.S. Pat. No. 7,527,973 SEQ ID NO: 104088 region, WNV MOSQ68 Light chain variable E16 light chain U.S. Pat.No. 7,572,456 SEQ ID NO: 25 4089 region, WNV version 1 MOSQ69 Lightchain variable E16 light chain U.S. Pat. No. 7,572,456 SEQ ID NO: 264090 region, WNV version 2 MOSQ70 Light chain variable 11 US20090130123SEQ ID NO: 34 4091 region, WNV MOSQ71 Light chain variable 71US20090130123 SEQ ID NO: 35 4092 region, WNV MOSQ72 Light chain variable73 US20090130123 SEQ ID NO: 36 4093 region, WNV MOSQ73 Light chainvariable 85 US20090130123 SEQ ID NO: 37 4094 region, WNV MOSQ74 Lightchain variable 15 US20090130123 SEQ ID NO: 38 4095 region, WNV MOSQ75Light chain variable 95 US20090130123 SEQ ID NO: 39 4096 region, WNVMOSQ76 Light chain variable 84 US20090130123 SEQ ID NO: 40 4097 region,WNV MOSQ77 Light chain variable 10 US20090130123 SEQ ID NO: 41 4098region, WNV MOSQ78 Light chain variable US20090130123 SEQ ID NO: 42 4099region, WNV MOSQ79 Light chain variable 79 US20090130123 SEQ ID NO: 434100 region, WNV MOSQ80 Light chain variable 94 US20090130123 SEQ ID NO:44 4101 region, WNV MOSQ81 Light chain variable 9FI2 WO2010093335 SEQ IDNO: 6 3393 region, WNV MOSQ82 Light chain variable Throsby, M.“Isolation and characterization 4102 region, partial sequence, of humanmonoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20470.1MOSQ83 Light chain variable Throsby, M. “Isolation and characterization4103 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20469.1 MOSQ84 Light chain variable Throsby,M. “Isolation and characterization 4104 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20468.1MOSQ85 Light chain variable Throsby, M. “Isolation and characterization4105 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20467.1 MOSQ86 Light chain variable Throsby,M. “Isolation and characterization 4106 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20466.1MOSQ87 Light chain variable Throsby, M. “Isolation and characterization4107 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20465.1 MOSQ88 Light chain variable Throsby,M. “Isolation and characterization 4108 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20464.1MOSQ89 Light chain variable Throsby, M. “Isolation and characterization4109 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20463.1 MOSQ90 Light chain variable Throsby,M. “Isolation and characterization 4110 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20462.1MOSQ91 Light chain variable Throsby, M. “Isolation and characterization4111 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J, Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20461.1 MOSQ92 Light chain variable Throsby,M. “Isolation and characterization 4112 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20460.1MOSQ93 Light chain variable Throsby, M. “Isolation and characterization4113 region, partial sequence, of human monoclonal antibodies from WNVindividuals infected with west nile virus” J. Virol. 80 (14), 6982-6992(2006), NCBI Accession # ABF20459.1 MOSQ94 Light chain variable Throsby,M. “Isolation and characterization 4114 region, partial sequence, ofhuman monoclonal antibodies from WNV individuals infected with west nilevirus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20458.1MOSQ95 Light chain translation, hu-E16/E16p U.S. Pat. No. 8,663,950 SEQID NO: 7 4115 WNV MOSQ96 Light chain variable anti-yellow feverThibodeaux, B. A. “A humanized IgG but not 4116 region, Yellow fevervirus vaccine IgM antibody is effective in prophylaxis and virus strain17D E therapy of yellow fever infection in an glycoprotein AG129/17D-204peripheral challenge mouse model” Antiviral Res. 94 (1), 1-8 (2012),NCBI Accession # ADO17684 MOSQ97 ScFv, WNV 9FI2 WO2010093335 SEQ ID NO:8 3442 MOSQ98 Fc region, WNV, mAb-11 WO2014144061 SEQ ID NO: 5 4117Dengue, St. Louis encephalitis, yellow fever virus, Japaneseencephalitis virus, Murray Valley encephalitis virus MOSQ99 Fc region,WNV, mAb-11-LALA WO2014144061 SEQ ID NO: 6 4118 Dengue, St. Louisencephalitis, yellow fever virus, Japanese encephalitis virus, MurrayValley encephalitis virus MOSQ100 ScFv, WNV 11 US20090130123 SEQ ID NO:12 4119 MOSQ101 ScFv, WNV 71 US20090130123 SEQ ID NO: 13 4120 MOSQ102ScFv, WNV 73 US20090130123 SEQ ID NO: 14 4121 MOSQ103 ScFv, WNV 85US20090130123 SEQ ID NO: 15 4122 MOSQ104 ScFv, WNV 15 US20090130123 SEQID NO: 16 4123 MOSQ105 ScFv, WNV 95 US20090130123 SEQ ID NO: 17 4124MOSQ106 ScFv, WNV 84 US20090130123 SEQ ID NO: 18 4125 MOSQ107 ScFv, WNV10 US20090130123 SEQ ID NO: 19 4126 MOSQ108 ScFv, WNV 69 US20090130123SEQ ID NO: 20 4127 MOSQ109 ScFv, WNV 79 US20090130123 SEQ ID NO: 21 4128MOSQ110 ScFv, WNV 94 US20090130123 SEQ ID NO: 22 4129 MOSQ111 ScFvs, WNVSC04-348 U.S. Pat. No. 8,911,738 SEQ ID NO: 26 4130 MOSQ112 ScFvs, WNVSC04-354 U.S. Pat. No. 8,911,738 SEQ ID NO: 28 4131 MOSQ113 ScFv, Yellowanti-yellow Daffis, S. et al. “Antibody responses against 4132 fevervirus fever virus E wild-type yellow fever virus and the 17D proteinscFv 7A vaccine strain: characterization with human monoclonal antibodyfragments and neutralization escape variants” Virology 337 (2), 262-272(2005), NCBI Accession # AAT76799 MOSQ114 ScFv, Yellow anti-yellowDaffis, S. et al. “Antibody responses against 4133 fever virus fevervirus E wild-type yellow fever virus and the 17D protein scFv vaccinestrain: characterization with human R3(27) monoclonal antibody fragmentsand neutralization escape variants” Virology 337 (2), 262-272 (2005),NCBI Accession # AAT76800 MOSQ115 ScFv, Yellow anti-yellow Daffis, S. etal. “Antibody responses against 4134 fever virus fever virus E wild-typeyellow fever virus and the 17D protein scFv 5A vaccine strain:characterization with human monoclonal antibody fragments andneutralization escape variants” Virology 337 (2), 262-272 (2005), NCBIAccession # AAT76801 MOSQ116 ScFv, Yellow anti-yellow Daffis, S. et al.“Antibody responses against 4135 fever virus fever virus E wild-typeyellow fever virus and the 17D protein scFv 1A vaccine strain:characterization with human monoclonal antibody fragments andneutralization escape variants” Virology 337 (2), 262-272 (2005), NCBIAccession # AAT76802 MOSQ117 ScFv, Yellow anti-yellow Daffis, S. et al.“Antibody responses against 4136 fever virus fever virus E wild-typeyellow fever virus and the 17D protein scFv 2A vaccine strain:characterization with human monoclonal antibody fragments andneutralization escape variants” Virology 337 (2), 262-272 (2005), NCBIAccession # AAT76803 MOSQ118 ScFv, Yellow anti-yellow Daffis, S. et al.“Antibody responses against 4137 fever virus fever virus E wild-typeyellow fever virus and the 17D protein scFv vaccine strain:characterization with human R3(9) monoclonal antibody fragments andneutralization escape variants” Virology 337 (2), 262-272 (2005), NCBIAccession # AAT76804

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inU.S. Pat. No. 6,399,062 and US Pub. No. US20110171225, the contents ofeach of which are herein incorporated by reference in their entirety,against Malaria.

Infectious Diseases

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the infectiousdisease related payload anti body polypeptides listed in Tables 21-42.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 21 against Influenza virus

TABLE 21 Antibodies against Influenza virus SEQ Antibody Antibody ID No.Description Name Reference Information NO INFL1 Fab Fragment Heavy ch65Whittle, J. R. et al., Broadly neutralizing 4138 chain human antibodythat recognizes the receptor-binding pocket of influenza virushemagglutinin; Proc. Natl. Acad. Sci. U.S.A. 108 (34), 14216-14221(2011), NCBI Accession #3SMS_H INFL2 Fab Heavy Chain Fab Cr6261Lingwood, D., et al., Structural and 4139 (Somatic Heavy genetic basisfor development of broadly Chain With neutralizing influenza antibodies;Nature Germline- 489 (7417), 566-570 (2012), NCBI Reverted LightAccession #4EVN_M (242aa) Chain) INFL3 Fab heavy chain Del2d1 Krause, J.C. et al., M Bio 2 (1), E00345- 4140 E00310 (2011), NCBI Accession#3QHF_H INFL4 Fab heavy chain Fld194 Fab Xiong, X. et al., Structures ofcomplexes 4141 formed by H5 influenza hemagglutinin with a potentbroadly neutralizing human monoclonal antibody; Proc. Natl. Acad. Sci.U.S.A. 112 (30), 9430-9435 (2015), NCBI Accession #5A3I_C (230aa) INFL5Fab heavy chain H5.3 Winarski, K. L., Thornburg, N. J. et al., 4142Vaccine-elicited antibody that neutralizes H5N1 influenza and variantsbinds the receptor site and polymorphic sites “PNAS 2015 112 (30)9346-9351”, NCBI Accession #4XNM_H INFL6 Fab Heavy chain 5j8 Hong, M. etal., Antibody Recognition of 4143 the Pandemic H1N1 Influenza VirusHemagglutinin Receptor Binding Site; J. Virol. 87 (22), 12471-12480(2013), NCBI Accession #4M5Z_H INFL7 Fab lambda heavy CR6261 Ekiert, D.C. et al., Antibody recognition 4144 chain of a highly conservedinfluenza virus epitope; Science 324 (5924), 246-251 (2009), NCBIAccession #3GBN_H INFL8 Fab lambda light CR6261 Ekiert, D. C. et al.,Antibody recognition 4145 chain of a highly conserved influenza virusepitope; Science 324 (5924), 246-251 (2009), NCBI Accession #3GBN_LINFL9 Fab lambda light Fab Cr6261 Lingwood, D., et al., Structural and4146 chain (Somatic Heavy genetic basis for development of broadly ChainWith neutralizing influenza antibodies; Nature Germline- 489 (7417),566-570 (2012), NCBI Reverted Light Accession #4EVN_N (217aa) Chain)INFL10 Fab light chain Del2d1 Krause, J. C. et al., M Bio 2 (1), E00345-4147 E00310 (2011), NCBI Accession #3QHF_L INFL11 Fab Light Chain Fld194Fab Xiong, X. et al., Structures of complexes 4148 formed by H5influenza hemagglutinin with a potent broadly neutralizing humanmonoclonal antibody; Proc. Natl. Acad, Sci. U.S.A. 112 (30), 9430-9435(2015), NCBI Accession #5A3I_D (219aa) INFL12 Fab, heavy chain F045-092Lee, P. S. et al., Receptor mimicry by 4149 antibody F045-092facilitates universal binding to the H3 subtype of influenza virus; NatCommun 5, 3614 (2014), NCBI Accession #4O5I_W INFL13 Fab, Light ChainF045-092 Lee, P. S. et al., Receptor mimicry by 4150 antibody F045-092facilitates universal binding to the H3 subtype of influenza virus; NatCommun 5, 3614 (2014), NCBI Accession #4O5I_V INFL14 Fab, light chainH5.3 Winarski, K. L., Thornburg, N. J. et al., 4151 “Vaccine-elicitedantibody that neutralizes H5N1 influenza and variants binds the receptorsite and polymorphic sites “PNAS 2015 112 (30) 9346-9351”, NCBIAccession #4XNM_L INFL15 Gamma heavy chain 8i10 U.S. Pat. No. 8,858,948SEQ ID NO: 69 4152 variable INFL16 Gamma heavy chain 23K12 U.S. Pat. No.8,858,948 SEQ ID NO: 100 4153 variable INFL17 Heavy chain CR6261, WO2008028946 4154 Diridavumab, CR- 6261 INFL18 Heavy chain Firivumab,CT-P22 US20130004505 4155 INFL19 Heavy chain CT-P22 US20130004505 SEQ IDNO: 41; WO 4156 2011/111966 INFL20 Heavy chain Navivumab, WO2013048153,US20140234336 SEQ 4157 CT149 ID NO: 40 INFL21 Heavy chain AT10-004US20150010566, WO2013081463 SEQ 4158 ID NO: 31 INFL22 Heavy chainAT10-003 US20150010566, WO2013081463 SEQ 4159 ID NO: 32 INFL23 Heavychain AT10-002 US20150010566, WO2013081463 SEQ 4160 ID NO: 33 INFL24Heavy chain AT10-001 US20150010566, WO2013081463 SEQ 4161 ID NO: 34INFL25 Heavy chain AT10-005 US20150010566, WO2013081463 SEQ 4162 ID NO:35 INFL26 Heavy chain CT104 WO2011111966, US20130004505 SEQ 4163 ID NO:37 INFL27 Heavy chain CT120 WO2011111966, US20130004505 SEQ 4164 ID NO:41 INFL28 Heavy chain CT123 WO2011111966, US20130004505 SEQ 4165 ID NO:45 INFL29 Heavy chain 2A US20140011982 SEQ ID NO: 2 4166 INFL30 Heavychain F005-126 WO2014049520, US20140086927 SEQ 4167 ID NO: 2 INFL31Heavy chain BF1-1 WO2008156763 SEQ ID NO: 7 4168 INFL32 Heavy chainBF1-19 WO2008156763 SEQ ID NO: 11 4169 INFL33 Heavy chain BF1-10WO2008156763 SEQ ID NO: 9 4170 INFL34 Heavy chain WO2010127252, U.S.Pat. No. 8,894,997 SEQ 4171 ID NO: 3 INFL35 Heavy chain A18 WO13170139SEQ ID NO: 94 4172 INFL36 Heavy chain Ab A18 U.S. Pat. No. 7,788,200 SEQID NO: 15 4173 INFL37 Heavy chain Ab 014, Ab 028 U.S. Pat. No. 7,788,200SEQ ID NO: 16 4174 INFL38 Heavy chain Ab 071 U.S. Pat. No. 7,788,200 SEQID NO: 162 4175 INFL39 Heavy chain Ab 072 U.S. Pat. No. 7,788,200 SEQ IDNO: 163 4176 INFL40 Heavy chain Ab 078, Ab 079, U.S. Pat. No. 7,788,200SEQ ID NO: 164 4177 Ab 080, Ab 081 INFL41 Heavy chain Ab 001, Ab 009,U.S. Pat. No. 7,788,200 SEQ ID NO: 17 4178 Ab 017, Ab 160, Ab 186, Ab187, Ab 188, Ab 189, Ab 190, Ab 191, Ab 192, Ab 193, Ab 202, Ab 211INFL42 Heavy chain Ab 002, Ab 010, U.S. Pat. No. 7,788,200 SEQ ID NO: 184179 Ab 026, Ab 203, Ab 212 INFL43 Heavy chain Ab 003, Ab 011, U.S. Pat.No. 7,788,200 SEQ ID NO: 19 4180 Ab 027, Ab 194, Ab 195, Ab 196, Ab 197,Ab 198, Ab 199, Ab 200, Ab 204, Ab 213 INFL44 Heavy chain Ab 086 U.S.Pat. No. 7,788,200 SEQ ID NO: 20 4181 INFL45 Heavy chain Ab 154, Ab 155,U.S. Pat. No. 7,788,200 SEQ ID NO: 21 4182 Ab 157 INFL46 Heavy chain Ab157, Ab 159 U.S. Pat. No. 7,788,200 SEQ ID NO: 22 4183 INFL47 Heavychain Ab 210, Ab 219 U.S. Pat. No. 7,788,200 SEQ ID NO: 23 4184 INFL48Heavy chain Ab A001, Ab U.S. Pat. No. 7,788,200 SEQ ID NO: 24 4185 A002,Ab A003, Ab A010, Ab A011, Ab 031, Ab 037 INFL49 Heavy chain Ab 004, Ab005, U.S. Pat. No. 7,788,200 SEQ ID NO: 25 4186 Ab 006, Ab 012, Ab 013,Ab 032, Ab 038, Ab 043, Ab 044, Ab 045, Ab 046, Ab 047, Ab 048, Ab 049,Ab 050, Ab 051, Ab 052, Ab 067, Ab 068, Ab 069, Ab 070, Ab 073, Ab 074,Ab 075, Ab 076, Ab 077 INFL50 Heavy chain Ab 007, Ab 008, U.S. Pat. No.7,788,200 SEQ ID NO: 26 4187 Ab A009, Ab A14, Ab 015, Ab 033, Ab 039INFL51 Heavy chain Ab 016, Ab A017, U.S. Pat. No. 7,788,200 SEQ ID NO:27 4188 Ab C18, Ab A019, Ab 034, Ab 040 INFL52 Heavy chain F005-126WO2014049520 SEQ ID 2 4189 INFL53 Heavy chain 8f24 WO2012045001 SEQ ID 14190 INFL54 Heavy chain 3E22 WO2012045001 SEQ ID 5 4191 INFL55 Heavychain 5117 WO2012045001 SEQ ID 9 4192 INFL56 Heavy chain WO2012045001SEQ ID 13 4193 INFL57 Heavy chain WO2012045001 SEQ ID 29 4194 INFL58Heavy chain WO2012045001 SEQ ID 33 4195 INFL59 Heavy chain WO2012045001SEQ ID 17 4196 INFL60 Heavy chain 10A14 WO2012045001 SEQ ID 21 4197INFL61 Heavy chain 8D4 WO2012045001 SEQ ID 25 4198 INFL62 Heavy chain2B9 U.S. Pat. No. 9,115,201 SEQ ID NO: 6 4199 INFL63 Heavy chain mAB 7A7US20150239960, US20140170163, 4200 U.S. Pat. No. 8,673,314,US20110027270, WO2010138564 SEQ ID NO: 6 INFL64 Heavy chain mAB 12D1US20150239960, US20140170163, 4201 U.S. Pat. No. 8,673,314,US20110027270, WO2010138564 SEQ ID NO: 12 INFL65 Heavy chain mAB 66A6US20150239960, US20140170163, 4202 U.S. Pat. No. 8,673,314,US20110027270, WO2010138564 SEQ ID NO: 16 INFL66 Heavy chain M1 D12US20110033473, WO2009125395 SEQ 4203 ID NO: 17 INFL67 Heavy chainmAB1.12 WO2013030165 SEQ ID NO: 1 4204 INFL68 Heavy chain mAB3.1WO2013030165 SEQ ID NO: 3 4205 INFL69 Heavy chain 5A7 WO2015120097 SEQID NO: 7 4206 INFL70 Heavy chain TRL053 WO2015120097 SEQ ID NO: 17 4207INFL71 Heavy chain TRL579 WO2015120097 SEQ ID NO: 27 4208 INFL72 Heavychain TRL784 WO2015120097 SEQ ID NO: 37 4209 INFL73 Heavy chain TRL794WO2015120097 SEQ ID NO: 47 4210 INFL74 Heavy chain TRL798 WO2015120097SEQ ID NO: 57 4211 INFL75 Heavy chain TRL799 WO2015120097 SEQ ID NO: 674212 INFL76 Heavy chain TRL809 WO2015120097 SEQ ID NO: 77 4213 INFL77Heavy chain TRL811 WO2015120097 SEQ ID NO: 87 4214 INFL78 Heavy chainTRL812 WO2015120097 SEQ ID NO: 97 4215 INFL79 Heavy chain TRL813WO2015120097 SEQ ID NO: 107 4216 INFL80 Heavy chain TRL823 WO2015120097SEQ ID NO: 117 4217 INFL81 Heavy chain TRL832 WO2015120097 SEQ ID NO:127 4218 INFL82 Heavy chain TRL833 WO2015120097 SEQ ID NO: 137 4219INFL83 Heavy chain TRL834 WO2015120097 SEQ ID NO: 147 4220 INFL84 Heavychain TRL835 WO2015120097 SEQ ID NO: 157 4221 INFL85 Heavy chain TRL835WO2015120097 SEQ ID NO: 158 4222 INFL86 Heavy chain TRL837 WO2015120097SEQ ID NO: 168 4223 INFL87 Heavy chain TRL839 WO2015120097 SEQ ID NO:178 4224 INFL88 Heavy chain TRL841 WO2015120097 SEQ ID NO: 188 4225INFL89 Heavy chain TRL842 WO2015120097 SEQ ID NO: 198 4226 INFL90 Heavychain TRL845 WO2015120097 SEQ ID NO: 208 4227 INFL91 Heavy chain TRL846WO2015120097 SEQ ID NO: 217 4228 INFL92 Heavy chain TRL847 WO2015120097SEQ ID NO: 227 4229 INFL93 Heavy chain TRL848 WO2015120097 SEQ ID NO:237 4230 INFL94 Heavy chain TRL849 WO2015120097 SEQ ID NO: 247 4231INFL95 Heavy chain TRL851 WO2015120097 SEQ ID NO: 257 4232 INFL96 Heavychain TRL854 WO2015120097 SEQ ID NO: 267 4233 INFL97 Heavy chain TRL856WO2015120097 SEQ ID NO: 277 4234 INFL98 Heavy chain TRL858 WO2015120097SEQ ID NO: 287 4235 INFL99 Heavy chain humM2e-hBiTE-1 WO2014140368 SEQID NO: 8 4236 INFL100 Heavy chain humM2e-hBiTE-2 WO2014140368 SEQ ID NO:16 4237 INFL101 Heavy chain humM2e-hBiTE-3 WO2014140368 SEQ ID NO: 244238 INFL102 Heavy chain humM2e-hBiTE-4 WO2014140368 SEQ ID NO: 32 4239INFL103 Heavy chain VH of humM2e- WO2014140368 SEQ ID NO: 40 4240hBiTE-5 INFL104 Heavy chain humM2e-hBiTE-6 WO2014140368 SEQ ID NO: 484241 INFL105 Heavy chain humM2e-hBiTE-7 WO2014140368 SEQ ID NO: 56 4242INFL106 Heavy chain humM2e-hBiTE-8 WO2014140368 SEQ ID NO: 64 4243INFL107 Heavy chain humM2e-hBiTE-9 WO2014140368 SEQ ID NO: 72 4244INFL108 Heavy chain murM2e-hBiTE WO2014140368 SEQ ID NO: 80 4245 INFL109Heavy chain FLA5.10 U.S. Pat. No. 8,124,092 SEQ ID NO: 1 4246 INFL110Heavy chain FLD21.140 U.S. Pat. No. 8,124,092 SEQ ID NO: 5 4247 INFL111Heavy chain FLA3.14 U.S. Pat. No. 8,124,092 SEQ ID NO: 9 4248 INFL112Heavy chain FLD20.19 U.S. Pat. No. 8,124,092 SEQ ID NO: 13 4249 INFL113Heavy chain FLD84 U.S. Pat. No. 8,124,092 SEQ ID NO: 42 4250 INFL114Heavy chain FLD93 U.S. Pat. No. 8,124,092 SEQ ID NO: 52 4251 INFL115Heavy chain FLD122 U.S. Pat. No. 8,124,092 SEQ ID NO: 62 4252 INFL116Heavy chain FLD127 U.S. Pat. No. 8,124,092 SEQ ID NO: 72 4253 INFL117Heavy chain FLD129 U.S. Pat. No. 8,124,092 SEQ ID NO: 82 4254 INFL118Heavy chain FLD132 U.S. Pat. No. 8,124,092 SEQ ID NO: 92 4255 INFL119Heavy chain FLD194 U.S. Pat. No. 8,124,092 SEQ ID NO: 102 4256 INFL120Heavy chain mAb2 WO2015112994 SEQ ID NO: 80 4257 INFL121 Heavy chainmAb3 WO2015112994 SEQ ID NO: 84 4258 INFL122 Heavy chain Tsibane, T. etal., Influenza Human 4259 Monoclonal Antibody 1F1 Interacts with ThreeMajor Antigenic Sites and Residues Mediating Human Receptor Specificityin H1N1 Viruses; PLoS Pathol. 8 (12), E1003067 (2012), NCBI Accession#4GXU_S INFL123 Heavy chain C05 Ekiert, D. C., et al.,Cross-neutralization 4260 of influenza A viruses mediated by a singleantibody loop; Nature 489 (7417), 526-532 (2012), NCBI Accession #4FNL_H(247aa) INFL124 Heavy chain CR8020 Ekiert, D. C., et al., A. highlyconserved 4261 neutralizing epitope on group 2 influenza A viruses;Science 333 (6044), 843-850 (2011); WO2010130636, NCBI Accession #3SDY_HINFL125 Heavy chain CR8043 Friesen, R. H. et al., A common solution 4262to group 2 influenza virus neutralization; Proc. Natl. Acad. Sci. U.S.A.111 (1), 445-450 (2014), NCBI Accession #4NM8_H INFL126 Heavy chainCR8059 Dreyfus, C. et al., Highly conserved 4263 protective epitopes oninfluenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBIAccession #4FQK_H INFL127 Heavy chain CR8071 Dreyfus, C. et al., Highlyconserved 4264 protective epitopes on influenza B viruses; Science 337(6100), 1343-1348 (2012), NCBI Accession #4FQJ_H (234aa) INFL128 Heavychain CR9114 WO2013079473; WO2014191435; 4265 Dreyfus, C., Laursen, N.S. et al., Highly conserved protective epitopes on influenza B viruses;Science 337 (6100), 1343-1348 (2012), NCBI Accession #4FQY_H (230aa)INFL129 Heavy chain Ch67 Schmidt, A. G., et al., Preconfiguration of4266 the antigen-binding site during affinity maturation of a broadlyneutralizing influenza virus antibody; Proc. Natl. Acad. Set. U.S.A. 110(1), 264-269 (2013), NCBI Accession #4HKX_A (231aa) INFL130 Heavy chainFab 26/9 Schulze-Gahmen, U. et al., J. Biol. 4267 Chem. 263 (32),17100-17105 (1988); Churchill, M. E., et al., J. Mol. Biol. 241 (4),534-556 (1994), NCBI Accession #1FRG_H INFL131 Heavy chain Fab 3.1Wyrzucki, A. et al., Alternative 4268 Recognition of the Conserved StemEpitope in Influenza A Virus Hemagglutinin by a VH3-30-EncodedHeterosubtypic Antibody; J. Virol. 88 (12), 7083-7092 (2014), NCBIAccession #4PY8_I INFL132 Heavy chain Fab 2g1 Xu, R. et al., A recurringmotif for 4269 antibody recognition of the receptor- binding site ofinfluenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013),NCBI Accession #4HG4_N (223aa) INFL133 Heavy chain Fab 8m2 Xu, R. etal., A recurring motif for 4270 antibody recognition of the receptor-binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3),363-370 (2013), NCBI Accession #4HFU_H (226aa) INFL134 Heavy chain Fab8f8 Xu, R. et al., A recurring motif for 4271 antibody recognition ofthe receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol.Biol. 20 (3), 363-370 (2013), NCBI Accession #4HF5_H (233aa) INFL135Heavy chain Fab 2d1 Xu, R., et al., Structural basis of 4272 preexistingimmunity to the 2009 H1N1 pandemic influenza virus; Science 328 (5976),357-360 (2010), NCBI Accession #3LZF_H (230aa) INFL136 Heavy chain Fi6v3Corti, D. et al., A neutralizing antibody 4273 selected from plasmacells that binds to group 1 and group 2 influenza A hemagglutinins;Science 333 (6044), 850-856 (2011), NCBI Accession #3ZTJ_G INFL137 HeavyChain Heavy chain Iba, Y., et al., Conserved Neutralizing 4274 3WHE_NEpitope at Globular Head of Hemagglutinin in H3N2 Influenza Viruses; J.Virol. (2014), NCBI Accession #3WHE_M (226aa) INFL138 Heavy chain 7A13Krause et al. “Human Monoclonal 4275 Antibodies to Pandemic 1957 H2N2and Pandemic 1968 H3N2 Influenza Viruses” J. Virol. 86 (11), 6334-6340(2012), NCBI Accession #AFH78447 INFL139 Heavy chain 2D1 WO2010127252,U.S. Pat. No. 8,894,997 SEQ ID 4276 NO: 7 INFL140 Heavy chain 1F1WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4277 NO: 1 INFL141 Heavychain WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4278 NO: 4 INFL142Heavy chain 1I20 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4279 NO: 5INFL143 Heavy chain 4D20 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID4280 NO: 9 INFL144 Heavy chain WO2010127252, U.S. Pat. No. 8,894,997 SEQID 4281 NO: 11 INFL145 Heavy chain US20140205614, US20100316654 SEQ 4282ID NO: 21 INFL146 Heavy chain US20140205614, US20100316654 SEQ 4283 IDNO: 22 INFL147 Heavy chain US20140205614, US20100316654 SEQ 4284 ID NO:23 INFL148 Heavy chain US20140205614, US20100316654 SEQ 4285 ID NO: 24INFL149 Heavy chain US20140205614, US20100316654 SEQ 4286 ID NO: 25INFL150 Heavy chain US20140205614, US20100316654 SEQ 4287 ID NO: 26INFL151 Heavy chain US20140205614, US20100316654 SEQ 4288 ID NO: 27INFL152 Heavy chain US20140205614, US20100316654 SEQ 4289 ID NO: 28INFL153 Heavy chain US20140205614, US20100316654 SEQ 4290 ID NO: 29INFL154 Heavy chain US20140205614, US20100316654 SEQ 4291 ID NO: 30INFL155 Heavy chain US20140205614, US20100316654 SEQ 4292 ID NO: 31INFL156 Heavy chain US20140205614, US20100316654 SEQ 4293 ID NO: 32INFL157 Heavy chain US20140205614, US20100316654 SEQ 4294 ID NO: 33INFL158 Heavy chain US20140205614, US20100316654 SEQ 4295 ID NO: 34INFL159 Heavy chain US20140205614, US20100316654 SEQ 4296 ID NO: 35INFL160 Heavy chain US20140205614, US20100316654 SEQ 4297 ID NO: 36INFL161 Heavy chain US20140205614, US20100316654 SEQ 4298 ID NO: 37INFL162 Heavy chain US20140205614, US20100316654 SEQ 4299 ID NO: 38INFL163 Heavy chain US20140205614, US20100316654 SEQ 4300 ID NO: 39INFL164 Heavy chain US20140205614, US20100316654 SEQ 4301 ID NO: 40INFL165 Heavy chain US20140205614, US20100316654 SEQ 4302 ID NO: 41INFL166 Heavy chain US20140205614, US20100316654 SEQ 4303 ID NO: 42INFL167 Heavy chain US20140205614, US20100316654 SEQ 4304 ID NO: 43INFL168 Heavy chain US20140205614, US20100316654 SEQ 4305 ID NO: 44INFL169 Heavy chain US20140205614, US20100316654 SEQ 4306 ID NO: 45INFL170 Heavy chain mAb1 WO2015112994 SEQ ID NO: 76 4307 INFL171 Heavychain CR8033 Dreyfus, C., Laursen, N. S. et al., Highly 4308 conservedprotective epitopes on influenza B viruses; Science 337 (6100),1343-1348 (2012), NCBI Accession # 4FQL_H INFL172 Heavy chain (Partial)monoclonal Burioni, R. et al., Monoclonal antibodies 4309 antibody PN-isolated from human B cells neutralize a SIA28 broad range of H1 subtypeinfluenza A viruses including swine-origin Influenza virus(S-OIV);Virology (2010), NCBI Accession #ACX30936.1 (122aa) INFL173 Heavy chain(Partial) monoclonal Burioni, R, et al., Monoclonal antibodies 4310antibody PN- isolated from human B cells neutralize a SIA49 broad rangeof H1 subtype influenza A viruses including swine-origin Influenzavirus(S-OIV); Virology (2010), NCBI Accession #ACX30937.1 (127aa)INFL174 Heavy chain cdr1 Ab1A2 WO2015028478 SEQ ID 6 4311 INFL175 Heavychain cdr2 Ab1A2 WO2015028478 SEQ ID 7 4312 INFL176 Heavy chain cdr3Ab1A2 WO2015028478 SEQ ID 8 4313 INFL177 Heavy chain constant U.S. Pat.No. 8,992,929 SEQ ID NO. 22 4314 region, Human igg1 INFL178 Heavy chainFab CT147 WO2013048153, US20140234336 SEQ 4315 ID NO: 38 INFL179 Heavychain Fab CT164 WO2013048153, US20140234336 SEQ 4316 ID NO: 42 INFL180Heavy chain Fab CT166 WO2013048153, US20140234336 SEQ 4317 ID NO: 44INFL181 Heavy chain G2 h2B9 U.S. Pat. No. 9,115,201 SEQ ID NO: 7 4318INFL182 Heavy chain G5 h2B10 U.S. Pat. No. 9,115,201 SEQ ID NO: 8 4319INFL183 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 1 4320(exemplary) US2013030234 INFL184 Heavy chain variable HC-VD fromUS2013030234 SEQ ID NO: 2 4321 (exemplary) US2013030234 INFL185 Heavychain variable HC-VD from US2013030234 SEQ ID NO: 3 4322 (exemplary)US2013030234 INFL186 Heavy chain variable HC-VD from US2013030234 SEQ IDNO: 4 4323 (exemplary) US2013030234 INFL187 Heavy chain variable HC-VDfrom US2013030234 SEQ ID NO: 5 4324 (exemplary) US2013030234 INFL188Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 6 4325(exemplary) US2013030234 INFL189 Heavy chain variable HC-VD fromUS2013030234 SEQ ID NO: 7 4326 (exemplary) US2013030234 INFL190 Heavychain variable HC-VD from US2013030234 SEQ ID NO: 8 4327 (exemplary)US2013030234 INFL191 Heavy chain variable HC-VD from US2013030234 SEQ IDNO: 9 4328 (exemplary) US2013030234 INFL192 Heavy chain variable HC-VDfrom US2013030234 SEQ ID NO: 10 4329 (exemplary) US2013030234 INFL193Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 11 4330(exemplary) US2013030234 INFL194 Heavy chain variable HC-VD fromUS2013030234 SEQ ID NO: 12 4331 (exemplary) US2013030234 INFL195 Heavychain variable HC-VD from US2013030234 SEQ ID NO: 13 4332 (exemplary)US2013030234 INFL196 Heavy chain variable HC-VD from US2013030234 SEQ IDNO: 14 4333 (exemplary) US2013030234 INFL197 Heavy chain variable HC-VDfrom US2013030234 SEQ ID NO: 15 4334 (exemplary) US2013030234 INFL198Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 16 4335(exemplary) US2013030234 INFL199 Heavy chain variable CR6141US20150104459 SEQ ID NO: 199 4336 region INFL200 Heavy chain variable39.18 B11 US20140161822 SEQ ID NO: 154 4337 region INFL201 Heavy chainvariable 39.18 E12 US20140161822 SEQ ID NO: 158 4338 region INFL202Heavy chain variable GG3 WO2014159960 SEQ ID NO: 17 4339 region INFL203Heavy chain variable N547 U.S. Pat. No. 8,003,106 SEQ ID NO: 28 4340region INFL204 Heavy chain variable L66 U.S. Pat. No. 8,003,106 SEQ IDNO: 30 4341 region INFL205 Heavy chain variable C40 U.S. Pat. No.8,003,106 SEQ ID NO: 26 4342 region INFL206 Heavy chain variable 14C2U.S. Pat. No. 8,080,244 SEQ ID NO: 6 4343 region INFL207 Heavy chainvariable h14C2 U.S. Pat. No. 8,080,244 SEQ ID NO: 2 4344 region INFL208Heavy chain variable 8G9 U.S. Pat. No. 8,603,467 SEQ ID NO: 2 4345region INFL209 Heavy chain variable 13D4 U.S. Pat. No. 8,603,467 SEQ IDNO: 6 4346 region INFL210 Heavy chain variable 20A11 U.S. Pat. No.8,603,467 SEQ ID NO: 10 4347 region INFL211 Heavy chain variableVN04-2-HuG1 US20100150941 SEQ ID NO: 5 4348 region INFL212 Heavy chainvariable VN04-3-HuG1 US20100150941 SEQ ID NO: 7 4349 region INFL213Heavy chain variable FI6 variant 1 U.S. Pat. No. 8,871,207 SEQ ID NO: 134350 region INFL214 Heavy chain variable FI6 variant 2 U.S. Pat. No.8,871,207 SEQ ID NO: 33 4351 region INFL215 Heavy chain variable FI6variant 3 U.S. Pat. No. 8,871,207 SEQ ID NO: 55 4352 region INFL216Heavy chain variable FI6 variant 4, FI6 U.S. Pat. No. 8,871,207 SEQ IDNO: 59 4353 region variant 5 INFL217 Heavy chain variable FI28 variant 1U.S. Pat. No. 8,871,207 SEQ ID NO: 29 4354 region INFL218 Heavy chainvariable FI28 variant 2 U.S. Pat. No. 8,871,207 SEQ ID NO: 35 4355region INFL219 Heavy chain variable 21B15 U.S. Pat. No. 8,858,948 SEQ IDNO: 44 4356 region INFL220 Heavy chain variable 3241_G23 U.S. Pat. No.8,858,948 SEQ ID NO: 116 4357 region INFL221 Heavy chain variable3244_I10 U.S. Pat. No. 8,858,948 SEQ ID NO: 120 4358 region INFL222Heavy chain variable 3243_J07 U.S. Pat. No. 8,858,948 SEQ ID NO: 1244359 region INFL223 Heavy chain variable 3259_J21 U.S. Pat. No.8,858,948 SEQ ID NO: 128 4360 region INFL224 Heavy chain variable3245_O19 U.S. Pat. No. 8,858,948 SEQ ID NO: 132 4361 region INFL225Heavy chain variable 3244_H04 U.S. Pat. No. 8,858,948 SEQ ID NO: 1364362 region INFL226 Heavy chain variable 3136_G05 U.S. Pat. No.8,858,948 SEQ ID NO: 140 4363 region INFL227 Heavy chain variable3252_C13 U.S. Pat. No. 8,858,948 SEQ ID NO: 144 4364 region INFL228Heavy chain variable 3255_J06 U.S. Pat. No. 8,858,948 SEQ ID NO: 1484365 region INFL229 Heavy chain variable 3420_I23 U.S. Pat. No.8,858,948 SEQ ID NO: 152 4366 region INFL230 Heavy chain variable3139_P23 U.S. Pat. No. 8,858,948 SEQ ID NO: 156 4367 region INFL231Heavy chain variable 3139_P23 U.S. Pat. No. 8,858,948 SEQ ID NO: 1584368 region INFL232 Heavy chain variable 3248_P18 U.S. Pat. No.8,858,948 SEQ ID NO: 162 4369 region INFL233 Heavy chain variable3253_P10 U.S. Pat. No. 8,858,948 SEQ ID NO: 166 4370 region INFL234Heavy chain variable 3260_D19 U.S. Pat. No. 8,858,948 SEQ ID NO: 1704371 region INFL235 Heavy chain variable 3362_B11 U.S. Pat. No.8,858,948 SEQ ID NO: 172 4372 region INFL236 Heavy chain variable3242_P05 U.S. Pat. No. 8,858,948 SEQ ID NO: 176 4373 region INFL237Heavy chain variable 2K11 Krause, J. C. et al. “Epitope-specific 4374region human influenza antibody repertoires diversify by B cellintraclonal sequence divergence and interclonal convergence” J. Immunol.187 (7), 3704-3711 (2011), NCBI Accession #AEO16793 INFL238 Heavy chainvariable 2O10 Krause, J. C. et al. “Epitope-specific 4375 region humaninfluenza antibody repertoires diversify by B cell intraclonal sequencedivergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711(2011), NCBI Accession #AEO16795 INFL239 Heavy chain variable 4K8Krause, J. C. et al. “Epitope-specific 4376 region human influenzaantibody repertoires diversify by B cell intraclonal sequence divergenceand interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBIAccession #AEO16799 INFL240 Heavy chain variable 6D9 Krause, J. C. etal. “Epitope-specific 4377 region human influenza antibody repertoiresdiversify by B cell intraclonal sequence divergence and interclonalconvergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession#AEO16801 INFL241 Heavy chain variable 4D20 Yu, X. et al “Neutralizingantibodies 4378 region derived from the B cells of 1918 influenzapandemic survivors”, Nature 455 (7212), 532-536, NCBI Accession#ACI04579 INFL242 Heavy chain variable 2B12 Yu, X. et al “Neutralizingantibodies 4379 region derived from the B cells of 1918 influenzapandemic survivors”, Nature 455 (7212), 532-536, NCBI Accession#ABY48866 INFL243 Heavy chain variable 8D4 NCBI Accession #AFI57036 4380region INFL244 Heavy chain variable 5B6 NCBI Accession #AFI57040 4381region INFL245 Heavy chain variable A66 WO2009079259, US20110038935,4382 region US20140011982 SEQ ID NO: 32 INFL246 Heavy chain variable D7WO2009079259, US20110038935, 4383 region US20140011982 SEQ ID NO: 6INFL247 Heavy chain variable D8, D80 WO2009079259, US20110038935, 4384region US20140011982 SEQ ID NO: 12 INFL248 Heavy chain variable E88WO2009079259, US20110038935, 4385 region US20140011982 SEQ ID NO: 36INFL249 Heavy chain variable E90, F10 WO2009079259, US20110038935, 4386region US20140011982 SEQ ID NO: 18 INFL250 Heavy chain variable F10WO2009079259, US20110038935, 4387 region US20140011982 SEQ ID NO: 112INFL251 Heavy chain variable G17 WO2009079259, US20110038935, 4388region US20140011982 SEQ ID NO: 24 INFL252 Heavy chain variable H40WO2009079259, US20110038935, 4389 region US20140011982 SEQ ID NO: 28INFL253 Heavy chain variable CH65 WO2013020074, US20140302043 SEQ 4390region ID NO: 14 INFL254 Heavy chain variable CH66 WO2013020074,US20140302043 SEQ 4391 region ID NO: 15 INFL255 Heavy chain variableCH67 WO2013020074, US20140302043 SEQ 4392 region ID NO: 16 INFL256 Heavychain variable CL86OUCA WO2013020074, US20140302043 SEQ 4393 region IDNO: 13 INFL257 Heavy chain variable Antibody 1 WO2015051010 SEQ ID NO: 24394 region INFL258 Heavy chain variable Antibody 2 WO2015051010 SEQ IDNO: 12 4395 region INFL259 Heavy chain variable Antibody 3 WO2015051010SEQ ID NO: 22 4396 region INFL260 Heavy chain variable Antibody 4WO2015051010 SEQ ID NO: 32 4397 region INFL261 Heavy chain variableAntibody 5 WO2015051010 SEQ ID NO: 42 4398 region INFL262 Heavy chainvariable Antibody 6 WO2015051010 SEQ ID NO: 52 4399 region INFL263 Heavychain variable Antibody 7 WO2015051010 SEQ ID NO: 62 4400 region INFL264Heavy chain variable Antibody 8 WO2015051010 SEQ ID NO: 72 4401 regionINFL265 Heavy chain variable Antibody 9 WO2015051010 SEQ ID NO: 82 4402region INFL266 Heavy chain variable Antibody 10 WO2015051010 SEQ ID NO:92 4403 region INFL267 Heavy chain variable Antibody 11 WO2015051010 SEQID NO: 102 4404 region INFL268 Heavy chain variable Antibody 12WO2015051010 SEQ ID NO: 112 4405 region INFL269 Heavy chain variableAntibody 13 WO2015051010 SEQ ID NO: 122 4406 region INFL270 Heavy chainvariable Antibody 14 WO2015051010 SEQ ID NO: 132 4407 region INFL271Heavy chain variable Antibody 15 WO201505I010 SEQ ID NO: 142 4408 regionINFL272 Heavy chain variable Antibody 3-GL WO2015051010 SEQ ID NO: 1524409 region INFL273 Heavy chain variable EM4C04 US20120282273 SEQ ID NO:2 4410 region INFL274 Heavy chain variable 005-2G02 WO2013059524,US20140348851 SEQ 4411 region ID NO: 1 INFL275 Heavy chain variable005-2G02 WO2013059524, US20140348851 SEQ 4412 region ID NO: 9 INFL276Heavy chain variable 09-2A06 WO2013059524, US20140348851 SEQ 4413 regionID NO: 21 INFL277 Heavy chain variable 09-2A06 WO2013059524,US20140348851 SEQ 4414 region ID NO: 29 INFL278 Heavy chain variable09-3A01 WO2013059524, US20140348851 SEQ 4415 region ID NO: 41 INFL279Heavy chain variable 09-3A01 WO2013059524, US20140348851 SEQ 4416 regionID NO: 49 INFL280 Heavy chain variable 70-IF02 WO2012096994,US20140046039 SEQ 4417 region ID NO: 18 INFL281 Heavy chain variableUS20120058124 SEQ ID NO: 10 4418 region INFL282 Heavy chain variableUS20120058124 SEQ ID NO: 11 4419 region INFL283 Heavy chain variableUS20120058124 SEQ ID NO: 12 4420 region INFL284 Heavy chain variableUS20120058124 SEQ ID NO: 13 4421 region INFL285 Heavy chain variableUS20120058124 SEQ ID NO: 14 4422 region INFL286 Heavy chain variable81.39 US20140161822, US20140248286, 4423 region WO2014078268 SEQ ID NO:111 INFL287 Heavy chain variable 81.39 US20140161822, US20140248286,4424 region WO2014078268 SEQ ID NO: 115 INFL288 Heavy chain variable39.29 US20140161822, US20140248286, 4425 region WO2014078268 SEQ ID NO:134 INFL289 Heavy chain variable 39.29 US20140161822, US20140248286,4426 region WO2014078268 SEQ ID NO: 138 INFL290 Heavy chain variable39.29 US20140161822, US20140248286, 4427 region WO2014078268 SEQ ID NO:142 INFL291 Heavy chain variable 39.29 US20140161822, US20140248286,4428 region WO2014078268 SEQ ID NO: 148 INFL292 Heavy chain variable36.89 US20140161822, US20140248286, 4429 region WO2014078268 SEQ ID NO:160 INFL293 Heavy chain variable 9.01F3 US20140161822, US20140248286,4430 region WO2014078268 SEQ ID NO: 164 INFL294 Heavy chain variable23.06C2 US20140161822, US20140248286, 4431 region WO2014078268 SEQ IDNO: 168 INFL295 Heavy chain variable 39.29 US20140161822, US20140248286,4432 region WO2014078268 SEQ ID NO: 234 INFL296 Heavy chain variable F16Variant 5 WO2013011347, US20140271655, 4433 region US8871207 SEQ ID NO:59 INFL297 Heavy chain variable F16 Variant 3 WO2013011347,US20140271655, 4434 region US8871207 SEQ ID NO: 55 INFL298 Heavy chainvariable F16 Variant 2 WO2010010466 SEQ ID NO: 33 4435 region INFL299Heavy chain variable FC41 WO2010010467 SEQ ID NO 60 4436 region INFL300Heavy chain variable FE43 WO2010010467 SEQ ID NO 74 4437 region INFL301Heavy chain variable FB75, FB110, WO2010010467 SEQ ID NO 121 4438 regionFB177 INFL302 Heavy chain variable FE17 WO2010010467 SEQ ID NO 105 4439region INFL303 Heavy chain variable FB79 WO2010010467 SEQ ID NO 131 4440region INFL304 Heavy chain variable FC1C WO2010010467 SEQ ID NO 139 4441region INFL305 Heavy chain variable FC6 WO2010010467 SEQ ID NO 45 4442region INFL306 Heavy chain variable FE53 WO2010010467 SEQ ID NO 89 4443region INFL307 Heavy chain variable 7A7 WO2010138564 SEQ ID NO: 6 4444region INFL308 Heavy chain variable 12DI WO2010138564 SEQ ID NO: 12 4445region INFL309 Heavy chain variable 66A6 WO2010138564 SEQ ID NO: 16 4446region INFL310 Heavy chain variable B-1 U.S. Pat. No. 8,975,378,US20110319600, 4447 region WO2010073647 SEQ ID NO: 27 INFL311 Heavychain variable D1 U.S. Pat. No. 8,975,378, US20110319600, 4448 regionWO2010073647 SEQ ID NO: 29 INFL312 Heavy chain variable E-2 U.S. Pat.No. 8,975,378, US20110319600, 4449 region WO2010073647 SEQ ID NO: 31INFL313 Heavy chain variable B-3 U.S. Pat. No. 8,975,378, US20110319600,4450 region WO2010073647 SEQ ID NO: 33 INFL314 Heavy chain variable 5A7WO2013114885, US20140377262 SEQ 4451 region ID NO: 33 INFL315 Heavychain variable 3A2 WO2013114885, US20140377262 SEQ 4452 region ID NO: 37INFL316 Heavy chain variable 10C4 WO2013114885, US20140377262 SEQ 4453region ID NO: 41 INFL317 Heavy chain variable Fab49 WO2009144667,US20110076265 SEQ 4454 region ID NO: 1 INFL318 Heavy chain variableFab28 IgG PN- WO2009115972, WO2011117848, 4455 region SIA28US20110014187 SEQ ID NO: 1 INFL319 Heavy chain variable TCN-522US20120207760, U.S. Pat. No. 8,916,160 SEQ ID 4456 region NO: 771; U.S.Pat. No. 8,900,590 SEQ ID NO: 32 INFL320 Heavy chain variable CR8019WO2010130636 SEQ ID NO: 26 4457 region INFL321 Heavy chain variableCR8020 WO2010130636 SEQ ID NO: 30 4458 region INFL322 Heavy chainvariable CR8021 WO2010130636 SEQ ID NO: 34 4459 region INFL323 Heavychain variable CR8038 WO2010130636 SEQ ID NO: 38 4460 region INFL324Heavy chain variable CR8039 WO2010130636 SEQ ID NO: 42 4461 regionINFL325 Heavy chain variable CR8040 WO2010130636 SEQ ID NO: 46 4462region INFL326 Heavy chain variable CR8041 WO2010130636 SEQ ID NO: 504463 region INFL327 Heavy chain variable CR8043 WO2010130636 SEQ ID NO:54 4464 region INFL328 Heavy chain variable CR8049 WO2010130636 SEQ IDNO: 58 4465 region INFL329 Heavy chain variable CR8050 WO2010130636 SEQID NO: 61 4466 region INFL330 Heavy chain variable CR8052 WO2010130636SEQ ID NO: 65 4467 region INFL331 Heavy chain variable CR8055WO2010130636 SEQ ID NO: 69 4468 region INFL332 Heavy chain variableCR8057 WO2010130636 SEQ ID NO: 73 4469 region INFL333 Heavy chainvariable CR8069 WO2010130636 SEQ ID NO: 77 4470 region INFL334 Heavychain variable CR6255 US20090311265, U.S. Pat. No. 8,691,223, 4471region U.S. Pat. No. 9,109,017, WO2008028946A SEQ ID NO: 59 INFL335Heavy chain variable CR6257 US20090311265, U.S. Pat. No. 8,691,223, 4472region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 61 INFL336 Heavychain variable CR6260 US20090311265, U.S. Pat. No. 8,691,223, 4473region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 63 INFL337 Heavychain variable CR6261 US20090311265, U.S. Pat. No. 8,691,223, 4474region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 65 INFL338 Heavychain variable CR6262 US20090311265, U.S. Pat. No. 8,691,223, 4475region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 67 INFL339 Heavychain variable CR6268 US20090311265, U.S. Pat. No. 8,691,223, 4476region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 69 INFL340 Heavychain variable CR6307 US20090311265, U.S. Pat. No. 8,691,223, 4477region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 71 INFL341 Heavychain variable CR6310 US20090311265, U.S. Pat. No. 8,691,223, 4478region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 73 INFL342 Heavychain variable CR6314 US20090311265, U.S. Pat. No. 8,691,223, 4479region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 75 INFL343 Heavychain variable CR6323 US20090311265, U.S. Pat. No. 8,691,223, 4480region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 77 INFL344 Heavychain variable CR6325 US20090311265, U.S. Pat. No. 8,691,223, 4481region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 79 INFL345 Heavychain variable CR6331 US20090311265, U.S. Pat. No. 8,691,223, 4482region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 81 INFL346 Heavychain variable CR6344 US20090311265, U.S. Pat. No. 8,691,223, 4483region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 83 INFL347 Heavychain variable CR6141 US20090311265, U.S. Pat. No. 8,691,223, 4484region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 317 INFL348Heavy chain variable CR6272 US20090311265, U.S. Pat. No. 8,691,223, 4485region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 321 INFL349Heavy chain variable CR6296 US20090311265, U.S. Pat. No. 8,691,223, 4486region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 325 INFL350Heavy chain variable CR6301 US20090311265, U.S. Pat. No. 8,691,223, 4487region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 329 INFL351Heavy chain variable CR6327 US20090311265, U.S. Pat. No. 8,691,223, 4488region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 333 INFL352Heavy chain variable CR6328 US20090311265, U.S. Pat. No. 8,691,223, 4489region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 337 INFL353Heavy chain variable CR6329 US20090311265, U.S. Pat. No. 8,691,223, 4490region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 341 INFL354Heavy chain variable CR6332 US20090311265, U.S. Pat. No. 8,691,223, 4491region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 345 INFL355Heavy chain variable CR6334 US20090311265, U.S. Pat. No. 8,691,223, 4492region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 349 INFL356Heavy chain variable CR6336 US20090311265, U.S. Pat. No. 8,691,223, 4493region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 353 INFL357Heavy chain variable CR6339 US20090311265, U.S. Pat. No. 8,691,223, 4494region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 357 INFL358Heavy chain variable CR6342 US20090311265, U.S. Pat. No. 8,691,223, 4495region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 361 INFL359Heavy chain variable CR6343 US20090311265, U.S. Pat. No. 8,691,223, 4496region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 365 INFL360Heavy chain variable CR9003 US20140120113 SEQ ID NO: 2 4497 regionINFL361 Heavy chain variable CR9004 US20140120113 SEQ ID NO: 6 4498region INFL362 Heavy chain variable CR9005 US20140120113 SEQ ID NO: 104499 region INFL363 Heavy chain variable CR9006 US20140120113 SEQ ID NO:14 4500 region INFL364 Heavy chain variable CR9007 US20140120113 SEQ IDNO: 18 4501 region INFL365 Heavy chain variable CR9008 US20140120113 SEQID NO: 22 4502 region INFL366 Heavy chain variable CR9009 US20140120113SEQ ID NO: 26 4503 region INFL367 Heavy chain variable CR9010US20140120113 SEQ ID NO: 30 4504 region INFL368 Heavy chain variableCR9011 US20140120113 SEQ ID NO: 34 4505 region INFL369 Heavy chainvariable CR9012 US20140120113 SEQ ID NO: 38 4506 region INFL370 Heavychain variable CR9029 US20140120113 SEQ ID NO: 42 4507 region INFL371Heavy chain variable CR9030 US20140120113 SEQ ID NO: 46 4508 regionINFL372 Heavy chain variable CR9031 US20140120113 SEQ ID NO: 50 4509region INFL373 Heavy chain variable CR9112 US20140120113 SEQ ID NO: 544510 region INFL374 Heavy chain variable CR9113 US20140120113 SEQ ID NO:58 4511 region INFL375 Heavy chain variable CR9114 US20140120113 SEQ IDNO: 62 4512 region INFL376 Heavy chain variable CR8033 U.S. Pat. No.8,852,595 SEQ ID NO: 71 4513 region INFL377 Heavy chain variable CR8059U.S. Pat. No. 8,852,595 SEQ ID NO: 75 4514 region INFL378 Heavy chainvariable CR8071 U.S. Pat. No. 8,852,595 SEQ ID NO: 78 4515 regionINFL379 Heavy chain variable CR10051 U.S. Pat. No. 8,852,595 SEQ ID NO:81 4516 region INFL380 Heavy chain variable CR10049 U.S. Pat. No.8,852,595 SEQ ID NO: 85 4517 region INFL381 Heavy chain variable CR10023U.S. Pat. No. 8,852,595 SEQ ID NO: 89 4518 region INFL382 Heavy chainvariable CR10032 U.S. Pat. No. 8,852,595 SEQ ID NO: 93 4519 regionINFL383 Heavy chain variable CR11035 U.S. Pat. No. 8,852,595 SEQ ID NO:101 4520 region INFL384 Heavy chain variable CR11036 U.S. Pat. No.8,852,595 SEQ ID NO: 105 4521 region INFL385 Heavy chain variableCR11038 U.S. Pat. No. 8,852,595 SEQ ID NO: 109 4522 region INFL386 Heavychain variable CR11039 U.S. Pat. No. 8,852,595 SEQ ID NO: 113 4523region INFL387 Heavy chain variable CR8031 U.S. Pat. No. 8,852,595 SEQID NO: 119 4524 region INFL388 Heavy chain variable CR8032 U.S. Pat. No.8,852,595 SEQ ID NO: 123 4525 region INFL389 Heavy chain variable CR8034U.S. Pat. No. 8,852,595 SEQ ID NO: 127 4526 region INFL390 Heavy chainvariable CR8035 U.S. Pat. No. 8,852,595 SEQ ID NO: 131 4527 regionINFL391 Heavy chain variable U.S. Pat. No. 8,992,929 SEQ ID NO: 4 4528region INFL392 Heavy chain variable M2e U.S. Pat. No. 8,420,794 SEQ IDNO: 2 4529 region INFL393 Heavy chain variable U.S. Pat. No. 8,715,743,US20140275492 SEQ ID 4530 region NO: 22 INFL394 Heavy chain variableU.S. Pat. No. 8,715,743, US20140275492 SEQ ID 4531 region NO: 25 INFL395Heavy chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 4532region NO: 36 INFL396 Heavy chain variable 4A10 Krause, J. C. et al.“Epitope-specific 4533 region human influenza antibody repertoiresdiversify by B cell intraclonal sequence divergence and interclonalconvergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession#AEO16797 INFL397 Heavy chain variable anti-1918 influenza Yu, X., etal., Neutralizing antibodies 4534 region HA Ig derived front the B cellsof 1918 influenza pandemic survivors; Nature 455 (7212), 532-536 (2008),NCBI Accession #ACI04579.1 (129aa) INFL398 Heavy chain variable TCN-522US20150086555 SEQ ID NO: 33 4535 region (3212_I12) INFL399 Heavy chainvariable TCN-521 US20150086555 SEQ ID NO: 21 4536 region (3280_D18)INFL400 Heavy chain variable TCN-523 US20150086555 SEQ ID NO: 45 4537region (5248_A17) INFL401 Heavy chain variable TCN-563 US20150086555 SEQID NO: 57 4538 region (5237_B21) INFL402 Heavy chain variable TCN-526US20150086555 SEQ ID NO: 69 4539 region (5084_C17) INFL403 Heavy chainvariable TCN-527 US20150086555 SEQ ID NO: 81 4540 region (5086_C06)INFL404 Heavy chain variable TCN-528 US20150086555 SEQ ID NO: 93 4541region (5087_P17) INFL405 Heavy chain variable TCN-529 US20150086555 SEQID NO: 105 4542 region (5297_H01) INFL406 Heavy chain variable TCN-530US20150086555 SEQ ID NO: 117 4543 region (5248_H10) INFL407 Heavy chainvariable TCN-531 US20150086555 SEQ ID NO: 129 4544 region (5091_H13)INFL408 Heavy chain variable TCN-532 US20150086555 SEQ ID NO: 141 4545region (5262_H18) INFL409 Heavy chain variable TCN-533 US20150086555 SEQID NO: 153 4546 region (5256_A17a), TCN-564 (5256_A17b) INFL410 Heavychain variable TCN-534 US20150086555 SEQ ID NO: 161 4547 region(5249_B02) INFL411 Heavy chain variable TCN-535 US20150086555 SEQ ID NO:173 4548 region (5246_P19), TCN-558 (5248_H10b) INFL412 Heavy chainvariable TCN-536 US20150086555 SEQ ID NO: 184 4549 region (5095_N01)INFL413 Heavy chain variable TCN-537 US20150086555 SEQ ID NO: 195 4550region (3194_D21) INFL414 Heavy chain variable TCN-538 US20150086555 SEQID NO: 207 4551 region (3206_O17) INFL415 Heavy chain variable TCN-539US20150086555 SEQ ID NO: 219 4552 region (5056_A08) INFL416 Heavy chainvariable TCN-540 US20150086555 SEQ ID NO: 231 4553 region (5060_F05)INFL417 Heavy chain variable TCN-541 US20150086555 SEQ ID NO: 243 4554region (5062_M11) INFL418 Heavy chain variable TCN-542 US20150086555 SEQID NO: 255 4555 region (5079_A16) INFL419 Heavy chain variable TCN-543US20150086555 SEQ ID NO: 267 4556 region (5081_G23) INFL420 Heavy chainvariable TCN-544 US20150086555 SEQ ID NO: 279 4557 region (5082_A19)INFL421 Heavy chain variable TCN-545 US20150086555 SEQ ID NO: 291 4558region (5082_I15) INFL422 Heavy chain variable TCN-546 US20150086555 SEQID NO: 302 4559 region (5089_L08) INFL423 Heavy chain variable TCN-547US20150086555 SEQ ID NO: 313 4560 region (5092_F11) INFL424 Heavy chainvariable TCN-548 US20150086555 SEQ ID NO: 325 4561 region (5092_P01)INFL425 Heavy chain variable TCN-549 US20150086555 SEQ ID NO: 335 4562region (5092_P04) INFL426 Heavy chain variable TCN-550 US20150086555 SEQID NO: 346 4563 region (5096_F06) INFL427 Heavy chain variable TCN-551US20150086555 SEQ ID NO: 358 4564 region (5243_D01) INFL428 Heavy chainvariable TCN-552 US20150086555 SEQ ID NO: 370 4565 region (5249_I23)INFL429 Heavy chain variable TCN-553 US20150086555 SEQ ID NO: 382 4566region (5261_C18) INFL430 Heavy chain variable TCN-554 US20150086555 SEQID NO: 392 4567 region (5277_M05) INFL431 Heavy chain variable TCN-555US20150086555 SEQ ID NO: 403 4568 region (5246_L16) INFL432 Heavy chainvariable TCN-556 US20150086555 SEQ ID NO: 408 4569 region (5089_K12)INFL433 Heavy chain variable TCN-557 US20150086555 SEQ ID NO: 420 4570region (5081_A04) INFL434 Heavy chain variable TCN-559 US20150086555 SEQID NO: 434 4571 region (5097_G08) INFL435 Heavy chain variable TCN-560US20150086555 SEQ ID NO: 446 4572 region (5084_P10) INFL436 Heavy chainvariable TCN-504 US20150086555 SEQ ID NO: 510 4573 region (3251_K17)INFL437 Heavy chain variable AB1 US20120093834, WO2009121004 SEQ 4574region ID NO: 4 INFL438 Heavy chain variable AB2 US20120093834,WO2009121004 SEQ 4575 region ID NO: 45 INFL439 Heavy chain variable AB3US20120093834, WO2009121004 SEQ 4576 region ID NO: 9 INFL440 Heavy chainvariable AB4, AB5, AB6 US20120093834, WO2009121004 SEQ 4577 region IDNO: 61 INFL441 Heavy chain variable VN04-2 WO2008033105 SEQ ID NO: 54578 region INFL442 Heavy chain variable VN04-3 WO2008033105 SEQ ID NO:7 4579 region INFL443 Heavy chain variable 1286-C05 WO2010132604,US20120128671 SEQ 4580 region ID NO: 1 INFL444 Heavy chain variable1286-A11 WO2010132604, US20120128671 SEQ 4581 region ID NO: 2 INFL445Heavy chain variable CR8001 WO2010130636 SEQ ID NO: 2 4582 regionINFL446 Heavy chain variable CR8003 WO2010130636 SEQ ID NO: 6 4583region INFL447 Heavy chain variable CR8015 WO2010130636 SEQ ID NO: 104584 region INFL448 Heavy chain variable CR8016 WO2010130636 SEQ ID NO:14 4585 region INFL449 Heavy chain variable CR8017 WO2010130636 SEQ IDNO: 18 4586 region INFL450 Heavy chain variable CR8018 WO2010130636 SEQID NO: 22 4587 region INFL451 Heavy chain variable anti-1918 influenzaYu, X., et al., Neutralizing antibodies 4588 region (Partial) HA Igderived from the B cells of 1918 influenza pandemic survivors; Nature455 (7212), 532-536 (2008), NCBI Accession #ACI04581.1 (145aa) INFL452Heavy chain variable 1A2 WO2015028478 SEQ ID NO: 2 4589 region mouse IgGINFL453 Heavy chain variable 7B8 WO2015028478 SEQ ID NO: 4 4590 regionmouse IgG INFL454 Heavy chain variable monoclonal Grandea, A. G. et al.,Human antibodies 4591 region, partial antibody TCN-031 reveal aprotective epitope that is highly conserved among human and nonhumaninfluenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663(2010), NCBI Accession #ADK23854.1 (120aa) INFL455 Heavy chain variablemonoclonal Grandea, A. G. et al., Human, antibodies 4592 region, partialantibody TCN-032 reveal a protective epitope that is highly conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23853.1 (120aa)INFL456 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4593 region, partial antibody 3362_B11 reveal a protectiveepitope that is highly conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23869.1 (123aa) INFL457 Heavy chain variablemonoclonal Grandea, A. G. et al., Human antibodies 4594 region, partialantibody reveal a protective epitope that is highly 3260_D19 conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23868.1 (118aa)INFL458 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4595 region, partial antibody 3253_P10 reveal a protectiveepitope that is highly conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23867.1 (121aa) INFL459 Heavy chain variablemonoclonal Grandea, A. G. et al., Human antibodies 4596 region, partialantibody 3248_P18 reveal a protective epitope that is highly conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23866.1 (120aa)INFL460 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4597 region, partial antibody 3139_P23 reveal a protectiveepitope that is highly conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23865.1 (119aa) INFL461 Heavy chain variablemonoclonal Grandea, A. G. et al., Human antibodies 4598 region, partialantibody 3420_I23 reveal a protective epitope that is highly conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23864.1 (121aa)INFL462 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4599 region, partial antibody 3255_J06 reveal a protectiveepitope that is highly conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23863.1 (119aa) INFL463 Heavy chain variablemonoclonal Grandea, A. G. et al., Human antibodies 4600 region, partialantibody 3252_C13 reveal a protective epitope that is highly conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession # ADK23862.1 (119aa)INFL464 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4601 region, partial antibody reveal a protective epitopethat is highly 3136_G05 conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23861.1 (120aa) INFL465 Heavy chain variablemonoclonal Grandea, A. G. et al., Human antibodies 4602 region, partialantibody reveal a protective epitope that is highly 3244_H04 conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23860.1 (118aa)INFL466 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4603 region, partial antibody reveal a protective epitopethat is highly 3245_O19 conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23859.1 (118aa) INFL467 Heavy chain variablemonoclonal Grandea, A. G. et al., Human antibodies 4604 region, partialantibody 3259_J21 reveal a protective epitope that is highly conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23858.1 (120aa)INFL468 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4605 region, partial antibody 3243_J07 reveal a protectiveepitope that is highly conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23857.1 (121aa) INFL469 Heavy chain variablemonoclonal Grandea, A. G. et al., Human antibodies 4606 region, partialantibody 3244_I10 reveal a protective epitope that is highly conservedamong human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci.U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession # ADK23856.1 (121aa)INFL470 Heavy chain variable monoclonal Grandea, A. G. et al., Humanantibodies 4607 region, partial antibody reveal a protective epitopethat is highly 3241_G23 conserved among human and nonhuman influenza Aviruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010),NCBI Accession #ADK23855.1 (122aa) INFL471 Heavy chain variableMonoclonal Yasugi, M. et al., Emerging Antigenic 4608 region, partialantibody clone 5E4 Variants at the Antigenic Site Sb in PandemicA(H1N1)2009 Influenza Virus in Japan Detected by a Human MonoclonalAntibody; PLoS ONE 8 (10), E77892 (2013), NCBI Accession #BAM76754.1(141aa) INFL472 Heavy chain variable 100F4-HV Hu, H., et al., A HumanAntibody 4609 region, partial Recognizing a Conserved Epitope of H5Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1Viruses; J. Virol. 86 (6), 2978- 2989 (2012), NCBI Accession #AEL30603.1(121aa) INFL473 Heavy chain variable anti-stem HA Pappas, L. et al.,Rapid development of 4610 region, partial, Anti- immunoglobulin broadlyinfluenza neutralizing antibodies stem HA through redundant mutations;Nature immunoglobulin (2014), NCBI Accession #AIN40460.1 (120aa) INFL474Heavy chain variable anti-stem HA Pappas, L. et al., Rapid developmentof 4611 region, partial, Anti- immunoglobulin broadly influenzaneutralizing antibodies stem HA through redundant mutations; Natureimmunoglobulin (2014), NCBI Accession #AIN40459.1 (127aa) INFL475 Heavychain variable anti-stem HA Pappas, L. et al., Rapid development of 4612region, partial, Anti- immunoglobulin broadly influenza neutralizingantibodies stem HA through redundant mutations; Nature immunoglobulin(2014), NCBI Accession #AIN40458.1 (129aa) INFL476 Heavy chain variableanti-stem HA Pappas, L. et al., Rapid development of 4613 region,partial, Anti- immunoglobulin broadly influenza neutralizing antibodiesstem HA through redundant mutations; Nature immunoglobulin (2014), NCBIAccession #AIN40457.1 (132aa) INFL477 Heavy chain variable anti-stem HAPappas, L. et al., Rapid development of 4614 region, partial, Anti-immunoglobulin broadly influenza neutralizing antibodies stem HA throughredundant mutations; Nature immunoglobulin (2014), NCBI Accession#AIN40456.1 (127aa) INFL478 Heavy chain variable anti-stem HA Pappas, L.et al., Rapid development of 4615 region, partial, Anti- immunoglobulinbroadly influenza neutralizing antibodies stem HA through redundantmutations; Nature immunoglobulin (2014), NCBI Accession #AIN40455.1(121aa) INFL479 Heavy chain variable anti-stem HA Pappas, L. et al.,Rapid development of 4616 region, partial, Anti- immunoglobulin broadlyinfluenza neutralizing antibodies stem HA through redundant mutations;Nature immunoglobulin (2014), NCBI Accession #AIN40454.1 (126aa) INFL480Heavy chain variable anti-stem HA Pappas, L. et al., Rapid developmentof 4617 region, partial, Anti- immunoglobulin broadly influenzaneutralizing antibodies stem HA through redundant mutations; Natureimmunoglobulin (2014), NCBI Accession #AIN40453.1 (120aa) INFL481 Heavychain variable anti-stem HA Pappas, L. et al., Rapid development of 4618region, partial, Anti- immunoglobulin broadly influenza neutralizingantibodies stem HA through redundant mutations; Nature immunoglobulin(2014), NCBI Accession #AIN40452.1 (122aa) INFL482 Heavy chain variableanti-stem HA Pappas, L. et al., Rapid development of 4619 region,partial, Anti- immunoglobulin broadly influenza neutralizing antibodiesstem HA through redundant mutations; Nature immunoglobulin (2014), NCBIAccession #AIN40451.1 (125aa) INFL483 Heavy chain variable anti-stem HAPappas, L. et al., Rapid development of 4620 region, partial, Anti-immunoglobulin broadly influenza neutralizing antibodies stem HA throughredundant mutations; Nature immunoglobulin (2014), NCBI Accession#AIN40450.1 (126aa) INFL484 Heavy chain variable anti-stem HA Pappas, L.et al., Rapid development of 4621 region, partial, Anti- immunoglobulinbroadly influenza neutralizing antibodies stem HA through redundantmutations; Nature immunoglobulin (2014), NCBI Accession #AIN40449.1(129aa) INFL485 Heavy chain variable anti-stem HA Pappas, L. et al.,Rapid development of 4622 region, partial, Anti- immunoglobulin broadlyinfluenza neutralizing antibodies stem HA through redundant mutations;Nature immunoglobulin (2014), NCBI Accession #AIN40448.1 (119aa) INFL486Heavy chain variable anti-stem HA Pappas, L. et al., Rapid developmentof 4623 region, partial, Anti- immunoglobulin broadly influenzaneutralizing antibodies stem HA through redundant mutations; Natureimmunoglobulin (2014), NCBI Accession #AIN40447.1 (120aa) INFL487 Heavychain variable anti-stem HA Pappas, L. et al., Rapid development of 4624region, partial, Anti- immunoglobulin broadly influenza neutralizingantibodies stem HA through redundant mutations; Nature immunoglobulin(2014), NCBI Accession #AIN40446.1 (120aa) INFL488 Heavy chain, HumanFab 39.29 Nakamura, G. et al., An in vivo human- 4625 igg, plasmablastenrichment technique allows rapid identification of therapeuticinfluenza a antibodies; Cell Host Microbe 14 (1), 93-103 (2013), NCBIAccession #4KVN_H (227aa) INFL489 Heavy chain, Igg1 Fab H5m9 Zhu, X., etal., A Unique and Conserved 4626 Neutralization Epitope in H5N1Influenza Viruses Identified by an Antibody against theA/Goose/Guangdong/1/96 Hemagglutinin; J. Virol. 87 (23), 12619- 12635(2013), NCBI Accession #4MHH_H (222aa) INFL490 Immunoglobulin T2-6AHuang, K.-Y. A., et al., Focused antibody- 4627 heavy chain variableresponse to influenza linked to antigenic region, partial drift; J.Clin. Invest. (2015), NCBI Accession #AKF02484.1 (124aa) INFL491 Kappalight chain U.S. Pat. No. 8,992,929 SEQ ID NO. 24 4628 constant region,human INFL492 Kappa light chain 8D4 NCBI Accession #AFI57037 4629variable INFL493 Kappa light chain 5B6 NCBI Accession #AFI57041 4630variable INFL494 Kappa light chain 8i10 U.S. Pat. No. 8,858,948 SEQ IDNO: 56 4631 variable region INFL495 Kappa light chain 23K12 U.S. Pat.No. 8,858,948 SEQ ID NO: 91 4632 variable region INFL496 Kappa lightchain 4K8 Krause, J. C. et al. “Epitope-specific 4633 variable regionhuman influenza antibody repertoires diversify by B cell intraclonalsequence divergence and interclonal convergence” J. Immunol. 187 (7),3704-3711 (2011), NCBI Accession #AEO16800 INFL497 Kappa light chain 6D9Krause, J. C. et al. “Epitope-specific 4634 variable region humaninfluenza antibody repertoires diversify by B cell intraclonal sequencedivergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711(2011), NCBI Accession #AEO16802 INFL498 Kappa light chain 8G9 U.S. Pat.No. 8,603,467 SEQ ID NO: 4 4635 variable region INFL499 Kappa lightchain 13D4 U.S. Pat. No. 8,603,467 SEQ ID NO: 8 4636 variable regionINFL500 Kappa light chain 20A11 U.S. Pat. No. 8,603,467 SEQ ID NO: 124637 variable region INFL501 Kappa light chain EM4C04 US20120282273 SEQID NO: 1 4638 variable region INFL502 Kappa, light chain Fab H5m9 Zhu,X., et al., A Unique and Conserved 4639 Neutralization Epitope in H5N1Influenza Viruses Identified by an Antibody against theA/Goose/Guangdong/1/96 Hemagglutinin; J. Virol. 87 (23), 12619- 12635(2013), NCBI Accession # 4MHH_L(218aa) INFL503 Lambda light chain 7A13Krause et al. “Human Monoclonal 4640 Antibodies to Pandemic 1957 H2N2and Pandemic 1968 H3N2 Influenza Viruses” J. Virol. 86 (11), 6334-6340(2012), NCBI Accession #AFH78448 INFL504 Lambda light chain 2K11 Krause,J. C. et al. “Epitope-specific 4641 variable human influenza antibodyrepertoires diversify by B cell intraclonal sequence divergence andinterclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBIAccession #AEO16794 INFL505 Lambda light chain 2O10 Krause, J. C. et al.“Epitope-specific 4642 variable human influenza antibody repertoiresdiversify by B cell intraclonal sequence divergence and interclonalconvergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession#AEO16796 INFL506 Lambda light chain Monoclonal Yasugi, M. et al.,Emerging Antigenic 4643 variable region, antibody clone 5E4 Variants atthe Antigenic Site Sb in partial Pandemic A(H1N1)2009 Influenza Virus inJapan Detected by a Human Monoclonal Antibody; PLoS ONE 8 (10), E77892(2013), NCBI Accession #BAM76755.1 (126aa) INFL507 Lambda light chainT2-6A Huang, K.-Y. A., et al., Focused antibody 4644 variable region,response to influenza linked to antigenic partial, drift; J. Clin.Invest. (2015), NCBI Immunoglobulin Accession #AKF02488.1 (113aa)INFL508 Light chain CR6261, WO2008028946 4645 Diridavumab, CR- 6261INFL509 Light chain Firivumab, CT-P22 US20130004505 4646 INFL510 Lightchain Navivumab, WO2013048153, US20140234336 SEQ 4647 CT149 ID NO: 39INFL511 Light chain AT10-004 US20150010566, WO2013081463 SEQ 4648 ID NO:36 INFL512 Light chain AT10-003 US20150010566, WO2013081463 SEQ 4649 IDNO: 37 INFL513 Light chain AT10-002 US20150010566, WO2013081463 SEQ 4650ID NO: 38 INFL514 Light chain AT10-001 US20150010566, WO2013081463 SEQ4651 ID NO: 39 INFL515 Light chain AT10-005 US20150010566, WO2013081463SEQ 4652 ID NO: 40 INFL516 Light chain CT104 WO2011111966, US20130004505SEQ 4653 ID NO: 36 INFL517 Light chain CT120 WO2011111966, US20130004505SEQ 4654 ID NO: 40 INFL518 Light chain CT123 WO2011111966, US20130004505SEQ 4655 ID NO: 44 INFL519 Light chain 2A US20140011982 SEQ ID NO: 44656 INFL520 Light chain F005-126 WO2014049520, US20140086927 SEQ 4657ID NO: 13 INFL521 Light chain BF1-1 WO2008156763 SEQ ID NO: 8 4658INFL522 Light chain BF1-19 WO2008156763 SEQ ID NO: 12 4659 INFL523 Lightchain BF1-10 WO2008156763 SEQ ID NO: 10 4660 INFL524 Light chain 2D1WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4661 NO: 8 INFL525 Lightchain 1F1 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4662 NO: 2INFL526 Light chain 4D20 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID4663 NO: 10 INFL527 Light chain A18 WO13170139 SEQ ID NO: 95 4664INFL528 Light chain Ab A18 U.S. Pat. No. 7,788,200 SEQ ID NO: 28 4665INFL529 Light chain Ab 067 U.S. Pat. No. 7,788,200 SEQ ID NO: 153 4666INFL530 Light chain Ab 068 U.S. Pat. No. 7,788,200 SEQ ID NO: 154 4667INFL531 Light chain Ab 069, Ab 079 U.S. Pat. No. 7,788,200 SEQ ID NO:155 4668 INFL532 Light chain Ab 070 U.S. Pat. No. 7,788,200 SEQ ID NO:156 4669 INFL533 Light chain Ab 073 U.S. Pat. No. 7,788,200 SEQ ID NO:165 4670 INFL534 Light chain Ab 074, Ab 080 U.S. Pat. No. 7,788,200 SEQID NO: 166 4671 INFL535 Light chain Ab 075 U.S. Pat. No. 7,788,200 SEQID NO: 167 4672 INFL536 Light chain Ab 076 U.S. Pat. No. 7,788,200 SEQID NO: 168 4673 INFL537 Light chain Ab 077, Ab 081 U.S. Pat. No.7,788,200 SEQ ID NO: 169 4674 INFL538 Light chain Ab 014, Ab 154, U.S.Pat. No. 7,788,200 SEQ ID NO: 29 4675 Ab 157 INFL539 Light chain Ab 028,Ab 155 U.S. Pat. No. 7,788,200 SEQ ID NO: 30 4676 INFL540 Light chain Ab001, Ab 002, U.S. Pat. No. 7,788,200 SEQ ID NO: 31 4677 Ab 003 INFL541Light chain Ab 009, Ab 010, U.S. Pat. No. 7,788,200 SEQ ID NO: 32 4678Ab 011 INFL542 Light chain Ab 017, Ab B18, U.S. Pat. No. 7,788,200 SEQID NO: 33 4679 Ab B18, Ab 019, Ab 019 INFL543 Light chain Ab 025, Ab026, U.S. Pat. No. 7,788,200 SEQ ID NO: 34 4680 Ab 027, Ab 028 INFL544Light chain Ab 159 U.S. Pat. No. 7,788,200 SEQ ID NO: 35 4681 INFL545Light chain Ab 160 U.S. Pat. No. 7,788,200 SEQ ID NO: 36 4682 INFL546Light chain Ab 186, Ab 194 U.S. Pat. No. 7,788,200 SEQ ID NO: 37 4683INFL547 Light chain Ab 187, Ab 195 U.S. Pat. No. 7,788,200 SEQ ID NO: 384684 INFL548 Light chain Ab 188, Ab 196 U.S. Pat. No. 7,788,200 SEQ IDNO: 39 4685 INFL549 Light chain Ab 189, Ab 197 U.S. Pat. No. 7,788,200SEQ ID NO: 40 4686 INFL550 Light chain Ab 190, Ab 198 U.S. Pat. No.7,788,200 SEQ ID NO: 41 4687 INFL551 Light chain Ab 191, Ab 199 U.S.Pat. No. 7,788,200 SEQ ID NO: 42 4688 INFL552 Light chain Ab 192, Ab 200U.S. Pat. No. 7,788,200 SEQ ID NO: 43 4689 INFL553 Light chain Ab 193U.S. Pat. No. 7,788,200 SEQ ID NO: 44 4690 INFL554 Light chain Ab 202,Ab 203, U.S. Pat. No. 7,788,200 SEQ ID NO: 45 4691 Ab 204, Ab 210, Ab031, Ab 032, Ab 033, Ab 034 INFL555 Light chain Ab 211, Ab 212, U.S.Pat. No. 7,788,200 SEQ ID NO: 46 4692 Ab 213, Ab 219, Ab 037, Ab 038, Ab039, Ab 040 INFL556 Light chain Ab A001, Ab 004, U.S. Pat. No. 7,788,200SEQ ID NO: 47 4693 Ab 007, Ab 016 INFL557 Light chain Ab A002, Ab 005,U.S. Pat. No. 7,788,200 SEQ ID NO: 48 4694 Ab 008, Ab A017 INFL558 Lightchain Ab A003, Ab 006, U.S. Pat. No. 7,788,200 SEQ ID NO: 49 4695 AbA009, Ab C18 INFL559 Light chain Ab A010, Ab 012, U.S. Pat. No.7,788,200 SEQ ID NO: 50 4696 Ab A14, Ab A019 INFL560 Light chain AbA011, Ab U.S. Pat. No. 7,788,200 SEQ ID NO: 51 4697 013m Ab 0135 INFL561Light chain Ab 044, Ab 071, U.S. Pat. No. 7,788,200 SEQ ID NO: 52 4698Ab 072, Ab 078 INFL562 Light chain Ab 051 U.S. Pat. No. 7,788,200 SEQ IDNO: 53 4699 INFL563 Light chain Ab 049 U.S. Pat. No. 7,788,200 SEQ IDNO: 54 4700 INFL564 Light chain Ab 047 U.S. Pat. No. 7,788,200 SEQ IDNO: 55 4701 INFL565 Light chain Ab 050 U.S. Pat. No. 7,788,200 SEQ IDNO: 56 4702 INFL566 Light chain Ab 045 U.S. Pat. No. 7,788,200 SEQ IDNO: 57 4703 INFL567 Light chain Ab 048 U.S. Pat. No. 7,788,200 SEQ IDNO: 58 4704 INFL568 Light chain Ab 046 U.S. Pat. No. 7,788,200 SEQ IDNO: 59 4705 INFL569 Light chain Ab 043 U.S. Pat. No. 7,788,200 SEQ IDNO: 60 4706 INFL570 Light chain Ab 052 U.S. Pat. No. 7,788,200 SEQ IDNO: 61 4707 INFL571 Light chain F005-126 WO2014049520 SEQ ID 13 4708INFL572 Light chain 8f24 WO2012045001 SEQ ID 3 4709 INFL573 Light chain3E22 WO2012045001 SEQ ID 7 4710 INFL574 Light chain 5117 WO2012045001SEQ ID 11 4711 INFL575 Light chain WO2012045001 SEQ ID 15 4712 INFL576Light chain WO2012045001 SEQ ID 31 4713 INFL577 Light chain WO2012045001SEQ ID 35 4714 INFL578 Light chain WO2012045001 SEQ ID 19 4715 INFL579Light chain 10A14 WO2012045001 SEQ ID 23 4716 INFL580 Light chain 8D4WO2012045001 SEQ ID 27 4717 INFL581 Light chain 2B9 U.S. Pat. No.9,115,201 SEQ ID NO: 5 4718 INFL582 Light chain mAB 7A7 US20150239960,US20140170163, 4719 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564SEQ ID NO: 7 INFL583 Light chain mAB 12D1 US20150239960, US20140170163,4720 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 13INFL584 Light chain mAB 66A6 US20150239960, US20140170163, 4721 U.S.Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 17 INFL585Light chain M1 D12 US20110033473, WO2009125395 SEQ 4722 ID NO: 15INFL586 Light chain mAB1.12 WO2013030165 SEQ ID NO: 2 4723 INFL587 Lightchain mAB3.1 WO2013030165 SEQ ID NO: 4 4724 INFL588 Light chain 5A7WO2015120097 SEQ ID NO: 8 4725 INFL589 Light chain TRL053 WO2015120097SEQ ID NO: 18 4726 INFL590 Light chain TRL579 WO2015120097 SEQ ID NO: 284727 INFL591 Light chain TRL784 WO2015120097 SEQ ID NO: 38 4728 INFL592Light chain TRL794 WO2015120097 SEQ ID NO: 48 4729 INFL593 Light chainTRL798 WO2015120097 SEQ ID NO: 58 4730 INFL594 Light chain TRL799WO2015120097 SEQ ID NO: 68 4731 INFL595 Light chain TRL809 WO2015120097SEQ ID NO: 78 4732 INFL596 Light chain TRL811 WO2015120097 SEQ ID NO: 884733 INFL597 Light chain TRL812 WO2015120097 SEQ ID NO: 98 4734 INFL598Light chain TRL813 WO2015120097 SEQ ID NO: 108 4735 INFL599 Light chainTRL823 WO2015120097 SEQ ID NO: 118 4736 INFL600 Light chain TRL832WO2015120097 SEQ ID NO: 128 4737 INFL601 Light chain TRL833 WO2015120097SEQ ID NO: 138 4738 INFL602 Light chain TRL834 WO2015120097 SEQ ID NO:148 4739 INFL603 Light chain TRL837 WO2015120097 SEQ ID NO: 167 4740INFL604 Light chain TRL839 WO2015120097 SEQ ID NO: 177 4741 INFL605Light chain TRL841 WO2015120097 SEQ ID NO: 187 4742 INFL606 Light chainTRL842 WO2015120097 SEQ ID NO: 197 4743 INFL607 Light chain TRL845WO2015120097 SEQ ID NO: 207 4744 INFL608 Light chain TRL846 WO2015120097SEQ ID NO: 218 4745 INFL609 Light chain TRL847 WO2015120097 SEQ ID NO:228 4746 INFL610 Light chain TRL848 WO2015120097 SEQ ID NO: 238 4747INFL611 Light chain TRL849 WO2015120097 SEQ ID NO: 248 4748 INFL612Light chain TRL851 WO2015120097 SEQ ID NO: 258 4749 INFL613 Light chainTRL854 WO2015120097 SEQ ID NO: 268 4750 INFL614 Light chain TRL856WO2015120097 SEQ ID NO: 278 4751 INFL615 Light chain TRL858 WO2015120097SEQ ID NO: 288 4752 INFL616 Light chain humM2e-hBiTE-1 WO2014140368 SEQID NO: 10 4753 INFL617 Light chain humM2e-hBiTE-2 WO2014140368 SEQ IDNO: 18 4754 INFL618 Light chain humM2e-hBiTE-3 WO2014140368 SEQ ID NO:26 4755 INFL619 Light chain humM2e-hBiTE-4 WO2014140368 SEQ ID NO: 344756 INFL620 Light chain VH of humM2e- WO2014140368 SEQ ID NO: 42 4757hBiTE-5 INFL621 Light chain humM2e-hBiTE-6 WO2014140368 SEQ ID NO: 504758 INFL622 Light chain humM2e-hBiTE-7 WO2014140368 SEQ ID NO: 58 4759INFL623 Light chain humM2e-hBiTE-8 WO2014140368 SEQ ID NO: 66 4760INFL624 Light chain humM2e-hBiTE-9 WO2014140368 SEQ ID NO: 74 4761INFL625 Light chain murM2e-hBiTE WO2014140368 SEQ ID NO: 82 4762 INFL626Light chain FLA5.10 U.S. Pat. No. 8,124,092 SEQ ID NO: 3 4763 INFL627Light chain FLD21.140 U.S. Pat. No. 8,124,092 SEQ ID NO: 7 4764 INFL628Light chain FLA3.14 U.S. Pat. No. 8,124,092 SEQ ID NO: 11 4765 INFL629Light chain FLD20.19 U.S. Pat. No. 8,124,092 SEQ ID NO: 15 4766 INFL630Light chain FLD84 U.S. Pat. No. 8,124,092 SEQ ID NO: 44 4767 INFL631Light chain FLD93 U.S. Pat. No. 8,124,092 SEQ ID NO: 54 4768 INFL632Light chain FLD122 U.S. Pat. No. 8,124,092 SEQ ID NO: 64 4769 INFL633Light chain FLD127 U.S. Pat. No. 8,124,092 SEQ ID NO: 74 4770 INFL634Light chain FLD129 U.S. Pat. No. 8,124,092 SEQ ID NO: 84 4771 INFL635Light chain FLD132 U.S. Pat. No. 8,124,092 SEQ ID NO: 94 4772 INFL636Light chain FLD194 U.S. Pat. No. 8,124,092 SEQ ID NO: 104 4773 INFL637Light chain mAb1 WO2015112994 SEQ ID NO: 77 4774 INFL638 Light chainmAb2 WO2015112994 SEQ ID NO: 81 4775 INFL639 Light chain mAb3WO2015112994 SEQ ID NO: 85 4776 INFL640 Light chain CT-P22 US20130004505SEQ ID NO: 40; 4777 WO2011/111966 INFL641 Light chain C05 Ekiert, D. C.,et al., Cross-neutralization 4778 of influenza A viruses mediated by asingle antibody loop; Nature 489 (7417), 526-532 (2012), NCBI Accession#4FNL_L (214aa) INFL642 Light chain CR8020 Ekiert, D. C., et al., Ahighly conserved 4779 neutralizing epitope on group 2 influenza Aviruses; Science 333 (6044), 843-850 (2011); WO2010130636, NCBIAccession #3SDY_L INFL643 Light chain CR8033 Dreyfus, C., Laursen, N. S.et al., Highly 4780 conserved protective epitopes on influenza Bviruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession # 4FQL_LINFL644 Light chain CR8043 Friesen, R. H. et al., A common solution 4781to group 2 influenza virus neutralization; Proc. Natl. Acad. Sci. U.S.A.111 (1), 445-450 (2014), NCBI Accession #4NM8_L INFL645 Light chainCR8059 Dreyfus, C. et al., Highly conserved 4782 protective epitopes oninfluenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBIAccession #4FQK_L INFL646 Light chain CR8071 Dreyfus, C. et al., Highlyconserved 4783 protective epitopes on influenza B viruses; Science 337(6100), 1343-1348 (2012), NCBI Accession # 4FQJ_L (216aa) INFL647 Lightchain CR9114 WO2013079473; WO2014191435; 4784 Dreyfus, C., Laursen, N.S. et al., Highly conserved protective epitopes on influenza B viruses;Science 337 (6100), 1343-1348 (2012), NCBI Accession #4FQY_L(216aa)INFL648 Light chain Ch67 Schmidt, A. G., et al., Preconfiguration of4785 the antigen-binding site during affinity maturation of a broadlyneutralizing influenza virus antibody; Proc. Natl. Acad. Sci. U.S.A. 110(1), 264-269 (2013), NCBI Accession #4HKX_B (214aa) INFL649 Light chainFab 26/9 Schulze-Gahmen, U. et al., J. Biol. 4786 Chem. 263 (32),17100-17105 (1988); Churchill, M. E., et al., J. Mol. Biol. 241 (4),534-556 (1994), NCBI Accession #LFRG_L INFL650 Light chain Fab 3.1Wyrzucki, A. et al., Alternative 4787 Recognition of the Conserved StemEpitope in Influenza A Virus Hemagglutinin by a VH3-30-EncodedHeterosubtypic Antibody; J. Virol. 88 (12), 7083-7092 (2014), NCBIAccession #4PY8_J INFL651 Light chain Fab 2g1 Xu, R. et al., A recurringmotif for 4788 antibody recognition of the receptor- binding site ofinfluenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013),NCBI Accession #4HG4_M (214aa) INFL652 Light chain Fab 8m2 Xu, R. etal., A recurring motif for 4789 antibody recognition of the receptor-binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3),363-370 (2013), NCBI Accession #4HFU_L (215aa) INFL653 Light chain Fab8f8 Xu, R. et al., A recurring motif for 4790 antibody recognition ofthe receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol.Biol. 20 (3), 363-370 (2013), NCBI Accession # 4HF5_L (218aa) INFL654Light chain Fab 2d1 Xu, R., et al., Structural basis of 4791 preexistingimmunity to the 2009 H1N1 pandemic influenza virus; Science 328 (5976),357-360 (2010), NCBI Accession #3LZF_L (217aa) INFL655 Light chain Fi6v3Corti, D. et al., A neutralizing antibody 4792 selected from plasmacells that binds to group 1 and group 2 influenza A hemagglutinins;Science 333 (6044), 850-856 (2011), NCBI Accession #3ZTN_L INFL656 Lightchain Light chain from Iba, Y., et al., Conserved Neutralizing 47933WHE_N Epitope at Globular Head of Hemagglutinin in H3N2 InfluenzaViruses; J. Virol. (2014), NCBI Accession #3WHE_N (220aa) INFL657 Lightchain monoclonal Burioni, R. et al., Monoclonal antibodies 4794(partial) antibody PN- isolated from human B cells neutralize a SIA28broad range of H1 subtype influenza A viruses including swine-originInfluenza virus(S-OIV); Virology (2010), NCBI Accession #ACX30939.1(105aa) INFL658 Light chain monoclonal Burioni, R. et al., Monoclonalantibodies 4795 (partial) antibody PN- isolated from human B cellsneutralize a SIA49 broad range of H1 subtype influenza A virusesincluding swine-origin Influenza virus(S-OIV); Virology (2010), NCBIAccession #ACX30938.1 (105aa) INFL659 Light chain; Fab 5j8 Hong, M. etal., Antibody Recognition of 4796 the Pandemic H1N1 Influenza VirusHemagglutinin Receptor Binding Site; J. Virol. 87 (22), 12471-12480(2013), NCBI Accession #4M5Z_L INFL660 Light chain CDR 1 Ab1A2WO2015028478 SEQ ID 9 4797 INFL661 Light chain CDR 2 Ab1A2 WO2015028478SEQ ID 10 4798 INFL662 Light chain CDR 3 Ab1A2 WO2015028478 SEQ ID 114799 INFL663 Light chain Fab CT147 WO2013048153, US20140234336 SEQ 4800ID NO: 37 INFL664 Light chain Fab CT164 WO2013048153, US20140234336 SEQ4801 ID NO: 41 INFL665 Light chain Fab CT166 WO2013048153, US20140234336SEQ 4802 ID NO: 43 INFL666 Light chain Human Fab 39.29 Nakamura, G. etal., An in vivo human- 4803 igg plasmablast enrichment technique allowsrapid identification of therapeutic influenza a antibodies; Cell HostMicrobe 14 (1), 93-103 (2013), NCBI Accession #4KVN_L (215aa) INFL667Light chain K3 h2B11 U.S. Pat. No. 9,115,201 SEQ ID NO: 9 4804 INFL668Light chain K3 h2B12 U.S. Pat. No. 9,115,201 SEQ ID NO: 10 4805 INFL669Light chain partial 4A10 Krause, J. C. et al. “Epitope-specific 4806region human influenza antibody repertoires diversify by B cellintraclonal sequence divergence and interclonal convergence” J. Immunol.187 (7), 3704-3711 (2011), NCBI Accession #AEO16798 INFL670 Light chainvariable LC-VD from US2013030234 SEQ ID NO: 33 4807 (exemplary)US2013030234 INFL671 Light chain variable LC-VD from US2013030234 SEQ IDNO: 34 4808 (exemplary) US2013030234 INFL672 Light chain variable LC-VDfrom US2013030234 SEQ ID NO: 35 4809 (exemplary) US2013030234 INFL673Light chain variable LC-VD from US2013030234 SEQ ID NO: 36 4810(exemplary) US2013030234 INFL674 Light chain variable LC-VD fromUS2013030234 SEQ ID NO: 37 4811 (exemplary) US2013030234 INFL675 Lightchain variable LC-VD from US2013030234 SEQ ID NO: 38 4812 (exemplary)US2013030234 INFL676 Light chain variable LC-VD from US2013030234 SEQ IDNO: 39 4813 (exemplary) US2013030234 INFL677 Light chain variable LC-VDfrom US2013030234 SEQ ID NO: 40 4814 (exemplary) US2013030234 INFL678Light chain variable LC-VD from US2013030234 SEQ ID NO: 41 4815(exemplary) US2013030234 INFL679 Light chain variable LC-VD fromUS2013030234 SEQ ID NO: 42 4816 (exemplary) US2013030234 INFL680 Lightchain variable LC-VD from US2013030234 SEQ ID NO: 43 4817 (exemplary)US2013030234 INFL681 Light chain variable 39.18 B11 US20140161822 SEQ IDNO: 156 4818 region INFL682 Light chain variable GG3 WO2014159960 SEQ IDNO: 25 4819 region INFL683 Light chain variable N547 U.S. Pat. No.8,003,106 SEQ ID NO: 29 4820 region INFL684 Light chain variable L66U.S. Pat. No. 8,003,106 SEQ ID NO: 31 4821 region INFL685 Light chainvariable C40 U.S. Pat. No. 8,003,106 SEQ ID NO: 27 4822 region INFL686Light chain variable 14C2 U.S. Pat. No. 8,080,244 SEQ ID NO: 7 4823region INFL687 Light chain variable h14C2 U.S. Pat. No. 8,080,244 SEQ IDNO: 1 4824 region INFL688 Light chain variable VN04-2-HuG1 US20100150941SEQ ID NO: 6 4825 region INFL689 Light chain variable VN04-3-HuG1US20100150941 SEQ ID NO: 8 4826 region INFL690 Light chain variable FI6variant 1, FI6 U.S. Pat. No. 8,871,207 SEQ ID NO: 14 4827 region variant2 INFL691 Light chain variable FI6 variant 3, FI6 U.S. Pat. No.8,871,207 SEQ ID NO: 57 4828 region variant 4 INFL692 Light chainvariable FI6 variant 5 U.S. Pat. No. 8,871,207 SEQ ID NO: 61 4829 regionINFL693 Light chain variable FI28 vanant 1, U.S. Pat. No. 8,871,207 SEQID NO: 30 4830 region FI28 variant 2 INFL694 Light chain variable 21B15U.S. Pat. No. 8,858,948 SEQ ID NO: 46 4831 region INFL695 Light chainvariable 3241_G23 U.S. Pat. No. 8,858,948 SEQ ID NO: 118 4832 regionINFL696 Light chain variable 3244_I10 U.S. Pat. No. 8,858,948 SEQ ID NO:122 4833 region INFL697 Light chain variable 3243_J07 U.S. Pat. No.8,858,948 SEQ ID NO: 126 4834 region INFL698 Light chain variable3259_J21 U.S. Pat. No. 8,858,948 SEQ ID NO: 130 4835 region INFL699Light chain variable 3245_O19 U.S. Pat. No. 8,858,948 SEQ ID NO: 1344836 region INFL700 Light chain variable 3244_H04 U.S. Pat. No.8,858,948 SEQ ID NO: 138 4837 region INFL701 Light chain variable3136_G05 U.S. Pat. No. 8,858,948 SEQ ID NO: 142 4838 region INFL702Light chain variable 3252_C13 U.S. Pat. No. 8,858,948 SEQ ID NO: 1464839 region INFL703 Light chain variable 3255_J06 U.S. Pat. No.8,858,948 SEQ ID NO: 150 4840 region INFL704 Light chain variable3420_I23 U.S. Pat. No. 8,858,948 SEQ ID NO: 154 4841 region INFL705Light chain variable 3248_P18 U.S. Pat. No. 8,858,948 SEQ ID NO: 1604842 region INFL706 Light chain variable 3253_P10 U.S. Pat. No.8,858,948 SEQ ID NO: 164 4843 region INFL707 Light chain variable3260_D19 U.S. Pat. No. 8,858,948 SEQ ID NO: 168 4844 region INFL708Light chain variable 3362_B11 U.S. Pat. No. 8,858,948 SEQ ID NO: 1744845 region INFL709 Light chain variable 3242_P05 U.S. Pat. No.8,858,948 SEQ ID NO: 178 4846 region INFL710 Light chain variable A66WO2009079259, US20110038935, 4847 region US20140011982 SEQ ID NO: 34INFL711 Light chain variable D7, H98 WO2009079259, US20110038935, 4848region US20140011982 SEQ ID NO: 8 INFL712 Light chain variable D8WO2009079259, US20110038935, 4849 region US20140011982 SEQ ID NO: 14INFL713 Light chain variable D80 WO2009079259, US20110038935, 4850region US20140011982 SEQ ID NO: 16 INFL714 Light chain variable E88WO2009079259, US20110038935, 4851 region US20140011982 SEQ ID NO: 38INFL715 Light chain variable E90 WO2009079259, US20110038935, 4852region US20140011982 SEQ ID NO: 22 INFL716 Light chain variable F10WO2009079259, US20110038935, 4853 region US20140011982 SEQ ID NO: 20INFL717 Light chain variable G17 WO2009079259, US20110038935, 4854region US20140011982 SEQ ID NO: 26 INFL718 Light chain variable H40WO2009079259, US20110038935, 4855 region US20140011982 SEQ ID NO: 30INFL719 Light chain variable H98 WO2009079259, US20110038935, 4856region US20140011982 SEQ ID NO: 10 INFL720 Light chain variable CH65WO2013020074, US20140302043 SEQ 4857 region ID NO: 10 INFL721 Lightchain variable CH66 WO2013020074, US20140302043 SEQ 4858 region ID NO:11 INFL722 Light chain variable CH67 WO2013020074, US20140302043 SEQ4859 region ID NO: 12 INFL723 Light chain variable CL86OUCAWO2013020074, US20140302043 SEQ 4860 region ID NO: 9 INFL724 Light chainvariable Antibody 1 WO2015051010 SEQ ID NO: 7 4861 region INFL725 Lightchain variable Antibody 2 WO2015051010 SEQ ID NO: 17 4862 region INFL726Light chain variable Antibody 3 WO2015051010 SEQ ID NO: 27 4863 regionINFL727 Light chain variable Antibody 4 WO2015051010 SEQ ID NO: 37 4864region INFL728 Light chain variable Antibody 5 WO2015051010 SEQ ID NO:47 4865 region INFL729 Light chain variable Antibody 6 WO2015051010 SEQID NO: 57 4866 region INFL730 Light chain variable Antibody 7WO2015051010 SEQ ID NO: 67 4867 region INFL731 Light chain variableAntibody 8 WO2015051010 SEQ ID NO: 77 4868 region INFL732 Light chainvariable Antibody 9 WO2015051010 SEQ ID NO: 87 4869 region INFL733 Lightchain variable Antibody 10 WO2015051010 SEQ ID NO: 97 4870 regionINFL734 Light chain variable Antibody 11 WO2015051010 SEQ ID NO: 1074871 region INFL735 Light chain variable Antibody 12 WO2015051010 SEQ IDNO: 117 4872 region INFL736 Light chain variable Antibody 13WO2015051010 SEQ ID NO: 127 4873 region INFL737 Light chain variableAntibody 14 WO2015051010 SEQ ID NO: 137 4874 region INFL738 Light chainvariable Antibody 15 WO2015051010 SEQ ID NO: 147 4875 region INFL739Light chain variable Antibody 3-GL WO2015051010 SEQ ID NO: 157 4876region INFL740 Light chain variable 005-2G02 WO2013059524, US20140348851SEQ 4877 region ID NO: 11 INFL741 Light chain variable 005-2G02WO2013059524, US20140348851 SEQ 4878 region ID NO: 19 INFL742 Lightchain variable 09-2A06 WO2013059524, US20140348851 SEQ 4879 region IDNO: 31 INFL743 Light chain variable 09-2A06 WO2013059524, US20140348851SEQ 4880 region ID NO: 39 INFL744 Light chain variable 09-3A01WO2013059524, US20140348851 SEQ 4881 region ID NO: 51 INFL745 Lightchain variable 09-3A01 WO2013059524, US20140348851 SEQ 4882 region IDNO: 59 INFL746 Light chain variable 70-IF02 WO2012096994, US20140046039SEQ 4883 region ID NO: 21 INFL747 Light chain variable US20120058124 SEQID NO: 15 4884 region INFL748 Light chain variable US20120058124 SEQ IDNO: 16 4885 region INFL749 Light chain variable US20120058124 SEQ ID NO:17 4886 region INFL750 Light chain variable US20120058124 SEQ ID NO: 184887 region INFL751 Light chain variable US20120058124 SEQ ID NO: 194888 region INFL752 Light chain variable US20120058124 SEQ ID NO: 204889 region INFL753 Light chain variable US20120058124 SEQ ID NO: 214890 region INFL754 Light chain variable US20120058124 SEQ ID NO: 224891 region INFL755 Light chain variable US20120058124 SEQ ID NO: 234892 region INFL756 Light chain variable US20120058124 SEQ ID NO: 244893 region INFL757 Light chain variable US20120058124 SEQ ID NO: 254894 region INFL758 Light chain variable US20120058124 SEQ ID NO: 264895 region INFL759 Light chain variable US20120058124 SEQ ID NO: 704896 region INFL760 Light chain variable 81.39 US20140161822,US20140248286, 4897 region WO2014078268 SEQ ID NO: 113 INFL761 Lightchain variable 81.39 US20140161822, US20140248286, 4898 regionWO2014078268 SEQ ID NO: 117 INFL762 Light chain variable 81.39US20140161822, US20140248286, 4899 region WO2014078268 SEQ ID NO: 119INFL763 Light chain variable 81.39 US20140161822, US20140248286, 4900region WO2014078268 SEQ ID NO: 122 INFL764 Light chain variable 81.39US20140161822, US20140248286, 4901 region WO2014078268 SEQ ID NO: 124INFL765 Light chain variable 81.39 US20140161822, US20140248286, 4902region WO2014078268 SEQ ID NO: 126 INFL766 Light chain variable 81.39US20140161822, US20140248286, 4903 region WO2014078268 SEQ ID NO: 128INFL767 Light chain variable 81.39 US20140161822, US20140248286, 4904region WO2014078268 SEQ ID NO: 130 INFL768 Light chain variable 81.39US20140161822, US20140248286, 4905 region WO2014078268 SEQ ID NO: 132INFL769 Light chain variable 39.29 US20140161822, US20140248286, 4906region WO2014078268 SEQ ID NO: 136 INFL770 Light chain variable 39.29US20140161822, US20140248286, 4907 region WO2014078268 SEQ ID NO: 140INFL771 Light chain variable 39.29 US20140161822, US20140248286, 4908region WO2014078268 SEQ ID NO: 144 INFL772 Light chain variable 39.29US20140161822, US20140248286, 4909 region WO2014078268 SEQ ID NO: 146INFL773 Light chain variable 39.29 US20140161822, US20140248286, 4910region WO2014078268 SEQ ID NO: 150 INFL774 Light chain variable 39.29US20140161822, US20140248286, 4911 region WO2014078268 SEQ ID NO: 152INFL775 Light chain variable 36.89 US20140161822, US20140248286, 4912region WO2014078268 SEQ ID NO: 162 INFL776 Light chain variable 9.01F3US20140161822, US20140248286, 4913 region WO2014078268 SEQ ID NO: 166INFL777 Light chain variable 23.06C2 US20140161822, US20140248286, 4914region WO2014078268 SEQ ID NO: 170 INFL778 Light chain variable 39.29US20140161822, US20140248286, 4915 region WO2014078268 SEQ ID NO: 235INFL779 Light chain variable F16 Variant 3 WO2013011347, US20140271655,4916 region U.S. Pat. No. 8,871,207 SEQ ID NO: 57 INFL780 Light chainvariable F16 Variant 5 WO2013011347, US20140271655, 4917 region U.S.Pat. No. 8,871,207 SEQ ID NO: 61 INFL781 Light chain variable FC41WO2010010467 SEQ ID NO 61 4918 region INFL782 Light chain variable FE43WO2010010467 SEQ ID NO 75 4919 region INFL783 Light chain variable FB75,FB110, WO2010010467 SEQ ID NO 122 4920 region FB177 INFL784 Light chainvariable FB17 WO2010010467 SEQ ID NO 106 4921 region INFL785 Light chainvariable FC6 WO2010010467 SEQ ID NO 46 4922 region INFL786 Light chainvariable FE53 WO2010010467 SEQ ID NO 90 4923 region INFL787 Light chainvariable 7A7 WO2010138564 SEQ ID NO: 7 4924 region INFL788 Light chainvariable 12DI WO2010138564 SEQ ID NO: 13 4925 region INFL789 Light chainvariable 66A6 WO2010138564 SEQ ID NO: 17 4926 region INFL790 Light chainvariable B-1 U.S. Pat. No. 8,975,378, US20110319600, 4927 regionWO2010073647 SEQ ID NO: 28 INFL791 Light chain variable D1 U.S. Pat. No.8,975,378, US20110319600, 4928 region WO2010073647 SEQ ID NO: 30 INFL792Light chain variable E-2 U.S. Pat. No. 8,975,378, US20110319600, 4929region WO2010073647 SEQ ID NO: 32 INFL793 Light chain variable B-3 U.S.Pat. No. 8,975,378, US20110319600, 4930 region WO2010073647 SEQ ID NO:34 INFL794 Light chain variable 5A7 WO2013114885, US20140377262 SEQ 4931region ID NO: 35 INFL795 Light chain variable 3A2 WO2013114885,US20140377262 SEQ 4932 region ID NO: 39 INFL796 Light chain variable10C4 WO2013114885, US20140377262 SEQ 4933 region ID NO: 43 INFL797 Lightchain variable Fab49 WO2009144667, US20110076265 SEQ 4934 region ID NO:2 INFL798 Light chain variable Fab28, IgG PN- WO2009115972,WO2011117848, 4935 region SIA28 US20110014187 SEQ ID NO: 2 INFL799 Lightchain variable TCN-522 US20120207760, U.S. Pat. No. 8,916,160 SEQ ID4936 region NO: 778; U.S. Pat. No. 8,900,590 SEQ ID NO: 33 INFL800 Lightchain variable CR8018 WO2010130636 SEQ ID NO: 24 4937 region INFL801Light chain variable CR8019 WO2010130636 SEQ ID NO: 28 4938 regionINFL802 Light chain variable CR8020 WO2010130636 SEQ ID NO: 32 4939region INFL803 Light chain variable CR8021 WO2010130636 SEQ ID NO: 364940 region INFL804 Light chain variable CR8038 WO2010130636 SEQ ID NO:40 4941 region INFL805 Light chain variable CR8039 WO2010130636 SEQ IDNO: 44 4942 region INFL806 Light chain variable CR8040 WO2010130636 SEQID NO: 48 4943 region INFL807 Light chain variable CR8041 WO2010130636SEQ ID NO: 52 4944 region INFL808 Light chain variable CR8043WO2010130636 SEQ ID NO: 56 4945 region INFL809 Light chain variableCR8049 WO2010130636 SEQ ID NO: 59 4946 region INFL810 Light chainvariable CR8050 WO2010130636 SEQ ID NO: 63 4947 region INFL811 Lightchain variable CR8052 WO2010130636 SEQ ID NO: 67 4948 region INFL812Light chain variable CR8055 WO2010130636 SEQ ID NO: 71 4949 regionINFL813 Light chain variable CR8057 WO2010130636 SEQ ID NO: 75 4950region INFL814 Light chain variable CR8069 WO2010130636 SEQ ID NO: 794951 region INFL815 Light chain variable CR6255 US20090311265, U.S. Pat.No. 8,691,223, 4952 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ IDNO: 85 INFL816 Light chain variable CR6257 US20090311265, U.S. Pat. No.8,691,223, 4953 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:87 INFL817 Light chain variable CR6260 US20090311265, U.S. Pat. No.8,691,223, 4954 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:89 INFL818 Light chain variable CR6261 US20090311265, U.S. Pat. No.8,691,223, 4955 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:91 INFL819 Light chain variable CR6262 US20090311265, U.S. Pat. No.8,691,223, 4956 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:93 INFL820 Light chain variable CR6268 US20090311265, U.S. Pat. No.8,691,223, 4957 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:95 INFL821 Light chain variable CR6307 US20090311265, U.S. Pat. No.8,691,223, 4958 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:97 INFL822 Light chain variable CR6310 US20090311265, U.S. Pat. No.8,691,223, 4959 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:99 INFL823 Light chain variable CR6314 US20090311265, U.S. Pat. No.8,691,223, 4960 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:101 INFL824 Light chain variable CR6323 US20090311265, U.S. Pat. No.8,691,223, 4961 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:103 INFL825 Light chain variable CR6325 US20090311265, U.S. Pat. No.8,691,223, 4962 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:105 INFL826 Light chain variable CR6331 US20090311265, U.S. Pat. No.8,691,223, 4963 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:107 INFL827 Light chain variable CR6344 US20090311265, U.S. Pat. No.8,691,223, 4964 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:109 INFL828 Light chain variable CR6141 US20090311265, U.S. Pat. No.8,691,223, 4965 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:319 INFL829 Light chain variable CR6272 US20090311265, U.S. Pat. No.8,691,223, 4966 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:323 INFL830 Light chain variable CR6296 US20090311265, U.S. Pat. No.8,691,223, 4967 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:327 INFL831 Light chain variable CR6301 US20090311265, U.S. Pat. No.8,691,223, 4968 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:331 INFL832 Light chain variable CR6327 US20090311265, U.S. Pat. No.8,691,223, 4969 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:335 INFL833 Light chain variable CR6328 US20090311265, U.S. Pat. No.8,691,223, 4970 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:339 INFL834 Light chain variable CR6329 US20090311265, U.S. Pat. No.8,691,223, 4971 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:343 INFL835 Light chain variable CR6332 US20090311265, U.S. Pat. No.8,691,223, 4972 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:347 INFL836 Light chain variable CR6334 US20090311265, U.S. Pat. No.8,691,223, 4973 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:351 INFL837 Light chain variable CR6336 US20090311265, U.S. Pat. No.8,691,223, 4974 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:355 INFL838 Light chain variable CR6339 US20090311265, U.S. Pat. No.8,691,223, 4975 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:359 INFL839 Light chain variable CR6342 US20090311265, U.S. Pat. No.8,691,223, 4976 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:363 INFL840 Light chain variable CR6343 US20090311265, U.S. Pat. No.8,691,223, 4977 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO:367 INFL841 Light chain variable CR9003 US20140120113 SEQ ID NO: 4 4978region INFL842 Light chain variable CR9004 US20140120113 SEQ ID NO: 84979 region INFL843 Light chain variable CR9005 US20140120113 SEQ ID NO:12 4980 region INFL844 Light chain variable CR9006 US20140120113 SEQ IDNO: 16 4981 region INFL845 Light chain variable CR9007 US20140120113 SEQID NO: 20 4982 region INFL846 Light chain variable CR9008 US20140120113SEQ ID NO: 24 4983 region INFL847 Light chain variable CR9009US20140120113 SEQ ID NO: 28 4984 region INFL848 Light chain variableCR9010 US20140120113 SEQ ID NO: 32 4985 region INFL849 Light chainvariable CR9011 US20140120113 SEQ ID NO: 36 4986 region INFL850 Lightchain variable CR9012 US20140120113 SEQ ID NO: 40 4987 region INFL851Light chain variable CR9029 US20140120113 SEQ ID NO: 44 4988 regionINFL852 Light chain variable CR9030 US20140120113 SEQ ID NO: 48 4989region INFL853 Light chain variable CR9031 US20140120113 SEQ ID NO: 524990 region INFL854 Light chain variable CR9112 US20140120113 SEQ ID NO:56 4991 region INFL855 Light chain variable CR9113 US20140120113 SEQ IDNO: 60 4992 region INFL856 Light chain variable CR9114 US20140120113 SEQID NO: 64 4993 region INFL857 Light chain variable CR8033 U.S. Pat. No.8,852,595 SEQ ID NO: 73 4994 region INFL858 Light chain variable CR8059U.S. Pat. No. 8,852,595 SEQ ID NO: 77 4995 region INFL859 Light chainvariable CR8071 U.S. Pat. No. 8,852,595 SEQ ID NO: 79 4996 regionINFL860 Light chain variable CR10051 U.S. Pat. No. 8,852,595 SEQ ID NO:83 4997 region INFL861 Light chain variable CR10049 U.S. Pat. No.8,852,595 SEQ ID NO: 87 4998 region INFL862 Light chain variable CR10023U.S. Pat. No. 8,852,595 SEQ ID NO: 91 4999 region INFL863 Light chainvariable CR10032 U.S. Pat. No. 8,852,595 SEQ ID NO: 95 5000 regionINFL864 Light chain variable CR11035 U.S. Pat. No. 8,852,595 SEQ ID NO:103 5001 region INFL865 Light chain variable CR11036 U.S. Pat. No.8,852,595 SEQ ID NO: 107 5002 region INFL866 Light chain variableCR11038 U.S. Pat. No. 8,852,595 SEQ ID NO: 111 5003 region INFL867 Lightchain variable CR11039 U.S. Pat. No. 8,852,595 SEQ ID NO: 115 5004region INFL868 Light chain variable CR8031 U.S. Pat. No. 8,852,595 SEQID NO: 121 5005 region INFL869 Light chain variable CR8032 U.S. Pat. No.8,852,595 SEQ ID NO: 125 5006 region INFL870 Light chain variable CR8034U.S. Pat. No. 8,852,595 SEQ ID NO: 129 5007 region INFL871 Light chainvariable U.S. Pat. No. 8,992,929 SEQ ID NO: 2 5008 region INFL872 Lightchain variable M2e U.S. Pat. No. 8,420,794 SEQ ID NO: 1 5009 regionINFL873 Light chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQID 5010 region NO: 16 INFL874 Light chain variable U.S. Pat. No.8,715,743, US20140275492 SEQ ID 5011 region NO: 19 INFL875 Light chainvariable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 5012 region NO:32 INFL876 Light chain variable anti-1918 influenza Yu, X., et al.,Neutralizing antibodies 5013 region HA Ig derived from the B cells of1918 influenza pandemic survivors; Nature 455 (7212), 532-536 (2008),NCBI Accession #ACI04582.1 (121aa) INFL877 Light chain variableanti-1918 influenza Yu, X., et al., Neutralizing antibodies 5014 regionHA Ig derived from the B cells of 1918 influenza pandemic survivors;Nature 455 (7212), 532-536 (2008), NCBI Accession #ACI04580.1 (118aa)INFL878 Light chain variable 4D20 Yu, X. et al “Neutralizing antibodies5015 region derived from the B cells of 1918 influenza pandemicsurvivors”, Nature 455 (7212), 532-536, NCBI Accession #ACI04580 INFL879Light chain variable 2B12 Yu, X. et al “Neutralizing antibodies 5016region derived from the B cells of 1918 influenza pandemic survivors”,Nature 455 (7212), 532-536, NCBI Accession #ABY48869 INFL880 Light chainvariable TCN-535 US20150086555 SEQ ID NO: 180 5017 region (5246_P19)INFL881 Light chain variable TCN-536 US20150086555 SEQ ID NO: 191 5018region (5095_N01) INFL882 Light chain variable TCN-537 US20150086555 SEQID NO: 202 5019 region (3194_D21) INFL883 Light chain variable TCN-538US20150086555 SEQ ID NO: 214 5020 region (3206_O17) INFL884 Light chainvariable TCN-539 US20150086555 SEQ ID NO: 226 5021 region (5056_A08)INFL885 Light chain variable TCN-540 US20150086555 SEQ ID NO: 238 5022region (5060_F05) INFL886 Light chain variable TCN-541 US20150086555 SEQID NO: 250 5023 region (5062_M11) INFL887 Light chain variable TCN-542US20150086555 SEQ ID NO: 262 5024 region (5079_A16) INFL888 Light chainvariable TCN-543 US20150086555 SEQ ID NO: 274 5025 region (5081_G23)INFL889 Light chain variable TCN-544 US20150086555 SEQ ID NO: 286 5026region (5082_A19) INFL890 Light chain variable TCN-545 US20150086555 SEQID NO: 298 5027 region (5082_I15) INFL891 Light chain variable TCN-546US20150086555 SEQ ID NO: 309 5028 region (5089_L08) INFL892 Light chainvariable TCN-547 US20150086555 SEQ ID NO: 320 5029 region (5092_F11)INFL893 Light chain variable TCN-548 US20150086555 SEQ ID NO: 331 5030region (5092_P01) INFL894 Light chain variable TCN-549 US20150086555 SEQID NO: 342 5031 region (5092_P04) INFL895 Light chain variable TCN-550US20150086555 SEQ ID NO: 353 5032 region (5096_F06) INFL896 Light chainvariable TCN-551 US20150086555 SEQ ID NO: 365 5033 region (5243_D01)INFL897 Light chain variable TCN-552 US20150086555 SEQ ID NO: 377 5034region (5249_I23) INFL898 Light chain variable TCN-553 US20150086555 SEQID NO: 389 5035 region (5261_C18) INFL899 Light chain variable TCN-554US20150086555 SEQ ID NO: 399 5036 region (5277_M05) INFL900 Light chainvariable TCN-555 US20150086555 SEQ ID NO: 405 5037 region (5246_L16)INFL901 Light chain variable TCN-556 US20150086555 SEQ ID NO: 415 5038region (5089_K12) INFL902 Light chain variable TCN-557 US20150086555 SEQID NO: 427 5039 region (5081_A04) INFL903 Light chain variable TCN-559US20150086555 SEQ ID NO: 441 5040 region (5097_G08) INFL904 Light chainvariable TCN-560 US20150086555 SEQ ID NO: 453 5041 region (5084_P10)INFL905 Light chain variable TCN-564 US20150086555 SEQ ID NO: 519 5042region (5256_A17b) INFL906 Light chain variable CR8001 WO2010130636 SEQID NO: 4 5043 region INFL907 Light chain variable CR8003 WO2010130636SEQ ID NO: 8 5044 region INFL908 Light chain variable CR8015WO2010130636 SEQ ID NO: 12 5045 region INFL909 Light chain variableCR8016 WO2010130636 SEQ ID NO: 16 5046 region INFL910 Light chainvariable CR8017 WO2010130636 SEQ ID NO: 20 5047 region INFL911 Lightchain variable TCN-522 US20150086555 SEQ ID NO: 40 5048 region(3212_I12) INFL912 Light chain variable TCN-521 US20150086555 SEQ ID NO:28 5049 region (3280_D18) INFL913 Light chain variable TCN-523US20150086555 SEQ ID NO: 52 5050 region (5248_A17), TCN-533 (5256_A17a),TCN-534 (5249_B02) INFL914 Light chain variable TCN-563 US20150086555SEQ ID NO: 64 5051 region (5237_B21) INFL915 Light chain variableTCN-526 US20150086555 SEQ ID NO: 76 5052 region (5084_C17) INFL916 Lightchain variable TCN-527 US20150086555 SEQ ID NO: 88 5053 region(5086_C06) INFL917 Light chain variable TCN-528 US20150086555 SEQ ID NO:100 5054 region (5087_P17) INFL918 Light chain variable TCN-529US20150086555 SEQ ID NO: 112 5055 region (5297_H01) INFL919 Light chainvariable TCN-530 US20150086555 SEQ ID NO: 124 5056 region (5248_H10),TCN-558 (5248_H10b) INFL920 Light chain variable TCN-531 US20150086555SEQ ID NO: 136 5057 region (5091_H13) INFL921 Light chain variableTCN-532 US20150086555 SEQ ID NO: 148 5058 region (5262_H18) INFL922Light chain variable TCN-534 US20150086555 SEQ ID NO: 168 5059 region(5249_B02) INFL923 Light chain variable TCN-504 US20150086555 SEQ ID NO:524 5060 region (3251_K17) INFL924 Light chain variable AB1US20120093834, WO2009121004 SEQ 5061 region ID NO: 71 INFL925 Lightchain variable AB2 US20120093834, WO2009121004 SEQ 5062 region ID NO:140 INFL926 Light chain variable AB3 US20120093834, WO2009121004 SEQ5063 region ID NO: 81 INFL927 Light chain variable AB4 US20120093834,WO2009121004 SEQ 5064 region ID NO: 158 INFL928 Light chain variable AB5US20120093834, WO2009121004 SEQ 5065 region ID NO: 159 INFL929 Lightchain variable AB6 US20120093834, WO2009121004 SEQ 5066 region ID NO:160 INFL930 Light chain variable VN04-2 WO2008033105 SEQ ID NO: 6 5067region INFL931 Light chain variable VN04-3 WO2008033105 SEQ ID NO: 85068 region INFL932 Light chain variable 1286-C05 WO2010132604,US20120128671 SEQ 5069 region ID NO: 3 INFL933 Light chain variable1286-C05 WO2010132604, US20120128671 SEQ 5070 region ID NO: 4 INFL934Light chain variable 1286-C05 WO2010132604, US20120128671 SEQ 5071region ID NO: 5 INFL935 Light chain variable 1286-A11 WO2010132604,US20120128671 SEQ 5072 region ID NO: 6 INFL936 Light chain variable IA2WO2015028478 SEQ ID NO: 3 5073 region mouse IgG INFL937 Light chainvariable 7B8 WO2015028478 SEQ ID NO: 5 5074 region mouse IgG INFL938Light chain variable monoclonal U.S. Pat. No. 8,900,590, US2012039899,Grandea, 5075 region, partial antibody TCN-031 A. G. et al., Humanantibodies reveal a protective epitope that is highly conserved amonghuman and nonhuman influenza A viruses; Proc. Natl. Acad. Set. U.S.A.107 (28), 12658-12663 (2010), NCBI Accession #ADK23871.1 (106aa) INFL939Light chain variable monoclonal Grandea, A. G. et al., Human antibodies5076 region, partial antibody TCN-032 reveal a protective epitope thatis highly conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23870.1 (107aa) INFL940 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5077 region, partial antibody 3362_B11reveal a protective epitope that is highly conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession # ADK23886.1 (107aa) INFL941 Lightchain variable monoclonal Grandea, A. G. et al., Human antibodies 5078region, partial antibody reveal a protective epitope that is highly3260_D19 conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23885.1 (106aa) INFL942 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5079 region, partial antibody 3253_P10reveal a protective epitope that is highly conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession #ADK23884.1(107aa) INFL943 Lightchain variable monoclonal Grandea, A. G. et al., Human antibodies 5080region, partial antibody 3248_P18 reveal a protective epitope that ishighly conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23883.1 (106aa) INFL944 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5081 region, partial antibody 3139_P23reveal a protective epitope that is highly conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession #ADK23882.1(107aa) INFL945 Lightchain variable monoclonal Grandea, A. G. et al., Human antibodies 5082region, partial antibody 3420_I23 reveal a protective epitope that ishighly conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23881.1(108aa) INFL946 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5083 region, partial antibody 3255_J06reveal a protective epitope that is highly conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession #ADK23880.1(108aa) INFL947 Lightchain variable monoclonal Grandea, A. G. et al., Human antibodies 5084region, partial antibody 3252_C13 reveal a protective epitope that ishighly conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23879.1 (108aa) INFL948 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5085 region, partial antibody reveal aprotective epitope that is highly 3136_G05 conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession #ADK23878.1 (108aa) INFL949 Lightchain variable monoclonal Grandea, A. G. et al., Human antibodies 5086region, partial antibody reveal a protective epitope that is highly3244_H04 conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23877.1 (107aa) INFL950 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5087 region, partial antibody reveal aprotective epitope that is highly 3245_O19 conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession #ADK23876.1 (107aa) INFL951 Lightchain variable monoclonal Grandea, A. G. et al., Human antibodies 5088region, partial antibody 3259_J21 reveal a protective epitope that ishighly conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23875.1 (107aa) INFL952 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5089 region, partial antibody 3243_J07reveal a protective epitope that is highly conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession #ADK23874.1 (108aa) INFL953 Lightchain variable monoclonal Grandea, A. G. et al., Human antibodies 5090region, partial antibody 3244_I10 reveal a protective epitope that ishighly conserved among human and nonhuman influenza A viruses; Proc.Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession#ADK23873.1 (108aa) INFL954 Light chain variable monoclonal Grandea, A.G. et al., Human antibodies 5091 region, partial antibody reveal aprotective epitope that is highly 3241_G23 conserved among human andnonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28),12658-12663 (2010), NCBI Accession #ADK23872.1 (108aa) INFL955 Lightchain variable 100F4-LV Hu, H., et al., A Human Antibody 5092 region,partial Recognizing a Conserved Epitope of H5 Hemagglutinin BroadlyNeutralizes Highly Pathogenic Avian Influenza H5N1 Viruses; J. Virol. 86(6), 2978- 2989 (2012), NCBI Accession #AEL30604.1 (112aa) INFL956 LightChain, Fab ch65 Whittle, J. R. et al., Broadly neutralizing 5093Fragment human antibody that recognizes the receptor-binding pocket ofinfluenza virus hemagglutinin; Proc. Natl. Acad. Sci. U.S.A. 108 (34),14216-14221 (2011), NCBI Accession #3SM5_L INFL957 Light chain 1I20WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 5094 NO: 6 INFL958 Lightchain WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 5095 NO: 12 INFL959Monoclonal antibody Neutralizing Wu, Y. et al., A potent broad-spectrum5096 heavy chain Human protective human monoclonal antibody Monoclonalcrosslinking two hemagglutinin Antibody With monomers of influenza Avirus; Nat 1968 H3 Ha Commun 6, 7708 (2015), NCBI Accession #4UBD_CINFL960 Monoclonal antibody Neutralizing Wu, Y. et al., A potentbroad-spectrum 5097 light chain Human protective human monoclonalantibody Monoclonal crosslinking two hemagglutinin Antibody Withmonomers of influenza A virus; Nat 1968 H3 Ha Commun 6, 7708 (2015),NCBI Accession #4UBD_D INFL961 Mutated heavy chain 8G9 mutated U.S. Pat.No. 8,603,467 SEQ ID NO: 42 5098 variable INFL962 Mutated heavy chain13D4 mutated U.S. Pat. No. 8,603,467 SEQ ID NO: 46 5099 variable (VH-LV)INFL963 Mutated heavy chain 13D4 mutated U.S. Pat. No. 8,603,467 SEQ IDNO: 44 5100 variable (VH-SV) INFL964 Nanobody 202-C8 US20110182897,WO2009147248 SEQ 5101 ID NO: 138 INFL965 Nanobody 203-B12 US20110182897,WO2009147248 SEQ 5102 ID NO: 2439 INFL966 Nanobody 203-H9 US20110182897,WO2009147248 SEQ 5103 ID NO: 2445 INFL967 Scfv JM7_B-G7 WO2012072788 SEQID NO: 7 5104 INFL968 Scfv JM7_S-F8 WO2012072788 SEQ ID NO: 15 5105INFL969 Scfv JM7JH-F1 WO2012072788 SEQ ID NO: 17 5106 INFL970 ScfvJM7_S-A9 WO2012072788 SEQ ID NO: 19 5107 INFL971 Scfv JM7_S-A10WO2012072788 SEQ ID NO: 21 5108 INFL972 Scfv JM7_B-H WO2012072788 SEQ IDNO: 23 5109 INFL973 Scfv JM6_SC-H1 WO2012072788 SEQ ID NO: 25 5110INFL974 Scfv jM6_SC_D3 WO2012072788 SEQ ID NO: 27 5111 INFL975 ScfvH2526 Schmidt, A. G. et al., Viral receptor- 5112 binding siteantibodies with diverse germline origins; Cell 161 (5), 1026- 1034(2015), NCBI Accession #4YJZ_L INFL976 Scfv fragment AVC4 WO2010040572A2FIG. 6 5113 INFL977 Scfv fragment AVD1 WO2010040572A2 FIG. 8 5114INFL978 Scfv fragment AVE2 WO2010040572A2 FIG. 10 5115 INFL979 Scfvfragment AVA6 WO2010040572A2 FIG. 12 5116 INFL980 Scfv fragment AVG4WO2010040572A2 FIG. 14 5117 INFL981 Scfv heavy chain SC06-141US20150104459 SEQ ID NO: 309 5118 variable region INFL982 Scfv heavychain SC06-255 US20150104459 SEQ ID NO: 313 5119 variable region INFL983Scfv heavy chain SC06-257 US20150104459 SEQ ID NO: 317 5120 variableregion INFL984 Scfv heavy chain SC6-260 US20150104459 SEQ ID NO: 3215121 variable region INFL985 Scfv heavy chain SC06-261 US20150104459 SEQID NO: 325 5122 variable region INFL986 Scfv heavy chain SC06-262US20150104459 SEQ ID NO: 329 5123 variable region INFL987 Scfv heavychain SC06-268 US20150104459 SEQ ID NO: 333 5124 variable region INFL988Scfv heavy chain SC06-272 US20150104459 SEQ ID NO: 337 5125 variableregion INFL989 Scfv heavy chain SC06-296 US20150104459 SEQ ID NO: 3415126 variable region INFL990 Scfv heavy chain SC06-301 US20150104459 SEQID NO: 345 5127 variable region INFL991 Scfv heavy chain SC06-307US20150104459 SEQ ID NO: 349 5128 variable region INFL992 Scfv heavychain SC06-310 US20150104459 SEQ ID NO: 353 5129 variable region INFL993Scfv heavy chain SC06-314 US20150104459 SEQ ID NO: 357 5130 variableregion INFL994 Scfv heavy chain SC06-323 US20150104459 SEQ ID NO: 3615131 variable region INFL995 Scfv heavy chain SC06-325 US20150104459 SEQID NO: 365 5132 variable region INFL996 Scfv heavy chain SC06-327US20150104459 SEQ ID NO: 369 5133 variable region INFL997 Scfv heavychain SC06-328 US20150104459 SEQ ID NO: 373 5134 variable region INFL998Scfv heavy chain SC06-329 US20150104459 SEQ ID NO: 377 5135 variableregion INFL999 Scfv heavy chain SC06-331 US20150104459 SEQ ID NO: 3815136 variable region INFL1000 Scfv heavy chain SC06-332 US20150104459SEQ ID NO: 385 5137 variable region INFL1001 Scfv heavy chain SC06-334US20150104459 SEQ ID NO: 389 5138 variable region INFL1002 Scfv heavychain SC06-336 US20150104459 SEQ ID NO: 393 5139 variable regionINFL1003 Scfv heavy chain SC06-339 US20150104459 SEQ ID NO: 397 5140variable region INFL1004 Scfv heavy chain SC06-342 US20150104459 SEQ IDNO: 401 5141 variable region INFL1005 Scfv heavy chain SC06-343US20150104459 SEQ ID NO: 405 5142 variable region INFL1006 Scfv heavychain SC06-344 US20150104459 SEQ ID NO: 409 5143 variable regionINFL1007 Scfv heavy chain CR6255 US20150104459 SEQ ID NO: 417 5144variable region INFL1008 Scfv heavy chain CR6257 US20150104459 SEQ IDNO: 423 5145 variable region INFL1009 Scfv heavy chain CR6260US20150104459 SEQ ID NO: 429 5146 variable region INFL1010 Scfv heavychain CR6261 US20150104459 SEQ ID NO: 435 5147 variable region INFL1011Scfv heavy chain CR6262 US20150104459 SEQ ID NO: 441 5148 variableregion INFL1012 Scfv heavy chain CR6268 US20150104459 SEQ ID NO: 4475149 variable region INFL1013 Scfv heavy chain CR6272 US20150104459 SEQID NO: 453 5150 variable region INFL1014 Scfv heavy chain CR696US20150104459 SEQ ID NO: 459 5151 variable region INFL1015 Scfv heavychain CR6301 US20150104459 SEQ ID NO: 465 5152 variable region INFL1016Scfv heavy chain CR6307 US20150104459 SEQ ID NO: 471 5153 variableregion INFL1017 Scfv heavy chain CR6310 US20150104459 SEQ ID NO: 4775154 variable region INFL1018 Scfv heavy chain CR6314 US20150104459 SEQID NO: 483 5155 variable region INFL1019 Scfv heavy chain CR6323US20150104459 SEQ ID NO: 489 5156 variable region INFL1020 Scfv heavychain CR6325 US20150104459 SEQ ID NO: 495 5157 variable region INFL1021Scfv heavy chain CR6327 US20150104459 SEQ ID NO: 501 5158 variableregion INFL1022 Scfv heavy chain CR6328 US20150104459 SEQ ID NO: 5075159 variable region INFL1023 Scfv heavy chain CR6329 US20150104459 SEQID NO: 513 5160 variable region INFL1024 Scfv heavy chain CR6331US20150104459 SEQ ID NO: 519 5161 variable region INFL1025 Scfv heavychain CR6332 US20150104459 SEQ ID NO: 525 5162 variable region INFL1026Scfv heavy chain CR6334 US20150104459 SEQ ID NO: 531 5163 variableregion INFL1027 Scfv heavy chain CR6336 US20150104459 SEQ ID NO: 5375164 variable region INFL1028 Scfv heavy chain CR6339 US20150104459 SEQID NO: 543 5165 variable region INFL1029 Scfv heavy chain CR6342US20150104459 SEQ ID NO: 550 5166 variable region INFL1030 Scfv heavychain CR6343 US20150104459 SEQ ID NO: 556 5167 variable region INFL1031Scfv heavy chain CR6344 US20150104459 SEQ ID NO: 562 5168 variableregion INFL1032 Scfv light chain SC06-141 US20150104459 SEQ ID NO: 3105169 variable region INFL1033 Scfv light chain SC06-255 US20150104459SEQ ID NO: 314 5170 variable region INFL1034 Scfv light chain SC06-257US20150104459 SEQ ID NO: 318 5171 variable region INFL1035 Scfv lightchain SC6-260 US20150104459 SEQ ID NO: 322 5172 variable region INFL1036Scfv light chain SC06-261 US20150104459 SEQ ID NO: 326 5173 variableregion INFL1037 Scfv light chain SC06-262 US20150104459 SEQ ID NO: 3305174 variable region INFL1038 Scfv light chain SC06-268 US20150104459SEQ ID NO: 334 5175 variable region INFL1039 Scfv light chain SC06-272US20150104459 SEQ ID NO: 338 5176 variable region INFL1040 Scfv lightchain SC06-296 US20150104459 SEQ ID NO: 342 5177 variable regionINFL1041 Scfv light chain SC06-301 US20150104459 SEQ ID NO: 346 5178variable region INFL1042 Scfv light chain SC06-307 US20150104459 SEQ IDNO: 350 5179 variable region INFL1043 Scfv light chain SC06-310US20150104459 SEQ ID NO: 354 5180 variable region INFL1044 Scfv lightchain SC06-314 US20150104459 SEQ ID NO: 358 5181 variable regionINFL1045 Scfv light chain SC06-323 US20150104459 SEQ ID NO: 362 5182variable region INFL1046 Scfv light chain SC06-325 US20150104459 SEQ IDNO: 366 5183 variable region INFL1047 Scfv light chain SC06-327US20150104459 SEQ ID NO: 370 5184 variable region INFL1048 Scfv lightchain SC06-328 US20150104459 SEQ ID NO: 374 5185 variable regionINFL1049 Scfv light chain SC06-329 US20150104459 SEQ ID NO: 378 5186variable region INFL1050 Scfv light chain SC06-331 US20150104459 SEQ IDNO: 382 5187 variable region INFL1051 Scfv light chain SC06-332US20150104459 SEQ ID NO: 386 5188 variable region INFL1052 Scfv lightchain SC06-334 US20150104459 SEQ ID NO: 390 5189 variable regionINFL1053 Scfv light chain SC06-336 US20150104459 SEQ ID NO: 394 5190variable region INFL1054 Scfv light chain SC06-339 US20150104459 SEQ IDNO: 398 5191 variable region INFL1055 Scfv light chain SC06-342US20150104459 SEQ ID NO: 402 5192 variable region INFL1056 Scfv lightchain SC06-343 US20150104459 SEQ ID NO: 406 5193 variable regionINFL1057 Scfv light chain SC06-344 US20150104459 SEQ ID NO: 410 5194variable region INFL1058 Scfv light chain CR6141 US20150104459 SEQ IDNO: 414 5195 variable region INFL1059 Scfv light chain CR6255US20150104459 SEQ ID NO: 420 5196 variable region INFL1060 Scfv lightchain CR6257 US20150104459 SEQ ID NO: 426 5197 variable region INFL1061Scfv light chain CR6260 US20150104459 SEQ ID NO: 432 5198 variableregion INFL1062 Scfv light chain CR6261 US20150104459 SEQ ID NO: 4385199 variable region INFL1063 Scfv light chain CR6262 US20150104459 SEQID NO: 444 5200 variable region INFL1064 Scfv light chain CR6268US20150104459 SEQ ID NO: 450 5201 variable region INFL1065 Scfv lightchain CR6272 US20150104459 SEQ ID NO: 456 5202 variable region INFL1066Scfv light chain CR696 US20150104459 SEQ ID NO: 462 5203 variable regionINFL1067 Scfv light chain CR6301 US20150104459 SEQ ID NO: 468 5204variable region INFL1068 Scfv light chain CR6307 US20150104459 SEQ IDNO: 474 5205 variable region INFL1069 Scfv light chain CR6310US20150104459 SEQ ID NO: 480 5206 variable region INFL1070 Scfv lightchain CR6314 US20150104459 SEQ ID NO: 486 5207 variable region INFL1071Scfv light chain CR6323 US20150104459 SEQ ID NO: 492 5208 variableregion INFL1072 Scfv light chain CR6325 US20150104459 SEQ ID NO: 4985209 variable region INFL1073 Scfv light chain CR6327 US20150104459 SEQID NO: 504 5210 variable region INFL1074 Scfv light chain CR6328US20150104459 SEQ ID NO: 510 5211 variable region INFL1075 Scfv lightchain CR6329 US20150104459 SEQ ID NO: 516 5212 variable region INFL1076Scfv light chain CR6331 US20150104459 SEQ ID NO: 522 5213 variableregion INFL1077 Scfv light chain CR6332 US20150104459 SEQ ID NO: 5285214 variable region INFL1078 Scfv light chain CR6334 US20150104459 SEQID NO: 534 5215 variable region INFL1079 Scfv light chain CR6336US20150104459 SEQ ID NO: 540 5216 variable region INFL1080 Scfv lightchain CR6339 US20150104459 SEQ ID NO: 547 5217 variable region INFL1081Scfv light chain CR6342 US20150104459 SEQ ID NO: 553 5218 variableregion INFL1082 Scfv light chain CR6343 US20150104459 SEQ ID NO: 5595219 variable region INFL1083 Scfv light chain CR6344 US20150104459 SEQID NO: 565 5220 variable region INFL1084 Vhch antibody 641 I-9 Schmidt,A. G. et al., Viral receptor- 5221 binding site antibodies with diversegermline origins; Cell 161 (5), 1026- 1034 (2015), NCBI Accession#4YK4_Z INFL1085 Vlcl antibody 641 I-9 Schmidt, A. G. et al., Viralreceptor- 5222 binding site antibodies with diverse germline origins;Cell 161 (5), 1026- 1034 (2015), NCBI Accession #4YK4_Y

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inU.S. Pat. Nos. 8,003,106 and 8,540,995. International Patent PublicationNo. WO2015028478, WO02012045001. US Publication No. US20150239960 andUS20130251715, the contents of each of which are herein incorporated byreference in their entirety, against influenza.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 22 against Respiratory SyncytialVirus.

TABLE 22 Antibodies against Respiratory Syncytial Virus Antibody SEQ IDNo. Description Antibody Name Reference Information NO RSV1 Heavy chainvariable, F and G clone 888 US20110189171; 5223 Proteins US7879329SEQ IDNO: 43 RSV2 Heavy chain variable, F and G mAb 824 US20110189171;US7879329 5224 Proteins SEQ ID NO: 178 RSV3 Heavy chain variable, F andG clone 735 US20110189171; US7879329 5225 Proteins SEQ ID NO: 1 RSV4Heavy chain variable, F and G clone 736 US20110189171; US7879329 5226Proteins SEQ ID NO: 2 RSV5 Heavy chain variable, F and G clone 744US20110189171; US7879329 5227 Proteins SEQ ID NO: 3 RSV6 Heavy chainvariable, F and G clone 793 US20110189171; US7879329 5228 Proteins SEQID NO: 4 RSV7 Heavy chain variable, F and G clone 795 US20110189171;US7879329 5229 Proteins SEQ ID NO: 5 RSV8 Heavy chain variable, F and Gclone 796 US2011018917; US7879329 5230 Proteins SEQ ID NO: 6 RSV9 Heavychain variable, F and G clone 799 US20110189171; US7879329 5231 ProteinsSEQ ID NO: 7 RSV10 Heavy chain variable, F and G clone 800US20110189171; US7879329 5232 Proteins SEQ ID NO: 8 RSV11 Heavy chainvariable, F and G clone 801 US20110189171; US7879329 5233 Proteins SEQID NO: 9 RSV12 Heavy chain variable, F and G clone 804 US20110189171;US7879329 5234 Proteins SEQ ID NO: 10 RSV13 Heavy chain variable, F andG clone 810 US20110189171; US7879329 5235 Proteins SEQ ID NO: 11 RSV14Heavy chain variable, F and G clone 811 US20110189171; US7879329 5236Proteins SEQ ID NO: 12 RSV15 Heavy chain variable, F and G clone 812US20110189171; US7879329 5237 Proteins SEQ ID NO: 13 RSV16 Heavy chainvariable, F and G clone 814 US20110189171; US7879329 5238 Proteins SEQID NO: 14 RSV17 Heavy chain variable, F and G clone 816 US20110189171;US7879329 5239 Proteins SEQ ID NO: 15 RSV18 Heavy chain variable, F andG clone 817 US20110189171; US7879329 5240 Proteins SEQ ID NO: 16 RSV19Heavy chain variable, F and G clone 818 US20110189171; US7879329 5241Proteins SEQ ID NO: 17 RSV20 Heavy chain variable, F and G clone 819US20110189171; US7879329 5242 Proteins SEQ ID NO: 18 RSV21 Heavy chainvariable, F and G clone 824 US20110189171; US7879329 5243 Proteins SEQID NO: 19 RSV22 Heavy chain variable, F and G clone 825 US20110189171;US7879329 5244 Proteins SEQ ID NO: 20 RSV23 Heavy chain variable, F andG clone 827 US20110189171; US7879329 5245 Proteins SEQ ID NO: 21 RSV24Heavy chain variable, F and G clone 829 US20110189171; US7879329 5246Proteins SEQ ID NO: 22 RSV25 Heavy chain variable, F and G clone 830US20110189171; US7879329 5247 Proteins SEQ ID NO: 23 RSV26 Heavy chainvariable, F and G clone 831 US20110189171; US7879329 5248 Proteins SEQID NO: 24 RSV27 Heavy chain variable, F and G clone 835 US20110189171;US7879329 5249 Proteins SEQ ID NO: 25 RSV28 Heavy chain variable, F andG clone 838 US20110189171; US7879329 5250 Proteins SEQ ID NO: 26 RSV29Heavy chain variable, F and G clone 841 US20110189171; US7879329 5251Proteins SEQ ID NO: 27 RSV30 Heavy chain variable, F and G clone 853US20110189171; US7879329 5252 Proteins SEQ ID NO: 28 RSV31 Heavy chainvariable, F and G clone 855 US20110189171; US7879329 5253 Proteins SEQID NO: 29 RSV32 Heavy chain variable, F and G clone 856 US20110189171;US7879329 5254 Proteins SEQ ID NO: 30 RSV33 Heavy chain variable, F andG clone 857 US20110189171; US7879329 5255 Proteins SEQ ID NO: 31 RSV34Heavy chain variable, F and G clone 858 US20110189171; US7879329 5256Proteins SEQ ID NO: 32 RSV35 Heavy chain variable, F and G clone 859US20110189171; US7879329 5257 Proteins SEQ ID NO: 33 RSV36 Heavy chainvariable, F and G clone 861 US20110189171; US7879329 5258 Proteins SEQID NO: 34 RSV37 Heavy chain variable, F and G clone 863 US20110189171;US7879329 5259 Proteins SEQ ID NO: 35 RSV38 Heavy chain variable, F andG clone 868 US20110189171; US7879329 5260 Proteins SEQ ID NO: 36 RSV39Heavy chain variable, F and G clone 870 US20110189171; US7879329 5261Proteins SEQ ID NO: 37 RSV40 Heavy chain variable, F and G clone 871US20110189171; US7879329 5262 Proteins SEQ ID NO: 38 RSV41 Heavy chainvariable, F and G clone 880 US20110189171; US7879329 5263 Proteins SEQID NO: 39 RSV42 Heavy chain variable, F and G clone 881 US20110189171;US7879329 5264 Proteins SEQ ID NO: 40 RSV43 Heavy chain variable, F andG clone 884 US20110189171; US7879329 5265 Proteins SEQ ID NO: 41 RSV44Heavy chain variable, F and G clone 886 US20110189171; US7879329 5266Proteins SEQ ID NO: 42 RSV45 Heavy chain variable, F and G clone 894US20110189171; US7879329 5267 Proteins SEQ ID NO: 44 RSV46 heavy chainvariable, F protein 3210 variant 1 WO2013140247 SEQ ID NO: 5268 of RSV,MPV, or PVM  13 RSV47 heavy chain variable, F protein 3210 variant 2,WO2013140247 SEQ ID NO: 5269 of RSV, MPV, or PVM 3210 variant 3,  173210 variant 6 RSV48 heavy chain variable, F protein 2430 variant 1WO2013140247 SEQ ID NO: 5270 of RSV, MPV, or PVM  29 RSV49 heavy chainvariable, F protein 2430 variant 2, WO2013140247 SEQ ID NO: 5271 of RSV,MPV, or PVM 2430 variant 5  33 RSV50 heavy chain variable, F protein3210 variant 4, WO2013140247 SEQ ID NO: 5272 of RSV, MPV, or PVM 3210variant 5  49 RSV51 heavy chain variable, F protein 2430 variant 3,WO2013140247 SEQ ID NO: 5273 of RSV, MPV, or PVM 2430 variant 4  59RSV52 Heavy chain variable, CDR US20140093501 SEQ ID NO: 5274 Grafted, FProtein,  31 RSV53 Heavy chain, F Protein AM22 US8568726 SEQ ID NO: 165275 RSV54 Heavy chain, F Protein RSVF2-5 US8221759 SEQ ID NO: 1 5276RSV55 Heavy chain, F Protein EP1259547; US8153133 SEQ 5277 ID NO: 4RSV56 Heavy chain, F Protein MEDI- EP1259547; US8153133 SEQ 5278493/Pavitizumab- ID NO: 2 N-VL (Brand name Synagis) RSV57 Heavy chain, FProtein EP1259547; US8153133 SEQ 5279 ID NO: 36 RSV58 Heavy chain, FProtein clone 18 EP1259547; US8153133 SEQ 5280 ID NO: 37 RSV59 Heavychain, F Protein clone 19 EP1259547; US8153133 SEQ 5281 ID NO: 39 RSV60Heavy chain, F Protein clone 20 EP1259547; US8153133 SEQ 5282 ID NO: 41RSV61 Heavy chain, F Protein clone 21 EP1259547; US8153133 SEQ 5283 IDNO: 43 RSV62 Heavy chain, F Protein clone 22 EP1259547; US8153133 SEQ5284 ID NO: 45 RSV63 Heavy chain, F Protein clone 23 EP1259547;US8153133 SEQ 5285 ID NO: 47 RSV64 Heavy chain, F Protein clone 24EP1259547; US8153133 SEQ 5286 ID NO: 49 RSV65 Heavy chain, F Proteinclone 25 EP1259547; US8153133 SEQ 5287 ID NO: 51 RSV66 Heavy chain, FProtein clone 26 EP1259547; US8153133 SEQ 5288 ID NO: 53 RSV67 Heavychain variable region, F US20140093501 SEQ ID NO: 5289 Protein  17 RSV68Heavy chain variable region, F MAb1308F US20140093501 SEQ ID NO: 5290Protein  18 RSV69 Heavy chain variable region, F huCOR US20140093501 SEQID NO: 5291 Protein  30 RSV70 Heavy chain variable region, F MAb1129US20140093501 SEQ ID NO: 5292 Protein  32 RSV71 Heavy chain variableregion, F RSV G8 US7867497 SEQ ID NO: 2 5293 Protein RSV72 Heavy chainvariable region, F Clone 1 US20120135006 SEQ ID NO: 5294 Protein  18RSV73 Heavy chain variable region, F Clone 2 US20120135006 SEQ ID NO:5295 Protein  20 RSV74 Heavy chain variable region, F Clone 3US20120135006 SEQ ID NO: 5296 Protein  22 RSV75 Heavy chain variableregion, F Clone 22 US20120135006 SEQ ID NO: 5297 Protein  24 RSV76 Heavychain variable region, F Clone 23 US20120135006 SEQ ID NO: 5298 Protein 26 RSV77 Heavy chain variable region, F RSV13-9 WO2009088159 SEQ ID NO:4 5299 Protein RSV78 HV3 heavy chain variable, F US20140093501 SEQ IDNO: 5300 Protein  16 RSV79 Constant heavy region, F B4HuVK EP636182;WO1993020210; 5301 protein SEQ ID NO: 6 RSV80 Constant heavy region, FB13/B14HuVK EP636182; WO1993020210; 5302 protein SEQ ID NO: 8 RSV81Heavy chain, F protein 58c5 US20140044719 SEQ ID NO: 1 5303 RSV82 Heavychain, F protein sc5 US20140044719 SEQ ID NO: 9 5304 RSV83 Heavy chain,F protein US20110027294 SEQ ID NO: 5305  74 RSV84 Heavy chain, F proteinUS20110027294 SEQ ID NO: 5306  75 RSV85 Heavy chain, F proteinUS20110027294 SEQ ID NO: 5307  76 RSV86 Heavy chain, F proteinUS20110027294 SEQ ID NO: 5308  77 RSV87 Heavy chain, F proteinUS20110027294 SEQ ID NO: 5309  78 RSV88 Heavy chain, F proteinUS20110027294 SEQ ID NO: 5310  79 RSV89 Heavy chain, F proteinUS20110027294 SEQ ID NO: 531,1  80 RSV90 Heavy chain, F protein Gλ-1US20050175986 SEQ ID NO: 5 5312 RSV91 Heavy chain, F protein A constructUS20050175986 SEQ ID NO: 7 5313 RSV92 Heavy chain, F protein B constructUS200501,75986 SEQ ID NO: 8 5314 RSV93 Heavy chain, F protein hu19AUS20050019758; 5315 WO1998019704 SEQ ID NO: 5 RSV94 Heavy chain, Fprotein hu19B US20050019758; 5316 WO1998019704 SEQ ID NO: 6 RSV95 Heavychain, F protein hu19C US20050019758; 5317 WO1998019704 SEQ ID NO: 7RSV96 Heavy chain, F protein hu19D US20050019758; 5318 WO1998019704 SEQID NO: 8 RSV97 Heavy chain, F protein B4HuVH EP636182; WO1993020210;5319 SEQ ID NO: 5 RSV98 Heavy chain, F protein B13/B14HuVK EP636182;WO1993020210; 5320 SEQ ID NO: 7 RSV99 Heavy chain, F protein RSV19EP636182; WO1993020210; 5321 SEQ ID NO: 10 RSV100 Heavy chain, F proteinWO19922004381 5322 RSV101 Heavy chain, F protein WO19922004381 5323RSV102 Heavy chain variable region, F P1212 US20140044719 SEQ ID NO:5324 Protein  122 RSV103 Heavy chain variable region, F P12f4US20140044719 SEQ ID NO: 5325 Protein  131 RSV104 Heavy chain variableregion, F P11d4 US20140044719 SEQ ID NO: 5326 Protein  137 RSV105 Heavychain variable region, F A1e9 US20140044719 SEQ ID NO: 5327 Protein  144RSV106 Heavy chain variable region, F A12a6 US20140044719 SEQ ID NO:5328 Protein  149 RSV107 Heavy chain variable region, F A13c4US20140044719 SEQ ID NO: 5329 Protein  155 RSV108 Heavy chain variableregion, F A17d4 US20140044719 SEQ ID NO: 5330 Protein  161 RSV109 Heavychain variable region, F A4B4 US20140044719 SEQ ID NO: 5331 Protein  167RSV110 Heavy chain variable region, F A8c7 US20140044719 SEQ ID NO: 5332Protein  172 RSV111 Heavy chain variable region, F IX-493L1RUS20140044719 SEQ ID NO: 5333 Protein  176 RSV112 Heavy chain variableregion, F M3H9 US20140044719 SEQ ID NO: 5334 Protein  181 RSV113 Heavychain variable region, F B21M US20110027294 SEQ ID NO: 5335 Protein  49RSV114 Heavy chain variable region, F 101F US20110027294 SEQ ID NO: 45336 Protein RSV115 Heavy chain variable region, F HNK20 EP1720908;WO2005079479 5337 Protein SEQ ID NO: 1 RSV116 Heavy chain variableregion, F P1212 US20140044719 SEQ ID NO: 5338 Protein  123 RSV117 Heavychain variable region, F P12f4 US20140044719 SEQ ID NO: 5339 Protein 132 RSV118 Heavy chain variable region, F P11d4 US20140044719 SEQ IDNO: 5340 Protein  138 RSV119 Heavy chain variable region, F A1e9US20140044719 SEQ ID NO: 5341 Protein  145 RSV120 Heavy chain variableregion, F A12a6 US20140044719 SEQ ID NO: 5342 Protein  150 RSV121 Heavychain variable region, F A13c4 US20140044719 SEQ ID NO: 5343 Protein 156 RSV122 Heavy chain variable region, F A17d4 US20140044719 SEQ IDNO: 5344 Protein  162 RSV123 Heavy chain variable region, F A4B4US20140044719 SEQ ID NO: 5345 Protein  168 RSV124 Heavy chain variableregion, F A8c7 US20140044719 SEQ ID NO: 5346 Protein  173 RSV125 Heavychain variable region, F IX-493L1FR US20140044719 SEQ ID NO: 5347Protein  177 RSV126 Heavy chain variable region, F H1 H3564PWO2014159822 SEQ ID NO: 2 5348 Protein RSV127 Heavy chain variableregion, F H1 H3565P WO2014159822 SEQ ID NO: 5349 Protein  18 RSV128Heavy chain variable region, F H1 H3566P WO2014159822 SEQ ID NO: 5350Protein  34 RSV129 Heavy chain variable region, F H1 H3567P WO2014159822SEQ ID NO: 5351 Protein  50 RSV130 Heavy chain variable region, F H1H3581P WO2014159822 SEQ ID NO: 5352 Protein  66 RSV131 Heavy chainvariable region, F H1 H3583P WO2014159822 SEQ ID NO: 5353 Protein  82RSV132 Heavy chain variable region, F H1 H3589P WO2014159822 SEQ ID NO:5354 Protein  98 RSV133 Heavy chain variable region, F H1 H3591 PWO2014159822 SEQ ID NO: 5355 Protein  114 RSV134 Heavy chain variableregion, F H1 H3592P WO2014159822 SEQ ID NO: 5356 Protein  130 RSV135Heavy chain variable region, F H1 H3597P WO2014159822 SEQ ID NO: 5357Protein  146 RSV136 Heavy chain variable region, F H1 H3598PWO2014159822 SEQ ID NO: 5358 Protein  162 RSV137 Heavy chain variableregion, F H1 H3603P WO2014159822 SEQ ID NO: 5359 Protein  178 RSV138Heavy chain variable region, F H1 H3604P WO2014159822 SEQ ID NO: 5360Protein  194 RSV139 Heavy chain variable region, F H1 H3605PWO2014159822 SEQ ID NO: 5361 Protein  210 RSV140 Heavy chain variableregion, F H1 H3607P WO2014159822 SEQ ID NO: 5362 Protein  226 RSV141Heavy chain variable region, F H1 H3608P2 WO2014159822 SEQ ID NO: 5363Protein  242 RSV142 Heavy chain variable region, F H1 H3592P2WO2014159822 SEQ ID NO: 5364 Protein  258 RSV143 Heavy chain variableregion, F H1 H3592P3 WO2014159822 SEQ ID NO: 5365 Protein  274 RSV144Heavy chain variable region, F H1 M3621 N WO2014159822 SEQ ID NO: 5366Protein  290 RSV145 Heavy chain variable region, F H1 M3622NWO2014159822 SEQ ID NO: 5367 Protein  306 RSV146 Heavy chain variableregion, F H1 M2634N WO2014159822 SEQ ID NO: 5368 Protein  322 RSV147Heavy chain variable region, F H1 M3627N WO2014159822 SEQ ID NO: 5369Protein  338 RSV148 Heavy chain variable region, F Clone No. 735US20120009623 SEQ ID NO: 1 5370 Protein RSV149 Heavy chain variableregion, F Clone No. 736 US20120009623 SEQ ID NO: 2 5371 Protein RSV150Heavy chain variable region, F Clone No. 744 US20120009623 SEQ ID NO: 35372 Protein RSV151 Heavy chain variable region, F Clone No. 793US20120009623 SEQ ID NO: 4 5373 Protein RSV152 Heavy chain variableregion, F Clone No. 795 US21120009623 SEQ ID NO: 5 5374 Protein RSV153Heavy chain variable region, F Clone No. 796 US20120009623 SEQ ID NO: 65375 Protein RSV154 Heavy chain variable region, F Clone No. 799US20120009623 SEQ ID NO: 7 5376 Protein RSV155 Heavy chain variableregion, F Clone No. 800 US20120009623 SEQ ID NO: 8 5377 Protein RSV156Heavy chain variable region, F Clone No. 801 US20120009623 SEQ ID NO: 95378 Protein RSV157 Heavy chain variable region, F Clone No. 804US20120009623 SEQ ID NO: 5379 Protein  10 RSV158 Heavy chain variableregion, F Clone No. 810 US20120009623 SEQ ID NO: 5380 Protein  11 RSV159Heavy chain variable region, F Clone No. 811 US20120009623 SEQ ID NO:5381 Protein  12 RSV160 Heavy chain variable region, F Clone No. 812US20120009623 SEQ ID NO: 5382 Protein  13 RSV161 Heavy chain variableregion, F Clone No. 814 US20120009623 SEQ ID NO: 5383 Protein  14 RSV162Heavy chain variable region, F Clone No. 816 US20120009623 SEQ ID NO:5384 Protein  15 RSV163 Heavy chain variable region, F Clone No. 817US20120009623 SEQ ID NO: 5385 Protein  16 RSV164 Heavy chain variableregion, F Clone No. 818 US20120009613 SEQ ID NO: 5386 Protein  17 RSV165Heavy chain variable region, F Clone No. 819 US20120009 23 SEQ ID NO:5387 Protein  18 RSV166 Heavy chain variable region, F Clone No. 824US20120009623 SEQ ID NO: 5388 Protein  19 RSV167 Heavy chain variableregion, F Clone No. 825 US20120009623 SEQ ID NO: 5389 Protein  20 RSV168Heavy chain variable region, F Clone No. 827 US20120009623 SEQ ID NO:5390 Protein  21 RSV169 Heavy chain variable region, F Clone No. 829US20120009623 SEQ ID NO: 5391 Protein  22 RSV170 Heavy chain variableregion, F Clone No. 830 US20120009623 SEQ ID NO: 5392 Protein  23 RSV171Heavy chain variable region, F Clone No. 831 US20120009623 SEQ ID NO:5393 Protein  24 RSV172 Heavy chain variable region, F Clone No. 835US20120009623 SEQ ID NO: 5394 Protein  25 RSV173 Heavy chain variableregion, F Clone No. 838 US20120009623 SEQ ID NO: 5395 Protein  26 RSV174Heavy chain variable region, F Clone No. 841 US20120009623 SEQ ID NO:5396 Protein  27 RSV175 Heavy chain variable region, F Clone No. 853US20120009623 SEQ ID NO: 5397 Protein  28 RSV176 Heavy chain variableregion, F Clone No. 855 US20120009623 SEQ ID NO: 5398 Protein  29 RSV177Heavy chain variable region, F Clone No. 856 US20120009623 SEQ ID NO:5399 Protein  30 RSV178 Heavy chain variable region, F Clone No. 857US20120009623 SEQ ID NO: 5400 Protein  31 RSV179 Heavy chain variableregion, F Clone No. 858 US20120009623 SEQ ID NO: 5401 Protein  32 RSV180Heavy chain variable region, F Clone No. 859 US20120009623 SEQ ID NO:5402 Protein  33 RSV181 Heavy chain variable region, F Clone No. 861US20120009623 SEQ ID NO: 5403 Protein  34 RSV182 Heavy chain variableregion, F Clone No. 863 US20120009623 SEQ ID NO: 5404 Protein  35 RSV183Heavy chain variable region, F Clone No. 868 US20120009623 SEQ ID NO:5405 Protein  36 RSV184 Heavy chain variable region, F Clone No. 870US20120009623 SEQ ID NO: 5406 Protein  37 RSV185 Heavy chain variableregion, F Clone No. 871 US20120009623 SEQ ID NO: 5407 Protein  38 RSV186Heavy chain variable region, F Clone No. 880 US20120009623 SEQ ID NO:5408 Protein  39 RSV187 Heavy chain variable region, F Clone No. 881US20120009623 SEQ ID NO: 5409 Protein  40 RSV188 Heavy chain variableregion, F Clone No. 884 US20120009623 SEQ ID NO: 5410 Protein  41 RSV189Heavy chain variable region, F Clone No. 886 US20120009623 SEQ ID NO:5411 Protein  42 RSV190 Heavy chain variable region, F Clone No. 888US20120009623 SEQ ID NO: 5412 Protein  43 RSV191 Heavy chain variableregion, F Clone No. 894 US20120009623 SEQ ID NO: 5413 Protein  44 RSV192Heavy chain variable region, F Gλ-1 US20050175986 SEQ ID NO: 4 5414Protein RSV193 Super humanized heavy chain SHVh1 EP1720908; WO20050794795415 based on HNK20, F protein SEQ ID NO: 3 RSV194 Super humanized heavychain SHVh2 EP1720908; WO2005079479 5416 based on HNK20, F protein SEQID NO: 4 RSV195 Super humanized heavy chain SHVh3 EP1720908;WO2005079479 5417 based on HNK20, F protein SEQ ID NO: 5 RSV196 Superhumanized heavy chain SHVh4 EP1720908; WO2005079479 5418 based on HNK20,F protein SEQ ID NO: 6 RSV197 Super humanized heavy chain SHVh5EP1720908; WO2005079479 5419 based on HNK20, F protein SEQ ID NO: 7RSV198 Super humanized heavy chain SHVh6 EP1720908; WO2005079479 5420based on HNK20, F protein SEQ ID NO: 8 RSV199 Super humanized heavychain SHVh7 EP1720908; WO2005079479 5421 based on HNK20, F protein SEQID NO: 9 RSV200 Heavy chain variable region, F B4 EP636182;WO1993020210; 5422 Protein SEQ ID NO: 3 RSV201 Heavy chain variableregion, F B13/14 EP636182; WO1993020210; 5423 Protein SEQ ID NO: 4RSV202 Heavy chain variable region, F RF-1 EP854730; WO1996040252; 5424Protein FIG. 7B RSV203 Heavy chain variable region, F RF-2 EP854730;WO1996040252; 5425 Protein FIG. 8B RSV204 Heavy chain, G Protein 1F12US8273354 SEQ ID NO: 28 5426 RSV205 Heavy chain, G Protein 3G12US8273354 SEQ ID NO: 29 5427 RSV206 Heavy chain, G Protein 1A5 US8273354SEQ ID NO: 30 5428 RSV207 Heavy chain, G Protein 3D3 US8273354 SEQ IDNO: 31 5429 RSV208 Heavy chain, G Protein 1G1 US8273354 SEQ ID NO: 325430 RSV209 Heavy chain, G Protein 2B11 US8273354 SEQ ID NO: 33 5431RSV210 Heavy chain, G Protein 5D8 US8273354 SEQ ID NO: 34 5432 RSV211Heavy chain, G Protein 2D10 US8273354 SEQ ID NO: 35 5433 RSV212 Heavychain, G Protein 3F9 US8273354 SEQ ID NO: 36 5434 RSV213 Heavy chain, GProtein 1D4 US8273354 SEQ ID NO: 37 5435 RSV214 Heavy chain, G Protein1G8 US8273354 SEQ ID NO: 38 5436 RSV215 Heavy chain, G Protein 6A12US8273354 SEQ ID NO: 39 5437 RSV216 Heavy chain, G Protein 10C6US8273354 SEQ ID NO: 40 5438 RSV217 Heavy chain, G Protein Hu 131-2GUS8273354 SEQ ID NO: 41 5439 RSV218 Heavy chain, G Protein AT46US20150004155 SEQ ID NO: 5440  109 RSV219 Heavy chain, G Protein AT32US20150004155 SEQ ID NO: 5441  110 RSV220 Heavy chain, G Protein AT33US20150004155 SEQ ID NO: 5442  111 RSV221 Heavy chain, G Protein AT34US20150004155 SEQ ID NO: 5443  112 RSV222 Heavy chain, G Protein AT735US20150004155 SEQ ID NO: 5444  113 RSV223 Heavy chain, G Protein AT36US20150004155 SEQ ID NO: 5445  114 RSV224 Heavy chain, G Protein AT737US20150004155 SEQ ID NO: 5446  115 RSV225 Heavy chain, G Protein AT39US20150004155 SEQ ID NO: 5447  116 RSV226 Heavy chain, G Protein AT40US20150004155 SEQ ID NO: 5448  117 RSV227 Heavy chain, G Protein AT42US2010004155 SEQ ID NO: 5449  118 RSV228 Heavy chain, G Protein AT43US20150004155 SEQ ID NO: 5450  119 RSV229 Heavy chain, G Protein AT44US20150004155 SEQ ID NO: 5451  120 RSV230 Heavy chain, G Protein AT45US20150004155 SEQ ID NO: 5452  121 RSV231 Heavy chain, G Protein AT47US20150004155 SEQ ID NO: 5453  122 RSV232 Heavy chain, G Protein AT49US20150004155 SEQ ID NO: 5454  123 RSV233 Heavy chain, G Protein AT50US20150004155 SEQ ID NO: 5455  124 RSV234 Heavy chain, G Protein AT51US20150004155 SEQ ID NO: 5456  125 RSV235 Heavy chain variable region, GCB058.1 WO2014170257 SEQ ID NO: 5457 Protein  37 RSV236 Heavy chainvariable region, G CB048.3 WO2014170257 SEQ ID NO: 5458 Protein  39RSV237 Heavy chain variable region, G CB010.7 WO2014170257 SEQ ID NO:5459 Protein  41 RSV238 Heavy chain variable region, G CB003.1WO2014170257 SEQ ID NO: 5460 Protein  43 RSV239 Heavy chain variableregion, G CB028.2 WO2014170257 SEQ ID NO: 5461 Protein  45 RSV240 Heavychain variable region, G CB002.1 WO2014170257 SEQ ID NO: 5462 Protein 47 RSV241 Heavy chain variable region, G CB017.3L WO2014170258 SEQ IDNO: 5463 Protein  73 RSV242 Heavy chain variable region, G CB017.5LWO2014170258 SEQ ID NO: 5464 Protein  75 RSV243 Heavy chain variableregion, G CB028.1 WO2014170258 SEQ ID NO: 5465 Protein  77 RSV244 Heavychain variable region, G CB030.1 WO2014170258 SEQ ID NO: 5466 Protein 79 RSV245 Heavy chain variable region, G CB047.1 WO2014170258 SEQ IDNO: 5467 Protein  81 RSV246 Heavy chain variable region, G CB04712WO2014170258 SEQ ID NO: 5468 Protein  83 RSV247 Heavy chain variableregion, G CB065.1 WO2014170258 SEQ ID NO: 5469 Protein  85 RSV248 Heavychain variable region, G CB071.1L WO2014170258 SEQ ID NO: 5470 Protein 87 RSV249 Heavy chain variable region, G CB072.1L WO2014170258 SEQ IDNO: 5471 Protein  89 RSV250 Heavy chain variable region, G CB073.1LWO2014170258 SEQ ID NO: 5472 Protein  91 RSV251 Heavy chain variableregion, G CB076.2L WO2014170258 SEQ ID NO: 5473 Protein  93 RSV252 Heavychain variable region, G CB079.1 WO2014170258 SEQ ID NO: 5474 Protein 95 RSV253 Heavy chain AM14 US20140377279 SEQ ID NO: 5475  78 RSV254Heavy chain AM16 US20140377279 SEQ ID NO: 5476  85 RSV255 Heavy chainAM23 US20140377279 SEQ ID NO: 5477  92 RSV256 Heavy chain D25US20140377279 SEQ ID NO: 7 5478 RSV257 Heavy chain AFFF US7635568 SEQ IDNO: 210 5479 RSV258 Heavy chain P12f2 US7635568 SEQ ID NO: 212 5480RSV259 Heavy chain P12f4 US7635568 SEQ ID NO: 214 5481 RSV260 Heavychain P11d4 US7635568 SEQ ID NO: 216 5482 RSV261 Heavy chain Ale9US7635568 SEQ ID NO: 218 5483 RSV262 Heavy chain A12a6 US7635568 SEQ IDNO: 220 5484 RSV263 Heavy chain A13c4 US7635568 SEQ ID NO: 222 5485RSV264 Heavy chain A17d4 US7635568 SEQ ID NO: 224 5486 RSV265 Heavychain A4B4 US7635568 SEQ ID NO: 226 5487 RSV266 Heavy chain A8c7US7635568 SEQ ID NO: 228 5488 RSV267 Heavy chain 1X-493L1FR US7635568SEQ ID NO: 230 5489 RSV268 Heavy chain H3-3F4 US7635568 SEQ ID NO: 2325490 RSV269 Heavy chain M3H9 US7635568 SEQ ID NO: 234 5491 RSV270 Heavychain Y10H6 US7635568 SEQ ID NO: 236 5492 RSV271 Heavy chain DGUS7635568 SEQ ID NO: 238 5493 RSV272 Heavy chain AFFF(1) US7635568 SEQID NO: 240 5494 RSV273 Heavy chain 6H8 US7635568 SEQ ID NO: 242 5495RSV274 Heavy chain L1-7E5 US7635568 SEQ ID NO: 244 5496 RSV275 Heavychain L2-15B10 US7635568 SEQ ID NO: 246 5497 RSV276 Heavy chain A13a11US7635568 SEQ ID NO: 248 5498 RSV277 Heavy chain A1h5 US7635568 SEQ IDNO: 250 5499 RSV278 Heavy chain A4B4(1) US7635568 SEQ ID NO: 252 5500RSV279 Heavy chain A4B4L1FR-S28R US7635568 SEQ ID NO: 254 5501(MEDI-524, Motavizumab, Numax) RSV280 Heavy chain A4B4-F52S US7635568SEQ ID NO: 256 5502 RSV281 Heavy chain US7364737 SEQ ID NO: 1 5503RSV282 Heavy chain US7364737 SEQ ID NO: 2 5504 RSV283 Heavy chainvariable region J variant WO2015108967 SEQ ID NO: 5505  12 RSV284 Heavychainvariable region L variant WO2015108967 SEQ ID NO: 5506  13 RSV285Heavy chain variable region LA variant WO2015108967 SEQ ID NO: 5507  14RSV286 Heavy chain variable region 1G7 WO2015108967 SEQ ID NO: 5508  15RSV287 Heavy chain variable region 1F5 WO2015108967 SEQ ID NO: 5509  16RSV288 Heavy chain variable region 2D10 WO2015108967 SEQ ID NO: 5510  17RSV289 Heavy chain variable region 1G7-GLM WO2015108967 SEQ ID NO: 5511 18 RSV290 Heavy chain variable region B12-1 WO2015108967 SEQ ID NO:5512  19 RSV291 Heavy chain variable region E3-5 WO2015108967 SEQ ID NO:5513  20 RSV292 Heavy chain variable region E9-2 WO2015108967 SEQ ID NO:5514  21 RSV293 Heavy chain variable region 1X-493L1FR US7635568 SEQ IDNO: 7 5515 RSV294 Heavy chain variable region AFFF, AFFF(1) US7635568SEQ ID NO: 9 5516 RSV295 Heavy chain variable region P12f2 US7635568 SEQID NO: 17 5517 RSV296 Heavy chain variable region P12f4 US7635568 SEQ IDNO: 24 5518 RSV297 Heavy chain variable region P11d4 US7635568 SEQ IDNO: 28 5519 RSV298 Heavy chain variable region Ale9, A1h5 US7635568 SEQID NO: 33 5520 RSV299 Heavy chain variable region A12a6 US7635568 SEQ IDNO: 36 5521 RSV300 Heavy chain variable region A13c4 US7635568 SEQ IDNO: 40 5522 RSV301 Heavy chain variable region A17d4 US7635568 SEQ IDNO: 44 5523 RSV302 Heavy chain variable region A4B4, A4B4(1), US7635568SEQ ID NO: 48 5524 A4B4L1FR-S28R (MEDI-524, Motavizumab, Numax), A4B4-F52S RSV303 Heavy chain variable region A8c7 US7635568 SEQ ID NO: 515525 RSV304 Heavy chain variable region H3-3F4, M3H9, US7635568 SEQ IDNO: 55 5526 Y10H6 RSV305 Heavy chain variable region DG, 6H8, L1-7E5,US7635568 SEQ ID NO: 78 5527 L2-15B10 RSV306 Heavy chain variable regionA13a11 US7635568 SEQ ID NO: 67 5528 RSV307 Heavy chain variable regionUS7364742 SEQ ID NO: 7 5529 RSV308 Heavy chain variable region US7364742SEQ ID NO: 8 5530 RSV309 Heavy chain variable region D2E7 EP1807111;WO2006041970 5531 SEQ ID NO: 2 RSV310 Heavy chain variable region 2SD4EP1807111; WO2006041970 5532 SEQ ID NO: 10 RSV311 Heavy chain, humanWen, X,, “Structure of the 5533 metapneumovirus fusion humanmetapneumovirus fusion protein with protein with neutralizingneutralizing antibody identifies antibody identifies a a pneumovirusantigenic site, pneumovirus antigenic site”, Nat. Struct. Mol. Biol. 19(4), 461-463 (2012), NCBI Accession # 4DAG_H(220 aa) RSV312 Heavy chainvariable, M2 1 8A4/G9-IgG US20140348858 SEQ ID NO: 3 5534 antigen RSV313Heavy chain, Pre fusion RSV F HMB2435 WO2015010792 SEQ ID NO: 5535protein  13 RSV314 Heavy chain, Pre fusion RSV F HMB2437 WO2015010792SEQ ID NO: 5536 protein  29 RSV315 Heavy chain, Pre fusion RSV F HMB2416WO2015010792 SEQ ID NO: 5537 protein  45 RSV316 Heavy chain, Pre fusionRSV F HMB2437 WO2015010792 SEQ ID NO: 5538 protein,  85 RSV317 Heavychain, Pre fusion RSV F CR9501 WO2014202570 SEQ ID NO: 5539 protein  53RSV318 Heavy chain, Pre fusion RSV F CR9502 WO2014202570 SEQ ID NO: 5540protein  57 RSV319 Heavy chain 1, Pre fusion RSV HMB2432 WO2015010792SEQ ID NO: 5541 F protein  61 RSV320 Heavy chain 2, Pre fusion RSVHMB2432 WO2015010792 SEQ ID NO: 5542 F protein  65 RSV321 Heavy chain FRLG, Pre HMB2435 WO2015010792 SEQ ID NO: 5543 fusion RSV F protein  75RSV322 light chain, F and G Proteins clone 735 US20110189171; US78793295544 SEQ ID NO: 89 RSV323 light chain, F and G Proteins clone 736US20110189171; US7879329 5545 SEQ ID NO: 90 RSV324 light chain, F and GProteins clone 744 US20110189171; US7879329 5546 SEQ ID NO: 91 RSV325light chain, F and G Proteins clone 793 US20110189171; US7879329 5547SEQ ID NO: 92 RSV326 light chain, F and G Proteins clone 795US20110189171; US7879329 5548 SEQ ID NO: 93 RSV327 light chain, F and GProteins clone 796 US20110189171; US7879329 5549 SEQ ID NO: 94 RSV328light chain, F and G Proteins clone 799 US20110189171; US7879329 5550SEQ ID NO: 95 RSV329 light chain, F and G Proteins clone 800US20110189171; US7879329 5551 SEQ ID NO: 96 RSV330 light chain, F and GProteins clone 801 US20110189171; US7879329 5552 SEQ ID NO: 97 RSV331light chain, F and G Proteins clone 804 US20110189171; US7879329 5553SEQ ID NO: 98 RSV332 light chain, F and G Proteins clone 810US20110189171; US7879329 5554 SEQ ID NO: 99 RSV333 light chain, F and GProteins clone 811 US20110189171; US7879329 5555 SEQ ID NO: 100 RSV334light chain, F and G Proteins clone 812 US20110189171; US7879329 5556SEQ ID NO: 101 RSV335 light chain, F and G Proteins clone 814US20110189171; US7879329 5557 SEQ ID NO: 102 RSV336 light chain, F and GProteins clone 816 US20110189171; US7879329 5558 SEQ ID NO: 103 RSV337light chain, F and G Proteins clone 817 US20110189171; US7879329 5559SEQ ID NO: 104 RSV338 light chain, F and G Proteins clone 818US20110189171; US7879329 5560 SEQ ID NO: 105 RSV339 light chain, F and GProteins clone 819 US20110189171; US7879329 5561 SEQ ID NO: 106 RSV340light chain, F and G Proteins clone 824 US20110189171; US7879329 5562SEQ ID NO: 107 RSV341 light chain, F and G Proteins clone 825US20110189171; US7879329 5563 SEQ ID NO: 108 RSV342 light chain, F and GProteins clone 827 US20110189171; US7879329 5564 SEQ ID NO: 109 RSV343light chain, F and G Proteins clone 829 US20110189171, US7879329 5565SEQ ID NO: 110 RSV344 light chain, F and G Proteins clone 830US20110189171; US7879329 5566 SEQ ID NO: 111 RSV345 light chain, F and GProteins clone 831 US20110189171; US7879329 5567 SEQ ID NO: 112 RSV346light chain, F and G Proteins clone 835 US20110189171; US7879329 5568SEQ ID NO, 113 RSV347 light chain, F and G Proteins clone 838US20110189171; US7879329 5569 SEQ ID NO: 114 RSV348 light chain, F and GProteins clone 841 US20110189171; US7879329 5570 SEQ ID NO: 115 RSV349light chain, F and G Proteins clone 853 US20110189171; US7879329 5571SEQ ID NO: 116 RSV350 light chain, F and G Proteins clone 855US20110189171; US7879329 5572 SEQ ID NO: 117 RSV351 light chain, F and GProteins clone 856 US20110189171; US7879329 5573 SEQ ID NO: 118 RSV352light chain, F and G Proteins clone 857 US20110189171; US7879329 5574SEQ ID NO: 119 RSV353 light chain, F and G Proteins clone 858US20110189171; US7879329 5575 SEQ ID NO: 120 RSV354 light chain, F and GProteins clone 859 US20110189171; US7879329 5576 SEQ ID NO: 121 RSV355light chain, F and G Proteins clone 861 US20110189171; US7879329 5577SEQ ID NO: 122 RSV356 light chain, F and G Proteins clone 863US20110189171; US7879329 5578 SEQ ID NO: 123 RSV357 light chain, F and GProteins clone 868 US20110189171; US7879329 5579 SEQ ID NO: 124 RSV358light chain, F and G Proteins clone 870 US20110189171; US7879329 5580SEQ ID NO: 125 RSV359 light chain, F and G Proteins clone 871US20110189171; US7879329 5581 SEQ ID NO: 126 RSV360 light chain, F and GProteins clone 880 US20110189171; US7879329 5582 SEQ ID NO: 127 RSV361light chain, F and G Proteins clone 881 US20110189171; US7879329 5383SEQ ID NO: 128 RSV62 light chain, F and G Proteins clone 884US20110189171; US7879329 5584 SEQ ID NO: 129 RSV363 light chain, F and GProteins clone 886 US20110189171; US7879329 5585 SEQ ID NO: 130 RSV364light chain, F and G Proteins clone 888 US20110189171; US7879329 5586SEQ ID NO: 131 RSV365 light chain, F and G Proteins clone 894US20110189171; US7879329 5587 SEQ ID NO: 132 RSV366 Light chainvariable, F protein 3210 variant 1, WO2013140247 SEQ ID NO: 5588 of RSV,MPV, or PVM 3210 variant 2,  14 3210 variant 5 RSV367 Light chainvariable, F protein 2430 variant 1, WO2013140247 SEQ ID NO: 5589 of RSV,MPV, or PVM 2430 variant 2,  30 2430 variant 4 RSV368 Light chainvariable, F protein 3210 variant 3 WO2013140247 SEQ ID NO: 5590 of RSV,MPV, or PVM  37 RSV369 Light chain variable, F protein 3210 variant 4,WO20113140247 SEQ ID NO: 5591 of RSV, MPV, or PVM 3210 variant 6  50RSV370 Light chain variable, F protein 2430 variant 3, WO2013140247 SEQID NO: 5592 of RSV, MPV, or PVM 2430 variant 5  60 RSV371 Light chain, FProtein clone 19 EP1259547; US8153133SEQ 5593 ID NO: 40 RSV372 Lightchain variable region, US20140093501 SEQ ID NO: 5594 CDR Grafted, FProtein  20 RSV373 Light chain variable region, US20140093501 SEQ ID NO:5595 CDR Grafted, F Protein  34 RSV374 Light chain, F Protein AM22US8568726 SEQ ID NO: 32 5596 RSV375 Light chain, F Protein RSVF2-5US8221759 SEQ ID NO: 9 5597 RSV376 Light chain, F Protein EP1259547;US8153133 SEQ 5598 ID NO: 3 RSV377 Light chain, F Protein MTDI-EP1259547; US8153133 SEQ 5599 493/Pavilizumab- ID NO: 1 N-VL (Brand nameSynagis) RSV378 Light chain, F Protein EP1259547; US8153133 SEQ 5600 IDNO: 35 RSV379 Light chain, F Protein clone 18 EP1259547; US8153133 SEQ5601 ID NO: 38 RSV380 Light chain, F Protein clone 20 ER1259547;US8153133 SEQ 5602 ID NO: 42 RSV381 Light chain, F Protein clone 21EP1259547; US8153133 SEQ 5603 ID NO: 44 RSV382 Light chain, F Proteinclone 22 ER1259547; US8153133 SEQ 5604 ID NO: 46 RSV383 Light chain, FProtein clone 23 EP1259547; US8153133 SEQ 5605 ID NO: 48 RSV384 Lightchain, F Protein clone 24 ER1259547; US8153133 SEQ 5606 ID NO: 50 RSV385Light chain, F Protein clone 25 EP1259547; US8153133 SEQ 5607 ID NO: 52RSV386 Light chain, F Protein clone 26 ER1259547; US8153133 SEQ 5608 IDNO: 54 RSV387 Light chain variable region, F huK102 US20140093501 SEQ IDNO: 5609 Protein  19 RSV388 Light chain variable region, F huK102US20140093501 SEQ ID NO: 5610 Protein  33 RSV389 Light chain variableregion, F RSV G8 US7867497 SEQ ID NO: 4 5611 Protein RSV390 Light chainvariable region, F Clone 1 US20120135006 SEQ ID NO: 5612 Protein  17RSV391 Light chain variable region, F Clone 2 US20120135006 SEQ ID NO:5613 Protein  19 RSV392 Light chain variable region, F Clone 3US20120135006 SEQ ID NO: 5614 Protein  21 RSV393 Light chain variableregion, F Clone 22 US20120135006 SEQ ID NO: 5615 Protein  23 RSV394Light chain variable region, F Clone 23 US20120135006 SEQ ID NO: 5616Protein  25 RSV395 Light chain variable region, F RSV13-9 WO2009088159SEQ ID NO: 2 5617 Protein RSV396 Light chain variable region, F MAb1308FUS20140093501 SEQ ID NO: 5618 Protein  21 RSV397 Light chain, F Protein58c5 US20140044719 SEQ ID NO: 5 5619 RSV398 Light chain, F Protein sc5US20140044719 SEQ ID NO: 5620  13 RSV399 Light chain, F Protein CloneNo. 735 US20120009623 SEQ ID NO: 5621  89 RSV400 Light chain, F ProteinClone No. 736 US20120009623 SEQ ID NO: 5622  90 RSV401 Light chain, FProtein Clone No. 744 US20120009623 SEQ ID NO: 5623  91 RSV402 Lightchain, F Protein Clone No. 793 US20120009623 SEQ ID NO: 5624  92 RSV403Light chain, F Protein Clone No. 795 US20120009623 SEQ ID NO: 5625  93RSV404 Light chain, F Protein Clone No. 796 US20120009623 SEQ ID NO:5626  94 RSV405 Light chain, F Protein Clone No. 799 US20120009623 SEQID NO: 5627  95 RSV406 Light chain, F Protein Clone No. 800US20120009623 SEQ ID NO: 5628  96 RSV407 Light chain, F Protein CloneNo. 801 US20120009623 SEQ ID NO: 5629  97 RSV408 Light chain, F ProteinClone No. 804 US20120009623 SEQ ID NO: 5630  98 RSV409 Light chain, FProtein Clone No. 810 US2012000923 SEQ ID NO: 5631  99 RSV410 Lightchain, F Protein Clone No. 811 US20120009623 SEQ ID NO: 5632  100 RSV411Light chain, F Protein Clone No. 812 US20120009623 SEQ ID NO: 5633  101RSV412 Light chain, F Protein Clone No. 814 US20120009623 SEQ ID NO:5634  102 RSV413 Light chain, F Protein Clone No. 816 US20120009623 SEQID NO: 5635  103 RSV414 Light chain, F Protein Clone No. 817US20120009623 SEQ ID NO: 5636  104 RSV415 Light chain, F Protein CloneNo. 818 US20120009623 SEQ ID NO: 5637  105 RSV416 Light chain, F ProteinClone No. 819 US20120009623 SEQ ID NO: 5638  106 RSV417 Light chain, FProtein Clone No. 824 US20120009623 SEQ ID NO: 5639  107 RSV41,8 Lightchain, F Protein Clone No. 825 US20120009623 SEQ ID NO: 5640  108 RSV419Light chain, F Protein Clone No. 827 US20120009623 SEQ ID NO: 5641  109RSV420 Light chain, F Protein Clone No. 829 US20120009623 SEQ ID NO:5642  110 RSV421 Light chain, F Protein Clone No. 830 US20120009623 SEQID NO: 5643  111 RSV422 Light chain, F Protein Clone No. 831US20120009623 SEQ ID NO: 5644  112 RSV23 Light chain, F Protein CloneNo. 835 US20120009623 SEQ ID NO: 5645  113 RSV424 Light chain, F ProteinClone No. 838 US20120009623 SEQ ID NO: 5646  114 RSV42S Light chain, FProtein Clone No. 841 US20120009623 SEQ ID NO: 5647  115 RSV426 Lightchain, F Protein Clone No. 853 US20120009623 SEQ ID NO: 5648  116 RSV427Light chain, F Protein Clone No. 855 US20120009623 SEQ ID NO: 5649  117RSV428 Light chain, F Protein Clone No. 856 US20120009623 SEQ ID NO:5650  118 RSV429 Light chain, F Protein Clone No. 857 US20120009623 SEQID NO: 5651  119 RSV430 Light chain, F Protein Clone No. 858US20120009623 SEQ ID NO: 5652  120 RSV431 Light chain, F Protein CloneNo. 859 US20120009623 SEQ ID NO: 5653  121 RSV432 Light chain, F ProteinClone No. 861 US20120009623 SEQ ID NO: 5654  122 RSV433 Light chain, FProtein Clone No. 863 US20120009623 SEQ ID NO: 5655  123 RSV434 Lightchain, F Protein Clone No. 868 US20120009623 SEQ ID NO: 5656  124 RSV435Light chain, F Protein Clone No. 870 US20120009623 SEQ ID NO: 5657  125RSV436 Light chain, F Protein Clone No. 871 US20120009623 SEQ ID NO:5658  126 RSV437 Light chain, F Protein Clone No. 880 US2012000962 SEQID NO: 5659  127 RSV438 Light chain, F Protein Clone No. 881US2012000923 SEQ ID NO: 5660  128 RSV439 Light chain, F Protein CloneNo. 884 US20120009623 SEQ ID NO: 5661  129 RSV440 Light chain, F ProteinClone No. 886 US20120009623 SEQ ID NO: 5662  130 RSV441 Light chain, FProtein Clone No. 888 US20120009623 SEQ ID NO: 5663  131 RSV442 Lightchain, F Protein Clone No. 894 US20120009623 SEQ ID NO: 5664  132 RSV443Light chain, F Protein US20110027294 SEQ ID NO: 5665  63 RSV444 Lightchain, F Protein US20110027294 SEQ ID NO: 5666  64 RSV445 Light chain, FProtein US20110027294 SEQ ID NO: 5667  65 RSV446 Light chain, F ProteinUS20110027294 SEQ ID NO: 5668  66 RSV447 Light chain, F ProteinUS20110027294 SEQ ID NO: 5669  67 RSV448 Light chain, F ProteinUS20110027294 SEQ ID NO: 5670  68 RSV449 Light chain, F ProteinUS20110027294 SEQ ID NO: 5671  69 RSV450 Light chain, F ProteinUS20110027294 SEQ ID NO: 5672  70 RSV451 Light chain, F ProteinUS20110027294 SEQ ID NO: 5673  71 RSV452 Light chain, F ProteinUS20110027294 SEQ ID NO: 5674  72 RSV453 Light chain, F ProteinUS20110027294 SEQ ID NO: 5675  73 RSV454 Light chain, F ProteinUS20110027294 SEQ ID NO: 5676  81 RSV455 Light chain, F ProteinUS20110027294 SEQ ID NO: 5677  82 RSV456 Light chain, F ProteinUS20110027294 SEQ ID NO: 5678  83 RSV457 Light chain, F ProteinUS20110027294 SEQ ID NO: 5679  84 RSV458 Light chain, F ProteinUS20110027294 SEQ ID NO: 5680  85 RSV459 Light chain, F ProteinUS20110027294 SEQ ID NO: 5681  86 RSV460 Light chain, F ProteinUS20110027294 SEQ ID NO: 5682  87 RSV461 Light chain, F ProteinUS20110027294 SEQ ID NO: 5683  88 RSV462 Light chain, F ProteinUS20110027294 SEQ ID NO: 5684  89 RSV463 Light chain, F ProteinUS20110027294 SEQ ID NO: 5685  90 RSV464 Light chain, F ProteinUS20110027294 SEQ ID NO: 5686  91 RSV465 Light chain, F ProteinUS20110027294 SEQ ID NO: 5687  92 RSV466 Light chain, F ProteinUS20110027294 SEQ ID NO: 5688  93 RSV467 Light chain, F ProteinUS20110027294 SEQ ID NO: 5689  94 RSV468 Light chain, F ProteinUS20110027294 SEQ ID NO: 5690  95 RSV469 Light chain, F ProteinUS20110027294 SEQ ID NO: 5691  96 RSV470 Light chain, F ProteinUS20110027294 SEQ ID NO: 5692  97 RSV471 Light chain, F ProteinUS20110027294 SEQ ID NO: 5693  98 RSV472 Light chain, F ProteinUS20110027294 SEQ ID NO: 5694   99 RSV473 Light chain, F ProteinUS20110027294 SEQ ID NO: 5695  100 RSV474 Light chain, F ProteinUS20110027294 SEQ ID NO: 5696  101 RSV475 Light chain, F ProteinUS20110027294 SEQ ID NO: 5697  102 RSV476 Light chain, F ProteinUS20110027294 SEQ ID NO: 5698  103 RSV477 Light chain, F ProteinUS20110027294 SEQ ID NO: 5699  104 RSV478 Light chain, F ProteinUS20110027294 SEQ ID NO: 5700  105 RSV479 Light chain, F ProteinUS20110027294 SEQ ID NO: 5701  106 RSV480 Light chain, F ProteinUS20110027294 SEQ ID NO: 5702  107 RSV481 Light chain, F ProteinUS20110027294 SEQ ID NO: 5703  108 RSV482 Light chain, F ProteinUS20110027294 SEQ ID NO: 5704  109 RSV483 Light chain, F ProteinUS20110027294 SEQ ID NO: 5705  110 RSV484 Light chain, F ProteinUS20110027294 SEQ ID NO: 5706  111 RSV485 Light chain, F ProteinUS20110027294 SEQ ID NO: 5707  112 RSV486 Light chain, F Protein Gλ-1AUS20050175986 SEQ ID NO: 9 5708 RSV487 Light chain, F Protein Aconstruct US20050175986 SEQ ID NO: 5709   11 RSV488 Light chain, FProtein B construct US20050175986 SEQ ID NO: 5710   12 RSV489 Lightchain, F Protein hu19A US20050019758; 5711 WO1998019704 SEQ ID NO:   10RSV490 Light chain, F Protein hu19B US20050019758; 5712 WO1998019704 SEQID NO:   11 RSV491 Light chain, F Protein hu19C US20050019758; 5713WO1998019704 SEQ ID NO:   12 RSV492 Light chain, F Protein hu19DUS20050019758; 5714 WO1998019704 SEQ ID NO:   13 RSV493 Light chain, FProtein RSV19 EP636182; WO1993020210; 5715 SEQ ID NO: 12 RSV494 Lightchain, F Protein, WO19922004381 5716 RSV495 Light chain variable region,F P1212 US20140044719 SEQ ID NO: 5717 Protein  127 RSV496 Light chainvariable region, F P12f4 US20140044719 SEQ ID NO: 5718 Protein  134RSV497 Light chain variable region, F P11d4 US20140044719 SEQ ID NO:5719 Protein  140 RSV498 Light chain variable region, F A1e9US20140044719 SEQ ID NO: 5720 Protein  146 RSV499 Light chain variableregion, F A12a6 US20140044719 SEQ ID NO: 5721 Protein  152 RSV500 Lightchain variable region, F A13c4 US20140044719 SEQ ID NO: 5722 Protein 158 RSV501 Light chain variable region, F A17d4 US20140044719 SEQ IDNO: 5723 Protein  164 RSV502 Light chain variable region, F A4B4US20140044719 SEQ ID NO: 5724 Protein  169 RSV503 Light chain variableregion, F A8c7 US20140044719 SEQ ID NO: 5725 Protein  174 RSV504 Lightchain variable region, F IX-493L1FR US20140044719 SEQ ID NO: 5726Protein  178 RSV505 Light chain variable region, F M3H9 US20140044719SEQ ID NO: 5727 Protein  180 RSV506 Light chain variable region, F B21MUS20110027294 SEQ ID NO: 5728 Protein   51 RSV507 Light chain variableregion, F 101F US20110027294 SEQ ID NO: 6 5729 Protein RSV508 Lightchain variable region, F HNK20 EP1720908; WO2005079479 5730 Protein SEQID NO: 2 RSV509 Light chain variable region, F P1212 US20140044719 SEQID NO: 5731 Protein  128 RSV510 Light chain variable region, F P12f4US20140044719 SEQ ID NO: 5732 Protein  135 RSV511 Light chain variableregion, F P11d4 US20140044719 SEQ ID NO: 5733 Protein  141 RSV512 Lightchain variable region, F A1e9 US20140044719 SEQ ID NO: 5734 Protein  147RSV513 Light chain variable region, F A12a6 US20140044719 SEQ ID NO:5735 Protein  153 RSV514 Light chain variable region, F A13c4US20140044719 SEQ ID NO: 5736 Protein  159 RSV515 Light chain variableregion, F A17d4 US20140044719 SEQ ID NO: 5737 Protein  165 RSV516 Lightchain variable region, F A4B4 US20140044719 SEQ ID NO: 5738 Protein  170RSV517 Light chain variable region, F A8c7 US20140044719 SEQ ID NO: 5739Protein  175 RSV518 Light chain variable region, F IX-493L1FRUS20140044719 SEQ ID NO: 5740 Protein  179 RSV519 Light chain variableregion, F H1 H3564P WO2014159822 SEQ ID NO: 5741 Protein  10 RSV520Light chain variable region, F H1 H3565P WO2014159822 SEQ ID NO: 5742Protein  26 RSV521 Light chain variable region, F H1 H3566P WO2014159822SEQ ID NO: 5743 Protein  42 RSV522 Light chain variable region, F H1H3567P WO2014159822 SEQ ID NO: 5744 Protein  58 RSV523 Light chainvariable region, F H1 H3581 P WO2014159822 SEQ ID NO: 5745 Protein  74RSV524 Light chain variable region, F H1 H3583P WO2014159822 SEQ ID NO:5746 Protein  90 RSV525 Light chain variable region, F H1 H3589PWO2014159822 SEQ ID NO: 5747 Protein  106 RSV526 Light chain variableregion, F H1 H3591 P WO2014159822 SEQ ID NO: 5748 Protein  122 RSV527Light chain variable region, F H1 H3592P WO2014159822 SEQ ID NO: 5749Protein  138 RSV528 Light chain variable region, F H1 H3597PWO2014159822 SEQ ID NO: 5750 Protein  154 RSV529 Light chain variableregion, F H1 H3598P WO2014159822 SEQ ID NO: 5751 Protein  170 RSV530Light chain variable region, F H1 H3603P WO2014159822 SEQ ID NO: 5752Protein  186 RSV531 Light chain variable region, F H1 H3604PWO2014159822 SEQ ID NO: 5753 Protein  202 RSV532 Light chain variableregion, F H1 H3605P WO2014159822 SEQ ID NO: 5754 Protein  218 RSV533Light chain variable region, F H1 H3607P WO2014159822 SEQ ID NO: 5755Protein  234 RSV534 Light chain variable region, F H1 H3608P2WO2014159822 SEQ ID NO: 5756 Protein  250 RSV535 Light chain variableregion, F H1 H3592P2 WO2014159822 SEQ ID NO: 5757 Protein  266 RSV536Light chain variable region, F H1 H3592P3 WO2014159822 SEQ ID NO: 5758Protein  282 RSV537 Light chain variable region, F H1 M3621 NWO2014159822 SEQ ID NO: 5759 Protein  298 RSV538 Light chain variableregion, F H1 M3622N WO2014159822 SEQ ID NO: 5760 Protein  314 RSV539Light chain variable region, F H1 M2634N WO2014159822 SEQ ID NO: 5761Protein  330 RSV540 Light chain variable region, F H1 M3627NWO2014159822 SEQ ID NO: 5762 Protein  346 RSV541 Light chain variableregion, F Gλ-1 US20050175986 SEQ ID NO: 2 5763 Protein RSV542 Lightchain variable region, F MAb1129 US20140093501 SEQ ID NO: 5764 Protein 35 RSV543 super humanized kappa light SHVl1 EP1720908; WO20050794795765 chain based on HNK20, F SEQ ID NO: 10 protein RSV544 superhumanized kappa light SHVl2 EP1720908; WO2005079479 5766 chain based onHNK20, F SEQ ID NO: 11 protein RSV545 super humanized kappa light SHVl3EP1720908; WO2005079479 5767 chain based on HNK20, F SEQ ID NO: 12protein RSV546 super humanized kappa light SHVl4 EP1720908; WO20050794795768 chain based on HNK20, F SEQ ID NO: 13 protein RSV547 superhumanized kappa light SHVl5 EP1720908; WO2005079479 5769 chain based onHNK20, F SEQ ID NO: 14 protein RSV548 super humanized kappa light SHVl6EP1720908; WO2005079479 5770 chain based on HNK20, F SEQ ID NO: 15protein RSV549 Light chain variable region, F B4 EP636182; WO1993020210;5771 Protein SEQ ID NO: 1 RSV550 Light chain variable region, F B13/14EP636182; WO1993020210; 5772 Protein SEQ ID NO: 2 RSV551 Light chainvariable region, F RF-1 EP854730; WO1996040252; 5773 Protein FIG. 7ARSV552 Light chain variable region, F RF-2 EP854730; WO1996040252; 5774Protein FIG. 8A RSV553 Light chain variable region CB058.1 WO2014170257SEQ ID NO: 5775 Kappa, G protein  38 RSV554 Light chain variable regionCB048.3 WO2014170257 SEQ ID NO: 5776 Kappa, G protein  40 RSV555 Lightchain variable region CB010.7 WO2014170257 SEQ ID NO: 5777 Kappa, Gprotein  42 RSV556 Light chain variable region CB003.1 WO2014170257 SEQID NO: 5778 Kappa, G protein  44 RSV557 Light chain variable regionCB028.2 WO2014170257 SEQ ID NO: 5779 Kappa, G protein  46 RSV558 Lightchain variable region CB002.1 WO2014170257 SEQ ID NO: 5780 Kappa, Gprotein  48 RSV559 Light chain, G Protein 1F12 US8273354 SEQ ID NO: 425781 RSV560 Light chain, G Protein 3G12 US8273354 SEQ ID NO: 43 5782RSV561 Light chain, G Protein 1A5 US8273354 SEQ ID NO: 44 5783 RSV562Light chain, G Protein 3D3 US8273354 SEQ ID NO: 45 5784 RSV563 Lightchain, G Protein 1G1 US8273354 SEQ ID NO: 46 5785 RSV564 Light chain, GProtein 2B11 US8273354 SEQ ID NO: 47 5786 RSV565 Light chain, G Protein5D8 US8273354 SEQ ID NO: 48 5787 RSV566 Light chain, G Protein 2D10US8273354 SEQ ID NO: 49 5788 RSV567 Light chain, G Protein 3F9 US8273354SEQ ID NO: 50 5789 RSV568 Light chain, G Protein 1D4 US8273354 SEQ IDNO: 51 5790 RSV569 Light chain, G Protein 1G8 US8273354 SEQ ID NO: 525791 RSV570 Light chain, G Protein 6A12 US8273354 SEQ ID NO: 53 5792RSV571 Light chain, G Protein 10C6 US8273354 SEQ ID NO: 54 5793 RSV572Light chain, G Protein Hu 131-2G US8273354 SEQ ID NO: 55 5794 RSV573Light chain, G Protein AT46 US20150004155 SEQ ID NO: 5795  127 RSV574Light chain, G Protein AT32 US20150004155 SEQ ID NO: 5796  128 RSV575Light chain, G Protein AT33 US20150004155 SEQ ID NO: 5797  129 RSV576Light chain, G Protein AT34 US20150004155 SEQ ID NO: 5798  130 RSV577Light chain, G Protein AT35 US20150004155 SEQ ID NO: 5799  131 RSV578Light chain, G Protein AT36 US20150004155 SEQ ID NO: 5800  132 RSV579Light chain, G Protein AT37 US20150004155 SEQ ID NO: 5801  133 RSV580Light chain, G Protein AT39 US20150004155 SEQ ID NO: 5802  134 RSV581Light chain, G Protein AT40 US20150004155 SEQ ID NO: 5803  135 RSV582Light chain, G Protein AT42 US20150004155 SEQ ID NO: 5804  136 RSV583Light chain, G Protein AT43 US20150004155 SEQ ID NO: 5805  137 RSV584Light chain, G Protein AT44 US20150004155 SEQ ID NO: 5806  138 RSV585Light chain, G Protein AT45 US20150004155 SEQ ID NO: 5807  139 RSV586Light chain, G Protein AT47 US20150004155 SEQ ID NO: 5808  140 RSV587Light chain, G Protein AT49 US20150004155 SEQ ID NO: 5809  141 RSV588Light chain, G Protein AT50 US20150004155 SEQ ID NO: 5810  142 RSV589Light chain, G Protein AT51 US20150004155 SEQ ID NO: 5811  143 RSV590Light chain variable region, G CB017.3L WO2014170258 SEQ ID NO: 5812Protein  74 RSV591 Light chain variable region, G CB017.5L WO2014170258SEQ ID NO: 5813 Protein  76 RSV592 Light chain variable region, GCB028.1 WO2014170258 SEQ ID NO: 5814 Protein  78 RSV593 Light chainvariable region, G CB030.1 WO2014170258 SEQ ID NO: 5815 Protein  80RSV594 Light chain variable region, G CB047.1 WO2014170258 SEQ ID NO:5816 Protein  82 RSV595 Light chain variable region, G CB047.2WO2014170258 SEQ ID NO: 5817 Protein  84 RSV596 Light chain variableregion, G CB065.1 WO2014170258 SEQ ID NO: 5818 Protein  86 RSV597 Lightchain variable region, G CB071.1L WO2014170258 SEQ ID NO: 5819 Protein 88 RSV598 Light chain variable region, G CB072.1L WO2014170258 SEQ IDNO: 5820 Protein  90 RSV599 Light chain variable region, G CB073.1LWO2014170258 SEQ ID NO: 5821 Protein  92 RSV600 Light chain variableregion, G CB076.2L WO2014170258 SEQ ID NO: 5822 Protein  94 RSV601 Lightchain variable region, G CB079.1 WO2014170258 SEQ ID NO: 5823 Protein 96 RSV602 Light chain, human Wen,X., “Structure of the 5824metapneumovirus fusion human metapueumovirus fusion protein with proteinwith neutralizing neutralizing antibody identifies antibody identifies aa pueumovirus antigenic site pneumovirus antigenic site”, Nat. Struct.Mol. Biol. 19 (4), 461-463 (2012), NCBI Accession # 4DAG_L(213 aa)RSV603 Light chain AM14 US20140377279 SEQ ID NO: 5825  79 RSV604 Lightchain AM16 US20140377279 SEQ ID NO: 5826  86 RSV605 Light chain AM23US20140377279 SEQ ID NO: 5827  93 RSV606 Light chain D25 US20140377279SEQ ID NO: 8 5828 RSV607 Light chain AFFF US7635568 SEQ ID NO: 211 5829RSV608 Light chain P12f2 US7635568 SEQ ID NO: 213 5830 RSV609 Lightchain P12f4 US7635568 SEQ ID NO: 215 5831 RSV610 Light chain P11d4US7635568 SEQ ID NO: 217 5832 RSV611 Light chain Ale9 US7635568 SEQ IDNO: 219 5833 RSV612 Light chain A12a6 US7635568 SEQ ID NO: 221 5834RSV613 Light chain A13c4 US7635568 SEQ ID NO: 223 5835 RSV614 Lightchain A17d4 US7635568 SEQ ID NO: 225 5836 RSV615 Light chain A4B4US7635568 SEQ ID NO: 227 5837 RSV616 Light chain A8c7 US7635568 SEQ IDNO: 229 5838 RSV617 Light chain 1X-493-L1FR US7635568 SEQ ID NO: 2315839 RSV618 Light chain H3-3F4, DG US7635568 SEQ ID NO: 233 5840 RSV619Light chain M3H9 US7635568 SEQ ID NO: 235 5841 RSV620 Light chain Y10H6US7635568 SEQ ID NO: 237 5842 RSV621 Light chain DG US7635568 SEQ ID NO:239 5843 RSV622 Light chain AFFF(1) US7635568 SEQ ID NO: 241 5844 RSV623Light chain 6H8 US7635568 SEQ ID NO: 243 5845 RSV624 Light chain L1-7E5US7635568 SEQ ID NO: 245 5846 RSV625 Light chain L2-15B10 US7635568 SEQID NO: 247 5847 RSV626 Light chain A13a11 US7635568 SEQ ID NO: 249 5848RSV627 Light chain A1h5 US7635568 SEQ ID NO: 251 5849 RSV628 Light chainA4B4(1) US7635568 SEQ ID NO: 253 5850 RSV629 Light chain A4B4L1FR-S28RUS7635568 SEQ ID NO: 255 5851 RSV630 Light chain A4B4-F52S US7635568 SEQID NO: 257 5852 RSV631 Light chain variable region AFFF US7635568 SEQ IDNO: 13 5853 RSV632 Light chain variable region P12f2 US7635568 SEQ IDNO: 21 5854 RSV633 Light chain variable region P12f4 US7635568 SEQ IDNO: 26 5855 RSV634 Light chain variable region P11d4 US7635568 SEQ IDNO: 30 5856 RSV635 Light chain variable region Ale9 US7635568 SEQ ID NO:34 5857 RSV636 Light chain variable region A12a6 US7635568 SEQ ID NO: 385858 RSV637 Light chain variable region A13c4 US7635568 SEQ ID NO: 425859 RSV638 Light chain variable region A17d4 US7635568 SEQ ID NO: 465860 RSV639 Light chain variable region A4B4 US7635568 SEQ ID NO: 495861 RSV640 Light chain variable region A8c7 US7635568 SEQ ID NO: 525862 RSV641 Light chain variable region 1X-493L1FR US7635568 SEQ ID NO:54 5863 RSV642 Light chain variable region H3-3F4, DG US7635568 SEQ IDNO: 56 5864 RSV643 Light chain variable region M3H9 US7635568 SEQ ID NO:70 5865 RSV644 Light chain variable region Y10H6 US7635568 SEQ ID NO: 585866 RSV645 Light chain variable region AFFF(1) US7635568 SEQ ID NO: 605867 RSV646 Light chain variable region 6H8 US7635568 SEQ ID NO: 62 5868RSV647 Light chain variable region L1-7E5 US7635568 SEQ ID NO: 64 5869RSV648 Light chain variable region L2-15B10 US7635568 SEQ ID NO: 65 5870RSV649 Light chain variable region A13a11 US7635568 SEQ ID NO: 68 5871RSV650 Light chain variable region A1h5 US7635568 SEQ ID NO: 71 5872RSV651 Light chain variable region A4B4(1) US7635568 SEQ ID NO: 74 5873RSV652 Light chain variable region A4B4L1FR-S28R US7635568 SEQ ID NO: 115874 RSV653 Light chain variable region A4B4-F52S US7635568 SEQ ID NO:76 5875 RSV654 Light chain variable region 6H; 11H; 21H; US7364737 SEQID NO: 21 5876 22H; and 23H RSV655 Light chain variable region 13H and19H US7364737 SEQ ID NO: 22 5877 RSV656 Light chain variable region 6L;11L; 21L; and US7364737 SEQ ID NO: 23 5878 22L RSV657 Light chainvariable region 23L US7364737 SEQ ID NO: 24 5879 RSV658 Light chainvariable region 13L and 19L US7364737 SEQ ID NO: 25 5880 RSV659 Lightchain variable region US7364742 SEQ ID NO: 9 5881 RSV660 Light chainvariable region US7364742 SEQ ID NO: 10 5882 RSV661 Light chain variableregion US7364742 SEQ ID NO: 11 5883 RSV662 Light chain variable regionUS7364742 SEQ ID NO: 12 5884 RSV663 Light chain variable region D2E7EP1807111; WO2006041970 5885 SEQ ID NO: 1 RSV664 Light chain variableregion 2SD4 EP1807111; WO2006041970 5886 SEQ ID NO: 9 RSV665 Light chainvariable, M2 1 8A4/G9-IgG US20140348858 SEQ ID NO: 4 5887 antigen RSV666Light chain, Pre fusion RSV F HMB2435 WO2015010792 SEQ ID NO: 5888protein  14 RSV667 Light chain, Pre fusion RSV F HMB2437 WO2015010792SEQ ID NO: 5889 protein  30 RSV668 Light chain, Pre fusion RSV F HMB2416WO2015010792 SEQ ID NO: 5890 protein  46 RSV669 Light chain, Pre fusionRSV F HMB2437 WO2015010792 SEQ ID NO: 5891 protein  86 RSV670 Lightchain, Pre fusion RSV F CR9501 WO2014202570 SEQ ID NO: 5892 protein  61RSV671 Light chain, Pre fusion RSV F CR9502 WO2014202570 SEQ ID NO: 5893protein  65 RSV672 Light chain 1, Pre fusion RSV HMB2432 WO2015010792SEQ ID NO: 5894 F protein  62 RSV673 Light chain FR GL, Pre fusionHMB2432 WO2015010792 SEQ ID NO: 5895 RSV F protein  66 RSV674 Lightchain 2, Pre fusion RSV HMB2435 WO2015010792 SEQ ID NO: 5896 F protein 76 RSV675 derived Ig variable region RSV19VH EP636182; WO1993020210;5897 amino acid sequence, F protein SEQ ID NO: 13 RSV676 derived Igvariable region pHuRSV19VH EP636182; WO1993020210; 5898 amino acidsequence, F protein SEQ ID NO: 14 RSV677 derived Ig variable regionpHuRSV19VHFNS EP636182; WO1993020210; 5899 amino acid sequence, Fprotein SEQ ID NO: 15 RSV678 derived Ig variable region pHuRSV19VHNIKEP636182; WO1993020210; 5900 amino acid sequence, F protein SEQ ID NO:16 RSV679 derived Ig variable region pHuRSV19VK EP636182; WO1993020210;5901 amino acid sequence, F protein SEQ ID NO: 17 RSV680 Nanobodybinding to RSV F LG202A10 US20110182897 SEQ ID NO: 5902 protein  126RSV681 Nanobody binding to RSV F LG202A12 US20110182897 SEQ ID NO: 5903protein  127 RSV682 Nanobody binding to RSV F LG202A5 US20110182897 SEQID NO: 5904 protein  128 RSV683 Nanobody binding to RSV F LG202A9US20110182897 SEQ ID NO: 5905 protein  129 RSV684 Nanobody binding toRSV F LG202B10 US20110182897 SEQ ID NO: 5906 protein  130 RSV685Nanobody binding to RSV F LG202B7 US20110182897 SEQ ID NO: 5907 protein 131 RSV686 Nanobody binding to RSV F LG202B8 US20110182897 SEQ ID NO:5908 protein  132 RSV687 Nanobody binding to RSV F LG202B9 US20110182897SEQ ID NO: 5909 protein  133 RSV688 Nanobody binding to RSV F LG202C1US20110182897 SEQ ID NO: 5910 protein  134 RSV689 Nanobody binding toRSV F LG202C11 US20110182897 SEQ ID NO: 5911 protein  135 RSV690Nanobody binding to RSV F LG202C2 US20110182897 SEQ ID NO: 5912 protein 136 RSV691 Nanobody binding to RSV F LG202C7 US20110182897 SEQ ID NO:5913 protein  137 RSV692 Nanobody binding to RSV F LG202C8 US20110182897SEQ ID NO: 5914 protein  138 RSV693 Nanobody binding to RSV F LG202C9US20110182897 SEQ ID NO: 5915 protein  139 RSV694 Nanobody binding toRSV F LG202D5 US20110182897 SEQ ID NO: 5916 protein  140 RSV695 Nanobodybinding to RSV F LG202D7 US20110182897 SEQ ID NO: 5917 protein  141RSV696 Nanobody binding to RSV F LG202D8 US20110182897 SEQ ID NO: 5918protein  142 RSV697 Nanobody binding to RSV F LG202E11 US20110182897 SEQID NO: 5919 protein  143 RSV698 Nanobody binding to RSV F LG202E2US20110182897 SEQ ID NO: 5920 protein  144 RSV699 Nanobody binding toRSV F LG202E5 US20110182897 SEQ ID NO: 5921 protein  145 RSV700 Nanobodybinding to RSV F LG202E6 US20110182897 SEQ ID NO: 5922 protein  146RSV701 Nanobody binding to RSV F LG202E7 US20110182897 SEQ ID NO: 5923protein  147 RSV702 Nanobody binding to RSV F LG202F10 US20110182897 SEQID NO: 5924 protein  148 RSV703 Nanobody binding to RSV F LG202F12US20110182897 SEQ ID NO: 5925 protein  149 RSV704 Nanobody binding toRSV F LG202F3 US20110182897 SEQ ID NO: 5926 protein  150 RSV705 Nanobodybinding to RSV F LG202F4 US20110182897 SEQ ID NO: 5927 protein  151RSV706 Nanobody binding to RSV F LG202F8 US20110182897 SEQ ID NO: 5928protein  152 RSV707 Nanobody binding to RSV F LG202G11 US20110182897 SEQID NO: 5929 protein  153 RSV708 Nanobody binding to RSV F LG202G3US20110182897 SEQ ID NO: 5930 protein  154 RSV709 Nanobody binding toRSV F LG202G8 US20110182897 SEQ ID NO: 5931 protein  155 RSV710 Nanobodybinding to RSV F LG202H2 US20110182897 SEQ ID NO: 5932 protein  156RSV711 Nanobody binding to RSV F LG202H8 US20110182897 SEQ ID NO: 5933protein  157 RSV712 Nanobody binding to RSV F LG191B9 US20110182897 SEQID NO: 5934 protein  158 RSV713 Nanobody binding to RSV F LG191D3US20110182897 SEQ ID NO: 5935 protein  159 RSV714 Nanobody binding toRSV F LG192A8 US20110182897 SEQ ID NO: 5936 protein  160 RSV715 Nanobodybinding to RSV F LG192B1 US20110182897 SEQ ID NO: 5937 protein  161RSV716 Nanobody binding to RSV F LG192C10 US20110182897 SEQ ID NO: 5938protein  162 RSV717 Nanobody binding to RSV F LG192C4 US20110182897 SEQID NO: 5939 protein  163 RSV718 Nanobody binding to RSV F LG192C6US20110182897 SEQ ID NO: 5940 protein  164 RSV719 Nanobody binding toRSV F LG192D3 US20110182897 SEQ ID NO: 5941 protein  165 RSV720 Nanobodybinding to RSV F LG191E4 US20110182897 SEQ ID NO: 5942 protein  166RSV721 Nanobody binding to RSV F LG192F2 US20110182897 SEQ ID NO: 5943protein  167 RSV722 Nanobody binding to RSV F LG192H1 US20110182897 SEQID NO: 5944 protein  168 RSV723 Nanobody binding to RSV F LG192H2US20110182897 SEQ ID NO: 5945 protein  169 RSV724 Nanobody binding toRSV F LG20610B US20110182897 SEQ ID NO: 5946 protein  170 RSV725Nanobody binding to RSV F LG20610C US20110182897 SEQ ID NO: 5947 protein 171 RSV726 Nanobody binding to RSV F LG20610D US20110182897 SEQ ID NO:5948 protein  172 RSV727 Nanobody binding to RSV F LG20610EUS20110182897 SEQ ID NO: 5949 protein  173 RSV728 Nanobody binding toRSV F LG20610F US20110182897 SEQ ID NO: 5950 protein  174 RSV729Nanobody binding to RSV F LG20611D US20110182897 SEQ ID NO: 5951 protein 175 RSV730 Nanobody binding to RSV F LG20611H US20110182897 SEQ ID NO:5952 protein  176 RSV731 Nanobody binding to RSV F LG20612FUS20110182897 SEQ ID NO: 5953 protein  177 RSV732 Nanobody binding toRSV F LG2062A US20110182897 SEQ ID NO: 5954 protein  178 RSV733 Nanobodybinding to RSV F LG2062C US20110182897 SEQ ID NO: 5955 protein  179RSV734 Nanobody binding to RSV F LG2062E US20110182897 SEQ ID NO: 5956protein  180 RSV735 Nanobody binding to RSV F LG2062F US20110182897 SEQID NO: 5957 protein  181 RSV736 Nanobody binding to RSV F LG2062GUS20110182897 SEQ ID NO: 5958 protein  182 RSV737 Nanobody binding toRSV F LG2062H US20110182897 SEQ ID NO: 5959 protein  183 RSV738 Nanobodybinding to RSV F LG2063A US20110182897 SEQ ID NO: 5960 protein  184RSV739 Nanobody binding to RSV F LG2063B US20110182897 SEQ ID NO: 5961protein  185 RSV740 Nanobody binding to RSV F LG2063C US20110182897 SEQID NO: 5962 protein  186 RSV741 Nanobody binding to RSV F LG2063DUS20110182897 SEQ ID NO: 5963 protein  187 RSV742 Nanobody binding toRSV F LG2063E US20110182897 SEQ ID NO: 5964 protein  188 RSV743 Nanobodybinding to RSV F LG2063F US20110182897 SEQ ID NO: 5965 protein  189RSV744 Nanobody binding to RSV F LG2064D US20110182897 SEQ ID NO: 5966protein  190 RSV745 Nanobody binding to RSV F LG2064G US20110182897 SEQID NO: 5967 protein  191 RSV746 Nanobody binding to RSV F LG2065AUS20110182897 SEQ ID NO: 5968 protein  192 RSV747 Nanobody binding toRSV F LG2065E US20110182897 SEQ ID NO: 5969 protein  193 RSV748 Nanobodybinding to RSV F LG2066A US20110182897 SEQ ID NO: 5970 protein  194RSV749 Nanobody binding to RSV F LG2066D US20110182897 SEQ ID NO: 5971protein  195 RSV750 Nanobody binding to RSV F LG2067B US20110182897 SEQID NO: 5972 protein  196 RSV751 Nanobody binding to RSV F LG2067CUS20110182897 SEQ ID NO: 5973 protein  197 RSV752 Nanobody binding toRSV F LG2067E US20110182897 SEQ ID NO: 5974 protein  198 RSV753 Nanobodybinding to RSV F LG2067G US20110182897 SEQ ID NO: 5975 protein  199RSV754 Nanobody binding to RSV F LG2067H US20110182897 SEQ ID NO: 5976protein  200 RSV755 Nanobody binding to RSV F LG20711A US20110182897 SEQID NO: 5977 protein  201 RSV756 Nanobody binding to RSV F LG20711BUS20110182897 SEQ ID NO: 5978 protein  202 RSV757 Nanobody binding toRSV F LG20711D US20110182897 SEQ ID NO: 5979 protein  203 RSV758Nanobody binding to RSV F LG20711E US20110182897 SEQ ID NO: 5980 protein 204 RSV759 Nanobody binding to RSV F LG20711F US20110182897 SEQ ID NO:5981 protein  205 RSV760 Nanobody binding to RSV F LG20711GUS20110182897 SEQ ID NO: 5982 protein  206 RSV761 Nanobody binding toRSV F LG20711H US20110182897 SEQ ID NO: 5983 protein  207 RSV762Nanobody binding to RSV F LG2071A US20110182897 SEQ ID NO: 5984 protein 208 RSV763 Nanobody binding to RSV F LG2071B US20110182897 SEQ ID NO:5985 protein  209 RSV764 Nanobody binding to RSV F LG2071C US20110182897SEQ ID NO: 5986 protein  210 RSV765 Nanobody binding to RSV F LG207D1US20110182897 SEQ ID NO: 5987 protein  211 RSV766 Nanobody binding toRSV F LG2071E US20110182897 SEQ ID NO: 5988 protein  212 RSV767 Nanobodybinding to RSV F LG2071F US20110182897 SEQ ID NO: 5989 protein  213RSV768 Nanobody binding to RSV F LG2074A US20110182897 SEQ ID NO: 5990protein  214 RSV769 Nanobody binding to RSV F LG2074B US20110182897 SEQID NO: 5991 protein  215 RSV770 Nanobody binding to RSV F LG2074DUS20110182897 SEQ ID NO: 5992 protein  216 RSV771 Nanobody binding toRSV F LG2074H US20110182897 SEQ ID NO: 5993 protein  217 RSV772 Nanobodybinding to RSV F LG2075A US20110182897 SEQ ID NO: 5994 protein  218RSV773 Nanobody binding to RSV F LG2075B US20110182897 SEQ ID NO: 5995protein  219 RSV774 Nanobody binding to RSV F LG2075C US20110182897 SEQID NO: 5996 protein  220 RSV775 Nanobody binding to RSV F LG2075DUS20110182897 SEQ ID NO: 5997 protein  221 RSV776 Nanobody binding toRSV F LG2075E US20110182897 SEQ ID NO: 5998 protein  222 RSV777 Nanobodybinding to RSV F LG2076A US20110182897 SEQ ID NO: 5999 protein  223RSV778 Nanobody binding to RSV F LG2076B US20110182897 SEQ ID NO: 6000protein  224 RSV779 Nanobody binding to RSV F LG2076C US20110182897 SEQID NO: 6001 protein  225 RSV780 Nanobody binding to RSV F LG2076DUS20110182897 SEQ ID NO: 6002 protein  226 RSV781 Nanobody binding toRSV F LG2076E US20110182897 SEQ ID NO: 6003 protein  227 RSV782 Nanobodybinding to RSV F LG2076F US20110182897 SEQ ID NO: 6004 protein  228RSV783 Nanobody binding to RSV F LG2079A US20110182897 SEQ ID NO: 6005protein  229 RSV784 Nanobody binding to RSV F LG2079B US20110182897 SEQID NO: 6006 protein  230 RSV785 Nanobody binding to RSV F LG2079CUS20110182897 SEQ ID NO: 6007 protein  231 RSV786 Nanobody binding toRSV F LG2079D US20110182897 SEQ ID NO: 6008 protein  232 RSV787 Nanobodybinding to RSV F LG2079E US20110182897 SEQ ID NO: 6009 protein  233RSV788 Nanobody binding to RSV F LG2079F US20110182897 SEQ ID NO: 6010protein  234 RSV789 Nanobody binding to RSV F LG2079G US20110182897 SEQID NO: 6011 protein  235 RSV790 Nanobody binding to RSV F LG2079HUS20110182897 SEQ ID NO: 6012 protein  236 RSV791 Nanobody binding toRSV F LG213B7 US20110182897 SEQ ID NO: 6013 protein  237 RSV792 Nanobodybinding to RSV F LG213D6 US20110182897 SEQ ID NO: 6014 protein  238RSV793 Nanobody binding to RSV F LG213D7 US20110182897 SEQ ID NO: 6015protein  239 RSV794 Nanobody binding to RSV F LG213E6 US20110182897 SEQID NO: 6016 protein  240 RSV795 Nanobody binding to RSV F LG213H7US20110182897 SEQ ID NO: 6017 protein  241 RSV796 Nanobody binding toRSV F LG214A8 US20110182897 SEQ ID NO: 6018 protein  242 RSV797 Nanobodybinding to RSV F LG214C10 US20110182897 SEQ ID NO: 6019 protein  243RSV798 Nanobody binding to RSV F LG214D10 US20110182897 SEQ ID NO: 6020protein  244 RSV799 Nanobody binding to RSV F LG214E8 US20110182897 SEQID NO: 6021 protein  245 RSV800 Nanobody binding to RSV F LG214F8US20110182897 SEQ ID NO: 6022 protein  246 RSV801 Nanobody binding toRSV F LG214H10 US20110182897 SEQ ID NO: 6023 protein  247 RSV802Nanobody binding to RSV F RSVPMP5C1 US20110182897 SEQ ID NO: 6024protein  248 RSV803 Nanobody binding to RSV F RSVPMP8A1 US20110182897SEQ ID NO: 6025 protein  249 RSV804 Nanobody binding to RSV F RSVPMP8G1US20110182897 SEQ ID NO: 6026 protein  250 RSV805 Nanobody binding toRSV F RSVPMP25B3 US20110182897 SEQ ID NO: 6027 protein  251 RSV806Nanobody binding to RSV F RSVPMP8C8 US20110182897 SEQ ID NO: 6028protein  252 RSV807 Nanobody binding to RSV F RSVPMP5A6 US20110182897SEQ ID NO: 6029 protein  253 RSV808 Nanobody binding to RSV F RSVPMP8E11US20110182897 SEQ ID NO: 6030 protein  254 RSV809 Nanobody binding toRSV F RSVPMP8F11 US20110182897 SEQ ID NO: 6031 protein  255 RSV810Nanobody binding to RSV F RSVPMP13F11 US20110182897 SEQ ID NO: 6032protein  256 RSV811 Nanobody binding to RSV F RSVPMP15B8 US20110182897SEQ ID NO: 6033 protein  257 RSV812 Nanobody binding to RSV FRSVPMP15G11 US20110182897 SEQ ID NO: 6034 protein  258 RSV813 Nanobodybinding to RSV F RSVPMP17C10 US20110182897 SEQ ID NO: 6035 protein  259RSV814 Nanobody binding to RSV F RSVPMP21E7 US20110182897 SEQ ID NO:6036 protein  260 RSV815 Nanobody binding to RSV F RSVPMP21F8US20110182897 SEQ ID NO: 6037 protein  261 RSV816 Nanobody binding toRSV F RSVPMP5A2 US20110182897 SEQ ID NO: 6038 protein  262 RSV817Nanobody binding to RSV F RSVPMP5B2 US20110182897 SEQ ID NO: 6039protein  263 RSV818 Nanobody binding to RSV F RSVPMP5C3 US20110182897SEQ ID NO: 6040 protein  264 RSV819 Nanobody binding to RSV F RSVPMP5D2US20110182897 SEQ ID NO: 6041 protein  265 RSV820 Nanobody binding toRSV F RSVPMP5E2 US20110182897 SEQ ID NO: 6042 protein  266 RSV821Nanobody binding to RSV F RSVPMP5F3 US20110182897 SEQ ID NO: 6043protein  267 RSV822 Nanobody binding to RSV F RSVPMP5G3 US20110182897SEQ ID NO: 6044 protein  268 RSV823 Nanobody binding to RSV F RSVPMP5H2US20110182897 SEQ ID NO: 6045 protein  269 RSV824 Nanobody binding toRSV F RSVPMP5H3 US20110182897 SEQ ID NO: 6046 protein  270 RSV825Nanobody binding to RSV F RSVPMP8C1 US20110182897 SEQ ID NO: 6047protein  271 RSV826 Nanobody binding to RSV F RSVPMP8F2 US20110182897SEQ ID NO: 6048 protein  272 RSV827 Nanobody binding to RSV F RSVPMP8G4US20110182897 SEQ ID NO: 6049 protein  273 RSV828 Nanobody binding toRSV F RSVPMP13A1 US20110182897 SEQ ID NO: 6050 protein  274 RSV829Nanobody binding to RSV F RSVPMP13A4 US20110182897 SEQ ID NO: 6051protein  275 RSV830 Nanobody binding to RSV F RSVPMP13B1 US20110182897SEQ ID NO: 6052 protein  276 RSV831 Nanobody binding to RSV F RSVPMP13B2US20110182897 SEQ ID NO: 6053 protein  277 RSV832 Nanobody binding toRSV F RSVPMP13C1 US20110182897 SEQ ID NO: 6054 protein  278 RSV833Nanobody binding to RSV F RSVPMP13C3 US20110182897 SEQ ID NO: 6055protein  279 RSV834 Nanobody binding to RSV F RSVPMP13D6 US20110182897SEQ ID NO: 6056 protein  280 RSV835 Nanobody binding to RSV F RSVPMP13E2US20110182897 SEQ ID NO: 6057 protein  281 RSV836 Nanobody binding toRSV F RSVPMP13E3 US20110182897 SEQ ID NO: 6058 protein  282 RSV837Nanobody binding to RSV F RSVPMP15A5 US20110182897 SEQ ID NO: 6059protein  283 RSV838 Nanobody binding to RSV F RSVPMP15A6 US20110182897SEQ ID NO: 6060 protein  284 RSV839 Nanobody binding to RSV F RSVPMP15B2US20110182897 SEQ ID NO: 6061 protein  285 RSV840 Nanobody binding toRSV F RSVPMP15B3 US20110182897 SEQ ID NO: 6062 protein  286 RSV841Nanobody binding to RSV F RSVPMP15E5 US20110182897 SEQ ID NO: 6063protein  287 RSV842 Nanobody binding to RSV F RSVPMP17C2 US20110182897SEQ ID NO: 6064 protein  288 RSV843 Nanobody binding to RSV F RSVPMP17D4US20110182897 SEQ ID NO: 6065 protein  289 RSV844 Nanobody binding toRSV F RSVPMP17G4 US20110182897 SEQ ID NO: 6066 protein  290 RSV845Nanobody binding to RSV F RSVPMP19B2 US20110182897 SEQ ID NO: 6067protein  291 RSV846 Nanobody binding to RSV F RSVPMP25A4 US20110182897SEQ ID NO: 6068 protein  292 RSV847 Nanobody binding to RSV F RSVPMP25A9US20110182897 SEQ ID NO: 6069 protein  293 RSV848 Nanobody binding toRSV F RSVPMP25B5 US20110182897 SEQ ID NO: 6070 protein  294 RSV849Nanobody binding to RSV F RSVPMP25G2 US20110182897 SEQ ID NO: 6071protein  295 RSV850 Nanobody binding to RSV F RSVPMP25H5 US20110182897SEQ ID NO: 6072 protein  296 RSV851 Nanobody binding to RSV FRSVPMP25E11 US20110182897 SEQ ID NO: 6073 protein  297 RSV852 Nanobodybinding to RSV F RSVPMP8G3 US20110182897 SEQ ID NO: 6074 protein  298RSV853 Nanobody binding to RSV F RSVPMP13B5 US20110182897 SEQ ID NO:6075 protein  299 RSV854 Nanobody binding to RSV F RSVPMP15F2US20110182897 SEQ ID NO: 6076 protein  300 RSV855 Nanobody binding toRSV F RSVPMP19E2 US20110182897 SEQ ID NO: 6077 protein  301 RSV856Nanobody binding to RSV F RSVPMP25D1 US20110182897 SEQ ID NO: 6078protein  302 RSV857 Nanobody binding to RSV F RSVPMP5A1 US20110182897SEQ ID NO: 6079 protein  303 RSV858 Nanobody binding to RSV F RSVPMP5G2US20110182897 SEQ ID NO: 6080 protein  304 RSV859 Nanobody binding toRSV F RSVPMP5H1 US20110182897 SEQ ID NO: 6081 protein  305 RSV860Nanobody binding to RSV F RSVPMP6B1 US20110182897 SEQ ID NO: 6082protein  306 RSV861 Nanobody binding to RSV F RSVPMP8H2 US20110182897SEQ ID NO: 6083 protein  307 RSV862 Nanobody binding to RSV F RSVPMP8H3US20110182897 SEQ ID NO: 6084 protein  308 RSV863 Nanobody binding toRSV F RSVPMP13A3 US20110182897 SEQ ID NO: 6085 protein  309 RSV864Nanobody binding to RSV F RSVPMP13C5 US20110182897 SEQ ID NO: 6086protein  310 RSV865 Nanobody binding to RSV F RSVPMP13H1 US20110182897SEQ ID NO: 6087 protein  311 RSV866 Nanobody binding to RSV F RSVPMP13H2US20110182897 SEQ ID NO: 6088 protein  312 RSV867 Nanobody binding toRSV F RSVPMP15E6 US20110182897 SEQ ID NO: 6089 protein  313 RSV868Nanobody binding to RSV F RSVPMP17A3 US20110182897 SEQ ID NO: 6090protein  314 RSV869 Nanobody binding to RSV F RSVPMP25G8 US20110182897SEQ ID NO: 6091 protein  315 RSV870 Nanobody binding to RSV F RSVPMP6D1US20110182897 SEQ ID NO: 6092 protein  316 RSV871 Nanobody binding toRSV F RSVPMP8D5 US20110182897 SEQ ID NO: 6093 protein  317 RSV872Nanobody binding to RSV F RSVPMP13B4 US20110182897 SEQ ID NO: 6094protein  318 RSV873 Nanobody binding to RSV F RSVPMP13B6 US20110182897SEQ ID NO: 6095 protein  319 RSV874 Nanobody binding to RSV F RSVPMP13E6US20110182897 SEQ ID NO: 6096 protein  320 RSV875 Nanobody binding toRSV F RSVPMP13F4 US20110182897 SEQ ID NO: 6097 protein  321 RSV876Nanobody binding to RSV F RSVPMP15H3 US20110182897 SEQ ID NO: 6098protein  322 RSV877 Nanobody binding to RSV F RSVPMP17E5 US20110182897SEQ ID NO: 6099 protein  323 RSV878 Nanobody binding to RSV F RSVPMP19D3US20110182897 SEQ ID NO: 6100 protein  324 RSV879 Nanobody binding toRSV F RSVPMP19F3 US20110182897 SEQ ID NO: 6101 protein  325 RSV880Nanobody binding to RSV F RSVPMP25C4 US20110182897 SEQ ID NO: 6102protein  326 RSV881 Nanobody binding to RSV F RSVPMP25E3 US20110182897SEQ ID NO: 6103 protein  327 RSV882 Nanobody binding to RSV F RSVPMP5G4US20110182897 SEQ ID NO: 6104 protein  328 RSV883 Nanobody binding toRSV F RSVPMP6G5 US20110182897 SEQ ID NO: 6105 protein  329 RSV884Nanobody binding to RSV F RSVPMP8E6 US20110182897 SEQ ID NO: 6106protein  330 RSV885 Nanobody binding to RSV F RSVPMP13A10 US20110182897SEQ ID NO: 6107 protein  331 RSV886 Nanobody binding to RSV FRSVPMP21H10 US20110182897 SEQ ID NO: 6108 protein  332 RSV887 Nanobodybinding to RSV F RSVPMP5A8 US20110182897 SEQ ID NO: 6109 protein  333RSV888 Nanobody binding to RSV F RSVPMP5A10 US20110182897 SEQ ID NO:6110 protein  334 RSV889 Nanobody binding to RSV F RSVPMPHA6US20110182897 SEQ ID NO: 6111 protein  335 RSV890 Nanobody binding toRSV F RSVPMP16A6 US20110182897 SEQ ID NO: 6112 protein  336 RSV891Nanobody binding to RSV F RSVPMP22D6 US20110182897 SEQ ID NO: 6113protein  337 RSV892 Nanobody binding to RSV F RSVPMP8E2 US20110182897SEQ ID NO: 6114 protein  338 RSV893 Nanobody binding to RSV F RSVPMP8C6US20110182897 SEQ ID NO: 6115 protein  339 RSV894 Nanobody binding toRSV F RSVPMP5C6 US20110182897 SEQ ID NO: 6116 protein  340 RSV895Nanobody binding to RSV F RSVPMP6D4 US20110182897 SEQ ID NO: 6117protein  341 RSV896 Nanobody binding to RSV F RSVPMP8B10 US20110182897SEQ ID NO: 6118 protein  342 RSV897 Nanobody binding to RSV F RSVPMP8E10US20110182897 SEQ ID NO: 6119 protein  343 RSV898 Nanobody binding toRSV F RSVPMP15A7 US20110182897 SEQ ID NO: 6120 protein  344 RSV899Nanobody binding to RSV F RSVPMP15E10 US20110182897 SEQ ID NO: 6121protein  345 RSV900 Nanobody binding to RSV F RSVPMP13C7 US20110182897SEQ ID NO: 6122 protein  346 RSV901 Nanobody binding to RSV F RSVPMP15A9US20110182897 SEQ ID NO: 6123 protein  347 RSV902 Nanobody binding toRSV F RSVPMP15F11 US20110182897 SEQ ID NO: 6124 protein  348 RSV903Nanobody binding to RSV F RSVPMP15A1 US20110182897 SEQ ID NO: 6125protein  349 RSV904 Nanobody binding to RSV F RSVPMP6H2 US20110182897SEQ ID NO: 6126 protein  350 RSV905 Nanobody binding to RSV F RSVPMP17A9US20110182897 SEQ ID NO: 6127 protein  351 RSV906 Nanobody binding toRSV F RSVPMP7G1 US20110182897 SEQ ID NO: 6128 protein  352 RSV907Nanobody binding to RSV F RSVPMP5A9 US20110182897 SEQ ID NO: 6129protein  353 RSV908 Nanobody binding to RSV F RSVPMP7B2 US20110182897SEQ ID NO: 6130 protein  354 RSV909 Nanobody binding to RSV F RSVPMP22A4US20110182897 SEQ ID NO: 6131 protein  355 RSV910 Nanobody binding toRSV F RSVPMP22E10 US20110182897 SEQ ID NO: 6132 protein  356 RSV911Nanobody binding to RSV F RSVPMP22H4 US20110182897 SEQ ID NO: 6133protein  357 RSV912 Nanobody binding to RSV F RSVPMP15C5 US20110182897SEQ ID NO: 6134 protein  358 RSV913 Nanobody binding to RSV F RSVNC39US20110182897 SEQ ID NO: 6135 protein  359 RSV914 Nanobody binding toRSV F RSVPMP7B9 US20110182897 SEQ ID NO: 6136 protein  360 RSV915Nanobody binding to RSV F RSVPMP15E11 US20110182897 SEQ ID NO: 6137protein  361 RSV916 Nanobody binding to RSV F RSVPMP7E7 US20110182897SEQ ID NO: 6138 protein  362 RSV917 Nanobody binding to RSV F RSVPMP14H3US20110182897 SEQ ID NO: 6139 protein  363 RSV918 Nanobody binding toRSV F RSVPMP24D6 US20110182897 SEQ ID NO: 6140 protein  364 RSV919Nanobody binding to RSV F RSVPMP23E5 US20110182897 SEQ ID NO: 6141protein  365 RSV920 Nanobody binding to RSV F RSVPMP8A6 US20110182897SEQ ID NO: 6142 protein  366 RSV921 Nanobody binding to RSV F RSVPMP14E2US20110182897 SEQ ID NO: 6143 protein  367 RSV922 Nanobody binding toRSV F RSVPMP25F3 US20110182897 SEQ ID NO: 6144 protein  368 RSV923Nanobody binding to RSV F RSVPMP19A6 US20110182897 SEQ ID NO: 6145protein  369 RSV924 Nanobody binding to RSV F RSVPMP23G1 US20110182897SEQ ID NO: 6146 protein  370 RSV925 Nanobody binding to RSV F RSVPMP15H8US20110182897 SEQ ID NO: 6147 protein  371 RSV926 Nanobody binding toRSV F RSVNC41 US20110182897 SEQ ID NO: 6148 protein  372 RSV927 Nanobodybinding to RSV F RSVPMP6A8 US20110182897 SEQ ID NO: 6149 protein  373RSV928 Nanobody binding to RSV F RSVPMP25H9 US20110182897 SEQ ID NO:6150 protein  374 RSV929 Nanobody binding to RSV F RSVPMP8B11US20110182897 SEQ ID NO: 6151 protein  375 RSV930 Nanobody binding toRSV F RSVPMP17E1 US20110182897 SEQ ID NO: 6152 protein  376 RSV931Nanobody binding to RSV F RSVPMP21A4 US20110182897 SEQ ID NO: 6153protein  377 RSV932 Nanobody binding to RSV F RSVPMP25A11 US20110182897SEQ ID NO: 6154 protein  378 RSV933 Nanobody binding to RSV F RSVPMP25C8US20110182897 SEQ ID NO: 6155 protein  379 RSV934 Nanobody binding toRSV F RSVNC23 US20110182897 SEQ ID NO: 6156 protein  380 RSV935 Nanobodybinding to RSV F RSVPMP20A11 US20110182897 SEQ ID NO: 6157 protein  381RSV936 Nanobody binding to RSV F RSVPMP20A9 US20110182897 SEQ ID NO:6158 protein  382 RSV937 Nanobody binding to RSV F RSVPMP1F7US20110182897 SEQ ID NO: 6159 protein  383 RSV938 Nanobody binding toRSV F RSVPMP20D6 US20110182897 SEQ ID NO: 6160 protein  384 RSV939Nanobody binding to RSV F RSVPMP1F1 US20110182897 SEQ ID NO: 6161protein  385 RSV940 Nanobody binding to RSV F RSVPMP3D3 US20110182897SEQ ID NO: 6162 protein  386 RSV941 Nanobody binding to RSV F RSVPMP3E6US20110182897 SEQ ID NO: 6163 protein  387 RSV942 Nanobody binding toRSV F RSVPMP1C8 US20110182897 SEQ ID NO: 6164 protein  388 RSV943Nanobody binding to RSV F RSVPMP1A2 US20110182897 SEQ ID NO: 6165protein  389 RSV944 Nanobody binding to RSV F RSVPMP1C5 US20110182897SEQ ID NO: 6166 protein  390 RSV945 Nanobody binding to RSV F RSVPMP20G5US20110182897 SEQ ID NO: 6167 protein  391 RSV946 Nanobody binding toRSV F RSVPMP4D8 US20110182897 SEQ ID NO: 6168 protein  392 RSV947Nanobody binding to RSV F RSVPMP20B6 US20110182897 SEQ ID NO: 6169protein  393 RSV948 Nanobody binding to RSV F RSVPMP1D11 US20110182897SEQ ID NO: 6170 protein  394 RSV949 Nanobody binding to RSV F RSVPMP20A8US20110182897 SEQ ID NO: 6171 protein  395 RSV950 Nanobody binding toRSV F RSVPMP20E7 US20110182897 SEQ ID NO: 6172 protein  396 RSV951Nanobody binding to RSV F RSVPMP20G8 US20110182897 SEQ ID NO: 6173protein  397 RSV952 Nanobody binding to RSV F RSVPMP2D3 US20110182897SEQ ID NO: 6174 protein  398 RSV953 Nanobody binding to RSV F RSVPMP2G5US20110182897 SEQ ID NO: 6175 protein  399 RSV954 Nanobody binding toRSV F RSVPMP2A6 US20110182897 SEQ ID NO: 6176 protein  400 RSV955Nanobody binding to RSV F RSVPMP3A2 US20110182897 SEQ ID NO: 6177protein  401 RSV956 Nanobody binding to RSV F RSVPMP4A8 US20110182897SEQ ID NO: 6178 protein  402 RSV957 Nanobody binding to RSV F RSVPMP4F9US20110182897 SEQ ID NO: 6179 protein  403 RSV958 Nanobody binding toRSV F RSVPMP1A6 US20110182897 SEQ ID NO: 6180 protein  404 RSV959Nanobody binding to RSV F RSVPMP3C2 US20110182897 SEQ ID NO: 6181protein  405 RSV960 Nanobody binding to RSV F RSVPMP4H9 US20110182897SEQ ID NO: 6182 protein  406 RSV961 Nanobody binding to RSV F RSVPMP4B10US20110182897 SEQ ID NO: 6183 protein  407 RSV962 Nanobody binding toRSV F 203B1 US20110182897 SEQ ID NO: 6184 protein 2431 RSV963 Nanobodybinding to RSV F 203B2 US20110182897 SEQ ID NO: 6185 protein 2432 RSV964Nanobody binding to RSV F 203G1 US20110182897 SEQ ID NO: 6186 protein2433 RSV965 Nanobody binding to RSV F 203H1 US20110182897 SEQ ID NO:6187 protein 2434 RSV966 Nanobody binding to RSV F 202E4 US20110182897SEQ ID NO: 6188 protein 2435 RSV967 Nanobody binding to RSV F 189E2US20110182897 SEQ ID NO: 6189 protein 2436 RSV968 Nanobody binding toRSV F 203A12 US20110182897 SEQ ID NO: 6190 protein 2437 RSV969 Nanobodybinding to RSV F 203A9 US20110182897 SEQ ID NO: 6191 protein 2438 RSV970Nanobody binding to RSV F 203B12 US20110182897 SEQ ID NO: 6192 protein2439 RSV971 Nanobody binding to RSV F 203D2 US20110182897 SEQ ID NO:6193 protein 2440 RSV972 Nanobody binding to RSV F 203D9 US20110182897SEQ ID NO: 6194 protein 2441 RSV973 Nanobody binding to RSV F 203G3US20110182897 SEQ ID NO: 6195 protein 2442 RSV974 Nanobody binding toRSV F 203G9 US20110182897 SEQ ID NO: 6196 protein 2443 RSV975 Nanobodybinding to RSV F 203G10 US20110182897 SEQ ID NO: 6197 protein 2444RSV976 Nanobody binding to RSV F 203H9 US20110182897 SEQ ID NO: 6198protein 2445 RSV977 Nanobody binding to RSV F 203H10 US20110182897 SEQID NO: 6199 protein 2446 RSV978 Nanobody binding to RSV F 202E4US20110182897 SEQ ID NO: 6200 protein 2447 RSV979 Nanobody binding toRSV F 189E2 US20110182897 SEQ ID NO: 6201 protein 2448 RSV980 Nanobodybinding to RSV F PRSVPMP20C3 US20110182897 SEQ ID NO: 6202 protein 2574RSV981 Nanobody binding to RSV F PRSVPMP20C5 US20110182897 SEQ ID NO:6203 protein 2575 RSV982 Nanobody binding to RSV F PRSVPMP20B2US20110182897 SEQ ID NO: 6204 protein 2576 RSV983 Nanobody binding toRSV F PRSVPMP20C1 US20110182897 SEQ ID NO: 6205 protein 2577 RSV984Nanobody binding to RSV F PRSVPMP1G8 US20110182897 SEQ ID NO: 6206protein 2578 RSV985 Nanobody binding to RSV F PRSVNMP1A4 US20110182897SEQ ID NO: 6207 protein 2579 RSV986 Nanobody binding to RSV FPRSVPMP13E12 US20110182897 SEQ ID NO: 6208 protein 2580 RSV987 Nanobodybinding to RSV F PRSVPMP5C6 US20110182897 SEQ ID NO: 6209 protein 2581RSV988 Nanobody binding to RSV F LG203E7 US20110182897 SEQ ID NO: 6210protein 2682 RSV989 Nanobody binding to RSV F LG203G8 US20110182897 SEQID NO: 6211 protein 2683 RSV990 Nanobody binding to RSV F LG211A10US20110182897 SEQ ID NO: 6212 protein 2684 RSV991 Nanobody binding toRSV F LG211A8 US20110182897 SEQ ID NO: 6213 protein 2685 RSV992 Nanobodybinding to RSV F LG211B10 US20110182897 SEQ ID NO: 6214 protein 2686RSV993 Nanobody binding to RSV F LG211B8 US20110182897 SEQ ID NO: 6215protein 2687 RSV994 Nanobody binding to RSV F LG211C12 US20110182897 SEQID NO: 6216 protein 2688 RSV995 Nanobody binding to RSV F LG211C8US20110182897 SEQ ID NO: 6217 protein 2689 RSV996 Nanobody binding toRSV F LG211D10 US20110182897 SEQ ID NO: 6218 protein 2690 RSV997Nanobody binding to RSV F LG211D8 US20110182897 SEQ ID NO: 6219 protein2691 RSV998 Nanobody binding to RSV F LG211E10 US20110182897 SEQ ID NO:6220 protein 2692 RSV999 Nanobody binding to RSV F LG211E12US20110182897 SEQ ID NO: 6221 protein 2693 RSV1000 Nanobody binding toRSV F LG211E8 US20110182897 SEQ ID NO: 6222 protein 2694 RSV1001Nanobody binding to RSV F LG211H8 US20110182897 SEQ ID NO: 6223 protein2695 RSV1002 Nanobody binding to RSV F LG212A10 US20110182897SEQ ID NO:6224 protein 2696 RSV1003 Nanobody binding to RSV F LG212A12US20110182897 SEQ ID NO: 6225 protein 2697 RSV1004 Nanobody binding toRSV F LG212A2 US20110182897 SEQ ID NO: 6226 protein 2698 RSV1005Nanobody binding to RSV F LG212A8 US20110182897 SEQ ID NO: 6227 protein2699 RSV1006 Nanobody binding to RSV F LG212B12 US20110182897 SEQ ID NO:6228 protein 2700 RSV1007 Nanobody binding to RSV F LG212B2US20110182897 SEQ ID NO: 6229 protein 2701 RSV1008 Nanobody binding toRSV F LG212C12 US20110182897 SEQ ID NO: 6230 protein 2702 RSV1009Nanobody binding to RSV F LG212D10 US20110182897 SEQ ID NO: 6231 protein2703 RSV1010 Nanobody binding to RSV F LG212D12 US20110182897 SEQ ID NO:6232 protein 2704 RSV1011 Nanobody binding to RSV F L0212D2US20110182897 SEQ ID NO: 6233 protein 2705 RSV1012 Nanobody binding toRSV F LG212E10 US20110182897 SEQ ID NO: 6234 protein 2706 RSV1013Nanobody binding to RSV F LG212E12 US20110182897 SEQ ID NO: 6235 protein2707 RSV1014 Nanobody binding to RSV F LG212E6 US20110182897 SEQ ID NO:6236 protein 2708 RSV1015 Nanobody binding to RSV F LG212F10US20110182897 SEQ ID NO: 6237 protein 2709 RSV1016 Nanobody binding toRSV F LG212F12 US20110182897 SEQ ID NO: 6238 protein 2710 RSV1017Nanobody binding to RSV F LG212F6 US20110182897 SEQ ID NO: 6239 protein2711 RSV1018 Nanobody binding to RSV F LG212F8 US20110182897 SEQ ID NO:6240 protein 2712 RSV1019 Nanobody binding to RSV F LG212G10US20110182897 SEQ ID NO: 6241 protein 2713 RSV1020 Nanobody binding toRSV F LG212G2 US20110182897 SEQ ID NO: 6242 protein 2714 RSV1021Nanobody binding to RSV F LG212H10 US20110182897 SEQ ID NO: 6243 protein2715 RSV1022 Nanobody binding to RSV F LG212H2 US20110182897 SEQ ID NO:6244 protein 2716 RSVI023 Nanobody binding to RSV F LG212H8US20110182897 SEQ ID NO: 6245 protein 2717 RSV1024 Nanobody binding toRSV F IV121 US20110182897 SEQ ID NO: 6246 protein 3064 RSV1025 Nanobodybinding to RSV F IV122 US20110182897 SEQ ID NO: 6247 protein 3065RSV1026 Nanobody binding to RSV F IV123 US20110182897 SEQ ID NO: 6248protein 3066 RSV1027 Nanobody binding to RSV F IV126 US20110182897 SEQID NO: 6249 protein 3067 RSV1028 Nanobody binding to RSV F IV127US20110182897 SEQ ID NO: 6250 protein 3068 RSV1029 Nanobody binding toRSV F IV131 US20110182897 SEQ ID NO: 6251 protein 3069 RSV1030 Nanobodybinding to RSV F IV132 US20110182897 SEQ ID NO: 6252 protein 3070RSV1031 Nanobody binding to RSV F IV133 US20110182897 SEQ ID NO: 6253protein 3071 RSV1032 Nanobody binding to RSV F IV134 US20110182897 SEQID NO: 6254 protein 3072 RSV1033 Nanobody binding to RSV F IV135US20110182897 SEQ ID NO: 6255 protein 3073 RSV1034 Nanobody binding toRSV F IV136 US20110182897 SEQ ID NO: 6256 protein 3074 RSV1035 Nanobodybinding to RSV F IV140 US20110182897 SEQ ID NO: 6257 protein 3075RSV1036 Nanobody binding to RSV F IV144 US20110182897 SEQ ID NO: 6258protein 3076 RSV1037 Nanobody binding to RSV F IV156 US20110182897 SEQID NO: 6259 protein 3077 RSV1038 Nanobody binding to RSV F IV157US20110182897 SEQ ID NO: 6260 protein 3078 RSV1039 Nanobody binding toRSV F IV160 US20110182897 SEQ ID NO: 6261 protein 3079 RSV1040 Nanobodybinding to RSV F IV124 US20110182897 SEQ ID NO: 6262 protein 3080RSV1041 Nanobody binding to RSV F IV125 US20110182897 SEQ ID NO: 6263protein 3081 RSV1042 Nanobody binding to RSV F IV145 US20110182897 SEQID NO: 6264 protein 3082 RSV1043 Nanobody binding to RSV F IV146US20110182897 SEQ ID NO: 6265 protein 3083 RSV1044 Nanobody binding toRSV F IV147 US20110182897 SEQ ID NO: 6266 protein 3084 RSV1045 Nanobodybinding to RSV F IV151 US20110182897 SEQ ID NO: 6267 protein 3085RSV1046 Nanobody binding to RSV F IV153 US20110182897 SEQ ID NO: 6268protein 3086 RSV1047 Nanobody binding to RSV F IV154 US20110182897 SEQID NO: 6269 protein 3087 RSV1048 Nanobody binding to RSV F IV155US20110182897 SEQ ID NO: 6270 protein 3088 RSV1049 Nanobody binding toRSV F IV1 US20110182897 SEQ ID NO: 6271 protein 3089 RSV1050 Nanobodybinding to RSV F IV2 US20110182897 SEQ ID NO: 6272 protein 3090 RSV1051Nanobody binding to RSV F IV3 US20110182897 SEQ ID NO: 6273 protein 3091RSV1052 Nanobody binding to RSV F IV4 US20110182897 SEQ ID NO: 6274protein 3092 RSV1053 Nanobody binding to RSV F IV6 US20110182897 SEQ IDNO: 6275 protein 3093 RSV1054 Nanobody binding to RSV F IV7US20110182897 SEQ ID NO: 6276 protein 3094 RSV1055 Nanobody binding toRSV F IV9 US20110182897 SEQ ID NO: 6277 protein 3095 RSV1056 Nanobodybinding to RSV F IV10 US20110182897 SEQ ID NO: 6278 protein 3096 RSV1057Nanobody binding to RSV F IV11 US20110182897 SEQ ID NO: 6279 protein3097 RSV1058 Nanobody binding to RSV F IV12 US20110182897 SEQ ID NO:6280 protein 3098 RSV1059 Nanobody binding to RSV F IV16 US20110182897SEQ ID NO: 6281 protein 3099 RSV1060 Nanobody binding to RSV F IV24US20110182897 SEQ ID NO: 6282 protein 3100 RSV1061 Nanobody binding toRSV F IV26 US20110182897 SEQ ID NO: 6283 protein 3101 RSV1062 Nanobodybinding to RSV F IV30 US20110182897 SEQ ID NO: 6284 protein 3102 RSV1063Nanobody binding to RSV F IV34 US20110182897 SEQ ID NO: 6285 protein3103 RSV1064 Nanobody binding to RSV F IV14 US20110182897 SEQ ID NO:6286 protein 3104 RSV1065 Nanobody binding to RSV F IV15 US20110182897SEQ ID NO: 6287 protein 3105 RSV1066 Nanobody binding to RSV F IV17US20110182897 SEQ ID NO: 6288 protein 3106 RSV1067 Nanobody binding toRSV F IV18 US20110182897 SEQ ID NO: 6289 protein 3107 RSV1068 Nanobodybinding to RSV F IV29 US20110182897 SEQ ID NO: 6290 protein 3108 RSV1069Nanobody binding to RSV F IV31 US20110182897 SEQ ID NO: 6291 protein3109 RSV1070 Nanobody binding to RSV F IV33 US20110182897 SEQ ID NO:6292 protein 3110 RSV1071 Nanobody binding to RSV F IV35 US20110182897SEQ ID NO: 6293 protein 3111 RSV1072 Nanobody binding to RSV F IV36US20110182897 SEQ ID NO: 6294 protein 3112 RSV1073 Nanobody binding toRSV F IV40 US20110182897 SEQ ID NO: 6295 protein 3113 RSV1074 Nanobodybinding to RSV F IV42 US20110182897 SEQ ID NO: 6296 protein 3114 RSV1075Nanobody binding to RSV F IV8 US20110182897 SEQ ID NO: 6297 protein 3115RSV1076 Nanobody binding to RSV F IV21 US20110182897 SEQ ID NO: 6298protein 3116 RSV1077 Nanobody binding to RSV F IV23 US20110182897 SEQ IDNO: 6299 protein 3117 RSV1078 Nanobody binding to RSV F IV45US20110182897 SEQ ID NO: 6300 protein 3118 RSV1079 Nanobody binding toRSV F IV47 US20110182897 SEQ ID NO: 6301 protein 3119 RSV1080 Nanobodybinding to RSV F IV48 US20110182897 SEQ ID NO: 6302 protein 3120 RSV1081Nanobody binding to RSV F IV50 US20110182897 SEQ ID NO: 6303 protein3121 RSV1082 Nanobody binding to RSV F IV22 US20110182897 SEQ ID NO:6304 protein 3122 RSV1083 Nanobody binding to RSV F IV37 US20110182897SEQ ID NO: 6305 protein 3123 RSV1084 Nanobody binding to RSV F IV38US20110182897 SEQ ID NO: 6306 protein 3124 RSV1085 Nanobody binding toRSV F IV5 US20110182897 SEQ ID NO: 6307 protein 3125 RSV1086 Nanobodybinding to RSV F IV27 US20110182897 SEQ ID NO: 6308 protein 3126 RSV1087Nanobody binding to RSV F IV25 US20110182897 SEQ ID NO: 6309 protein3127 RSV1088 Nanobody binding to RSV F IV28 US20110182897 SEQ ID NO:6310 protein 3128

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described in USPublication No. US20140363427, and International Publication No.WO2004083373, the contents of each of which are herein incorporated byreference in their entirety, against RSV F or RSV G protein.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 23 against Hepatitis B, HepatitisC and/or Hepatitis D.

TABLE 23 Antibodies against Hepatitis B, C, D viruses SEQ AntibodyAntibody ID No. Description Name Reference Information NO HEPBD1Anti-preS1 Park, S.G., et al., Hepatitis B virus- 6311 immunoglobulin,neutralizing anti-pre-S1 human antibody HBV Ab fragments from largenaive antibody phage library; Antiviral Res. 68 (3), 109-115 (2005);NCBI Accession # AAW82034.1 (107aa) HEPBD2 Anti-preS1 Park, S.G., etal., Hepatitis B virus- 6312 immunoglobulin, neutralizing anti-pre-S1human antibody HBV Ab fragments from large naive antibody phage library;Antiviral Res. 68 (3), 109-115 (2005); NCBI Accession # AAW82035.1(132aa) HEPBD3 Anti-preS1 Park, S.G., et al., Hepatitis B virus- 6313immunoglobulin, neutralizing anti-pre-S1 human antibody HBV Ab fragmentsfrom large naive antibody phage library; Antiviral Res. 68(3), 109-115(2005); NCBI Accession # AAW82033.1(111aa) HEPBD4 Anti-preS1 Park, S.G.,et al., Hepatitis B virus- 6314 immunoglobulin, neutralizing anti-pre-S1human antibody HBV Ab fragments from large naive antibody phage library;Antiviral Res. 68(3), 109-115 (2005); NCBI Accession # AAW82032.1(142aa) HEPBD5 HCV Ab Hu5b3.v3 Pantua, H., et al., Glycan shifting on6315 hepatitis C virus(HCV) e2 glycoprotein is a mechanism for escapefrom broadly neutralizing antibodies; J. Mol. Biol. 425 (11), 1899-1914(2013) NCBI Accession # 4HS8_H(228aa) HEPBD6 HCV Ab Igh526 Kong L., etal., Structure of Hepatitis C 6316 Virus Envelope Glycoprotein E1Antigenic Site 314-324 in Complex with Antibody IGH526; J. Mol. Biol.427 (16), 2617-2628 (2015) NCBI Accession # 4N0Y_H(231aa) HEPBD7 Heavychain partial, Esposito, G., et al., Recombinant human 6317 HCV Abantibodies specific for hepatitis C virus proteins; Arch. Virol. 142(3), 601-610 (1997) NCBI Accession # CAA54914 (122aa) HEPBD8 Heavy chainvariable EP0521348 6318 gene, Chimeric HBV Ab HEPBD9 Heavy chainvariable Keck, Z.Y., et al., Human monoclonal 6319 region partial, HCVantibody to hepatitis C virUSE1 Ab glycoprotein that blocks virusattachment and viral infectivity; J. Virol. 78 (13), 7257-7263 (2004)NCBI Accession # AAS47839 (142aa) HEPBD10 Heavy chain variable E183/A2US20120308580 SEQ ID NO: 33; WO 6320 region, HBV Ab 2011062562;CN102781961, EP2501723 HEPBD11 Heavy chain variable US20100260712 SEQ IDNO: 1; 6321 region, HBV Ab WO2009069917 HEPBD12 Heavy chain variableWO2015107126 SEQ ID NO: 2 6322 region, HBV Ab HEPBD13 Heavy chainvariable HB48-33, US8840895 SEQ ID NO: 1 6323 region, HBV Ab HB48-35,HB48-59 HEPBD14 Heavy chain variable HFW141 US7435414 SEQ ID NO: 35;6324 region, HBV Ab US20060014937; WO2005100400; CN1980956 HEPBD15 Heavychain variable US7112664 SEQ ID NO: 8; US6680053, 6325 region, HBV AbUS6924368, US20020061581, US20040191259, US20050249753, WO2001092529HEPBD16 Heavy chain variable Ab17.1.4 1 USRE39586 SEQ ID NO: 4;US6146629; 6326 region, HBV Ab WO1997047653 HEPBD17 Heavy chain variableAb 19.79.5 USRE40831 SEQ ID NO: 4 6327 region, HBV Ab HEPBD18 Heavychain variable US20150232537 SEQ ID NO: 7; 6328 region, HB V AbWO2014048910; CA2884388; CN104662041A; EP2900692 HEPBD19 Heavy chainvariable WO2013165972 SEQ ID NO: 45 6329 region, HBV Ab HEPBD20 Heavychain variable WO2013165972 SEQ ID NO: 54 6330 region, HBV Ab HEPBD21Heavy chain variable WO2013165972 SEQ ID NO: 63 6331 region, HBV AbHEPBD22 Heavy chain variable WO2013165972 SEQ ID NO: 72 6332 region, HBVAb HEPBD23 Heavy chain variable WO2013165972 SEQ ID NO: 81 6333 region,HBV Ab HEPBD24 Heavy chain variable WO2013165972 SEQ ID NO: 90 6334region, HBV Ab HEPBD25 Heavy chain variable WO2013165972 SEQ ID NO: 996335 region, HBV Ab HEPBD26 Heavy chain variable WO2013165972 SEQ ID NO:108 6336 region, HBV Ab HEPBD27 Heavy chain variable WO2013165972 SEQ IDNO: 117 6337 region, HBV Ab HEPBD28 Heavy chain variable WO2013165972SEQ ID NO: 126 6338 region, HBV Ab HEPBD29 Heavy chain variableWO2013165972 SEQ ID NO: 135 6339 region, HBV Ab HEPBD30 Heavy chainvariable WO2013165972 SEQ ID NO: 144 6340 region, HBV Ab HEPBD31 Heavychain variable WO2013165972 SEQ ID NO: 153 6341 region, HBV Ab HEPBD32Heavy chain variable WO2013165972 SEQ ID NO: 162 6342 region, HBV AbHEPBD33 Heavy chain variable WO2013165972 SEQ ID NO: 171 6343 region,HBV Ab HEPBD34 Heavy chain variable WO2013165972 SEQ ID NO: 180 6344region, HBV Ab HEPBD35 Heavy chain variable WO2013165972 SEQ ID NO: 1896345 region, HBV Ab HEPBD36 Heavy chain variable WO2013165972 SEQ ID NO:198 6346 region, HBV Ab HEPBD37 Heavy chain variable WO2013165972 SEQ IDNO: 207 6347 region, HBV Ab HEPBD38 Heavy chain variable WO2013165972SEQ ID NO: 405 6348 region, HBV Ab HEPBD39 Heavy chain variableWO2013165972 SEQ ID NO: 409 6349 region, HBV Ab HEPBD40 Heavy chainvariable WO2013165972 SEQ ID NO: 412 6350 region, HBV Ab HEPBD41 Heavychain variable WO2013165972 SEQ ID NO: 418 6351 region, HBV Ab HEPBD42Heavy chain variable WO2013165972 SEQ ID NO: 421 6352 region, HBV AbHEPBD43 Heavy chain variable WO2009069916 SEQ ID NO: 1 6353 region, HBVAb HEPBD44 Heavy chain variable PE1-1 WO1994011495 6354 region, HBV AbHEPBD45 Heavy chain variable ZM1-1 WO1994011495 6355 region, HBV AbHEPBD46 Heavy chain variable ZM1-2 WO1994011495 6356 region, HBV AbHEPBD47 Heavy chain variable MD3-4 WO1994011495 6357 region, HBV AbHEPBD48 Heavy chain variable A2E2 CN102757492 SEQ ID NO: 2 6358 region,HBV Ab HEPBD49 Heavy chain variable C9G9 CN102757492 SEQ ID NO: 6 6359region, HBV Ab HEPBD50 Heavy chain variable CN104530228 SEQ ID NO: 36360 region, HBV Ab HEPBD51 Heavy chain variable CN104530228 SEQ ID NO:4 6361 region, HBV Ab HEPBD52 Heavy chain variable Ab19 US8580256 SEQ IDNO: 2 6362 region, HBV Ab HEPBD53 Heavy chain variable Ab17 US8580256SEQ ID NO: 4 6363 region, HBV Ab HEPBD54 Heavy chain variable KR127US8420353 SEQ ID NO: 28 6364 region, HBV Ab HEPBD55 Heavy chain variableDP7 US8420353 SEQ ID NO: 32 6365 region, HBV Ab HEPBD56 Heavy chainvariable HZ1 US8420353 SEQ ID NO: 36 6366 region, HBV Ab HEPBD57 Heavychain variable MBL-HCV1 US8551484 SEQ ID NO: 1 6367 region, HCV Ab(Antibody produced by clone 83-128) HEPBD58 Heavy chain variableMBL-HCV1 US8551484 SEQ ID NO: 3 6368 region, HCV Ab (Antibody producedby clone 95-2) HEPBD59 Heavy chain variable MBL-HCV1 US8551484 SEQ IDNO: 5 6369 region, HCV Ab (Antibody produced by clone 95-14) HEPBD60Heavy chain variable Clone 13 US7250166 SEQ ID NO: 1 6370 region, HCV AbHEPBD61 Heavy chain variable Clone 98 US7250166 SEQ ID NO: 3 6371region, HCV Ab HEPBD62 Heavy chain variable Clone 1:4 US7250166 SEQ IDNO: 5 6372 region, HCV Ab HEPBD63 Heavy chain variable Clone 1:8US7250166 SEQ ID NO: 7 6373 region, HCV Ab HEPBD64 Heavy chain variableClone 1:9 US7250166 SEQ ID NO: 9 6374 region, HCV Ab HEPBD65 Heavy chainvariable Clone 1:10 US7250166 SEQ ID NO: 11 6375 region, HCV Ab HEPBD66Heavy chain variable Clone 4:6 US7250166 SEQ ID NO: 13 6376 region, HCVAb HEPBD67 Heavy chain variable Clone 6a:5 US7250166 SEQ ID NO: 15 6377region, HCV Ab HEPBD68 Heavy chain variable Clone2a:2 US7250166 SEQ IDNO: 17 6378 region, HCV Ab HEPBD69 Heavy chain variable Clone 2a:4US7250166 SEQ ID NO: 19 6379 region, HCV Ab HEPBD70 Heavy chain variableClone 2a:5 US7250166 SEQ ID NO: 21 6380 region, HCV Ab HEPBD71 Heavychain variable Clone 2a:13 US7250166 SEQ ID NO: 23 6381 region, HCV AbHEPBD72 Heavy chain variable Clone 2a:14 US7250166 SEQ ID NO: 25 6382region, HCV Ab HEPBD73 Heavy chain variable Clone 2a:23 US7250166 SEQ IDNO: 27 6383 region, HCV Ab HEPBD74 Heavy chain variable Clone 2a:23US7250166 SEQ ID NO: 29 6384 region, HCV Ab HEPBD75 Heavy chain variableClone 2a:25 US7250166 SEQ ID NO: 31 6385 region, HCV Ab HEPBD76 Heavychain variable Clone 2a:30 US7250166 SEQ ID NO: 33 6386 region, HCV AbHEPBD77 Heavy chain variable Clone 2a:32 US7250166 SEQ ID NO: 35 6387region, HCV Ab HEPBD78 Heavy chain variable Clone 2a:33 US7250166 SEQ IDNO: 37 6388 region, HCV Ab HEPBD79 Heavy chain variable Clone 2a:37US7250166 SEQ ID NO: 39 6389 region, HCV Ab HEPBD80 Heavy chain variableClone 2a:40 US7250166 SEQ ID NO: 41 6390 region, HCV Ab HEPBD81 Heavychain variable Clone 2b:1 US7250166 SEQ ID NO: 43 6391 region, HCV AbHEPBD82 Heavy chain variable Clone 2b:3 US7250166 SEQ ID NO: 45 6392region, HCV Ab HEPBD83 Heavy chain variable Clone 2b:4 US7250166 SEQ IDNO: 47 6393 region, HCV Ab HEPBD84 Heavy chain variable Clone 2b:5US7250166 SEQ ID NO: 49 6394 region, HCV Ab HEPBD85 Heavy chain variableClone 2b:7 US7250166 SEQ ID NO: 51 6395 region, HCV Ab HEPBD86 Heavychain variable Clone 2b:9 US7250166 SEQ ID NO: 53 6396 region, HCV AbHEPBD87 Heavy chain variable Clone 2b:10 US7250166 SEQ ID NO: 55 6397region, HCV Ab HEPHD88 Heavy chain variable anti-NS3 Fab US7314919 SEQID NO: 1 6398 region, HCV Ab HEPBD89 Heavy chain variable AntibodyUS8551484 SEQ ID NO: 32 6399 region, HCV Ab produced by clone 95-14HEPBD90 Heavy chain variable Antibody US8551484 SEQ ID NO: 33 6400region, HCV Ab produced by clone 95-38 HEPBD91 Heavy chain variableAntibody US8551484 SEQ ID NO: 34 6401 region, HCV Ab produced by clone95-25 HEPBD92 Heavy chain variable Antibody US8551484 SEQ ID NO: 35 6402region, HCV Ab produced by clone 95.42 HEPBD93 Heavy chain variableAntibody US8551484 SEQ ID NO: 36 6403 region, HCV Ab produced by clone95-43 HEPBD94 Heavy chain variable Antibody US8551484 SEQ ID NO: 37 6404region, HCV Ab produced by clone 95-49 HEPBD95 Heavy chain variableAntibody US8551484 SEQ ID NO: 38 6405 region, HCV Ab produced by clone95-54 HEPBD96 Heavy chain variable Antibody US8551484 SEQ ID NO: 39 6406region, HCV Ab produced by clone 95-58 HEPBD97 Heavy chain variableAntibody US8551484 SEQ ID NO: 40 6407 region, HCV Ab produced by clone95-62 HEPBD98 Heavy chain variable HC-84.1 US20130084301 SEQ ID NO: 556408 region, HCV Ab HEPBD99 Heavy chain variable HC-84.20 US20130084301SEQ ID NO: 56 6409 region, HCV Ab HEPBD100 Heavy chain variable HC-84.21US20130084301 SEQ ID NO: 57 6410 region, HCV Ab HEPBD101 Heavy chainvariable HC-84.22 US20130084301 SEQ ID NO: 58 6411 region, HCV AbHEPBD102 Heavy chain variable HC-23 US20130084301 SEQ ID NO: 59 6412region, HCV Ab HEPBD103 Heavy chain variable HC-84.24 US20130084301 SEQID NO: 60 6413 region, HCV Ab HEPBD104 Heavy chain variable HC-84.25US20130084301 SEQ ID NO: 61 6414 region, HCV Ab HEPBD105 Heavy chainvariable HC-84.26 US20130084301 SEQ ID NO: 62 6415 region, HCV AbHEPBD106 Heavy chain variable HC-84.27. US20130084301 SEQ ID NO: 63 6416region, HCV Ab HEPBD107 Heavy chain variable AOT3 US20120009196 SEQ IDNO: 1 6417 region, HCV Ab HEPBD108 Heavy chain variable C11-3US20120009196 SEQ ID NO: 3 6418 region, HCV Ab HEPBD109 Heavy chainvariable C11-7 US20120009196 SEQ ID NO: 5 6419 region, HCV Ab HEPBDI10Heavy chain variable C11-9 US20120009196 SEQ ID NO: 7 6420 region, HCVAb HEPBD111 Heavy chain variable C11-14 US20120009196 SEQ ID NO: 9 6421region, HCV Ab HEPBD112 Heavy chain variable WO2014065822 SEQ ID NO: 36422 region, HCV Ab HEPBD113 Heavy chain variable WO2014065822 SEQ IDNO: 7 6423 region, HCV Ab HEPBD114 Heavy chain variable mPA-29WO2007143701 SEQ ID NO: 2 6424 region, HCV Ab HEPBD115 Heavy chainvariable Hc33.1 Li Y. et al., Structural basis for penetration 6425region, HCV Ab of the glycan shield of hepatitis C virUSe2 glycoproteinby a broadly neutralizing human antibody; J. Biol. Chem. 290 (16),10117-10125 (2015) NCBI Accession # 4XVJ_H (141aa) HEPBD116 Heavy chainvariable Martin, F., et al., Affinity selection of a 6426 region, HCV Abcamelized V(H) domain antibody inhibitor of hepatitis C virUSNS3protease; Protein Eng. 10(5), 607-614 (1997NCBI Accession # 1OL0_B(121aa) HEPBD117 Heavy chain variable US20150118242 SEQ ID NO: 2 6427region, HCV Ab HEPBD118 Heavy chain variable US20150166637 SEQ ID NO: 1,6428 region, Human HBV WO2014010890; CA2878155, antibody that binds toCN104487090, EP2858674 the surface antigen (HBsAg) HEPBD119 Heavy chainvariable US20150166637 SEQ ID NO: 2; 6429 region, Human HBVWO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674the surface antigen (HBsAg) HEPBD120 Heavy chain variable US20150166637SEQ ID NO: 3; 6430 region, Human HBV WO2014010890; CA2878155, antibodythat binds to CN104487090, EP2858674 the surface antigen (HBsAg)HEPBD121 Heavy chain variable US20150166637 SEQ ID NO: 4; 6431 region,Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090,EP2858674 the surface antigen (HBsAg) HEPBD122 Heavy chain variableUS20150166637 SEQ ID NO: 5; 6432 region, Human HBV WO2014010890;CA2878155, antibody that binds to CN104487090, EP2858674 the surfaceantigen (HBsAg) HEPBD123 Heavy chain variable c18/A2 US20120308580 SEQID NO: 2; WO 6433 region, Monoclonal 2011062562; CN102781961, EP2501723HBV antibody HEPBD124 Heavy chain variable US20110097270 SEQ ID NO: 16434 region, Neutralizing monoclonal HBV antibody HEPBD125 Heavy chain,full US20150232537 SEQ ID NO: 9; 6435 HBV Ab WO2014048910; CA2884388;CN104662041A; EP2900692 HEPBD126 Heavy chain, HBV Ab HBFab21 CN103588874SEQ ID NO: 2 6436 HEPBD127 Heavy chain, HCV Ab Fab clone 1:5 US6747136SEQ ID NO: 1 6437 HEPBD128 Heavy chain, HCV Ab Fab clone 1:7 US6747136SEQ ID NO: 2 6438 HEPBD129 Heavy chain, ACV Ab Fab clone 1:11 US6747136SEQ ID NO: 3 6439 HEPBD130 Heavy chain, HCV Ab Fab clone L3 US6747136SEQ ID NO: 4 6440 HEPBD131 Heavy chain, HCV Ab Fab clone L1 US6747136SEQ ID NO: 5 6441 HEPBD132 Heavy chain, HCV Ab Fab clone A8 US6747136SEQ ID NO: 6 6442 HEPBD133 Heavy chain, HCV Ab Fab clone A12 US6747136SEQ ID NO: 7 6443 HEPBD134 Heavy chain, HCV Ab HCV-AB 68 US7241445 SEQID NO: 3 6444 HEPBD135 Heavy chain, HCV Ab e8 US7727529 SEQ ID NO: 16445 HEPBD136 Heavy chain, HCV Ab e10 US7727529 SEQ ID NO: 3 6446HEPBD137 Heavy chain, HCV Ab e20 US7727529 SEQ ID NO: 5 6447 HEPBD138Heavy chain, HCV Ab e137 US7727529 SEQ ID NO: 7 6448 HEPBD139 Heavychain, HCV Ab e301 US7727529 SEQ ID NO: 9 6449 HEPBD140 Heavy chain, HCVAb e509 US7727529 SEQ ID NO: 11 6450 HEPBD141 Heavy chain, HCV Ab 5D2US20090104207 SEQ ID NO: 7 6451 HEPBD142 Heavy chain, HCV Ab Mab VWO2013186752 SEQ ID NO: 3 6452 HEPBD143 Heavy chain, HCV Ab Mab VIWO2013186752 SEQ ID NO: 5 6453 HEPBD144 Heavy chain, HCV Ab WO2007143701SEQ ID NO: 12 6454 HEPBD145 Heavy chain, HCV Ab HuPA29VH#1 WO2007143701SEQ ID NO: 15 6455 HEPBD146 Heavy chain, HCV Ab HuPA29VH#2 WO2007143701SEQ ID NO: 16 6456 HEPBD147 Heavy chain, HCV Ab HuPA29VH#3 WO2007143701SEQ ID NO: 17 6457 HEPBD148 Heavy chain, HCV Ab PA29 WO2007143701 SEQ IDNO: 28 6458 HEPBD149 Heavy chain, HCV Ab Ap33 Kong, L., et al.,Structure of Hepatitis C 6459 Virus Envelope Glycoprotein E2 AntigenicSite 412 to 423 in Complex with Antibody AP33; J. Virol. 86 (23),13085-13088 (2012) NCBI Accession # 4G6A _H (224aa) HEPBD50 Heavy chain,HCV Ab Single Chain Fv Gilmartin, A.A., et al., Protein Eng. Des. 6460Fragment 1:7 Sel. 25 (2), 59-66 (2012) NCBI Accession # 3U6R_A(149aa)HEPBD151 Heavy Chain, HCV Ar3c Kong, L., etal., Hepatitis C virUSE2 6461Fab envelope glycoprotein core structure; Science 342 (6162), 1090-1094(2013) NCBI Accession # 4MWF_A (233aa) HEPBD152 Heavy Chain, HCVMrct10.v362 Pantua, H., et al., Glycan shifting on 6462 Fab hepatitis Cvirus (HCV) e2 glycoprotein is a mechanism for escape from broadlyneutralizing antibodies; J. Mol. Biol. 425 (11), 1899-1914 (2013) NCBIAccession # HS6_H (226aa) HEPBD153 Heavy Chain, Hcv1 Hcv1, P2(1) Kong,L., et al., Structural basis of 6463 HCV Ab Form hepatitis C virusneutralization by broadly neutralizing antibody HCV1; Proc. Natl. Acad.Sci. U.S.A. 109 (24), 9499-9504 (2012) NCBI Accession # 4DGV_H (226aa)HEPBD154 Heavy Chain, Hcv1 Hcv1, C2 Form Kong, L., etal., Structuralbasis of 6464 HCV Ab hepatitis C virus neutralization by broadlyneutralizing antibody HCV1; Proc. Natl. Acad. Sci. U.S.A. 109 (24),9499-9504 (2012) NCBI Accession # 4DGY_H (226aa) HEPBD155 Heavy gammachain P18-9E US8592559 SEQ ID NO: 13 6465 variable, HCV Ab HEPBD156Heavy-chain-only, VHH D03 WO2014053634 SEQ ID NO: 4 6466 HCV Ab HEPBD157Heavy-chain-only, VHH C09 WO2014053634 SEQ ID NO: 5 6467 HCV Ab HEPBD158Heavy-chain-only, B1 1 WO2014053634 SEQ ID NO: 6 6468 HCV Ab HEPBD159Heavy-chain-only, D04 WO2014053634 SEQ ID NO: 7 6469 HCV Ab HEPBD160Light chain full, HBV US20150232537 SEQ ID NO: 10; 6470 Ab WO2014048910;CA2884388; CN104662041A; EP2900692 HEPBD161 Light chain kappa, Esposito,C., et al., Recombinant human 6471 partial, HCV Ab antibodies specificfor hepatitis C virus proteins; Arch. Virol. 142 (3), 601-610 (1997)NCBI Accession # CAA54913.1(110aa) HEPBD162 Light chain variable c18/A2US20120308580 SEQ ID NO: 1; WO 6472 domain, monoclonal 2011062562;CN102781961, EP2501723 HBV antibody HEPBD163 Light chain variableUS20110097270 SEQ ID NO: 9 6473 domain, neutralizing monoclonal HBVantibody, HEPBD164 Light chain variable EP0521348 6474 gene, ChimericHBV Ab HEPBD165 Light chain variable E183/A2 US20120308580 SEQ ID NO:32; WO 6475 region, HBV Ab 2011062562; CN102781961, EP2501723 HEPBD166Light chain variable HB48-33 US8840895 SEQ ID NO: 2 6476 region, HBV AbHEPBD167 Light chain variable HB48-35 US8840895 SEQ ID NO: 3 6477region, HBV Ab HEPBD168 Light chain variable HB48-59 US8840895 SEQ IDNO: 4 6478 region, HBV Ab HEPBD169 Light chain variable LFW22-31US7435414 SEQ ID NO: 36; 6479 region, HBV Ab US20060014937;WO2005100400; CN1980956 HEPBD170 Light chain variable LFW22-312US7435414 SEQ ID NO: 37; 6480 region, HBV Ab US20060014937;WO2005100400; CN1980956 HEPBD171 Light chain variable WO2013165972 SEQID NO: 216 6481 region, HBV Ab HEPBD172 Light chain variableWO2013165972 SEQ ID NO: 225 6482 region, HBV Ab HEPBD173 Light chainvariable WO2013165972 SEQ ID NO: 234 6483 region, HBV Ab HEPBD174 Lightchain variable WO2013165972 SEQ ID NO: 243 6484 region, HBV Ab HEPBD175Light chain variable WO2013165972 SEQ ID NO: 252 6485 region, HBV AbHEPBD176 Light chain variable WO2013165972 SEQ ID NO: 261 6486 region,HBV Ab HEPBD177 Light chain variable WO2013165972 SEQ ID NO: 270 6487region, HBV Ab HEPBD178 Light chain variable WO2013165972 SEQ ID NO: 2796488 region, HBV Ab HEPBD179 Light chain variable WO2013165972 SEQ IDNO: 288 6489 region, HBV Ab HEPBD180 Light chain variable WO2013165972SEQ ID NO: 297 6490 region, HBV Ab HEPBD181 Light chain variableWO2013165972 SEQ ID NO: 306 6491 region, HBV Ab HEPBD182 Light chainvariable WO2013165972 SEQ ID NO: 315 6492 region, HBV Ab HEPBD183 Lightchain variable WO2013165972 SEQ ID NO: 324 6493 region, HBV Ab HEPBD184Light chain variable WO2013165972 SEQ ID NO: 333 6494 region, HBV AbHEPBD185 Light chain variable WO2013165972 SEQ ID NO: 342 and 351 6495region, HBV Ab HEPBD186 Light chain variable WO2013165972 SEQ ID NO: 3606496 region, HBV Ab HEPBD187 Light chain variable WO2013165972 SEQ IDNO: 369 6497 region, HBV Ab HEPBD188 Light chain variable WO2013165972SEQ ID NO: 378 6498 region, HBV Ab HEPBD189 Light chain variableWO2013165972 SEQ ID NO: 387 6499 region, HBV Ab HEPBD190 Light chainvariable WO2013165972 SEQ ID NO: 396 6500 region, HBV Ab HEPBD191 Lightchain variable WO2009069916 SEQ ID NO: 2 6501 region, HBV Ab HEPBD192Light chain variable PE1-1 WO1994011495 6502 region, HBV Ab HEPBD193Light chain variable ZM1-1 WO1994011495 6503 region, HBV Ab HEPBD194Light chain variable ZM1-2 WO1994011495 6504 region, HB V Ab HEPBD195Light chain variable MD3 -4 WO1994011495 6505 region, HBV Ab HEPBD196Light chain variable A2E2 CN102757492 SEQ ID NO: 4 6506 region, HBV AbHEPBD197 Light chain variable C9G9 CN102757492 SEQ ID NO: 8 6507 region,HBV Ab HEPBD198 Light chain variable CN104530228 SEQ ID NO: 1 6508region, HBV Ab HEPBD199 Light chain variable CN104530228 SEQ ID NO: 26509 region, HBV Ab HEPBD200 Light chain variable Ab19 US8580256 SEQ IDNO: 1 6510 region, HBV Ab HEPBD201 Light chain variable Ab17 US8580256SEQ ID NO: 3 6511 region, HBV Ab HEPBD202 Light chain variable KR127US8420353 SEQ ID NO: 4 6512 region, HBV Ab HEPBD203 Light chain variableKR127 US8420353 SEQ ID NO: 2 6513 region, HBV Ab HEPBD204 Light chainvariable KR127 US8420353 SEQ ID NO: 30 6514 region, HBV Ab HEPBD205Light chain variable DPK12 US8420353 SEQ ID NO: 34 6515 region, HBV AbHEPBD206 Light chain variable HZI US8420353 SEQ ID NO: 38 6516 region,HBV Ab HEPBD207 Light chain variable US7112664 SEQ ID NO: 7; US6680053,6517 region, HBV Ab US6924368, US20020061581, US20040191259,US20050249753, WO2001092529 HEPBD208 Light chain variable Ab17.1.4 1USRE39586 SEQ ID NO: 2; US6146629; 6518 region, HBV Ab WO1997047653HEPBD209 Light chain variable Ab 19.79.5 USRE40831 SEQ ID NO: 2 6519region, HBV Ab HEPBD210 Light chain variable US20150232537 SEQ ID NO: 8;6520 region, HBV Ab WO2014048910; CA2884388; CN104662041A; EP2900692HEPBD211 Light chain variable US20100260712 SEQ ID NO: 2; 6521 region,HBV Ab WO2009069917 HEPBD212 Light chain variable WO2015107126 SEQ IDNO: 4 6522 region, HBV Ab HEPBD213 Light chain variable MBL-HCV1US8551484 SEQ ID NO: 2 6523 region, HCV Ab (Antibody produced by clone83-128) HEPBD214 Light chain variable MBL-HCV1 US8551484 SEQ ID NO: 46524 region, HCV Ab (Antibody produced by clone 95-2) HEPBD215 Lightchain variable MBL-HV1 US8551484 SEQ ID NO: 6 6525 region, HCV Ab(Antibody produced by clone 073-1) HEPBD216 Light chain variable Clone13 US7250166 SEQ ID NO: 2 6526 region, HCV Ab HEPBD217 Light chainvariable Clone 98 US7250166 SEQ ID NO: 4 6527 region, HCV Ab HEPBD218Light chain variable Clone 1:4 US7250166 SEQ ID NO: 6 6528 region, HCVAb HEPBD219 Light chain variable Clone 1:8 US7250166 SEQ ID NO: 8 6529region, HCV Ab HEPBD220 Light chain variable Clone 1:9 US7250166 SEQ IDNO: 10 6530 region, HCV Ab HEPBD221 Light chain variable Clone 1:10US7250166 SEQ ID NO: 12 6531 region, HCV Ab HEPBD222 Light chainvariable Clone 4:6 US7250166 SEQ ID NO: 14 6532 region, HCV Ab HEPBD223Light chain variable Clone 6a:5 US7250166 SEQ ID NO: 16 6533 region, HCVAb HEPBD224 Light chain variable Clone 2a:2 US7250166 SEQ ID NO: 18 6534region, HCV Ab HEPBD225 Light chain variable Clone 2a:4 US7250166 SEQ IDNO: 20 6535 region, HCV Ab HEPBD226 Light chain variable Clone 2a:5US7250166 SEQ ID NO: 22 6536 region, HCV Ab HEPBD227 Light chainvariable Clone 2a:13 US7250166 SEQ ID NO: 24 6537 region, HCV AbHEPBD228 Light chain variable Clone 2a:14 US7250166 SEQ ID NO: 26 6538region, HCV Ab HEPBD229 Light chain variable Clone 2a:23 US7250166 SEQID NO: 28 6539 region, HCV Ab HEPBD230 Light chain variable Clone 2a:23US7250166 SEQ ID NO: 30 6540 region, HCV Ab HEPBD231 Light chainvariable Clone 2a:25 US7250166 SEQ ID NO: 32 6541 region, HCV AbHEPBD232 Light chain variable Clone 2a:30 US7250166 SEQ ID NO: 34 6542region, HCV Ab HEPBD233 Light chain variable Clone 2a:32 US7250166 SEQID NO: 36 6543 region, HCV Ab HEPBD234 Light chain variable Clone 2a:33US7250166 SEQ ID NO: 38 6544 region, HCV Ab HEPBD235 light chainvariable Clone 2a:37 US7250166 SEQ ID NO: 40 6545 region, HCV AbHEPBD236 Light chain variable Clone 2a:40 US7250166 SEQ ID NO: 42 6546region, HCV Ab HEPBD237 Light chain variable Clone 2b:1 US7250166 SEQ IDNO: 44 6547 region, HCV Ab HEPBD238 Light chain variable Clone 2b:3US7250166 SEQ ID NO: 46 6548 region, HCV Ab HEPBD239 Light chainvariable Clone 2b:4 US7250166 SEQ ID NO: 48 6549 region, HCV Ab HEPBD240Light chain variable Clone 2b:5 US7250166 SEQ ID NO: 50 6550 region, HCVAb HEPBD241 Light chain variable Clone 2b:7 US7250166 SEQ ID NO: 52 6551region, HCV Ab HEPBD242 Light chain variable Clone 2b:9 US7250166 SEQ IDNO: 54 6552 region, HCV Ab HEPBD243 Light chain variable Clone 2b:10US7250166 SEQ ID NO: 56 6553 region, HCV Ab HEPBD244 Light chainvariable anti-NS3 Fab US7314919 SEQ ID NO: 6 6554 region, HCV AbHEPBD245 Light chain variable US7507408 SEQ ID NO: 2 6555 region, HCV AbHEPBD246 Light chain variable US7507408 SEQ ID NO: 4 6556 region, HCV AbHEPBD247 Light chain variable US7507408 SEQ ID NO: 6 6557 region, HCV AbHEPBD248 Light chain variable Antibody US8551484 SEQ ID NO: 44 6558region, HCV Ab produced by clone 95-14 HEPBD249 Light chain variableAntibody US8551484 SEQ ID NO: 53 6559 region, HCV Ab produced by clone95-38 HEPBD250 Light chain variable HC-84.1 US20130084301 SEQ ID NO: 646560 region, HCV Ab HEPBD251 Light chain variable HC-84.20 US20130084301SEQ ID NO: 65 6561 region, HCV Ab HEPBD252 Light chain variable HC-84.21US20130084301 SEQ ID NO: 66 6562 region, HCV Ab HEPBD253 Light chainvariable HC-84.22 US20130084301 SEQ ID NO: 67 6563 region, HCV AbHEPBD254 Light chain variable HC-23 US20130084301 SEQ ID NO: 68 6564region, HCV Ab HEPBD255 Light chain variable HC-84.24 US20130084301 SEQID NO: 69 6565 region, HCV Ab HEPBD256 Light chain variable HC-84.25US20130084301 SEQ ID NO: 70 6566 region, HCV Ab HEPBD257 Light chainvariable HC-84,26 US20130084301 SEQ ID NO: 71 6567 region, HCV AbHEPBD258 Light chain variable HC-84.27. US20130084301 SEQ ID NO. 72 6568region, HCV Ab HEPBD259 Light chain variable AOT3 US20120009196 SEQ IDNO: 2 6569 region, HCV Ab HEPBD260 Light chain variable C11-3US20120009196 SEQ ID NO: 4 6570 region, HCV Ab HEPBD261 Light chainvariable C11-7 US20120009196 SEQ ID NO: 6 6571 region, HCV Ab HEPBD262Light chainvariable C11-9 US20120009196 SEQ ID NO: 8 6572 region, HCV AbHEPBD263 Light chain variable C11-14 US20120009196 SEQ ID NO: 10 6573region, HCV Ab HEPBD264 Light chain variable WO2014065822 SEQ ID NO: 56574 region, HCV Ab HEPBD265 Light chain variable WO2014065822 SEQ IDNO: 9 6575 region, HCV Ab HEPBD266 Light chain variable Antibody lightWO2007143701 SEQ ID NO: 1 6576 region, HCV Ab chain from WO2007143701HEPBD267 Light chain variable Hc33.1 Li Y. et al., Structural basis forpenetration 6577 region, HCV Ab of the glycan shield of hepatitis CvirUSe2 glycoprotein by a broadly neutralizing human antibody; J. Biol.Chem. 290 (16), 10117-10125 (2015) NCBI Accession # 4XVJ_L (115aa)HEPBD268 Light chain variable US20150118242 SEQ ID NO: 3 6578 region,HCV Ab HEPBD269 Light chain variable US20150166637 SEQ ID NO: 6; 6579region, Human HVB WO2014010890; CA2878155, antibody that binds toCN104487090; EP2858674 the surface antigen (HBsAg) HEPBD270 Light chainvariable US20150166637 SEQ ID NO: 7; 6580 region, Human HBVWO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674the surface antigen (HBsAg) HEPBD271 Light chain variable US20150166637SEQ ID NO: 8; 6581 region, Human HBV WO2014010890; CA2878155, antibodythat binds to CN104487090, EP2858674 the surface antigen (HBsAg)HEPBD272 Light chain variable US20150166637 SEQ ID NO: 9; 6582 region,Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090,EP2858674 the surface antigen (HBsAg) HEPBD273 Light chain variableUS20150166637 SEQ ID NO: 10; 6583 region, Human HBV WO2014010890,CA2878155, antibody that binds to CN104487090, EP2858674 the surfaceantigen (HBsAg) HEPBD274 Light chain variable Keck, Z.Y., et al., Humanmonoclonal 6584 region, partial, HCV antibody to hepatitis C virUSE1 Abglycoprotein that blocks virus attachment and viral infectivity; J.Virol. 78(13), 7257-7263 (2004) NCBI Accession # AAS47840 (147aa)HEPBD275 Light chain, HCV Ab Hu5b3.v3 Pantua, B., et al., Glycanshifting on 6585 hepatitis C virus (HCV) e2 glycoprotein is a mechanismfor escape from broadly neutralizing antibodies; J. Mol. Biol. 425 (11),1899-1914 (2013) NCBI Accession # 4HS8_L (218aa) HEPBD276 Light chain,HCV Ab Ap33 Kong, L., et al., Structure of Hepatitis C 6586 VirusEnvelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex withAntibody AP33; J. Virol. 86 (23), 13085-13088 (2012) NCBI Accession #4G6A_L (218aa) HEPBD277 Light chain, HBV Ab HBFab21 CN103588874 SEQ IDNO: 1 6587 HEPBD278 Light chain, HBV Ab Fab clone 1:5 US6747136 SEQ IDNO: 8 6588 HEPBD279 Light chain, HCV Ab Fab clone 1:7 US6747136 SEQ IDNO: 9 6589 HEPBD280 Light chain, HCV Ab Fab clone 1:11 US6747136 SEQ IDNO: 10 6590 HEPBD281 Light chain, HCV Ab Fab clone L3 US6747136 SEQ IDNO: 11 6591 HEPBD282 Light chain, HCV Ab Fab clone L1 US6747136 SEQ IDNO: 12 6592 HEPBD283 Light chain, HCV Ab Fab clone A8 US6747136 SEQ IDNO: 13 6593 HEPBD284 Light chain, HCV Ab Fab clone A12 US6747136 SEQ IDNO: 14 6594 HEPBD285 Light chain, HCV Ab HCV#1 US6924362 SEQ ID NO: 16595 HEPBD286 Light chain, HCV Ab HCV#4 US6924362 SEQ ID NO: 2 6596HEPBD287 Light chain, HCV Ab HCV#7 US6924362 SEQ ID NO: 3 6597 HEPBD288Light chain, HEV Ab HCV#12 US6924362 SEQ ID NO: 4 6598 HEPBD289 Lightchain, HCV Ab HGV#13 US6924362 SEQ ID NO: 5 6599 HEPBD290 Light chain,HCV Ab HCV-AB 68 US7241445 SEQ ID NO: 4 6600 HEPBD291 Light chain, HCVAb e8 US7727529 SEQ ID NO: 2 6601 HEPBD292 Light chain, HCV Ab e10US7727529 SEQ ID NO: 4 6602 HEPBD293 Light chain, HEV Ab e20 US7727529SEQ ID NO: 6 6603 HEPBD294 Light chain, HCV Ab e137 US7727529 SEQ ID NO:8 6604 HEPBD295 Light chain, HCV Ab e301 US7727529 SEQ ID NO: 10 6605HEPBD296 Light chain, HCV Ab e509 US7727529 SEQ ID NO: 12 6606 HEPBD297Light chain, HCV Ab 5D2 US20090104207 SEQ ID NO: 8 6607 HEPBD298 Lightchain, HCV Ab MabV WO2013186752 SEQ ID NO: 4 6608 HEPBD299 Light chain,HCV Ab Mab VI WO2013186752 SEQ ID NO: 6 6609 HEPBD300 Light chain, HCVAb WO2007143701 SEQ ID NO: 11 6610 HEPBD301 Light chain, HCV AbHuPA29VH#1 WO2007143701 SEQ ID NO: 18 6611 HEPBD302 Light chain, HCV AbHuPA29VH#2 WO2007143701 SEQ ID NO: 19 6612 HEPBD303 Light chain, HCV AbPA29 WO2007143701 SEQ ID NO: 29 6613 HEPBD304 Light chain, HCV Ab SingleChain Fv Gilmartin, A.A., et al., Protein Eng. Des. 6614 Fragment 1:7Sel. 25 (2), 59-66 (2012) NCBI Accession # 3U6R_B (143aa) HEPBD305 Lightchain, HCV Ab Igh526 Kong L., et al., Structure of Hepatitis C 6615Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex withAntibody 1GH526; J. Mol. Biol. 427 (16), 2617-2628 (2015) NCBI Accession# 4N0Y_L (218aa) HEPBD306 Light chain, HCV Fab Ar3c Kong, L., et al.,Hepatitis C virUSE2 6616 envelope glycoprotein core structure; Science342 (6162), 1090-1094 (2013) NCBI Accession # 4MWF_B (214aa) HEPBD307Light chain, HCV Fab Mrct10.v362 Pantua, H., et al., Glycan shifting on6617 hepatitis C virus (HCV) e2 glycoprotein is a mechanism for escapefrom broadly neutralizing antibodies; J. Mol. Biol. 425 (11), 1899-1914(2013) NCBI Accession # 4HS6_L (218aa) HEPBD308 Light chain, Hcv1 Hcv1,C2 Form Kong, L., et al., Structural basis of 6618 HCV Ab hepatitis Cvirus neutralization by broadly neutralizing antibody HCV1; Proc. Natl.Acad. Sci, U.S.A. 109 (24), 9499-9504 (2012) NCBI Accession # 4DGY_L(213aa) HEPBD309 Light chain, Hcv1 Hcv1, P2(1) Kong, L., et al.,Structural basis of 6619 HCV Ab Form hepatitis C virus neutralization bybroadly neutralizing antibody HCV1; Proc. Natl. Acad. Sci, U.S.A. 109(24), 9499-9504 (2012) NCBI Accession # 4DGV_L (213aa) HEPBD310 Lightkappa chain P18-9E US8592559 SEQ ID NO: 14 6620 variable, HCV AbHEPBD311 PEGylated anti-E2 WO2006028634 SEQ ID NO: 1 6621 heavy chain,HCV Ab HEPBD312 PEGylated anti-E2 WO2006028634 SEQ ID NO: 2 6622 heavychain, HCV Ab HEPBD313 PEGylated anti-E2 WO2006028634 SEQ ID NO: 3 6623heavy chain, HCV Ab HEPBD314 PEGylated anti-E2 WO2006028634 SEQ ID NO: 46624 heavy chain, HCV Ab HEPBD315 PEGylated anti-E2 WO2006028634 SEQ IDNO: 8 6625 heavy chain, HCV Ab HEPBD316 single chain, HBV Ab US6562599SEQ ID NO: 4 6626 HEPBD317 single chain, HBV Ab US6562599 SEQ ID NO: 66627

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inU.S. Pat. Nos. 7,241,445, and 8,858,947, the contents of each of whichare herein incorporated by reference in their entirety, against HCV.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described in USPublication No. US20150072885 and US20110046354, U.S. Pat. No.5,204,095, European Publication No. EP0232921, EP0038642, and EP0186371,and International Publication No. WO1994011495, the contents of each ofwhich are herein incorporated by reference in their entirety, againstHBV.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inU.S. Pat. No. 6,020,195, the contents of which are herein incorporatedby reference in their entirety, against HGV (hepatitis G virus).

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 24 against Herpes Virus.

TABLE 24 Antibodies against Herpesvirus SEQ Antibody Antibody ID No.Description Name Reference Information NO HERP1 Chain A, HSV E317 FabLee, C. et al., “Structural basis for the 6628 antibody neutralizationof herpes simplex virus” Acta Crystallogr. D Biol. Crystallogr. 69 (PT10), 1935-1945 (2013), NCBI Accession # 3W9D_A HERP2 Chain B, HSV E317Fab Lee, C. et al., “Structural basis for the 6629 antibodyneutralization of herpes simplex virus” Acta Crystallogr. D Biol.Clystallogr. 69 (PT 10), 1935-1945 (2013), NCBI Accession # 3W9D_B HERP3Chain C, HSV E317 Fab Lee, C. et al., “Structural basis for the 6630antibody neutralization of herpes simplex virus” Acta Crystatlogr. DBiol. Crystallogr. 69 (PT 10), 1935-1945 (2013), NCBI Accession # 3W9D_CHERP4 Chain D, HSV E317 Fab Lee, C. et al., “Structural basis for the6631 antibody neutralization of herpes simplex virus” Acta Crystallogr.D Biol. Clystallogr. 69 (PT 10), 1935-1945 (2013), NCBI Accession #3W9D_D HERP5 Chimeric anti- Tanner, J.E., “Peptides Designed ToSpatially 6632 EBVs Depict the Epstein-Barr Virus Major Virion gp350antibody Glycoprotein gp350 Neutralization Epitope Elicit AntibodiesThat Block Virus- Neutralizing Antibody 72A1 Interaction with the Nativegp350 Molecule””, J. Virol. 89 (9), 4932-4911(2015), NCBI Accession#AJR20276 HERP6 Chimeric anti- Tanner, J.E., “Peptides Designed ToSpatially 6633 EBVs Depict the Epstein-Barr Virus Major Virion gp350antibody Glycoprotein gp350 Neutralization Epitope Elicit AntibodiesThat Block Virus- Neutralizing Antibody 72A1 Interaction with the Nativegp350 Molecule””, J. Virol. 89 (9), 4932-4941 (2015), NCBI Accession#AJR20275 HERP7 CMV AE11F/3-20L1 Lantto, J. et al., Bindingcharacteristics 6634 determine the neutralizing potential of antibodyfragments specific for antigenic domain 2 on glycoprotein B of humancytomegalovirus, Virology 305 (1), 201-209 (2003), NCBI Accession #AAN87569.1 (256 aa) HERP8 Fv, EBV G5 Fang, C.Y., “Modulation ofEpstein-Barr virus 6635 latent membrane protein 1 activity byintrabodies”, Intervirology 50 (4), 254-263 (2007), NCBI Accession#ABA55015 HERP9 Fv, EBV A4 Fang, C.Y., “Modulation of Epstein-Barr virus6636 latent membrane protein 1 activity by intrabodies”, Intervirology50(4), 254-263 (2007), NCBI Accession #ABA55014 HERP10 Fv, EBV B8 Fang,CY., “Modulation of Epstein-Barr virus 6637 latent membrane protein 1activity by intrabodies”, Intervirology 50 (4), 254-263 (2007), NCBIAccession #ABA55013 HERP11 Fv, EBV F5 Fang, C.Y., “Modulation ofEpstein-Barr virus 6638 latent membrane protein 1 activity byintrabodies”, Intervirology 50(4), 254-263 (2007), NCBI Accession#ABA55012 HERP12 Fv, EBV E2 Fang, C.Y., “Modulation of Epstein-Barrvirus 6639 latent membrane protein 1 activity by intrabodies”,Intervirology 50 (4), 254-263 (2007), NCBI Accession #ABA55011 HERP13Fv, EBV H3 Fang, C,Y., “Modulation of Epstein-Barr virus 6640 latentmembrane protein 1 activity by intrabodies”, Intervirology 50 (4),254-263 (2007), NCBI Accession #ABA55010 HERP14 Heavy chain, DDF-VZV1US20100074906 SEQ ID NO: 20 6641 FLAGhis tagged sequence, VZV HERP15Heavy chain ACHDV1 Burioni, R. et al. “Recombinant human Fab to 6642variable domain, glycoprotein D neutralizes infectivity and clone 11,HSV prevents cell-to-cell transmission of herpes simplex viruses 1 and 2in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 ( 1), 355-359 (1994), NCBIAccession # AAB29447 HERP16 Heavy chain ACHDV1 Burioni, R. et al.“Recombinant human Fab to 6643 variable domain, glycoprotein Dneutralizes infectivity and clone 13, HSV prevents cell-to-celltransmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl.Acad. Sci. U.S.A. 91 ( 1), 355-359 (1994), NCBI Accession # AAB29449HERP17 Heavy chain ACHDV2 Burioni, R, et al, “Recombinant human Fab to6644 variable domain, glycoprotein D neutralizes infectivity and clone15, HSV prevents cell-to-cell transmission of herpes simplex viruses 1and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 ( 1), 355-359 (1994),NCBI Accession # AAB29456 HERP18 Heavy chain ACHDV1 Burioni, R. et al.“Recombinant human Fab to 6645 variable domain, glycoprotein Dneutralizes infectivity and clone 15, HSV prevents cell-to-celltransmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl.Acad. Sci. U.S.A. 91 (1), 355-359 (1994,) NCBI Accession # AAB29450HERP19 Heavy chain ACHDV1 Burioni, R. et al. “Recombinant human Fab to6646 variable domain, glycoprotein D neutralizes infectivity and clone18, HSV prevents cell-to-cell transmission of herpes simplex viruses 1and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 (1), 355-359 (1994,)NCBI Accession # AAB29448 HERP20 Heavy chain ACHDV1 Burioni, R. et al.“Recombinant human Fab to 6647 variable domain, glycoprotein Dneutralizes infectivity and clone 2, HSV prevents cell-to-celltransmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl.Acad. Sci. U.S.A. 91 (1), 355-359 (1994), NCBI Accession # AAB29455HERP21 Heavy chain 1F7 US8202518 SEQ ID NO: 5 6648 variable region, CMVHERP22 Heavy chain Humanized 57.4 WO2014200898 SEQ ID NO: 633 6649variable region, CMV HERP23 Heavy chain Humanized 57.4 WO2014200898 SEQID NO: 634 6650 variable region, CMV HERP24 Heavy chain Humanized 58.5WO2014200898 SEQ ID NO: 637 6651 variable region, CMV HERP25 Heavy chainHumanized 58.5 WO2014200898 SEQ ID NO: 638 6652 variable region, CMVHERP26 Heavy chain Humanized WO2014200898 SEQ ID NO: 641 6653 variableregion, 272.7 CMV HERP27 Heavy chain Humanized WO2014200898 SEQ ID NO:644 6654 variable region, 276.10 CMV HERP28 Heavy chain HumanizedWO2014200898 SEQ ID NO: 645 6655 variable region, 276.10 CMV HERP29Heavy chain Sm5-1 Li, B., Construction and characterization of a 6656variable region, high-affinity humanized SMS-1 monoclonal CMV antibody,Biochem. Biophys. Res. Commun. 357 (4), 951-956 (2007), NCBI Accession #ABI22831.1 HERP30 Heavy chain Schoppel, K. et al., Antibodies specificfor the 6657 variable region, antigenic domain 1 of glycoprotein B CMV(gpUL55) of human cytomegalovirus bind to different substructures,Virology 216 (1), 133- 145 (1996), NCBI Accession # AAB26953.1 (163 aa)HERP1 Heavy chain Schoppel, K. et al., Antibodies specific for the 6658variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) ofhuman cytomegalovirus bind to different substructures, Virology 216 (1),133- 145 (1996), NCBI Accession # AAB26952.1 (161 aa) HERP32 Heavy chainSchoppel, K. et al., Antibodies specific for the 6659 variable region,antigenic domain 1 of glycoprotein B CMV (gpUL55) of humancytomegalovirus bind to different substructures, Virology 216 (1), 133-145 (1996), NCBI Accession # AAB26951.1 (158 aa) HERP33 Heavy chainPotzsch, S., B Cell Repertoire Analysis 6660 variable region, IdentifiesNew Antigenic Domains on CMV Glycoprotein B of Human Cytomegaloviruswhich Are Target of Neutralizing Antibodies, NCBI Accession # AEF33814.1HERP34 Heavy chain 1F11 US9149524 SEQ ID NO: 7 6661 variable region,CMV, a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131AHERP35 Heavy chain 2F4 US9149524 SEQ ID NO: 17 6662 variable region,CMV, a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131AHERP36 Heavy chain 5A2 US9149524 SEQ ID NO: 39 6663 variable region,CMV, a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131AHERP37 Heavy chain EV2038 US8492529 SEQ ID NO: 10 6664 variable region,CMV, AD1 region of HMV glycoprotein gB HERP38 Heavy chain US20150064174SEQ ID 1 6665 variable region, EBV HERP39 Heavy chain US20150064174 SEQID 2 6666 variable region, EBV HERP40 Heavy chain HCMV16 WO1994009136,FIG. 1 6667 variable region, gH glycoprotein of HCMV HERP41 Heavy chainNejatollahi, F. and Bagheri, V., “Isolation of 6668 variable region,neutralizing human specific single-chain HSV antibodies against HerpesSimplex Virus type 1 glycoproiein D”, unpublished, NCBI Accession #AGO59015 HERP42 Heavy chain E317 US8431118 SEQ ID NO: 1; US8252906 6669variable region, HSV 1&2 HERP43 Heavy chain E425 US8431118 SEQ ID NO: 3;US8252906 6670 variable region, HSV 1&2 HERP44 Heavy chain Y571US8431118 SEQ ID NO: 41; US8252906 6671 variable region, HSV 1&2 HERP45Heavy chain US5506132 SEQ ID NO: 4 6672 variable region, VZV HERP46Heavy chain DDF-VZV2 US20100074906 SEQ ID NO: 26 6673 variable region,VZV HERP47 Heavy chain EV2038 US8492529 SEQ ID NO: 6 6674 without asignal sequence, CMV, AD1 region of HCMV glycoprote in gB HERP48 Heavychain, 8f9 McLean, G.R. et al., Recognition of human 6675 CMVcytomegalovirus by human primary immunoglobulins identifies an innatefoundation to an adaptive immune response, J. Immunol. 174 (8),4768-4778 (2005), NCBI Accession # CAE54374.1 HERP49 Heavy chain, Mab109 Simpson, J.A. et al., Neutralizing monoclonal 6676 CMV antibodiesthat distinguish three antigenic sites on human cytomegalovirusglycoprotein H have conformationally distinct binding sites, J. Virol.67 (1), 489-496 (1993), NCBI Accession # AAB24505.1 (119 aa) HERP50Heavy chain, Mab 115 Simpson, J.A. et al., Neutralizing monoclonal 6677CMV antibodies that distinguish three antigenic sites on humancytomegalovirus glycoprotein H have conformationaly distinct bindingsites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24504.1(117 aa) HERP51 Heavy chain, Mab 33 Simpson, J.A. et al., Neutralizingmonoclonal 6678 CMV antibodies that distinguish three antigenic sites onhuman cytomegalovirus glycoprotein H have conformationally distinctbinding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession #AAB24503.1 (120 aa) HERP52 Heavy chain, Mab 5 Simpson, J.A. et at,Neutralizing monoclonal 6679 CMV antibodies that distinguish threeantigenic sites on human cytomegalovirus glycoprotein H haveconformationaly distinct binding sites, J. Virol. 67 (1), 489-496(1993), NCBI Accession # AAB24502.1 (120 aa) HERP53 Heavy chain, 6G4WO2010007463 SEQ ID NO: 7 6680 CMV, a combination of the hCMV proteinsUL128, UL130 and UL131A HERP54 Heavy chain, US20140093526 SEQ ID 12 6681HHV-6 HERP55 Heavy chain, FabHS V 8. US6156313 SEQ ID NO: 2 6682 HSV 1&2HERP56 Heavy chain, 64-683 US5646041 SEQ ID NO: 2; EP876478 6683 HSV 1&2HERP57 Heavy chain, H005157 US20140302062 SEQ ID NO: 3 6684 HSV 1&2HERP58 Heavy chain, H005158 US20140302062 SEQ ID NO: 4 6685 HSV 1&2HERP59 Heavy chain, H005159 US20140302062 SEQ ID NO: 5 6686 HSV 1&2HERP60 Heavy chain, H005160 US20140302062 SEQ ID NO: 6 6687 HSV 1&2HERP61 Heavy chain, H005188 US20140302062 SEQ ID NO: 7 6688 HSV 1&2HERP62 Heavy chain, H005190 US20140302062 SEQ ID NO: 8 6689 HSV 1&2HERP63 Heavy chain, H005192 US20140302062 SEQ ID NO: 9 6690 HSV 1&2HERP64 Light chain HCMV16 WO1994009136, FIG. 2 6691 variable region, gHglycoprotein of HCMV HERP65 Light chain DDF-VZV1 US20100074906 SEQ IDNO: 22 6692 recombinant, VZV HERP66 Light chain 1F7 US8202518 SEQ ID NO:10 6693 variable region, CMV HERP67 Light chain Humanized 57.4WO2014200898 SEQ ID NO: 631 6694 variable region, CMV HERP68 Light chainHumanized 57.4 WO2014200898 SEQ ID NO: 632 6695 variable region, CMVHERP69 Light chain Humanized 58.5 WO2014200898 SEQ ID NO: 635 6696variable region, CMV HERP70 Light chain Humanized 58.5 WO2014200898 SEQID NO: 636 6697 variable region, CMV HERP71 Light chain HumanizedWO2014200898 SEQ ID NO: 639 6698 variable region, 272.7 CMV HERP72 Lightchain Humanized WO2014200898 SEQ ID NO: 640 6699 variable region, 272.7CMV HERP73 Light chain Humanized WO2014200898 SEQ ID NO: 642 6700variable region, 276.10 CMV HERP74 Light chain Humanized WO2014200898SEQ ID NO: 643 6701 variable region, 276.10 CMV HERP75 Light chain Sm5-1Li, B., Construction and characterization of a 6702 variable region,high-affinity humanized SM5-1 monoclonal CMV antibody, Biochem. Biophys.Res. Commun. 357 (4), 951-956 (2007), NCBI Accession # AB122832.1 HERP76Light chain 8f9 Schoppel, K. et al., Antibodies specific for the 6703variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) ofhuman cytomegalovirus bind to different substructures, Virology 216 (1),133- 145 (1996), NCBI Accession # AAB26956.1 (146 aa) HERP77 Light chainSchoppel, K. et al., Antibodies specific for the 6704 variable region,antigenic domain 1 of glycoprotein B CMV (gpUL55) of humancytomegalovirus bind to different substructures, Virology 216 (1), 133-145 (1996), NCBI Accession # AAB26955.1 (141 aa) HERP78 Light chainSchoppel, K. et al., Antibodies specific for the 6705 variable region,antigenic domain 1 of glycoprotein B CMV (gpUL55) of humancytomegalovirus bind to different substructures, Virology 216 (1), 133-45 (1996), NCBI Accession # AAB26954.1 (152 aa) HERP79 Light chainPotzsch, S., B Cell Repertoire Analysis 6706 variable region, IdentifiesNew Antigenic Domains on CMV Glycoprotein B of Human Cytomegaloviruswhich Are Target of Neutralizing Antibodies, NCBI Accession # AEF33824.1HERP80 Light chain 1F11 US9149524 SEQ ID NO: 8 6707 variable region,CMV, a combination of the hCMV proteins UL128, UL130 and UL131A HERP81Light chain 2F4 US9149524 SEQ ID NO: 18 6708 variable region, CMV, acombination of the hCMV proteins UL128, ULL30 and UL131A HERP82 Lightchain 5A2 US9149524 SEQ ID NO: 40 6709 variable region, CMV, acombination of the hCMV proteins IUL128, UL130 and UL131A HERP83 Lightchain EV2038 US8492529 SEQ ID NO. 12 6710 variable region, CMV, AD1region of HCMV glycoprotein gB HERP84 Light chain US20150064174 SEQ ID 36711 variable region, EBV HERP85 Light chain US20150064174 SEQ ID 4 6712variable region, EBV HERP86 Light chain Nejatollahi, F. and Bagheri, V.,“Isolation of 6713 variable region, neutralizing human specificsingle-chain HSV antibodies against Herpes Simplex Virus type 1glycoprotein D”, unpublished”, NCBI Accession # AGO59016 HERP87 Lightchain E317 US8431118 SEQ ID NO: 2; US8252906 6714 variable region, HSV1&2 HERP88 Light chain E425 US8431118 SEQ ID NO: 4; US8252906 6715variable region, HSV 1&2 HERP89 Light chain Y571 US8431118 SEQ ID NO:42; US8252906 6716 variable region, HSV 1&2 HERP90 Light chain US5506132SEQ ID NO: 2 6717 variable region, VZV HERP91 Light chain DDF-VZV2US20100074906 SEQ ID NO: 24 6718 variable region, VZV HERP92 Light chainEV2038 US8492529 SEQ ID NO: 8 6719 without a signal sequence, CMV, AD1region of HCMV glycoprotein gB HERP93 Light chain, CMV 8f9 McLean, G.R.et al., Recognition of human 6720 cytomegalovirus by human primaryimmunoglobulins identifies an innate foundation to an adaptive immuneresponse, J. Immunol. 174 (8), 4768-4778 (2005), NCBI Accession #CAE54366.1 HERP94 Light chain, CMV Mab 109 Simpson, J.A. et al.,Neutralizing monoclonal 6721 antibodies that distinguish three antigenicsites on human cytomegalovirus glycoprotein H have conformationallydistinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession# A AB24501.1 (111 aa) HERP95 Light chain, CMV Mab 115 Simpson, J.A. etal., Neutralizing monoclonal 6722 antibodies that distinguish threeantigenic sites on human cytomegalovirus glycoprotein H haveconformationaly distinct binding sites, J. Virol. 67 (1), 489-496(1993), NCBI Accession # AAB24500.1 (107 aa) HERP96 Light chain, CMV Mab33 Simpson, J.A. et al., Neutralizing monoclonal 6723 antibodies thatdistinguish three antigenic sites on human cytomegalovirus glycoproteinH have conformationally distinct binding sites, J. Virol. 67 (1),489-496 (1993), NCBI Accession # AAB24499.1 (107 aa) HERP97 Light chain,CMV Mab 5 Simpson, J.A. et al., Neutralizing monoclonal 6724 antibodiesthat distinguish three antigenic sites on human cytomegalovirusglycoprotein H have conformationally distinct binding sites, J. Virol.67 (1), 489-496 (1993), NCBI Accession # AAB24498.1 (107 aa) HERP98Light chain, 6G4 WO2010007463 SEQ ID NO: 8 6725 CMV, a combination ofthe hCMV proteins UL128, UL130 and UL131A HERP99 Light chain,US20140093526 SEQ ID 10 6726 HHV-6 HERP100 Light chain, HSV 64-683US5646041 SEQ ID NO: 4; EP876478 6727 1&2 HERP101 Light chain, HSVK003927 US20140302062 SEQ ID NO: 10 6728 1&2 HERP102 Light chain, HSVK003928 US20140302062 SEQ ID NO: 11 6729 1&2 HERP103 Light chain, HSVK003929 US20140302062 SEQ ID NO: 12 6730 1&2 HERP104 Light chain, HSVK003930 US20140302062 SEQ ID NO: 13 6731 1&2 HERP105 Light chain, HSVK003946 US20140302062 SEQ ID NO: 14 6732 1&2 HERP106 Light chain, HSVK003948 US20140302062 SEQ ID NO: 15 6733 1&2 HERP107 Light chain, HSVK003949 US20140302062 SEQ ID NO: 16 6734 1&2 HERP108 Light chain, HSVL00184-4 US20140302062 SEQ ID NO: 17 6735 1&2 HERP109 Single chain FvLantto, J. et al., Non-germ-line encoded 6736 antibody, residues arecritical for effective antibody glycoprotein B recognition of a poorlyimmunogenic recombinant, neutralization epitope on glycoprotein B of CMVhuman cytomegalovirus, Eur. J. Immunol. 32 (6), 1659-1669 (2002), NCBIAccession # AAM92769.1 (255 aa)

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inInternational Publication No. WO2010109874, and WO1997026329, thecontents of each of which are herein incorporated by reference in theirentirety, against HSV.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inInternational Publication No. WO1995031546, the contents of which areherein incorporated by reference in their entirety, against VZV.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody poly peptides listed in Table 25 against Coronavirus.

TABLE 25 Antibodies against Coronaviruses SEQ Antibody AntibodyReference ID No. Description Name Information NO CORV1 Heavy chainpartial sequence, Liu, J., unpublished, NCBI 6737 Human anti-SARSantibody, Ig Accession # BAE94186.1(228aa) CORV2 Heavy chain partialsequence H12 AAX19356.1(127aa) 6738 Human SARS neutralization antibody,Ig CORV3 Heavy chain variable partial Leung et at., PLoS Med. 3 (7),6739 sequence, Human neutralizing E237 (2006), NCBI Accession # SARSantibody ABA54614.1(113aa) CORV4 Heavy chain variable region, M396Prabakaran etal., J. Biol. Chem. 6740 Human anti-SARS antibody 281 (23),15829-15836 (2006), NCBI Accession # 2G75_D (213aa) CORV5 Heavy chainvariable region, Prabakaran etal., J. Biol. Chem. 6741 Humanneutralizing SARS 281 (23), 15829-15836 (2006), antibody NCBI Accession# 2DD8_L (213aa) CORV6 Heavy chain variable region, CN103864924 SEQ IDNO: 1 6742 Humanized neutralizing murine monoclonal MERS CORV7 Heavychain variable region, CN104447986 SEQ ID NO: 1 6743 MERs CORV8 Heavychain variable region, US7750123 SEQ ID NO: 12; 6744 Neutralizingantibody (binds to WO2005060520; CN1914226; the spike protein (5) ofSARS- US20050249739 cov) CORV9 Heavy chain variable region, s110.4US20110159001 SEQ ID NO: 62; 6745 SARS antibody WO2009128963; EP2242768;CN102015767 CORV10 Heavy chain variable region, s124.5 US20110159001 SEQID NO: 66; 6746 SARS antibody WO2009128963; EP2242768; CN102015767CORV11 Heavy chain variable region, s215.17 US20110159001 SEQ ID NO: 70;6747 SARS antibody WO2009128963; EP2242768; CN102015767 CORV12 Heavychain variable region, s218.9 US20110159001 SEQ ID NO: 74; 6748 SARSantibody WO2009128963; EP2242768; CN102015767 CORV13 Heavy chainvariable region, s223.4 US20110159001 SEQ ID NO: 78; 6749 SARS antibodyWO2009128963; EP2242768; CN102015767 CORV14 Heavy chain variable region,s22512 US20110159001 SEQ ID NO: 82; 6750 SARS antibody WO2009128963;EP2242768; CN102015767 CORV15 Heavy chain variable region, s231.19US20110159001 SEQ ID NO: 86; 6751 SARS antibody WO2009128963; EP2242768;CN102015767 CORV16 Heavy chain variable region, s230.14 + 15US20110159001 SEQ ID NO: 90; 6752 SARS antibody WO2009128963; EP2242768;CN102015767 CORV17 Heavy chain variable region, s227. 14 US20110159001SEQ ID NO: 94; 6753 SARS antibody WO2009128963; EP2242768; CN102015767CORV18 Heavy chain variable region, s109.8 US20110159001 SEQ ID NO: 98;6754 SARS antibody WO2009128963; EP2242768; CN102015767 CORV19 Heavychain variable region, Fab58 CN1513874 6755 SARS antibody CORV20 Heavychain variable region, Fab59 CN1513874 6756 SARS antibody CORV21 Heavychain variable region, 3C7 US7728110 SEQ ID NO: 60; 6757 SARS humanmonoclonal WO2008060331; EP2035454A2, antibody US20080248043 CORV22Heavy chain variable region, F26G18 US7622112 SEQ ID NO: 5; 6758 SARShuman monoclonal WO2005054469; antibody US20080248043; US20080081047CORV23 Heavy chain variable region A, WO2006095180 SEQ ID NO: 24 6759humanized antibody binding to S2 domain of SARS CORV24 Heavy chainHumanized CN103864924 SEQ ID NO: 3 6760 neutralizing murine monoclonalMERS CORV25 Heavy chain, MERS m336 WO2015057942 SEQ ID NO: 1 6761 CORV26Heavy chain, MERS m337 WO2015057942 SEQ ID NO: 9 6762 CORV27 Fleavychain, MERS m338 WO2015057942 SEQ ID NO: 16 6763 CORV28 Heavy chain,MERS 2e 6 CN104447986 SEQ ID NO: 3 6764 CORV29 Heavy chain, MERS M336Ying et al., Nat Commun 6, 8223 6765 (2015), NCBI Accession #4XAK_H(252aa) CORV30 Human anti-SARS antibody Leung et al., PLoS Med. 3(7), 6766 E237 (2006), NCBI Accession # ABA54613.1(117aa) CORV31 Humanmonoclonal MERS Mers-27 CN104628848 SEQ ID NO: 1 6767 CORV32 Humanmonoclonal MERS Mers-27 CN104628848 SEQ ID NO. 3 6768 CORV33 Humanmonoclonal MERS Mers-4 CN104628849 SEQ ID NO: 1 6769 CORV34 Humanmonoclonal MERS Mers-4 CN104628849 SEQ ID NO: 3 6770 CORV35 Kappa lightchain partial H12 AX19355.1(108aa) 6771 sequence, human SARSneutralization antibody, Ig CORV36 Light chain partial sequence, Liu,J., unpublished, NCBI 6772 Human anti-SARS antibody, Ig Accession #BAE94187.1(219aa) CORV37 Light chain variable domain, CN104447986 SEQ IDNO: 2 6773 MERS CORV38 Light chain variable partial 80R Hwang et al., J.Biol. Chem. 281 6774 sequence, Human neutralizing (45), 34610-34616(2006), NCBI SARS antibody Accession # 2GHW_D (247aa) CORV39 Light chainvariable region, A WO2006095180 SEQ ID NO: 25 6775 humanized antibodybinding to S2 domain of SARS CORV40 Light chain variable region, M396Prabakaran et al., J. Biol. Chem. 6776 human anti-SARS antibody 281(23), 15829-15836 (2006), NCBI Accession # 2G75_C (245aa) CORV41 Lightchain variable region, Prabakaran et al., J. Biol. Chem. 6777 Humanneutralizing SARS 281 (23), 15829-15836 (2006), antibody NCBI Accession# 2DD8_H(245aa) CORV42 Light chain variable region, CN103864924 SEQ IDNO: 2 6778 Humanized neutralizing murine monoclonal MERS CORV43 Lightchain variable region, US7750123 SEQ ID NO: 20; 6779 neutralizingantibody (binds to WO2005060520; CN1914226; the spike protein (S) ofSARS- US20050249739 cov) CORV44 Light chain variable region, s110.4US20110159001 SEQ ID NO: 64; 6780 SARS antibody WO2009128963; EP2242768;CN102015767 CORV45 Light chain variable region, s124.5 US20110159001 SEQID NO: 68; 6781 SARS antibody WO2009128963; EP2242768; CN102015767CORV46 Light chain variable region, s215.17 US20110159001 SEQ ID NO: 72;6782 SARS antibody WO2009128963; EP2242768; CN102015767 CORV47 Lightchain variable region, s218.9 US20110159001 SEQ ID NO: 76; 6783 SARSantibody WO2009128963; EP2242768; CN102015767 CORV48 Light chainvariable region, s223.4 US20110159001 SEQ ID NO: 80; 6784 SARS antibodyWO2009128963; EP2242768; CN102015767 CORV49 Light chain variable region,s225.1.2 US20110159001 SEQ ID NO: 84; 6785 SARS antibody WO2009128963;EP2242768; CN102015767 CORV50 Light chain variable region, s231.19US20110159001 SEQ ID NO: 88; 6786 SARS antibody WO2009128963; EP2242768;CN102015767 CORV51 Light chain variable region, s230.14 + 15US20110159001 SEQ ID NO: 92; 6787 SARS antibody WO2009128963; EP2242768;CN102015767 CORV52 Light chain variable region, s227.14 US20110159001SEQ ID NO: 96; 6788 SARS antibody WO2009128963; EP2242768; CN102015767CORV53 Light chain variable region, s109.8 US20110159001 SEQ ID NO: 6789SARS antibody 101; WO2009128963; EP2242768; CN102015767 CORV54 Lightchain variable region, Fab58 CN1513874 6790 SARS antibody CORV55 Lightchain variable region, Fab59 CN1513874 6791 SARS antibody CORN56 Lightchain variable region, 3C7 US7728110 SEQ ID NO: 58; 6792 SARS humanmonoclonal WO2008060331; EP2035454A2, antibody US20080248043 CORV57Light chain variable region, F26G18 US7622112 SEQ ID NO: 14; 6793 SARShuman monoclonal WO2005054469; antibody US20080248043; US20080081047CORV58 Light chain, Humanized CN103864924 SEQ ID NO: 4 6794 neutralizingmurine monoclonal MERS CORV59 Light chain, MERS m336 WO2015057942 SEQ IDNO: 2 6795 CORV60 Light chain, MERS m337 WO2015057942 SEQ ID NO: 10 6796CORV61 Light chain, MERS m338 WO2015057942 SEQ ID NO: 17 6797 CORV62Light chain, MERS 2E 6 CN104447986 SEQ ID NO: 4 6798 CORV63 Light chain,MERS M336 Ying et al., Nat Commun 6, 8223 6799 (2015), NCBI Accession #4XAK_L (214aa) CORV64 Variable heavy chain-constant 4C2Fab CN103864924SEQ ID NO: 7 6800 heavy chain 1, Humanized neutralizing murinemonoclonal MERS CORV65 Variable light chain-constant 4C2Fab CN103864924SEQ ID NO: 9 6801 light chain 1, Humanized neutralizing murinemonoclonal MERS

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inU.S. Pat. No. 7,629,443, US Publication No US20080254440, ChinesePublication No. CN103613666. CN1570638, CN101522208, CN1673231,CN1590409, CN1557838, and CN1488645, the contents of each of which areherein incorporated by reference in their entirety, against SARS.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 26 against John Cunningham Virus.

TABLE 26 Antibodies against John Cunningham Virus Anti- SEQ bodyAntibody Reference ID No. Description Name Information NO JCV1 Heavychain 14G8 US20150056188 6802 SEQ ID NO: 1 JCV2 Heavy chain 16H5US20150056188 6803 SEQ ID NO: 5 JCV3 Heavy chain 18C9 US20150056188 6804SEQ ID NO: 9 JCV4 Heavy chain 34C6 US20150056188 6805 SEQ ID NO: 13 JCV5Heavy chain 18C9 N55S US20150056188 6806 SEQ ID NO: 16 JCV6 Heavy chain18C9 N55Q US20150056188 6807 SEQ ID NO: 18 JCV7 Heavy chain 18C9 N55DUS20150056188 6808 SEQ ID NO: 20 JCV8 Heavy chain 18C9 N55HUS20150056188 6809 SEQ ID NO: 22 JCV9 Heavy chain 18C9 N55TUS20150056188 6810 SEQ ID NO: 24 JCV10 Heavy chain 18C9 N55AUS20150056188 6811 SEQ ID NO: 26 JCV11 Heavy chain 18C9 N55LUS20150056188 6812 SEQ ID NO: 28 JCV12 Heavy chain 18C9 N55XUS20150056188 6813 SEQ ID NO: 30 JCV13 Heavy chain 18C9 G56AUS20150056188 6814 SEQ ID NO: 32 JCV14 Heavy chain 18C9 G56VUS20150056188 6815 SEQ ID NO: 34 JCV15 Heavy chain 18C9 G56PUS20150056188 6816 SEQ ID NO: 36 JCV16 Heavy chain 18C9 G56XUS20150056188 6817 SEQ ID NO: 38 JCV17 Heavy chain 399-h (C35AUS20150050271 6818 V50A) SEQ ID NO: 20 JCV18 Heavy chain Antibody fromUS20150050271 6819 US20150050271 SEQ ID NO: 66 JCV19 Heavy chain H0US20150050271 6820 SEQ ID NO: 51 JCV20 Heavy chain H1 US20150050271 6821SEQ ID NO: 52 JCV21 Heavy chain H3 US20150050271 6822 SEQ ID NO: 54JCV22 Heavy chain H4 US20150050271 6823 SEQ ID NO: 55 JCV23 Heavy chainH5 US20150050271 6824 SEQ ID NO: 56 JCV24 Heavy chain H6 US201500502716825 SEQ ID NO: 57 JCV25 Heavy chain H7 US20150050271 6826 SEQ ID NO: 58JCV26 Heavy chain H8 US20150050271 6827 SEQ ID NO: 59 JCV27 Heavy chainH9 US20150050271 6828 SEQ ID NO: 60 JCV28 Heavy chain L0 US201500502716829 SEQ ID NO: 48 JCV29 Heavy chain jcv411_vh US20150050271 6830 SEQ IDNO: 43 JCV30 Heavy chain IGHV3-30-3x01 US20150050271 6831 SEQ ID NO: 44JCV31 Heavy chain H0 US20150050271 6832 SEQ ID NO: 19 JCV32 Heavy chainH0 V50G US20150050271 6833 SEQ ID NO: 21 JCV33 Heavy chain H1US20150050271 6834 SEQ ID NO: 22 JCV34 Heavy chain H2 US20150050271 6835SEQ ID NO: 23 JCV35 Heavy chain H3 US20150050271 6836 SEQ ID NO: 24JCV36 Heavy chain H4 US20150050271 6837 SEQ ID NO: 25 JCV37 Heavy chainH5 US20150050271 6838 SEQ ID NO: 26 JCV38 Heavy chain H6 US201500502716839 SEQ ID NO: 27 JCV39 Heavy chain H7 US20150050271 6840 SEQ ID NO: 28JCV40 Heavy chain H8 US20150050271 6841 SEQ ID NO: 29 JCV41 Heavy chainH9 US20150050271 6842 SEQ ID NO: 30 JCV42 Heavy chain GRE1 US201501915306843 variable SEQ ID NO: 1 region JCV43 Heavy chain R399 US201500502716844 variable SEQ ID NO: 6 region JCV44 Light chain 14G8 US201500561886845 SEQ ID NO: 3 JCV45 Light chain 16H5 US20150056188 6846 SEQ ID NO: 7JCV46 Light chain 18C9 US20150056188 6847 SEQ ID NO: 11 JCV47 Lightchain 34C6 US20150056188 6848 SEQ ID NO: 14 JCV48 Light chain 18C9 C96LUS20150056188 6849 SEQ ID NO: 40 JCV49 Light chain 18C9 C96SUS20150056188 6850 SEQ ID NO: 42 JCV50 Light chain 18C9 C96AUS20150056188 6851 SEQ ID NO: 44 JCV51 Light chain 18C9 C96XUS20150056188 6852 SEQ ID NO: 46 JCV52 Light chain 399-1 (N31G),US20150050271 6853 L SEQ ID NO: 15 JCV53 Light chain Antibody fromUS20150050271 6854 US20150050271 SEQ ID NO: 67 JCV54 Light chain H2US20150050271 6855 SEQ ID NO: 53 JCV55 Light chain L1 US20150050271 6856SEQ ID NO: 49 JCV56 Light chain L2 US20150050271 6857 SEQ ID NO: 50JCV57 Light chain 1GKV1D-13x01 US20150050271 6858 SEQ ID NO: 39 JCV58Light chain L0 US20150050271 6859 SEQ ID NO: 11 JCV59 Light chain L1US20150050271 6860 SEQ ID NO: 12 JCV60 Light chain L2 US20150050271 6861SEQ ID NO: 13 JCV61 Light chain L2 N31A US20150050271 6862 SEQ ID NO: 14JCV62 Heavy chain GRE1 US20150191530 6863 variable SEQ ID NO: 2 regionJCV63 Heavy chain R399 US20150050271 6864 variable SEQ ID NO: 1 regionJCV64 Heavy chain R411.jcv411_vh US20150050271 6865 variable SEQ ID NO:38 region

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 27 against Poxvirus.

TABLE 27 Antibodies against Poxvirus Antibody Antibody Reference SEQ IDNo. Description Name Information NO POXV1 Heavy chain B5R bindingUS8623370 6866 variable region, antibody SEQ ID NO: 2 B5R envelopeprotein POXV2 Heavy chain B5R binding US8623370 6867 variable region,antibody SEQ ID NO: 6 B5R envelope protein POXV3 Heavy chain B5R bindingUS8623370 6868 variable region, antibody SEQ ID NO: B5R envelope 10protein POXV4 Heavy chain B5R binding US8623370 6869 variable region,antibody SEQ ID NO: B5R envelope 14 protein POXV5 Heavy chain, H3Lbinding US20140186370 6870 H3L envelope antibody SEQ ID protein NO: 14POXV6 Light chain variable B5R binding US8623370 6871 region, B5Rantibody SEQ ID NO: 4 envelope protein POXV7 Light chain variable B5Rbinding US8623370 6872 region, B5R antibody SEQ ID NO: 8 envelopeprotein POXV8 Light chain variable B5R binding US8623370 6873 region,B5R SEQ ID NO: envelope protein antibody 12 POXV9 Light chain variableB5R binding US8623370 6874 region, B5R SEQ ID NO: envelope proteinantibody 16 POXV10 Light chain, H3L binding US20140186370 6875 H3Lenvelope antibody SEQ ID protein NO: 16

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 28 against Enterovirus 71.

TABLE 28 Antibodies against Enterovirus 71 SEQ Antibody Reference ID No.Description Antibody Name Information NO ENTV1 Heavy chain CN102718864A6876 variable region SEQ ID NO: 2 ENTV2 Heavy chain E18 WO20150926686877 variable region SEQ ID NO: 1 ENTV3 Heavy chain E19 WO20150926686878 variable region SEQ ID NO: 3 ENTV4 Heavy chain E20 WO20150926686879 variable region SEQ ID NO: 5 ENTV5 Heavy chain E19 humanizedWO2015092668 6880 variable region VH1 SEQ ID NO: 19 ENTV6 Heavy chainE19 humanized WO2015092668 6881 variable region VH2 SEQ ID NO: 20 ENTV7Heavy chain E19 humanized WO2015092668 6882 variable region VH3 SEQ IDNO: 21 ENTV8 Heavy chain E19 humanized WO2015092668 6883 variable regionVH4 SEQ ID NO: 22 ENTV9 Light chain CN102718864A 6884 variable regionSEQ ID NO: 1 ENTV10 Light chain E18 WO2015092668 6885 variable regionSEQ ID NO: 2 ENTV11 Light chain E19 WO2015092668 6886 variable regionSEQ ID NO: 4 ENTV12 Light chain E20 WO2015092668 6887 variable regionSEQ ID NO: 6 ENTV13 Light chain E18 VL2 WO2015092668 6888 variableregion SEQ ID NO: 15 ENTV14 Light chain E19 humanized WO2015092668 6889variable region VL1 SEQ ID NO: 16 ENTV15 Light chain E19 humanizedWO2015092668 6890 variable region VL2 SEQ ID NO: 17 ENTV16 Light chainE19 humanized WO2015092668 6891 variable region VL3 SEQ ID NO: 18

In one embodiment, the payload region of the AA particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inChinese Publication No. CN104357400, the contents of which are hereinincorporated by reference in their entirety, against EV71.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants encoding MAB979,fragments or variants thereof for treating a disease and/or disorder orpreventing a disease and/or disorder. As a non-limiting example, thedisease and/or disorder is EV71.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 29 against Rubella Virus.

TABLE 29 Antibodies against Rubella Virus Antibody Antibody SEQ ID No.Description Name Reference Information NO RUBV1 Heavy chain DDF-RuV1US20100143376 6892 variable region SEQ ID NO: 2 RUBV2 Heavy chainDDF-RuV2 US20100143376 6893 variable region SEQ ID NO: 9 RUBV3 Lightchain DDF-RuV1 US20100143376 6894 variable region SEQ ID NO: 7 RUBV4Light chain DDF-RuV2 US20100143376 6895 variable region SEQ ID NO: 14

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 30 against Human Papilloma Virus.

TABLE 30 Antibodies against Human Papilloma Virus Antibody SEQ No.Description Reference Information ID NO HPV1 Heavy chain WO2015096269SEQ ID NO: 1 6896 variable region HPV2 Light chain WO2015096269 SEQ IDNO: 2 6897 variable region

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described in USPublication No. US20130337438, the contents of which are hereinincorporated by reference in their entirety, against HBV.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the broadlyneutralizing payload antibody polypeptides listed in Table 31 againstviruses.

TABLE 31 Broadly Neutralizing Antibodies for Viruses Anti- SEQ bodyAntibody Reference ID No. Description Name Information NO VIR1 Heavychain variable 3G4 US7611704 6898 region, hepatitis, influenza, SEQ IDHIV, herpes, NO: 2 paramyxovirus, poxvirus, rhabdovirus or arenavirusVIR2 Heavy chain variable 3G4 US7611704 6899 region, hepatitis,influenza, SEQ ID HIV, herpes, NO: 4 paramyxovirus, poxvirus,rhabdovirus or arenavirus VIR3 Heavy chain variable 679 US7429381 6900region, HIV, herpes, SEQ ID cytomegalovirus, rabies, NO: 4 influenza,hepatitis B, Sendai, feline leukemia, Reo, polio, human serumparvo-like, simian 40, respiratory syncytial, mouse mammary tumor,Varicella-Zoster, light chain variable region, Dengue, rubella, measles,adenovirus, human T-cell leukemias, Epstein- Barr, murine leukemia,mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wartand blue tongue VIR4 Heavy chain variable Mu-9V US7429381 6901 region,HIV, herpes, SEQ ID cytomegalovirus, rabies, NO: 10 influenza, hepatitisB, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster,Dengue, rubella, measles, adenovirus, human T- cell leukemias,Epstein-Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis,lymphocytic choriomeningitis, wart and blue tongue, light chain variableregion VIR5 Heavy chain variable humanized US7429381 6902 region, HIV,herpes, Mu-9 SEQ ID cytomegalovirus, rabies, NO: 14 influenza, hepatitisB, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster,Dengue, rubella, measles, adenovirus, human T- cell leukemias,Epstein-Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis,lymphocytic choriomeningitis, wart and blue tongue, light chain variableregion VIR6 Heavy chain variable Fab-2 US20120269801 6903 region, HumanClone3 SEQ cytomegalovirus, HCMV, ID NO: 6 human T-cell leukemia virustype 1, HIV-1, simian immunodeficiency virus, Ebola virus, Herpesvirussaimiri virus, influenza virus, and vaccinia virus VIR7 Heavy chainvariable Fab-3 US20120269801 6904 region, Human Clone 7 SEQcytomegalovirus, HCMV, ID NO: 10 human T-cell leukemia virus type 1,HIV-1, simian immunodeficiency virus, Ebola virus, Herpesvirus saimirivirus, influenza virus, and vaccinia virus VIR8 Light chain variableMu-9V US7429381 6905 region, HIV, herpes, SEQ ID cytomegalovirus,rabies, NO: 8 influenza, hepatitis B, Sendai, feline leukemia, Reo,polio, human serum parvo-like, simian 40, respiratory syncytial, mousemammary tumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus,human T- cell leukemias, Epstein-Bair, murine leukemia, mumps, vesicularstomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue,light chain variable region VIR9 Light chain variable humanizedUS7429381 6906 region, HIV, herpes, Mu-9 SEQ ID cytomegalovirus, rabies,NO: 12 influenza, hepatitis B, Sendai, feline leukemia, Reo, polio,human serum parvo-like, simian 40, respiratory syncytial, mouse mammarytumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T-cell leukemias, Epstein-Barr, murine leukemia, mumps, vesicularstomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue,light chain variable region VIR10 Light chain variable 679 US74293816907 region, HIV, herpes, SEQ ID cytomegalovirus, rabies, NO: 2influenza, hepatitis B, Sendai, feline leukemia, Reo, polio, human serumparvo-like, simian 40, respiratory syncytial, mouse mammary tumor,Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T- cellleukemias, Epstein-Barr, murine leukemia, mumps, vesicular stomatitis,Sindbis, lymphocytic choriomeningitis, wart and blue tongue VIR11 Lightchain variable Fab-3 US20120269801 6908 region, Human Clone 7 SEQcytomegalovirus, HCMV, ID NO: 8 human T-cell leukemia virus type 1,HIV-1, simian immunodeficiency virus, Ebola virus, Herpesvirus saimirivirus, influenza virus, and vaccinia virus VIR12 Light chain variable,Fab-2 US20120269801 6909 Human cytomegalovirus, Clone3 SEQ HCMV, humanT-cell ID NO: 4 leukemia virus type 1, HIV-1, simian immunodeficiencyvirus, Ebola virus, Herpesvirus saimiri virus, influenza virus, andvaccinia virus, region VIR13 ScFv, hepatitis, influenza, 3A2 US76117046910 HIV, herpes, SEQ ID paramyxovirus, poxvirus, NO: 6 rhabdovirus orarenavirus VIR14 ScFv, HIV, herpes, 679 US7429381 6911 cytomegalovirus,rabies, SEQ ID influenza, hepatitis B, NO: 6 Sendai, feline leukemia,Reo, polio, human serum parvo-like, simian 40, respiratory syncytial,mouse mammary tumor, Varicella-Zoster, Dengue, rubella, measles,adenovirus, human T-cell leukemias, Epstein- Barr, murine leukemia,mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wartand blue tongue

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 32 against Pseudomonas aeruginosa

TABLE 32 Antibodies against Pseudomonas Aeruginosa Anti- SEQ bodyReference ID No. Description Antibody Name Information NO PSEU1 Bivalent260 (1E11- US20150044215 6912 nanobody 40GS-2B10) SEQ ID NO: 118 PSEU2Bivalent 272 (11B09- US20150044215 6913 nanobody 40GS- SEQ ID NO: 11910C05) PSEU3 Bivalent 308 (6B05- US20150044215 6914 nanobody 40GS-1E11)SEQ ID NO: 120 PSEU4 Bivalent 264 (1E11- US20150044215 6915 nanobody40GS-2B02) SEQ ID NO: 121 PSEU5 Bivalent 302 (5H01- US20150044215 6916nanobody 40GS-7C10) SEQ ID NO: 122 PSEU6 Bivalent 234 (7C10-US20150044215 6917 nanobody 40GS-5H01) SEQ ID NO: 123 PSEU7 Bivalent 064(13F07- US20150044215 6918 nanobody 40GS-7C10) SEQ ID NO: 124 PSEU8Bivalent 275 (2G09- US20150044215 6919 nanobody 40GC-5H10) SEQ ID NO:125 PSEU9 Bivalent 083 (7C10- US20150044215 6920 nanobody 40GS-11B09)SEQ ID NO: 126 PSEU10 Bivalent 087 (1E11- US20150044215 6921 nanobody40GS-7C10) SEQ ID NO: 127 PSEU11 Bivalent 269 (6B05- US20150044215 6922nanobody 40GS-13F07) SEQ ID NO: 128 PSEU12 Bivalent 256 (13F07-US20150044215 6923 nanobody 40GS-5H01) SEQ ID NO: 129 PSEU13 Bivalent277 (5H01- US20150044215 6924 nanobody 40GS-11B09) SEQ ID NO: 130 PSEU14Bivalent 257 (13F07- US20150044215 6925 nanobody 40GS-2B10) SEQ ID NO:131 PSEU15 Bivalent 285 (13F07- US20150044215 6926 nanobody 40GS-2B02)SEQ ID NO: 132 PSEU16 Bivalent 115 (11B09- US20150044215 6927 nanobody40GS-13F07) SEQ ID NO: 133 PSEU17 Bivalent 258 (13F07- US201500442156928 nanobody 40GS-14E10) SEQ ID NO: 134 PSEU18 Bivalent 283 (7E09-US20150044215 6929 nanobody 40G5-6B05) SEQ ID NO: 135 PSEU19 Bivalent271 (7C10- US20150044215 6930 nanobody 40GS-14E10) SEQ ID NO: 136 PSEU20Bivalent 259 (1E11- US20150044215 6931 nanobody 40GS-5H01) SEQ ID NO:137 PSEU21 Bivalent 319 (13F07- US20150044215 6932 nanobody 40GS-6B05)SEQ ID NO: 138 PSEU22 Bivalent 335 (5H01- US20150044215 6933 nanobody40G5-1E11) SEQ ID NO: 139 PSEU23 Bivalent 261 (5H01- US20150044215 6934nanobody 40GS-2B10) SEQ ID NO: 140 PSEU24 Bivalent 262 (7E09-US20150044215 6935 nanobody 40GS-7C10) SEQ ID NO: 141 PSEU25 ConstantUS20150044215 6936 heavy chain SEQ ID NO: 148 PSEU26 ConstantUS20150044215 6937 light chain SEQ ID NO: 149 PSEU27 Heavy chainPanobacumab US8197816 6938 SEQ ID NO: 8 PSEU28 Heavy chain US201301566966939 SEQ ID NO: 2 PSEU29 Heavy chain US7494653 6940 SEQ ID NO: 2 PSEU30Heavy chain KB0001 US8044181 6941 variable SEQ ID NO: 3 region PSEU31Heavy chain KB0001 US8044181 6942 variable SEQ ID NO: 5 region PSEU32Heavy chain KB0001 US8044181 6943 variable SEQ ID NO: 7 region PSEU33Heavy chain KB0001 US8044181 6944 variable SEQ ID NO: 9 region PSEU34Heavy chain KB0001 US8044181 6945 variable SEQ ID NO: 11 region PSEU35Heavy chain 1F3 US9085611 6946 variable SEQ ID NO: 11 region PSEU36Heavy chain 2A4 US9085611 6947 variable SEQ ID NO: 13 region PSEU37Heavy chain US9085611 6948 variable SEQ ID NO: 27 region PSEU38 Heavychain mAbs LST-001 US8653242 6949 variable SEQ ID NO: 29 region PSEU39Heavy chain rnAbs LST-002 US8653242 6950 variable SEQ ID NO: 49 regionPSEU40 Heavy chain mAbs LST-005 US8653242 6951 variable SEQ ID NO: 52region PSEU41 Heavy chain rnAbs LST-006 US8653242 6952 variable SEQ IDNO: 54 region PSEU42 Heavy chain mAbs LST-007 US8653242 6953 variableSEQ ID NO: 13 region PSEU43 Heavy chain mAbs LST-008 US8653242 6954variable SEQ ID NO: 15 region PSEU44 Heavy chain 310BO6 US7597893 6955variable SEQ ID NO: 8 region PSEU45 Heavy chain Cam-003 US201402272856956 variable SEQ ID NO: 1 region PSEU46 Heavy chain Cam-004US20140227285 6957 variable SEQ ID NO: 3 region PSEU47 Heavy chainCam-005 US20140227285 6958 variable SEQ ID NO: 4 region PSEU48 Heavychain WapR-001 US20140227285 6959 variable SEQ ID NO: 5 region PSEU49Heavy chain WapR-002 US20140227285 6960 variable SEQ ID NO: 7 regionPSEU50 Heavy chain WapR-003 US20140227285 6961 variable SEQ ID NO: 9region PSEU51 Heavy chain WapR-004 US20140227285 6962 variable SEQ IDNO: 11 region PSEU52 Heavy chain WapR-007 US20140227285 6963 variableSEQ ID NO: 13 region PSEU53 Heavy chain WapR-016 US20140227285 6964variable SEQ ID NO: 15 region PSEU54 Heavy chain 1584 US20130045207 6965variable SEQ ID NO: 8 region PSEU55 Heavy chain 1573 US20130045207 6966variable SEQ ID NO: 16 region PSEU56 Heavy chain 1572 US20130045207 6967variable SEQ ID NO: 24 region PSEU57 Heavy chain 1587 US20130045207 6968variable SEQ ID NO: 32 region PSEU58 Heavy chain 3099 US20130022604 6969variable SEQ ID NO: 8 region PSEU59 Heavy chain 2745 US20130022604 6970variable SEQ ID NO: 16 region PSEU60 Heavy chain 2459 US20130022604 6971variable SEQ ID NO: 24 region PSEU61 Heavy chain 2316 US20130022606 6972variable SEQ ID NO: 8 region PSEU62 Heavy chain 1838 US20130022606 6973variable SEQ ID NO: 16 region PSEU63 Heavy chain 2314 US20130022606 6974variable SEQ ID NO: 24 region PSEU64 Heavy chain 2326 US20130022606 6975variable SEQ ID NO: 32 region PSEU65 Heavy chain 2328 US20130022606 6976variable SEQ ID NO: 40 region PSEU66 Heavy chain 2438 US20130022606 6977variable SEQ ID NO: 48 region PSEU67 Heavy chain 1774 US20130004500 6978variable SEQ ID NO: 8 region PSEU68 Heavy chain 1660 US20130004500 6979variable SEQ ID NO: 16 region PSEU69 Heavy chain 1923 US20130004500 6980variable SEQ ID NO: 24 region PSEU70 Heavy chain 1656 US20130004499 6981variable SEQ ID NO: 8 region PSEU71 Heavy chain 1640 US20130004499 6982variable SEQ ID NO: 16 region PSEU72 Heavy chain 2459 US20130004499 6983variable SEQ ID NO: 24 region PSEU73 Heavy chain US20120114657 6984variable SEQ ID NO: 8 region PSEU74 Heavy chain Anti-It-2 US201101770876985 variable SEQ ID NO: 13 region PSEU75 Heavy chain Anti-It-3US20110177087 6986 variable SEQ ID NO: 14 region PSEU76 Heavy chainAnti-It-4 US20110177087 6987 variable SEQ ID NO: 15 region PSEU77 Heavychain Anti-It-5 US20110177087 6988 variable SEQ ID NO: 16 region PSEU78Heavy chain Anti-It-6 US20110177087 6989 variable SEQ ID NO: 17 regionPSEU79 Heavy chain Anti-170003 US20110177087 6990 variable SEQ ID NO: 18region PSEU80 Heavy chain Anti-170006 US20110177087 6991 variable SEQ IDNO: 19 region PSEU81 Heavy chain Anti-Pa01 US20110177087 6992 variableSEQ ID NO: 20 region PSEU82 Heavy chain Anti-IATS016 US20110177087 6993variable SEQ ID NO: 21 region PSEU83 Heavy chain US20090191186 6994variable SEQ ID NO: 1 region PSEU84 Heavy chain US20090191186 6995variable SEQ ID NO: 11 region PSEU85 Heavy chain US20090191186 6996variable SEQ ID NO: 3 region PSEU86 Heavy chain US20090191186 6997variable SEQ ID NO: 7 region PSEU87 Heavy chain US20090191186 6998variable SEQ ID NO: 9 region PSEU88 Heavy chain US20090191186 6999variable SEQ ID NO: 5 region PSEU89 Heavy chain US20090191186 7000variable SEQ ID NO: 13 region PSEU90 Heavy chain US20090191186 7001variable SEQ ID NO: 21 region PSEU91 Heavy chain US20090191186 7002variable SEQ ID NO: 17 region PSEU92 Heavy chain US20090191186 7003variable SEQ ID NO: 26 region PSEU93 Heavy chain US20090191186 7004variable SEQ ID NO: 25 region PSEU94 Heavy chain US20090191186 7005variable SEQ ID NO: 23 region PSEU95 Heavy chain US20090191186 7006variable SEQ ID NO: 29 region PSEU96 Heavy chain US20090191186 7007variable SEQ ID NO: 35 region PSEU97 Heavy chain V2L2 WO2014074528 7008variable SEQ ID NO: 216 region PSEU98 Heavy chain V2L2-MD WO20140745287009 variable SEQ ID NO: 255 region PSEU99 Heavy chain V2L2-MDWO2O14074528 7010 variable and V2L2- SEQ ID NO: 256 region GL PSEU100Heavy chain V2L2-GL WO2014074528 7011 variable SEQ ID NO: 257 regionPSEU101 Heavy chain 2409 WO2013024905 7012 variable SEQ ID NO: 16 regionPSEU102 Heavy chain 2453 WO2013024905 7013 variable SEQ ID NO: 24 regionPSEU103 Heavy chain S20 US7972845 7014 variable SEQ ID NO: 2 regionPSEU104 Heavy chain Fab 13.37 US20150044215 7015 variable SEQ ID NO: 142region PSEU105 Heavy chain Fab 26.24 US20150044215 7016 variable SEQ IDNO: 144 region PSEU106 Heavy chain Fab 35.36 US20150044215 7017 variableSEQ ID NO: 146 region PSEU107 Heavy chain KB0001 US8044181 7018 variableSEQ ID NO: 1 region PSEU108 Heavy Horn., M.P. et al. 7019 chain, LPS“Preclinical In serotype Vitro and In Vivo IATS-O11. characterization ofthe fully human monoclonal IgM antibody KBPA101 specific for Pseudomonasaeruginosa serotype IATS- O11”, Antimicrob. Agents Chemother. 54 (6),2338- 2344 (2010) PSEU109 J chain Panobacumab 7020 PSEU110 Light chainPanobacumab US8197816 7021 SEQ ID NO: 7 PSEU111 Light chainUS20130156696 7022 SEQ ID NO: 4 PSEU112 Light chain US7494653 7023 SEQID NO: 4 PSEU113 Light chain 1F3 US9085611 7024 variable SEQ ID NO: 2region PSEU114 Light chain 2A4 US9085611 7025 variable SEQ ID NO: 4region PSEU115 Light chain US9085611 7026 variable SEQ ID NO: 28 regionPSEU116 Light chain mAbS LST-001 US8653242 7027 variable SEQ ID NO: 18region PSEU117 Light chain mAbs LST-006 US8653242 7028 variable SEQ IDNO: 53 region PSEU118 Light chain mAbs LST-008 US8653242 7029 variableSEQ ID NO: 14 region PSEU119 Light chain mAbs LST-008 US8653242 7030variable SEQ ID NO: 16 region PSEU120 Light chain 310BO6 US7597893 7031variable SEQ ID NO: 7 region PSEU121 Light chain Cam-003, US201402272857032 variable Cam-004, SEQ ID NO: 2 region Cam-005 PSEU122 Light chainWapR-001 US20140227285 7033 variable SEQ ID NO: 6 region PSEU123 Lightchain WapR-002 US20140227285 7034 variable SEQ ID NO: 8 region PSEU124Light chain WapR-003 US20140227285 7035 variable SEQ ID NO: 10 regionPSEU125 Light chain WapR-004, US20140227285 7036 variable WapR- SEQ IDNO: 12 region 004-RAD PSEU126 Light chain WapR-007 US20140227285 7037variable SEQ ID NO: 14 region PSEU127 Light chain WapR-016 US201402272857038 variable SEQ ID NO: 16 region PSEU128 Light chain 1584US20130045207 7039 variable SEQ ID NO: 7 region PSEU129 Light chain 1573US20130045207 7040 variable SEQ ID NO: 5 region PSEU130 Light chain 1572US20130045207 7041 variable SEQ ID NO: 23 region PSEU131 Light chain1587 US20130045207 7042 variable SEQ ID NO: 31 region PSEU132 Lightchain 3099 US20130022604 7043 variable SEQ ID NO: 7 region PSEU133 Lightchain 2745 US20130022604 7044 variable SEQ ID NO: 15 region PSEU134Light chain 2459 US20130022604 7045 variable SEQ ID NO: 23 regionPSEU135 Light chain 2316 US20130022606 7046 variable SEQ ID NO: 7 regionPSEU136 Light chain 1838 US20130022606 7047 variable SEQ ID NO: 15region PSEU137 Light chain 2314 US20130022606 7048 variable SEQ ID NO:23 region PSEU138 Light chain 2326 US20130022606 7049 variable SEQ IDNO: 31 region PSEU139 Light chain 2328 US20130022606 7050 variable SEQID NO: 39 region PSEU140 Light chain 2438 US20130022606 7051 variableSEQ ID NO: 47 region PSEU141 Light chain 1774 US20130004500 7052variable SEQ ID NO: 7 region PSEU142 Light chain 1660 US20130004500 7053variable SEQ ID NO: 15 region PSEU143 Light chain 1923 US201300045007054 variable SEQ ID NO: 23 region PSEU144 Light chain 1656US20130004499 7055 variable SEQ ID NO: 7 region PSEU145 Light chain 1640US20130004499 7056 variable SEQ ID NO: 5 region PSEU146 Light chain 2459US20130004499 7057 variable SEQ ID NO: 23 region PSEU147 Light chainUS20120114657 7058 variable SEQ ID NO: 7 region PSEU148 Light chainAnti-It-2 US20110177087 7059 variable SEQ ID NO: 22 region PSEU149 Lightchain Anti-It-3 US20110177087 7060 variable SEQ ID NO: 23 region PSEU150Light chain Anti-It-4 US20110177087 7061 variable SEQ ID NO: 24 regionPSEU151 Light chain Anti-It-5 US20110177087 7062 variable SEQ ID NO: 25region PSEU152 Light chain Anti-It-6 US20110177087 7063 variable SEQ IDNO: 26 region PSEU153 Light chain Anti-170003 US20110177087 7064variable SEQ ID NO: 27 region PSEU154 Light chain Anti-170006US20110177087 7065 variable SEQ ID NO: 28 region PSEU155 Light chainAnti-Pa01 US20110177087 7066 variable SEQ ID NO: 29 region PSEU156 Lightchain Anti- US20110177087 7067 variable IATS016 SEQ ID NO: 30 regionPSEU157 Light chain US20090191186 7068 variable SEQ ID NO: 2 regionPSEU158 Light chain US20090191186 7069 variable SEQ ID NO: 12 regionPSEU159 Light chain US20090191186 7070 variable SEQ ID NO: 8 regionPSEU160 Light chain US20090191186 7071 variable SEQ ID NO: 10 regionPSEU161 Light chain US20090191186 7072 variable SEQ ID NO: 6 regionPSEU162 Light chain US20090191186 7073 variable SEQ ID NO: 37 regionPSEU163 Light chain US20090191186 7074 variable SEQ ID NO: 18 regionPSEU164 Light chain US20090191186 7075 variable SEQ ID NO: 24 regionPSEU165 Light chain US20090191186 7076 variable SEQ ID NO: 20 regionPSEU166 Light chain US20090191186 7077 variable SEQ ID NO: 36 regionPSEU167 Light chain US20090191186 7078 variable SEQ ID NO: 28 regionPSEU168 Light chain US20090191186 7079 variable SEQ ID NO: 30 regionPSEU169 Light chain US20090191186 7080 variable SEQ ID NO: 34 regionPSEU170 Light chain US20090191186 7081 variable SEQ ID NO: 32 regionPSEU171 Light chain V2L2 WO2014074528 7082 variable SEQ ID NO: 217region PSEU172 Light chain 2409 WO2013024905 7083 variable SEQ ID NO: 15region PSEU173 Light chain 2453 WO2013024905 7084 variable SEQ ID NO: 23region PSEU174 Light chain S20 US7972845 7085 variable SEQ ID NO: 4region PSEU175 Light chain Fab 13.37 US20150044215 7086 variable SEQ IDNO: 143 region PSEU176 Light chain Fab 26.24 US20150044215 7087 variableSEQ ID NO: 45 region PSEU177 Light chain Fab 35.36 US20150044215 7088variable SEQ ID NO: 147 region PSEU178 Light chain mAbs US8653242 7089variable LST-002 SEQ ID NO: 32 region majority PSEU179 Light chain mAbsUS8653242 7090 variable LST-006 SEQ ID NO: 55 region majority PSEU180Light chain mAbs US8653242 7091 variable LST-002 SEQ ID NO: 51 regionminority PSEU181 Light chain mAbs LST-007 US8653242 7092 variable SEQ IDNO: 56 region minority PSEU182 Light chain, Horn, M.P. et al. 7093Anti-P. “Preclinical In Aeuginosa LPS Vitro and in Vivo serotypecharacterization IATS-O11, of the fully human monoclonal IgM antibodyKBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11”,Antimicrob. Agents Chemother. 54 (6), 2338- 2344 (2010) PSEU183 Lightkappa KB0001 US8044181 7094 chain SEQ ID NO: 10 variable region PSEU184Light kappa KB0001 US8044181 7095 chain SEQ ID NO: 2 variable regionPSEU185 Light kappa KB0001 US8044181 7096 chain SEQ ID NO: 4 variableregion PSEU186 Light kappa KB0001 US8044181 7097 chain SEQ ID NO: 6variable region PSEU187 Light kappa KB0001 US8044181 7098 chain SEQ IDNO: 8 variable region PSEU188 Monovalent 5H01 US20150044215 7099nanobody SEQ ID NO: 1 PSEU189 Monovalent 7C10 US20150044215 7100nanobody SEQ ID NO: 2 PSEU190 Monovalent 1E11 US20150044215 7101nanobody SEQ ID NO: 3 PSEU191 Monovalent 2B02 US20150044215 7102nanobody SEQ ID NO: 4 PSEU192 Monovalent 2B10 US20150044215 7103nanobody SEQ ID NO: 5 PSEU193 Monovalent 2G09 US20150044215 7104nanobody SEQ ID NO: 6 PSEU194 Monovalent 6B05 US20150044215 7105nanobody SEQ ID NO: 7 PSEU195 Monovalent 10C05 US20150044215 7106nanobody SEQ ID NO: 8 PSEU196 Monovalent 11B09 US20150044215 7107nanobody SEQ ID NO: 9 PSEU197 Monovalent 14E10 US20150044215 7108nanobody SEQ ID NO: 10 PSEU198 Monovalent 7E09 US20150044215 7109nanobody SEQ ID NO: 11 PSEU199 Monovalent 13F07 US20150044215 7110nanobody SEQ ID NO: 12 PSEU200 Monovalent 3B11 US20150044215 7111nanobody SEQ ID NO: 13 PSEU201 Monovalent 4C03 US20150044215 7112nanobody SEQ ID NO: 14 PSEU202 Monovalent 4G10 US20150044215 7113nanobody SEQ ID NO: 15 PSEU203 Monovalent 12B02 US20150044215 7114nanobody SEQ ID NO: 16 PSEU204 Monovalent 14B10 US20150044215 7115nanobody SEQ ID NO: 17 PSEU205 Monovalent 3E10 US20150044215 7116nanobody SEQ ID NO: 18 PSEU206 Monovalent 5E02 US20150044215 7117nanobody SEQ ID NO: 19 PSEU207 Scfv-Fc W4-M1 WO2014074528 7118 SEQ IDNO: 78 PSEU208 Scfv-Fc W4-M5 WO2014074528 7119 SEQ ID NO: 79 PSEU209Scfv-Fc W4-M6 WO2014074528 7120 SEQ ID NO: 80 PSEU210 Scfv-Fc W4-M7WO2014074528 7121 SEQ ID NO: 81 PSEU211 Scfv-Fc W4-M8 WO2014074528 7122SEQ ID NO: 82 PSEU212 Scfv-Fc W4-M9 WO2014074528 7123 SEQ ID NO: 83PSEU213 Scfv-Fc W4-M11 WO2014074528 7124 SEQ ID NO: 84 PSEU214 Scfv-FcW4-M12 WO2014074528 7125 SEQ ID NO: 85 PSEU215 Scfv-Fc W4-M14WO2014074528 7126 SEQ ID NO: 86 PSEU216 Scfv-Fc W4-M15 WO2014074528 7127SEQ ID NO: 87 PSEU217 Scfv-Fc W4-M16 WO2014074528 7128 SEQ ID NO: 88PSEU218 Scfv-Fc W4-M17 WO2014074528 7129 SEQ ID NO: 89 PSEU219 Scfv-FcW4-M19 WO2014074528 7130 SEQ ID NO: 90 PSEU220 Scfv-Fc W4-M20WO2014074528 7131 SEQ ID NO: 91 PSEU221 Sefv-Fc W4-M4 WO2014074528 7132SEQ ID NO: 92 PSEU222 Scfv-Fc W4-M10 WO2014074528 7133 SEQ ID NO: 93PSEU223 Scfv-Fc W4-HC1-LCP WO2014074528 7134 SEQ ID NO: 94 PSEU224Scfv-Fc W4-HC1-LC7 WO2014074528 7135 SEQ ID NO: 95 PSEU225 Scfv-FcW4-HC2-LC7 WO2014074528 7136 SEQ ID NO: 96 PSEU226 Scfv-Fc W4-HC3-LCPWO2014074528 7137 SEQ ID NO: 97 PSEU227 Scfv-Fc W4-HC4-LCP WO20140745287138 SEQ ID NO: 98 PSEU228 Scfv-Fc W4-HC5-LCP WO2014074528 7139 SEQ IDNO: 99 PSEU229 Scfv-Fc W4-HC5-LC7 WO2014074528 7140 SEQ ID NO: 100PSEU230 Scfv-Fc W4-HC7-LCP WO2014074528 7141 SEQ ID NO: 101 PSEU231Scfv-Fc W4-VH1-VL8 WO2014074528 7142 SEQ ID NO: 102 PSEU232 Scfv-FcW4-VH2-VLP WO2014074528 7143 SEQ ID NO: 103 PSEU233 Scfv-Fc W4-VH2-VL8WO2014074528 7144 SEQ ID NO: 104 PSEU234 Scfv-Fc W4-VH3-VL7 WO20140745287145 SEQ ID NO: 105 PSEU235 Scfv-Fc W4-VH3-VL8 WO2014074528 7146 SEQ IDNO: 106 PSEU236 Scfv-Fc W4-VH5-VL8 WO2014074528 7147 SEQ ID NO: 107PSEU237 Scfv-Fc W4-VH6-VL7 WO2014074528 7148 SEQ ID NO: 108 PSEU238Scfv-Fc W4-VH6-VL8 WO2014074528 7149 SEQ ID NO: 109 PSEU239 Scfv-FcW4-VH6-VLP WO2014074528 7150 SEQ ID NO: 110 PSEU240 Scfv-Fc W4-VH7-VLPWO2014074528 7151 SEQ ID NO: 111 PSEU241 Scfv-Fc W4-VH7-VL7 WO20140745287152 SEQ ID NO: 112 PSEU242 Scfv-Fc W4-VH7-VL8 WO2014074528 7153 SEQ IDNO: 113 PSEU243 Scfv-Fc W4-VH9-VLP WO2014074528 7154 SEQ ID NO: 114PSEU244 Scfv-Fc W4-VH10-VLP WO2014074528 7155 SEQ ID NO: 115 PSEU245Scfv-Fc W4-VH11-VLP WO2014074528 7156 SEQ ID NO: 116 PSEU246 Scfv-FcW4-VH12-VLP WO2014074528 7157 SEQ ID NO: 117 PSEU247 Scfv-Fc W4-VH15-VLPWO2014074528 7158 SEQ ID NO: 118 PSEU248 Scfv-Fc W4-VH16-VLPWO2014074528 7159 SEQ ID NO: 119 PSEU249 Scfv-Fc W4-VH20-VLPWO2014074528 7160 SEQ ID NO: 120 PSEU250 Scfv-Fc W4-VH31-VLPWO2014074528 7161 SEQ ID NO: 121 PSEU251 Scfv-Fc W4-VH37-VLPWO2014074528 7162 SEQ ID NO: 122 PSEU252 Scfv-Fc W4-VH41-VLPWO2014074528 7163 SEQ ID NO: 123 PSEU253 Scfv-Fc W4-VH42-VLPWO2014074528 7164 SEQ ID NO: 124 PSEU254 Scfv-Fc W4-VH35-VLPWO2014074528 7165 SEQ ID NO: 125 PSEU255 Scfv-Fc W4-VH36-VLPWO2014074528 7166 SEQ ID NO: 126 PSEU256 Scfv-Fc W4-VH52-VLPWO2014074528 7167 SEQ ID NO: 127 PSEU257 Scfv-Fc W4-VH53-VLPWO2014074528 7168 SEQ ID NO: 128 PSEU258 Scfv-Fc W4-VH54-VLPWO2014074528 7169 SEQ ID NO: 129 PSEU259 Scfv-Fc W4-VH55-VLPWO2014074528 7170 SEQ ID NO: 130 PSEU260 Scfv-Fc W4-VH56-VLPWO2014074528 7171 SEQ ID NO: 131 PSEU261 Scfv-Fc W4-VH57-VLPWO2014074528 7172 SEQ ID NO: 132 PSEU262 Scfv-Fc W4-VH58-VLPWO2014074528 7173 SEQ ID NO: 133 PSEU263 Scfv-Fc W4-VH60-VLPWO2014074528 7174 SEQ ID NO: 134 PSEU264 Scfv-Fc W4-VH61-VLPWO2014074528 7175 SEQ ID NO: 135 PSEU265 Scfv-Fc W4-VH62-VLPWO2014074528 7176 SEQ ID NO: 136 PSEU266 Scfv-Fc W4-VH63-VLPWO2014074528 7177 SEQ ID NO: 137 PSEU267 Scfv-Fc W4-VH64-VLPWO2014074528 7178 SEQ ID NO: 138 PSEU268 Scfv-Fc W4-VH65-VLPWO2014074528 7179 SEQ ID NO: 139 PSEU269 Scfv-Fc W4-VH66-VLPWO2014074528 7180 SEQ ID NO: 140 PSEU270 Scfv-Fc W4-VH67-VLPWO2014074528 7181 SEQ ID NO: 141 PSEU271 Scfv-Fc W4-VH69-VLPWO2014074528 7182 SEQ ID NO: 142 PSEU272 Scfv-Fc W4-VH70-VLPWO2014074528 7183 SEQ ID NO: 143 PSEU273 Scfv-Fc W4-VH72-VLPWO2014074528 7184 SEQ ID NO: 144 PSEU274 Scfv-Fc W4-VH79-VLPWO2014074528 7185 SEQ ID NO: 145 PSEU275 Scfv-Fc W4-VH80-VLPWO2014074528 7186 SEQ ID NO: 146 PSEU276 Scfv-Fc W4-M9 WO2014074528 7187SEQ ID NO: 152 PSEU277 Scfv-Fc Psl0170 WO2014074528 7188 SEQ ID NO: 245PSEU278 Scfv-Fc Psl0304 WO2014074528 7189 SEQ ID NO: 246 PSEU279 Scfv-FcPsl0348 WO2014074528 7190 SEQ ID NO: 247 PSEU280 Scfv-Fc Psl0573WO2014074528 7191 SEQ ID NO: 248 PSEU281 Scfv-Fc Psl0574 WO20140745287192 SEQ ID NO: 249 PSEU282 Scfv-Fc Psl0582 WO2014074528 7193 SEQ ID NO:250 PSEU283 Scfv-Fc Psl0584 WO2014074528 7194 SEQ ID NO: 251 PSEU284Scfv-Fc Psl0585 WO2014074528 7195 SEQ ID NO: 252 PSEU285 Scfv-Fc Psl0589WO2014074528 7196 SEQ ID NO: 253

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 33 against Streptococcus bacteria.

TABLE 33 Antibodies against Streptococcus bacteria Anti- SEQ bodyAntibody Reference ID No. Description Name Information NO STRP1 Heavychair US7625561 7197 variable region, SEQ ID NO: 5 Diabody forStreptococcus STRP2 Heavy chain US7625561 7198 variable region, SEQ IDNO: 3 Diabody for Streptococcus STRP3 Heavy chain US7625561 7199variable region, SEQ ID NO: 7 Diabody for Streptococcus STRP4 Heavychain DP-54 Lucas, A.H. 7200 variable region, “Combinatorial partial,library Streptococcus cloning of human pneumoniae antibodies toStreptococcus pneumoniae capsular polysaccharides: variable regionprimary structures and evidence for somatic mutation of Fab fragmentsspecific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2),853-864 (2001), NCBI Accession # AAD48823 STRP5 Heavy chain DP-35 Lucas,A.H. 7201 variable “Combinatorial region, library partial, cloning ofhuman Streptococcus antibodies to pneumoniae Streptococcus pueumoniaecapsular polysaccharides: variable region primary structures andevidence for somatic mutation of Fab fragments specific for capsularserotypes 6B, 14, and 23F,” Infect. Immun. 69 (2), 853-864 (2001), NCBIAccession # AAD48825 STRP6 Heavy chain DP-47 Lucas, A.H. 7202 variable“Combinatorial region, library partial, cloning of human Streptococcusantibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48827 S'I7RP7 Heavy chain DP-47 Lucas, A.H. 7203 variable“Combinatorial region, library partial, cloning of human Streptococcusantibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001,) NCBI Accession #AAD48828 S'IRP8 Heavy chain LSG-6 1 Lucas, A.H. 7204 variable“Combinatorial region, library partial, cloning of hurnan Streptococcusantibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48830 STRP9 Heavy chain LSG6.1 Lucas, A.H. 7205 variable“Combinatorial region, library partial, cloning of human Streptococcusantibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48832 STRP10 Heavy chain DP-47 Lucas, A.H. 7206 variable“Combinatorial region, library partial, cloning of human Streptococcusantibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48835 STRP11 Heavy chain humanized US7429381 6902 variable region,Mu-9 SEQ ID NO: 14 Streptococcus agalactiae, Legionella pneumophilia,Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae,Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B. Treponemapallidum, Lyme disease spirochetes, Pseudomonas aeruginosa,Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis.STRP12 Heavy chain Anti-PsaA US20070003561 7207 variable region. 7-1G9SEQ ID NO: 16 Streptococcus pneumoniae STRP13 Heavy chain Anti-PsaAUS20070003561 7208 variable region, 1-15E5 SEQ ID NO: 32 Streptococcuspneumoniae STRP14 Heavy chain Anti-PsaA US20070003561 7209 variableregion, 9A7 SEQ ID NO: 48 Streptococcus pneumoniae STRP15 Heavy chain23f Fab Bryson, S., 7210 variable region, 023.102, “MultitaskingStreptococcus chain B immimoglobulin pneumoniae V-Genes And Somatic DivCdr3 Loops Generate Binding Sites For Chemically Di Antigens FromBacterial And. Viral Pathogens” Unpublished″, NCBI Accession # 4HIE BSTRP16 Heavy chain 5.12.14 US5686070 7211 variable region, SEQ ID NO: 22Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosaSIRP17 Heavy chain 6G4.2.5 US5686070 7212 variable region, SEQ ID NO: 50Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosaSTRP18 Heavy chain chimeric US5686070 7213 variable region, 6G4.2.5 SEQID NO: 58 Streptococcus pneumoniae Escherichia coli, or Pseudomonasaeruginosa STRP19 Heavy chain, Mab6679 US7429381 6900 Streptococcus SEQID NO: 4 agalactiae, Legionella pneumophilia, Streptococcus pyogenes,Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis,Pneumococcus, Hemophilis influenzae B, Treponema palliduni Lyrae diseasespirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucellaabortus and Mycobacterium tuberculosis. STRP20 Light chain US76255617214 variable region, SEQ ID NO: 6 Diabody for Streptococcus STRP21Light chain US7625561 7215 variable region, SEQ ID NO: 8 Diabody forStreptococcus STRP22 Light chain US7625561 7216 variable region, SEQ IDNO: 4 Diabody for Streptococcus STRP23 Light chain A2 Lucas, A.H. 7217variable “Combinatorial region, library partial, cloning of humanStreptococcus antibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48824 STRP24 Light chain 133 Lucas, A.H. 7218 variable “Combinatorialregion, library partial, cloning of human Streptococcus antibodies topneumoniae Streptococcus pneumoniae capsular polysaccharides: variableregion primary structures and evidence for somatic mutation of Fabfragments specific for capsular serotypes 6B, 14, and 23F” Infect.Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48822 STRP25 Lightchain A23 Lucas, A.H. 7219 variable “Combinatorial region, librarypartial, cloning of human Streptococcus antibodies to pneumoniaeStreptococcus pneumoniae capsular polysaccharides: variable regionprimary structures and evidence for somatic mutation of Fab fragmentsspecific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2),853-864 (2001), NCBI Accession # AAD48826 STRP26 Light chain L2 Lucas,A.H. 7220 variable “Combinatorial region, library partial, cloning ofhuman Streptococcus antibodies to pneumoniae Streptococcus pneumoniaecapsular polysaccharides: variable region primary structures andevidence for somatic mutation of Fab fragments specific for capsularserotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBIAccession # AAD48829 STRP27 Light chain DPL5 Lucas, A.H. 7221 variable“Combinatorial region, library partial, cloning of human Streptococcusantibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48831 STRP28 Light chain DPL5 Lucas, A.H. 7222 variable“Combinatorial region, library partial, cloning of human Streptococcusantibodies to pneumoniae Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48833 STRP29 Light chain L2 Lucas, A.H. 7223 variable region,“Combinatorial partial, library Streptococcus cloning of humanpneumoniae antibodies to Streptococcus pneumoniae capsularpolysaccharides: variable region primary structures and evidence forsomatic mutation of Fab fragments specific for capsular serotypes 6B,14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession #AAD48834 STRP30 Light chain Anti-PsaA US20070003561 7224 variableregion, 7-1G9 SEQ ID NO: 8 Streptococcus pneumoniae STRP31 Light chainAnti-PsaA US20070003561 7225 variable region, 1-15E5 SEQ ID NO: 24Streptococcus pneumoniae STRP32 Light chain Anti-pSaA US20070003561 7226variable region, 9A7 SEQ ID NO: 40 Streptococcus pneumoniae STRP33 Lightchain 5.12.14 US5686070 7227 variable region, SEQ ID NO: 20Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosaSTRP34 Light chain 6G4.2.5 US5686070 7228 variable region, SEQ ID NO: 48Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosaSTRP35 Light chain chimeric US5686070 7229 variable region, 6G4.2.5 SEQID NO: 56 Streptococcus pneumoniae, Escherichia coli, or Pseudomonasaeruginosa STRP36 Light chain, Mab679 US7429381 6907 Streptococcus SEQID NO: 2 agalactiae, Legionella pneumophilia, Streptococcus pyogenes,Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis,Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme diseasespirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucellaabortus and Mycobacterium tuberculosis STRP37 scFv, Streptococcus Mab679US7429381 6911 agalactiae, SEQ ID NO: 6 Legionella pneumophilia,Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae,Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponemapallidum, Lyme disease spirochetes, Pseudomonas aeruginosa,Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosisSTRP38 scFv, Streptococcus Mu-9V US7429381 6905 agalactiae, SEQ ID NO: 8Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli,Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilisinfluenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonasaeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacteriumtuberculosis STRP39 scFv, Streptococcus Mu-9V US7429381 6901 agalactiae,SEQ ID NO: 10 Legionella pneumophilia, Streptococcus pyogenes,Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis,Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme diseasespirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucellaabortus and Mycobacterium tuberculosis STRP40 scFv, Streptococcushumanized US7429381 6906 agalactiae, Mu-9 SEQ ID NO: 12 Legionellapneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseriagonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzaeB, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa,Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described in USPub No. US20040198960 and US20130195876, the contents of each of whichare herein incorporated by reference in their entirety, againstStreptococcus pneumoniae infection.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants encodingAfelimomab, fragments or variants thereof for treating a disease and/ordisorder or preventing a disease and/or disorder. As a non-limitingexample, the disease and/or disorder is sepsis.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants encoding Nebacumab,fragments or variants thereof for treating a disease and/or disorder orpreventing a disease and/or disorder. As a non-limiting example, thedisease and/or disorder is sepsis.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 34 against Staphylococcal bacteriaand related bacteria.

TABLE 34 Antibodies against Staphylococcal bacteria and related bacteriaSEQ Antibody Antibody ID No. Description Name Reference Information NOSTPH1 Heavy chain variable region, S. aureus U.S. Pat. No. 8,609,1027230 SEQ ID NO: 2 STPH2 Heavy chain variable region, S. aureus U.S. Pat.No. 8,609,102 7231 SEQ ID NO: 6 STPH3 Heavy chain variable region, S.aureus SAR279356 U.S. Pat. No. 7,786,255 7232 or S. epidermidis, E.coli, Yersinia SEQ ID NO: 1 pestis (Y. pestis), Y. entercolitica,Xanthomnonas axonopodis (X. axonopodis), Pseudonmonas fuorescerns (P.fluorescens), Actinobacillus actinomycetemcomitans (A.actinomycetemcomitans), A. pleuropneumoniae, Ralstonia solanacearum (R.solanacearum), Bordetella pertussis (B. pertussis), B. parapertussis orB. bronchiseptica STPH4 Heavy chain variable region, S. aureus SAR279356US20110002932 SEQ ID 7233 or S. epidermidis, E. coli, Yersinia NO: 1pestis (Y. pestis), Y. entercolitica, Xanthomnonas axonopodis (X.axonopodis), Pseudonmonas fuorescerns (P. fluorescens), Actinobacillusactinomycetemcomitans (A. actinomycetemcomitans), A. pleuropneumoniae,Ralstonia solanacearum (R. solanacearum), Bordetella pertussis (B.pertussis), B. parapertussis or B. bronchiseptica STPH5 Heavy chainvariable region, S. 108-1 U.S. Pat. No. 8,475,798 7234 epidermidis SEQID NO: 18 STPH6 Heavy chain variable region, S. 108-36 U.S. Pat. No.8,475,798 7235 epidermidis SEQ ID NO: 22 STPH7 Heavy chain variableregion, S. 110-15 U.S. Pat. No. 8,475,798 7236 epidermidis SEQ ID NO: 26STPH8 Heavy chain variable region, S. 108-1VH- U.S. Pat. No. 8,475,7987237 epidermidis Hu SEQ ID NO: 28 STPH9 Heavy chain variable region, S.108-36VH- U.S. Pat. No. 8,475,798 7238 epidermidis Hu SEQ ID NO: 30STPH10 Heavy chain variable region, S. 110-15VH- U.S. Pat. No. 8,475,7987239 epidermidis Hu SEQ ID NO: 32 STPH11 Heavy chain variable region,Pagibaximab U.S. Pat. No. 8,372,958 7240 Staphylococcal sepsis SEQ IDNO: 87 STPH12 Heavy chain variable region, Pagibaximab U.S. Pat. No.8,372,958 7241 Staphylococcal sepsis SEQ ID NO: 12 STPH13 Heavy chainvariable region, Pagibaximab U.S. Pat. No. 8,372,958 7242 Staphylococcalsepsis SEQ ID NO: 17 STPH14 Heavy chain variable region, F628 U.S. Pat.No. 8,912,314 7243 Staphylococci such as S. aureus and S. SEQ ID NO: 3epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH15 Heavy chain variable region, F630 U.S.Pat. No. 8,912,314 7244 Staphylococci such as S. aureus and S. SEQ IDNO: 5 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH16 Heavy chain variable region, F598 U.S.Pat. No. 8,912,314 7245 Staphylococci such as S. aureus and S. SEQ IDNO: 55 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH17 Heavy chain variable region, F628 U.S.Pat. No. 8,912,314 7246 Staphylococci such as S. aureus and S. SEQ IDNO: 58 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH18 Heavy chain variable region, F598 U.S.Pat. No. 8,912,314 7247 Staphylococci such as S. aureus and S. SEQ IDNO: 1 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH19 Heavy chain variable region, 108-3BVH-U.S. Pat. No. 8,475,798 7248 Staphylococcus epidermidis Hu SEQ ID NO: 34STPH20 Heavy chain, MRSA, MSSA 2B2 U.S. Pat. No. 8,735,554 7249 SEQ IDNO: 3 STPH21 Heavy chain, MRSA, MSSA 2G7 U.S. Pat. No. 8,735,554 7250SEQ ID NO: 5 STPH22 Heavy chain, MRSA, MSSA 3B12 U.S. Pat. No. 8,735,5547251 SEQ ID NO: 7 STPH23 Heavy chain, S. aureus DF1.1 U.S. Pat. No.8,715,673 7252 SEQ ID NO: 2 STPH24 Heavy chain, S. aureus DF1 U.S. Pat.No. 8,715,673 7253 SEQ ID NO: 4 STPH25 Heavy chain, S. aureus DF2 U.S.Pat. No. 8,715,673 7254 SEQ ID NO: 35 STPH26 Heavy chain, S. aureus DF3U.S. Pat. No. 8,715,673 7255 SEQ ID NO: 36 STPH27 Heavy chain, S. aureusDF4 U.S. Pat. No. 8,715,673 7256 SEQ ID NO: 37 STPH28 Heavy chain, S.aureus DF5 U.S. Pat. No. 8,715,673 7257 SEQ ID NO: 38 STPH29 Heavychain, S. aureus DF6 U.S. Pat. No. 8,715,673 7258 SEQ ID NO: 39 STPH30Heavy chain, S. aureus DF7 U.S. Pat. No. 8,715,673 7259 SEQ ID NO: 40STPH31 Heavy chain, S. aureus DF8 U.S. Pat. No. 8,715,673 7260 SEQ IDNO: 41 STPH32 Heavy chain, S. aureus DF9 U.S. Pat. No. 8,715,673 7261SEQ ID NO: 42 STPH33 Heavy chain, S. aureus DF10 U.S. Pat. No. 8,715,6737262 SEQ ID NO: 43 STPH34 Heavy chain, S. aureus DF11 U.S. Pat. No.8,715,673 7263 SEQ ID NO: 44 STPH35 Heavy chain, S. aureus DF12 U.S.Pat. No. 8,715,673 7264 SEQ ID NO: 45 STPH36 Heavy chain, S. aureus DF13U.S. Pat. No. 8,715,673 7265 SEQ ID NO: 46 STPH37 Heavy chain, S. aureusDF14 U.S. Pat. No. 8,715,673 7266 SEQ ID NO: 47 STPH38 Heavy chain, S.aureus DF15 U.S. Pat. No. 8,715,673 7267 SEQ ID NO: 48 STPH39 Heavychain, S. aureus DF16 U.S. Pat. No. 8,715,673 7268 SEQ ID NO: 49 STPH40Heavy chain, S. aureus DF17 U.S. Pat. No. 8,715,673 7269 SEQ ID NO: 50STPH41 Heavy chain, S. aureus DF18 U.S. Pat. No. 8,715,673 7270 SEQ IDNO: 51 STPH42 Heavy chain, S. aureus DF19 U.S. Pat. No. 8,715,673 7271SEQ ID NO: 52 STPH43 Heavy chain, S. aureus DF20 U.S. Pat. No. 8,715,6737272 SEQ ID NO: 53 STPH44 Heavy chain, S. aureus and S. CR2430 U.S. Pat.No. 8,460,666 7273 epidermidis SEQ ID NO: 26 STPH45 Heavy chain, S.aureus and S. CR5132 U.S. Pat. No. 8,460,666 7274 epidermidis SEQ ID NO:28 STPH46 Heavy chain, S. aureus and S. CR5133 U.S. Pat. No. 8,460,6667275 epidermidis SEQ ID NO: 30 STPH47 Heavy chain, S. aureus and S.CR6166 U.S. Pat. No. 8,460,666 7276 epidermidis SEQ ID NO: 117 STPH48Heavy chain, S. aureus and S. CR6171 U.S. Pat. No. 8,460,666 7277epidermidis SEQ ID NO: 119 STPH49 Heavy chain, S. aureus and S. CR6176U.S. Pat. No. 8,460,666 7278 epidermidis SEQ ID NO: 121 STPH50 Heavychain, S. aureus and S. CR6187 U.S. Pat. No. 8,460,666 7279 epidermidisSEQ ID NO: 123 STPH51 Heavy chain, S. aureus and S. CR6193 U.S. Pat. No.8,460,666 7280 epidermidis SEQ ID NO: 125 STPH52 Heavy chain, S. aureusand S. CR6249 U.S. Pat. No. 8,460,666 7281 epidermidis SEQ ID NO: 127STPH53 Heavy chain, S. aureus and S. CR6273 U.S. Pat. No. 8,460,666 7282epidermidis SEQ ID NO: 129 STPH54 Heavy chain, S. aureus and S. CR6389U.S. Pat. No. 8,460,666 7283 epidermidis SEQ ID NO: 131 STPH55 Heavychain, S. aureus and S. CR6403 U.S. Pat. No. 8,460,666 7284 epidermidisSEQ ID NO: 133 STPH56 Heavy chain, S. aureus and S. CR6406 U.S. Pat. No.8,460,666 7285 epidermidis SEQ ID NO: 135 STPH57 Heavy chain, S. aureusand S. CR6410 U.S. Pat. No. 8,460,666 7286 epidermidis SEQ ID NO: 137STPH58 Heavy chain, S. aureus and S. CR6446 U.S. Pat. No. 8,460,666 7287epidermidis SEQ ID NO: 139 STPH59 Heavy chain, S. aureus and S. CR6450U.S. Pat. No. 8,460,666 7288 epidermidis SEQ ID NO: 141 STPH60 Heavychain, S. aureus and S. CR6452 U.S. Pat. No. 8,460,666 7289 epidermidisSEQ ID NO: 143 STPH61 Heavy chain, S. aureus and S. CR6453 U.S. Pat. No.8,460,666 7290 epidermidis SEQ ID NO: 145 STPH62 Heavy chain, S. aureusand S. CR6464 U.S. Pat. No. 8,460,666 7291 epidermidis SEQ ID NO: 147STPH63 Heavy chain, S. aureus and S. CR6471 U.S. Pat. No. 8,460,666 7292epidermidis SEQ ID NO: 149 STPH64 Heavy chain, S. aureus and S. CR6516U.S. Pat. No. 8,460,666 7293 epidermidis SEQ ID NO: 151 STPH65 Heavychain, S. aureus and S. CR6517 U.S. Pat. No. 8,460,666 7294 epidermidisSEQ ID NO: 153 STPH66 Heavy chain, S. aureus and S. CR6526 U.S. Pat. No.8,460,666 7295 epidermidis SEQ ID NO: 155 STPH67 Heavy chain, S. aureusand S. CR6528 U.S. Pat. No. 8,460,666 7296 epidermidis SEQ ID NO: 157STPH68 Heavy chain, S. aureus and S. CR6531 U.S. Pat. No. 8,460,666 7297epidermidis SEQ ID NO: 159 STPH69 Heavy chain, S. aureus and S. CR6533U.S. Pat. No. 8,460,666 7298 epidermidis SEQ ID NO: 161 STPH70 Heavychain, S. aureus and S. CR6536 U.S. Pat. No. 8,460,666 7299 epidermidisSEQ ID NO: 163 STPH71 Heavy chain, S. aureus and S. CR6537 U.S. Pat. No.8,460,666 7300 epidermidis SEQ ID NO: 165 STPH72 Heavy chain, S. aureusand S. CR6538 U.S. Pat. No. 8,460,666 7301 epidermidis SEQ ID NO: 167STPH73 Heavy chain, S. aureus and S. CR6540 U.S. Pat. No. 8,460,666 7302epidermidis SEQ ID NO: 169 STPH74 Heavy chain, S. aureus and S. CR6544U.S. Pat. No. 8,460,666 7303 epidermidis SEQ ID NO: 171 STPH75 Heavychain, S. aureus and S. CR6566 U.S. Pat. No. 8,460,666 7304 epidermidisSEQ ID NO: 173 STPH76 Heavy chain, S. aureus and S. CR6625 U.S. Pat. No.8,460,666 7305 epidermidis SEQ ID NO: 175 STPH77 Heavy chain, S. aureus,Enterococcus CR5140 U.S. Pat. No. 8,628,776 7306 SEQ ID NO: 395 STPH78Heavy chain, S. aureus, Enterococcus CR5159 U.S. Pat. No. 8,628,776 7307SEQ ID NO: 82 STPH79 Heavy chain, S. aureus, Enterococcus CR5179 U.S.Pat. No. 8,628,776 7308 SEQ ID NO: 399 STPH80 Heavy chain, S. aureus,Enterococcus CR6016 U.S. Pat. No. 8,628,776 7309 SEQ ID NO: 88 STPH81Heavy chain, S. aureus, Enterococcus CR6049 U.S. Pat. No. 8,628,776 7310SEQ ID NO: 92 STPH82 Heavy chain, S. aureus. Enterococcus CR6071 U.S.Pat. No. 8,628,776 7311 SEQ ID NO: 94 STPH83 Heavy chain, S. aureus,Enterococcus CR6078 U.S. Pat. No. 8,628,776 7312 SEQ ID NO: 96 STPH84Heavy chain, S. aureus, Enterococcus CR6086 U.S. Pat. No. 8,628,776 7313SEQ ID NO: 407 STPH85 Heavy chain, S. aureus, Enterococcus CR6089 U.S.Pat. No. 8,628,776 7314 SEQ ID NO: 213 STPH86 Heavy chain, S. aureus,Enterococcus CR6191 UU.S. Pat. No. 8,628,776 7315 SEQ ID NO: 411 STPH87Heavy chain, S. aureus, Enterococcus CR6198 U.S. Pat. No. 8,628,776 7316SEQ ID NO: 415 STPH88 Heavy chain, S. aureus, Enterococcus CR6242 U.S.Pat. No. 8,628,776 7317 SEQ ID NO: 417 STPH89 Heavy chain, S. aureus,Enterococcus CR6252 U.S. Pat. No. 8,628,776 7318 SEQ ID NO: 100 STPH90Heavy chain, S. aureus, Enterococcus CR6389 0U.S. Pat. No. 8,628,7767319 SEQ ID NO: 423 STPH91 Heavy chain, S. aureus, Enterococcus CR6402U.S. Pat. No. 8,628,776 7320 SEQ ID NO: 427 STPH92 Heavy chain, S.aureus, Enterococcus CR6415 U.S. Pat. No. 8,628,776 7321 SEQ ID NO: 431STPH93 Heavy chain, S. aureus, Enterococcus CR6429 U.S. Pat. No.8,628,776 7322 SEQ ID NO: 435 STPH94 Heavy chain, S. aureus,Enterococcus CR5140 U.S. Pat. No. 8,628,776 7323 SEQ ID NO: 439 STPH95Heavy chain, S. aureus, Enterococcus CR5159 U.S. Pat. No. 8,628,776 7324SEQ ID NO: 102 STPH96 Heavy chain, S. aureus, Enterococcus CR5179 U.S.Pat. No. 8,628,776 7325 SEQ ID NO: 443 STPH97 Heavy chain, S. aureus,Enterococcus CR6016 U.S. Pat. No. 8,628,776 7326 SEQ ID NO: 108 STPH98Heavy chain, S. aureus, Enterococcus CR6049 U.S. Pat. No. 8,628,776 7327SEQ ID NO: 112 STPH99 Heavy chain, S. aureus, Enterococcus CR6071 U.S.Pat. No. 8,628,776 7328 SEQ ID NO: 114 STPH100 Heavy chain, S. aureus,Enterococcus CR6078 U.S. Pat. No. 8,628,776 7329 SEQ ID NO: 116 STPH101Heavy chain, S. aureus, Enterococcus CR6086 U.S. Pat. No. 8,628,776 7330SEQ ID NO: 451 STPH102 Heavy chain, S. aureus, Enterococcus CR6089 U.S.Pat. No. 8,628,776 7331 SEQ ID NO: 217 STPH103 Heavy chain, S. aureus,Enterococcus CR6191 U.S. Pat. No. 8,628,776 7332 SEQ ID NO: 455 STPH104Heavy chain, S. aureus, Enterococcus CR6198 U.S. Pat. No. 8,628,776 7333SEQ ID NO: 459 STPH105 Heavy chain, S. aureus, Enterococcus CR6242 U.S.Pat. No. 8,628,776 7334 SEQ ID NO: 461 STPH106 Heavy chain, S. aureus,Enterococcus CR6252 U.S. Pat. No. 8,628,776 7335 SEQ ID NO: 120 STPH107Heavy chain, S. aureus, Enterococcus CR6389 U.S. Pat. No. 8,628,776 7336SEQ ID NO: 467 STPH108 Heavy chain, S. aureus, Enterococcus CR6402 U.S.Pat. No. 8,628,776 7337 SEQ ID NO: 471 STPH109 Heavy chain, S. aureus,Enterococcus CR6415 U.S. Pat. No. 8,628,776 7338 SEQ ID NO: 475 STPH110Heavy chain, S. aureus, Enterococcus CR6429 U.S. Pat. No. 8,628,776 7339SEQ ID NO: 479 STPH111 Heavy chain, S. aureus, S. epidermidis, F1antibody U.S. Pat. No. 8,617,556 7340 S. caprae, S. saprophyticus, S.capitis, or variant SEQ ID NO: 7 methicillin-resistant S. aureus (MRSA)STPH112 Heavy chain, S. aureus, S. epidermidis, F1 antibody U.S. Pat.No. 8,617,556 7341 S. caprae, S. saprophyticus, S. capitis, or variantSEQ ID NO: 9 methicillin-resistant S. aureus (MRSA) STPH113 Heavy chain,S. aureus, S. epidermidis, rF1 U.S. Pat. No. 8,617,556 7342 S. caprae,S. saprophyticus, S. capitis, or SEQ ID NO: 55 methicillin-resistant S.aureus (MRSA) STPH114 Heavy chain, S. aureus, S. epidermidis, rF1 A114CU.S. Pat. No. 8,617,556 7343 S. caprae, S. saprophyticus, S. capitis, orSEQ ID NO: 56 methicillin-resistant S. aureus (MRSA) STPH115 Heavychain, S. aureus, S. epidermidis, rF1 U.S. Pat. No. 8,617,556 7344 S.caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 63methicillin-resistant S. aureus (MRSA) STPH116 Heavy chain, S. aureus,S. epidermidis, rF1 A114C U.S. Pat. No. 8,617,556 7345 S. caprae, S.saprophyticus, S. capitis, or SEQ ID NO: 62 methicillin-resistant S.aureus (MRSA) STPH117 Light chain U.S. Pat. No. 8,609,102 7346 SEQ IDNO: 4 STPH118 Light chain variable region, S. aureus U.S. Pat. No.8,609,102 7347 SEQ ID NO: 8 STPH119 Light chain variable region, S.aureus or SAR279356 U.S. Pat. No. 7,786,255 7348 S. epidermidis, E.coli, Yersinia SEQ ID NO: 2 pestis (Y. pestis), Y. entercolitica,Xanthomnonas axonopodis (X. axonopodis), Pseudonmonas fuorescerns (P.fluorescens), Actinobacillus actinomycetemcomitans (A.actinomycetemcomitans), A. pleuropneumoniae, Ralstonia solanacearum (R.solanacearum), Bordetella pertussis (B. pertussis), B. parapertussis orB. bronchiseptica STPH120 Light chain variable region, S. aureus orSAR279356 US20110002932 SEQ ID 7349 S. epidermidis, E. coli, YersiniaNO: 2 pestis (Y. pestis), Y. entercolitica, Xanthomnonas axonopodis (X.axonopodis), Pseudonmonas fuorescerns (P. fluorescens), Actinobacillusactinomycetemcomitans (A. actinomycetemcomitans), A. pleuropneumoniae,Ralstonia solanacearum (R. solanacearum), Bordetella pertussis (B.pertussis), B. parapertussis or B. bronchiseptica STPH121 Light chainvariable region, S. 108-1 U.S. Pat. No. 8,475,798 7350 epidermidis SEQID NO: 16 STPH122 Light chain variable region, S. 108-36 U.S. Pat. No.8,475,798 7351 epidermidis SEQ ID NO: 20 STPH123 Light chain variableregion, S. 110-15 U.S. Pat. No. 8,475,798 7352 epidermidis SEQ ID NO: 24STPH124 Light chain variable region, S. 108-1VL- U.S. Pat. No. 8,475,7987353 epidermidis Hu SEQ ID NO: 27 STPH125 Light chain variable region,S. 108-36VL- U.S. Pat. No. 8,475,798 7354 epidermidis Hu SEQ ID NO: 29STPH126 Light chain variable region, S. 110-15VL- U.S. Pat. No.8,475,798 7355 epidermidis Hu SEQ ID NO: 31 STPH127 Light chain variableregion, Pagibaximab U.S. Pat. No. 8,372,958 7356 Staphylococcal sepsisSEQ ID NO: 89 STPH128 Light chain variable region, Pagibaximab U.S. Pat.No. 8,372,958 7357 Staphylococcal sepsis SEQ ID NO: 10 STPH129 Lightchain variable region, Pagibaximab U.S. Pat. No. 8,372,958 7358Staphylococcal sepsis SEQ ID NO: 16 STPH130 Light chain variable region,F598 U.S. Pat. No. 8,912,314 7359 Staphylococci such as S. aureus and S.SEQ ID NO: 2 epidermidis, E. coli such as E. coli strains O157:H7 andCFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH131 Light chain variable region, F628 U.S.Pat. No. 8,912,314 7360 Staphylococci such as S. aureus and S. SEQ IDNO: 4 epidermidis, E. coli such as E. coli strains O157: H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH132 Light chain variable region, F630 U.S.Pat. No. 8,912,314 7361 Staphylococci such as S. aureus and S. SEQ IDNO: 6 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH133 Light chain variable region, F598 U.S.Pat. No. 8,912,314 7362 Staphylococci such as S. aureus and S. SEQ IDNO: 57 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH134 Light chain variable region, F630 U.S.Pat. No. 8,912,314 7363 Staphylococci such as S. aureus and S. SEQ IDNO: 60 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073,Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis,Pseudomonas fluorescens (all of which are sequenced species withcomplete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA),Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g.,megaplasmid form), Bordetella pertussis, Bordetella parapertussis andBordetella bronchiseptica STPH135 Light chain, MRSA, MSSA 2B2 U.S. Pat.No. 8,735,554 7364 SEQ ID NO: 2 STPH136 Light chain. MRSA, MSSA 2G7 U.S.Pat. No. 8,735,554 7365 SEQ ID NO: 4 STPH137 Light chain, MRSA, MSSA3B12 U.S. Pat. No. 8,735,554 7366 SEQ ID NO: 6 STPH138 Light chain, S.aureus DFLI U.S. Pat. No. 8,715,673 7367 SEQ ID NO: 1 STPH139 Lightchain, S. aureus DF1-DF20 U.S. Pat. No. 8,715,673 7368 SEQ ID NO: 3STPH140 Light chain, S. aureus and S. epidermidis CR2430 U.S. Pat. No.8,460,666 7369 SEQ ID NO: 32 STPH141 Light chain, S. aureus and S.epidermidis CR5132 U.S. Pat. No. 8,460,666 7370 SEQ ID NO: 34 STPH142Light chain, S. aureus and S. epidermidis CR5133 U.S. Pat. No. 8,460,6667371 SEQ ID NO: 36 STPH143 Light chain, S. aureus and S. epidermidisCR6166 U.S. Pat. No. 8,460,666 7372 SEQ ID NO: 177 STPH144 Light chain,S. aureus and S. epidermidis CR6171 U.S. Pat. No. 8,460,666 7373 SEQ IDNO: 179 STPH145 Light chain, S. aureus and S. epidermidis CR6176 U.S.Pat. No. 8,460,666 7374 SEQ ID NO: 181 STPH146 Light chain, S. aureusand S. epidermidis CR6187 U.S. Pat. No. 8,460,666 7375 SEQ ID NO: 183STPH147 Light chain, S. aureus and S. epidermidis CR6193 U.S. Pat. No.8,460,666 7376 SEQ ID NO: 185 STPH148 Light chain, S. aureus and S.epidermidis CR6249 U.S. Pat. No. 8,460,666 7377 SEQ ID NO: 187 STPH149Light chain, S. aureus and S. epidermidis CR6273 U.S. Pat. No. 8,460,6667378 SEQ ID NO: 189 STPH150 Light chain, S. aureus and S. epidermidisCR6389 U.S. Pat. No. 8,460,666 7379 SEQ ID NO: 191 STPH151 Light chain,S. aureus and S. epidermidis CR6403 U.S. Pat. No. 8,460,666 7380 SEQ IDNO: 193 STPH152 Light chain, S. aureus and S. epidermidis CR6406 U.S.Pat. No. 8,460,666 7381 SEQ ID NO: 195 STPH153 Light chain, S. aureusand S. epidermidis CR6410 U.S. Pat. No. 8,460,666 7382 SEQ ID NO: 197STPH154 Light chain, S. aureus and S. epidermidis CR6446 U.S. Pat. No.8,460,666 7383 SEQ ID NO: 199 STPH155 Light chain, S. aureus and S.epidermidis CR6450 U.S. Pat. No. 8,460,666 7384 SEQ ID NO: 201 STPH156Light chain, S. aureus and S. epidermidis CR6452 U.S. Pat. No. 8,460,6667385 SEQ ID NO: 203 STPH157 Light chain, S. aureus and S. epidermidisCR6453 U.S. Pat. No. 8,460,666 7386 SEQ ID NO: 205 STPH158 Light chain,S. aureus and S. epidermidis CR6464 U.S. Pat. No. 8,460,666 7387 SEQ IDNO: 207 STPH159 Light chain, S. aureus and S. epidermidis CR6471 U.S.Pat. No. 8,460,666 7388 SEQ ID NO: 209 STPH160 Light chain, S. aureusand S. epidermidis CR6516 U.S. Pat. No. 8,460,666 7389 SEQ ID NO: 211STPH161 Light chain, S. aureus and S. epidermidis CR6517 U.S. Pat. No.8,460,666 7390 SEQ ID NO: 213 STPH162 Light chain, S. aureus and S.epidermidis CR6526 U.S. Pat. No. 8,460,666 7391 SEQ ID NO: 215 STPH163Light chain, S. aureus and S. epidermidis CR6528 U.S. Pat. No. 8,460,6667392 SEQ ID NO: 217 STPH164 Light chain, S. aureus and S. epidermidisCR6531 U.S. Pat. No. 8,460,666 7393 SEQ ID NO: 219 STPH165 Light chain,S. aureus and S. epidermidis CR6533 U.S. Pat. No. 8,460,666 7394 SEQ IDNO: 221 STPH166 Light chain, S. aureus and S. epidermidis CR6536 U.S.Pat. No. 8,460,666 7395 SEQ ID NO: 223 STPH167 Light chain, S. aureusand S. epidermidis CR6537 U.S. Pat. No. 8,460,666 7396 SEQ ID NO: 225STPH168 Light chain, S. aureus and S. epidermidis CR6538 U.S. Pat. No.8,460,666 7397 SEQ ID NO: 227 STPH169 Light chain, S. aureus and S.epidermidis CR6540 U.S. Pat. No. 8,460,666 7398 SEQ ID NO: 229 STPH170Light chain, S. aureus and S. epidermidis CR6544 U.S. Pat. No. 8,460,6667399 SEQ ID NO: 231 STPH171 Light chain, S. aureus and S. epidermidisCR6566 U.S. Pat. No. 8,460,666 7400 SEQ ID NO: 233 STPH172 Light chain,S. aureus and S. epidermidis CR6625 U.S. Pat. No. 8,460,666 7401 SEQ IDNO: 235 STPH173 Light chain, S. aureus, Enterococcus CR6157 U.S. Pat.No. 8,628,776 7402 SEQ ID NO: 397 STPH174 Light chain, S. aureus,Enterococcus CR5166 U.S. Pat. No. 8,628,776 7403 SEQ ID NO: 84 STPH175Light chain, S. aureus, Enterococcus CR5187 U.S. Pat. No. 8,628,776 7404SEQ ID NO: 86 STPH176 Light chain, S. aureus, Enterococcus CR6043 U.S.Pat. No. 8,628,776 7405 SEQ ID NO: 90 STPH177 Light chain, S. aureus,Enterococcus CR6050 U.S. Pat. No. 8,628,776 7406 SEQ ID NO: 401 STPH178Light chain, S. aureus, Enterococcus CR6077 U.S. Pat. No. 8,628,776 7407SEQ ID NO: 403 STPH179 Light chain, S. aureus, Enterococcus CR6079 U.S.Pat. No. 8,628,776 7408 SEQ ID NO: 405 STPH180 Light chain, S. aureus,Enterococcus CR6087 U.S. Pat. No. 8,628,776 7409 SEQ ID NO: 211 STPH181Light chain, S. aureus, Enterococcus CR6092 U.S. Pat. No. 8,628,776 7410SEQ ID NO: 409 STPH182 Light chain, S. aureus, Enterococcus CR6195 U.S.Pat. No. 8,628,776 7411 SEQ ID NO: 413 STPH183 Light chain, S. aureus,Enterococcus CR6241 U.S. Pat. No. 8,628,776 7412 SEQ ID NO: 98 STPH184Light chain, S. aureus, Enterococcus CR6246 U.S. Pat. No. 8,628,776 7413SEQ ID NO: 419 STPH185 Light chain, S. aureus, Enterococcus CR6388 U.S.Pat. No. 8,628,776 7414 SEQ ID NO: 421 STPH186 Light chain, S. aureus,Enterococcus CR6396 U.S. Pat. No. 8,628,776 7415 SEQ ID NO: 425 STPH187Light chain, S. aureus, Enterococcus CR6409 U.S. Pat. No. 8,628,776 7416SEQ ID NO: 429 STPH188 Light chain, S. aureus, Enterococcus CR6421 U.S.Pat. No. 8,628,776 7417 SEQ ID NO: 433 STPH189 Light chain, S. aureus,Enterococcus CR6432 U.S. Pat. No. 8,628,776 7418 SEQ ID NO: 437 STPH190Light chain, S. aureus, Enterococcus CR5157 U.S. Pat. No. 8,628,776 7419SEQ ID NO: 441 STPH191 Light chain, S. aureus, Enterococcus CR5166 U.S.Pat. No. 8,628,776 7420 SEQ ID NO: 104 STPH192 Light chain, S. aureus,Enterococcus CR5187 U.S. Pat. No. 8,628,776 7421 SEQ ID NO: 106 STPH193Light chain, S. aureus, Enterococcus CR6043 U.S. Pat. No. 8,628,776 7422SEQ ID NO: 110 STPH194 Light chain, S. aureus, Enterococcus CR6050 U.S.Pat. No. 8,628,776 7423 SEQ ID NO: 445 STPH195 Light chain, S. aureus,Enterococcus CR6077 U.S. Pat. No. 8,628,776 7424 SEQ ID NO: 447 STPH196Light chain, S. aureus, Enterococcus CR6079 U.S. Pat. No. 8,628,776 7425SEQ ID NO: 449 STPH197 Light chain, S. aureus, Enterococcus CR6087 U.S.Pat. No. 8,628,776 7426 SEQ ID NO: 215 STPH198 Light chain, S. aureus,Enterococcus CR6092 U.S. Pat. No. 8,628,776 7427 SEQ ID NO: 453 STPH199Light chain, S. aureus, Enterococcus CR6195 U.S. Pat. No. 8,628,776 7428SEQ ID NO: 457 STPH200 Light chain, S. aureus, Enterococcus CR6241 U.S.Pat. No. 8,628,776 7429 SEQ ID NO: 118 STPH201 Light chain, S. aureus,Enterococcus CR6246 U.S. Pat. No. 8,628,776 7430 SEQ ID NO: 463 STPH202Light chain, S. aureus, Enterococcus CR6388 U.S. Pat. No. 8,628,776 7431SEQ ID NO: 465 STPH203 Light chain, S. aureus, Enterococcus CR6396 U.S.Pat. No. 8,628,776 7432 SEQ ID NO: 469 STPH204 Light chain, S. aureus,Enterococcus CR6409 U.S. Pat. No. 8,628,776 7433 SEQ ID NO: 473 STPH205Light chain, S. aureus, Enterococcus CR6421 U.S. Pat. No. 8,628,776 7434SEQ ID NO: 477 STPH206 Light chain, S. aureus, Enterococcus CR6432 U.S.Pat. No. 8,628,776 7435 SEQ ID NO: 481 STPH207 Light chain, S. aureus,S. epidermidis, S. F1 antibody U.S. Pat. No. 8,617,556 7436 caprae, S.saprophyticus, S. capitis, or variant SEQ ID NO: 8 methicillin-resistantS. aureus (MRSA) STPH208 Light chain, S. aureus, S. epidermidis, S. F1antibody U.S. Pat. No. 8,617,556 7437 caprae, S. saprophyticus, S.capitis, or variant SEQ ID NO: 10 methicillin-resistant S. aureus (MRSA)STPH209 Light chain, S. aureus, S. epidermidis, S. F1 antibody U.S. Pat.No. 8,617,556 7438 caprae, S. saprophyticus, S. capitis, or variant SEQID NO: 11 methicillin-resistant S. aureus (MRSA) STPH210 Light chain, S.aureus, S. epidermidis, S. rF1 U.S. Pat. No. 8,617,556 7439 caprae, S.saprophyticus, S. capitis, or SEQ ID NO: 57 methicillin-resistant S.aureus (MRSA) STPH211 Light chain, S. aureus, S. epidermidis, S. rF1V205C U.S. Pat. No. 8,617,556 7440 caprae, S. saprophyticus, S. capitis,or SEQ ID NO: 58 methicillin-resistant S. aureus (MRSA) STPH212 Lightchain, S. aureus, S. epidermidis, S. rF1 U.S. Pat. No. 8,617,556 7441caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 64methicillin-resistant S. aureus (MRSA) STPH213 ScFv, S. aureus and S.epidermidis SC02-430 U.S. Pat. No. 8,460,666 7442 SEQ ID NO: 20 STPH214ScFv, S. aureus and S. epidermidis SC05-132 U.S. Pat. No. 8,460,666 7443SEQ ID NO: 22 STPH215 ScFv, S. aureus and S. epidermidis SC05-133 U.S.Pat. No. 8,460,666 7444 SEQ ID NO: 24 STPH216 ScFv, S. aureus,Enterococcus SC05-140 U.S. Pat. No. 8,628,776 7445 SEQ ID NO: 351STPH217 ScFv, S. aureus, Enterococcus SC05-157 U.S. Pat. No. 8,628,7767446 SEQ ID NO: 353 STPH218 ScFv, S. aureus, Enterococcus SC05-159 U.S.Pat. No. 8,628,776 7447 SEQ ID NO: 62 STPH219 ScFv, S. aureus,Enterococcus SC05-166 U.S. Pat. No. 8,628,776 7448 SEQ ID NO: 64 STPH220ScFv, S. aureus, Enterococcus SC05-179 U.S. Pat. No. 8,628,776 7449 SEQID NO: 355 STPH221 ScFv, S. aureus, Enterococcus SC05-187 U.S. Pat. No.8,628,776 7450 SEQ ID NO: 66 STPH222 ScFv, S. aureus, EnterococcusSC06-016 U.S. Pat. No. 8,628,776 7451 SEQ ID NO: 68 STPH223 ScFv, S.aureus, Enterococcus SC06-043 U.S. Pat. No. 8,628,776 7452 SEQ ID NO: 70STPH224 ScFv, S. aureus, Enterococcus SC06-049 U.S. Pat. No. 8,628,7767453 SEQ ID NO: 72 STPH225 ScFv, S. aureus, Enterococcus SC06-050 U.S.Pat. No. 8,628,776 7454 SEQ ID NO: 357 STPH226 ScFv, S. aureus,Enterococcus SC06-071 U.S. Pat. No. 8,628,776 7455 SEQ ID NO: 74 STPH227ScFv, S. aureus, Enterococcus SC06-077 U.S. Pat. No. 8,628,776 7456 SEQID NO: 359 STPH228 ScFv, S. aureus, Enterococcus SC06-078 U.S. Pat. No.8,628,776 7457 SEQ ID NO: 76 STPH229 ScFv, S. aureus, EnterococcusSC06-079 U.S. Pat. No. 8,628,776 7458 SEQ ID NO: 361 STPH230 ScFv, S.aureus, Enterococcus SC06-086 U.S. Pat. No. 8,628,776 7459 SEQ ID NO:363 STPH231 ScFv, S. aureus, Enterococcus SC06-087 U.S. Pat. No.8,628,776 7460 SEQ ID NO: 207 STPH232 ScFv, S. aureus, EnterococcusSC06-089 U.S. Pat. No. 8,628,776 7461 SEQ ID NO: 209 STPH233 ScFv, S.aureus, Enterococcus SC06-092 U.S. Pat. No. 8,628,776 7462 SEQ ID NO:365 STPH234 ScFv, S. aureus, Enterococcus SC06-091 U.S. Pat. No.8,628,776 7463 SEQ ID NO: 367 STPH235 ScFv, S. aureus, EnterococcusSC06-195 U.S. Pat. No. 8,628,776 7464 SEQ ID NO: 369 STPH236 ScFv, S.aureus, Enterococcus SC06-198 U.S. Pat. No. 8,628,776 7465 SEQ ID NO:371 STPH237 ScFv, S. aureus, Enterococcus SC06-241 U.S. Pat. No.8,628,776 7466 SEQ ID NO: 78 STPH238 ScFv, S. aureus, EnterococcusSC06-242 U.S. Pat. No. 8,628,776 7467 SEQ ID NO: 373 STPH239 ScFv, S.aureus, Enterococcus SC06-246 U.S. Pat. No. 8,628,776 7468 SEQ ID NO:375 STPH240 ScFv, S. aureus, Enterococcus SC06-252 U.S. Pat. No.8,628,776 7469 SEQ ID NO: 80 STPH241 ScFv, S. aureus, EnterococcusSC06-388 U.S. Pat. No. 8,628,776 7470 SEQ ID NO: 377 STPH242 ScFv, S.aureus, Enterococcus SC06-389 U.S. Pat. No. 8,628,776 7471 SEQ ID NO:379 STPH243 ScFv, S. aureus, Enterococcus SC06-396 U.S. Pat. No.8,628,776 7472 SEQ ID NO: 381 STPH244 ScFv, S. aureus, EnterococcusSC06-402 U.S. Pat. No. 8,628,776 7473 SEQ ID NO: 383 STPH245 ScFv, S.aureus, Enterococcus SC06-409 U.S. Pat. No. 8,628,776 7474 SEQ ID NO:385 STPH246 ScFv, S. aureus, Enterococcus SC06-415 U.S. Pat. No.8,628,776 7475 SEQ ID NO: 387 STPH247 ScFv, S. aureus, EnterococcusSC06-421 U.S. Pat. No. 8,628,776 7476 SEQ ID NO: 389 STPH248 ScFv, S.aureus, Enterococcus SC06-429 U.S. Pat. No. 8,628,776 7477 SEQ ID NO:391 STPH249 ScFv, S. aureus, Enterococcus SC06-432 U.S. Pat. No.8,628,776 7478 SEQ ID NO: 393

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inInternational Publication No. WO2000071585, WO2013162751, WO2015089502,WO2015088346 (e.g., SEQ ID NO: 17), US Pub No. US20030224000,US20080014202, US20140037650, US20140170134, U.S. Pat. No. 8,460,666,the contents of each of which are herein incorporated by reference intheir entirety, against Staphylococcus infection.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 35 against Clostridium tetani.

TABLE 35 Antibodies against Clostridium Tetani SEQ Antibody Antibody IDNo. Description Name Reference Information NO CTET1 Heavy chain Sims, G.P. “Tetanus toxoid specific antibody heavy chain 7479 partial V-genesequence”, Unpublished, CNBI Accession # AAC69189.1 CTET2 Heavy chainF5-20 Sims, G. P. “Tetanus toxoid specific antibody heavy chain 7480variable region V-gene sequence”, Unpublished, CNBI Accession #AAB50736.1 CTET3 Heavy chain Larrick, J. W., “Therapeutic humanantibodies derived 7481 variable region from PCR amplification of B-cellvariable regions”, Immunol. Rev. 130, 69-85 (1992), CNBI Accession #AAB25318.1 CTET4 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7482 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36976.1 CTET5 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7483 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36975.1 CTET6 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7484 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36974.1 CTET7 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7485 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36973.1 CTET8 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7486 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36972.1 CTET9 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7487 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36971.1 CTET10 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7488 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36970.1 CTET11 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7489 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36969.1 CTET12 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7490 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36968.1 CTET13 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7491 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol, Biol, immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36967.1 CTET14 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7492 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36966.1 CTET15 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7493 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36965.1 CTET16 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7494 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36964.1 CTET17 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7495 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36963.1 CTET18 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7496 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36962.1 CTET19 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7497 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36961.1 CTET20 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7498 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36960.1 CTET21 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7499 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36958.1 CTET22 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7500 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36959.1 CTET23 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7501 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36957.1 CTET24 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7502 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36956.1 CTET25 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7503 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36955.1 CTET26 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7504 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36954.1 CTET27 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7505 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36953.1 CTET28 Heavy chain de Kruif, J, et al., “Human immunoglobulinrepertoires 7506 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36952.1 CTET29 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7507 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36951.1 CTET30 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7508 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36950.1 CTET31 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7509 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36949.1 CTET32 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7510 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36948.1 CTET33 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7511 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36947.1 CTET34 Heavy chain de Kruif, J, et al., “Human immunoglobulinrepertoires 7512 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36946.1 CTET35 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7513 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36924.1 CTET36 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7514 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36925.1 CTET37 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7515 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36926.1 CTET38 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7516 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36927.1 CTET39 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7517 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36928.1 CTET40 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7518 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J,Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36929.1 CTET41 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7519 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36930.1 CTET42 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7520 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36931.1 CTET43 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7521 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36932.1 CTET44 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7522 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36933.1 CTET45 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7523 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36934.1 CTET46 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7524 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36935.1 CTET47 Heavy chain de Kruif, J. et al., “Human immunoglobulinrepertoires 7525 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36936.1 CTET48 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7526 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36937.1 CTET49 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7527 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36938.1 CTET50 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7528 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36939.1 CTET51 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7529 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36940.1 CTET52 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7530 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36941.1 CTET53 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7531 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36943.1 CTET54 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7532 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36942.1 CTET55 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7533 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36944.1 CTET56 Heavy chain e Kruif, J. et al., “Human immunoglobulinrepertoires 7534 variable region, against tetanus toxoid contain a largeand diverse fraction Human of high-affinity promiscuous V(H) genes”, J.Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession #ACL36945.1 CTET57 Light chain Larrick, J. W.. “Therapeutic humanantibodies derived 7535 variable region from PCR amplification of B-cellvariable regions”, Immunol. Rev. 130, 69-85 (1992), CNBI Accession #AAB25319.1

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 36 against Bordetella pertussisand/or Bordetella parapertussis.

TABLE 36 Antibodies against Bordetella Pertussis and BordetellaParapertussis SEQ Antibody Antibody ID No. Description Name Referenceinformation NO BORT1 Heavy chain 42.1 1.D4 WO2014160098 SEQ ID NO: 477536 BORT2 Heavy chain 42.12.G2 WO2014160098 SEQ ID NO: 51 7537 BORT3Heavy chain 42.12.A12 WO2014160098 SEQ ID NO: 55 7538 BORT4 Heavy chain42.12.A9 WO2014160098 SEQ ID NO: 59 7539 BORT5 Heavy chain 42.18.E12WO2014160098 SEQ ID NO: 63 7540 BORT6 Heavy chain 55.12.A8 WO2014160098SEQ ID NO: 67 7541 BORT7 Heavy chain 55.15.H5 WO2014160098 SEQ ID NO: 717542 BORT8 Heavy chain 55.17.D8 WO2014160098 SEQ ID NO: 75 7543 BORT9Heavy chain 55.22.E7 WO2014160098 SEQ ID NO: 79 7544 BORT10 Light chain42,1 1.D4 WO2014160098 SEQ ID NO: 49 7545 BORT11 Light chain 42.12.G2WO2014160098 SEQ ID NO: 53 7546 BORT12 Light chain 42.12.A12WO2014160098 SEQ ID NO: 57 7547 BORT13 Light chain 42.12.A9 WO2014160098SEQ ID NO: 61 7548 BORT14 Light chain 42.18.E12 WO2014160098 SEQ ID NO:65 7549 BORT15 Light chain 55.12.A8 WO2014160098 SEQ ID NO: 69 7550BORT16 Light chain 55.15.H5 WO2014160098 SEQ ID NO: 73 7551 BORT17 Lightchain 55.17.D8 WO2014160098 SEQ ID NO: 77 7552 BORT18 Light chain55.22.E7 WO2014160098 SEQ ID NO: 81 7553 BORT19 Single chain variableHussein, A. H. et al. “Construction and 7554 fragment antibody typecharacterization of single-chain variable 1 a1, single chain fragmentantibodies directed against the variable region Bordetella pertussissurface adhesins filamentous hemagglutinin and pertactin” Infect. Immun.75 (11), 5476-5482 (2007), NCBI Accession # ABB13478.1 BORT20 Singlechain variable Hussein, A. H. et al. “Construction and 7555 fragmentantibody type characterization of single-chain variable 18 a18, singlechain fragment antibodies directed against the variable regionBordetella pertussis surface adhesins filamentous hemagglutinin andpertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession #ABB13483.1 BORT21 Single chain variable Hussein, A. H, el al.“Construction and 7556 fragment antibody type characterization ofsingle-chain variable 2 a2, single chain fragment antibodies directedagainst the variable region Bordetella pertussis surface adhesinsfilamentous hemagglutinin and pertactin” Infect. Immun. 75 (11),5476-5482 (2007), NCBI Accession # ABB13479.1 BORT22 Single chainvariable Hussein, A. H. et al. “Construction and 7557 fragment antibodytype characterization of single-chain variable 4 b4, single chainfragment antibodies directed against the variable region Bordetellapertussis surface adhesins filamentous hemagglutinin and pertactin”Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13480.1BORT23 Single chain variable Hussein, A. H. et al. “Construction and7558 fragment antibody type characterization of single-chain variable 5c5, single chain fragment antibodies directed against the variableregion Bordetella pertussis surface adhesins filamentous hemagglutininand pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession# ABB13481.1 BORT24 Single chain variable Hussein, A. H. et al.“Construction and 7559 fragment antibody type characterization ofsingle-chain variable 6 d6, single chain fragment antibodies directedagainst the variable region Bordetella pertussis surface adhesinsfilamentous hemagglutinin and pertactin” Infect. Immun. 75 (11),5476-5482 (2007), NCBI Accession # ABB13482.1 BORT25 Single chainvariable Hussein, A. H. et al. “Construction and 7560 fragment antibodytype characterization of single-chain variable 7 e, single chainfragment antibodies directed against the variable region Bordetellapertussis surface adhesins filamentous hemagglutinin and pertactin”Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13484.1

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 37 against Mycobacteria

TABLE 37 Antibodies against Mycobacteria SEQ Antibody Antibody ID No,Description Name Reference Information NO MYCO1 Autod2 Single-chainvariable Berger et al., Microbes Infect, 9 7561 fragment antibody, Tbantibody, anti- (8), 963-970 (2007), NCBI neutrophil cytoplasmicantibodies Accession # ABI81486.1 cross-react with mycobacterium aviumsubsp. Paratuberculosis antigens MYCO2 autoh1 single-chain variablefragment Berger et al., Microbes Infect. 9 7562 antibody, Tb antibody,anti-neutrophil (8), 963-970 (2007), NCBI cytoplasmic antibodiescross-react Accession # ABI81485.1 with mycobacterium avium subsp.Paratuberculosis antigens, MYCO3 Heavy chain constant region, moG2a/US20130309237 SEQ ID NO: 7563 Mycobacteria moG2afull 10 MYCO4 Heavychain constant region, hG1mG2a US20130309237 SEQ ID NO: 7564Mycobacteria 11 MYCO5 Heavy chain constant region, hG3mG2a US20130309237SEQ ID NO: 7565 Mycobacteria 12 MYCO6 Heavy chain constant region,huG1full US20130309237 SEQ ID NO: 7566 Mycobacteria 13 MYCO7 Heavy chainconstant region, huG3full US20130309237 SEQ ID NO: 7567 Mycobacteria 14MYCO8 Heavy chain variable region, 2F12 IgGs US20130309237 SEQ ID NO:7568 Mycobacteria 15 MYCO9 Heavy chain variable region, 2F12 IgGsUS20130309237 SEQ ID NO: 7569 Mycobacteria 18 MYCO10 Heavy chainvariable region, partial 16a1 Al-sayyed et al., Tuberculosis 7570sequence, Tb antibody, mouse (Edinb) 87 (6), 489-497 (2007), monoclonalmpt51 NCBI Accession # ABS20005.1 MYCO11 Light chain constant region,HuCK US20130309237 SEQ ID NO: 7571 Mycobacteria 16 MYCO12 Light chainvariable region, MoCK US20130309237 SEQ ID NO: 7572 Mycobacteria 17MYCO13 Light chain variable region, partial 16a1 Al-sayyed el al.,Tuberculosis 7573 sequence, Tb antibody, mouse (Edinb) 87 (6), 489-497(2007), monoclonal mpt51 NCBI Accession # ABS20006.1 MYC014 Scfv, Tbantibody, an engineered US20060229438 SEQ ID NO: 3 7574 single chainantibody MYC015 Scfv, Tb antibody, an engineered US20060229438 SEQ IDNO: 4 7575 single chain antibody MYC016 Scfv, Tb antibody, an engineeredUS20060229438 SEQ ID NO: 2 7576 single chain antibody

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 38 against Francisella tularensis.

TABLE 38 Antibodies against Francisella Tularensis SEQ Antibody AntibodyID No. Description Name Reference Information NO FRAN1 Chain H Ab-52Rynkiewicz, M. J. et al., “Structural Analysis of a Protective 7577Epitope of the Francisella tularensis O-Polysaccharide”, Biochemistry-51 (28), 5684-5694 (2012), NCBI Accession # 3UJT_H FRAN2 Chain H N62 Lu,Z., et al., “The binding sites of monoclonal antibodies to 7578 thenon-reducing end of Francisella tularensis O-antigen accommodate mainlythe terminal saccharide”, Immunology 140 (3), 374-389 (2013), NCBIAccession # 4KPH_H FRAN3 Chain H Ab64 Lu, Z. et al., “B-cell epitopes inGroEL of Francisella 7579 tularensis”, PLoS ONE 9 (6), E99847 (2014),NCBI Accession # 4PB9_H FRAN4 Chain H Ab53 Lu, Z, et al., “B-cellepitopes in GroEL of Francisella 7580 tularensis”, PLoS ONE 9 (6),E99847 (2014), NCBI Accession # 4PB0_H FRAN5 Chain H N203 Lu, Z. et al.,“Functional and Structural Characterization of 7581 Francisellatularensis O-Antigen Antibodies at the Low End of Antigen Reactivity”,Monoclonal Antib Immunodiagn Immunother 33 (4), 235-245 (2014), NCBIAccession # 4OTX_H FRAN6 Chain I Ab-52 Rynkiewicz, M. J., et al.,“Structural Analysis of a Protective 7582 Epitope of the Francisellatularensis O-Polysaccharide”, Biochemistry 51 (28), 5684-5694 (2012),NCBI Accession # 3UJT_I FRAN7 Chain I N62 Lu, Z., et al., “The bindingsites of monoclonal antibodies to 7583 the non-reducing end ofFrancisella tularensis O-antigen accommodate mainly the terminalsaccharide”, Immunology 140 (3), 374-389 (2013), NCBI Accession # 4KPH_IFRAN8 Chain I N203 Lu, Z. et al., “Functional and StructuralCharacterization of 7584 Francisella tularensis O-Antigen Antibodies atthe Low End of Antigen Reactivity”, Monoclonal Antib ImmunodiagnImmunother 33 (4), 235-245 (2014), NCBI Accession # 4OTX_I FRAN9 Chain LAb-52 Rynkiewicz, M. J., et al., “Structural Analysis of a Protective7585 Epitope of the Francisella tularensis O-Polysaccharide”,Biochemistry 51 (28), 5684-5694 (2012), NCBI Accession # 3UJT_L FRAN10Chain L N62 Lu, Z., et al., “The binding sites of monoclonal antibodiesto 7586 the non-reducing end of Francisella tularensis O-antigenaccommodate mainly the terminal saccharide”, Immunology 140 (3), 374-389(2013), NCBI Accession # 4KPH_L FRAN11 Chain L Ab64 Lu, Z. et al.,“B-cell epitopes in GroEL of Francisella 7587 tularensis”, PLoS ONE 9(6), E99847 (2014), NCBI Accession # 4PB9_L FRAN12 Chain L Ab53 Lu, Z.et al., “B-cell epitopes in GroEL of Francisella 7588 tularensis”, PLoSONE 9 (6), E99847 (2014), NCBI Accession # 4PB0_L FRAN13 Chain L N203Lu, Z, et al., “Functional and Structural Characterization of 7589Francisella tularensis O-Antigen Antibodies at the Low End of AntigenReactivity”, Monoclonal Antib Immunodiagn Immunother 33 (4), 235-245(2014), NCBI Accession # 4OTX_L FRAN14 Chain M Ab-52 Rynkiewicz, M. J.et al., “Structural Analysis of a Protective 7590 Epitope of theFrancisella tularensis O-Polysaccharide”, Biochemistry 51 (28),5684-5694 (2012), NCBI Accession # 3UJT_M FRAN15 Chain M N62 Lu, Z., etal., “The binding sites of monoclonal antibodies to 7591 thenon-reducing end of Francisella tularensis O-antigen accommodate mainlythe terminal saccharide”, Immunology 140 (3), 374-389 (2013), NCBIAccession # 4KPH_M FRAN16 Chain M N203 Lu, Z, et al., “Functional andStructural Characterization of 7592 Francisella tularensis O-AntigenAntibodies at the Low End of Antigen Reactivity”, Monoclonal AntibImmunodiagn Immunother 33 (4), 235-245 (2014), NCBI Accession # 4OTX_M

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 39 against Bacteria.

TABLE 39 Antibodies against Bacteria SEQ Antibody ID No. DescriptionAntibody Name Reference Information NO BACI1 Heavy chain variableUS20080038266 SEQ ID NO: 1 7593 region, Enterococcus faecium,Enterococcus faecalis, Clostridium difficile BACI2 Heavy chain variableNaid60 US20060073139 SEQ ID NO: 5 7594 region, Neisseria meningitidis,BACI3 Heavy chain, Neisseria Fernandez de Cossio, M. E., et al. 7595meningitidis, “Human monoclonal antibodies against an epitope on theclass 5c outer membrane protein common to many pathogenic strains ofNeisseria meningitidis”, J. Infect. Dis. 166 (6), 1322-1328 (1992),AAB18935 BACI4 Heavy chain, Neisseria Fernandez de Cossio, M. E., et al.7596 meningitidis, “Human monoclonal antibodies against an epitope onthe class 5c outer membrane protein common to many pathogenic strains ofNeisseria meningitidis”, J. Infect. Dis. 166 (6), 1322-1328 (1992),AAB18934 BACI5 Heavy chain, Septic Edobacomab, 7597 shock, meningococcalE5, XMMEN- septic shock 0E5 BACI6 Ig kappa chain V-I Goni, F. andFrangione, B., “Amino acid 7598 region WEA, sequence of the Fv region ofa human Klebsiella bacteria monoclonal IgM (protein WEA) with antibodyactivity against 3,4-pyruvylated galactose in Klebsiella polysaccharidesK30 and K33”, Proc. Natl. Acad. Sci. U.S.A. 80 (15), 4837-4841 (1983).P01610 BACI7 Ig kappa chain V-I Goni, F. and Frangione, B., “Amino acid7599 region WEA, sequence of the Fv region of a human Klebsiellabacteria monoclonal IgM (protein WEA) with antibody activity against3,4-pyruvylated galactose in Klebsiella polysaccharides K30 and K33”,Proc. Natl. Acad. Sci. U.S.A. 80 (15), 4837-4841 (1983), P01763 BACI8Light chain variable US20080038266 SEQ ID NO: 16 7600 region,Enterococcus faecium, Enterococcus faecalis, Clostridium difficile BACI9Light chain variable Naid60 US20060073139 SEQ ID NO: 6 7601 region,Neisseria meningitidis BACI10 Light chain, Septic Edobacomab, 7602shock, meningococcal E5, XMMEN- septic shock, 0E5 BACI11 scFv antibody,Anti- Zou, N., et al. “Human Single-Chain Fv 7603 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ABI97022.1 BACI12 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7604 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ABI97023.1 BACI13 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7605 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ABI97021.1 BACI14 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7606 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ABI97018.1 BACI15 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7607 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ABI97024.1 BACI16 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7608 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ACZ65033.1 BACI17 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7609 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ACZ65032.1 BACI18 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7610 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ACZ65031.1 BACI19 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7611 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ACZ65030.1 BACI20 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain. Fv 7612 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ACZ65029.1 BACI21 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7613 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ACZ65028.1 BAC122 scFv antibody, Anti-Zou, N,, et al. “Human Single-Chain Fv 7614 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # AB197020.1 BACI23 scFv antibody, Anti-Zou, N., et al. “Human Single-Chain Fv 7615 Burkholderia malleiAntibodies against Burkholderia mallei and Burkholderia pseudomallei”,unpublished, NCBI Accession # ABI97019.1 BACI24 Single chain variable,CB515 LaRocca, T. J., et al. “Bactericidal action 7616 Borrelia, of acomplement-independent relapsing fever Borrelia resides in its variableregion”, J. Immunol. 180 (9), 6222-6228 (2008), NCBI Accession #ABV22509

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants encodingDoxorubicin, fragments or variants thereof for treating a disease and/ordisorder or preventing a disease and/or disorder. As a non-limitingexample, the disease and/or disorder is bacterial infection.

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 40 against Toxoplasma gondii.

TABLE 40 Antibodies against Toxoplasma gondii Antibody SEQ ID No.Description Antibody Name Reference Information NO TOXO1 4f11e12 FabHeavy Chain Variable Graille, M. et al., J. Mol. Biol. 354 7617 Region,Surface antigen 1 (2), 447-458 (2005), NCBI Accession (SAG1) # 1YNT_D(218aa) TOXO2 4f11e12 Fab Light Chain Variable Graille, M. et al., J.Mol, Biol. 354 7618 Region, Surface antigen 1 (2), 447-458 (2005), NCBIAccession (SAG1) # 1YNT_C (213aa)

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 41 against Candida Yeast

TABLE 41 Antibodies against Candida Yeast Antibody SEQ ID No.Description Antibody Name NO CAND1 Efungumab Candida 7619

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences encoding one or more of the payloadantibody polypeptides listed in Table 42.

TABLE 42 HIV Antibodies SEQ Antibody Antibody ID No. Description NameReference Information NO HIV1 4e10 Antibody 4e10antibody NCBI Accession# 4OB5_H (127aa) 7620 Germline Precursor 7 Heavy Chain Fv HIV2 4e10Antibody 4e10antibody NCBI Accession # 4OB5_L (114aa) 7621 GermlinePrecursor 7 Light Chain Fv HIV3 Antigen Binding Ch103 Liao et al.,Co-evolution of a broadly 7622 Fragment Of Heavy neutralizing HIV-1antibody and founder virus; Chain Nature 496 (7446), 469-476 (2013),NCBI Accession # 4JAM_H (226aa) HIV4 Antigen Binding Ch103 Liao et al.,Co-evolution of a broadly 7623 Fragment Of Light neutralizing HIV-1antibody and founder virus; Chain Nature 496 (7446), 469-476 (2013),NCBI Accession # 4JAM_L (209aa) HIV5 Fab Fragment, Heavy N12-i15 NCBIAccession # 3QEH_G (232aa) 7624 Chain HIV6 Fab Fragment, Light N12-i15NCBI Accession # 3QEH_H (218aa) 7625 Chain HIV7 Fab Heavy Chain 35o22Huang et al., Broad and potent HIV-1 7626 neutralization by a humanantibody that binds the gp41-gp120 interface; Nature 515 (7525), 138-142(2014), NCBI Accession # 4TOY_H (243 aa) HIV8 Fab Heavy Chain 8anc195Scharf, L., et al., Cell Rep 7 (3), 785-795 7627 (2014), NCBI Accession# 4P9H_H (244aa) HIV9 Fab Heavy Chain B13 Chen L. et al., Science 326(5956), 1123-1127 7628 (2009), NCBI Accession # 3IDY_B (231aa) HIV10 FabHeavy Chain Ch58 Liao et al., vaccine Induction of Antibodies 7629against a Structurally Heterogeneous Site of Immune Pressure withinHIV-1 Envelope Protein Variable region 1 and 2; Immunity 38 (1), 176-186(2013), NCBI Accession # 4HQQ_H (231aa) HIV11 Fab Heavy Chain Ch59 Liaoet al., vaccine Induction of Antibodies 7630 against a StructurallyHeterogeneous Site of Immune Pressure within HIV-1 Envelope ProteinVariable region 1 and 2; Immunity 38 (1), 176-186 (2013), NCBI Accession# 4HPY_H (225aa) HIV12 Fab Heavy Chain E51 Huang C et al., Proc. Natl,Acad. Sci. U.S.A. 7631 101 (9), 2706-2711 (2004), NCBI Accession #1RZF_H (235aa) HIV13 Fab Heavy Chain N26-i1 Fab NCBI Accession #4FZE_H(232aa) 7632 HIV14 Fab Heavy Chain Pgt145 McLellan, J. S. et al.,Structure of HIV-1 gp120 7633 V1 V2 domain with broadly neutralizingantibody PG9; Nature 480 (7377), 336-343 (2011), NCBI Accession # 3U1S_H(267aa) HIV15 Fab Heavy Chain Of A32 Fab NCBI Accession # 3TNM_A (231aa)7634 Human Anti-hiv-1 Env Antibody A32 HIV16 Fab Heavy Chain Of C11 FabNCBI Accession # 4FZ8_H (237aa) 7635 Human Anti-hiv-1 Env Antibody C11HIV17 Fab Light Chain 35o22 Huang et al., Broad and potent HIV-1 7636neutralization by a human antibody that binds the gp41-gp120 interface;Nature 515 (7525), 138-142 (2014), NCBI Accession # 4TOY_L (216aa) HIV18Fab Light Chain 8anc195 Scharf, L., et al., Cell Rep 7 (3), 785-795 7637(2014), NCBI Accession # 4P9H_L (215aa) HIV19 Fab Light Chain B13 ChenL. et al., Science 326 (5956), 1123-1127 7638 (2009), NCBI Accession #3IDY_C (215aa) HIV20 Fab Light Chain Ch58 Liao et al., vaccine Inductionof Antibodies 7639 against a Structurally Heterogeneous Site of ImmunePressure within HIV-1 Envelope Protein Variable region 1 and 2; Immunity38 (1), 176-186 (2013), NCBI Accession # 4HQQ_L (216aa) HIV21 Fab LightChain Ch59 Liao et al., vaccine Induction of Antibodies 7640 against aStructurally Heterogeneous Site of Immune Pressure within HIV-1 EnvelopeProtein Variable region 1 and 2; Immunity 38 (1), 176-186 (2013), NCBIAccession # 4HPY_L (215aa) HIV22 Fab Light Chain E51 Huang C et al.,Proc. Natl. Acad. Sci. U.S.A. 7641 101 (9), 2706-2711 (2004), NCBIAccession # 1RZF_L (213aa) HIV23 Fab Light Chain Monoclonal Bartesaghi,A. et al., Perfusion structure of 7642 Antibody trimeric HIV-1 envelopeglycoprotein Vrc03 determined by cryo-electron microscopy; Nat. Struct.Mol. Biol. 20 (12), 1352-1357 (2013), NCBI Accession # 4CC8_L (209aa)HIV24 Fab Light Chain N26-i1 Fab NCBI Accession# 4FZE_L (212aa) 7643HIV25 Fab Light Chain Pgt145 McLellan, J. S. et al., Structure of HIV-1gp120 7644 V1 V2 domain with broadly neutralizing antibody PG9; Nature480 (7377), 336-343 (2011), NCBI Accession # 3U1S_L (239aa) HIV26 FabLight Chain Of A32 Fab NCBI Accession # 3TNM_B (216aa) 7645 HumanAnti-hiv-1 Env Antibody A32 HIV27 Fab Light Chain Of C11 Fab NCBIAccession # 4FZ8_L (218aa) 7646 Human Anti-hiv-1 Env Antibody C11 HIV28Fab Region Of The Fab 2558 Gorny et al., PLoS ONE 6 (12), E27780 (2011),7647 Heavy Chain NCBI Accession # 3UJI_H (223aa) HIV29 Fab Region Of TheFab 4025 Gorny et al., PLoS ONE 6 (12), E27780 (2011), 7648 Heavy ChainNCBI Accession # 3UJJ_H (230aa) HIV30 Fab, Heavy Chain 3bnc60 Scheid, J.F., et al,. Science 333 (6049), 1633- 7649 1637 (2011), NCBI Accession #3RPI_A (229aa) HIV31 Fab, Heavy Chain 48d Huang C C et al., Proc. Natl.Acad. Sci. U.S.A. 7650 101 (9), 2706-2711 (2004), NCBI Accession #1R27_H (219aa) HIV32 Fab, Heavy Chain 4e10Fab Bird et al., Nat. Struct.Mol. Biol. (2014), NCBI 7651 Accession # 4NGH_H (228aa) HIV33 Fab, HeavyChain Ch58-ua Nicely et al. Ebiomedicine 2 (2015), NCBI 7652 Accession #4RIS_H (230aa) HIV34 Fab, Heavy chain Mab 2909 Spurrier, B., et al.,Structure 19 (5), 691-699 7653 (2011), NCBI Accession # 3Q6F_J (233aa)HIV35 Fab, Heavy Chain Monoclonal Bartesaghi, A. et al., Perfusionstructure of 7654 Antibody trimeric HIV-1 envelope glycoprotein Vrc03determined by cryo-electron microscopy; Nat. Struct. Mol. Biol. 20 (12),1352-1357 (2013), NCBI Accession # 4CC8_I (233aa) HIV36 Fab, light chain3bnc60 Scheid, J. F., et al., Science 333 (6049), 1633- 7655 1637(2011), NCBI Accession # 3RPI_B (206aa) HIV37 Fab, Light Chain 48d HuangC C et al., Proc. Natl. Acad. Sci. U.S.A. 7656 101 (9), 2706-2711.(2004), NCBI Accession # 1RZ7_L (212aa) HIV38 Fab, Light Chain 4e10FabBird et al., Nat. Struct. Mol. Biol. (2014), NCBI 7657 Accession #4NGH_L (215aa) HIV39 Fab, Light Chain Ch58-ua Nicely et al. Ebiomedicine2 (2015), NCBI 7658 Accession # 4RIS_L (216aa) HIV40 Fab, light ChainMab 2909 Spurrier, B., et al., Structure 19 (5), 691-699 7659 (2011),NCBI Accession # 3Q6F_K (213aa) HIV41 Gamma heavy chain 1443_C16 U.S.Pat. No. 9,051,362 SEQ ID NO: 12 7660 HIV42 Gamma heavy chain 1471 M23U.S. Pat. No. 9,051,362 SEQ ID NO: 139 7661 HIV43 Gamma heavy chain1489_I13 U.S. Pat. No. 9,051,362 SEQ ID NO: 59 7662 HIV44 Gamma heavychain 1503_H05 U.S. Pat. No. 9,051,362 SEQ ID NO: 53 7663 HIV45 Gammaheavy chain 1456_A12 U.S. Pat. No. 9,051,362 SEQ ID NO: 48 7664 variableregion HIV46 Gamma heavy chain 1456_P20 U.S. Pat. No. 9,051,362 SEQ IDNO: 33 7665 variable region HIV47 Gamma heavy chain 1460_G14 U.S. Pat.No. 9,051,362 SEQ ID NO: 35 7666 variable region HIV48 Gamma heavy chain1470_M23 U.S. Pat. No. 9,051,362 SEQ ID NO: 140 7667 variable regionHIV49 Gamma heavy chain 1480_I08 U.S. Pat. No. 9,051,362 SEQ ID NO: 317668 variable region HIV50 Gamma heavy chain 1480_I08 U.S. Pat. No.9,051,362 SEQ ID NO: 65 7669 variable region HIV51 Gamma heavy chain1489_I13 U.S. Pat. No. 9,051,362 SEQ ID NO: 60 7670 variable regionHIV52 Gamma heavy chain 1495_C14 U.S. Pat. No. 9,051,362 SEQ ID NO: 377671 variable region HIV53 Gamma heavy chain 1503_H05 U.S. Pat. No.9,051,362 SEQ ID NO: 54 7672 variable region HIV54 Gamma heavy chain1496_C09 U.S. Pat. No. 9,051,362 SEQ ID NO: 39 7673 variable regionHIV55 Gamma heavy chain 1456_A12 U.S. Pat. No. 9,051,362 SEQ ID NO: 477674 HIV56 Gamma heavy chain 1460_G14 U.S. Pat. No. 9,051,362 SEQ ID NO:20 7675 HIV57 Gamma heavy chain 1495_C14 U.S. Pat. No. 9,051,362 SEQ IDNO: 24 7676 HIV58 Gamma heavy chain 1496_C09 U.S. Pat. No. 9,051,362 SEQID NO: 28 7677 HIV59 Gamma heavy 1456_P20 U.S. Pat. No. 9,051,362 SEQ IDNO: 16 7678 HIV60 Gp41-specific US20140348785 SEQ ID NO: 11 7679antibody, heavy chain HIV61 Gp41-specific US20140348785 SEQ ID NO: 1467680 antibody, heavy chain consensus HIV62 Gp41-specific US20140348785SEQ ID NO: 187 7681 antibody, heavy chain consensus variable regionHIV63 Gp41-specific US20140348785 SEQ ID NO: 188 7682 antibody, heavychain consensus variable region HIV64 Gp41-specific US20140348785 SEQ IDNO: 153 7683 antibody, heavy chain variable region HIV65 Gp41-specificUS20140348785 SEQ ID NO: 154 7684 antibody, heavy chain variable regionHIV66 Gp41-specific US20140348785 SEQ ID NO: 155 7685 antibody, heavychain variable region HIV67 Gp41-specific US20140348785 SEQ ID NO: 1567686 antibody, heavy chain variable region HIV68 Gp41-specificUS20140348785 SEQ ID NO: 157 7687 antibody, heavy chain variable regionHIV69 Gp41-specific US20140348785 SEQ ID NO: 158 7688 antibody, heavychain variable region HIV70 Gp41-specific US20140348785 SEQ ID NO: 1597689 antibody, heavy chain variable region HIV71 Gp41-specificUS20140348785 SEQ ID NO: 160 7690 antibody, heavy chain variable regionHIV72 Gp41-specific US20140348785 SEQ ID NO: 161 7691 antibody, heavychain variable region HIV73 Gp41-specific US20140348785 SEQ ID NO: 1627692 antibody, heavy chain variable region HIV74 Gp41 -specificUS20140348785 SEQ ID NO: 163 7693 antibody, heavy chain variable regionHIV75 Gp41-specific US20140348785 SEQ ID NO: 189 7694 antibody, heavychain variable region HIV76 Gp41-specific US20140348785 SEQ ID NO: 1907695 antibody, heavy chain variable region HIV77 Gp41-specificUS20140348785 SEQ ID NO: 191 7696 antibody, heavy chain variable regionHIV78 Gp41-specific US20140348785 SEQ ID NO: 192 7697 antibody, heavychain variable region HIV79 Gp41-specific US20140348785 SEQ ID NO: 2007698 antibody, heavy chain variable region HIV80 Gp41-specificUS20140348785 SEQ ID NO: 201 7699 antibody, heavy chain variable regionHIV81 Gp41-specific US20140348785 SEQ ID NO: 202 7700 antibody, heavychain variable region HIV82 Gp41-specific US20140348785 SEQ ID NO: 2037701 antibody, heavy chain variable region HIV83 Gp41-specificUS20140348785 SEQ ID NO: 204 7702 antibody, heavy chain variable regionHIV84 Gp41-specific US20140348785 SEQ ID NO: 205 7703 antibody, heavychain variable region HIV85 Gp41-specific US20140348785 SEQ ID NO: 2067704 antibody, heavy chain variable region HIV86 Gp41-specificUS20140348785 SEQ ID NO: 207 7705 antibody, heavy chain variable regionHIV87 Gp41-specific US20140348785 SEQ ID NO: 208 7706 antibody, heavychain variable region HIV88 Gp41-specific US20140348785 SEQ ID NO: 2097707 antibody, heavy chain variable region HIV89 Gp41-specificUS20140348785 SEQ ID NO: 12 7708 antibody, light chain variable regionHIV90 Gp41-specific US20140348785 SEQ ID NO: 164 7709 antibody, lightchain variable region HIV91 Gp41-specific US20140348785 SEQ ID NO: 1657710 antibody, light chain variable region HIV92 Gp41-specificUS20140348785 SEQ ID NO: 166 7711 antibody, light chain variable regionHIV93 Gp41-specific US20140348785 SEQ ID NO: 167 7712 antibody, lightchain variable region HIV94 Gp41-specific US20140348785 SEQ ID NO: 1687713 antibody, light chain variable region HIV95 Gp41-specificUS20140348785 SEQ ID NO: 169 7714 antibody, light chain variable regionHIV96 Gp41-specific US20140348785 SEQ ID NO: 170 7715 antibody, lightchain variable region HIV97 Gp41-specific US20140348785 SEQ ID NO: 1717716 antibody, light chain variable region HIV98 Gp41-specificUS20140348785 SEQ ID NO: 172 7717 antibody, light chain variable regionHIV99 Gp41-specific US20140348785 SEQ ID NO: 173 7718 antibody, lightchain variable region HIV100 Gp41-specific US20140348785 SEQ ID NO: 1747719 antibody, light chain variable region HIV101 Gp41-specificUS20140348785 SEQ ID NO: 175 7720 antibody, light chain variable regionHIV102 Gp41-specific US20140348785 SEQ ID NO: 176 7721 antibody, lightchain variable region HIV103 Gp41-specific US20140348785 SEQ ID NO: 1777722 antibody, light chain variable region HIV104 Gp41-specificUS20140348785 SEQ ID NO: 178 7723 antibody, light chain variable regionHIV105 Gp41-specific US20140348785 SEQ ID NO: 179 7724 antibody, lightchain variable region HIV106 Gp41-specific US20140348785 SEQ ID NO: 1807725 antibody, light chain variable region HIV107 Gp41-specificUS20140348785 SEQ ID NO: 181 7726 antibody, light chain variable regionHIV108 Gp41-specific US20140348785 SEQ ID NO: 182 7727 antibody, lightchain variable region HIV109 Gp41-specific US20140348785 SEQ ID NO: 1837728 antibody, light chain variable region HIV110 Gp41-specificUS20140348785 SEQ ID NO: 184 7729 antibody, light chain variable regionHIV111 Gp41-specific US20140348785 SEQ ID NO: 185 7730 antibody, lightchain variable region HIV112 Gp41-specific US20140348785 SEQ ID NO: 1867731 antibody, light chain variable region HIV113 Gp41-specificUS20140348785 SEQ ID NO: 197 7732 antibody, light chain variable regionHIV114 Gp41-specific US20140348785 SEQ ID NO: 198 7733 antibody, lightchain variable region HIV115 Gp41-specific US20140348785 SEQ ID NO: 1997734 antibody, light chain variable region HIV116 Heavy chain Vrc06b Wu,X., et al., Maturation and Diversity of the 7735 VRC01-Antibody Lineageover 15 Years of Chronic HIV-1 Infection; Cell 161 (3), 470-485 (2015),NCBI Accession # 4XNZ_E (234aa) HIV117 Heavy Chain 2424 Kumar, R., etal., Functional and Structural 7736 Characterization of HumanV3-Specific Monoclonal Antibody 2424 with Neutralizing Activity againstHIV-1 JRFL; J. Virol. 89 (17), 9090-9102 (2015), NCBI Accession #4XML_H(223aa) HIV118 Heavy chain 5827 US20140205607 Table S13 7737HIV119 Heavy chain 7863 US20140205607 Table S13 7738 HIV120 Heavy Chain8062 Gustchina, E., PLoS ONE 8 (11), E78187 7739 (2013), NCBI Accession# 4KHX_H(245aa) HIV121 Heavy chain 18761 US20140205607 Table S13 7740HIV122 Heavy chain 19891 US20140205607 Table S13 7741 HIV123 Heavy chain22425 US20140205607 Table S13 7742 HIV124 Heavy chain 28241US20140205607 Table S13 7743 HIV125 Heavy chain 61272 US20140205607Table S13 7744 HIV126 Heavy chain 61822 US20140205607 Table S13 7745HIV127 Heavy chain 65030 US20140205607 Table S13 7746 HIV128 Heavy chain70085 US20140205607 Table S13 7747 HIV129 Heavy chain 70542US20140205607 Table S13 7748 HIV130 Heavy chain 80585 US20140205607Table S13 7749 HIV131 Heavy chain 87722 US20140205607 Table S13 7750HIV132 Heavy chain 96362 US20140205607 Table S13 7751 HIV133 Heavy chain103787 US20140205607 Table S13 7752 HIV134 Heavy chain 146940US20140205607 Table S13 7753 HIV135 Heavy chain 153849 US20140205607Table S13 7754 HIV136 Heavy chain 1.00E+09 US20140348785 SEQ ID NO: 17755 HIV137 Heavy chain 104625_2 US20140205607 Table S14 7756 HIV138Heavy chain 105239_4 US20140205607 Table S14 7757 HIV139 Heavy chain10731_1 US20140205607 Table S14 7758 HIV140 Heavy Chain 10e8 Huang J etal., Nature 491 (7424), 406-412 7759 (monoclonal) (2012), NCBI Accession# 4G6F_B (236aa) HIV141 Heavy chain 120119_4 US20140205607 Table S147760 HIV142 Heavy chain 121325_4 US20140205607 Table S14 7761 HIV143Heavy chain 12467_3 US20140205607 Table S14 7762 HIV144 Heavy chain124918_2 US20140205607 Table S14 7763 HIV145 Heavy chain 127586_4US20140205607 Table S14 7764 HIV146 Heavy chain 12A10HC US20140328862SEQ ID NO: 147 7765 HIV147 Heavy chain 12A12HC US20140328862 SEQ ID NO:148 7766 HIV148 Heavy chain 12A13HC US20140328862 SEQ ID NO: 149 7767HIV149 Heavy chain 12A16HC US20140328862 SEQ ID NO: 150 7768 HIV150Heavy chain 12A17HC US20140328862 SEQ ID NO: 151 7769 HIV151 Heavy chain12A1HC US20140328862 SEQ ID NO: 152 7770 HIV152 Heavy chain 12A20HCUS20140328862 SEQ ID NO: 153 7771 HIV153 Heavy Chain 12a21 NCBIAccession # 4JPW_H (225aa) 7772 HIV154 Heavy chain 12A21HC US20140328862SEQ ID NO: 154 7773 HIV155 Heavy chain I2A22HC US20140328862 SEQ ID NO:155 7774 HIV156 Heavy chain 12A23HC US20140328862 SEQ ID NO: 156 7775HIV157 Heavy chain 12A27HC US20140328862 SEQ ID NO: 157 7776 HIV158Heavy chain 12A2HC US20140328862 SEQ ID NO: 158 7777 HIV159 Heavy chain12A30HC US20140328862 SEQ ID NO: 159 7778 HIV160 Heavy chain 12A37HCUS20140328862 SEQ ID NO: 160 7779 HIV161 Heavy chain 12A46HCUS20140328862 SEQ ID NO: 161 7780 HIV162 Heavy chain 12A4HCUS20140328862 SEQ ID NO: 162 7781 HIV163 Heavy chain 12A55HCUS20140328862 SEQ ID NO: 163 7782 HIV164 Heavy chain 12A56HCUS20140328862 SEQ ID NO: 164 7783 HIV165 Heavy chain 12A6HCUS20140328862 SEQ ID NO: 165 7784 HIV166 Heavy chain 12A7HCUS20140328862 SEQ ID NO: 166 7785 HIV167 Heavy chain 12A9HCUS20140328862 SEQ ID NO: 167 7786 HIV168 Heavy chain 132797_4US20140205607 Table S14 7787 HIV169 Heavy chain 135083_3 US20140205607Table S14 7788 HIV170 Heavy chain 13826_2 US20140205607 Table S14 7789HIV171 Heavy chain 143251_3 US20140205607 Table S14 7790 HIV172 Heavychain 149590_4 US20140205607 Table S14 7791 HIV173 Heavy chain 149768_4US20140205607 Table S14 7792 HIV174 Heavy chain 151901_4 US20140205607Table S14 7793 HIV175 Heavy chain 156858_3 US20140205607 Table S14 7794HIV176 Heavy chain 164202_3 US20140205607 Table S14 7795 HIV177 Heavychain 164922_3 US20140205607 Table S14 7796 HIV178 Heavy chain 165478_2US20140205607 Table S14 7797 HIV179 Heavy chain 166726_3 US20140205607Table S14 7798 HIV180 Heavy chain 167612_4 US20140205607 Table S14 7799HIV181 Heavy chain 168509_2 US20140205607 Table S14 7800 HIV182 Heavychain 169094_4 US20140205607 Table S14 7801 HIV183 Heavy chain 17720_4US20140205607 Table S14 7802 HIV184 Heavy chain 178037_3 US20140205607Table S14 7803 HIV185 Heavy chain 179400_4 US20140205607 Table S14 7804HIV186 Heavy chain 179500_4 US20140205607 Table S14 7805 HIV187 Heavychain 179888_3 US20140205607 Table S14 7806 HIV188 Heavy Chain 17bKwong, P. D., et al., structure of an HIV gp120 7807 envelopeglycoprotein in complex with the CD4 receptor and a neutralizing humanantibody; Nature 393 (6686), 648-659 (1998), NCBI Accession# 1G9M_H(229aa) HIV189 Heavy chain 18278_1 US20140205607 Table S14 7808 HIV190Heavy chain 184939_4 US20140205607 Table S14 7809 HIV191 Heavy chain185961_4 US20140205607 Table S14 7810 HIV192 Heavy chain 186066_4US20140205607 Table S14 7811 HIV193 Heavy chain 186275_2 US20140205607Table S14 7812 HIV194 Heavy chain 186640_2 US20140205607 Table S14 7813HIV195 Heavy chain 190244_4 US20140205607 Table S14 7814 HIV196 Heavychain 193526_4 US20140205607 Table S14 7815 HIV197 Heavy chain 193896_4US20140205607 Table S14 7816 HIV198 Heavy chain 195462_4 US20140205607Table S14 7817 HIV199 Heavy chain 196147_4 US20140205607 Table S14 7818HIV200 Heavy chain 196283_4 US20140205607 Table S14 7819 HIV201 HeavyChain 1b2530 Zhou T el al., Structural Repertoire of HIV-1- 7820Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell161 (6), 1280- 1292 (2015), NCBI Accession # 4YFL_H (227aa) HIV202 Heavychain 1F7 U.S. Pat. No. 6,057,421A FIG. 8 7821 HIV203 Heavy chain 1NC9WO2012154312 SEQ ID NO: 2471 7822 HIV204 Heavy Chain 2.2C Acharya, P.,et al., Structural Definition of an 7823 Antibody-Dependent CellularCytotoxicity Response Implicated in Reduced Risk for HIV- 1 Infection;J. Virol. 88 (21), 12895-12906 (2014), NCBI Accession # 4R4N_H (220aa)HIV205 Heavy chain 24972_4 US20140205607 Table S14 7824 HIV206 Heavychain 28936_1 US20140205607 Table S14 7825 HIV207 Heavy chain 2F5 U.S.Pat. No. 8,637,036B2 SEQ ID NO: 5 7826 HIV208 Heavy chain 2F5 F100BWU.S. Pat. No. 8,637,036B2 SEQ ID NO: 7 7827 HIV209 Heavy chain 2F5L100AW U.S. Pat. No. 8,637,036B2 SEQ ID NO: 6 7828 HIV210 Heavy chain2F5 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 9 7829 L100AW- V100DW HIV211Heavy chain 2F5 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 8 7830 V100DWHIV212 Heavy chain 30263_2 US20140205607 Table S14 7831 HIV213 Heavychain 3040HC WO2015117008 SEQ ID NO: 14 7832 HIV214 Heavy chain 3044HCWO20S5117008 SEQ ID NO: 17 7833 HIV215 Heavy chain 31458_3 US20140205607Table S14 7834 HIV216 Heavy chain 3430HC WO2015117008 SEQ ID NO: 15 7835HIV217 Heavy chain 3484HC WO2015117008 SEQ ID NO: 16 7836 HIV218 Heavychain 3630HC WO2015117008 SEQ ID NO: 18 7837 HIV219 Heavy chain 3A124HCUS20140328862 SEQ ID NO: 261 7838 HIV220 Heavy chain 3A125HCUS20140328862 SEQ ID NO: 262 7839 HIV221 Heavy chain 3A140HCUS20140328862 SEQ ID NO: 263 7840 HIV222 Heavy chain 3A144HCUS20140328862 SEQ ID NO: 264 7841 HIV223 Heavy chain 3A160HCUS20140328862 SEQ ID NO: 265 7842 HIV224 Heavy chain 3A18HCUS20140328862 SEQ ID NO: 266 7843 HIV225 Heavy chain 3A204HCUS20140328862 SEQ ID NO: 267 7844 HIV226 Heavy chain 3A228HCUS20140328862 SEQ ID NO: 268 7845 HIV227 Heavy chain 3A233HCUS20140328862 SEQ ID NO: 269 7846 HIV228 Heavy chain 3A244HCUS20140328862 SEQ ID NO: 270 7847 HIV229 Heavy chain 3A255HCUS20140328862 SEQ ID NO: 271 7848 HIV230 Heavy chain 3A296HCUS20140328862 SEQ ID NO: 272 7849 HIV231 Heavy chain 3A334HCUS20140328862 SEQ ID NO: 273 7850 HIV232 Heavy chain 3A366HCUS20140328862 SEQ ID NO: 274 7851 HIV233 Heavy chain 3A381HCUS20140328862 SEQ ID NO: 275 7852 HIV234 Heavy chain 3A384HCUS20140328862 SEQ ID NO: 276 7853 HIV235 Heavy chain 3A419HCUS20140328862 SEQ ID NO: 277 7854 HIV236 Heavy chain 3a426hcUS20140328862 SEQ ID NO: 343 7855 HIV237 Heavy chain 3A461HCUS20140328862 SEQ ID NO: 278 7856 HIV238 Heavy chain 3A474HCUS20140328862 SEQ ID NO: 279 7857 HIV239 Heavy chain 3a515hcUS20140328862 SEQ ID NO: 344 7858 HIV240 Heavy chain 3A518HCUS20140328862 SEQ ID NO: 280 7859 HIV241 Heavy chain 3A539HCUS20140328862 SEQ ID NO: 281 7860 HIV242 Heavy chain 3A576HCUS20140328862 SEQ ID NO: 282 7861 HIV243 Heavy chain 3A613HCUS20140328862 SEQ ID NO: 283 7862 HIV244 Heavy chain 3A64HCUS20140328862 SEQ ID NO: 284 7863 HIV245 Heavy chain 3A650HCUS20140328862 SEQ ID NO: 285 7864 HIV246 Heavy chain 3A67HCUS20140328862 SEQ ID NO: 286 7865 HIV247 Heavy chain 3A779HCUS20140328862 SEQ ID NO: 287 7866 HIV248 Heavy chain 3A816HCUS20140328862 SEQ ID NO: 288 7867 HIV249 Heavy chain 3A869HCUS20140328862 SEQ ID NO: 289 7868 HIV250 Heavy chain 3A93HCUS20140328862 SEQ ID NO: 290 7869 HIV251 Heavy chain 3A966HCUS20140328862 SEQ ID NO: 291 7870 HIV252 Heavy chain 3A978HCUS20140328862 SEQ ID NO: 292 7871 HIV253 Heavy chain 3ANC32HCUS20140328862 SEQ ID NO: 346 7872 HIV254 Heavy chain 3ANC3HCUS20140328862 SEQ ID NO: 293 7873 HIV255 Heavy chain 3ANC3HCUS20140328862 SEQ ID NO: 347 7874 HIV256 Heavy chain 3ANC41HCUS20140328862 SEQ ID NO: 348 7875 HIV257 Heavy chain 3ANC42HCUS20140328862 SEQ ID NO: 294 7876 HIV258 Heavy chain 3ANC42HCUS20140328862 SEQ ID NO: 349 7877 HIV259 Heavy chain 3ANC66HCUS20140328862 SEQ ID NO: 295 7878 HIV260 Heavy chain 3ANC66HCUS20140328862 SEQ ID NO: 350 7879 HIV261 Heavy chain 3ANC70HCUS20140328862 SEQ ID NO: 351 7880 HIV262 Heavy chain 3ANC75HCUS20140328862 SEQ ID NO: 352 7881 HIV263 Heavy chain 3ANC79HCUS20140328862 SEQ ID NO: 296 7882 HIV264 Heavy chain 3ANC79HCUS20140328862 SEQ ID NO: 353 7883 HIV265 Heavy chain 3ANC87HCUS20140328862 SEQ ID NO: 354 7884 HIV266 Heavy chain 3ANC8HCUS20140328862 SEQ ID NO: 355 7885 HIV267 Heavy chain 3ANC96HCUS20140328862 SEQ ID NO: 356 7886 HIV268 Heavy chain 3B106HCUS20140328862 SEQ ID NO: 357 7887 HIV269 Heavy chain 3B10HCUS20140328862 SEQ ID NO: 297 7888 HIV270 Heavy chain 3B120HCUS20140328862 SEQ ID NO: 298 7889 HIV271 Heavy chain 3B126HCUS20140328862 SEQ ID NO: 299 7890 HIV272 Heavy chain 3B129HCUS20140328862 SEQ ID NO: 300 7891 HIV273 Heavy chain 3B142HCUS20140328862 SEQ ID NO: 301 7892 HIV274 Heavy chain 3B154HCUS20140328862 SEQ ID NO: 302 7893 HIV275 Heavy chain 3B165HCUS20140328862 SEQ ID NO: 303 7894 HIV276 Heavy chain 3B16HCUS20140328862 SEQ ID NO: 358 7895 HIV277 Heavy chain 3B171HCUS20140328862 SEQ ID NO: 304 7896 HIV278 Heavy chain 3B17HCUS20140328862 SEQ ID NO: 305 7897 HIV279 Heavy chain 3B180HCUS20140328862 SEQ ID NO: 359 7898 HIV280 Heavy chain 3B183HCUS20140328862 SEQ ID NO: 360 7899 HIV281 Heavy chain 3B186HCUS20140328862 SEQ ID NO: 306 7900 HIV282 Heavy chain 3B191HCUS20140328862 SEQ ID NO: 361 7901 HIV283 Heavy chain 3B193HCUS20140328862 SEQ ID NO: 307 7902 HIV284 Heavy chain 3B21HCUS20140328862 SEQ ID NO: 362 7903 HIV285 Heavy chain 3B22HCUS20140328862 SEQ ID NO: 308 7904 HIV286 Heavy chain 3B27HCUS20140328862 SEQ ID NO: 309 7905 HIV287 Heavy chain 3B29HCUS20140328862 SEQ ID NO: 310 7906 HIV288 Heavy chain 3B2HC US20140328862SEQ ID NO: 311 7907 HIV289 Heavy chain 3B31HC US20140328862 SEQ ID NO:312 7908 HIV290 Heavy chain 3B33HC US20140328862 SEQ ID NO: 313 7909HIV291 Heavy chain 3B40HC US20140328862 SEQ ID NO: 314 7910 HIV292 Heavychain 3B41HC US20140328862 SEQ ID NO: 315 7911 HIV293 Heavy chain 3B44HCUS20140328862 SEQ ID NO: 316 7912 HIV294 Heavy chain 3B45HCUS20140328862 SEQ ID NO: 317 7913 HIV295 Heavy chain 3b46HCUS20140328862 SEQ ID NO: 345 7914 HIV296 Heavy chain 3B48HCUS20140328862 SEQ ID NO: 318 7915 HIV297 Heavy chain 3B50HCUS20140328862 SEQ ID NO: 319 7916 HIV298 Heavy chain 3B51HCUS20140328862 SEQ ID NO: 320 7917 HIV299 Heavy chain 3B56HCUS20140328862 SEQ ID NO: 321 7918 HIV300 Heavy chain 3B57HCUS20140328862 SEQ ID NO: 322 7919 HIV301 Heavy chain 3B5HC US20140328862SEQ ID NO: 323 7920 HIV302 Heavy chain 3B61HC US20140328862 SEQ ID NO:324 7921 HIV303 Heavy chain 3B6HC US20140328862 SEQ ID NO: 325 7922HIV304 Heavy chain 3B77HC US20140328862 SEQ ID NO: 326 7923 HIV305 Heavychain 3B79HC US20140328862 SEQ ID NO: 327 7924 HIV306 Heavy chain 3B84HCUS20140328862 SEQ ID NO: 328 7925 HIV307 Heavy chain 3B86HCUS20140328862 SEQ ID NO: 329 7926 HIV308 Heavy chain 3B8HC US20140328862SEQ ID NO: 330 7927 HIV309 Heavy chain 3B93HC US20140328862 SEQ ID NO:331 7928 HIV310 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 363 7929HIV311 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 364 7930 HIV312 Heavychain 3BBM60 US20140328862 SEQ ID NO: 365 7931 HIV313 Heavy chain 3BBM60US20140328862 SEQ ID NO: 366 7932 HIV314 Heavy chain 3BBM60US20140328862 SEQ ID NO: 367 7933 HIV315 Heavy chain 3BBM60US20140328862 SEQ ID NO: 368 7934 HIV316 Heavy chain 3BBM60US20140328862 SEQ ID NO: 369 7935 HIV317 Heavy chain 3BBM60US20140328862 SEQ ID NO: 370 7936 HIV318 Heavy chain 3BBM60US20140328862 SEQ ID NO: 371 7937 HIV319 Heavy chain 3BBM60US20140328862 SEQ ID NO: 372 7938 HIV320 Heavy chain 3BBM60US20140328862 SEQ ID NO: 373 7939 HIV321 Heavy chain 3BBM60US20140328862 SEQ ID NO: 374 7940 HIV322 Heavy chain 3BBM60US20140328862 SEQ ID NO: 375 7941 HIV323 Heavy chain 3BBM60US20140328862 SEQ ID NO: 376 7942 HIV324 Heavy chain 3BBM60US20140328862 SEQ ID NO: 377 7943 HIV325 Heavy chain 3BNC101HCUS20140328862 SEQ ID NO: 332 7944 HIV326 Heavy chain 3BNC101HCUS20140328862 SEQ ID NO: 378 7945 HIV327 Heavy chain 3BNC102HCUS20140328862 SEQ ID NO: 379 7946 HIV328 Heavy chain 3BNC104HCUS20140328862 SEQ ID NO: 380 7947 HIV329 Heavy chain 3BNC105HCUS20140328862 SEQ ID NO: 381 7948 HIV330 Heavy chain 3BNC106HCUS20140328862 SEQ ID NO: 382 7949 HIV331 Heavy chain 3BNC107HCUS20140328862 SEQ ID NO: 383 7950 HIV332 Heavy chain 3BNC108HCUS20140328862 SEQ ID NO: 384 7951 HIV333 Heavy chain 3BNC10HCUS20140328862 SEQ ID NO: 385 7952 HIV334 Heavy chain 3BNC114HCUS20140328862 SEQ ID NO: 386 7953 HIV335 Heavy Chain 3bnc117 Zhou T etal., Immunity 39 (2), 245-258 (2013), 7954 NCBI Accession # 4LSV_H(226aa) HIV336 Heavy chain 3BNC117HC US20140328862 SEQ ID NO: 387 7955HIV337 Heavy chain 3BNC124HC US20140328862 SEQ ID NO: 333 7956 HIV338Heavy chain 3BNC126HC US20140328862 SEQ ID NO: 388 7957 HIV339 Heavychain 3BNC127HC US20140328862 SEQ ID NO: 389 7958 HIV340 Heavy chain3BNC130HC US20140328862 SEQ ID NO: 334 7959 HIV341 Heavy chain 3BNC134HCUS20140328862 SEQ ID NO: 390 7960 HIV342 Heavy chain 3BNC140HCUS20140328862 SEQ ID NO: 391 7961 HIV343 Heavy chain 3BNC141HCUS20140328862 SEQ ID NO: 392 7962 HIV344 Heavy chain 3BNC142HCUS20140328862 SEQ ID NO: 393 7963 HIV345 Heavy chain 3BNC148HCUS20140328862 SEQ ID NO: 394 7964 HIV346 Heavy chain 3BNC149HCUS20140328862 SEQ ID NO: 335 7965 HIV347 Heavy chain 3BNC149HCUS20140328862 SEQ ID NO: 395 7966 HIV348 Heavy chain 3BNC151HCUS20140328862 SEQ ID NO: 396 7967 HIV349 Heavy chain 3BNC153HCUS20140328862 SEQ ID NO: 397 7968 HIV350 Heavy chain 3BNC156HCUS20140328862 SEQ ID NO: 398 7969 HIV351 Heavy chain 3BNC158HCUS20140328862 SEQ ID NO: 399 7970 HIV352 Heavy chain 3BNC159HCUS20140328862 SEQ ID NO: 400 7971 HIV353 Heavy chain 3BNC15HCUS20140328862 SEQ ID NO: 401 7972 HIV354 Heavy chain 3BNC173HCUS20140328862 SEQ ID NO: 402 7973 HIV355 Heavy chain 3BNC175HCUS20140328862 SEQ ID NO: 403 7974 HIV356 Heavy chain 3BNC176HCUS20140328862 SEQ ID NO: 404 7975 HIV357 Heavy chain 3BNC177HCUS20140328862 SEQ ID NO: 336 7976 HIV358 Heavy chain 3BNC17HCUS20140328862 SEQ ID NO: 337 7977 HIV359 Heavy chain 3BNC181HCUS20140328862 SEQ ID NO: 405 7978 HIV360 Heavy chain 3BNC186HCUS20140328862 SEQ ID NO: 406 7979 HIV361 Heavy chain 3BNC18HCUS20140328862 SEQ ID NO: 407 7980 HIV362 Heavy chain 3BNC193HCUS20140328862 SEQ ID NO: 408 7981 HIV363 Heavy chain 3BNC196HCUS20140328862 SEQ ID NO: 409 7982 HIV364 Heavy chain 3BNC20HCUS20140328862 SEQ ID NO: 410 7983 HIV365 Heavy chain 3BNC29HCUS20140328862 SEQ ID NO: 411 7984 HIV366 Heavy chain 3BNC31HCUS20140328862 SEQ ID NO: 412 7985 HIV367 Heavy chain 3BNC33HCUS20140328862 SEQ ID NO: 413 7986 HIV368 Heavy chain 3BNC42HCUS20140328862 SEQ ID NO: 414 7987 HIV369 Heavy chain 3BNC44HCUS20140328862 SEQ ID NO: 415 7988 HIV370 Heavy chain 3BNC45HCUS20140328862 SEQ ID NO: 416 7989 HIV371 Heavy chain 3BNC48HCUS20140328862 SEQ ID NO: 338 7990 HIV372 Heavy chain 3BNC53HCUS20140328862 SEQ ID NO: 417 7991 HIV373 Heavy chain 3BNC54HCUS20140328862 SEQ ID NO: 418 7992 HIV374 Heavy chain 3BNC55HCUS20140328862 SEQ ID NO: 419 7993 HIV375 Heavy chain 3BNC58HCUS20140328862 SEQ ID NO: 339 7994 HIV376 Heavy chain 3BNC59HCUS20140328862 SEQ ID NO: 420 7995 HIV377 Heavy chain 3BNC60HCUS20140328862 SEQ ID NO: 421 7996 HIV378 Heavy chain 3BNC62HCUS20140328862 SEQ ID NO: 422 7997 HIV379 Heavy chain 3BNC64HCUS20140328862 SEQ ID NO: 423 7998 HIV380 Heavy chain 3BNC65HCUS20140328862 SEQ ID NO: 424 7999 HIV381 Heavy chain 3BNC66HCUS20140328862 SEQ ID NO: 425 8000 HIV382 Heavy chain 3BNC6HCUS20140328862 SEQ ID NO: 426 8001 HIV383 Heavy chain 3BNC72HCUS20140328862 SEQ ID NO: 427 8002 HIV384 Heavy chain 3BNC75HCUS20140328862 SEQ ID NO: 428 8003 HIV385 Heavy chain 3BNC78HCUS20140328862 SEQ ID NO: 340 8004 HIV386 Heavy chain 3BNC79HCUS20140328862 SEQ ID NO: 429 8005 HIV387 Heavy chain 3BNC81HCUS20140328862 SEQ ID NO: 430 8006 HIV388 Heavy chain 3BNC82HCUS20140328862 SEQ ID NO: 341 8007 HIV389 Heavy chain 3BNC84HCUS20140328862 SEQ ID NO: 431 8008 HIV390 Heavy chain 3BNC86HCUS20140328862 SEQ ID NO: 432 8009 HIV391 Heavy chain 3BNC87HCUS20140328862 SEQ ID NO: 433 8010 HIV392 Heavy chain 3BNC89HCUS20140328862 SEQ ID NO: 434 8011 HIV393 Heavy chain 3BNC8HCUS20140328862 SEQ ID NO: 342 8012 HIV394 Heavy chain 3BNC91HCUS20140328862 SEQ ID NO: 435 8013 HIV395 Heavy chain 3BNC92HCUS20140328862 SEQ ID NO: 436 8014 HIV396 Heavy chain 3BNC94HCUS20140328862 SEQ ID NO: 437 8015 HIV397 Heavy chain 3BNC95HCUS20140328862 SEQ ID NO: 438 8016 HIV398 Heavy Chain 412d Huang et al.,Science 317 (5846), 1930-1934 8017 (2007), NCBI Accession # 2QAD_H(231aa) HIV399 Heavy chain 43243_3 US20140205607 Table S14 8018 HIV400Heavy chain 43359_2 US20140205607 Table S14 8019 HIV401 Heavy chain43555_1 US20140205607 Table S14 8020 HIV402 Heavy chain 43567_2US20140205607 Table S14 8021 HIV403 Heavy Chain 44-vrc13.01 Zhou T etal., Structural Repertoire of HIV-1- 8022 Neutralizing AntibodiesTargeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292(2015), NCBI Accession # 4YDJ_A(238aa) HIV404 Heavy chain 45-46m2Diskin, R., et al., Restricting HIV-1 pathways 8023 for escape usingrationally designed anti-HIV-1 antibodies; J. Exp. Med. 210 (6),1235-1249 (2013), NCBI Accession # 4JKP_H (229aa) HIV405 Heavy chain46260_1 US20140205607 Table S14 8024 HIV406 Heavy chain 47890_1US20140205607 Table S14 8025 HIV407 Heavy Chain 4e10 Fv Finton, K. A.,et al., PLoS Pathol. 9 (9), 8026 E1003639 (2013), NCBI Accession #4LLV_A (129aa) HIV408 Heavy chain 53821_1 US20140205607 Table S14 8027HIV409 Heavy chain 57729_2 US20140205607 Table S14 8028 HIV410 Heavychain 61048_1 US20140205607 Table S14 8029 HIV411 Heavy chain 69713_1US20140205607 Table S14 8030 HIV412 Heavy chain 70679_1 US20140205607Table S14 8031 HIV413 Heavy chain 71632_2 US20140205607 Table S14 8032HIV414 Heavy chain 74400_3 US20140205607 Table S14 8033 HIV415 Heavychain 74511_1 US20140205607 Table S14 8034 HIV416 Heavy chain 76927_2US20140205607 Table S14 8035 HIV417 Heavy Chain 7b2 Santra, S., et al.,PLoS Pathol. 11 (8), 8036 E1005042 (2015), NCBI Accession # 4YDV_H(252aa) HIV418 Heavy chain 7H6 US20140348785 SEQ ID NO: 3 8037 HIV419Heavy chain 7N16 US20140348785 SEQ ID NO: 5 8038 HIV420 Heavy chain8460_4 US20140205607 Table S14 8039 HIV421 Heavy chain 86277_2US20140205607 Table S14 8040 HIV422 Heavy chain 86343_1 US20140205607Table S14 8041 HIV423 Heavy chain 86984_2 US20140205607 Table S14 8042HIV424 Heavy chain 89680_4 US20140205607 Table S14 8043 HIV425 Heavychain 8A253HC US20140328862 SEQ ID NO: 5 8044 HIV426 Heavy chain 8A275HCUS20140328862 SEQ ID NO: 6 8045 HIV427 Heavy chain 8ABM11 US20140328862SEQ ID NO: 7 8046 HIV428 Heavy chain 8ABM12 US20140328862 SEQ ID NO: 88047 HIV429 Heavy chain 8ABM13 US20140328862 SEQ ID NO: 9 8048 HIV430Heavy chain 8ABM14 US20140328862 SEQ ID NO: 10 8049 HIV431 Heavy chain8ABM20 US20140328862 SEQ ID NO: 11 8050 HIV432 Heavy chain 8ABM24US20140328862 SEQ ID NO: 12 8051 HIV433 Heavy chain 8ABM26 US20140328862SEQ ID NO: 13 8052 HIV434 Heavy chain 8ABM27 US20140328862 SEQ ID NO: 148053 HIV435 Heavy chain 8ANC103HC US20140328862 SEQ ID NO: 36 8054HIV436 Heavy chain 8ANC105HC US20140328862 SEQ ID NO: 15 8055 HIV437Heavy chain 8ANC106HC US20140328862 SEQ ID NO: 37 8056 HIV438 Heavychain 8ANC107HC US20140328862 SEQ ID NO: 38 8057 HIV439 Heavy chain8ANC108HC US20140328862 SEQ ID NO: 39 8058 HIV440 Heavy chain 8ANC109HCUS20140328862 SEQ ID NO: 40 8059 HIV441 Heavy chain 8ANC10HCUS20140328862 SEQ ID NO: 41 8060 HIV442 Heavy chain 8ANC111HCUS20140328862 SEQ ID NO: 42 8061 HIV443 Heavy chain 8ANC112HCUS20140328862 SEQ ID NO: 43 8062 HIV444 Heavy chain 8ANC113HCUS20140328862 SEQ ID NO: 44 8063 HIV445 Heavy chain 8ANC114HCUS20140328862 SEQ ID NO: 45 8064 HIV446 Heavy chain 8ANC115HCUS20140328862 SEQ ID NO: 46 8065 HIV447 Heavy chain 8ANC116HCUS20140328862 SEQ ID NO: 16 8066 HIV448 Heavy chain 8ANC117HCUS20140328862 SEQ ID NO: 47 8067 HIV449 Heavy chain 8ANC11HCUS20140328862 SEQ ID NO: 48 8068 HIV450 Heavy chain 8ANC121HCUS20140328862 SEQ ID NO: 49 8069 HIV451 Heavy chain 8ANC126HCUS20140328862 SEQ ID NO: 50 8070 HIV452 Heavy chain 8ANC127HCUS20140328862 SEQ ID NO: 17 8071 HIV453 Heavy chain 8ANC130HCUS20140328862 SEQ ID NO: 51 8072 HIV454 Heavy Chain 8anc131 Zhou T etal., Structural Repertoire of HIV-1- 8073 Neutralizing AntibodiesTargeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292(2015), NCBI Accession # 4RWY_H (227aa) HIV455 Heavy chain 8ANC131HCUS20140328862 SEQ ID NO: 18 8074 HIV456 Heavy chain 8ANC132HCUS20140328862 SEQ ID NO: 52 8075 HIV457 Heavy chain 8ANC133HCUS20140328862 SEQ ID NO: 53 8076 HIV458 Heavy Chain 8anc134 Zhou T etal., Structural Repertoire of HIV-1- 8077 Neutralizing AntibodiesTargeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292(2015), NCBI Accession # 4RX4_H (229aa) HIV459 Heavy chain 8ANC134HCUS20140328862 SEQ ID NO: 19 8078 HIV460 Heavy chain 8ANC136HCUS20140328862 SEQ ID NO: 54 8079 HIV461 Heavy chain 8ANC137HCUS20140328862 SEQ ID NO: 55 8080 HIV462 Heavy chain 8ANC139HCUS20140328862 SEQ ID NO: 56 8081 HIV463 Heavy chain 8ANC13HCUS20140328862 SEQ ID NO: 20 8082 HIV464 Heavy chain 8ANC140HCUS20140328862 SEQ ID NO: 57 8083 HIV465 Heavy chain 8ANC142HCUS20140328862 SEQ ID NO: 58 8084 HIV466 Heavy chain 8ANC143HCUS20140328862 SEQ ID NO: 59 8085 HIV467 Heavy chain 8ANC144HCUS20140328862 SEQ ID NO: 60 8086 HIV468 Heavy chain 8ANC145HCUS20140328862 SEQ ID NO: 61 8087 HIV469 Heavy chain 8ANC146HCUS20140328862 SEQ ID NO: 62 8088 HIV470 Heavy chain 8ANC147HCUS20140328862 SEQ ID NO: 63 8089 HIV471 Heavy chain 8ANC148HCUS20140328862 SEQ ID NO: 64 8090 HIV472 Heavy chain 8ANC149HCUS20140328862 SEQ ID NO: 65 8091 HIV473 Heavy chain 8ANC14HCUS20140328862 SEQ ID NO: 66 8092 HIV474 Heavy chain 8ANC150HCUS20140328862 SEQ ID NO: 67 8093 HIV475 Heavy chain 8ANC151HCUS20140328862 SEQ ID NO: 68 8094 HIV476 Heavy chain 8ANC153HCUS20140328862 SEQ ID NO: 69 8095 HIV477 Heavy chain 8ANC154HCUS20140328862 SEQ ID NO: 70 8096 HIV478 Heavy chain 8ANC155HCUS20140328862 SEQ ID NO: 71 8097 HIV479 Heavy chain 8ANC156HCUS20140328862 SEQ ID NO: 72 8098 HIV480 Heavy chain 8ANC157HCUS20140328862 SEQ ID NO: 73 8099 HIV481 Heavy chain 8ANC158HCUS20140328862 SEQ ID NO: 74 8100 HIV482 Heavy chain 8ANC160HCUS20140328862 SEQ ID NO: 75 8101 HIV483 Heavy chain 8ANC161HCUS20140328862 SEQ ID NO: 76 8102 HIV484 Heavy chain 8ANC162HCUS20140328862 SEQ ID NO: 77 8103 HIV485 Heavy chain 8ANC163HCUS20140328862 SEQ ID NO: 78 8104 HIV486 Heavy chain 8ANC164HCUS20140328862 SEQ ID NO: 79 8105 HIV487 Heavy chain 8ANC165HCUS20140328862 SEQ ID NO: 80 8106 HIV488 Heavy chain 8ANC166HCUS20140328862 SEQ ID NO: 81 8107 HIV489 Heavy chain 8ANC168HCUS20140328862 SEQ ID NO: 82 8108 HIV490 Heavy chain 8ANC169HCUS20140328862 SEQ ID NO: 83 8109 HIV491 Heavy chain 8ANC16HCUS20140328862 SEQ ID NO: 84 8110 HIV492 Heavy chain 8ANC171HCUS20140328862 SEQ ID NO: 21 8111 HIV493 Heavy chain 8ANC173HCUS20140328862 SEQ ID NO: 85 8112 HIV494 Heavy chain 8ANC174HCUS20140328862 SEQ ID NO: 86 8113 HIV495 Heavy chain 8ANC175HCUS20140328862 SEQ ID NO: 87 8114 HIV496 Heavy chain 8ANC176HCUS20140328862 SEQ ID NO: 88 8115 HIV497 Heavy chain 8ANC177HCUS20140328862 SEQ ID NO: 89 8116 HIV498 Heavy chain 8ANC178HCUS20140328862 SEQ ID NO: 90 8117 HIV499 Heavy chain 8ANC179HCUS20140328862 SEQ ID NO: 91 8118 HIV500 Heavy chain 8ANC17HCUS20140328862 SEQ ID NO: 92 8119 HIV501 Heavy chain 8ANC18 US20140328862SEQ ID NO: 22 8120 HIV502 Heavy chain 8ANC180HC US20140328862 SEQ ID NO:93 8121 HIV503 Heavy chain 8ANC181HC US20140328862 SEQ ID NO: 94 8122HIV504 Heavy chain 8ANC182HC US20140328862 SEQ ID NO: 23 8123 HIV505Heavy chain 8ANC184HC US20140328862 SEQ ID NO: 95 8124 HIV506 Heavychain 8ANC185HC US20140328862 SEQ ID NO: 96 8125 HIV507 Heavy chain8ANC186HC US20140328862 SEQ ID NO: 97 8126 HIV508 Heavy chain 8ANC187HCUS20140328862 SEQ ID NO: 98 8127 HIV509 Heavy chain 8ANC188HCUS20140328862 SEQ ID NO: 99 8128 HIV510 Heavy chain 8ANC191HCUS20140328862 SEQ ID NO: 100 8129 HIV511 Heavy chain 8ANC192HCUS20140328862 SEQ ID NO: 24 8130 HIV512 Heavy chain 8ANC193HCUS20140328862 SEQ ID NO: 101 8131 HIV513 Heavy chain 8ANC194HCUS20140328862 SEQ ID NO: 102 8132 HIV514 Heavy chain 8ANC195HCUS20140328862 SEQ ID NO: 103 8133 HIV515 Heavy chain 8ANC196HCUS20140328862 SEQ ID NO: 104 8134 HIV516 Heavy chain 8ANC20HCUS20140328862 SEQ ID NO: 105 8135 HIV517 Heavy chain 8ANC21HCUS20140328862 SEQ ID NO: 106 8136 HIV518 Heavy chain 8ANC22HCUS20140328862 SEQ ID NO: 25 8137 HIV519 Heavy chain 8ANC24HCUS20140328862 SEQ ID NO: 107 8138 HIV520 Heavy chain 8ANC25HCUS20140328862 SEQ ID NO: 108 8139 HIV521 Heavy chain 8ANC26HCUS20140328862 SEQ ID NO: 26 8140 HIV522 Heavy chain 8ANC27HCUS20140328862 SEQ ID NO: 109 8141 HIV523 Heavy chain 8ANC2HCUS20140328862 SEQ ID NO: 27 8142 HIV524 Heavy chain 8ANC30HCUS20140328862 SEQ ID NO: 28 8143 HIV525 Heavy chain 8ANC31HCUS20140328862 SEQ ID NO: 110 8144 HIV526 Heavy chain 8ANC33HCUS20140328862 SEQ ID NO: 111 8145 HIV527 Heavy chain 8ANC34HCUS20140328862 SEQ ID NO: 112 8146 HIV528 Heavy chain 8ANC36HCUS20140328862 SEQ ID NO: 113 8147 HIV529 Heavy chain 8ANC37HCUS20140328862 SEQ ID NO: 29 8148 HIV530 Heavy chain 8ANC38HCUS20140328862 SEQ ID NO: 114 8149 HIV531 Heavy chain 8ANC39HCUS20140328862 SEQ ID NO: 115 8150 HIV532 Heavy chain 8ANC3HCUS20140328862 SEQ ID NO: 116 8151 HIV533 Heavy chain 8ANC40HCUS20140328862 SEQ ID NO: 30 8152 HIV534 Heavy chain 8ANC41HCUS20140328862 SEQ ID NO: 31 8153 HIV535 Heavy chain 8ANC43HCUS20140328862 SEQ ID NO: 117 8154 HIV536 Heavy chain 8ANC45HCUS20140328862 SEQ ID NO: 32 8155 HIV537 Heavy chain 8ANC46HCUS20140328862 SEQ ID NO: 118 8156 HIV538 Heavy chain 8ANC48HCUS20140328862 SEQ ID NO: 119 8157 HIV539 Heavy chain 8ANC49HCUS20140328862 SEQ ID NO: 120 8158 HIV540 Heavy chain 8ANC50HCUS20140328862 SEQ ID NO: 33 8159 HIV541 Heavy chain 8ANC51HCUS20140328862 SEQ ID NO: 121 8160 HIV542 Heavy chain 8ANC53HCUS20140328862 SEQ ID NO: 34 8161 HIV543 Heavy chain 8ANC57HCUS20140328862 SEQ ID NO: 122 8162 HIV544 Heavy chain 8ANC58HCUS20140328862 SEQ ID NO: 123 8163 HIV545 Heavy chain 8ANC5HCUS20140328862 SEQ ID NO: 124 8164 HIV546 Heavy chain 8ANC60HCUS20140328862 SEQ ID NO: 125 8165 HIV547 Heavy chain 8ANC63HCUS20140328862 SEQ ID NO: 126 8166 HIV548 Heavy chain 8ANC65HCUS20140328862 SEQ ID NO: 127 8167 HIV549 Heavy chain 8ANC67HCUS20140328862 SEQ ID NO: 128 8168 HIV550 Heavy chain 8ANC69HCUS20140328862 SEQ ID NO: 129 8169 HIV551 Heavy chain 8ANC6HCUS20140328862 SEQ ID NO: 130 8170 HIV552 Heavy chain 8ANC70HCUS20140328862 SEQ ID NO: 131 8171 HIV553 Heavy chain 8ANC71HCUS20140328862 SEQ ID NO: 132 8172 HIV554 Heavy chain 8ANC72HCUS20140328862 SEQ ID NO: 133 8173 HIV555 Heavy chain 8ANC74HCUS20140328862 SEQ ID NO: 134 8174 HIV556 Heavy chain 8ANC75HCUS20140328862 SEQ ID NO: 135 8175 HIV557 Heavy chain 8ANC76HCUS20140328862 SEQ ID NO: 136 8176 HIV558 Heavy chain 8ANC78HCUS20140328862 SEQ ID NO: 137 8177 HIV559 Heavy chain 8ANC79HCUS20140328862 SEQ ID NO: 138 8178 HIV560 Heavy chain 8ANC7HCUS20140328862 SEQ ID NO: 139 8179 HIV561 Heavy chain 8ANC80HCUS20140328862 SEQ ID NO: 140 8180 HIV562 Heavy chain 8ANC82HCUS20140328862 SEQ ID NO: 141 8181 HIV563 Heavy chain 8ANC83HCUS20140328862 SEQ ID NO: 142 8182 HIV564 Heavy chain 8ANC88HCUS20140328862 SEQ ID NO: 35 8183 HIV565 Heavy chain 8ANC91HCUS20140328862 SEQ ID NO: 143 8184 HIV566 Heavy chain 8ANC92HCUS20140328862 SEQ ID NO: 144 8185 HIV567 Heavy chain 8ANC93HCUS20140328862 SEQ ID NO: 145 8186 HIV568 Heavy chain 8ANC9HCUS20140328862 SEQ ID NO: 146 8187 HIV569 Heavy chain 94565_1US20140205607 Table S14 8188 HIV570 Heavy chain 95589_2 US20140205607Table S14 8189 HIV571 Heavy chain 96298_1 US20140205607 Table S14 8190HIV572 Heavy chain 9815_2 US20140205607 Table S14 8191 HIV573 Heavychain 99473_3 US20140205607 Table S14 8192 HIV574 Heavy chain 99989_1US20140205607 Table S14 8193 HIV575 Heavy chain Antibody US20140328862SEQ ID NO: 439 8194 HIV576 Heavy chain Anti-HcG Fotinou C. et al“Structure of an Fab fragment 8195 against a C-terminal peptide of hCGat 2.0 A resolution” J. Biol. Chem. 273 (35), 22515- 22518 (1998); NCBIAccession # 1SBS_H HIV577 Heavy Chain B12 Zhou T et al., Structuraldefinition of a 8196 conserved neutralization epitope on HIV-1 gp120;Nature 445 (7129), 732-737 (2007), NCBI Accession # 2NY7_H (230aa)HIV578 Heavy Chain C38-vrc16.01 Zhou T et al., Structural Repertoire ofHIV-1- 8197 Neutralizing Antibodies Targeting the CD4 Supersite in 14Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDK_H (234aa)HIV579 Heavy Chain C38-vrc18.02 Zhou T et al., Structural Repertoire ofHIV-1- 8198 Neutralizing Antibodies Targeting the CD4 Supersite in 14Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDL_H (226aa)HIV580 Heavy chain CAP256- WO2015128846 SEQ ID NO: 13 8199 VRC26.01HIV581 Heavy chain CAP256- WO2015128846 SEQ ID NO: 17 8200 VRC26.02HIV582 Heavy chain CAP256- WO2015128846 SEQ ID NO: 21 8201 VRC26.03HIV583 Heavy chain CAP256- WO2015128846 SEQ ID NO: 25 8202 VRC26.04HIV584 Heavy chain CAP256- WO2015128846 SEQ ID NO: 29 8203 VRC26.05HIV585 Heavy chain CAP256- WO2015128846 SEQ ID NO: 33 8204 VRC26.06HIV586 Heavy chain CAP256- WO2015128846 SEQ ID NO: 37 8205 VRC26.07HIV587 Heavy chain CAP256- WO2015128846 SEQ ID NO: 41 8206 VRC26.08HIV588 Heavy chain CAP256- WO2015128846 SEQ ID NO: 45 8207 VRC26.09HIV589 Heavy chain CAP256- WO2015128846 SEQ ID NO: 49 8208 VRC26.10HIV590 Heavy chain CAP256- WO2015128846 SEQ ID NO: 53 8209 VRC26.11HIV591 Heavy chain CAP256- WO2015128846 SEQ ID NO: 57 8210 VRC26.12HIV592 Heavy chain CAP256- WO2015128846 SEQ ID NO: 170 8211 VRC26.25HIV593 Heavy chain CAP256- WO2015128846 SEQ ID NO: 178 8212 VRC26.26HIV594 Heavy chain CAP256- WO2015128846 SEQ ID NO: 186 8213 VRC26.27HIV595 Heavy chain CAP256- WO2015128846 SEQ ID NO: 5 8214 VRC26-I1HIV596 Heavy chain CAP256- WO2015128846 SEQ ID NO: 9 8215 VRC26-I2.HIV597 Heavy chain CAP256- WO2015128846 SEQ ID NO: 1 8216 VRC26- UCA.HIV598 Heavy chain construct WO2015013390 SEQ ID NO: 3 8217 #2816, #2859HIV599 Heavy chain construct WO2015013390 SEQ ID NO: 4 8218 #2817 HIV600Heavy chain construct WO2015013390 SEQ ID NO: 8 8219 #2858, #2860 HIV601Heavy Chain Fab 2219 Stanfield, R. L., et al., J. Virol. 80 (12), 6093-8220 6105 (2006), NCBI Accession # 2B0S_H (226aa) HIV602 Heavy Chain Fab2g12 Doores. K. J., et al., J. Virol. 84 (20), 10690- 8221 10699 (2010),NCBI Accession # 3OAU_H (225aa) HIV603 Heavy Chain Fab 2g12 Stanfield,R. L. et al., Crystal structure of the 8222 HIV neutralizing antibody2G12 in complex with a bacterial oligosaccharide analog of mammalianoligomannose; Glycobiology 25 (4), 412-419 (2015), NCBI Accession #4RBP_H (224aa) HIV604 Heavy Chain Fab F425- Bell et al., J. Mol. Biol.375 (4), 969-978 8223 b4e8 (2008), NCBI Accession # 2QSC_H (222aa)HIV605 Heavy chain fusion protein US20080038280 SEQ ID NO: 5 8224 of A32and m9 HIV606 Heavy chain g20 WO2015117008 SEQ ID NO: 4 8225 HIV607Heavy chain g22 WO2015117008 SEQ ID NO: 7 8226 HIV608 Heavy chain g23WO2015117008 SEQ ID NO: 2 8227 HIV609 Heavy chain g3 WO2015117008 SEQ IDNO: 13 8228 HIV610 Heavy chain g4 WO2015117008 SEQ ID NO: 9 8229 HIV611Heavy chain g44 WO2015117008 SEQ ID NO: 11 8230 HIV612 Heavy chain g46WO2015117008 SEQ ID NO: 10 8231 HIV613 Heavy chain G4D US20130195881 SEQID NO: 9 8232 HIV614 Heavy chain G4H US20130195881 SEQ ID NO: 8 8233HIV615 Heavy chain g50 WO2015117008 SEQ ID NO: 12 8234 HIV616 Heavychain g52 WO2015117008 SEQ ID NO: 1 8235 HIV617 Heavy chain g59WO2015117008 SEQ ID NO: 5 8236 HIV618 Heavy chain g62 WO2015117008 SEQID NO: 6 8237 HIV619 Heavy chain g8 WO2015117008 SEQ ID NO: 3 8238HIV620 Heavy chain gl5 WO2015117008 SEQ ID NO: 8 8239 HIV621 Heavy chaingVRC- WO2013090644 SEQ ID NO: 45 8240 H5(d74)/VR C-PG04LC HIV622 Heavychain gVRCOH12(D74)/ WO2013090644 SEQ ID NO: 46 8241 VRC- PG04LC HIV623Heavy Chain I2 (unbound) Fera, D. et al., Affinity maturation in an HIV8242 From Ch103 broadly neutralizing B-cell lineage through Lineagereorientation of variable domains; Proc. Natl. Acad. Sci. U.S.A. 111(28), 10275-10280 (2014), NCBI Accession # 4QHN_A (232aa) HIV624 Heavychain IGHV3- US20140348785 SEQ ID NO: 7 8243 15*05 HIV625 Heavy chainLSSB2055HC US20140328862 SEQ ID NO: 229 8244 HIV626 Heavy chainLSSB2066HC US20140328862 SEQ ID NO: 230 8245 HIV627 Heavy chainLSSB2068HC US20140328862 SEQ ID NO: 231 8246 HIV628 Heavy chainLSSB2080HC US20140328862 SEQ ID NO: 232 8247 HIV629 Heavy chainLSSB2133HC US20140328862 SEQ ID NO: 233 8248 HIV630 Heavy chainLSSB2182HC US20140328862 SEQ ID NO: 234 8249 HIV631 Heavy chainLSSB218HC US20140328862 SEQ ID NO: 235 8250 HIV632 Heavy chainLSSB2277HC US20140328862 SEQ ID NO: 236 8251 HIV633 Heavy chainLSSB2288HC US20140328862 SEQ ID NO: 237 8252 HIV634 Heavy chainLSSB2339HC US20140328862 SEQ ID NO: 168 8253 HIV635 Heavy chainLSSB2351HC US20140328862 SEQ ID NO: 169 8254 HIV636 Heavy chainLSSB2361HC US20140328862 SEQ ID NO: 170 8255 HIV637 Heavy chainLSSB2364HC US20140328862 SEQ ID NO: 171 8256 HIV638 Heavy chainLSSB2367HC US20140328862 SEQ ID NO: 172 8257 HIV639 Heavy chainLSSB2416HC US20140328862 SEQ ID NO: 173 8258 HIV640 Heavy chainLSSB2434HC US20140328862 SEQ ID NO: 174 8259 HIV641 Heavy chainLSSB2483HC US20140328862 SEQ ID NO: 175 8260 HIV642 Heavy chainLSSB2490HC US20140328862 SEQ ID NO: 176 8261 HIV643 Heavy chainLSSB2503HC US20140328862 SEQ ID NO: 177 8262 HIV644 Heavy chainLSSB2525HC US20140328862 SEQ ID NO: 178 8263 HIV645 Heavy chainLSSB2530HC US20140328862 SEQ ID NO: 179 8264 HIV646 Heavy chainLSSB2538HC US20140328862 SEQ ID NO: 180 8265 HIV647 Heavy chainLSSB2554HC US20140328862 SEQ ID NO: 181 8266 HIV648 Heavy chainLSSB2573HC US20140328862 SEQ ID NO: 182 8267 HIV649 Heavy chainLSSB2578HC US20140328862 SEQ ID NO: 183 8268 HIV650 Heavy chainLSSB2586HC US20140328862 SEQ ID NO: 184 8269 HIV651 Heavy chainLSSB2609HC US20140328862 SEQ ID NO: 185 8270 HIV652 Heavy chainLSSB2612HC US20140328862 SEQ ID NO: 186 8271 HIV653 Heavy chainLSSB2630HC US20140328862 SEQ ID NO: 187 8272 HIV654 Heavy chainLSSB2640HC US20S40328862 SEQ ID NO: 188 8273 HIV655 Heavy chainLSSB2644HC US20140328862 SEQ ID NO: 189 8274 HIV656 Heavy chainLSSB2665HC US20S40328862 SEQ ID NO: 190 8275 HIV657 Heavy chainLSSB2666HC US20140328862 SEQ ID NO: 191 8276 HIV658 Heavy chainLSSB2669HC US20S40328862 SEQ ID NO: 192 8277 HIV659 Heavy chainLSSB2680HC US20140328862 SEQ ID NO: 193 8278 HIV660 Heavy chainLSSB2683HC US20S40328862 SEQ ID NO: 194 8279 HIV661 Heavy chainLSSB331HC US20140328862 SEQ ID NO: 238 8280 HIV662 Heavy chain LSSB344HCUS20140328862 SEQ ID NO: 195 8281 HIV663 Heavy chain LSSNEC101HCUS20140328862 SEQ ID NO: 239 8282 HIV664 Heavy chain LSSNEC106HCUS20140328862 SEQ ID NO: 240 8283 HIV665 Heavy chain LSSNEC107HCUS20140328862 SEQ ID NO: 196 8284 HIV666 Heavy chain LSSNEC108HCUS20140328862 SEQ ID NO: 197 8285 HIV667 Heavy chain LSSNEC109HCUS20140328862 SEQ ID NO: 198 8286 HIV668 Heavy chain LSSNEC110HCUS20140328862 SEQ ID NO: 199 8287 HIV669 Heavy chain LSSNEC112HCUS20140328862 SEQ ID NO: 241 8288 HIV670 Heavy chain LSSNEC115HCUS20140328862 SEQ ID NO: 242 8289 HIV671 Heavy chain LSSNEC116HCUS20140328862 SEQ ID NO: 200 8290 HIV672 Heavy chain LSSNEC117HCUS20140328862 SEQ ID NO: 201 8291 HIV673 Heavy chain LSSNEC118HCUS20140328862 SEQ ID NO: 202 8292 HIV674 Heavy chain LSSNEC11HCUS20140328862 SEQ ID NO: 203 8293 HIV675 Heavy chain LSSNEC122HCUS20140328862 SEQ ID NO: 204 8294 HIV676 Heavy chain LSSNEC123HCUS20140328862 SEQ ID NO: 205 8295 HIV677 Heavy chain LSSNEC124HCUS20140328862 SEQ ID NO: 243 8296 HIV678 Heavy chain LSSNEC125HCUS20140328862 SEQ ID NO: 244 8297 HIV679 Heavy chain LSSNEC126HCUS20140328862 SEQ ID NO: 245 8298 HIV680 Heavy chain LSSNEC127HCUS20140328862 SEQ ID NO: 206 8299 HIV681 Heavy chain LSSNEC14HCUS20140328862 SEQ ID NO: 246 8300 HIV682 Heavy chain LSSNEC16HCUS20140328862 SEQ ID NO: 247 8301 HIV683 Heavy chain LSSNEC18HCUS20140328862 SEQ ID NO: 207 8302 HIV684 Heavy chain LSSNEC21HCUS20140328862 SEQ ID NO: 248 8303 HIV685 Heavy chain LSSNEC24HCUS20140328862 SEQ ID NO: 208 8304 HIV686 Heavy chain LSSNEC29HCUS20140328862 SEQ ID NO: 209 8305 HIV687 Heavy chain LSSNEC2HCUS20140328862 SEQ ID NO: 210 8306 HIV688 Heavy chain LSSNEC30HCUS20140328862 SEQ ID NO: 249 8307 HIV689 Heavy chain LSSNEC33HCUS20140328862 SEQ ID NO: 211 8308 HIV690 Heavy chain LSSNEC34HCUS20140328862 SEQ ID NO: 212 8309 HIV691 Heavy chain LSSNEC3HCUS20140328862 SEQ ID NO: 213 8310 HIV692 Heavy chain LSSNEC46HCUS20140328862 SEQ ID NO: 214 8311 HIV693 Heavy chain LSSNEC48HCUS20140328862 SEQ ID NO: 215 8312 HIV694 Heavy chain LSSNEC49HCUS20140328862 SEQ ID NO: 250 8313 HIV695 Heavy chain LSSNEC52HCUS20140328862 SEQ ID NO: 216 8314 HIV696 Heavy chain LSSNEC54HCUS20140328862 SEQ ID NO: 251 8315 HIV697 Heavy chain LSSNEC55HCUS20140328862 SEQ ID NO: 252 8316 HIV698 Heavy chain LSSNEC56HCUS20140328862 SEQ ID NO: 217 8317 HIV699 Heavy chain LSSNEC57HCUS20140328862 SEQ ID NO: 253 8318 HIV700 Heavy chain LSSNEC5HCUS20140328862 SEQ ID NO: 254 8319 HIV701 Heavy chain LSSNEC60HCUS20140328862 SEQ ID NO: 218 8320 HIV702 Heavy chain LSSNEC66HCUS20140328862 SEQ ID NO: 219 8321 HIV703 Heavy chain LSSNEC67HCUS20140328862 SEQ ID NO: 255 8322 HIV704 Heavy chain LSSNEC70HCUS20140328862 SEQ ID NO: 220 8323 HIV705 Heavy chain LSSNEC72HCUS20140328862 SEQ ID NO: 221 8324 HIV706 Heavy chain LSSNEC74HCUS20140328862 SEQ ID NO: 256 8325 HIV707 Heavy chain LSSNEC77HCUS20140328862 SEQ ID NO: 257 8326 HIV708 Heavy chain LSSNEC7HCUS20140328862 SEQ ID NO: 222 8327 HIV709 Heavy chain LSSNEC82HCUS20140328862 SEQ ID NO: 223 8328 HIV710 Heavy chain LSSNEC85HCUS20140328862 SEQ ID NO: 258 8329 HIV711 Heavy chain LSSNEC89HCUS20140328862 SEQ ID NO: 224 8330 HIV712 Heavy chain LSSNEC8HCUS20140328862 SEQ ID NO: 225 8331 HIV713 Heavy chain LSSNEC91HCUS20140328862 SEQ ID NO: 259 8332 HIV714 Heavy chain LSSNEC92HCUS20140328862 SEQ ID NO: 260 8333 HIV715 Heavy chain LSSNEC94HCUS20140328862 SEQ ID NO: 226 8334 HIV716 Heavy chain LSSNEC95HCUS20140328862 SEQ ID NO: 227 8335 HIV717 Heavy chain LSSNEC9HCUS20140328862 SEQ ID NO: 228 8336 HIV718 Heavy chain m12_Fd-aa U.S. Pat.No. 7,803,913B2 SEQ ID NO: 3 8337 HIV719 Heavy chain m14-Fd-aa U.S. Pat.No. 7,803,913B2 SEQ ID NO: 1 8338 HIV720 Heavy chain m16-Fd-aa U.S. Pat.No. 7,803,913B2 SEQ ID NO: 4 8339 HIV721 Heavy chain m18 Fd-aa U.S. Pat.No. 7,803,913B2 SEQ ID NO: 2 8340 HIV722 Heavy Chain M66 Ofek, G., etal., Structural Basis for HIV-1 8341 Neutralization by 2F5-LikeAntibodies m66 and m66.6; J. Virol. 88 (5), 2426-2441 (2014), NCBIAccession # 4NRY_L (220aa) HIV723 Heavy Chain M66.6 Ofek, G., et al.,Structural Basis for HIV-1 8342 Neutralization by 2F5-Like Antibodiesm66 and m66.6; J. Virol. 88 (5), 2426-2441 (2014), NCBI Accession #4NRZ_H (234aa) HIV724 Heavy Chain Mab 2158 Spurrier, B., et al.,Functional Implications of 8343 the Binding Mode of a HumanConformation- Dependent V2 Monoclonal Antibody against HIV; J. Virol, 88(8), 4100-4112 (2014), NCBI Accession # 4OAW_D (236aa) HIV725 Heavychain MV1 US20130195881 SEQ ID NO: 10 8344 HIV726 Heavy Chain Pg16 FabPancera, M., et al., Nat. Struct. Mol. Biol. 20 8345 (7), 804-813(2013), NCBI Accession # 4DQO_H (246aa) HIV727 Heavy Chain Pg9 Willis,J. R., et al., J. Clin. Invest. 125 (6), 2523- 8346 2531 (2015), NCBIAccession # 4YAQ_H(248aa) HIV728 Heavy Chain Pgt121-Gl Mouquet H et al.,Complex-type N-glycan 8347 Fab recognition by potent broadlyneutralizing HIV antibodies; Proc Natl Acad Sci USA. 2012 Nov. 20;109(47): E3268-77, NCBI Accession # 4FQQ_B (244aa) HIV729 Heavy ChainPgt122 Julien, J. P., et al., PLoS Pathol. 9 (5), 8348 E1003342 (2013),NCBI Accession # 4JY5_H (235aa) HIV730 Heavy Chain Pgt123 Julien, J. P.,et al., PLoS Pathol. 9 (5), 8349 E1003342 (2013), NCBI Accession #4JY6_B (235aa) HIV731 Heavy Chain Pgt124 Garces, F., et al., StructuralEvolution of 8350 Glycan Recognition by a Family of Potent HIVAntibodies; Cell 159 (1), 69-79 (2014), NCBI Accession # 4R26_H (236aa)HIV732 Heavy Chain Pgt130 Doores, K. J., et al., J. Virol. 89 (2),1105-1118 8351 (2015), NCBI Accession # 4RNR_A (233aa) HIV733 HeavyChain Pgt135 Grover et al., Science 343 (6171), 656-661 8352 (2014),NCBI Accession # 4NZR_H (234aa) HIV734 Heavy chain S19 US20110059015 SEQID NO: 6 8353 HIV735 Heavy chain S20 US20110059015 SEQ ID NO: 8 8354HIV736 Heavy chain S8 US20110059015 SEQ ID NO: 4 8355 HIV737 Heavy ChainVrc- Pg04 Wu, X., et al., Focused evolution of HIV-1 8356 neutralizingantibodies revealed by structures and deep sequencing; Science 333(6049), 1593-1602 (2011)”, NCBI Accession # 3SE9_H (228aa) HIV738 Heavychain VRC01 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 1 8357 HIV739 Heavychain VRC01HC/VRCO3LC WO2013090644 SEQ ID NO: 2 8358 HIV740 Heavy chainVRC02 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 3 8359 HIV741 Heavy chainVRC03 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 27 8360 HIV742 Heavy chainVRC03HC- WO2013090644 SEQ ID NO: 32 8361 VRC01LC HIV743 Heavy chainVRC07 US20140322163 SEQ ID NO: 258 8362 G54H, S58N HIV744 Heavy chainVRC07 I37V, US20140322163 SEQ ID NO: 260 8363 G54H, S58N, T93A HIV745Heavy chain VRC07 I37V, US20140322163 SEQ ID NO: 259 8364 G54H, T93AHIV746 Heavy Chain Vrc08c Wu, X., et al., Maturation and Diversity ofthe 8365 VRC01-Antibody Lineage over 15 Years of Chronic HIV-1Infection; Cell 161 (3), 470-485 (2015), NCBI Accession # 4XNY_H (235aa)HIV747 Heavy Chain Vrc23 Georgiev, I. S., et al., Delineating antibody8366 recognition in polyclonal sera from patterns of HIV-1 isolateneutralization; Science 340 (6133), 751-756 (2013), NCBI Accession #4J6R_H (224aa) HIV748 Heavy chain VRC-CH30 WO2013090644 SEQ ID NO: 228367 HIV749 Heavy Chain Vrc-ch31 Zhou T et al., Immunity 39 (2), 245-258(2013), 8368 NCBI Accession # 4LSP_H (236aa) HIV750 Heavy chain VRC-CH32Wu X. et al, “Focused evolution of HIV-1 8369 neutralizing antibodiesrevealed by structures and deep sequencing” Science 333 (6049),1593-1602 (2011), NCBI Accession # AEM62724 HIV751 Heavy chain VRC-CH33WO2013090644 SEQ ID NO: 28 8370 HIV752 Heavy chain VRC-CH34 WO2013090644SEQ ID NO: 30 8371 HIV753 Heavy chain VRCO7 US20140322163 SEQ ID NO: 338372 G54H HIV754 Heavy chain VRC-PG04 Wu X. et al, “Focused evolution ofHIV-1 8373 neutralizing antibodies revealed by structures and deepsequencing” Science 333 (6049), 1593-1602 (2011), NCBI Accession #AEM62752 HIV755 Heavy chain VRC-PG04b WO2013090644 SEQ ID NO: 44 8374HIV756 Heavy Chain Vrc-pg20 Zhou T et al., Immunity 39 (2), 245-258(2013), 8375 NCBI Accession # 4LSU_H (227aa) HIV757 Heavy chain X5 U.S.Pat. No. 7,378,093B2 SEQ ID NO: 3 8376 HIV758 Heavy chain X5 U.S. Pat.No. 8,110,192B2 SEQ ID NO: 5 8377 HIV759 Heavy chain X5 variant U.S.Pat. No. 7,378,093B2 SEQ ID NO: 11 8378 HIV760 Heavy Chain Z13e1Stanfield, R. L., et al, J. Mol. Biol. 414 (3). 460- 8379 476 (2011),NCBI Accession # 3Q1S_H(230aa) HIV761 Heavy Chain Z258- Zhou. T et al.,Structural Repertoire of HIV-1- 8380 vrc27.01 Neutralizing AntibodiesTargeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292(2015), NCBI Accession # 4YDI_H(227aa) HIV762 Heavy Chain NCBI Accession# 1N0X_K (230aa) 8381 HIV763 Heavy chain U.S. Pat. No. 5,804,440A SEQ IDNO: 142 8382 HIV764 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 1438383 HIV765 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 144 8384HIV766 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 145 8385 HIV767Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 146 8386 HIV768 Heavychain U.S. Pat. No. 5,804,440A SEQ ID NO: 66 8387 HIV769 Heavy chainU.S. Pat. No. 5,804,440A SEQ ID NO: 67 8388 HIV770 Heavy chain U.S. Pat.No. 5,804,440A SEQ ID NO: 68 8389 HIV771 Heavy chain U.S. Pat. No.5,804,440A SEQ ID NO: 70 8390 HIV772 Heavy chain U.S. Pat. No.5,804,440A SEQ ID NO: 72 8391 HIV773 Heavy chain U.S. Pat. No.5,804,440A SEQ ID NO: 73 8392 HIV774 Heavy chain U.S. Pat. No.5,804,440A SEQ ID NO: 74 8393 HIV775 Heavy chain U.S. Pat. No.5,804,440A SEQ ID NO: 75 8394 HIV776 Heavy chain U.S. Pat. No.5,804,440A SEQ ID NO: 78 8395 HIV777 Heavy chain WO2014063059 SEQ ID NO:10 8396 HIV778 Heavy chain WO2014063059 SEQ ID NO: 12 8397 HIV779 Heavychain WO2014063059 SEQ ID NO: 130 8398 HIV780 Heavy chain WO2014063059SEQ ID NO: 14 8399 HIV781 Heavy chain WO2014063059 SEQ ID NO: 16 8400HIV782 Heavy chain WO2014063059 SEQ ID NO: 18 8401 HIV783 Heavy chainWO2014063059 SEQ ID NO: 20 8402 HIV784 Heavy chain WO2014063059 SEQ IDNO: 22 8403 HIV785 Heavy chain WO2014063059 SEQ ID NO: 24 8404 HIV786Heavy chain WO2014063059 SEQ ID NO: 4 8405 HIV787 Heavy chainWO2014063059 SEQ ID NO: 6 8406 HIV788 Heavy chain WO2014063059 SEQ IDNO: 8 8407 HIV789 Heavy chain WO2014063059 SEQ ID NO: 2 8408 consensusHIV790 Heavy chain constant G4D US20130195881 SEQ ID NO: 6 8409 regionHIV791 Heavy chain constant G4H US20130195881 SEQ ID NO: 5 8410 regionHIV792 Heavy chain constant MV1 US20130195881 SEQ ID NO: 7 8411 regionHIV793 Heavy chain constant TNX-355, US20130195881 SEQ ID NO: 4 8412region Idalizumab HIV794 Heavy Chain Fab Ch04 McLellan, J. S., et al.Nature 480 (7377), 336- 8413 343 (2011), NCBI Accession # 3U46_A (238aa)HIV795 Heavy Chain Of 21C Diskin, R., et al, Nat. Struct. Mol. Biol. 17(5), 8414 Anti-HIV Fab From 608-613 (2010), NCBI Accession # 3LMJ_HHuman 21c Antibody (231aa) HIV796 Heavy Chain Of 830a Pan et al, J.Virol. 89 (15), 8003-8010 (2015), 8415 Anti-hiv-1 Gp120 NCBI Accession #4YWG_H (226aa) V1v2 Antibody 830a HIV797 Heavy chain partial 412D HuangC. et al “Structural basis of tyrosine 8416 sulfation and VH-gene usagein antibodies that recognize the HIV type 1 coreceptor-binding site ongp120” Proc. Natl. Acad. Sci. U.S.A. 101 (9), 2706-2711 (2004), NCBIAccession # AAR88379 HIV798 Heavy chain variable 0.5γ(1C10) U.S. Pat.No. 8,722,861B2 SEQ ID NO: 1 8417 region HIV799 Heavy chain variable0.5δ (3D6) U.S. Pat. No. 8,722,861B2 SEQ ID NO: 5 8418 region HIV800Heavy chain variable 10J4 mAb WO2015103549 SEQ ID NO: 3 8419 regionHIV801 Heavy chain variable 10M6 mAb WO2015103549 SEQ ID NO: 5 8420region HIV802 Heavy chain variable 13110 mAb WO2015103549 SEQ ID NO: 78421 region HIV803 Heavy chain variable 2N5mAb WO2015103549 SEQ ID NO: 98422 region HIV804 Heavy chain variable 35022 mAb WO2015103549 SEQ IDNO: 1 8423 region HIV805 Heavy chain variable 42F9 U.S. Pat. No.8,722,861B2 SEQ ID NO: 7 8424 region HIV806 Heavy chain variable4835_F12 US20140205612 SEQ ID NO: 404 8425 region (PGT-124) HIV807 Heavychain variable 4838_L06 US20140205612 SEQ ID NO: 66 8426 region(PGT-121) HIV808 Heavy chain variable 4858_P08 US20140205612 SEQ ID NO:167 8427 region (PGT-123) HIV809 Heavy chain variable 4869-K15US20140205612 SEQ ID NO: 419 8428 region (PGT-133) HIV810 Heavy chainvariable 4873_E03 US20140205612 SEQ ID NO: 62 8429 region (PGT-121)HIV811 Heavy chain variable 4876_M06 US20140205612 SEQ ID NO: 434 8430region (PGT-134) HIV812 Heavy chain variable 4877_D15 US20140205612 SEQID NO: 155 8431 region (PGT-122) HIV813 Heavy chain variable 4964_G22US20140205612 SEQ ID NO: 275 8432 region (PGT-141), 4993_K13 (PGT-141)HIV814 Heavy chain variable 4970_K22 US20140205612 SEQ ID NO: 306 8433region (PGT-144) HIV815 Heavy chain variable 4980_N08 US20140205612 SEQID NO: 297 8434 region (PGT-143) HIV816 Heavy chain variable 4995_E20US20140205612 SEQ ID NO: 291 8435 region (PGT-142) HIV817 Heavy chainvariable 4995_P16 US20140205612 SEQ ID NO: 400 8436 region (PGT-145)HIV818 Heavy chain variable 49G2 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 98437 region HIV819 Heavy chain variable 4O20mAb WO2015103549 SEQ ID NO:11 8438 region HIV820 Heavy chain variable 5114_A19 US20140205612 SEQ IDNO: 333 8439 region (PGT-128) HIV821 Heavy chain variable 5120_N10US20140205612 SEQ ID NO: 462 8440 region (PGT-139) HIV822 Heavy chainvariable 5131_A17 US20140205612 SEQ ID NO: 443 8441 region (PGT-132)HIV823 Heavy chain variable 5136_H01 US20140205612 SEQ ID NO: 345 8442region (PGT-131) HIV824 Heavy chain variable 5138_G07 US20140205612 SEQID NO: 453 8443 region (PGT-138) HIV825 Heavy chain variable 5141_B17US20140205612 SEQ ID NO: 199 8444 region (PGT-126) HIV826 Heavy chainvariable 5145_B14 US20140205612 SEQ ID NO: 318 8445 region (PGT-127)HIV827 Heavy chain variable 5147_N06 US20140205612 SEQ ID NO: 215 8446region (PGT-130) HIV828 Heavy chain variable 5329_C19 US20140205612 SEQID NO: 248 8447 region (PGT-136), 5366_P21 (PGT-136) HIV829 Heavy chainvariable 5343_B08 US20140205612 SEQ ID NO: 231 8448 region (PGT-135),5344_E16 (PGT-135) HIV830 Heavy chain variable 5345_I01 US20140205612SEQ ID NO: 362 8449 region (PGT-137) HIV831 Heavy chain variable 5G2U.S. Pat. No. 8,722,861B2 SEQ ID NO: 3 8450 region HIV832 Heavy chainvariable 6808_B09 US20140205612 SEQ ID NO: 546 8451 region (PGT-156)HIV833 Heavy chain variable 6831_A21 US20140205612 SEQ ID NO: 473 8452region (PGT-151) HIV834 Heavy chain variable 6843_G20 US20140205612 SEQID NO: 516 8453 region (PGT-154) HIV835 Heavy chain variable 6881_N05US20140205612 SEQ ID NO: 572 8454 region (PGT-158). HIV836 Heavy chainvariable 6889_117 US20140205612 SEQ ID NO: 489 8455 region (PGT-152)HIV837 Heavy chain variable 6891_F06 US20140205612 SEQ ID NO: 501 8456region (PGT-153) HIV838 Heavy chain variable 6892_C23 US20140205612 SEQID NO: 559 8457 region (PGT-157) HIV839 Heavy chain variable 6892_D19US20140205612 SEQ ID NO: 531 8458 region (PGT-155) HIV840 Heavy chainvariable 7B9mAb WO2015103549 SEQ ID NO: 13 8459 region HIV841 Heavychain variable 7K3mAb WO2015103549 SEQ ID NO: 15 8460 region HIV842Heavy chain variable B4 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 2 8461region HIV843 Heavy chain variable B4DIVHv.1 U.S. Pat. No. 7,872,110B2SEQ ID NO: 5 8462 region HIV844 Heavy chain variable B4DIVHv.2 U.S. Pat.No. 7,872,110B2 SEQ ID NO: 6 8463 region HIV845 Heavy chain variableB4DTVHv.3 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 7 8464 region HIV846Heavy chain variable B4DIVHv.4 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 88465 region HIV847 Heavy chain variable bI2 IgA2 WO2014040024 SEQ ID NO:29 8466 region antibody HIV848 Heavy chain variable CHμ39.1 U.S. Pat.No. 5,773,247 SEQ ID NO: 10 8467 region HIV849 Heavy chain variableCHμ5.5 U.S. Pat. No. 5,773,247 SEQ ID NO: 14 8468 region HIV850 Heavychain variable F425-Alg8 WO2014040024 SEQ ID NO: 9 8469 region antibodyHIV851 Heavy chain variable Fab 43 US20090191216 SEQ ID NO: 8 8470region HIV852 Heavy chain variable HGN194 US20110212106 SEQ ID NO: 458471 region HIV853 Heavy chain variable HJ16 US20110212106 SEQ ID NO: 138472 region HIV854 Heavy chain variable HK20 US20110212106 SEQ ID NO: 298473 region HIV855 Heavy chain variable IgA antibody WO2014040024 SEQ IDNO: 11 8474 region HIV856 Heavy chain variable L1719A11 US20150158934SEQ ID NO: 175 8475 region HIV857 Heavy chain variable L1719A12US20150158934 SEQ ID NO: 176 8476 region HIV858 Heavy chain variableL1719A9 US20150158934 SEQ ID NO: 174 8477 region HIV859 Heavy chainvariable L1719B12 US20150158934 SEQ ID NO: 177 8478 region HIV860 Heavychain variable L1719C1 US20150158934 SEQ ID NO: 178 8479 region HIV861Heavy chain variable L1719D10 US20150158934 SEQ ID NO: 179 8480 regionHIV862 Heavy chain variable L1719E1 US20150158934 SEQ ID NO: 180 8481region HIV863 Heavy chain variable L1719E11 US20150158934 SEQ ID NO: 1818482 region HIV864 Heavy chain variable L1719E12 US20150158934 SEQ IDNO: 182 8483 region HIV865 Heavy chain variable L1719F11 US20150158934SEQ ID NO: 183 8484 region HIV866 Heavy chain variable L1719H10US20150158934 SEQ ID NO: 185 8485 region HIV867 Heavy chain variableL1719H9 US20150158934 SEQ ID NO: 184 8486 region HIV868 Heavy chainvariable L1720C1 US20150158934 SEQ ID NO: 186 8487 region HIV869 Heavychain variable L1720E4 US20150158934 SEQ ID NO: 187 8488 region HIV870Heavy chain variable L1721A3 US20150158934 SEQ ID NO: 188 8489 regionHIV871 Heavy chain variable L1721A5 US20150158934 SEQ ID NO: 189 8490region HIV872 Heavy chain variable L1721A8 US20150158934 SEQ ID NO: 1908491 region HIV873 Heavy chain variable L1721H4 US20150158934 SEQ ID NO:191 8492 region HIV874 Heavy chain variable L1723A10 US20150158934 SEQID NO: 193 8493 region HIV875 Heavy chain variable L1723A11US20150158934 SEQ ID NO: 194 8494 region HIV876 Heavy chain variableL1723A9 US20150158934 SEQ ID NO: 192 8495 region HIV877 Heavy chainvariable L1723E5 US20150158934 SEQ ID NO: 195 8496 region HIV878 Heavychain variable L2319G11 US20150158934 SEQ ID NO: 197 8497 region HIV879Heavy chain variable L2319G7 US20150158934 SEQ ID NO: 196 8498 regionHIV880 Heavy chain variable L2319H7 US20150158934 SEQ ID NO: 198 8499region HIV881 Heavy chain variable L2320E9 US20150158934 SEQ ID NO: 1998500 region HIV882 Heavy chain variable L2320F9 US20150158934 SEQ ID NO:200 8501 region HIV883 Heavy chain variable L2321B7 US20150158934 SEQ IDNO: 201 8502 region HIV884 Heavy chain variable L2321H6 US20150158934SEQ ID NO: 202 8503 region HIV885 Heavy chain variable L81C11US20150158934 SEQ ID NO: 15 8504 region HIV886 Heavy chain variableL81C9 US20150158934 SEQ ID NO: 30 8505 region HIV887 Heavy chainvariable L81D9 US20150158934 SEQ ID NO: 10 8506 region HIV888 Heavychain variable L81E1 US20150158934 SEQ ID NO: 18 8507 region HIV889Heavy chain variable L81E7 US20150158934 SEQ ID NO: 16 8508 regionHIV890 Heavy chain variable L81F1 US20150158934 SEQ ID NO: 19 8509region HIV891 Heavy chain variable L81G7 US20150158934 SEQ ID NO: 138510 region HIV892 Heavy chain variable L81H1 US20150158934 SEQ ID NO:98 8511 region HIV893 Heavy chain variable L81H2 US20150158934 SEQ IDNO: 23 8512 region HIV894 Heavy chain variable L81H7 US20150158934 SEQID NO: 11 8513 region HIV895 Heavy chain variable L81H9 US20150158934SEQ ID NO: 28 8514 region HIV896 Heavy chain variable L82B12AUS20150158934 SEQ ID NO: 105 8515 region HIV897 Heavy chain variableL82B1A US20150158934 SEQ ID NO: 99 8516 region HIV898 Heavy chainvariable L82B1D US20150158934 SEQ ID NO: 100 8517 region HIV899 Heavychain variable L82B2A US20150158934 SEQ ID NO: 101 8518 region HIV900Heavy chain variable L82B3F US20150158934 SEQ ID NO: 102 8519 regionHIV901 Heavy chain variable L82B4A US20150158934 SEQ ID NO: 103 8520region HIV902 Heavy chain variable L82B4E US20150158934 SEQ ID NO: 1048521 region HIV903 Heavy chain variable L82B4F US20150158934 SEQ ID NO:21 8522 region HIV904 Heavy chain variable L832G6 US20150158934 SEQ IDNO: 113 8523 region HIV905 Heavy chain variable L833E1 US20150158934 SEQID NO: 72 8524 region HIV906 Heavy chain variable L833F5 US20150158934SEQ ID NO: 17 8525 region HIV907 Heavy chain variable L833H1US20150158934 SEQ ID NO: 114 8526 region HIV908 Heavy chain variableL833H3 US20150158934 SEQ ID NO: 115 8527 region HIV909 Heavy chainvariable L88B10B US20150158934 SEQ ID NO: 27 8528 region HIV910 Heavychain variable L88B11B US20150158934 SEQ ID NO: 12 8529 region HIV911Heavy chain variable L88B12G US20150158934 SEQ ID NO: 29 8530 regionHIV912 Heavy chain variable L88B1D US20150158934 SEQ ID NO: 20 8531region HIV913 Heavy chain variable L88B2A US20150158934 SEQ ID NO: 1068532 region HIV914 Heavy chain variable L88FA2 US20150158934 SEQ ID NO:26 8533 region HIV915 Heavy chain variable L88FA3 US20150158934 SEQ IDNO: 107 8534 region HIV916 Heavy chain variable L88FA5 US20150158934 SEQID NO: 108 8535 region HIV917 Heavy chain variable L88FB1 US20150158934SEQ ID NO: 25 8536 region HIV918 Heavy chain variable L88FC11US20150158934 SEQ ID NO: 22 8537 region HIV919 Heavy chain variableL88FD12 US20150158934 SEQ ID NO: 24 8538 region HIV920 Heavy chainvariable L89B12D US20150158934 SEQ ID NO: 112 8539 region HIV921 Heavychain variable L89B1D US20150158934 SEQ ID NO: 109 8540 region HIV922Heavy chain variable L89B2C US20150158934 SEQ ID NO: 110 8541 regionHIV923 Heavy chain variable L89B3E US20150158934 SEQ ID NO: 14 8542region HIV924 Heavy chain variable L89B6B US20150158934 SEQ ID NO: 1118543 region HIV925 Heavy chain variable L8Cb15 US20150158934 SEQ ID NO:116 8544 region HIV926 Heavy chain variable L8Cj3 US20150158934 SEQ IDNO: 73 8545 region HIV927 Heavy chain variable L8Fe2 US20150158934 SEQID NO: 117 8546 region HIV928 Heavy chain variable L8Fg12 US20150158934SEQ ID NO: 118 8547 region HIV929 Heavy chain variable L8Fj19US20150158934 SEQ ID NO: 119 8548 region HIV930 Heavy chain variableL8Fo17 US20150158934 SEQ ID NO: 120 8549 region HIV931 Heavy chainvariable L8Fp6 US20150158934 SEQ ID NO: 121 8550 region HIV932 Heavychain variable L8Hi20 US20150158934 SEQ ID NO: 122 8551 region HIV933Heavy chain variable L911B11E US20150158934 SEQ ID NO: 140 8552 regionHIV934 Heavy chain variable L911B12B US20150158934 SEQ ID NO: 71 8553region HIV935 Heavy chain variable L911B1E US20150158934 SEQ ID NO: 1378554 region HIV936 Heavy chain variable L911B1G US20150158934 SEQ ID NO:65 8555 region HIV937 Heavy chain variable L911B2E US20150158934 SEQ IDNO: 138 8556 region HIV938 Heavy chain variable L911B3D US20150158934SEQ ID NO: 75 8557 region HIV939 Heavy chain variable L911B9AUS20150158934 SEQ ID NO: 139 8558 region HIV940 Heavy chain variableL911F12B US20150158934 SEQ ID NO: 142 8559 region HIV941 Heavy chainvariable L911F1B US20150158934 SEQ ID NO: 141 8560 region HIV942 Heavychain variable L911F1F US20150158934 SEQ ID NO: 77 8561 region HIV943Heavy chain variable L911F4C US20150158934 SEQ ID NO: 33 8562 regionHIV944 Heavy chain variable L91A1 US20150158934 SEQ ID NO: 123 8563region HIV945 Heavy chain variable L91B5 US20150158934 SEQ ID NO: 378564 region HIV946 Heavy chain variable L91B5, 4A7 US20150158934 SEQ IDNO: 97 8565 region HIV947 Heavy chain variable L91B5, A12 US20150158934SEQ ID NO: 92 8566 region HIV948 Heavy chain variable L91B5, A4US20150158934 SEQ ID NO: 90 8567 region HIV949 Heavy chain variableL91B5, A7 US20150158934 SEQ ID NO: 91 8568 region HIV950 Heavy chainvariable L91B5, B2 US20150158934 SEQ ID NO: 93 8569 region HIV951 Heavychain variable L91B5, D4 US20150158934 SEQ ID NO: 94 8570 region HIV952Heavy chain variable L91B5, F11 US20150158934 SEQ ID NO: 96 8571 regionHIV953 Heavy chain variable L91B5, F4 US20150158934 SEQ ID NO: 95 8572region HIV954 Heavy chain variable L91C2 US20150158934 SEQ ID NO: 618573 region HIV955 Heavy chain variable L91E1 US20150158934 SEQ ID NO:45 8574 region HIV956 Heavy chain variable L91E2 US20150158934 SEQ IDNO: 124 8575 region HIV957 Heavy chain variable L91F10 US20150158934 SEQID NO: 69 8576 region HIV958 Heavy chain variable L91G2 US20150158934SEQ ID NO: 64 8577 region HIV959 Heavy chain variable L91H3US20150158934 SEQ ID NO: 128 8578 region HIV960 Heavy chain variableL91H9 US20150158934 SEQ ID NO: 41 8579 region HIV961 Heavy chainvariable L922B2 US20150158934 SEQ ID NO: 143 8580 region HIV962 Heavychain variable L922B4 US20150158934 SEQ ID NO: 144 8581 region HIV963Heavy chain variable L922E1 US20150158934 SEQ ID NO: 145 8582 regionHIV964 Heavy chain variable L922E2 US20150158934 SEQ ID NO: 53 8583region HIV965 Heavy chain variable L923A1 US20150158934 SEQ ID NO: 1468584 region HIV966 Heavy chain variable L923A4 US20150158934 SEQ ID NO:32 8585 region HIV967 Heavy chain variable L92A11 US20150158934 SEQ IDNO: 125 8586 region HIV968 Heavy chain variable L92C7 US20150158934 SEQID NO: 62 8587 region HIV969 Heavy chain variable L92D4 US20150158934SEQ ID NO: 126 8588 region HIV970 Heavy chain variable L92E6US20150158934 SEQ ID NO: 63 8589 region HIV971 Heavy chain variableL92E7 US20150158934 SEQ ID NO: 74 8590 region HIV972 Heavy chainvariable L92E7, A1 US20150158934 SEQ ID NO: 85 8591 region HIV973 Heavychain variable L92E7, A2 US20150158934 SEQ ID NO: 86 8592 region HIV974Heavy chain variable L92E7, A3 US20150158934 SEQ ID NO: 87 8593 regionHIV975 Heavy chain variable L92E7, A4 US20150158934 SEQ ID NO: 80 8594region HIV976 Heavy chain variable L92E7, A4 US20150158934 SEQ ID NO: 888595 region HIV977 Heavy chain variable L92E7, A5 US20150158934 SEQ IDNO: 89 8596 region HIV978 Heavy chain variable L92E7, B5 US20150158934SEQ ID NO: 78 8597 region HIV979 Heavy chain variable L92E7. CUS20150158934 SEQ ID NO: 79 8598 region HIV980 Heavy chain variableL92E7, C3 US20150158934 SEQ ID NO: 82 8599 region HIV981 Heavy chainvariable L92E7, D3 US20150158934 SEQ ID NO: 83 8600 region HIV982 Heavychain variable L92E7, E1 US20150158934 SEQ ID NO: 84 8601 region HIV983Heavy chain variable L92E7, G4 US20150158934 SEQ ID NO: 81 8602 regionHIV984 Heavy chain variable L932A9 US20150158934 SEQ ID NO: 58 8603region HIV985 Heavy chain variable L932E10 US20150158934 SEQ ID NO: 358604 region HIV986 Heavy chain variable L932E8 US20150158934 SEQ ID NO:147 8605 region HIV987 Heavy chain variable L932G9 US20150158934 SEQ IDNO: 34 8606 region HIV988 Heavy chain variable L933D10 US20150158934 SEQID NO: 50 8607 region HIV989 Heavy chain variable L93B3 US20150158934SEQ ID NO: 70 8608 region HIV990 Heavy chain variable L93B4US20150158934 SEQ ID NO: 127 8609 region HIV991 Heavy chain variableL93C3 US20150158934 SEQ ID NO: 51 8610 region HIV992 Heavy chainvariable L93C6 US20150158934 SEQ ID NO: 67 8611 region HIV993 Heavychain variable L93D3 US20150158934 SEQ ID NO: 129 8612 region HIV994Heavy chain variable L93D4 US20150158934 SEQ ID NO: 43 8613 regionHIV995 Heavy chain variable L93D9 US20150158934 SEQ ID NO: 130 8614region HIV996 Heavy chain variable L93E3 US20150158934 SEQ ID NO: 558615 region HIV997 Heavy chain variable L93E6 US20150158934 SEQ ID NO:131 8616 region HIV998 Heavy chain variable L93F12 US20150158934 SEQ IDNO: 133 8617 region HIV999 Heavy chain variable L93F2 US20150158934 SEQID NO: 132 8618 region HIV1000 Heavy chain variable L93F2 US20150158934SEQ ID NO: 59 8619 region HIV1001 Heavy chain variable L93H6US20150158934 SEQ ID NO: 38 8620 region HIV1002 Heavy chain variableL93H9 US20150158934 SEQ ID NO: 134 8621 region HIV1003 Heavy chainvariable L94A12 US20150158934 SEQ ID NO: 46 8622 region HIV1004 Heavychain variable L94C2 US20150158934 SEQ ID NO: 31 8623 region HIV1005Heavy chain variable L94D12 US20150158934 SEQ ID NO: 42 8624 regionHIV1006 Heavy chain variable L94D4 US20150158934 SEQ ID NO: 47 8625region HIV1007 Heavy chain variable L94E3 US20150158934 SEQ ID NO: 398626 region HIV1008 Heavy chain variable L94E4 US20150158934 SEQ ID NO:54 8627 region HIV1009 Heavy chain variable L94E5 US20150158934 SEQ IDNO: 57 8628 region HIV1010 Heavy chain variable L94H1 US20150158934 SEQID NO: 36 8629 region HIV1011 Heavy chain variable L94H2 US20150158934SEQ ID NO: 40 8630 region HIV1012 Heavy chain variable L94H5US20150158934 SEQ ID NO: 48 8631 region HIV1013 Heavy chain variableL94H7 US20150158934 SEQ ID NO: 135 8632 region HIV1014 Heavy chainvariable L95B10D US20150158934 SEQ ID NO: 136 8633 region HIV1015 Heavychain variable L95B12A US20150158934 SEQ ID NO: 68 8634 region HIV1016Heavy chain variable L95B12E US20150158934 SEQ ID NO: 66 8635 regionHIV1017 Heavy chain variable L95B8A US20150158934 SEQ ID NO: 60 8636region HIV1018 Heavy chain variable L98FB10 US20150158934 SEQ ID NO: 768637 region HIV1019 Heavy chain variable L9Ab16 US20150158934 SEQ ID NO:148 8638 region HIV1020 Heavy chain variable L9Ab19 US20150158934 SEQ IDNO: 149 8639 region HIV1021 Heavy chain variable L9Ad13 US20150158934SEQ ID NO: 151 8640 region HIV1022 Heavy chain variable L9Ad14US20150158934 SEQ ID NO: 152 8641 region HIV1023 Heavy chain variableL9Ad3 US20150158934 SEQ ID NO: 150 8642 region HIV1024 Heavy chainvariable L9Aj2 US20150158934 SEQ ID NO: 153 8643 region HIV1025 Heavychain variable L9An7 US20150158934 SEQ ID NO: 154 8644 region HIV1026Heavy chain variable L9Ao15 US20150158934 SEQ ID NO: 155 8645 regionHIV1027 Heavy chain variable L9Ap11 US20150158934 SEQ ID NO: 156 8646region HIV1028 Heavy chain variable L9Bb3 US20150158934 SEQ ID NO: 1578647 region HIV1029 Heavy chain variable L9Bc6 US20150158934 SEQ ID NO:158 8648 region HIV1030 Heavy chain variable L9Bd8 US20150158934 SEQ IDNO: 159 8649 region HIV1031 Heavy chain variable L9Bd9 US20150158934 SEQID NO: 160 8650 region HIV1032 Heavy chain variable L9Be11 US20150158934SEQ ID NO: 161 8651 region HIV1033 Heavy chain variable L9Bf11US20150158934 SEQ ID NO: 49 8652 region HIV1034 Heavy chain variableL9Bf19 US20150158934 SEQ ID NO: 162 8653 region HIV1035 Heavy chainvariable L9Bj13 US20150158934 SEQ ID NO: 163 8654 region HIV1036 Heavychain variable L9Bm10 US20150158934 SEQ ID NO: 164 8655 region HIV1037Heavy chain variable L9Bm16 US20150158934 SEQ ID NO: 56 8656 regionHIV1038 Heavy chain variable L9Bp16 US20150158934 SEQ ID NO: 165 8657region HIV1039 Heavy chain variable L9Bp5 US20150158934 SEQ ID NO: 448658 region HIV1040 Heavy chain variable L9Ca12 US20150158934 SEQ ID NO:166 8659 region HIV1041 Heavy chain variable L9Ca13 US20150158934 SEQ IDNO: 167 8660 region HIV1042 Heavy chain variable L9Cd12 US20150158934SEQ ID NO: 168 8661 region HIV1043 Heavy chain variable L9Cf15US20150158934 SEQ ID NO: 169 8662 region HIV1044 Heavy chain variableL9Cl22 US20150158934 SEQ ID NO: 52 8663 region HIV1045 Heavy chainvariable L9Cm18 US20150158934 SEQ ID NO: 170 8664 region HIV1046 Heavychain variable L9Co22 US20150158934 SEQ ID NO: 171 8665 region HIV1047Heavy chain variable L9Cp5 US20150158934 SEQ ID NO: 172 8666 regionHIV1048 Heavy chain variable L9Cpl3 US20150158934 SEQ ID NO: 173 8667region HIV1049 Heavy chain variable Makandal US20100111990 SEQ ID NO: 48668 region monoclonal antibody (Mmab) HIV1050 Heavy chain variableNM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 17 8669 region HIV1051 Heavychain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 27 8670 regionHuVH HIV1052 Heavy chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ IDNO: 29 8671 region HuVK HIV1053 Heavy chain variable NM-01 U.S. Pat. No.5,665,569 SEQ ID NO: 31 8672 region HuVKF HIV1054 Heavy chain variablePGT125 Walker L. M. et al “Broad neutralization 8673 region coverage ofHIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470(2011), NCBI Accession # AEN14393 HIV1055 Heavy chain variable PGT126Walker L. M. et al “Broad neutralization 8674 region coverage of HIV bymultiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011),NCBI Accession # AEN14394 HIV1056 Heavy chain variable PGT131 Walker L.M. et al “Broad neutralization 8675 region coverage of HIV by multiplehighly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBIAccession # AEN14389 HIV1057 Heavy chain variable PGT136 Walker L. M. etal “Broad neutralization 8676 region coverage of HIV by multiple highlypotent antibodies”, Nature 477 (7365),466-470 (2011), NCBI Accession #AEN14400 HIV1058 Heavy chain variable PGT137 Walker L. M. et al “Broadneutralization 8677 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14401 HIV1059 Heavy chain variable PGT141 Walker L. M. et al “Broadneutralization 8678 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14402 HIV1060 Heavy chain variable PGT142 Walker L. M. et al “Broadneutralization 8679 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14368 HIV1061 Heavy chain variable PGT143 Walker L. M. et al “Broadneutralization 8680 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14404 HIV1062 Heavy chain variable PGT144 Walker L. M. et al “Broadneutralization 8681 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14405 HIV1063 Heavy chain variable PGT151 Falkowska, E. et al“Broadly Neutralizing HIV 8682 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC3535 HIV1064 Heavy chain variable PGT152 Falkowska, E. etal “Broadly Neutralizing HIV 8683 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32536 HIV1065 Heavy chain variable PGT153 Falkowska, E.et al “Broadly Neutralizing HIV 8684 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32537 HIV1066 Heavy chain variable PGT154 Falkowska, E.et al “Broadly Neutralizing HIV 8685 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32521 HIV1067 Heavy chain variable PGT155 Falkowska, E.et al “Broadly Neutralizing HIV 8686 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32539 HIV1068 Heavy chain variable PGT156 Falkowska, E.et al “Broadly Neutralizing HIV 8687 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32540 HIV1069 Heavy chain variable PGT157 Falkowska, E.et al “Broadly Neutralizing HIV 8688 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32541 HIV1070 Heavy chain variable PGT158 Falkowska, E.et al “Broadly Neutralizing HIV 8689 region Antibodies Define aGlycan-Dependent Epitope on the Perfusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32542 HIV1071 Heavy chain variable rF105 WO1993012232 SEQID NO: 4 8690 region HIV1072 Heavy chain variable ScFvX5- U.S. Pat. No.7,378,093B2 SEQ ID NO: 14 8691 region CD4 HIV1073 Heavy chain variableTNX-355, US20130195881 SEQ ID NO: 3 8692 region Idalizumab HIV1074 Heavychain variable VCR14 US20150044137 SEQ ID NO: 13 8693 region HIV1075Heavy chain variable VCR14b US20150044137 SEQ ID NO: 14 8694 regionHIV1076 Heavy chain variable VCR14c US20150044137 SEQ ID NO: 15 8695region HIV1077 Heavy chain variable VCR16 US20150044137 SEQ ID NO: 298696 region HIV1078 Heavy chain variable VCR16b US20150044137 SEQ ID NO:30 8697 region HIV1079 Heavy chain variable VCR16c US20150044137 SEQ IDNO: 31 8698 region HIV1080 Heavy chain variable VCR16d US20150044137 SEQID NO: 32 8699 region HIV1081 Heavy chain variable VLP_A14 US20150158934SEQ ID NO: 203 8700 region HIV1082 Heavy chain variable VLP_B9US20150158934 SEQ ID NO: 204 8701 region HIV1083 Heavy chain variableVLP3_B21 US20150158934 SEQ ID NO: 205 8702 region HIV1084 Heavy chainvariable VRC13 US20150044137 SEQ ID NO: 5 8703 region HIV1085 Heavychain variable VRC13b US20150044137 SEQ ID NO: 6 8704 region HIV1086Heavy chain variable VRC13c US20150044137 SEQ ID NO: 7 8705 regionHIV1087 Heavy chain variable VRC13d US20150044137 SEQ ID NO: 8 8706region HIV1088 Heavy chain variable VRC13e US20150044137 SEQ ID NO: 98707 region HIV1089 Heavy chain variable VRC13f US20150044137 SEQ ID NO:10 8708 region HIV1090 Heavy chain variable VRC13g US20150044137 SEQ IDNO: 11 8709 region HIV1091 Heavy chain variable VRC13h US20150044137 SEQID NO: 12 8710 region HIV1092 Heavy chain variable VRC15 US20150044137SEQ ID NO: 16 8711 region HIV1093 Heavy chain variable US20150004190 SEQID NO: 56 8712 region HIV1094 Heavy chain variable P7 NCBI Accession #AAB41043.1 (136aa) 8713 region, partial HIV1095 Heavy Chain, Fab Ch04McLellan, J. S. et al., Structure of HIV-1 gp120 8714 V1 V2 domain withbroadly neutralizing antibody PG9; Nature 480 (7377), 336-343 (2011),NCBI Accession # 3TCL_A (237aa) HIV1096 Heavy Chain, Fab N5-i5 Acharya,P., et al., Structural Definition of an 8715 Antibody-Dependent CellularCytotoxicity Response Implicated in Reduced Risk for HIV- 1 infection;J. Virol. 88 (21), 12895-12906 (2014), NCBI Accession # 4H8W_H (226aa)HIV1097 Heavy Chain, Fab N60-i3 Gohain, N., et al., Cocrystal Structuresof 8716 Antibody N60-i3 and Antibody JR4 in Complex with gp120 DefineMore Cluster A Epitopes Involved in Effective Antibody- DependentEffector Function against HIV-1; J. Virol. 89 (17), 8840-8854 (2015),NCBI Accession # 4RFO_H (229aa) HIV1098 Heavy Chain, Ig Nih45-46 FabDiskin, R., et al., Science 334 (6060), 1289- 8717 Gamma-1 Chain C 1293(2011), NCBI Accession # 3U7Y_H Region (229aa) HIV1099 Heavy Chain, IgPgt127 Pejchal, R., et al., Science 334 (6059), 1097- 8718 Gamma-1 ChainC 1103 (2011), NCBI Accession # Region 3TWC_H(239aa) HIV1100 HeavyChain, Ig Pgt128 Pejchal, R., et al., Science 334 (6059), 1097- 8719Gamma-1 Chain C 1103 (2011), NCBI Accession # Region 3TV3_H(239aa)HIV1101 HIV, heavy chain Suvizumab 8720 HIV1102 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 43 8721 antibody, heavy chain antibody HIV1103HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 44 8722 antibody, heavychain antibody HIV1104 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 458723 antibody, heavy chain antibody HIV1105 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 46 8724 antibody, heavy chain antibody HIV1106HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 47 8725 antibody, heavychain antibody HIV1107 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 488726 antibody, heavy chain antibody HIV1108 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 49 8727 antibody, heavy chain antibody HIV1109HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 57 8728 antibody, heavychain antibody HIV1110 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 588729 antibody, heavy chain antibody HIV1111 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 59 8730 antibody, heavy chain antibody HIV1112HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 60 8731 antibody, heavychain antibody HIV1113 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 618732 antibody, heavy chain antibody HIV1114 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 62 8733 antibody, heavy chain antibody HIV1115HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 63 8734 antibody, heavychain antibody HIV1116 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 648735 antibody, heavy chain antibody HIV1117 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 73 8736 antibody, heavy chain antibody HIV1118HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 74 8737 antibody, heavychain antibody HIV1119 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 758738 antibody, heavy chain antibody HIV1120 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 76 8739 antibody, heavy chain antibody HIV1121HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 77 8740 antibody, heavychain antibody HIV1122 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 788741 antibody, heavy chain antibody HIV1123 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 50 8742 antibody, light chain antibody HIV1124HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 51 8743 antibody, lightchain antibody HIV1125 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 528744 antibody, light chain antibody HIV1126 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 53 8745 antibody, light chain antibody HIV1127HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 54 8746 antibody, lightchain antibody HIV1128 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 558747 antibody, light chain antibody HIV1129 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 56 8748 antibody, light chain antibody HIV1130HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 65 8749 antibody, lightchain antibody HIV1131 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 668750 antibody, light chain antibody HIV1132 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 67 8751 antibody, light chain antibody HIV1133HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 68 8752 antibody, lightchain antibody HIV1134 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 698753 antibody, light chain antibody HIV1135 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 70 8754 antibody, light chain antibody HIV1136HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 71 8755 antibody, lightchain antibody HIV1137 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 728756 antibody, light chain antibody HIV1138 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 79 8757 antibody, light chain antibody HIV1139HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 80 8758 antibody, lightchain antibody HIV1140 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 818759 antibody, light chain antibody HIV1141 HIV1 gp120 HIV1 gp120WO2001000678 SEQ ID NO: 82 8760 antibody, light chain antibody HIV1142HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 83 8761 antibody, lightchain antibody HIV1143 Kappa light chain 1460_G14 U.S. Pat. No.9,051,362 SEQ ID NO: 22 8762 HIV1144 Kappa light chain 1456_P20 U.S.Pat. No. 9,051,362 SEQ ID NO: 34 8763 variable region HIV1145 Kappalight chain 1460_G14 U.S. Pat. No. 9,051,362 SEQ ID NO: 36 8764 variableregion HIV1146 Kappa light chain 1456_P20 U.S. Pat. No. 9,051,362 SEQ IDNO: 18 8765 HIV1147 Lambda light chain 1456_A12 U.S. Pat. No. 9,051,362SEQ ID NO: 50 8766 HIV1148 Lambda light chain 1469 M23 U.S. Pat. No.9,051,362 SEQ ID NO: 142 8767 HIV1149 Lambda light chain 1489_I13 U.S.Pat. No. 9,051,362 SEQ ID NO: 14 8768 HIV1150 Lambda light chain1495_C14 U.S. Pat. No. 9,051,362 SEQ ID NO: 26 8769 HIV1151 Lambda lightchain 1489_I13 U.S. Pat. No. 9,051,362 SEQ ID NO: 32 8770 variableregion HIV1152 Lambda light chain 1495_C14 U.S. Pat. No. 9,051,362 SEQID NO: 38 8771 variable region HIV1153 Lambda light chain 1496_C09 U.S.Pat. No. 9,051,362 SEQ ID NO: 40 8772 variable region HIV1154 Lambdalight chain 1456_A12 U.S. Pat. No. 9,051,362 SEQ ID NO: 51 8773 variableregion HIV1155 Lambda light chain 1503_H05 U.S. Pat. No. 9,051,362 SEQID NO: 56 8774 variable region HIV1156 Lambda light chain 1496_C09 U.S.Pat. No. 9,051,362 SEQ ID NO: 30 8775 HIV1157 Light chain 2424 Kumar,R., et al., Functional and Structural 8776 Characterization of HumanV3-Specific Monoclonal Antibody 2424 with Neutralizing Activity againstHIV-1 JRFL; J. Virol. 89 (17), 9090-9102 (2015), NCBI Accession #4XML_L(215aa) HIV1158 Light chain 8062 Gustchina, E., PLoS ONE 8 (11),E78187 8777 (2013), NCBI Accession # 4KHX_L(213aa) HIV1159 Light chain1.00E+09 US20140348785 SEQ ID NO: 2 8778 HIV1160 Light Chain 10e8 HuangJ et al., Nature 491 (7424), 406-412 8779 (monoclonal) (2012), NCBIAccession # 4G6F_D (215aa) HIV1161 Light chain 12a12kc US20140328862 SEQID NO: 453 8780 HIV1162 Light chain 12a13kc US20140328862 SEQ ID NO: 4548781 HIV1163 Light chain 12a16kc US20140328862 SEQ ID NO: 455 8782HIV1164 Light chain 12a1kc US20140328862 SEQ ID NO: 456 8783 HIV1165Light chain 12a20kc US20140328862 SEQ ID NO: 457 8784 HIV1166 Lightchain 12a21 NCBI Accession # 4JPW_L (210aa) 8785 HIV1167 Light chain12a21kc US20140328862 SEQ ID NO: 458 8786 HIV1168 Light chain 12a22kcUS20140328862 SEQ ID NO: 459 8787 HIV1169 Light chain 12a23kcUS20140328862 SEQ ID NO: 460 8788 HIV1170 Light chain 12a27kcUS20140328862 SEQ ID NO: 461 8789 HIV1171 Light chain 12a46kcUS20140328862 SEQ ID NO: 462 8790 HIV1172 Light chain 12a55kcUS20140328862 SEQ ID NO: 463 8791 HIV1173 Light chain 12a56kcUS20140328862 SEQ ID NO: 464 8792 HIV1174 Light chain 12a6kcUS20140328862 SEQ ID NO: 465 8793 HIV1175 Light chain 12a7kcUS20140328862 SEQ ID NO: 466 8794 HIV1176 Light chain 17b Kwong, P. D.,et al., structure of an HIV gp120 8795 envelope glycoprotein in complexwith the CD4 receptor and a neutralizing human antibody; Nature 393(6686). 648-659 (1998), NCBI Accession # 1G9M_L(214aa) HIV1177 Lightchain 1b2530 Zhou T et al., Structural Repertoire of HIV-1- 8796Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell161 (6), 1280- 1292 (2015), NCBI Accession # 4YFL_L (215aa) HIV1178Light chain 1F7 U.S. Pat. No. 6,057,421A FIG. 8 8797 HIV1179 Light chain1NC9 WO2012154312 SEQ ID NO: 2472 8798 HIV1180 Light chain 2.2C Acharya,P., et al., Structural Definition of an 8799 Antibody-Dependent CellularCytotoxicity Response Implicated in Reduced Risk for HIV- 1 Infection;J. Virol. 88 (21), 12895-12906 (2014), NCBI Accession # 4R4N_L (210aa)HIV1181 Light chain 2F5 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 10 8800HIV1182 Light chain 3040LC WO2015117008 SEQ ID NO: 29 8801 HIV1183 Lightchain 3044LC WO2015117008 SEQ ID NO: 32 8802 HIV1184 Light chain 3430LCWO2015117008 SEQ ID NO: 30 8803 HIV1185 Light chain 3484LC WO2015117008SEQ ID NO: 31 8804 HIV1186 Light chain 3630LC WO2015117008 SEQ ID NO: 338805 HIV1187 Light chain 3A124KC US20140328862 SEQ ID NO: 506 8806HIV1188 Light chain 3A125KC US20140328862 SEQ ID NO: 507 8807 HIV1189Light chain 3A140LC US20140328862 SEQ ID NO: 508 8808 HIV1190 Lightchain 3A144KC US20140328862 SEQ ID NO: 509 8809 HIV1191 Light chain3A160KC US20140328862 SEQ ID NO: 510 8810 HIV1192 Light chain 3A18KCUS20140328862 SEQ ID NO: 511 8811 HIV1193 Light chain 3A204KCUS20140328862 SEQ ID NO: 512 8812 HIV1194 Light chain 3A228KCUS20140328862 SEQ ID NO: 513 8813 HIV1195 Light chain 3A233LCUS20140328862 SEQ ID NO: 514 8814 HIV1196 Light chain 3A244LCUS20140328862 SEQ ID NO: 515 8815 HIV1197 Light chain 3A255LCUS20140328862 SEQ ID NO: 516 8816 HIV1198 Light chain 3A296KCUS20140328862 SEQ ID NO: 517 8817 HIV1199 Light chain 3A334LCUS20140328862 SEQ ID NO: 518 8818 HIV1200 Light chain 3A366KCUS20140328862 SEQ ID NO: 519 8819 HIV1201 Light chain 3A384KCUS20140328862 SEQ ID NO: 520 8820 HIV1202 Light chain 3A419KCUS20140328862 SEQ ID NO: 521 8821 HIV1203 Light chain 3a426kcUS20140328862 SEQ ID NO: 535 8822 HIV1204 Light chain 3A461KCUS20140328862 SEQ ID NO: 522 8823 HIV1205 Light chain 3A474KCUS20140328862 SEQ ID NO: 523 8824 HIV1206 Light chain 3a515kcUS20140328862 SEQ ID NO: 536 8825 HIV1207 Light chain 3A518KCUS20140328862 SEQ ID NO: 524 8826 HIV1208 Light chain 3A539LCUS20140328862 SEQ ID NO: 525 8827 HIV1209 Light chain 3A576LCUS20140328862 SEQ ID NO: 526 8828 HIV1210 Light chain 3A613LCUS20140328862 SEQ ID NO: 527 8829 HIV1211 Light chain 3A64KCUS20140328862 SEQ ID NO: 528 8830 HIV1212 Light chain 3A650KCUS20140328862 SEQ ID NO: 529 8831 HIV1213 Light chain 3A67KCUS20140328862 SEQ ID NO: 530 8832 HIV1214 Light chain 3A779KCUS20140328862 SEQ ID NO: 531 8833 HIV1215 Light chain 3A816KCUS20140328862 SEQ ID NO: 532 8834 HIV1216 Light chain 3A869KCUS20140328862 SEQ ID NO: 533 8835 HIV1217 Light chain 3A93LCUS20140328862 SEQ ID NO: 534 8836 HIV1218 Light chain 3anc3kcUS20140328862 SEQ ID NO: 547 8837 HIV1219 Light chain 3b106kcUS20140328862 SEQ ID NO: 548 8838 HIV1220 Light chain 3b129kcUS20140328862 SEQ ID NO: 537 8839 HIV1221 Light chain 3b16kcUS20140328862 SEQ ID NO: 549 8840 HIV1222 Light chain 3b171lcUS20140328862 SEQ ID NO: 538 8841 HIV1223 Light chain 3b180kcUS20140328862 SEQ ID NO: 550 8842 HIV1224 Light chain 3b183kcUS20140328862 SEQ ID NO: 551 8843 HIV1225 Light chain 3b191kcUS20140328862 SEQ ID NO: 552 8844 HIV1226 Light chain 3b21kcUS20140328862 SEQ ID NO: 553 8845 HIV1227 Light chain 3b27kcUS20140328862 SEQ ID NO: 539 8846 HIV1228 Light chain 3b41kcUS20140328862 SEQ ID NO: 540 8847 HIV1229 Light chain 3b46kcUS20140328862 SEQ ID NO: 542 8848 HIV1230 Light chain 3b57lcUS20140328862 SEQ ID NO: 543 8849 HIV1231 Light chain 3b5kcUS20140328862 SEQ ID NO: 541 8850 HIV1232 Light chain 3b8kcUS20140328862 SEQ ID NO: 544 8851 HIV1233 Light chain 3bnc102kcUS20140328862 SEQ ID NO: 554 8852 HIV1234 Light chain 3bnc104kcUS20140328862 SEQ ID NO: 555 8853 HIV1235 Light chain 3bnc105kcUS20140328862 SEQ ID NO: 556 8854 HIV1236 Light chain 3bnc107kcUS20140328862 SEQ ID NO: 557 8855 HIV1237 Light chain 3bnc108kcUS20140328862 SEQ ID NO: 558 8856 HIV1238 Light chain 3bnc117 Zhou T etal., Immunity 39 (2), 245-258 (2013), 8857 NCBI Accession #4LSV_L(206aa) HIV1239 Light chain 3bnc117kc US20140328862 SEQ ID NO: 5598858 HIV1240 Light chain 3bnc134kc US20140328862 SEQ ID NO: 560 8859HIV1241 Light chain 3bnc142kc US20140328862 SEQ ID NO: 561 8860 HIV1242Light chain 3bnc151kc US20140328862 SEQ ID NO: 562 8861 HIV1243 Lightchain 3bnc153kc US20140328862 SEQ ID NO: 563 8862 HIV1244 Light chain3bnc156kc US20140328862 SEQ ID NO: 564 8863 HIV1245 Light chain3bnc158kc US20140328862 SEQ ID NO: 565 8864 HIV1246 Light chain3bnc159kc US20140328862 SEQ ID NO: 566 8865 HIV1247 Light chain 3bnc15kcUS20140328862 SEQ ID NO: 567 8866 HIV1248 Light chain 3bnc176kcUS20140328862 SEQ ID NO: 568 8867 HIV1249 Light chain 3bnc193kcUS20140328862 SEQ ID NO: 569 8868 HIV1250 Light chain 3bnc196kcUS20140328862 SEQ ID NO: 570 8869 HIV1251 Light chain 3bnc31kcUS20140328862 SEQ ID NO: 571 8870 HIV1252 Light chain 3bnc42kcUS20140328862 SEQ ID NO: 572 8871 HIV1253 Light chain 3bnc53kcUS20140328862 SEQ ID NO: 573 8872 HIV1254 Light chain 3BNC55KCUS20140328862 SEQ ID NO: 545 8873 HIV1255 Light chain 3BNC60KCUS20140328862 SEQ ID NO: 546 8874 HIV1256 Light chain 3bnc62kcUS20140328862 SEQ ID NO: 574 8875 HIV1257 Light chain 3bnc65kcUS20140328862 SEQ ID NO: 575 8876 HIV1258 Light chain 3bnc66kcUS20140328862 SEQ ID NO: 576 8877 HIV1259 Light chain 3bnc75kcUS20140328862 SEQ ID NO: 577 8878 HIV1260 Light chain 3bnc79kcUS20140328862 SEQ ID NO: 578 8879 HIV1261 Light chain 3bnc81kcUS20140328862 SEQ ID NO: 579 8880 HIV1262 Light chain 3bnc84kcUS20140328862 SEQ ID NO: 580 8881 HIV1263 Light chain 3bnc87kcUS20140328862 SEQ ID NO: 581 8882 HIV1264 Light chain 3bnc89kcUS20140328862 SEQ ID NO: 582 8883 HIV1265 Light chain 3bnc91kcUS20140328862 SEQ ID NO: 583 8884 HIV1266 Light chain 3bnc95kcUS20140328862 SEQ ID NO: 584 8885 HIV1267 Light chain 412d Huang et al.,Science 317 (5846), 1930-1934 8886 (2007), NCBI Accession # 2QAD_G(214aa) HIV1268 Light Chain 44-vrc13.01 Zhon T et al., StructuralRepertoire of HIV-1- 8887 Neutralizing Antibodies Targeting the CD4Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession# 4YDJ_B (206aa) HIV1269 Light chain 45-46m2 Diskin, R., et al.,Restricting HIV-1 pathways 8888 for escape using rationally designedanti-HIV-1 antibodies; J. Exp. Med. 210 (6), 1235-1249 (2013), NCBIAccession # 4JKP_L (210aa) HIV1270 Light chain 4835_F12 US20140205612SEQ ID NO: 413 8889 (PGT-124) HIV1271 Light chain 4838_L06 US20140205612SEQ ID NO: 148 8890 (PGT-121) HIV1272 Light chain 4858_P08 US20140205612SEQ ID NO: 176 8891 (PGT-123) HIV1273 Light chain 4869-K15 US20140205612SEQ ID NO: 428 8892 (PGT-133) HIV1274 Light chain 4873_E03 US20140205612SEQ ID NO: 147 8893 (PGT-121) HIV1275 Light chain 4876_M06 US20140205612SEQ ID NO: 439 8894 (PGT-134) HIV1276 Light chain 4877_D15 US20140205612SEQ ID NO: 160 8895 (PGT-122) HIV1277 Light chain 4964_G22 US20140205612SEQ ID NO: 284 8896 (PGT-141), 4993_K13 (PGT-141), 4995_E20 (PGT-142)HIV1278 Light chain 4970_K22 US20140205612 SEQ ID NO: 312 8897 (PGT-144)HIV1279 Light chain 4980_N08 US20140205612 SEQ ID NO: 301 8898 (PGT-143)HIV1280 Light chain 4995_P16 US20140205612 SEQ ID NO: 385 8899 (PGT-145)HIV1281 Light chain 4e10 Fv Finton, K. A., et al., PLoS Pathol. 9 (9),8900 E1003639 (2013), NCBI Accession # 4LLV_B (112aa) HIV1282 Lightchain 5114_A19 US20140205612 SEQ ID NO: 392 8901 (PGT-128) HIV1283 Lightchain 5120_N10 US20140205612 SEQ ID NO: 469 8902 (PGT-139) HIV1284 Lightchain 5131_A17 US20140205612 SEQ ID NO: 488 8903 (PGT-132) HIV1285 Lightchain 5136_H01 US20140205612 SEQ ID NO: 355 8904 (PGT-131) HIV1286 Lightchain 5138_G07 US20140205612 SEQ ID NO: 483 8905 (PGT-138) HIV1287 Lightchain 5141_B17 US20140205612 SEQ ID NO: 208 8906 (PGT-126) HIV1288 Lightchain 5145_B14 US20140205612 SEQ ID NO: 329 8907 (PGT-127) HIV1289 Lightchain 5147_N06 US20140205612 SEQ ID NO: 244 8908 (PGT-130) HIV1290 Lightchain 5329_C19 US20140205612 SEQ ID NO: 257 8909 (PGT-136), 5366_P21(PGT-136) HIV1291 Light chain 5343_B08 US20140205612 SEQ ID NO: 240 8910(PGT-135), 5344_E16 (PGT-135) HIV1292 Light chain 5345_I01 US20140205612SEQ ID NO: 396 8911 (PGT-137) HIV1293 Light chain 6808_B09 US20140205612SEQ ID NO: 553 8912 (PGT-156) HIV1294 Light chain 6831_A21 US20140205612SEQ ID NO: 482 8913 (PGT-151) HIV1295 Light chain 6843_G20 US20140205612SEQ ID NO: 524 8914 (PGT-154) HIV1296 Light chain 6881_N05 US20140205612SEQ ID NO: 578 8915 (PGT-158). HIV1297 Light chain 6889_I17US20140205612 SEQ ID NO: 496 8916 (PGT-152) HIV1298 Light chain 6891_F06US20140205612 SEQ ID NO: 510 8917 (PGT-153) HIV1299 Light chain 6892_C23US20140205612 SEQ ID NO: 565 8918 (PGT-157) HIV1300 Light chain 6892_D19US20140205612 SEQ ID NO: 539 8919 (PGT-155) HIV1301 Light chain 7H6US20140348785 SEQ ID NO: 4 8920 HIV1302 Light chain 7N16 US20140348785SEQ ID NO: 6 8921 HIV1303 Light chain 8anc131 Zhou T et al. StructuralRepertoire of HIV-1- 8922 Neutralizing Antibodies Targeting the CD4Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession# 4RWY_L (213aa) HIV1304 Light chain 8ANC131KC US20140328862 SEQ ID NO:440 8923 HIV1305 Light chain 8anc134 Zhou T et al, Structural Repertoireof HIV-1- 8924 Neutralizing Antibodies Targeting the CD4 Supersite in 14Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4RX4_L (213aa)HIV1306 Light chain 8ANC134KC US20140328862 SEQ ID NO: 441 8925 HIV1307Light chain 8ANC13KC US20140328862 SEQ ID NO: 442 8926 HIV1308 Lightchain 8ANC14KC US20140328862 SEQ ID NO: 448 8927 HIV1309 Light chain8ANC16KC US20140328862 SEQ ID NO: 449 8928 HIV1310 Light chain 8anc182kcUS20140328862 SEQ ID NO: 446 8929 HIV1311 Light chain 8anc192kcUS20140328862 SEQ ID NO: 447 8930 HIV1312 Light chain 8ANC195KCUS20140328862 SEQ ID NO: 450 8931 HIV1313 Light chain 8ANC24KCUS20140328862 SEQ ID NO: 451 8932 HIV1314 Light chain 8ANC45KCUS20140328862 SEQ ID NO: 443 8933 HIV1315 Light chain 8ANC50KCUS20140328862 SEQ ID NO: 444 8934 HIV1316 Light chain 8ANC5KCUS20140328862 SEQ ID NO: 452 8935 HIV1317 Light chain 8ANC88KCUS20140328862 SEQ ID NO: 445 8936 HIV1318 Light chain Anti-HcG FotinouC. et al “Structure of an Fab fragment 8937 against a C-terminal peptideof hCG at 2.0 A resolution” J. Biol. Chem. 273 (35), 22515- 22518(1998); NCBI Accession # 1SBS_L HIV1319 Light chain B12 Zhou T et al.,Structural definition of a 8938 conserved neutralization epitope onHIV-1 gp120; Nature 445 (7129), 732-737 (2007), NCBI Accession # 2NY7_L(215aa) HIV1320 Light Chain C38-vrc16.01 Zhou T et al., StructuralRepertoire of HIV-1- 8939 Neutralizing Antibodies Targeting the CD4Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession# 4YDK_L (214aa) HIV1321 Light chain C38-vrc18.02 Zhou T et al.,Structural Repertoire of HIV-1- 8940 Neutralizing Antibodies Targetingthe CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBIAccession # 4YDL_L (211aa) HIV1322 Light chain CAP256- WO2015128846 SEQID NO: 14 8941 VRC26.01 HIV1323 Light chain CAP256- WO2015128846 SEQ IDNO: 18 8942 VRC26.02 HIV1324 Light chain CAP256- WO2015128846 SEQ ID NO:22 8943 VRC26.03 HIV1325 Light chain CAP256- WO2015128846 SEQ ID NO: 268944 VRC26.04 HIV1326 Light chain CAP256- WO2015128846 SEQ ID NO: 308945 VRC26.05 HIV1327 Light chain CAP256- WO2015128846 SEQ ID NO: 348946 VRC26.06 HIV1328 Light chain CAP256- WO2015128846 SEQ ID NO: 388947 VRC26.07 HIV1329 Light chain CAP256- WO2015128846 SEQ ID NO: 428948 VRC26.08 HIV1330 Light chain CAP256- WO2015128846 SEQ ID NO: 468949 VRC26.09 HIV1331 Light chain CAP256- WO2015128846 SEQ ID NO: 508950 VRC26.10 HIV1332 Light chain CAP256- WO2015128846 SEQ ID NO: 548951 VRC26.11 HIV1333 Light chain CAP256- WO2015128846 SEQ ID NO: 588952 VRC26.12 HIV1334 Light chain CAP256- WO2015128846 SEQ ID NO: 1718953 VRC26.25 HIV1335 Light chain CAP256- WO2015128846 SEQ ID NO: 1798954 VRC26.26 HIV1336 Light chain CAP256- WO2015128846 SEQ ID NO: 1878955 VRC26.27 HIV1337 Light chain CAP256- WO2015128846 SEQ ID NO: 6 8956VRC26-I1 HIV1338 Light chain CAP256- WO2015128846 SEQ ID NO: 10 8957VRC26-I2 HIV1339 Light chain CAP256- WO2015128846 SEQ ID NO: 2 8958VRC26- UCA. HIV1340 Light chain construct WO2015013390 SEQ ID NO: 5 8959#2816, #2861 HIV1341 Light chain construct WO2015013390 SEQ ID NO: 68960 #2817, #2860 HIV1342 Light chain construct WO2015013390 SEQ ID NO:7 8961 #2858, #2859, #2861 HIV1343 Light chain Fab 2219 Stanfield, R.L., et al., J. Virol. 80 (12), 6093- 8962 6105 (2006), NCBI Accession #2B0S_L (215aa) HIV1344 Light chain Fab 2g12 Doores, K. J., et al., J.Virol. 84 (20), 10690- 8963 10699 (2010), NCBI Accession # 3OAU_L(212a)HIV1345 Light chain Fab 2g12 Stanfield, R. L. et al., Crystal structureof the 8964 HIV neutralizing antibody 2G12, in complex with a bacterialoligosaccharide analog of mammalian oligomannose; Glycobiology 25 (4),412-419 (2015), NCBI Accession # 4RBP_L (213aa) HIV1346 Light chain FabF425- Bell et al., J. Mol. Biol. 375 (4), 969-978 8965 b4e8 (2008), NCBIAccession # 2QSC_L (215aa) HIV1347 Light chain G4D US20130195881 SEQ IDNO: 39 8966 HIV1348 Light chain G4H US20130195881 SEQ ID NO: 38 8967HIV1349 Light chain gVRC-H5(d74)/ WO2013090644 SEQ ID NO: 19 8968VRC-PG04LC, gVRCOH12(D74)/ VRC-PG04LC HIV1350 Light chain 12 (unbound)Fera, D. et al., Affinity maturation in an HIV 8969 From Ch103 broadlyneutralizing B-cell lineage through Lineage reorientation of variabledomains; Proc. Natl. Acad. Sci. U.S.A. 111 (28), 10275-10280 (2014),NCBI Accession # 4QHN_B (213aa) HIV1351 Light chain IGLV3- US20140348785SEQ ID NO: 8 8970 19*01 HIV1352 Light chain k3 WO2015117008 SEQ ID NO:19 8971 HIV1353 Light chain k5 WO2015117008 SEQ ID NO: 20 8972 HIV1354Light chain k53 WO2015117008 SEQ ID NO: 24 8973 HIV1355 Light chain k59WO2015117008 SEQ ID NO: 21 8974 HIV1356 Light chain k61 WO2015117008 SEQID NO: 25 8975 HIV1357 Light chain k62 WO2015117008 SEQ ID NO: 22 8976HIV1358 Light chain k81 WO2015117008 SEQ ID NO: 28 8977 HIV1359 Lightchain kl 1 WO2015117008 SEQ ID NO: 26 8978 HIV1360 Light chain kl8WO2015117008 SEQ ID NO: 23 8979 HIV1361 Light chain kl9 WO2015117008 SEQID NO: 27 8980 HIV1362 Light chain LSSB2066KC US20140328862 SEQ ID NO:501 8981 HIV1363 Light chain LSSB2080KC US20140328862 SEQ ID NO: 5028982 HIV1364 Light chain LSSB2133KC US20140328862 SEQ ID NO: 503 8983HIV1365 Light chain LSSB2182KC US20140328862 SEQ ID NO: 504 8984 HIV1366Light chain LSSB2339LC US20140328862 SEQ ID NO: 467 8985 HIV1367 Lightchain LSSB2351LC US20140328862 SEQ ID NO: 468 8986 HIV1368 Light chainLSSB2364LC US20140328862 SEQ ID NO: 469 8987 HIV1369 Light chainLSSB2367LC US20140328862 SEQ ID NO: 470 8988 HIV1370 Light chainLSSB2490LC US20140328862 SEQ ID NO: 471 8989 HIV1371 Light chainLSSB2530LC US20140328862 SEQ ID NO: 472 8990 HIV1372 Light chainLSSB2554LC US20140328862 SEQ ID NO: 473 8991 HIV1373 Light chainLSSB2586LC US20140328862 SEQ ID NO: 474 8992 HIV1374 Light chainLSSB2612LC US20140328862 SEQ ID NO: 475 8993 HIV1375 Light chainLSSB2640LC US20140328862 SEQ ID NO: 476 8994 HIV1376 Light chainLSSB2644LC US20140328862 SEQ ID NO: 477 8995 HIV1377 Light chainLSSB2666LC US20140328862 SEQ ID NO: 478 8996 HIV1378 Light chainLSSB2680LC US20140328862 SEQ ID NO: 479 8997 HIV1379 Light chainLSSB2683LC US20140328862 SEQ ID NO: 480 8998 HIV1380 Light chainLSSB331KC US20140328862 SEQ ID NO: 505 8999 HIV1381 Light chainLSSB344LC US20140328862 SEQ ID NO: 481 9000 HIV1382 Light chainLSSNEC107LC US20140328862 SEQ ID NO: 482 9001 HIV1383 Light chainLSSNEC108LC US20140328862 SEQ ID NO: 483 9002 HIV1384 Light chainLSSNEC117LC US20140328862 SEQ ID NO: 484 9003 HIV1385 Light chainLSSNEC118LC US20140328862 SEQ ID NO: 485 9004 HIV1386 Light chainLSSNEC122LC US20140328862 SEQ ID NO: 486 9005 HIV1387 Light chainLSSNEC24LC US20140328862 SEQ ID NO: 487 9006 HIV1388 Light chainLSSNEC2LC US20140328862 SEQ ID NO: 488 9007 HIV1389 Light chainLSSNEC33LC US20140328862 SEQ ID NO: 489 9008 HIV1390 Light chainLSSNEC46LC US20140328862 SEQ ID NO: 490 9009 HIV1391 Light chainLSSNEC48LC US20140328862 SEQ ID NO: 491 9010 HIV1392 Light chainLSSNEC52LC US20140328862 SEQ ID NO: 492 9011 HIV1393 Light chainLSSNEC56LC US20140328862 SEQ ID NO: 493 9012 HIV1394 Light chainLSSNEC60LC US20140328862 SEQ ID NO: 494 9013 HIV1395 Light chainLSSNEC70LC US20140328862 SEQ ID NO: 495 9014 HIV1396 Light chainLSSNEC72LC US20140328862 SEQ ID NO: 496 9015 HIV1397 Light chainLSSNEC7LC US20140328862 SEQ ID NO: 497 9016 HIV1398 Light chainLSSNEC89LC US20140328862 SEQ ID NO: 498 9017 HIV1399 Light chainLSSNEC94LC US20140328862 SEQ ID NO: 499 9018 HIV1400 Light chainLSSNEC9LC US20140328862 SEQ ID NO: 500 9019 HIV1401 Light chainm12-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 7 9020 HIV1402 Lightchain m14-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 5 9021 HIV1403Light chain m16-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 8 9022HIV1404 Light chain m18 Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 69023 HIV1405 Light chain M66 Ofek, G., et al., Structural Basis forHIV-1 9024 Neutralization by 2F5-Like Antibodies m66 and m66.6; J.Virol. 88 (5), 2426-2441 (2014), NCBI Accession # 4NRY_H (235aa) HIV1406Light chain M66.6 Ofek, G., et al., Structural Basis for HIV-1 9025Neutralization by 2F5-Like Antibodies m66 and m66.6; J. Virol. 88 (5),2426-2441 (2014), NCBI Accession # 4NRZ_L (213aa) HIV1407 Light ChainMab 2158 Spurrier, B., et al., Functional Implications of 9026 theBinding Mode of a Human Conformation- Dependent V2 Monoclonal Antibodyagainst HIV; J. Virol, 88 (8), 4100-4112 (2014), NCBI Accession # 4OAW_C(214aa) HIV1408 Light chain MV1 US20130195881 SEQ ID NO: 40 9027 HIV1409Light chain Pg16 Fab Pancera, M., et al., Nat. Struct. Mol. Biol. 209028 (7), 804-813 (2013), NCBI Accession # 4DQO_L (216aa) HIV1410 Lightchain Pg9 Willis, J. R., et al., J. Clin. Invest. 125 (6), 2523- 90292531 (2015), NCBI Accession # 4YAQ_L (216aa) HIV1411 Light chainPgt121-Gl Mouquet H et al., Complex-type N-glycan 9030 Fab recognitionby potent broadly neutralizing HIV antibodies; Proc Natl Acad Sci USA.2012 Nov. 20; 109(47): E3268-77, NCBI Accession # 4FQQ_A (215aa) HIV1412Light chain Pgt122 Julien, J. P., et al., PLoS Pathol. 9 (5), 9031E1003342 (2013)”, NCBI Accession # 4JY5_L (211aa) HIV1413 Light chainPgt123 Julien, J. P., et al., PLoS Pathol. 9 (5), 9032 E1003342 (2013)”,NCBI Accession # 4JY6_A (211aa) HIV1414 Light chain Pgt124 Garces, F.,et al., Structural Evolution of 9033 Glycan Recognition by a Family ofPotent HIV Antibodies; Cell 159 (1), 69-79 (2014), NCBI Accession #4R26_L (214aa) HIV1415 Light chain Pgt130 Doores, K. J., et al., J.Virol. 89 (2), 1105-1118 9034 (2015), NCBI Accession # 4RNR_B (216aa)HIV1416 Light chain Pgt135 Grover et al., Science 343 (6171), 656-6619035 (2014), NCBI Accession # 4NZR_L (214aa) HIV1417 Light chain S8,S19, S20 US20110059015 SEQ ID NO: 2 9036 HIV1418 light chain Suvizumab9037 HIV1419 Light Chain Vrc- Pg04 Wu, X., et al., Focused evolution ofHIV-1 9038 neutralizing antibodies revealed by structures and deepsequencing; Science 333 (6049), 1593-1602 (2011)”, NCBI Accession #3SE9_L (208aa) HIV1420 Light chain VRC01 U.S. Pat. No. 8,637,036B2 SEQID NO: 2 9039 HIV1421 Light chain VRC01 US2014 0322163 SEQ ID NO: 539040 E1/12 deletion HIV1422 Light chain VRC01 US2014 0322163 SEQ ID NO:222 9041 E1/I2del F97D HIV1423 Light chain VRC01 US2014 0322163 SEQ IDNO: 225 9042 E1/I2del F97H HIV1424 Light chain VRC01 US2014 0322163 SEQID NO: 223 9043 E1/I2del F97K HIV1425 Light chain VRC01 US2014 0322163SEQ ID NO: 224 9044 E1/I2del F97S HIV1426 Light chain VRC01 US20140322163 SEQ ID NO: 219 9045 E1/I2del V3E HIV1427 Light chain VRC01US2014 0322163 SEQ ID NO: 227 9046 E1/I2del V3E, F97H HIV1428 Lightchain VRC01 US2014 0322163 SEQ ID NO: 226 9047 E1/I2del V3E, F97SHIV1429 Light chain VRC01 US2014 0322163 SEQ ID NO: 220 9048 E1/I2delV3K HIV1430 Light chain VRC01 US2014 0322163 SEQ ID NO: 221 9049E1/I2del V3S HIV1431 Light chain VRC01HC/ WO2013090644 SEQ ID NO: 319050 VRC03LC HIV1432 Light chain VRC01hpL02 US2014 0322163 SEQ ID NO: 509051 HIV1433 Light chain VRC01hpL02 US2014 0322163 SEQ ID NO: 232 9052E1/I2- deletion, V3S HIV1434 Light chain VRC01hpL03 US2014 0322163 SEQID NO: 228 9053 HIV1435 Light chain VRC01hpL04 US2014 0322163 SEQ ID NO:229 9054 HIV1436 Light chain VRC01hpL05 US2014 0322163 SEQ ID NO: 2309055 HIV1437 Light chain VRC01hpL06 US2014 0322163 SEQ ID NO: 231 9056HIV1438 Light chain VRC01LhpL US2014 0322163 SEQ ID NO: 233 9057 03E1/I2- deletion, V3S HIV1439 Light chain VRC01LhpL US2014 0322163 SEQ IDNO: 237 9058 04 E1/I2- deletion, V3E HIV1440 Light chain VRC01LhpLUS2014 0322163 SEQ ID NO: 234 9059 04 E1/I2- deletion, V3S HIV1441 Lightchain VRC01LhpL US2014 0322163 SEQ ID NO: 235 9060 05 E1/12 deletion,V3S HIV1442 Light chain VRC01LhpL US2014 0322163 SEQ ID NO: 236 9061 06E1/I2- deletion, V3S HIV1443 Light chain VRC02 U.S. Pat. No. 8,637,036B2SEQ ID NO: 4 9062 HIV1444 Light chain VRC03 U.S. Pat. No. 8,637,036B2SEQ ID NO: 28 9063 HIV1445 Light chain VRC03HC- WO2013090644 SEQ ID NO:1 9064 VRC01LC HIV1446 Light chain Vrc06b Wu, X., et al., Maturation andDiversity of the 9065 VRC01-Antibody Lineage over 15 Years of ChronicHIV-1 Infection; Cell 161 (3), 470-485 (2015), NCBI Accession # 4XNZ_F(209aa) HIV1447 Light chain Vrc08c Wu, X., et al., Maturation andDiversity of the 9066 VRC01-Antibody Lineage over 15 Years of ChronicHIV-1 Infection; Cell 161 (3), 470-485 (2015), NCBI Accession # 4XNY_L(211aa) HIV1448 Light chain Vrc23 Georgiev, I. S., et al., Delineatingantibody 9067 recognition in polyclonal sera from patterns of HIV-1isolate neutralization; Science 340 (6133), 751-756 (2013), NCBIAccession # 4J6R_L (210aa) HIV1449 Light chain VRC-CH30 WO2013090644 SEQID NO: 21 9068 HIV1450 Light chain Vrc-ch31 Zhou T et al., Immunity 39(2), 245-258 (2013), 9069 NCBI Accession # 4LSP_L (210aa) HIV1451 Lightchain VRC-CH32 Wu X. et al., “Focused evolution of HIV-1 9070neutralizing antibodies revealed by structures and deep sequencing”Science 333 (6049), 1593-1602 (2011), NCBI Accession # AEM62727 HIV1452Light chain VRC-CH33 WO2013090644 SEQ ID NO: 27 9071 HIV1453 Light chainVRC-CH34 WO2013090644 SEQ ID NO: 29 9072 HIV1454 Light chain VRC-PG04 WuX. et al,“Focused evolution of HIV-1 9073 neutralizing antibodiesrevealed by structures and deep sequencing” Science 333 (6049),1593-1602 (2011), NCBI Accession # AEM62754 HIV1455 Light chainVRC-PG04b WO2013090644 SEQ ID NO: 43 9074 HIV1456 Light chain Vrc-pg20Zhou T et al., immunity 39 (2), 245-258 (2013), 9075 NCBI Accession #4LSU_L (204aa) HIV1457 Light chain X5 U.S. Pat. No. 7,378,093B2 SEQ IDNO: 2 9076 HIV1458 Light chain X5 U.S. Pat. No. 8,110,192B2 SEQ ID NO: 49077 HIV1459 Light chain Z13e1 Stanfield. R. L., et al, J. Mol. Biol.414 (3), 460- 9078 476 (2011), NCBI Accession # 3Q1S_L (212aa) HIV1460Light Chain Z258- Zhon T et al., Structural Repertoire of HIV-1- 9079vrc27.01 Neutralizing Antibodies Targeting the CD4 Supersite in 14Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDI_L (210aa)HIV1461 Light chain NCBI Accession # 1N0X_M (215aa) 9080 HIV1462 Lightchain Okada, N., et al., Human IgM Monoclonal 9081 Antibodies Reactivewith HIV-1-Infected Cells Generated Using a Trans-Chromosome Mouse;Microbiol. Immunol. 49 (5), 447-459 (2005), NCBI Accession #AAS01772.1(236aa) HIV1463 Light chain U.S. Pat. No. 5,804,440A SEQ IDNO: 101 9082 HIV1464 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 1029083 HIV1465 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 103 9084HIV1466 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 104 9085 HIV1467Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 105 9086 HIV1468 Lightchain U.S. Pat. No. 5,804,440A SEQ ID NO: 107 9087 HIV1469 Light chainU.S. Pat. No. 5,804,440A SEQ ID NO: 110 9088 HIV1470 Light chain U.S.Pat. No. 5,804,440A SEQ ID NO: 115 9089 HIV1471 Light chain U.S. Pat.No. 5,804,440A SEQ ID NO: 118 9090 HIV1472 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 121 9091 HIV1473 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 122 9092 HIV1474 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 124 9093 HIV1475 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 132 9094 HIV1476 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 147 9095 HIV1477 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 148 9096 HIV1478 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 149 9097 HIV1479 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 150 9098 HIV1480 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 151 9099 HIV1481 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 95 9100 HIV1482 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 96 9101 HIV1483 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 97 9102 HIV1484 Light chain U.S. Pat. No.5,804,440A SEQ ID NO: 98 9103 HIV1485 Light chain WO2014063059 SEQ IDNO: 11 9104 HIV1486 Light chain WO2014063059 SEQ ID NO: 129 9105 HIV1487Light chain WO2014063059 SEQ ID NO: 13 9106 HIV1488 Light chainWO2014063059 SEQ ID NO: 15 9107 HIV1489 Light chain WO2014063059 SEQ IDNO: 17 9108 HIV1490 Light chain WO2014063059 SEQ ID NO: 19 9109 HIV1491Light chain WO2014063059 SEQ ID NO: 21 9110 HIV1492 Light chainWO2014063059 SEQ ID NO: 23 9111 HIV1493 Light chain WO2014063059 SEQ IDNO: 3 9112 HIV1494 Light chain WO2014063059 SEQ ID NO: 5 9113 HIV1495Light chain WO2014063059 SEQ ID NO: 7 9114 HIV1496 Light chainWO2014063059 SEQ ID NO: 9 9115 HIV1497 Light chain WO2014063059 SEQ IDNO: 1 9116 consensus HIV1498 Light chain constant TNX-355, US20130195881SEQ ID NO: 2 9117 region Idalizumab HIV1499 Light Chain Fab Ch02McLellan, J. S., et al., Nature 480 (7377), 336- 9118 343 (2011), NCBIAccession # 3U46_B (215aa) HIV1500 Light Chain Of Anti- 21C Diskin, R.,et al., Nat. Struct. Mol. Biol. 17 (5), 9119 HIV Fab From 608-613(2010), NCBI Accession # 3LMJ_L Human 21c Antibody (217aa) HIV1501 LightChain Of Anti- 830a Pan et al., J. Virol. 89 (15), 8003-8010 (2015),9120 hiv-1 Gp120 V1v2 NCBI Accession # 4YWG_L (216aa) Antibody 830aHIV1502 Light Chain Of Anti- Fab 2558 Gorny et al., PLoS ONE 6 (12),E27780 (2011), 9121 hiv-1 V3 Monoclonal NCBI Accession # 3UJI_L (209aa)Antibody HIV1503 Light Chain Of Anti- Fab 4025 Gorny et al., PLoS ONE 6(12), E27780 (2011), 9122 hiv-1 V3 Monoclonal NCBI Accession # 3UJJ_L(213aa) Antibody HIV1504 Light chain partial 412D Huang C. et al“Structural basis of tyrosine 9123 sulfation and VH-gene usage inantibodies that recognize the HIV type 1 coreceptor-binding site ongp120” Proc. Natl. Acad. Sci. U.S.A. 101 (9), 2706-2711 (2004), NCBIAccession # AAR88380 HIV1505 Light chain partial 694/98D Li L. et al, “Abroad range of mutations in HIV- 9124 1 neutralizing human monoclonalantibodies specific for V2, V3, and the CD4 binding site”, Mol. Immunol.66 (2), 364-374 (2015); NCBI Accession # AKH36512 HIV1506 Light chainvariable 0.5γ (1C10) U.S. Pat. No. 8,722,861B2 SEQ ID NO: 2 9125 regionHIV1507 Light chain variable 0.5γ (3D6) U.S. Pat. No. 8,722,861B2 SEQ IDNO: 6 9126 region HIV1508 Light chain variable 10J4 mAb WO2015103549 SEQID NO: 4 9127 region HIV1509 Light chain variable 10M6 mAb WO2015103549SEQ ID NO: 6 9128 region HIV1510 Light chain variable 13110 mAbWO2015103549 SEQ ID NO: 8 9129 region HIV1511 Light chain variable2N5mAb WO2015103549 SEQ ID NO: 10 9130 region HIV1512 Light chainvariable 35022 mAb WO2015103549 SEQ ID NO: 2 9131 region HIV1513 Lightchain variable 42F9 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 8 9132 regionHIV1514 Light chain variable 49G2 U.S. Pat. No. 8,722,861B2 SEQ ID NO:10 9133 region HIV1515 Light chain variable 4O20mAb WO2015103549 SEQ IDNO: 12 9134 region HIV1516 Light chain variable 5G2 U.S. Pat. No.8,722,861B2 SEQ ID NO: 4 9135 region HIV1517 Light chain variable 7B9mAbWO2015103549 SEQ ID NO: 14 9136 region HIV1518 Light chain variable7K3mAb WO2015103549 SEQ ID NO: 16 9137 region HIV1519 Light chainvariable B4 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 4 9138 region HIV1520Light chain variable B4DIVKv.1 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 99139 region HIV1521 Light chain variable B4DIVKv.2 U.S. Pat. No.7,872,110B2 SEQ ID NO: 10 9140 region HIV1522 Light chain variableB4DIVKv.3 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 11 9141 region HIV1523Light chain variable bl2 IgA2 WO2014040024 SEQ ID NO: 30 9142 regionantibody HIV1524 Light chain variable CHμ39.1 U.S. Pat. No. 5,773,247SEQ ID NO: 12 9143 region HIV1525 Light chain variable CHμ5.5 U.S. Pat.No. 5,773,247 SEQ ID NO: 16 9144 region HIV1526 Light chain variableF425-Alg8 WO2014040024 SEQ ID NO: 13 9145 region antibody HIV1527 Lightchain variable Fab 43 US20090191216 SEQ ID NO: 9 9146 region HIV1528Light chain variable HGN194 US20110212106 SEQ ID NO: 46 9147 regionHIV1529 Light chain variable HJ16 US20110212106 SEQ ID NO: 14 9148region HIV1530 Light chain variable HK20 US20110212106 SEQ ID NO: 309149 region HIV1531 Light chain variable IgA antibody WO2014040024 SEQID NO: 15 9150 region HIV1532 Light chain variable MakandalUS20100111990 SEQ ID NO: 3 9151 region monoclonal antibody (Mmab)HIV1533 Light chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 189152 region HIV1534 Light chain variable NM-01 U.S. Pat. No. 5,665,569SEQ ID NO: 28 9153 region HuVH HIV1535 Light chain variable NM-01 U.S.Pat. No. 5,665,569 SEQ ID NO: 30 9154 region HuVK HIV1536 Light chainvariable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 32 9155 region HuVKFHIV1537 Light chain variable PGT125 Walker L. M. et al “Broadneutralization 9156 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14410 HIV1538 Light chain variable PGT126 Walker L. M. et al “Broadneutralization 9157 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14411 HIV1539 Light chain variable PGT131 Walker L. M. et al “Broadneutralization 9158 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AENT4415 HIV1540 Light chain variable PGT136 Walker L. M. et al “Broadneutralization 9159 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14417 HIV1541 Light chain variable PGT137 Walker L. M. et al “Broadneutralization 9160 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14418 HIV1542 Light chain variable PGT141 Walker L. M. et al “Broadneutralization 9161 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession# AEN14419HIV1543 Light chain variable PGT142 Walker L.M. et al “Broadneutralization 9162 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (20 1 I), NCBI Accessiots #AEN14385 HIV1544 Light chain variable PGT143 Walker L.M. et al “Broadneutralization 9163 region coverage of HIV by multiple liighly potentantibodies”. Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14421 HIV1545 Light chain variable PGT144 Walker L.M. et al “Broadneutralization 9164 region coverage of HIV by multiple highly potentantibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession #AEN14422 HIV1546 Light chain variable PGT151 Falkowska, E. et al“Broadly Neutralizing HIV 9165 region Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on CleavedEnvelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession #AIC32543 HIV1547 Light chain variable PGT152 Falkowska, E. et al“Broadly Neutralizing HIV 9166 region Antibodies Define aGlycan-Dependent Epitope on the Prefusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32544 HIV1548 Light chain variable PGT153 Falkowska, E.et al “Broadly Neutralizing HIV 9167 region Antibodies Define aGlycan-Dependent Epitope on the Profusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (>). 657-668 (2014), NCBIAccession # AIC32545 HIV1549 Light chain variable PGT154 Falkowska, E.et al “Broadly Neutralizing HIV 9168 region Antibodies Define aGlycan-Dependent Epitope on the Prefusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32529 HIV1550 Light chain variable PGT155 Falkowska, E.et al “Broadly Neutralizing HIV 9169 region Antibodies Define aGlycan-Dependent Epitope on the Prefusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32547 HIV1551 Light chain variable PGT156 Falkowska, E.et al “Broadly Neutralizing HIV 9170 region Antibodies Define aGlycan-Dependent Epitope on the Prefusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32548 HIV1552 Light chain variable PGT157 Falkowska, E.et al “Broadly Neutralizing HIV 9171 region Antibodies Define aGlycan-Dependent Epitope on the Prefusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32549 HIV1553 Light chain variable PGTI58 Falkowska, E.et al “Broadly Neutralizing HIV 9172 region Antibodies Define aGlycan-Dependent Epitope on the Prefusion Conformation of gp41 onCleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBIAccession # AIC32550 HIV1554 Light chain variable rF105 WO1993012232 SEQID NO: 3 9173 region HIV1555 Light chain variable ScFvX5-CD4 U.S. Pat.No. 7,378,093B2 SEQ ID NO: 15 9174 region HIV1556 Light chain variableTNX-355, US20130195881 SEQ ID NO: 1 9175 region Idalizumab HIV1557 Lightchain variable VCR14 US20150044137 SEQ ID NO: 25 9176 region HIV1558Light chain variable VCR14b US20150044137 SEQ ID NO: 26 9177 regionHIV1559 Light chain variable VCR14c US20150044137 SEQ ID NO: 27 9178region HIV1560 Light chain variable VCR16 US20150044137 SEQ ID NO: 339179 region HIV1561 Light chain variable VCR16b US20150044137 SEQ ID NO:34 9180 region HIV1562 Light chain variable VCR16c US20150044137 SEQ IDNO: 35 9181 region HIV1563 Light chain variable VCR16d US20150044137 SEQID NO: 36 9182 region HIV1564 Light chain variable VRC13 US20150044137SEQ ID NO: 17 9183 region HIV1565 Light chain variable VRC13bUS20150044137 SEQ ID NO: 18 9184 region HIV1566 Light chain variableVRC13c US20150044137 SEQ ID NO: 19 9185 region HIV1567 Light chainvariable VRC13d US20150044137 SEQ ID NO: 20 9186 region HIV1568 Lightchain variable VRC13e US20150044137 SEQ ID NO: 21 9187 region HIV1569Light chain variable VRC13f US20150044137 SEQ ID NO: 22 9188 regionHIV1570 Light chain variable VRC13g US20150044137 SEQ ID NO: 23 9189region HIV1571 Light chain variable VRC13h US20150044137 SEQ ID NO: 249190 region HIV1572 Light chain variable VRC15 US20150044137 SEQ ID NO:28 9191 region HIV1573 Light chain variable US20150004190 SEQ ID NO: 579192 region HIV1574 Light Chain, Fab Ch04 McLellan, J. S. et al.,Structure of HIV-1 gp120 9193 V1 V2 domain with broadly neutralizingantibody PC9; Nature 480 (7377), 336-343 (2011), NCBI Accession # 3TCL_B(215aa) HIV1575 Light Chain, Fab N5-i5 Acharya, P., et al., StructuralDefinition of an 9194 Antibody-Dependent Cellular Cytotoxicity ResponseImplicated in Reduced Risk for HIV- 1 Infection; J. Virol. 88 (21),12895-12906 (2014), NCBI Accession # 4H8W_L (217aa) HIV1576 Light Chain,Ig Nih45-46 Fab Diskin, R., et al., Science 334 (6060), 1289- 9195 KappaChain C 1293 (2011), NCBI Accession # 3U7Y_L Region (210aa) HIV1577Light Chain, Ig Pgt127 Pejchal, R., et al., Science 334 (6059), 1097-9196 Lambda-2 Chain C 1103 (2011), NCBI Accession # region 3TWC_L(211aa)HIV1578 Light Chain, Ig 7b2 Santra, S., et al., PLoS Pathol. 11 (8),9197 Kappa Chain C E1005042 (2015), NCBI Accession # 4YDV_L Region(265aa) HIV1579 Light Chain; Fab N60-i3 Gohain, N., et al., CocrystalStructures of 9198 Antibody N60-i3 and Antibody JR4 in Complex withgp120 Define More Cluster A Epitopes Invoked in Effective Antibody-Dependent Effector Function against HIV-1; J. Virol. 89 (17), 8840-8854(2015), NCBI Accession # 4RFO_L (221aa) HIV1580 Light Chain; Ig Pgt128Pejchal, R., et al., Science 334 (6059), 1097- 9199 Lambda-2 Chain C1103 (2011), NCBI Accession # 3TV3_L region (211aa) HIV1581 Scfv B11U.S. Pat. No. 7,744,887B2 SEQ ID NO: 8 9200 HIV1582 Scfv U.S. Pat. No.8,110,192B2 SEQ ID NO: 1 9201 HIV1583 Scfv U.S. Pat. No. 8,110,192B2 SEQID NO: 2 9202 HIV1584 Scfv U.S. Pat. No. 8,110,192B2 SEQ ID NO: 3 9203HIV1585 Scfv (SEQRES) 3b3 variant Clark et al., Protein Sci. 18 (12),2429-2441 9204 (2009), NCBI Accession # 3JUY_A (256aa) HIV1586 Scfv D5U.S. Pat. No. 7,744,887B2 SEQ ID NO: 2 9205 HIV1587 Scfv-cd4 fusion U.S.Pat. No. 8,110,192B2 SEQ ID NO: 8 9206 protein HIV1588 447-52d Dhillon,A. K., et al., Acta Crystallogr. D Biol. 9207 Crystallogr. D64 (PT 7),792-802 (2008), NCBI Accession # 3C2A_1(231aa) HIV1589 447-52d Dhillon,A. K., et al., Acta Crystallogr, D Biol. 9208 Crystallogr. D64 (PT 7),792-802 (2008), NCBI Accession # 3C2A_M (216aa) HIV1590 F105 Wilkinson,R. A., et al., J. Virol. 79 (20), 13060- 9209 13069 (2005), NCBIAccession # 1U6A_H (224aa) HIV1591 F105 Wilkinson, R. A., et al., J.Virol. 79 (20), 13060- 9210 13069 (2005), NCBI Accession # 1U6A_L(215aa) HIV1592 Fab 8062 Frisch, C., et al., PLoS Pathol. 6 (11), 9211E1001182 (2010), NCBI Accession # 3MAC_H (245aa) HIV1593 Fab 8062Frisch, C., et al., PLoS Pathol. 6 (11), 9212 E1001182 (2010), NCBIAccession # 3MAC_L (213aa) HIV1594 Fab 8066 Frisch, C., et al., PLoSPathol. 6 (11), 9213 E1001182 (2010), NCBI Accession # 3MA9_H (245aa)HIV1595 Fab 8066 Frisch, C., et al., PLoS Pathol. 6 (11), 9214 E1001182(2010), NCBI Accession # 3MA9_L (213aa) HIV1596 Fab′2F5 U.S. Pat. No.6,482,928 SEQ ID NO: 6 9215 fragment HIV1597 Fab′2F5 U.S. Pat. No.6,482,928 SEQ ID NO: 7 9216 fragment HIV1598 M18 Fab Prabakaran, P., etal., J. Mol. Biol. 357 (1), 82- 9217 99 (2006), NCBI Accession # 2AJ3_D(228aa) HIV1599 M18 Fab Prabakaran, P., et al., J. Mol. Biol. 357 (1),82- 9218 99 (2006), NCBI Accession # 2AJ3_E (213aa) HIV1600 Pg16Pancera, M. et al., J. Virol. 84 (16), 8098-8110 9219 (2010), NCBIAccession # 3MME_A (238aa) HIV1601 Pg16 Paneera, M, et al., J. Virol. 84(16), 8098-8110 9220 (2010), NCBI Accession # 3MME_B (216aa)

In one embodiment, the payload region of the AAV particle comprises oneor more nucleic acid sequences, fragment or variants thereof or encodesone or more polypeptides, fragments or variants thereof described inEuropean Patent Publication No. EP327000, EP478689, EP554401, EP581353and EP711439, US Publication No US20110104163, US20110212106,US20130215726 and US20130251726, U.S. Pat. Nos. 5,266,479, 5,804,440,6,657,050, 8,637,036, and 9,090,675, and International Publication No.WO2012154312, WO2013163427, WO2014043386, WO2015048462, WO2015048610,WO2015048770 the contents of each of which are herein incorporated byreference in their entirety, against HIV.

Disease Specific Epitopes, Innate Defense Regulator Peptides, CyclicPeptides

In one embodiment, the viral genomes of the AAV particles may comprisenucleic acids which have been engineered to enable expression ofantibodies binding to disease-specific epitopes of proteins. Suchantibodies may be used to diagnose, prevent, and/or treat thecorresponding medical conditions by targeting epitopes of the proteinpresented by or accessible on native or non-native forms (e.g.,misfolded forms of native proteins) of the target Such epitopes may bespecific to diseases involved with misfolding of a protein due topathologic condition and resulting in misfolded aggregates. Thedisease-specific proteins are considered to be toxic to neurons and tohave a role in neuronal cell death and dysfunction in neurodegenerativediseases including, but not limited to. Alzheimer's disease (AD),armyotrophic lateral sclerosis (ALS), Parkinson's disease, dementia byLew body (DLB), and prion diseases. e.g. Creutzfeldt-Jakob disease(CJD), Gerstmann-Straussler-Scheinker syndrome (GSS), kuru, and fatalfarnilial insomnia (FFI).

In one embodiment, the encoded disease-specific epitopes may includeepitopes on SOD1 that are revealed as SOD1 (Superoxide dismutase[Cu—Zn]) dissociates from its homodimeric, normal state. The SODepitopes may be selectively presented or accessible in non-native SOD1forms including misfolded SOD1 monomer, misfolded SOD1 dimer, and theepitopes selectively presented or accessible in SOD1 aggregates. Suchepitopes may be specific to neurodegenerative diseases including, butnot limited to, armyotrophic lateral sclerosis (ALS), Alzheimer's (AD).Parkinson's (PD), and Lewr body diseases (LBD).

In one embodiment, the expressed antibodies may bind to epitopespresented by or accessible on non-native forms of SOD1, such as thosepresented by SEQ ID NO: 2, 3, 5, 6, and 7 of U.S. Pat. No. 7,977,314(the contents of which are herein incorporated by reference in itsentirety), or presented by or accessible on monomeric forms of SOD1,such as those presented by SEQ ID NOs: 1 and 4 of U.S. Pat. No.7,977,314, the contents of which are herein incorporated by reference intheir entirety. In one embodiment, the expressed antibodies may compriseisolated peptides corresponding to such epitopes, such as thosepresented in SEQ ID NOs: 1-8 or SEQ ID NOs-8-16, or epitopes presentedby SEQ ID NOs: 34-63, 65-79 of U.S. Pat. No. 7,977,314, the contents ofwhich are herein incorporated by reference in their entirety.

In one embodiment, the encoded disease-specific epitopes may be specificto diseases associated with prion protein (PrP), familial amyloidpolyneuropathy or senile systemic amyloidosis or a disease related bythe presence of misfolded transthyretine (TTR); renal accumulation of1(2 microglobulin amyloid deposits or a disease related by the presenceof misfolded D12 microglobulin, amyotrophic lateral sclerosis (ALS) or adisease related by the presence of misfolded SOD1; leukemias or myelomasor a disease related by the presence of misfolded cluster ofdifferentiation 38 (CD38); colon cancer metastasis and or a diseaserelated by the presence of misfolded cluster of differentiation (CD44);tumors associated with tumor necrosis factor receptor (TNFR); cancersincluding cervical, head and neck, endometrial, lung and breastcarcinomas, pleural mesotheliomas, malignant melanomas, Hodgkinlymphomas, anaplastic large cell non-Hodgkin lymphomas, or a diseaserelated by the presence of misfolded Notch homolog 1 (NOTCH1) e.g. acutemyeloid leukemias and B-cell chronic lymphoid leukemias; cancer in whichFas receptor (FasR) is implicated, cancers and related disorders inwhich misfolded epidermal growth factor (EGFR) is implicated; and/orother related diseases, disorders and conditions.

In one embodiment, the encoded disease specific epitopes may includeepitopes that are revealed as the proteins misfold. In one embodiment,the expressed antibodies may bind to predicted epitopes of human PrP,such as those presented by SEQ ID NOs: 1-10 of US Patent Publication No.US20100233176; bovine PrP, such as those presented by SEQ ID NOs: 11-15of US Patent Publication No. US20100233176. TTR, such as those presentedby SEQ ID NOs: 16-22 of US Patent Publication No US20100233176; beta-2microglobulin, such as those presented by SEQ ID NOs: 23-26 of US PatentPublication No. US20100233176; SOD1, such as those presented by SEQ IDNOs: 27-40 of US Patent Publication No. US201100233176; CD38, such asthose presented by SEQ ID NOs: 41-45 of US Patent Publication No.US20100233176; CD44, such as those presented by 46-50 of US PatentPublication No. US20100233176; TNFR, such as those presented by 51-55 ofUS Patent Publication No. US20100233176; notch protein, such as thosepresented in SEQ ID NOs: 56-60 of US Patent Publication NoUS201100233176; FasR, such as those presented by SEQ ID NOs: 61-65 of USPatent Publication No. US20100233176 and EGFR, such as those presentedby SEQ ID NOs: 66-80 of US Patent Publication No. US20100233176; thecontents of which are herein incorporated by reference in theirentirety.

In one embodiment, the expressed antibodies may comprise peptidescorresponding to such epitopes. In one embodiment, the expressedantibodies may comprise prion-specific peptides, such as those presentedby SEQ ID NOs: 81-88 of US Patent Publication No. US20100233176, thecontents of which are herein incorporated by reference in theirentirety, and variations thereof.

In one embodiment, the encoded disease-specific epitopes may be specificto prion diseases, including transmissible spongiform encephalopathies(TSEs) or other prion diseases. In one embodiment, the expressedantibodies may bind to predicted epitopes of PrP, such as thosepresented by SEQ ID NOs: 24, 26, 28, 30, 32, 34, 36, 39-43, of US PatentPublication No. US20150004185, the contents of which are hereinincorporated by reference in their entirety. In one embodiment, theexpressed antibodies may comprise prion-specific peptides or peptidefusions, such as those presented by SEQ ID NOs: 12-23, 25, 27, 29, 31,33, 35, 37, 38, 43, and 44-48 of US Patent Publication No.US20150004185, the contents of which are herein incorporated byreference in their entirety.

In one embodiment, the expressed antibodies may comprise prion peptidesbinding to prion specific abnormal isoform of the prion protein, such asthose presented by SEQ ID NOs: 2-10 of US Patent Publication No.US20040072236, the contents of which are herein incorporated byreference in their entirety.

In one embodiment, the viral genomes of the AAV particles may comprisenucleic acids which have been engineered to express innate defenseregulator (IDR) peptides. IDRs are immunomodulatory peptides that actdirectly on cells to effect an innate immune response. Such IDRs may beused to treat neurodegenerative diseases associated withneuroinflammation, e.g. amyotrophic lateral sclerosis (ALS), Alzheimer'sdisease, Friedreich's ataxia. Huntington's disease, Lewr body disease,Parkinson's disease, spinal muscular atrophy, and multiple sclerosis(MS) and other neurodegenerative diseases. In one embodiment. IDRs maybe those presented by SEQ ID NOS: 1-969, and 973-1264 of InternationalPublication No. WO2013034982, the contents of which are hereinincorporated by reference in their entirety, or analogs, derivatives,amidated variations and conservative variations thereof.

In one embodiment, the viral genomes of the AAV particles may comprisenucleic acids which have been engineered to express antibodies bindingto an epitope of the Tropomyosin receptor kinase (TrkC) receptor. Suchantibodies may comprise a peptide, such as one presented by SEQ ID NO: 1of U.S. Pat. No. 9,200,080, the contents of which are hereinincorporated by reference in their entirety.

In some embodiments, the viral genomes of the AAV particles may comprisenucleic acids which have been engineered to express cyclic peptides withan amino acid sequence SNK, Non-limiting examples of other cyclicpeptides include SEQ ID NO: 1-7 of U.S. Pat. No. 9,216,217, the contentsof which are herein incorporated by reference in their entirety. Themethod of preparing the antibodies may include hyperimmune preparationmethod, as described in U.S. Pat. No. 9,216,217, the contents of whichare herein incorporated by reference in their entirety.

Prions

In one embodiment, the viral genomes of the AAV particles may comprise anucleic acid sequence encoding antibodies comprising prion peptidescomprising prion epitopes, and fusions and repeats thereof, such asthose presented by SEQ ID NOs: 8-32, 35, and 36 of U.S. Pat. No.9,056,918, the contents of which are herein incorporated by reference intheir entirety.

In one embodiment, the viral genomes of the AAV particles may comprise anucleic acid sequence encoding prion binding proteins (PrPBP). In oneembodiment, the PrPBPs are cadherins, such as those presented by SEQ IDNOs: 1 and 2 of International Publication WO 1997/045746, the contentsof which are herein incorporated by reference in their entirety. In oneembodiment, the PrPBPs are cadherins, such as those presented by SEQ IDNOs: 2 and 7-9 of International Publication No. WO2001000235, thecontents of which are herein incorporated by reference in theirentirety.

The Nature of the Polypeptides and Variants

Antibodies encoded by payload regions of the viral genomes of theinvention may be translated as a whole polypeptide, a plurality ofpolypeptides or fragments of polypeptides, which independently may beencoded by one or more nucleic acids, fragments of nucleic acids orvariants of any of the aforementioned. As used herein, “polypeptide”means a polymer of amino acid residues (natural or unnatural) linkedtogether most often by peptide bonds. The term, as used herein, refersto proteins, polypeptides, and peptides of any size, structure, orfunction. In some instances, the polypeptide encoded is smaller thanabout 50 amino acids and the polypeptide is then termed a peptide. Ifthe polypeptide is a peptide, it will be at least about 2, 3, 4, or atleast 5 amino acid residues long. Thus, polypeptides include geneproducts, naturally occurring polypeptides, synthetic polypeptides,homologs, orthologs, paralogs, fragments and other equivalents,variants, and analogs of the foregoing. A polypeptide may be a singlemolecule or may be a multi-molecular complex such as a dimer, trimer ortetramer. They may also comprise single chain or multichain polypeptidesand may be associated or linked. The term polypeptide may also apply toamino acid polymers in which one or more amino acid residues are anartificial chemical analogue of a corresponding naturally occurringamino acid.

The term “polypeptide variant” refers to molecules which differ in theiramino acid sequence from a native or reference sequence. The amino acidsequence variants may possess substitutions, deletions, and/orinsertions at certain positions within the amino acid sequence, ascompared to a native or reference sequence Ordinarily, variants willpossess at least about 50% identity (homology) to a native or referencesequence, and preferably, they will be at least about 80%, morepreferably at least about 90% identical (homologous) to a native orreference sequence.

In some embodiments “variant mimics” are provided. As used herein, theterm “variant mimic” is one which contains one or more amino acids whichwould mimic an activated sequence. For example, glutamate may serve as amimic for phosphoro-threonine and/or phosphoro-serine. Alternatively,variant mimics may result in deactivation or in an inactivated productcontaining the mimic, e.g., phenylalanine may act as an inactivatingsubstitution for tyrosine; or alanine may act as an inactivatingsubstitution for serine.

The term “amino acid sequence variant” refers to molecules with somedifferences in their amino acid sequences as compared to a native orstarting sequence. The amino acid sequence variants may possesssubstitutions, deletions, and/or insertions at certain positions withinthe amino acid sequence. “Native” or “starting” sequence should not beconfused with a wild type sequence. As used herein, a native or startingsequence is a relative term referring to an original molecule againstwhich a comparison may be made. “Native” or “starting” sequences ormolecules may represent the wild-type (that sequence found in nature)but do not have to be the wild-type sequence.

Ordinarily, variants will possess at least about 70% homology to anative sequence, and preferably, they will be at least about 80%, morepreferably at least about 90% homologous to a native sequence.“Homology” as it applies to amino acid sequences is defined as thepercentage of residues in the candidate amino acid sequence that areidentical with the residues in the amino acid sequence of a secondsequence after aligning the sequences and introducing gaps, ifnecessary, to achieve the maximum percent homology. Methods and computerprograms for the alignment are well known in the art. It is understoodthat homology depends on a calculation of percent identity but maydiffer in value due to gaps and penalties introduced in the calculation.

By “homologs” as it applies to amino acid sequences is meant thecorresponding sequence of other species having substantial identity to asecond sequence of a second species.

“Analogs” is meant to include polypeptide variants which differ by oneor more amino acid alterations, e.g., substitutions, additions ordeletions of amino acid residues that still maintain the properties ofthe parent polypeptide.

Sequence tags or amino acids, such as one or more lysines, can be addedto the peptide sequences of the invention (e.g., at the N-terminal orC-terminal ends). Sequence tags can be used for peptide purification orlocalization. Lysines can be used to increase peptide solubility or toallow for biotinylation. Alternatively, amino acid residues located atthe carboxy and amino terminal regions of the amino acid sequence of apeptide or protein may optionally be deleted providing for truncatedsequences. Certain amino acids (e.g., C-terminal or N-terminal residues)may alternatively be deleted depending on the use of the sequence, asfor example, expression of the sequence as part of a larger sequencewhich is soluble, or linked to a solid support.

“Substitutional variants” when referring to proteins are those that haveat least one amino acid residue in a native or starting sequence removedand a different amino acid inserted in its place at the same position.The substitutions may be single, where only one amino acid in themolecule has been substituted, or they may be multiple, where two ormore amino acids have been substituted in the same molecule.

As used herein the term “conservative amino acid substitution” refers tothe substitution of an amino acid that is normally present in thesequence with a different amino acid of similar size, charge, orpolarity. Examples of conservative substitutions include thesubstitution of a non-polar (hydrophobic) residue such as isoleucine,valine and leucine for another non-polar residue. Likewise, examples ofconservative substitutions include the substitution of one polar(hydrophilic) residue for another such as between arginine and lysine,between glutamine and asparagine, and between glycine and serine.Additionally, the substitution of a basic residue such as lysine,arginine or histidine for another, or the substitution of one acidicresidue such as aspartic acid or glutamic acid for another acidicresidue are additional examples of conservative substitutions. Examplesof non-conservative substitutions include the substitution of anon-polar (hydrophobic) amino acid residue such as isoleucine, valine,leucine, alanine, methionine for a polar (hydrophilic) residue such ascysteine, glutanane, glutamic acid or lysine and/or a polar residue fora non-polar residue.

“Insertional variants” when referring to proteins are those with one ormore amino acids inserted immediately adjacent to an amino acid at aparticular position in a native or starting sequence. “Immediatelyadjacent” to an amino acid means connected to either the alpha-carboxyor alpha-amino functional group of the amino acid.

“Deletional variants” when referring to proteins, are those with one ormore amino acids in the native or starting amino acid sequence removed.Ordinarily, deletional variants will have one or more amino acidsdeleted in a particular region of the molecule.

As used herein, the term “derivative” is used synonymously with the term“variant” and refers to a molecule that has been modified or changed inany way relative to a reference molecule or starting molecule. In someembodiments, derivatives include native or starting proteins that havebeen modified with an organic proteinaceous or non-proteinaceousderivatizing agent, and post-translational modifications. Covalentmodifications are traditionally introduced by reacting targeted aminoacid residues of the protein with an organic derivatizing agent that iscapable of reacting with selected side-chains or terminal residues, orby harnessing mechanisms of post-translational modifications thatfunction in selected recombinant host cells. The resultant covalentderivatives are useful in programs directed at identifying residuesimportant for biological activity, for immunoassays, or for thepreparation of anti-protein antibodies for immunoaffinity purificationof the recombinant glycoprotein. Such modifications are within theordinary skill in the art and are performed without undueexperimentation.

Certain post-translational modifications are the result of the action ofrecombinant host cells on the expressed polypeptide. Glutaminyl andasparaginyl residues are frequently post-translationally deaminated tothe corresponding glutamyl and aspartyl residues. Alternatively, theseresidues are deaminated under mildly acidic conditions. Either form ofthese residues may be present in the proteins used in accordance withthe present invention.

Other post-translational modifications include hydroxylation of prolineand lysine, phosphorylation of hydroxyl groups of seryl or threonylresidues, methylation of the alpha-amino groups of lysine, arginine, andhistidine side chains (T. E. Creighton, Proteins: Structure andMolecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86(1983)).

“Features” when referring to proteins are defined as distinct amino acidsequence-based components of a molecule. Features of the proteins of thepresent invention include surface manifestations, local conformationalshape, folds, loops, half-loops, domains, half-domains, sites, terminior any combination thereof.

As used herein when referring to proteins the term “surfacemanifestation” refers to a polypeptide based component of a proteinappearing on an outermost surface.

As used herein when referring to proteins the term “local conformationalshape” means a polypeptide based structural manifestation of a proteinwhich is located within a definable space of the protein.

As used herein when referring to proteins the term “fold” means theresultant conformation of an amino acid sequence upon energyminimization. A fold may occur at the secondary or tertiary level of thefolding process. Examples of secondary level folds include beta sheetsand alpha helices Examples of tertiary folds include domains and regionsformed due to aggregation or separation of energetic forces. Regionsformed in this way include hydrophobic and hydrophilic pockets, and thelike.

As used herein the term “turn” as it relates to protein conformationmeans a bend which alters the direction of the backbone of a peptide orpolypeptide and may involve one, two, three or more amino acid residues.

As used herein when referring to proteins the term “loop” refers to astructural feature of a peptide or polypeptide which reverses thedirection of the backbone of a peptide or polypeptide and comprises fouror more amino acid residues. Oliva et al. have identified at least 5classes of protein loops (J. Mol Biol 266 (4): 814-830: 1997).

As used herein when referring to proteins the term “half-loop” refers toa portion of an identified loop having at least half the number of aminoacid residues as the loop from which it is derived. It is understoodthat loops may not always contain an even number of amino acid residues.Therefore, in those cases where a loop contains or is identified tocomprise an odd number of amino acids, a half-loop of the odd-numberedloop will comprise the whole number portion or next whole number portionof the loop (number of amino acids of the loop/2+/−0.5 amino acids). Forexample, a loop identified as a 7 amino acid loop could producehalf-loops of 3 amino acids or 4 amino acids (7/2=3.5+/−0.5 being 3 or4).

As used herein when referring to proteins the term “domain” refers to amotif of a polypeptide having one or more identifiable structural orfunctional characteristics or properties (e.g., binding capacity,serving as a site for protein-protein interactions).

As used herein when referring to proteins the term “half-domain” meansportion of an identified domain having at least half the number of aminoacid residues as the domain from which it is derived. It is understoodthat domains may not always contain an even number of amino acidresidues. Therefore, in those cases where a domain contains or isidentified to comprise an odd number of amino acids, a half-domain ofthe odd-numbered domain will comprise the whole number portion or nextwhole number portion of the domain (number of amino acids of thedomain/2+/−0.5 amino acids). For example, a domain identified as a 7amino acid domain could produce half-domains of 3 amino acids or 4 aminoacids (7/2=3.5+/−0.5 being 3 or 4). It is also understood thatsub-domains may be identified within domains or half-domains, thesesubdomains possessing less than all of the structural or functionalproperties identified in the domains or half domains from which theywere derived. It is also understood that the amino acids that compriseany of the domain types herein need not be contiguous along the backboneof the poly peptide (i.e., nonadjacent amino acids may fold structurallyto produce a domain, half-domain or subdomain).

As used herein when referring to proteins the terms “site” as itpertains to amino acid based embodiments is used synonymous with “aminoacid residue” and “amino acid side chain”. A site represents a positionwithin a peptide or polypeptide that may be modified, manipulated,altered, derivatized or varied within the polypeptide based molecules ofthe present invention.

As used herein the terms “termini or terminus” when referring toproteins refers to an extremity of a peptide or polypeptide. Suchextremity is not limited only to the first or final site of the peptideor polypeptide but may include additional amino acids in the terminalregions. The polypeptide based molecules of the present invention may becharacterized as having both an N-terminus (terminated by an amino acidwith a free amino group (NH2)) and a C-terminus (terminated by an aminoacid with a free carboxyl group (COOH)). Proteins of the invention arein some cases made up of multiple polypeptide chains brought together bydisulfide bonds or by non-covalent forces (multimers, oligomers). Thesesorts of proteins will have multiple N- and C-termini. Alternatively,the termini of the polypeptides may be modified such that they begin orend, as the case may be, with a non-polypeptide based moiety such as anorganic conjugate.

Once any of the features have been identified or defined as a componentof a molecule of the invention, any of several manipulations and/ormodifications of these features may be performed by moving, swapping,inverting, deleting, randomizing or duplicating. Furthermore, it isunderstood that manipulation of features may result in the same outcomeas a modification to the molecules of the invention. For example, amanipulation which involves deleting a domain would result in thealteration of the length of a molecule just as modification of a nucleicacid to encode less than a full-length molecule would.

Modifications and manipulations can be accomplished by methods known inthe art such as site directed mutagenesis. The resulting modifiedmolecules may then be tested for activity using in vitro or in vivoassays such as those described herein or any other suitable screeningassay known in the art.

AAV Production

The present invention provides methods for the generation of parvoviralparticles, e.g. AAV particles, by viral genome replication in a viralreplication cell.

In accordance with the invention, the viral genome comprising a payloadregion encoding an antibody, an antibody-based composition or fragmentthereof, will be incorporated into the AAV particle produced in theviral replication cell. Methods of making AAV particles are well knownin the art and are described in e.g., U.S. Pat. Nos. 6,204,059,5,756,283, 6,258,595, 6,261,551, 6,270,996, 6,281,10, 6,365,394,6,475,769, 6,482,634, 6,4859,669, 6,943,01, 6,953,690, 7,022,519,7,238,526, 7,291,498 and 7,491,508, 5,064,764, 6,194,191, 6,566,118,8,137,948, or International Publication Nos. WO1996039530, WO1998010088,WO999014354, WO1999015685, WO1999047691, WO2000055342, WO2000075353 andWO2001023597; Methods In Molecular Biology, ed. Richard, Humana Press, NJ (1995); O'Reilly et al., Baculovirus Expression Vectors, A LaboratoryManual. Oxford Univ. Press (1994); Samulski et al., J. Vir. 63:3822-8(1989); Kajigaya et al., Proc. Nat'l. Acad. Sci. USA 88: 4646-50 (1991);Ruffing et al., J. Vir. 66:6922-30 (1992); Kimbauer et al., Vir.219:37-44 (1996); Zhao et al., Vir. 272:382-93 (2000); the contents ofeach of which are herein incorporated by reference in their entirety. Inone embodiment, the AAV particles are made using the methods describedin WO2015191508, the contents of which are herein incorporated byreference in their entirety.

Viral replication cells commonly used for production of recombinant AAVviral vectors include but are not limited to 293 cells, COS cells. HeLacells, KB cells, and other mammalian cell lines as described in U.S.Pat. Nos. 6,156,303, 5,387,484, 5,741,683, 5,691,176, and 5,688,676;U.S. patent publication No. 2002/0081721, and International PatentPublication Nos. WO 00/47757, WO 00/24916, and WO 96/17947, the contentsof each of which are herein incorporated by reference in theirentireties.

In some embodiments, the present invention provides a method forproducing an AAV particle having enhanced (increased, improved)transduction efficiency comprising the steps of: 1) co-transfectingcompetent bacterial cells with a bacmid vector and either a viralconstruct vector and/or AAV payload construct vector, 2) isolating theresultant viral construct expression vector and AAV payload constructexpression vector and separately transfecting viral replication cells,3) isolating and purifying resultant payload and viral constructparticles comprising viral construct expression vector or AAV payloadconstruct expression vector, 4) co-infecting a viral replication cellwith both the AAV payload and viral construct particles comprising viralconstruct expression vector or AAV payload construct expression vector,and 5) harvesting and purifying the AAV particle comprising a viralgenome.

In some embodiments, the present invention provides a method forproducing an AAV particle comprising the steps of 1) simultaneouslyco-transfecting mammalian cells, such as, but not limited to HEK293cells, with a pay load region, a construct expressing rep and cap genesand a helper construct, 2) harvesting and purifying the AAV particlecomprising a viral genome.

In some embodiments, the viral genome of the AAV particle of theinvention optionally encodes a selectable marker. The selectable markermay comprise a cell-surface marker, such as any protein expressed on thesurface of the cell including, but not limited to receptors. CD markers,lectins, integrins, or truncated versions thereof.

In some embodiments, selectable marker reporter genes as described inInternational application No WO 96/23810, Heirn et al, Current Biology2:178-182 (1996); Heim et al., Proc. Natl. Acad. Sci. USA (1995); orHeim et al., Science 373:663-664 (1995); WO 96/30540, the contents ofeach of which are incorporated herein by reference in their entireties).

II. Formulation and Delivery Pharmaceutical Compositions

According to the present invention the AAV particles may be prepared aspharmaceutical compositions. It will be understood that suchcompositions necessarily comprise one or more active ingredients and,most often, a pharmaceutically acceptable excipient.

Relative amounts of the active ingredient (e.g. AAV particle), apharmaceutically acceptable excipient, and/or any additional ingredientsin a pharmaceutical composition in accordance with the presentdisclosure may vary, depending upon the identity, size, and/or conditionof the subject being treated and further depending upon the route bywhich the composition is to be administered. For example, thecomposition may comprise between 0.1% and 99% (w/w) of the activeingredient. By way of example, the composition may comprise between 0.1%and 100%, e.g., between 5 and 50%, between 1-30%, between 5-80%, atleast 80% (w/w) active ingredient.

In some embodiments, the AAV particle pharmaceutical compositionsdescribed herein may comprise at least one pa load. As a non-limitingexample, the pharmaceutical compositions may contain an AAV particlewith 1, 2, 3, 4 or 5 payloads. In one embodiment, the pharmaceuticalcomposition may contain a nucleic acid encoding a payload constructencoding proteins selected from antibodies and/or antibody-basedcompositions.

Although the descriptions of pharmaceutical compositions provided hereinare principally directed to pharmaceutical compositions which aresuitable for administration to humans, it will be understood by theskilled artisan that such compositions are generally suitable foradministration to any other animal, e.g., to non-human animals, e.g.non-human mammals. Modification of pharmaceutical compositions suitablefor administration to humans in order to render the compositionssuitable for administration to various animals is well understood, andthe ordinarily skilled veterinary pharmacologist can design and/orperform such modification with merely ordinary, if any, experimentation.Subjects to which administration of the pharmaceutical compositions iscontemplated include, but are not limited to, humans and/or otherprimates; mammals, including commercially relevant mammals such ascattle, pigs, horses, sheep, cats, dogs, mice, rats, birds, includingcommercially relevant birds such as poultry, chickens, ducks, geese,and/or turkeys.

In some embodiments, compositions are administered to humans, humanpatients or subjects.

Formulations

The AAV particles of the invention can be formulated using one or moreexcipients to: (1) increase stability; (2) increase cell transfection ortransduction; (3) permit the sustained or delayed expression of thepayload; (4) alter the biodistribution (e.g., target the viral particleto specific tissues or cell types); (5) increase the translation ofencoded protein; (6) alter the release profile of encoded protein and/or(7) allow for regulatable expression of the payload.

Formulations of the present invention can include, without limitation,saline, liposomes, lipid nanoparticles, polymers, peptides, proteins,cells transfected with viral vectors (e.g., for transfer ortransplantation into a subject) and combinations thereof.

Formulations of the pharmaceutical compositions described herein may beprepared by any method known or hereafter developed in the art ofpharmacology. As used herein the term “pharmaceutical composition”refers to compositions comprising at least one active ingredient andoptionally one or more pharmaceutically acceptable excipients.

In general, such preparatory methods include the step of associating theactive ingredient with an excipient and/or one or more other accessoryingredients. As used herein, the phrase “active ingredient” generallyrefers either to an AAV particle carrying a payload region encoding thepolypeptides of the invention or to the antibody or antibody-basedcomposition encoded by a viral genome of by an AAV particle as describedherein.

Formulations of the AAV particles and pharmaceutical compositionsdescribed herein may be prepared by any method known or hereafterdeveloped in the art of pharmacology. In general, such preparatorymethods include the step of bringing the active ingredient intoassociation with an excipient and/or one or more other accessoringredients, and then, if necessary and/or desirable, dividing, shapingand/or packaging the product into a desired single- or multi-dose unit.

A pharmaceutical composition in accordance with the present disclosuremay be prepared, packaged, and/or sold in bulk, as a single unit dose,and/or as a plurality of single unit doses. As used herein, a “unitdose” refers to a discrete amount of the pharmaceutical compositioncomprising a predetermined amount of the active ingredient. The amountof the active ingredient is generally equal to the dosage of the activeingredient which would be administered to a subject and/or a convenientfraction of such a dosage such as, for example, one-half or one-third ofsuch a dosage.

In one embodiment, the AAV particles of the invention may be formulatedin PBS with 0.001% of pluronic acid (F-68) at a pH of about 7.0.

Relative amounts of the active ingredient (e.g. AAV particle), thepharmaceutically acceptable excipient, and/or any additional ingredientsin a pharmaceutical composition in accordance with the presentdisclosure may vary, depending upon the identity, size, and/or conditionof the subject being treated and further depending upon the route bywhich the composition is to be administered. For example, thecomposition may comprise between 0.1% and 99% (w/w) of the activeingredient. By way of example, the composition may comprise between 0.1%and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, atleast 80% (w/w) active ingredient.

In some embodiments, the AAV formulations described herein may containsufficient AAV particles for expression of at least one expressedfunctional antibody or antibody-based composition. As a non-limitingexample, the AAV particles may contain viral genomes encoding 1, 2, 3, 4or 5 functional antibodies.

According to the present invention AAV particles may be formulated forCNS delivery. Agents that cross the brain blood barrier may be used. Forexample, some cell penetrating peptides that can target molecules to thebrain blood barrier endothelium may be used for formulation (e.g.,Mathupala, Expert Opin Ther Pat., 2009, 19, 137-140; the content ofwhich is incorporated herein by reference in its entirety).

Excipients and Diluents

The AAV particles of the invention can be formulated using one or moreexcipients or diluents to (1) increase stability; (2) increase celltransfection or transduction; (3) permit the sustained or delayedrelease; (4) alter the biodistribution (e.g. target the viral particleto specific tissues or cell types); (5) increase the translation ofencoded protein in vivo; (6) alter the release profile of encodedprotein in vivo and/or (7) allow for regulatable expression of thepolypeptides of the invention.

In some embodiments, a pharmaceutically acceptable excipient may be atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% pure. In some embodiments, an excipient is approved for use forhumans and for veterinary use. In some embodiments, an excipient may beapproved by United States Food and Drug Administration. In someembodiments, an excipient may be of pharmaceutical grade. In someembodiments, an excipient may meet the standards of the United StatesPharmacopoeia (USP), the European Pharmacopoeia (EP), the BritishPharmacopoeia, and/or the International Pharmacopoeia.

Excipients, as used herein, include, but are not limited to, any and allsolvents, dispersion media, diluents, or other liquid vehicles,dispersion or suspension aids, surface active agents, isotonic agents,thickening or emulsifying agents, preservatives, and the like, as suitedto the particular dosage form desired. Various excipients forformulating pharmaceutical compositions and techniques for preparing thecomposition are known in the art (see Remington: The Science andPractice of Pharmacy, 21st Edition, A R Gennaro. Lippincott, Williams &Wilkins, Baltimore, Md., 2006; incorporated herein by reference in itsentirety). The use of a conventional excipient medium may becontemplated within the scope of the present disclosure, except insofaras any conventional excipient medium may be incompatible with asubstance or its derivatives, such as by producing any undesirablebiological effect or otherwise interacting in a deleterious manner withany other component(s) of the pharmaceutical composition.

Exemplary diluents include, but are not limited to, calcium carbonate,sodium carbonate, calcium phosphate, dicalcium phosphate, calciumsulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose,cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol,inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc.,and/or combinations thereof.

Inactive Ingredients

In some embodiments, AAV particle formulations may comprise at least oneinactive ingredient. As used herein, the term “inactive ingredient”refers to one or more agents that do not contribute to the activity ofthe active ingredient of the pharmaceutical composition included informulations. In some embodiments, all, none or some of the inactiveingredients which may be used in the formulations of the presentinvention may be approved by the US Food and Drug Administration (FDA).

In one embodiment, the AAV particle pharmaceutical compositions compriseat least one inactive ingredient such as, but not limited to,1,2,6-Hexanetriol;1,2-Dimyristoyl-Sn-Glycero-3-(Phospho-S-(1-Glycerol));1,2-Dilmyristoyl-Sn-Glycero-3-Phospho choline;1,2-Dioleoyl-Sn-Glycero-3-Phosphocholine;1,2-Dialmitoyl-Sn-Glycero-3-(Phospho-Rac-(1-Glycerol));1,2-Distearyl-Sn-Glycero-3-(Phospho-Rac-(1-Glycerol));1,2-Distearoyl-Sn-Glycero-3-Phosphocholine; 1-O-Tolylbiguanide;2-Ethyl-1,6-Hexanediol; Acetic Acid; Acetic Acid, Glacial; AceticAnhydride; Acetone, Acetone Sodium Bisulfite; Acetylated LanolinAlcohols; Acetylated Monoglycerides; Acetylcysteine; Acetyltryptophan.DL-; Acrylates Copolymer; Acrylic Acid-Isooctyl Acrylate Copolymer;Acrylic Adhesive 788; Activated Charcoal; Adcote 72A103; Adhesive Tape;Adipic Acid; Aerotex Resin 3730; Alanine; Albumin Aggregated; AlbuminColloidal, Albumin Human, Alcohol, Alcohol, Dehydrated; Alcohol,Denatured; Alcohol; Diluted; Alfadex; Alginic Acid; Alkyl AmmoniumSulfonic Acid Betaine; Alkyl Aryl Sodium Sulfonate; Allantoin; Allyl.Alpha-Ionone; Almond Oil; Alpha-Terpineol; Alpha-Tocopherol;Alpha-Tocopherol Acetate; Dl-; Alpha-Tocopherol; Dl-; Aluminum Acetate;Aluminum Chlorhydroxy Allantoinate; Aluminum Hydroxide; AluminumHydroxide-Sucrose; Hydrated; Aluminum Hydroxide Gel; Aluminum HydroxideGel F 500; Aluminum Hydroxide Gel F 5000; Aluminum Monostearate;Aluminum Oxide; Aluminum Polyester; Aluminum Silicate; Aluminum StarchOctenylsuccinate; Aluminum Stearate; Aluminum Subacetate; AluminumSulfate Anhydrous; Amerchol C; Amerchol-Cab; Aminomethylpropanol;Ammonia; Ammonia Solution; Ammonia Solution; Strong; Ammonium Acetate;Ammonium Hydroxide; Ammonium Lauryl Sulfate; Ammonium Nonoxynol-4Sulfate; Ammonium Salt Of C-12-C-15 Linear Primary Alcohol Ethoxylate;Ammonium Sulfate; Ammonyx; Amphoteric-2; Amphoteric-9; Anethole;Anhydrous Citric Acid; Anhydrous Dextrose; Anhydrous Lactose; AnhydrousTrisodium Citrate; Aniseed Oil; Anoxid Sbn; Antifoam; Antipyrine;Apaflurane; Apricot Kernel Oil Peg-6 Esters; Aquaphor; Arginine;Arlacel; Ascorbic Acid; Ascorbyl Palmitate; Aspartic Acid; Balsam Peru;Barium Sulfate; Beeswax; Beeswax; Synthetic; Beheneth-10; Bentonite;Benzalkonium Chloride; Benzenesulfonic Acid; Benzethonium Chloride;Benzododecinium Bromide; Benzoic Acid; Benzyl Alcohol; Benzyl Benzoate;Benzyl Chloride; Betadex; Bibapcitide; Bismuth Subgallate; Boric Acid;Brocrinat; Butane; Butyl Alcohol; Butyl Ester Of Vinyl MethylEther/Maleic Anhydride Copolymer (125000) Mw); Butyl Stearate; ButylatedHydroxyanisole; Butylated Hydroxytoluene; Butylene Glycol; Butylparaben;Butyric Acid; C20-40 Pareth-24; Caffeine; Calcium; Calcium Carbonate;Calcium Chloride; Calcium Gluceptate; Calcium Hydroxide; CalciumLactate; Calcobutrol; Caldiamide Sodium; Caloxetate Trisodium;Calteridol Calcium; Canada Balsam; Caprylic/Capric Triglyceride;Caprylic/Capric/Stearic Triglyceride; Captan; Captisol; Caramel;Carbomer 1342; Carbomer 1382; Carbomer 934; Carbomer 934p; Carbomer 940;Carbomer 941; Carbomer 980; Carbomer 981; Carbomer Homopolymer Type B(Allyl Pentaerythrtol Crosslinked); Carbomer Homopolymer Type C (AllylPentaerythritol Crosslinked); Carbon Dioxide; Carboxy Vinyl Copolymer;Carboxymethylcellulose; Carboxymethylcellulose Sodium;Carboxypolymethylene; Carrageenan; Carrageenan Salt; Castor Oil; CedarLeaf Oil; Cellulose; Cellulose; Microcrystalline; Cerasynt-Se; Ceresin;Ceteareth-12; Ceteareth-15; Ceteareth-30; Cetearyl Alcohol/Ceteareth-20;Cetearyl Ethylhexanoate; Ceteth-10; Ceteth-2; Ceteth-20; Ceteth-23;Cetostearyl Alcohol; Cetrimonium Chloride; Cetyl Alcohol; Cetyl EstersWax; Cetyl Palmitate; Cetylpyridinium Chloride; Chlorobutanol;Chlorobutanol H-Hhemihydrate; Chlorobutanol; Anhydrous; Chlorocresol;Chloroxylenol; Cholesterol; Choleth; Choleth-24; Citrate; Citric Acid;Citric Acid Monohydrate; Citric Acid, Hydrous. Cocamide Ether Sulfate;Cocamine Oxide; Coco Betaine; Coco Diethanolamide; CocoMonoethanolamide, Cocoa Butter; Coco-Glycerides; Coconut Oil; CoconutOil; Hydrogenated; Coconut Oil/Palm Kernel Oil Glycerides, Hydrogenated;Cocoyl Caprylocaprate; Cola Nitida Seed Extract; Collagen; ColoringSuspension, Corn Oil. Cottonseed Oil; Cream Base; Creatine; Creatinine;Cresol; Croscarmellose Sodium; Crospovidone; Cupric Sulfate, CupricSulfate Anhydrous; Cyclomethicone; Cyclomethicone/Dimethicone Copolyol;Cysteine; Cysteine Hydrochloride; Cysteine Hydrochloride Anhydrous;Cysteine, D1-; D&C Red No. 28; D&C Red No. 33; D&C Red No. 36; D&C RedNo. 39, D&C Yellow No. 10; Dalfampridine; Daubert 1-5 Pestr (Matte)164z; Decyl Methyl Sulfoxide; Dehydag Wax Sx; Dehydroacetic Acid;Dehymuls E; Denatonium Benzoate; Deoxycholic Acid; Dextran; Dextran 40;Dextrin; Dextrose; Dextrose Monohydrate, Dextrose Solution; DiatrizoicAcid; Diazolidinyl Urea; Dichlorobenzl Alcohol; Dichlorodifluoromethane;Dichlorotetrafluoroethane; Diethanolamine, Diethyl Pyrocarbonate;Diethyl Sebacate; Diethylene Glycol Monoethyl Ether; DiethylhexylPhthalate; Dihydroxyaluminum Aminoacetate; Diisopropanolamine;Diisopropyl Adipate; Diisopropyl Dilinoleate, Dimethicone 350;Dimethicone Copolyol; Dimethicone Mdx4-4210; Dimethicone Medical Fluid360; Dimethyl Isosorbide; Dimethyl Sulfoxide; DimethylaminoethylMethacrylate-Butyl Methacrylate—Methyl Methacrylate Copolymer;Dimethyldioctadecylammonium Bentonite;Dimethylsiloxane/Methylvinylsiloxane Copolymer; Dinoseb Ammonium Salt;Dipalmitoylphosphatidylglycerol, Dl-; Dipropylene Glycol; DisodiumCocoamphodiacetate; Disodium Laureth Sulfosuccinate; Disodium LaurylSulfosuccinate; Disodium Sulfosalicylate; Disofenin; DivinylbenzeneStyrene Copolymer; Dmdm Hydantoin; Docosanol; Docusate Sodium, Duro-Tak280-2516; Duro-Tak 387-2516; Duro-Tak 80-1196, Duro-Tak 87-2070;Duro-Tak 87-2194; Duro-Tak 87-2287; Duro-Tak 87-2296; Duro-Tak 87-2888;Duro-Tak 87-2979; Edetate Calcium Disodium; Edetate Disodium; EdetateDisodium Anhydrous; Edetate Sodium; Edetic Acid; Egg Phospholipids,Entsufon; Entsufon Sodium; Epilactose; Epitetracycline Hydrochloride;Essence Bouquet 9200; Ethanolamine Hydrochloride, Ethyl Acetate; EthylOleate; Ethylcelluloses; Ethylene Glycol; Ethylene Vinyl AcetateCopolymer; Ethylenediamrne; Ethylenediamrne Dihydrochloride.Ethylene-Propylene Copolymer; Ethylene-Vinyl Acetate Copolymer (28%Vinyl Acetate), Ethylene-Vinyl Acetate Copolymer (9% Vinylacetate);Ethylhexyl Hydroxystearate; Ethylparaben; Eucalyptol; Exametazime; Fat,Edible; Fat, Hard; Fatty Acid Esters; Fatty Acid Pentaerythriol Ester;Fatty Acids; Fatty Alcohol Citrate; Fatty Alcohols; Fd&C Blue No. 1;Fd&C Green No. 3; Fd&C Red No. 4; Fd&C Red No. 40; Fd&C Yellow No. 10(Delisted); Fd&C Yellow No 5; Fd&C Yellow No 6; Ferric Chloride; FerricOxide; Flavor 89-186; Flavor 89-259. Flavor Df-119; Flavor Df-1530;Flavor Enhancer; Flavor Fig 827118; Flavor Raspberry Pfc-8407; FlavorRhodia Pharmaceutical No. Rf 451; Fluorochlorohydrocarbons;Formaldehyde; Formaldehyde Solution; Fractionated Coconut Oil; Fragrance3949-5; Fragrance 520a; Fragrance 6.007; Fragrance 91-122; Fragrance9128-Y; Fragrance 93498g; Fragrance Balsam Pine No. 5124. FragranceBouquet 10328; Fragrance Chemoderm 6401-B; Fragrance Chemoderm 6411,Fragrance Cream No. 73457, Fragrance Cs-28197; Fragrance Felton 066m;Fragrance Firmenich 47373; Fragrance Givaudan Ess 9090/1c; FragranceH-6540; Fragrance Herbal 10396, Fragrance Nj-1085; Fragrance PO Fl-147.Fragrance Pa 52805; Fragrance Pera Derm D, Fragrance Rbd-9819; FragranceShaw Mudge U-7776; Fragrance Tf 044078; Fragrance Ungerer Honeysuckle K2771; Fragrance Ungerer N5195; Fructose; Gadolinium Oxide; Galactose;Gamma Cyclodextrin; Gelatin; Gelatin, Crosslinked; Gelfoam Sponge;Gellan Gum (Low Acyl); Gelva 737; Gentisic Acid; Gentisic AcidEthanolamide, Gluceptate Sodium; Gluceptate Sodium Dihydrate;Gluconolactone, Glucuronic Acid; Glutamic Acid; D1-; Glutathione;Glycerin; Glycerol Ester Of Hydrogenated Rosin; Glyceryl Citrate;Glyceryl Isostearate, Glyceryl Laurate; Glyceryl Monostearate; GlycerylOleate; Glyceryl Oleate/Propylene Glycol; Glyceryl Palmitate; GlycerylRicinoleate; Glyceryl Stearate; Glyceryl Stearate-Laureth-23; GlycerylStearate/Peg Stearate; Glyceryl Stearate/Peg-100 Stearate; GlycerylStearate/Peg-40 Stearate; Glyceryl Stearate-StearamidoethylDiethylamine; Glyceryl Trioleate; Glycine; Glycine Hydrochloride; GlycolDistearate; Glycol Stearate; Guanidine Hydrochloride; Guar Gum; HairConditioner (18n195-1m); Heptane, Hetastarch; Hexylene Glycol; HighDensity Polyethylene; Histidine; Human Albumin Microspheres; HyaluronateSodium; Hydrocarbon; Hydrocarbon Gel, Plasticized; Hydrochloric Acid;Hydrochloric Acid, Diluted; Hydrocortisone; Hydrogel Polymer; HydrogenPeroxide; Hydrogenated Castor Oil; Hydrogenated Palm Oil; HydrogenatedPalm/Palm Kernel Oil Peg-6 Esters; Hydrogenated Polybutene 635-690;Hydroxide Ion; Hydroxyethyl Cellulose; Hydroxyethylpiperazine EthaneSulfonic Acid; Hydroxymethyl Cellulose; HydroxyoctacosanylHydroxystearate; Hydroxypropyl Cellulose; Hydroxypropyl Methylcellulose2906; Hydroxypropyl-Beta-cyclodextrn; Hypromellose 2208 (15000 Mpa S);Hypromellose 2910 (1500 Mpa·S); Hypromellose; Imidurea; Iodine;Iodoxamic Acid; Iofetamine Hydrochloride; Irish Moss Extract; Isobutane;Isoceteth-20; Isoleucine; Isooctyl Acrylate; Isopropyl Alcohol;Isopropyl Isostearate; Isopropyl Myristate; Isopropyl Myristate-MyristylAlcohol; Isopropyl Palmatate; Isopropyl Stearate; Isostearic Acid;Isostearyl Alcohol; Isotonic Sodium Chloride Solution; Jelene, Kaolin;Kathon Cg; Kathon Cg II, Lactate; Lactic Acid; Lactic Acid. Dl-; LacticAcid. L-; Lactobionic Acid; Lactose; Lactose Monohydrate; Lactose,Hydrous, Laneth; Lanolin, Lanolin Alcohol-Mineral Oil; Lanolin Alcohols;Lanolin Anhydrous; Lanolin Cholesterols; Lanolin Nonionic Derivatives;Lanolin, Ethoxylated; Lanolin, Hydrogenated, Lauralkonium Chloride;Lauramine Oxide; Laurdimonium Hydrolyzed Animal Collagen; LaurethSulfate; Laureth-2; Laureth-23; Laureth-4; Lauric Diethanolamide; LauricMyristic Diethanolamide; Lauroyl Sarcosine; Lauryl Lactate; LaurylSulfate; Lavandula Angustifolia Flowering Top; Lecithin; LecithinUnbleached; Lecithin, Egg; Lecithin, Hydrogenated; Lecithin,Hydrogenated Soy; Lecithin, Soybean; Lemon Oil; Leucine; Levulinic Acid;Lidofenin; Light Mineral Oil; Light Mineral Oil (85 Ssu); Limonene,(+/−)-; Lipocol Sc-15; Lysine. Lysine Acetate; Lysine Monohydrate,Magnesium Aluminum Silicate, Magnesium Aluminum Silicate Hydrate;Magnesium Chloride; Magnesium Nitrate; Magnesium Stearate; Maleic Acid;Mannitol; Maprofix; Mebrofenin; Medical Adhesive Modified S-15; MedicalAntiform A-F Emulsion. Medronate Disodium; Medronic Acid. Meglumine;Menthol; Metacresol; Metaphosphoric Acid; Methanesulfonic Acid,Methionine; Methyl Alcohol; Methyl Gluceth-10; Methyl Gluceth-20; MethylGluceth-20 Sesquistearate; Methyl Glucose Sesquistearate; MethylLaurate; Methyl Pyrrolidone; Methyl Salicylate; Methyl Stearate;Methylboronic Acid; Methylcellulose (4000 Mpa·S); Methylcelluloses;Methylchloroisothiazolinone; Methylene Blue, Methylisothiazolinone;Methylparaben; Microcrystalline Wax; Mineral Oil; Mono and Diglyceride;Monostearyl Citrate; Monothioglycerol; Multisterol Extract; MyristylAlcohol; Myristyl Lactate; Myristyl-.Gamma.-Picolinium Chloride,N-(Carbamoyl-Methoxy Peg-40)-1,2-Distearoyl-Cephalin Sodium;N,N-Dimethylacetamide; Niacinamide, Nioxime; Nitric Acid; Nitrogen;Nonoxynol Iodine; Nonoxynol-15; Nonoxynol-9; Norflurane; Oatmeal;Octadecene-1/Maleic Acid Copolymer; Octanoic Acid; Octisalate;Octoxynol-1; Octoxynol-40, Octoxynol-9. Octyldodecanol, OctylphenolPolymethylene, Oleic Acid; Oleth-10/Oleth-5; Oleth-2; Oleth-20; OleylAlcohol; Oleyl Oleate; Olive Oil; Oxidronate Disodium; Oxyquinoline;Palm Kernel Oil; Palmitamine Oxide; Parabens; Paraffin; Paraffin, WhiteSoft; Parfum Creme 45/3; Peanut Oil; Peanut Oil, Refined. Pectin; Peg6-32 Stearate/Glycol Stearate; Peg Vegetable Oil; Peg-100 Stearate;Peg-12 Glyceryl Laurate; Peg-120 Glyceryl Stearate; Peg-120 MethylGlucose Dioleate; Peg-15 Cocanmine; Peg-150 Distearate; Peg-2 Stearate;Peg-20 Sorbitan Isostearate; Peg-22 Methyl Ether/Dodecyl GlycolCopolymer; Peg-25 Propylene Glycol Stearate; Peg-4 Dilaurate; Peg-4Laurate, Peg-40 Castor Oil; Peg-40 Sorbitan Diisostearate;Peg-45/Dodecyl Glycol Copolymer; Peg-5 Oleate; Peg-50 Stearate; Peg-54Hydrogenated Castor Oil; Peg-6 Isostearate; Peg-60 Castor Oil; Peg-60Hydrogenated Castor Oil; Peg-7 Methyl Ether; Peg-75 Lanolin; Peg-8Laurate; Peg-8 Stearate, Pegoxol 7 Stearate; Pentadecalactone;Pentaerythrtol Cocoate; Pentasodium Pentetate, Pentetate CalciumTrisodium, Pentetic Acid, Peppermint Oil; Perflutren; Perfume 25677;Perfume Bouquet, Perfume E-1991; Perfume Gd 5604; Perfume Tana 90/42Scba; Perfume W-1952-1, Petrolatum, Petrolatum; White; PetroleumDistillates; Phenol; Phenol; Liquefied; Phenonip; Phenoxyethanol;Phenylalanine; Phenylethyl Alcohol; Phenylmercuric Acetate;Phenylmercuric Nitrate; Phosphatidyl Glycerol; Egg; Phospholipid;Phospholipid, Egg; Phospholipon 90g; Phosphoric Acid, Pine Needle Oil(Pinus Sylvestris); Piperazine Hexahydrate; Plastibase-50w; Polacrilin;Polidronium Chloride, Poloxamer 124; Poloxamer 181; Poloxamer 182;Poloxamer 188; Poloxamer 237; Poloxamer 407;Poly(Bis(P-Carboxyphenoxy)Propane Anhydride); Sebacic Acid;

Poly(Dimethylsiloxane/Methylvinylsiloxane/Methylhydrogensiloxane)Dimethylvinyl Or Dimethylhydroxy Or Trimethyl Endblocked;Poly(Dl-Lactic-Co-Glycolic Acid), (50:50; Poly(Dl-Lactic-Co-GlycolicAcid), Ethyl Ester Terminated; (50:50; Polyacrylic Acid (250000 Mw);Polybutene (1400 Mw); Polycarbophil; Polyester; Polyester Pol amineCopolymer; Polyester Rayon, Polyethylene Glycol 1000; PolyethyleneGlycol 1450; Polyethylene Glycol 1500); Polyethylene Glycol 1540;Polyethylene Glycol 200; Polyethylene Glycol 300; Polyethylene Glycol300-1600, Polyethylene Glycol 3350; Polyethylene Glycol 400;Polyethylene Glycol 4000; Polyethylene Glycol 540; Polyethylene Glycol600; Polyethylene Glycol 6000; Polyethylene Glycol 8000; PolyethyleneGlycol 900; Polyethylene High Density Containing Ferric Oxide Black(<1%); Polyethylene Low Density Containing Barium Sulfate (20-24%);Polyethylene T; Polyethylene Terephthalates; Polyglactin; Polyglyceryl-3Oleate; Polyglyceryl-4 Oleate, Ppolyhydroxyethyl Methacrylate,Polyisobutylene, Polyisobutylene (1100000 Mw); Polyisobutylene (35000Mw); Polyisobutylene 178-236; Polyisobutylene 241-294; Polyisobutylene35-39; Polyisobutylene Low Molecular Weight; Polyisobutylene MediumMolecular Weight; Polyisobutylene/Polybutene Adhesive; Polylactide;Polyols, Polyoxyethylene Polyoxypropylene 1800; PolyoxyethyleneAlcohols; Polyoxyethylene Fatty Acid Esters; Polyoxyethylene Propylene;Polyoxyl 20 Cetostearyl Ether; Polyoxyl 35 Castor Oil; Polyoxyl 40Hydrogenated Castor Oil; Polyoxyl 40 Stearate; Polyoxyl 400 Stearate;Polyoxyl 6 And Polyoxyl 32 Palmitostearate; Polyoxyl Distearate;Polyoxyl Glyceryl Stearate, Polyoxyl Lanolin; Polyoxyl Palmitate;Polyoxyl Stearate; Polypropylene; Polypropylene Glycol;Polyquarternium-10; Polyquarternium-7 (70/30 Acrylamide/Dadmac;Polysiloxane; Polysorbate 20; Polysorbate 40; Polysorbate 60,Polysorbate 65, Polysorbate 80; Polyurethane; Polyvinyl Acetate,Polyvinyl Alcohol; Polyvinyl Chloride; Polyvinyl Chloride-PolyvinylAcetate Copolymer; Polyvinylpyridine; Poppy Seed Oil; Potash; PotassiumAcetate; Potassium Alum; Potassium Bicarbonate; Potassium Bisulfate;Potassium Chloride; Potassium Citrate; Potassium Hydroxide; PotassiumMetabisulfite; Potassium Phosphate, Dibasic; Potassium Phosphate,Monobasic; Potassium Soap; Potassium Sorbate; Povidone AcrylateCopolymer; Povidone Hydrogel; Povidone K17; Povidone K25; PovidoneK29/32, Povidone K30, Povidone K90; Povidone K90f; Povidone/EicoseneCopolymer; Povidones; Ppg-12/Smdi Copolymer; Ppg-15 Stearyl Ether;Ppg-20 Methyl Glucose Ether Distearate; Ppg-26 Oleate; Product Wat;Proline; Promulgen D; Promulgen G; Propane; Propellant A-46; PropylGallate; Propylene Carbonate; Propylene Glycol; Propylene GlycolDiacetate; Propylene Glycol Dicaprylate, Propylene Glycol Monolaurate;Propylene Glycol Monopalmitostearate; Propylene Glycol Palmitostearate;Propylene Glycol Ricinoleate; Propylene Glycol/DiazolidinylUrea/Methylparaben/Propylparben; Propylparaben; Protamine Sulfate;Protein Hydrolysate, Pvm/Ma Copolymer; Quaternium-15; Quaternium-15Cis-Form; Quaternium-52; Ra-2397; Ra-3011; Saccharin; Saccharin Sodium;Saccharin Sodium Anhydrous; Safflower Oil; Sd Alcohol 3a; Sd Alcohol 40;Sd Alcohol 40-2; Sd Alcohol 40b, Sepineo P600; Serine; Sesame Oil; SheaButter, Silastic Brand Medical Grade Tubing; Silastic Medical Adhesive,Silicone Type A; Silica, Dental; Silicon; Silicon Dioxide; SiliconDioxide, Colloidal; Silicone; Silicone Adhesive 4102; Silicone Adhesive4502, Silicone Adhesive Bio-Psa Q7-4201; Silicone Adhesive Bio-PsaQ7-4301; Silicone Emulsion, Silicone/Polyester Film Strip; Simethicone;Simethicone Emulsion; Sipon Ls 20np; Soda Ash; Sodium Acetate; SodiumAcetate Anhydrous; Sodium Alkyl Sulfate; Sodium Ascorbate; SodiumBenzoate; Sodium Bicarbonate; Sodium Bisulfate; Sodium Bisulfite; SodiumBorate; Sodium Borate Decahydrate; Sodium Carbonate; Sodium CarbonateDecahydrate, Sodium Carbonate Monohydrate; Sodium Cetostearyl Sulfate,Sodium Chlorate, Sodium Chloride; Sodium Chloride Injection; SodiumChloride Injection, Bacteriostatic; Sodium Cholesteryl Sulfate, SodiumCitrate; Sodium Cocoyl Sarcosinate; Sodium Desoxycholate; SodiumDithionite; Sodium Dodecylbenzenesulfonate; Sodium FormaldehydeSulfoxylate; Sodium Gluconate; Sodium Hydroxide; Sodium Hypochlorite;Sodium Iodide; Sodium Lactate; Sodium Lactate, L-; Sodium Laureth-2Sulfate; Sodium Laureth-3 Sulfate; Sodium Laureth-5 Sulfate; SodiumLauroyl Sarcosinate, Sodium Lauryl Sulfate; Sodium Lauryl Sulfoacetate;Sodium Metabisulfite; Sodium Nitrate; Sodium Phosphate; Sodium PhosphateDihydrate; Sodium Phosphate, Dibasic; Sodium Phosphate, Dibasic,Anhydrous; Sodium Phosphate, Dibasic; Dihydrate; Sodium Phosphate,Dibasic, Dodecahydrate; Sodium Phosphate, Dibasic, Heptahydrate; SodiumPhosphate, Monobasic; Sodium Phosphate; Monobasic; Anhydrous, SodiumPhosphate, Monobasic; Dihydrate; Sodium Phosphate, Monobasic;Monohydrate; Sodium Polyacrylate (2500000 Mw); Sodium Pyrophosphate;Sodium Pyrrolidone Carboxylate; Sodium Starch Glycolate; SodiumSuccinate Hexahydrate; Sodium Sulfate; Sodium Sulfate Anhydrous; SodiumSulfate Decahydrate; Sodium Sulfite; Sodium Sulfosuccinated UndecyclenicMonoalkylolamide; Sodium Tartrate; Sodium Thioglycolate; SodiumThiomalate, Sodium Thiosulfate; Sodium Thiosulfate Anhydrous; SodiumTrimetaphosphate, Sodium Xylenesulfonate; Somay 44; Sorbic Acid;Sorbitan; Sorbitan Isostearate; Sorbitan Monolaurate; SorbitanMonooleate; Sorbitan Monopalmitate; Sorbitan Monostearate; SorbitanSesquioleate; Sorbitan Trioleate; Sorbitan Tristearate; Sorbitol;Sorbitol Solution, Soybean Flour; Soybean Oil; Spearmint Oil,Spermaceti; Squalane; Stabilized Oxychloro Complex; Stannous2-Ethylhexanoate; Stannous Chloride; Stannous Chloride Anhydrous;Stannous Fluoride; Stannous Tartrate; Starch; Starch 1500;Pregelatinized; Starch, Corn; Stearalkoniun Chloride; StearalkoniumHectorite/Propylene Carbonate; Stearamidoethyl Diethylamine;Steareth-10, Steareth-100; Steareth-2; Steareth-20; Steareth-21;Steareth-40; Stearic Acid; Stearic Diethanolamide;Stearoxytrimethylsilane; Steartrimonium Hydrolyzed Animal Collagen;Stearyl Alcohol; Sterile Water For Inhalation; Styrene/Isoprene/StyreneBlock Copolymer; Succimer; Succinic Acid; Sucralose; Sucrose; SucroseDistearate; Sucrose Polyesters; Sulfacetamide Sodium; Sulfobutylether.Beta.-Cyclodextrin; Sulfur Dioxide; Sulfuric Acid; Sulfurous Acid;Surfactol Qs; Tagatose, D-; Talc; Tall Oil; Tallow Glycerides; TartaricAcid; Tartaric Acid; Dl-; Tenox; Tenox-2, Tert-Butyl Alcohol; Tert-ButylHydroperoxide; Tert-Butvlhydroquinone;Tetrakis(2-Methoxyisobutylisocyanide)Copper(I) Tetrafluoroborate;Tetrapropyl Orthosilicate; Tetrofosmin; Theophylline; Thimerosal;Threonine; Thymol; Tin; Titanium Dioxide; Tocopherol; Tocophersolan;Total parenteral nutrition, lipid emulsion; Triacetin; Tricaprylin;Trichloromonofluoromethane; Trideceth-10; Triethanolamine LaurylSulfate, Trifluoroacetic Acid; Triglycerides, Medium Chain;Trihydroxystearin; Trilaneth-4 Phosphate; Trilaureth-4 Phosphate,Trisodium Citrate Dihydrate; Trisodium Hedta; Triton 720; Triton X-200;Trolamine; Tromantadine; Tromethamine (TRIS); Typtophan; Tyloxapol;Tyrosine; Undecylenic Acid; Union 76 Amsco-Res 6038; Urea; Valine;Vegetable Oil; Vegetable Oil Glyceride, Hydrogenated; Vegetable Oil,Hydrogenated; Versetamide; Viscarin; Viscose/Cotton; Vitamin E; Wax,Emulsifying; Wecobee Fs; White Ceresin Wax; White Wax; Xanthan Gum;Zinc; Zinc Acetate; Zinc Carbonate; Zinc Chloride; and Zinc Oxide.

Pharmaceutical composition formulations of AAV particles disclosedherein may include cations or anions. In one embodiment, theformulations include metal cations such as, but not limited to, Zn2+,Ca2+, Cu2+, Mn2+, Mg+ and combinations thereof. As a non-limitingexample, formulations may include polymers and complexes with a metalcation (See e.g., U.S. Pat. Nos. 6,265,389 and 6,555,525, each of whichis herein incorporated by reference in its entirety).

Formulations of the invention may also include one or morepharmaceutically acceptable salts. As used herein, “pharmaceuticallyacceptable salts” refers to derivatives of the disclosed compoundswherein the parent compound is modified by converting an existing acidor base moiety to its salt form (e.g., by reacting the free base groupwith a suitable organic acid). Examples of pharmaceutically acceptablesalts include, but are not limited to, mineral or organic acid salts ofbasic residues such as amines; alkali or organic salts of acidicresidues such as carboxylic acids; and the like. Representative acidaddition salts include acetate, acetic acid, adipate, alginate,ascorbate, aspartate, benzenesulfonate, benzene sulfonic acid, benzoate,bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate,hexanoate, hydrobromide, hydrochloride, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, toluenesulfonate, undecanoate, valerate salts, and thelike. Representative alkali or alkaline earth metal salts includesodium, lithium, potassium, calcium, magnesium, and the like, as well asnontoxic ammonium, quaternary ammonium, and amine cations, including,but not limited to ammonium, tetramethylammonium, tetraethylammonium,methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine,and the like. The pharmaceutically acceptable salts of the presentdisclosure include the conventional non-toxic salts of the parentcompound formed, for example, from non-toxic inorganic or organic acids.

Solvates may be prepared by crystallization, recrystallization, orprecipitation from a solution that includes organic solvents, water, ora mixture thereof. Examples of suitable solvents are ethanol, water (forexample, mono-, di-, and tri-hydrates), N-methylpyrrolidinone (NMP),dimethyl sulfoxide (DMSO), N,N′-dimethylformamide (DMF),N,N′-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU),1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile(ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone,benzyl benzoate, and the like. When water is the solvent, the solvate isreferred to as a “hydrate”

III. Administration and Dosing Administration

The AAV particles of the present invention may be administered by anydelivery route which results in a therapeutically effective outcome.These include, but are not limited to, enteral (into the intestine),gastroenteral, epidural (into the dura mater), oral (by way of themouth), transdermal, intracerebral (into the cerebrum),intracerebroventricular (into the cerebral ventricles), epicutaneous(application onto the skin), intradermal. (into the skin itself),subcutaneous (under the skin), nasal administration (through the nose),intravenous (into a vein), intravenous bolus, intravenous drip,intra-arterial (into an artery), intramuscular (into a muscle),intracardiac (into the heart), intraosseous infusion (into the bonemarrow), intrathecal (into the spinal canal), intraparenchymal (intobrain tissue), Intraperitoneal. (infusion or injection into theperitoneum), Intravesical infusion, intravitreal, (through the eye),intracavernous injection (into a pathologic cavity) intracavitary (intothe base of the penis), intravaginal administration, intrauterine,extra-amniotic administration, transdermal (diffusion through the intactskin for systemic distribution), transmucosal (diffusion through amucous membrane), transvaginal, insufflation (snorting), sublingual,sublabial, enema, eye drops (onto the conjunctiva), or in ear drops,auricular (in or by way of the ear), buccal (directed toward the cheek),conjunctival, cutaneous, dental (to a tooth or teeth), electro-osmosis,endocervical, endosinusial, endotracheal, extracorporeal, hemodialysis,infiltration, interstitial, intra-abdominal, intra-amniotic,intra-articular, intrabiliary, intrabronchial, intrabursal,intracartilaginous (within a cartilage), intracaudal (within the caudaequine), intracisternal (within the cisterna magna cerebellomedularis),intracorneal (within the cornea), dental intracornal, intracoronary(within the coronary arteries), intracorporus cavernosum (within thedilatable spaces of the corporus cavernosa of the penis), intradiscal(within a disc), intraductal (within a duct of a gland), intraduodenal(within the duodenum), intradural (within or beneath the dura),intraepidermal (to the epidermis), intraesophageal (to the esophagus),intragastric (within the stomach), intragingival (within the gingivae),intraileal (within the distal portion of the small intestine),intralesional (within or introduced directly to a localized lesion),intraluminal (within a lumen of a tube), intralymphatic (within thelymph), intramedullary (within the marrow cavity of a bone),intrameningeal (within the meninges), intramyocardial (within themyocardium), intraocular (within the eye), intraovarian (within theovary), intrapericardial (within the pericardium), intrapleural (withinthe pleura), intraprostatic (within the prostate gland), intrapulmonary(within the lungs or its bronchi), intrasinal (within the nasal orperiorbital sinuses), intraspinal (within the vertebral column),intrasynovial (within the synovial cavity of a joint), intratendinous(within a tendon), intratesticular (within the testicle), intrathecal(within the cerebrospinal fluid at any level of the cerebrospinal axis),intrathoracic (within the thorax), intratubular (within the tubules ofan organ), intratumor (within a tumor), intratympanic (within the aurusmedia), intravascular (within a vessel or vessels), intraventricular(within a ventricle), iontophoresis (by means of electric current whereions of soluble salts migrate into the tissues of the body), irrigation(to bathe or flush open wounds or body cavities), laryngeal (directlyupon the larynx), nasogastric (through the nose and into the stomach),occlusive dressing technique (topical route administration which is thencovered by a dressing which occludes the area), ophthalmic (to theexternal eye), oropharyngeal (directly to the mouth and pharynx),parenteral, percutaneous, periarticular, peridural, perineural,periodontal, rectal, respiratory (within the respiratory tract byinhaling orally or nasally for local or systemic effect), retrobulbar(behind the pons or behind the eyeball), soft tissue, subarachnoid,subconjunctival, submucosal, topical, transplacental (through or acrossthe placenta), transtracheal (through the wall of the trachea),transtympanic (across or through the tympanic cavity), ureteral (to theureter), urethral (to the urethra), vaginal, caudal block, diagnostic,nerve block, biliary perfusion, cardiac perfusion, photopheresis andspinal.

In some embodiments, compositions may be administered in a way whichallows them to cross the blood-brain barrier, vascular barrier, or otherepithelial barrier. The AAV particles of the present invention may beadministered in any suitable form, either as a liquid solution orsuspension, as a solid form suitable for liquid solution or suspensionin a liquid solution. The AAV particles may be formulated with anyappropriate and pharmaceutically acceptable excipient.

In one embodiment, the AAV particles of the present invention may bedelivered to a subject, in a single route administration.

In one embodiment, the AAV particles of the present invention may bedelivered to a subject via a multi-site route of administration. Asubject may be administered at 2, 3, 4, 5 or more than 5 sites.

In one embodiment, a subject may be administered the AAV particles ofthe present invention using a bolus infusion.

In one embodiment, a subject may be administered the AAV particles ofthe present invention using sustained delivery over a period of minutes,hours or days. The infusion rate may be changed depending on thesubject, distribution, formulation or another delivery parameter.

In one embodiment, the AAV particles of the present invention may bedelivered by intramuscular delivery route. (See, e.g., U.S. Pat. No.6,506,379, the content of which is incorporated herein by reference inits entirety). Non-limiting examples of intramuscular administrationinclude an intravenous injection or a subcutaneous injection.

In one embodiment, the AAV particles of the present invention may bedelivered by oral administration. Non-limiting examples of oraladministration include a digestive tract administration and a buccaladministration.

In one embodiment, the AAV particles of the present invention may bedelivered by intraocular delivery route A non-limiting example ofintraocular administration include an intravitreal injection.

In one embodiment, the AAV particles of the present invention may bedelivered by intranasal delivery route. Non-limiting examples ofintranasal delivery include administration of nasal drops or nasalsprays.

In some embodiments, the AAV particles that may be administered to asubject by peripheral injections. Non-limiting examples of peripheralinjections include intraperitoneal, intramuscular, intravenous,conjunctival or joint injection. It was disclosed in the art that theperipheral administration of AAV vectors can be transported to thecentral nervous system, for example, to the motor neurons (e.g., U.S.Patent Publication Nos. 20100240739; and 20100130594; the content ofeach of which is incorporated herein by reference in their entirety).

In one embodiment, the AAV particles may be delivered by injection intothe CSF pathway. Non-limiting examples of delivery to the CSF pathwayinclude intrathecal and intracerebroventricular administration.

In one embodiment, the AAV particles may be delivered by systemicdelivery. As a non-limiting example, the systemic delivery may be byintravascular administration.

In one embodiment, the AAV particles of the present invention may beadministered to a subject by intracranial delivers' (See, e.g., U.S.Pat. No. 8,119,611; the content of which is incorporated herein byreference in its entirety).

In one embodiment, the AAV particles of the present invention may beadministered to a subject by intraparenchymal administration.

In one embodiment, the AAV particles of the present invention may beadministered to a subject by intramuscular administration.

In one embodiment, the AAV particles of the present invention areadministered to a subject and transduce muscle of a subject. As anon-limiting example, the AAV particles are administered byintramuscular administration.

In one embodiment, the AAV particles of the present invention may beadministered to a subject by intravenous administration.

In one embodiment, the AAV particles of the present invention may beadministered to a subject by subcutaneous administration.

In one embodiment, the AAV particles of the present invention may beadministered to a subject by topical administration.

In one embodiment, the AAV particles may be delivered by directinjection into the brain. As a non-limiting example, the brain deliverymay be by intrastriatal administration.

In one embodiment, the AAV particles may be delivered by more than oneroute of administration. As non-limiting examples of combinationadministrations, AAV particles may be delivered by intrathecal andintracerebroventricular, or by intravenous and intraparenchymaladministration.

Parenteral and Injectable Administration

In some embodiments, pharmaceutical compositions, AAV particles of thepresent invention may be administered parenterally. Liquid dosage formsfor oral and parenteral administration include, but are not limited to,pharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups, and/or elixirs. In addition to active ingredients,liquid dosage forms may comprise inert diluents commonly used in the artsuch as, for example, water or other solvents, solubilizing agents andemulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate,ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol,1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed,groundnut, corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof. Besides inert diluents, oralcompositions can include adjuvants such as wetting agents, emulsifyingand suspending agents, sweetening, flavoring, and/or perfuming agents.In certain embodiments for parenteral administration, compositions aremixed with solubilizing agents such as CREMOPHOR®, alcohols, oils,modified oils, glycols, polysorbates, cyclodextrins, polymers, and/orcombinations thereof. In other embodiments, surfactants are includedsuch as hydroxypropylcellulose.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions may be formulated according to the known artusing suitable dispersing agents, wetting agents, and/or suspendingagents. Sterile injectable preparations may be sterile injectablesolutions, suspensions, and/or emulsions in nontoxic parenterallyacceptable diluents and/or solvents, for example, as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution, U.S.P, and isotonic sodiumchloride solution. Sterile, fixed oils are conventionally employed as asolvent or suspending medium. For this purpose, any bland fixed oil canbe employed including synthetic mono- or diglycerides Fatty acids suchas oleic acid can be used in the preparation of injectables.

Injectable formulations may be sterilized, for example, by filtrationthrough a bacterial-retaining filter, and/or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

In order to prolong the effect of active ingredients, it is oftendesirable to slow the absorption of active ingredients from subcutaneousor intramuscular injections. This may be accomplished by the use ofliquid suspensions of crystalline or amorphous material with poor watersolubility. The rate of absorption of active ingredients depends uponthe rate of dissolution which, in turn, may depend upon crystal size andcrystalline form. Alternatively, delayed absorption of a parenterallyadministered drug form is accomplished by dissolving or suspending thedrug in an oil vehicle. Injectable depot forms are made by formingmicroencapsule matrices of the drug in biodegradable polymers such aspolylactide-polyglycolide. Depending upon the ratio of drug to polymerand the nature of the particular polymer employed, the rate of drugrelease can be controlled. Examples of other biodegradable polymersinclude poly(orthoesters) and poly(anhydrides). Depot injectableformulations are prepared by entrapping the drug in liposomes ormicroemulsions which are compatible with body tissues.

Rectal and Vaginal Administration

In some embodiments, pharmaceutical compositions, AAV particles of thepresent invention may be administered rectally and/or vaginallyCompositions for rectal or vaginal administration are typicallysuppositories which can be prepared by mixing compositions with suitablenon-irritating excipients such as cocoa butter, polyethylene glycol or asuppository wax which are solid at ambient temperature but liquid atbody temperature and therefore melt in the rectum or vaginal cavity andrelease the active ingredient.

Oral Administration

In some embodiments, pharmaceutical compositions, AAV particles of thepresent invention may be administered orally. Solid dosage forms fororal administration include capsules, tablets, pills, powders, andgranules. In such solid dosage forms, an active ingredient is mixed withat least one inert, pharmaceutically acceptable excipient such as sodiumcitrate or dicalcium phosphate and/or fillers or extenders (e.g.starches, lactose, sucrose, glucose, mannitol, and silicic acid),binders (e.g. carboxymethylcellulose, alginates, gelatin,polyvinylpyrrolidinone, sucrose, and acacia), humectants (e.g.glycerol), disintegrating agents (e.g. agar, calcium carbonate, potatoor tapioca starch, alginic acid, certain silicates, and sodiumcarbonate), solution retarding agents (e.g. paraffin), absorptionaccelerators (e.g. quaternary ammonium compounds), wetting agents (e.g.cetyl alcohol and glycerol monostearate), absorbents (e.g. kaolin andbentonite clay), and lubricants (e.g. talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate), andmixtures thereof. In the case of capsules, tablets and pills, the dosageform may comprise buffering agents.

Topical or Transdermal Administration

As described herein, pharmaceutical compositions, AAV particles of thepresent invention may be formulated for administration topically. Theskin may be an ideal target site for delivery as it is readilyaccessible. Three routes are commonly considered to deliverpharmaceutical compositions, AAV particles of the present invention tothe skin: (i) topical application (e.g. for local/regional treatmentand/or cosmetic applications); (ii) intradermal injection (e.g. forlocal/regional treatment and/or cosmetic applications), and (iii)systemic delivery (e.g. for treatment of dermatologic diseases thataffect both cutaneous and extracutaneous regions). Pharmaceuticalcompositions, AAV particles of the present invention can be delivered tothe skin by several different approaches known in the art.

In some embodiments, the invention provides for a variety of dressings(e.g., wound dressings) or bandages (e.g., adhesive bandages) forconveniently and/or effectively carrying out methods of the presentinvention. Typically dressing or bandages may comprise sufficientamounts of pharmaceutical compositions, AAV particles of the presentinvention described herein to allow users to perform multipletreatments.

Dosage forms for topical and/or transdermal administration may includeointments, pastes, creams, lotions, gels, powders, solutions, sprays,inhalants and/or patches. Generally, active ingredients are admixedunder sterile conditions with pharmaceutically acceptable excipientsand/or any needed preservatives and/or buffers. Additionally, thepresent invention contemplates the use of transdermal patches, whichoften have the added advantage of providing controlled delivery ofpharmaceutical compositions, AAV particles of the present invention tothe body. Such dosage forms may be prepared, for example, by dissolvingand/or dispensing pharmaceutical compositions, AAV particles in theproper medium. Alternatively, or additionally, rates may be controlledby either providing rate controlling membranes and/or by dispersingpharmaceutical compositions, AAV particles in a polymer matrix and/orgel.

Formulations suitable for topical administration include, but are notlimited to, liquid and/or semi liquid preparations such as liniments,lotions, oil in water and/or water in oil emulsions such as creams,ointments and/or pastes, and/or solutions and/or suspensions.

Topically-administrable formulations may, for example, comprise fromabout 1% to about 10% (w/w) active ingredient, although theconcentration of active ingredient may be as high as the solubilitylimit of the active ingredient in the solvent. Formulations for topicaladministration may further comprise one or more of the additionalingredients described herein.

Depot Administration

As described herein, in some embodiments, pharmaceutical compositions,AAV particles of the present invention are formulated in depots forextended release. Generally, specific organs or tissues (“targettissues”) are targeted for administration.

In some aspects of the invention, pharmaceutical compositions, AAVparticles of the present invention are spatially retained within orproximal to target tissues. Provided are methods of providingpharmaceutical compositions, AAV particles, to target tissues ofmammalian subjects by contacting target tissues (which comprise one ormore target cells) with pharmaceutical compositions, AAV particles,under conditions such that they are substantially retained in targettissues, meaning that at least 10, 20, 30, 40, 50, 60, 70, 80, 85, 90,95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of thecomposition is retained in the target tissues. Advantageously, retentionis determined by measuring the amount of pharmaceutical compositions,AAV particles, that enter one or more target cells. For example, atleast 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%,96%, 97%, 98%, 99%, 99.9%, 99.99% or greater than 99.99% ofpharmaceutical compositions, AAV particles, administered to subjects arepresent intracellularly at a period of time following administration.For example, intramuscular injection to mammalian subjects may beperformed using aqueous compositions comprising pharmaceuticalcompositions, AAV particles of the present invention and one or moretransfection reagents, and retention is determined by measuring theamount of pharmaceutical compositions, AAV particles, present in musclecells.

Certain aspects of the invention are directed to methods of providingpharmaceutical compositions, AAV particles of the present invention to atarget tissues of mammalian subjects, by contacting target tissues(comprising one or more target cells) with pharmaceutical compositions,AAV particles under conditions such that they are substantially retainedin such target tissues. Pharmaceutical compositions, AAV particlescomprise enough active ingredient such that the effect of interest isproduced in at least one target cell. In some embodiments,pharmaceutical compositions, AAV particles generally comprise one ormore cell penetration agents, although “naked” formulations (such aswithout cell penetration agents or other agents) are also contemplated,with or without pharmaceutically acceptable carriers.

Pulmonary Administration

In some embodiments, pharmaceutical compositions, AAV particles of thepresent invention may be prepared, packaged, and/or sold in formulationssuitable for pulmonary administration. In some embodiments, suchadministration is via the buccal cavity. In some embodiments,formulations may comprise dry particles comprising active ingredients.In such embodiments, dry particles may have a diameter in the range fromabout 0.5 nm to about 7 nm or from about 1 nm to about 6 nm. In someembodiments, formulations may be in the form of dry powders foradministration using devices comprising dry powder reservoirs to whichstreams of propellant may be directed to disperse such powder. In someembodiments, self-propelling solvent/powder dispensing containers may beused. In such embodiments, active ingredients may be dissolved and/orsuspended in low-boiling propellant in sealed containers. Such powdersmay comprise particles wherein at least 98% of the particles by weighthave diameters greater than 0.5 nm and at least 95% of the particles bynumber have diameters less than 7 nm. Alternatively, at least 95% of theparticles by weight have a diameter greater than 1 nm and at least 90%of the particles by number have a diameter less than 6 nm. Dry powdercompositions may include a solid fine powder diluent such as sugar andare conveniently provided in a unit dose form.

Low boiling propellants generally include liquid propellants having aboiling point of below 65° F. at atmospheric pressure. Generally,propellants may constitute 50% to 99.9% (w/w) of the composition, andactive ingredient may constitute 0.1% to 20% (w/w) of the composition.Propellants may further comprise additional ingredients such as liquidnon-ionic and/or solid anionic surfactant and/or solid diluent (whichmay have particle sizes of the same order as particles comprising activeingredients).

Pharmaceutical compositions formulated for pulmonary delivery mayprovide active ingredients in the form of droplets of solution and/orsuspension. Such formulations may be prepared, packaged, and/or sold asaqueous and/or dilute alcoholic solutions and/or suspensions, optionallysterile, comprising active ingredients, and may conveniently beadministered using any nebulization and/or atomization device. Suchformulations may further comprise one or more additional ingredientsincluding, but not limited to, a flavoring agent such as saccharinsodium, a volatile oil, a buffering agent, a surface active agent,and/or a preservative such as methylhydroxybenzoate. Droplets providedby this route of administration may have an average diameter in therange from about 0.1 nm to about 200 nm.

Intranasal, Nasal and Buccal Administration

In some embodiments, pharmaceutical compositions, AAV particles of thepresent invention may be administered nasally and/or intranasal. In someembodiments, formulations described herein useful for pulmonary deliverymay also be useful for intranasal deliver. In some embodiments,formulations for intranasal administration comprise a coarse powdercomprising the active ingredient and having an average particle fromabout 0.2 μm to 500 μm. Such formulations are administered in the mannerin which snuff is taken, i.e. by rapid inhalation through the nasalpassage from a container of the powder held close to the nose.

Formulations suitable for nasal administration may, for example,comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) ofactive ingredient, and may comprise one or more of the additionalingredients described herein. A pharmaceutical composition may beprepared, packaged, and/or sold in a formulation suitable for buccaladministration. Such formulations may, for example, be in the form oftablets and/or lozenges made using conventional methods, and may, forexample, 0.1% to 20% (w/w) active ingredient, the balance comprising anorally dissolvable and/or degradable composition and, optionally, one ormore of the additional ingredients described herein. Alternately,formulations suitable for buccal administration may comprise powdersand/or an aerosolized and/or atomized solutions and/or suspensionscomprising active ingredients. Such powdered, aerosolized, and/oraerosolized formulations, when dispersed, may comprise average particleand/or droplet sizes in the range of from about 0.1 nm to about 200 nm,and may further comprise one or more of any additional ingredientsdescribed herein

Ophthalmic or Otic Administration

In some embodiments, pharmaceutical compositions, AAV particles of thepresent invention may be prepared, packaged, and/or sold in formulationssuitable for ophthalmic and/or otic administration. Such formulationsmay, for example, be in the form of eye and/or ear drops including, forexample, a 0.1/1.0% (w/w) solution and/or suspension of the activeingredient in aqueous and/or oily liquid excipients. Such drops mayfurther comprise buffering agents, salts, and/or one or more other ofany additional ingredients described herein. Otherophthalmically-administrable formulations which are useful include thosewhich comprise active ingredients in microcrystalline form and/or inliposomal preparations. Subretinal inserts may also be used as forms ofadministration.

Delivery to Cells

The present disclosure provides a method of delivering to a cell ortissue any of the above-described AAV particles, comprising contactingthe cell or tissue with said AAV particle or contacting the cell ortissue with a formulation comprising said AAV particle, or contactingthe cell or tissue with any of the described compositions, includingpharmaceutical compositions. The method of delivering the AAV particleto a cell or tissue can be accomplished in vitro, ex vivo, or in vivo.

Delivery to Subjects

The present disclosure additionally provides a method of delivering to asubject, including a mammalian subject, any of the above-described AAVparticles comprising administering to the subject said AAV particle, oradministering to the subject a formulation comprising said AAV particle,or administering to the subject any of the described compositions,including pharmaceutical compositions.

Dose and Regimen

The present invention provides methods of administering AAV particles inaccordance with the invention to a subject in need thereof. Thepharmaceutical, diagnostic, or prophylactic AAV particles andcompositions of the present invention may be administered to a subjectusing any amount and any route of administration effective forpreventing, treating, managing, or diagnosing diseases, disorders and/orconditions. The exact amount required will vary from subject to subject,depending on the species, age, and general condition of the subject, theseverity of the disease, the particular composition, its mode ofadministration, its mode of activity, and the like. The subject may be ahuman, a mammal, or an animal. Compositions in accordance with theinvention are typically formulated in unit dosage form for ease ofadministration and uniformity of dosage. It will be understood, however,that the total daily usage of the compositions of the present inventionmay be decided by the attending physician within the scope of soundmedical judgment. The specific therapeutically effective,prophylactically effective, or appropriate diagnostic dose level for anyparticular individual will depend upon a variety of factors includingthe disorder being treated and the severity of the disorder; theactivity of the specific payload employed; the specific compositionemployed; the age, body weight, general health, sex and diet of thepatient; the time of administration, route of administration, and rateof excretion of the specific AAV particle employed; the duration of thetreatment; drugs used in combination or coincidental with the specificAAV particle employed; and like factors well known in the medical arts.

In certain embodiments, AAV particle pharmaceutical compositions inaccordance with the present invention may be administered at dosagelevels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg,from about 0.001 mg/kg to about 0.05 mg/kg, from about 0.005 mg/kg toabout 0.05 mg/kg, from about 0.001 mg/kg to about 0.005 mg/kg, fromabout 0.05 mg/kg to about 0.5 mg/kg, from about 0.01 mg/kg to about 50mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg toabout 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, ofsubject body weight per day, one or more times a day, to obtain thedesired therapeutic, diagnostic, or prophylactic, effect. It will beunderstood that the above dosing concentrations may be converted to vgor viral genomes per kg or into total viral genomes administered by oneof skill in the art.

In certain embodiments, AAV particle pharmaceutical compositions inaccordance with the present disclosure may be administered at about 10to about 600 μl/site, 50 to about 500 μl/site, 100 to about 400 μl/site,120 to about 300 μl/site, 140 to about 200 μl/site, about 160 μl/site.As non-limiting examples, AAV particles may be administered at 50μl/site and/or 150 μl/site.

The desired dosage of the AAV particles of the present invention may bedelivered only once, three times a day, two times a day, once a day,every other day, every third day, every week, every two weeks, everythree weeks, or every four weeks. In certain embodiments, the desireddosage may be delivered using multiple administrations (e.g., two,three, four, five, six, seven, eight, nine, ten, eleven, twelve,thirteen, fourteen, or more administrations). When multipleadministrations are employed, split dosing regimens such as thosedescribed herein may be used. As used herein, a “split dose” is thedivision of “single unit dose” or total daily dose into two or moredoses, e.g., two or more administrations of the “single unit dose”. Asused herein, a “single unit dose” is a dose of any therapeuticadministered in one dose/at one time/single route/single point ofcontact, i.e., single administration event.

The desired dosage of the AAV particles of the present invention may beadministered as a “pulse dose” or as a “continuous flow” As used herein,a “pulse dose” is a series of single unit doses of any therapeuticadministered with a set frequency over a period of time. As used herein,a “continuous flow” is a dose of therapeutic administered continuouslyfor a period of time in a single route/single point of contact, i.e.,continuous administration event. A total daily dose, an amount given orprescribed in 24 hour period, may be administered by any of thesemethods, or as a combination of these methods, or by any other methodssuitable for a pharmaceutical administration.

In one embodiment, delivery of the AAV particles of the presentinvention to a subject provides neutralizing activity to a subject. Theneutralizing activity can be for at least 1 month, 2 months, 3 months, 4months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11months, 1 year, 13 months, 14 months, 15 months, 16 months, 17 months,18 months, 19 months, 20 months, 20 months, 21 months, 22 months, 23months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9years, 10 years or more than 10 years.

In one embodiment, delivery, of the AAV particles of the presentinvention results in minimal serious adverse events (SAEs) as a resultof the delivery of the AAV particles.

In one embodiment, delivery of AAV particles to cells of the centralnervous system (e.g., parenchyma) may comprise a total dose betweenabout 1×10⁶ VG and about 1×10¹⁶ VG, In some embodiments, delivery maycomprise a total dose of about 1×10⁶, 2×10⁶, 3×10⁶, 4×10⁶, 5×10⁶, 6×10⁶,7×10⁶, 8×10⁶, 9×10⁶, 1×10⁷, 2×10⁷, 3×10⁷, 4×10⁷, 5×10⁷, 6×10⁷, 7×10⁷,8×10⁷, 9×10⁷, 1×10⁸, 2×10⁸, 3×10⁸, 4×10⁸, 5×10⁸, 6×10⁸, 7×10⁸, 8×10⁸,9×10⁸, 1×10⁹, 2×10⁹, 3×10⁹, 4×10⁹, 5×10⁹, 6×10⁹, 7×10⁹, 8×10⁹, 9×10⁹,1×10¹⁰, 1.9×10¹⁰, 2×10¹⁰, 3×10¹⁰, 3.73×10¹⁰, 4×10¹⁰, 5×10¹⁰, 6×10¹⁰,7×10¹⁰, 8×10¹⁰, 9×10¹⁰, 1×10¹¹, 2×10¹¹, 2.5×10¹¹, 3×10¹¹, 4×10¹¹,5×10¹¹, 6×10¹¹, 7×10¹¹, 8×10¹¹, 9×10¹¹, 1×10¹², 2×10¹², 3×10¹², 4×10¹²,5×10¹², 6×10¹², 7×10¹², 8×10¹², 9×10¹², 1×10¹³, 2×10¹³, 3×10¹³, 4×10¹³,4×10¹³, 6×10¹³, 7×10¹³, 8×10¹³, 9×10¹³, 1×10¹⁴, 2×10¹⁴, 3×10¹⁴, 4×10¹⁴,5×10¹⁴, 6×10¹⁴, 7×10¹⁴, 8×10¹⁴, 9×10¹⁴, 1×10¹⁵, 2×10¹⁵, 3×10¹⁵, 4×10¹⁵,5×10¹⁵, 6×10¹⁵, 7×10¹⁵, 8×10¹⁵, 9×10¹⁵, or 1×10¹⁶ VG. As a non-limitingexample, the total dose is 1×10¹³ VG. As another non-limiting example,the total dose is 2.1×10¹² VG.

In one embodiment, delivery of AAV particles to cells of the centralnervous system (e.g., parenchyma) may comprise a compositionconcentration between about 1×10⁶ VG/mL and about 1×10¹⁶ VG/mL. In someembodiments, delivery may comprise a composition concentration of about1×10⁶, 2×10⁶, 3×10⁶, 4×10⁶, 5×10⁶, 6×10⁶, 7×10⁶, 8×10⁶, 9×10⁶, 1×10⁷,2×10⁷, 3×10⁷, 4×10⁷, 5×10⁷, 6×10⁷, 7×10⁷, 8×10⁷, 9×10⁷, 1×10⁸, 2×10⁸,3×10⁸, 4×10⁸, 5×10⁸, 6×10⁸, 7×10⁸, 8×10⁸, 9×10⁸, 1×10⁹, 2×10⁹, 3×10⁹,4×10⁹, 5×10⁹, 6×10⁹, 7×10⁹, 8×10⁹, 9×10⁹, 1×10¹⁰, 2×10¹⁰, 3×10¹⁰,4×10¹⁰, 5×10¹⁰, 6×10¹⁰, 7×10¹⁰, 8×10¹⁰, 9×10¹⁰, 1×10¹¹, 2×10¹¹, 3×10¹¹,4×10¹¹, 5×10¹¹, 6×10¹¹, 7×10¹¹, 8×10¹¹, 9×10¹¹, 1×10¹², 2×10¹², 3×10¹²,4×10¹², 5×10¹², 6×10¹², 7×10¹², 8×10¹², 9×10¹², 1×10¹³, 2×10¹³, 3×10¹³,4×10¹³, 5×10¹³, 6×10¹³, 7×10¹³, 8×10¹³, 9×10¹³, 1×10¹⁴, 2×10¹⁴, 3×10¹⁴,4×10¹⁴, 5×10¹⁴, 6×10¹⁴, 7×10¹⁴, 8×10¹⁴, 9×10¹⁴, 1×10¹⁵, 2×10¹⁵, 3×10¹⁵,4×10¹⁵, 5×10¹⁵, 6×10¹⁵, 7×10¹⁵, 8×10¹⁵, 9×10¹⁵, or 1×10¹⁶ VG/mL. In oneembodiment, the delivery comprises a composition concentration of 1×10¹³VG/mL. In one embodiment, the delivery comprises a compositionconcentration of 2.1×10¹² VG/mL.

Combinations

The AAV particles may be used in combination with one or more othertherapeutic, prophylactic, research or diagnostic agents. By “incombination with,” it is not intended to imply that the agents must beadministered at the same time and/or formulated for delivery together,although these methods of delivery are within the scope of the presentinvention. Compositions can be administered concurrently with, prior to,or subsequent to, one or more other desired therapeutics or medicalprocedures. In general, each agent will be administered at a dose and/oron a time schedule determined for that agent. In some embodiments, thepresent disclosure encompasses the delivery of pharmaceutical,prophylactic, research, or diagnostic compositions in combination withagents that may improve their bioavailability, reduce and/or modifytheir metabolism, inhibit their excretion, and/or modify theirdistribution within the body.

Measurement of Expression

Expression of payloads from viral genomes may be determined usingvarious methods known in the art such as, but not limited toimmunochemistry (e.g., IHC), in situ hybridization (ISH), enzyme-linkedimmunosorbant assay (ELISA), affinity ELISA, ELISPOT, flow cytometry,immunocytology, surface plasmon resonance analysis, kinetic exclusionassay, liquid chromatography-mass spectrometry (LCMS), high-performanceliquid chromatography (HPLC). BCA assay, immunoelectrophoresis. Westernblot, SDS-PAGE, protein immunoprecipitation, and/or PCR,

Bioavalability

The AAV particles, when formulated into a composition with a deliveryagent as described herein, can exhibit an increase in bioavailability ascompared to a composition lacking a delivery agent as described herein.As used herein, the term “bioavailability” refers to the systemicavailability of a given amount of AAV particle or expressed payloadadministered to a mammal. Bioavailability can be assessed by measuringthe area under the curve (AUC) or the maximum serum or plasmaconcentration (C_(max)) of the composition following. AUC is adetermination of the area under the curve plotting the serum or plasmaconcentration of a compound (e.g., AAV particles or expressed payloads)along the ordinate (Y-axis) against time along the abscissa (X-axis).Generally, the AUC for a particular compound can be calculated usingmethods known to those of ordinary skill in the art and as described inG. S. Banker, Modern Pharmaceutics, Drugs and the PharmaceuticalSciences, v. 72, Marcel Dekker, New York, Inc., 1996, the contents ofwhich are herein incorporated by reference in its entirety.

The C_(max) value is the maximum concentration of the AAV particle orexpressed payload achieved in the serum or plasma of a mammal followingadministration of the AAV particle to the mammal. The C_(max) value ofcan be measured using methods known to those of ordinary skill in theart. The phrases “increasing bioavailability” or “improving thepharmacokinetics,” as used herein mean that the systemic availability ofa first AAV particle or expressed payload, measured as AUC, C_(max), orC_(min) in a mammal is greater, when co-administered with a deliveryagent as described herein, than when such co-administration does nottake place. In some embodiments, the bioavailability can increase by atleast about 2%, at least about 5%, at least about 10%, at least about15%, at least about 20%, at least about 25%, at least about 30%, atleast about 35%, at least about 40%, at least about 45%, at least about50%, at least about 55%, at least about 60%, at least about 65%, atleast about 70%, at least about 75%, at least about 80%, at least about85%, at least about 90%, at least about 95%, or about 100%.

Therapeutic Window

As used herein “therapeutic window” refers to the range of plasmaconcentrations, or the range of levels of therapeutically activesubstance at the site of action, with a high probability of eliciting atherapeutic effect. In some embodiments, the therapeutic window of theAAV particle as described herein can increase by at least about 2%, atleast about 5%, at least about 10%, at least about 15%, at least about20%, at least about 25%, at least about 30%, at least about 35%, atleast about 40%, at least about 45%, at least about 50%, at least about55%, at least about 60%, at least about 65%, at least about 70%, atleast about 75%, at least about 80%, at least about 85%, at least about90%, at least about 95%, or about 100%.

Volume of Distribution

As used herein, the term “volume of distribution” refers to the fluidvolume that would be required to contain the total amount of the drug inthe body at the same concentration as in the blood or plasma: V_(dist)equals the amount of drug in the body/concentration of drug in blood orplasma. For example, for a 10 mg dose and a plasma concentration of 10mg/L, the volume of distribution would be 1 liter. The volume ofdistribution reflects the extent to which the drug is present in theextravascular tissue. A large volume of distribution reflects thetendency of a compound to bind to the tissue components compared withplasma protein binding. In a clinical setting, V_(dist) can be used todetermine a loading dose to achieve a steady state concentration. Insome embodiments, the volume of distribution of the AAV particles asdescribed herein can decrease at least about 2%, at least about 5%, atleast about 10%, at least about 15%, at least about 20%, at least about25%, at least about 30%, at least about 35%, at least about 40%, atleast about 45%, at least about 50%, at least about 55%, at least about60%, at least about 65%, at least about 70%.

Biological Effect

In one embodiment, the biological effect of the AAV particles deliveredto the animals may be categorized by analyzing the payload expression inthe animals. The payload expression may be determined from analyzing abiological sample collected from a mammal administered the AAV particlesof the present invention. For example, a protein expression of 50-200pg/ml for the protein encoded by the AAV particles delivered to themammal may be seen as a therapeutically effective amount of protein inthe mammal.

IV. Methods and Uses of the Compositions of the Invention

The present disclosure provides a method for treating a disease,disorder and/or condition in a mammalian subject, including a humansubject, comprising administering to the subject any of the AAVparticles described herein or administering to the subject any of thedescribed compositions, including pharmaceutical compositions, describedherein.

In one embodiment, the AAV particles of the present invention areadministered to a subject prophylactically.

In one embodiment, the AAV particles of the present invention areadministered to a subject having at least one of the diseases describedherein.

In one embodiment, the AAV particles of the present invention areadministered to a subject to treat a disease or disorder describedherein. The subject may have the disease or disorder or may be at-riskto developing the disease or disorder.

In one embodiment, the AAV particles of the present invention are partof an active immunization strategy to protect against diseases anddisorders. In an active immunization strategy, a vaccine or AAVparticles are administered to a subject to prevent an infectious diseaseby activating the subject's production of antibodies that can fight offinvading bacteria or viruses.

In one embodiment, the AAV particles of the present invention are partof a passive immunization strategy. In a passive immunization strategy,antibodies against a particular infectious agent are given directly tothe subject.

Diseases and Toxins

Various infectious diseases may be treated with pharmaceuticalcompositions, AAV particles, of the present invention. As used herein,the term “infectious disease” refers to any disorders caused byorganisms such as bacteria, viruses, fungi or parasites. As anon-limiting example, the infectious disease may be Acute bacterialrhinosinusitis, 14-day measles. Acne, Acrodermatitis chronicaatrophicans (ACA)-(late skin manifestation of latent Lyme disease),Acute hemorrhagic conjunctivitis, Acute hemorrhagic cystitis, Acuterhinosinusitis, Adult T-cell Leukemia-Lymphoma (ATLL), African SleepingSickness, AIDS (Acquired Immunodeficiency Syndrome), Alveolar hydatid,Amebiasis, Amebic meningoencephalitis, Anaplasmosis, Anthrax, Arboviralor parainfectious, Ascariasis—(Roundworm infections), Asepticmeningitis, Athlete's foot (Tinea pedis), Australian tick typhus, AvianInfluenza, Babesiosis, Bacillary angiomatosis, Bacterial meningitis,Bacterial vaginosis, Balanitis, Balantidiasis, Bang's disease, BarmahForest virus infection, Bartonellosis (Verruga peruana; Carrion'sdisease; Oroya fever), Bat Lyssavirus Infection, Bay sore (Chiclero'sulcer), Baylisascaris infection (Racoon roundworm infection), Beaverfever, Beef tapeworm, Bejel (endemic syphilis), Biphasicmeningoencephalitis, Black Bane, Black death, Black piedra, BlackwaterFever, Blastomycosis, Blennorrhea of the newborn, Blepharitis, Boils,Bomholm disease (pleurodynia), Borrelia miyamotoi Disease, Botulism,Boutonneuse fever, Brazilian purpuric fever, Break Bone fever, Brill,Bronchiolitis, Bronchitis, Brucellosis (Bang's disease), Bubonic plague,Bullous impetigo, Burkholderia mallei (Glanders), Burkholderiapseudomallei (Melioidosis), Buruli ulcers (also Mycoburuli ulcers),Busse Busse-Buschke disease (Cryptococcosis), California groupencephalitis, Campylobacteriosis, Candidiasis, Canefield fever (Canicolafever; 7-day fever; Weil's disease; leptospirosis; canefield fever),Canicola fever, Capillanasis, Carate, Carbapenem-resistantEnterobacteriaceae (CRE), Carbuncle, Carrion's disease, Cat Scratchfever, Cave disease, Central Asian hemorrhagic fever, Central Europeantick, Cervical cancer, Chagas disease, Chancroid (Soft chancre), Chicagodisease, Chickenpox (Varicella), Chiclero's ulcer, Chikungunya fever,Chlarmydial infection, Cholera, Chromoblastomycosis, Ciguatera, Clap,Clonorchiasis (Liver fluke infection), Clostridium difficile Infection,Clostridium perfringens (Epsilon Toxin), Coccidioidonycosis fungalinfection (Valley fever; desert rheumatism), Coenurosis, Colorado tickfever, Condyloma accuminata, Condyloma accununata (Warts), Condylomalata, Congo fever, Congo hemorrhagic fever virus, Conjunctivitis,cowpox, Crabs, Crimean, Croup, Cryptococcosis, Cryptosporidiosis(Crypto), Cutaneous Larval Migrans, Cyclosporiasis, Cystic hydatid,Cysticercosis, Cystatis, Czechoslovak tick, D68 (EV-D68), Dacryocytitis,Dandy fever, Darling's Disease, Deer fly fever, Dengue fever (1, 2, 3and 4), Desert rheumatism, Devil's grip, Diphasic milk fever,Diphtheria, Disseminated Intravascular Coagulation, Dog tapeworm,Donovanosis, Donovanosis (Granuloma inguinale), Dracontiasis,Dracunculosis, Duke's disease, Dum Dum Disease, Durand-Nicholas-Favredisease, Dwarf tapeworm, E, Coli infection (E. Coli), Eastern equineencephalitis, Ebola Hemorrhagic Fever (Ebola virus disease EVD),Ectothrix, Ehrlichiosis (Sennetsu fever), Encephalitis, EndemicRelapsing fever, Endemic syphilis, Endophthalmitis, Endothrix,Enterobiasis (Pinworm infection), Enterotoxin-B Poisoning (Staph FoodPoisoning), Enterovirus Infection, Epidemic Keratoconjunctivitis,Epidemic Relapsing fever, Epidemic typhus, Epiglottitis, Erysipelis,Ervsipeloid (Erysipelothricosis), Erythema chronicum migrans, Erythemainfectiosum, Erythema marginatum, Enrthema multiforme, Erythema nodosum,Erythema nodosum leprosum Erythrasma, Espundia, Euniycotic mycetoma,European blastomycosis, Exanthem subitumn (Sixth disease), Eyeworm, FarEastern tick, Fascioliasis, Fievre boutonneuse (Tick typhus), FifthDisease (erythema infectiosum), Filatow-Dukes' Disease (Scalded SkinSyndrome; Ritter's Disease), Fish tapeworm, Fitz-Hugh-Curtissyndrome—Perihepatitis, Flinders Island Spotted Fever, Flu (Influenza),Folliculitis, Four Corners Disease, Four Corners Disease (HumanPulmonary Syndrome (HPS)), Frambesia, Francis disease, Furunculosis, Gasgangrene, Gastroenteritis, Genital Herpes, Genital Warts, Germanmeasles, Gerstmann-Straussler-Scheinker (GSS), Giardiasis, Gilchrist'sdisease, Gingivitis, Gingivostomatitis, Glanders, Glandular fever(infectious mononucleosis), Gnathostomiasis, Gonococcal Infection(Gonorrhea), Gonorrhea, Granuloma inguinale (Donovanosis), Guinea Worm,Haemophilus Influenza disease, Hamburger disease, Hansen'sdisease—leprosy, Hantaan disease, Hantaan-Korean hemorrhagic fever,Hantavirus Pulmonary Syndrome, Hantavirus Pulmonary Syndrome (HPS), Hardchancre, Hard measles, Haverhill fever—Rat bite fever, Head and BodyLice, Heartland fever, Helicobacterosis, Hemolytic Uremic Syndrome(HUS), Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E,Herpangina, Herpes—genital, Herpes labialis, Herpes—neonatal,Hidradenitis, Histoplasmosis, Histoplasmosis infection (Histoplasmosis),His-Werner disease, HIV infection, Hookworm infections, Hordeola,Hordeola (Stye), HTLV, HTLV-associated myelopathy (HAM), Humangranulocytic ehrlichiosis, Human monocytic ehrlichiosis, HumanPapillomavirus (HPV), Human Pulmonary Syndrome, Hydatid cyst,Hydrophobia, Impetigo, Including congenital (German Measles), Inclusionconjunctivitis, Inclusion conjunctivitis+Swimming Poolconjunctivitis—Pannus, Infantile diarrhea, Infectious Mononucleosis,Infectious myocarditis, Infectious pericarditis, Influenza,Isosporiasis, Israeli spotted fever, Japanese Encephalitis, Jock itch,Jorge Lobo disease—Iobomycosis, Jungle yellow fever, Junin Argentinianhemorrhagic fever, Kala Azar, Kaposi's sarcoma, Keloidal blastomycosis,Keratoconjunctivitis, Kuru, Kyasanur forest disease, LaCrosseencephalitis, Lassa hemorrhagic fevter, Legionellosis (LegionnairesDisease), Legionnaires pneumonia, Lemierre's Syndrome (Postanginalsepticemia), Lemming fever, Leprosy, Leptospirosis (Nanukayami fever:Well's disease), Listeriosis (Listeria), Liver fluke infection, Lobo'smycosis, Lockjaw, Loiasis, Louping Ill, Ludwig's angina, Lung flukeinfection, Lung fluke infection (Paragonimiasis), Lyme disease,Lymphogranuloma venereum infection (LGV), Machupo Bolivian hemorrhagicfever, Madura foot, Mal del pinto, Malaria, Malignant pustule, Maltafever, Marburg hemorrhagic fever, Masters disease, Maternal Sepsis(Puerperal fever), Measles, Mediterannean spotted fever, Melioidosis(Whitmore's disease), Meningitis, Meningococcal Disease, MERS, Milker'snodule, Molluscum contagiosum, Moniliasis, monkeypox, Mononucleosis,Mononucleosis-like syndrome, Montezuma's Revenge, Morbillih, MRSA(methicillin-resistant Staphylococcus aureus) infection,Mucormycosis-Zygonmycosis, Multiple Organ Dysfunction Syndrome or MODS,Multiple-system atrophy (MSA), Mumps, Murine typhus, Murray ValleyEncephalitis (MVE), Mycoburuli ulcers, Mycoburuli ulcers-Buruli ulcers,Mycotic vulvovaginitis, Myositis, Nanukavami fever, Necrotizingfasciitis, Necrotizing fasciitis—Type 1, Necrotizing fasciitis—Type 2,Negishi, New world spotted fever, Nocardiosis, Nongonococcal urethritis,Non-Polio (Non-Polio Enterovirus), Norovirus infection, North Americanblastonmycosis, North Asian tick typhus, Norwalk virus infection,Norwegian itch, O'Hara disease, Omsk hemorrhagic fever, Onchocerciasis,Onychomycosis, Opisthorchiasis, Opthalmia neonatorium, Oral hairyleukoplakia, Orf, Oriental Sore, Oriental Spotted Fever, Omithosis(Parrot fever; Psittacosis), Oroya fever, Otitis externa, Otitis media,Pannus, Paracoccidioidomycosis, Paragonimiasis, Paralytic ShellfishPoisoning (Paralytic Shellfish Poisoning), Paronychia (Whitlow),Parotitis, PCP pneumonia, Pediculosis, Peliosis hepatica, PelvicInflammatory Disease, Pertussis (also called Whooping cough),Phaeohyphomycosis, Pharyngoconjunctival fever, Piedra (White Piedra),Piedra(Black Piedra), Pigbel, Pink eye conjunctivitis, Pinta, Pinworminfection, Pitted Keratolysis, Pityriasis versicolor (Tinea versicolor),Plague; Bubonic, Pleurodynia, Pneumococcal Disease, Pneumocystosis,Pneumonia, Pneumonic (Plague), Polio or Poliominvelitis, Polycystichydatid, Pontiac fever, Pork tapeworm, Posada-Wemicke disease,Postanginal septicemia, Powassan, Progressive multifocalleukencephalopathy, Progressive Rubella Panencephalitis, Prostatitis,Pseudomembranous colitis, Psittacosis, Puerperal fever, Pustular Rashdiseases (Small pox), Pyelonephritis, Pylephlebitis, Q-Fever, Quinsy,Quintana fever (5-day fever), Rabbit fever, Rabies, Racoon roundworminfection, Rat bite fever, Rat tapeworm, Reiter Syndrome, Relapsingfever, Respiratory syncytial virus (RSV) infection, Rheumatic fever,Rhodotorulosis, Ricin Poisoning, Rickettsialpox, Rickettsiosis, RiftValley Fever, Ringworm, Ritter's Disease, River Blindness, RockyMountain spotted fever, Rose Handler's disease (Sporotrichosis), Roserash of infants, Roseola, Ross River fever, Rotavirus infection,Roundworm infections, Rubella, Rubeola, Russian spring, Salmonellosisgastroenteritis, San Joaquin Valley fever, Sao Paulo Encephalitis, SaoPaulo fever, SARS, Scabies Infestation (Scabies) (Norwegian itch),Scalded Skin Syndrome, Scarlet fever (Scarlatina), Schistosomiasis,Scombroid, Scrub typhus, Sennetsu fever, Sepsis (Septic shock), SevereAcute Respiratory Syndrome, Severe Acute Respiratory Syndrome (SARS),Shiga Toxigenic Escherichia coli (STEC/VTEC), Shigellosisgastroenteritis (Shigella), Shinbone fever, Shingles, Shipping fever,Siberian tick typhus, Sinusitis, Sixth disease, Slapped cheek disease,Sleeping sickness, Smallpox (Variola), Snail Fever, Soft chancre,Southern tick associated rash illness, Sparganosis, Spelunker's disease,Sporadic typhus, Sporotrichosis, Spotted fever, Spring, St, Louisencephalitis, Staphylococcal Food Poisoning, Staphylococcal Infection,Strep, throat, Streptococcal Disease, Streptococcal Toxic-ShockSyndrome, Strongyloiciasis, Stye, Subacute Sclerosing Panencephalitis,Subacute Sclerosing Panencephalitis (SSPE), Sudden Acute RespiratorySyndrome, Sudden Rash, Swimmer's ear, Swimmer's Itch, Swimming Poolconjunctivitis, Sylvatic yellow fever, Syphilis, Systemic InflammatoryResponse Syndrome (SIRS), Tabes dorsalis (tertiary syphilis), Taeniasis,Taiga encephalitis, Tanner's disease, Tapeworm infections, Temporal lobeencephalitis, Temporal lobe encephalitis, tetani (Lock Jaw), TetanusInfection, Threadwonn infections, Thrush, Tick, Tick typhus, Tineabarbae, Tinea capitis, Tinea corporis, Tinea cruris, Tinea manuum, Tineanigra, Tinea pedis, Tinea unguiunm, Tinea versicolor, Torulopsosis,Torulosis, Toxic Shock Syndrome, Toxoplasmosis, transmissiblespongioform (CJD), Traveler's diarrhea, Trench fever 5, Trichinellosis,Trichomoniasis, Trichomycosis axillaris, Trichuriasis, Tropical SpasticParaparesis (TSP), Trypanosomiasis, Tuberculosis (TB), Tuberculousis,Tularemia, Typhoid Fever, Typhus fever, Ulcus molle, Undulant fever,Urban yellow fever, Urethritis, Vaginitis, Vaginosis, VancomycinIntermediate (VISA), Vancomycin Resistant (VRSA), Varicella, VenezuelanEquune encephalitis, Verruga peruana, Vibrio cholerae (Cholera),Vibriosis (Vibrio), Vincent's disease or Trench mouth, Viralconjunctivitis, Viral Meningitis, Viral meningoencephalitis, Viral rash,Visceral Larval Migrans, Vornito negro, Vulvovaginitis, Warts,Waterhouse, Weil's disease, West Nile Fever, Western equineencephalitis, Whipple's disease, Whipworm infection, White Piedra,Whitlow, Whitmore's disease, Winter diarrhea, Wolhynia fever, Woolsorters' disease, Yaws, Yellow Fever, Yersinosis, Yersinosis (Yersinia),Zahorsky's disease, Zika virus disease, Zoster, Zygornmcosis, JohnCunningham Virus (JCV), Human immunodeficiency virus (HIV), Influenzavirus, Hepatitis B, Hepatitis C, Hepatitis D, Respiratory syncytialvirus (RSV), Herpes simplex virus 1 and 2, Human Cytomegalovirus,Epstein-Barr virus, Varicella zoster virus, Coronaviruses, Poxviruses,Enterovirus 71, Rubella virus, Human papilloma virus, Streptococcuspneumoniae, Streptococcus viridans, Staphylococcus aureus (S. aureus),Methicillin-resistant Staphylococcus aureus (MRSA),Vancomycin-intermediate Staphylococcus aureus (VISA),Vancomycin-resistant Staphylococus aureus (VRSA), Staphylococcusepidermidis (S. epidermidis), Clostridium teltani, Bordetella pertussis,Bordetelia paratussis, Mycobacterium, Francisella yularensis, Toxoplasmagondii, Candida ((C. albicans, C. glabrata, C. parapsilosis, C.tropicalis, C. krusei and C. lusiltaniae) and/or any other infectiousdiseases, disorders or syndromes.

Various toxins may be treated with the pharmaceutical compositions, AAVparticles, of the present invention. Non-limited examples of toxinsinclude Ricin, Bacillus anthracis, Shiga toxin and Shiga-like toxin,Botulinum toxins.

Various tropical diseases may be treated with pharmaceuticalcompositions, AAV particles, of the present invention. Non-limitedexamples of tropical diseases include Chikungunya fever. Dengue fever.Chagas disease, Rabies, Malaria. Ebola virus, Marburg virus, West NileVirus, Yellow Fever, Japanese encephalitis virus. St Louis encephalitisvirus.

Various foodborne illnesses and gastroenteritis may be treated withpharmaceutical compositions, AAV particles, of the present invention.Non-limited examples of foodborne illnesses and gastroenteritis includeRotavirus, Norwalk virus (Norovirus), Campylobacter jejuni, Clostridiumdifficile, Entamoeba histolytica, Helicobacter pylori, Enterotoxin B ofStaphylococcus aureus, H-lepatitis A virus (HAV), Hepatitis E. Listeriamonocytogenes, Salmonella, Clostridium perfringens, and Salmonella.

Various infectious agents may be treated with pharmaceuticalcompositions, AAV particles, of the present invention. Non-limitedexamples of infectious agents include adenoviruses. Anaplasmaphagocytophilium, Ascaris lumbricoides, Bacillus anthracis, Bacilluscereus, Bacteroides sp, Barmah Forest virus, Bartonella bacilliformis,Bartonella henselae, Bartonella quintana, beta-toxin of Clostridiumperifingens, Bordetella pertussis, Bordetella parapertussis, Borreliaburgdorferi, Borrelia miyamotoi, Borrelia recurrentis, Borreha sp.,Botulinum toxin, Brucella sp., Burkholderia pseudomallei, Californiaencephalitis virus, Campylobacter, Candida albicans, chikungunya virus,Chlamydia psittaci, Chlamydia trachomatis, Clonorchts sinensis,Clostridium difficile bacteria, Clostridium tetani, Colorado tick fevervirus, Corynebacterium diphtheriae, Corynebacterium minutissimum,Coxiella burneii, coxsackie A, coxsackie B, Crimean-Congo hemorrhagicfever virus, cytomegalovirus, dengue virus, Eastern Equine encephalitisvirus, Ebola viruses, echovirus, Ehrlichia chaffeensis, Ehrlichia equi,Ehrlichia sp., Entamoeba histolytica, Enterobacter sp., Enterococcusfeacalis, Enterovirus 71, Epstein-Barr virus (EBV), Erysipelothrixrhusioplathiae, Escherichia coli, Flavivirus, Fusobacterium necrophorum,Gardnerella vaginalis, Group B streptococcus, Haemophilus aegyptius,Haemophilus ducreyi, Haemophilus influenzae, hantavirus, Helicobacterpylori, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E,herpes simplex virus 1 and 2, human herpes virus 6, human herpes Virus8, human immunodeficiency virus 1 and 2, human T-cell leukemia viruses 1and 11, influenza viruses (A, B, C), Jamestown Canyon virus, Japaneseencephalitis antigenic, Japanese encephalitis virus, John Cunninghamvirus, juninvirus, Kaposi's Sarcoma-associated Herpes Virus (KSHV),Klebsiella granulomatis, Klebsiella sp., Kyasanur Forest Disease virus,La Crosse virus, Lassavirus, Legionella pneumophila, Leptospirainterrogans, Listeria monocytogenes, lymphocytic choriomeningitis virus,lyssavirus, Machupovirus, Marburg virus, measles virus, MERS coronavirus(MERS-CoV), Micrococcus sedentarius, Mobiliuncus sp., Molluscipeoxvirus,Moraxella catarrhalis, Morbilli-Ruheola virus, Mumpsvirus, Mycobacteriumleprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasmagenitalium, Mycoplasma sp. Nairovirus, Neisseria gonorrhoeae, Neisseriamenigitidis, Nocardia, Norwalk virus, norovirus, Onmsk hemorrhagic fevervirus, papilloma virus, parainfluenza viruses 1-3, parapoxvirus,parvovirus B19, Peptostreptococccus sp., Plasmodium sp., poliovirusestypes 1, 11, and III, Proteus sp., Pseudomonas aeruginosa, Pseudomonaspseudomallei, Pseudomonas sp., rabies virus, respiratory syncytialvirus, ricin toxin, Rickettsia australis, Rickettsia conori, Rickettsiahonei, Rickettsia prowazekii, Ross River Virus, rotavirus, rubellavirus,Saint Louis encephalitis, Salmonella typhi, Sarcoptes scabiei,SARS-associated coronavirus (SARS-CoV), Serratia sp., Shiga toxin andShiga-like toxin, Shigella sp., Sin Nombre Virus, Snowshoe hare virus,Staphylococcus aureus, Staphylococcus epidermidis, Streptobacillusmoniliformis, Streptococcus pneumoniae, Streptococcus agalactiae,Streptococcus agalacticae, Streptococcus group A-H, Streptococcuspneumoniae, Streptcoccus pyogenes, Treponema pallidum subsp. Pallidum,Treponema pallidum var. carateum, Treponema pallidum var. endemicum,Tropheryma whippelii, Ureaplasma urealytcum, Varicella-Zoster virus,variola virus, Vibrio cholerae, West Nile virus, yellow fever virus,Yersinia enterocolitica, Yersinia pestis, and Zika virus.

Various rare diseases may be treated with pharmaceutical compositions,AAV particles, of the present invention. As used herein, the term “raredisease” refers to any disease that affects a small percentage of thepopulation. As a non-limiting example, the rare disease may beAcrocephalosyndactylia, Acrodermatitis, Addison Disease, Adie Syndrome,Alagille Syndrome, Amylose, Amyotrophic Lateral Sclerosis, AngelmanSyndrome, Angiolymphoid Hyperplasia with Eosinophilia, Arnold-ChiariMalformation, Arthritis, Juvenile Rheumatoid, Asperger Syndrome,Bardet-Biedl Syndrome, Barrett Esophagus, Beckwith-Wiedemann Syndrome,Behcet Syndrome, Bloom Syndrome, Bowen's Disease, Brachial PlexusNeuropathies, Brown-Sequard Syndrome, Budd-Chiari Syndrome, BurkittLymphoma, Carcinoma 256, Walker, Caroli Disease, Charcot-Marie-ToothDisease, Chediak-Hiigashi Syndrome, Chiari-Frommel Syndrome,Chondrodysplasia Punctata, Colonic Pseudo-Obstruction, ColorectalNeoplasms, Hereditary Nonpolyposis, Craniofacial Dysostosis,Creutzfeldt-Jakob Syndrome, Crohn Disease, Cushing Syndrome, CysticFibrosis, Dandy-Walker Syndrome, De Lange Syndrome, Dementia, Vascular,Dermatitis Herpetiformis, DiGeorge Syndrome, Diffuse Cerebral Sclerosisof Schilder, Duane Retraction Syndrome, Dupuytren Contracture, EbsteinAnomaly, Eisenmenger Complex, Ellis-Van Creveld Syndrome, Encephalitis,Enchondromatosis, Epidermal Necrolysis, Toxic, Facial Hemiatrophy,Factor XII Deficiency, Fanconi Anemia, Felty's Syndrome, FibrousDyvsplasia, Polvostotic, Fox-Fordyce Disease, Friedreich Ataxia,Fusobacterium, Gardner Syndrome, Gaucher Disease, Gerstmann Syndrome,Giant Lymph Node Hyperplasia, Glycogen Storage Disease Type I, GlycogenStorage Disease Type II, Glycogen Storage Disease Type IV, GlycogenStorage Disease Type V, Glycogen Storage Disease Type VII, GoldenharSyndrome, Guillain-Barre Syndrome, Hallermann's Syndrome, HamartomaSyndrome, Multiple, Hartnup Disease, Hepatolenticular Degeneration,Hepatolenticular Degeneration, Hereditary Sensory and Motor Neuropathy,Hirschsprung Disease, Histiocytic Necrotizing Lymphadenitis,Histiocytosis, Langerhans-Cell, Hodgkin Disease, Homer Syndrome,Huntington Disease, Hyperaldosteronism, Hyperhidrosis, Hyperostosis,Diffuse Idiopathic Skeletal, Hypopituitarism, Inappropriate ADHSyndrome, Intestinal Polyps, Isaacs Syndrome, Kartagener Syndrome,Keams-Sayre Syndrome, Klippel-Feil Syndrome, Klippel-Trenaunay-WeberSyndrome, Kluver-Bucy Syndrome, Korsakoff Syndrome, Lafora Disease,Lambert-Eaton Myasthenic Syndrome, Landau-Kleffner Syndrome,Langer-Giedion Syndrome, Leigh Disease, Lesch-Nyhan Syndrome,Leukodystrophy, Globoid Cell, Li-Fraumeni Syndrome, Long QT Syndrome,Machado-Joseph Disease, Mallory-Weiss Syndrome, Marek Disease, MarfanSyndrome, Meckel Diverticulum, Meige Syndrome, Melkersson-RosenthalSyndrome, Meniere Disease, Mikulicz' Disease, Miller Fisher Syndrome,Mobius Syndrome, Moyamoya Disease, Mucocutaneous Lymph Node Syndrome,Mucopoly saccharidosis I, Mucopolysaccharidosis II,Mucopolysaccharidosis III, Mucopolysaccharidosis IV,Mucopolysaccharidosis VI, Multiple Endocrine Neoplasia Type 1,Munchausen Syndrome by Proxy, Muscular Atrophy, Spinal, Narcolepsy,Neuroaxonal Dystrophies, Neuromyelitis Optica, NeuronalCeroid-Lipofuscinoses, Niemann-Pick Diseases, Noonan Syndrome, OpticAtrophies, Hereditary, Osteitis Deformans, Osteochondritis,Osteochondrodysplasias, Osteolysis, Essential, Paget DiseaseExtramammary, Paget's Disease, Mammary, Panuuculitis, NodularNonsuppurative, Papillon-Lefevre Disease, Paralysis,Pelizaeus-Merzbacher Disease, Pemphigus, Benign Familial, PenileInduration, Pericarditis, Constrictive, Peroxisomal Disorders,Peutz-Jeghers Syndrome, Pick Disease of the Brain, Pierre RobinSyndrome, Pigmentation Disorders, Pityriasis Lichenoides, PolycysticOvary Syndrome, Polyendocrinopathies, Autoimmune, Prader-Willi Syndrome,Pupil Disorders, Rett Syndrome, Reye Syndrome, Rubinstein-TaybiSyndrome, Sandhoff Disease, Sarcoma, Ewing's, Schnitzler Syndrome,Sjogren's Syndrome, Sjogren-Larsson Syndrome, Smith-Lemli-OpitzSyndrome, Spinal Muscular Atrophies of Childhood, Sturge-Weber Syndrome,Sweating, Gustatory, Takayasu Arteritis, Tangier Disease, Tay-SachsDisease, Thromboangiitis Obliterans, Thyroiditis, Autoimmune, Tietze'sSyndrome, Togaviridae Infections, Tolosa-Hunt Syndrome, TouretteSyndrome, Uveomeningoencephalitic Syndrome, Waardenburg's Syndrome,Wegener Granulomatosis, Weil Disease, Werner Syndrome, WilliamsSyndrome, Wilms Tumor, Wolff-Parkinson-White Syndrome, Wolfram Syndrome,Wolman Disease, Zellweger Syndrome, Zollinger-Ellison Syndrome, and vonWillebrand Diseases.

Various autoimmune diseases and autoimmune-related diseases may betreated with pharmaceutical compositions, AAV particles, of the presentinvention. As used herein, the term “autoimmune disease” refers to adisease in which the body produces antibodies that attack its owntissues. As a non-limiting example, the autoimmune disease may be AcuteDisseminated Encephalomyelitis (ADEM), Acute necrotizing hemorrhagicleukoencephalitis, Addison's disease, Agammaglobulinemia, Alopeciaareata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBMnephritis, Antiphospholipid syndrome (APS), Autoimmune angioedema,Autoimmune aplastic anemia, Autoimmune dysautonomia, Autoimmunehepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency,Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmuneoophoritis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmunethrombocytopenic purpura (ATP), Autoimmune thyroid disease, Autoimmuneurticaria, Axonal & neuronal neuropathies, Balo disease, Behcet'sdisease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiacdisease, Chagas disease, Chronic fatigue syndrome**, Chronicinflammatory demyelinating polyneuropathy (CIDP), Chronic recurrentmultifocal ostomyelitis (CRMO), Churg-Strauss syndrome, Cicatricialpemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome,Cold agglutinin disease, Congenital heart block, Coxsackle myocarditis,CREST disease, Essential mixed cryoglobulinemia, Demyelinatingneuropathies, Dermatitis herpetiformis, Dermatomyositis, Devic's disease(neuromyelitis optica), Discoid lupus, Dressler's syndrome,Endometriosis, Eosinophilic esophagitis, Eosinophilic fasciitis,Erythema nodosum, Experimental allergic encephalomyelitis, Evanssyndrome, Fibromyalgia**, Fibrosing alveolitis, Giant cell arteritis(temporal arteritis), Giant cell myocarditis, Glomerulonephritis,Goodpasture's syndrome, Granulomatosis with Polyangiitis (GPA) (formerlycalled Wegener's Granulomatosis), Graves' disease, Guillain-Barresyndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, Hemolyticanemia, Henoch-Schonlein purpura, Herpes gestationis,Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgAnephropathy, IgG4-related sclerosing disease, Immunoregulatorylipoproteins, Inclusion body myositis, Interstitial cystitis, Juvenilearthritis, Juvenile diabetes (Type 1 diabetes), Juvenile myositis,Kawasaki syndrome, Lambert-Eaton syndrome, Leukocytoclastic vasculitis,Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgAdisease (LAD), Lupus (SLE), Lyme disease, chronic, Meniere's disease,Microscopic polyangiitis, Mixed connective tissue disease (MCTD),Mooren's ulcer, Mucha-Habermann disease, Multiple sclerosis, Myastheniagravis, Myositis, Narcolepsy, Neurormelitis optica (Devic's),Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromicrheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric DisordersAssociated with Streptococcus), Paraneoplastic cerebellar degeneration,Paroxysmal nocturnal hemoglobnuria (PNH), Parry Romberg syndrome,Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis),Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis,Pernicious anemia, POEMS syndrome, Polyarteritis nodosa, Type I, II, &III autoimmune polyglandular syndromes, Polymyalgia rheumatica,Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomysyndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primarysclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathicpulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia,Raynauds phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy,Reiter's syndrome, Relapsing polychondritis, Restless legs syndrome,Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis,Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren'ssyndrome, Sperm & testicular autoimmunity, Stiff person syndrome,Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympatheticophthalmia, Takayasu's arteritis, Temporal arteritis/Giant cellarteritis, Thrombocy topenic purpura (TTP), Tolosa-Hunt syndrome,Transverse myelitis, Ulcerative colitis, Undifferentiated connectivetissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis,Vitiligo, and Wegener's granulomatosis (now termed Granulomatosis withPolyangiitis (GPA).

Various kidney diseases may be treated with pharmaceutical compositions,AAV particles, of the present invention. As a non-limiting example, thekidney disease Abderhalden-Kaufmann-Lignac syndrome (NephropathicCystinosis), Abdominal Compartment Syndrome, Acute Kidney Failure/AcuteKidney Injury, Acute Lobar Nephronia, Acute Phosphate Nephropathy, AcuteTubular Necrosis, Adenine Phosphoribosyltransferase Deficiency,Adenovirus Nephritis, Alport Syndrome, Amyloidosis, ANCA VasculitisRelated to Endocarditis and Other Infections, Angiomyolipoma, AnalgesicNephropathy, Anorexia Nervosa and Kidney Disease, Angiotensin Antibodiesand Focal Segmental Glomerulosclerosis, Antiphospholipid Syndrome,Anti-TNF-α Therapy-related Glomerulonephritis, APOL1 Mutations, ApparentMineralocorticoid Excess Syndrome, Aristolochic Acid Nephropathy,Chinese Herbal Nephropathy, Balkan Endemic Nephropathy, BartterSyndrome, Beeturia, β-Thalassemia Renal Disease, Bile Cast Nephropathy,BK Polyoma Virus Nephropathy in the Native Kidney, Bladder Rupture,Bladder Sphincter Dyssynergia, Bladder Tamponade, Border-Crossers'Nephropathy, Bourbon Virus and Acute Kidney Injury, Burnt SugarcaneHarvesting and Acute Renal Dysfunction, Byetta and Renal Failure, C1qNephropathy, Cannabinoid Hyperemesis Acute Renal Failure, Cardiorenalsyndrome, Carfilzomib-Induced Renal Injury, CFHR5 nephropathy,Charcot-Marie-Tooth Disease with Glomerulopathy, Cherry Concentrate andAcute Kidney Injury, Cholesterol Emboli, Churg-Strauss syndrome,Chyluria, Colistin Nephrotoxicity, Collagenofibrotic Glomerulopathy,Collapsing Glomerulopathy, Collapsing Glomerulopathy Related to CMV,Congenital Nephrotic Syndrome, Conorenal syndrome (Mainzer-SaldinoSyndrome or Saldino-Mainzer Disease), Contrast Nephropathy, CopperSulpfate Intoxication, Cortical Necrosis, Crizotinib-related AcuteKidney Injury, Cryoglobinemia, Crystalglobulin-Induced Nephropathy,Crystal-Induced Acute Kidney injury, Cystic Kidney Disease, Acquired,Cystinuria, Dasatinib-Induced Nephrotic-Range Proteinuria, Dense DepositDisease (MPGN Type 2), Dent Disease (X-linked RecessiveNephrolithiasis), Dialysis Disequilibrium Syndrome, Diabetes andDiabetic Kidney Disease, Diabetes Insipidus, Dietary Supplements andRenal Failure, Drugs of Abuse and Kidney Disease, Duplicated Ureter,EAST syndrome, Ebola and the Kidney, Ectopic Kidney, Ectopic Ureter,Edema, Swelling, Erdheim-Chester Disease, Fabry's Disease, FamilialHypocalciuric Hypercalcemia, Fanconi Syndrome, Fraser syndrome,Fibronectin Glomerulopathy, Fibrillary Glomerulonephritis andImmunotactoid Glomerulopathy, Fraley syndrome, Focal SegmentalGlomerulosclerosis, Focal Sclerosis, Focal Glomerulosclerosis, GallowayMowat syndrome, Giant Cell (Temporal) Arteritis with Kidney Involvement,Gestational Hypertension, Gitelman Syndrome, Glomerular Diseases,Glomerular Tubular Reflux, Glycosuria, Goodpasture Syndrome, Hair DyeIngestion and Acute Kidney Injury, Hantavirus Infection Podocytopathy,Hematuria (Blood in Urine), Hemolytic Urermic Syndrome (HUS), AtypicalHemolytic Uremic Syndrome (aHUS), Hemophagocytic Syndrome, HemorrhagicCystitis, Hemorrhagic Fever with Renal Syndrome (HFRS, Hantavirus RenalDisease, Korean Hemorrhagic Fever, Epidemic Hemorrhagic Fever,Nephropathis Epidemica), Hemosiderosis related to Paroxysmal NocturnalHemoglobinuria and Hemolytic Anemia, Hepatic Glomerulopathy, HepaticVeno-Occlusive Disease, Sinusoidal Obstruction Syndrome, HepatitisC-Associated Renal Disease, Hepatorenal Syndrome, Herbal Supplements andKidney Disease, High Blood Pressure and Kidney Disease, HIV-AssociatedNephropathy (HIVAN), Horseshoe Kidney (Renal Fusion), Hunner's Ulcer,Hyperaldosteronism, Hypercalcemia, Hyperkalemia, Hypermagnesemia,Hypermanesemia, Hypernatremia, Hyperoxaluria, Hyperphosphatemia,Hypocalcemia, Hypokalemia, Hypokalemia-induced renal dysfunction,Hypokalemic Periodic Paralysis, Hypomagnesemia, Hyponatremia,Hypophosphatemia, IgA Nephropathy, IgG4 Nephropathy, InterstitialCystitis, Painful Bladder Syndrome (Questionnaire), InterstitialNephritis, Ivemark's syndrome, Ketamine-Associated Bladder Dysfunction,Kidney Stones, Nephrolithiasis, Kombucha Tea Toxicity, Lead Nephropathyand Lead-Related Nephrotoxicity, Leptospirosis Renal Disease, LightChain Deposition Disease, Monoclonal Immunoglobulin Deposition Disease,Liddle Syndrome, Lightwood-Albright Syndrome, LipoproteinGlomerulopathy, Lithium Nephrotoxicity, LMXIB Mutations Cause HereditaryFSGS, Loin Pain Hematuria, Lupus, Systemic Lupus Erythematosis, LupusKidney Disease, Lupus Nephritis, Lupus Nephritis with AntineutrophilCytoplasmic Antibody Seropositivity, Lyme Disease-AssociatedGlomerulonephritis, Malarial Nephropathy, Malignancy-Associated RenalDisease, Malignant Hypertension, Malakoplakia, Meatal Stenosis,Medullary Cystic Kidney Disease, Medullary Sponge Kidney, Megaureter,Melamine Toxicity and the Kidney, MembranoproliferativeGlomerulonephritis, Membranous Nephropathy, MesoAmerican Nephropathy,Metabolic Acidosis, Metabolic Alkalosis, Methotrexate-related RenalFailure, Microscopic Polyangiitis, Milk-alkalai syndrome, Minimal ChangeDisease, MDMA (Molly, Ecstacy; 3,4-Methylenedioxymnethamphetamine) andKidney Failure, Multicystic dysplastic kidney, Multiple Myeloma,Myeloproliferative Neoplasms and Glomerulopathy, Nail-patella Syndrome,Nephrocalcinosis, Nephrogenic Systemic Fibrosis, Nephroptosis (FloatingKidney, Renal Ptosis), Nephrotic Syndrome, Neurogenic Bladder, NodularGlomerulosclerosis, NonGonococcal Urethritis, Nutcracker syndrome,Orofaciodigital Syndrome, Orotic Aciduria, Orthostatic Hypotension,Orthostatic Proteinurina, Osmotic Diuresis, Ovarian HyperstimulationSyndrome, Page Kidney, Papillary Necrosis, Papillorenal Syndrome(Renal-Coloboma Syndrome, Isolated Renal Hypoplasia), Parvovirus B19 andthe Kidney, The Peritoneal-Renal Syndrome, Posterior Urethral Valve,Post-infectious Glomerulonephritis, Post-streptococcalGlomerulonephritis, Polyarteritis Nodosa, Polycystic Kidney Disease,Posterior Urethral Valves, Preeclampsia, Propofol infusion syndrome,Proliferative Glomerulonephritis with Monoclonal IgG Deposits (NasrDisease), Propolis (Honeybee Resin) Related Renal Failure, Proteinuria(Protein in Urine), Pseudohyperaldosteronism, Pseudohypobicarbonatemia,Pseudohypoparathyroidism, Pulmonary-Renal Syndrome, Pyelonephritis(Kidney Infection), Pyonephrosis, Radiation Nephropathy, Ranolazine andthe Kidney, Refeeding syndrome, Reflux Nephropathy, Rapidly ProgressiveGlomerulonephritis, Renal Abscess, Peripnephric Abscess, Renal Agenesis,Renal Arcuate Vein Microthrombi-Associated Acute Kidney Injury, RenalArtery Aneurysm, Renal Artery Stenosis, Renal Cell Cancer, Renal Cyst,Renal Hypouricemia with Exercise-induced Acute Renal Failure, RenalInfarction, Renal Osteodystrophy, Renal Tubular Acidosis, ReninSecreting Tumors (Juxtaglomerular Cell Tumor), Reset Osmostat,Retrocaval Ureter, Retroperitoneal Fibrosis, Rhabdomyolysis,Rhabdomyolysis related to Bariatric Sugery, RheumatoidArthritis-Associated Renal Disease, Sarcoidosis Renal Disease, SaltWasting, Renal and Cerebral, Schistosomiasis and Glomerular Disease,Schimke immuno-osseous dysplasia, Scleroderma Renal Crisis, SerpentineFibula-Polycystic Kidney Syndrome, Exner Syndrome, Sickle CellNephropathy, Silica Exposure and Chronic Kidney Disease, Sri LankanFarmers' Kidney Disease, Sjögren's Syndrome and Renal Disease, SyntheticCannabinoid Use and Acute Kidney Injury, Kidney Disease FollowingHematopoietic Cell Transplantation, Kidney Disease Related to Stem CellTransplantation, Thin Basement Membrane Disease, Benign FamilialHematuria, Trigonitis, Tuberculosis, Genitourinary, Tuberous Sclerosis,Tubular Dysgenesis, Immune Complex Tubulointerstitial Nephritis Due toAutoantibodies to the Proximal Tubule Brush Border, Tumor LysisSyndrome, Uremia, Uremic Optic Neuropathy, Ureteritis Cystica,Ureterocele, Urethral Caruncle, Urethral Stricture, UrinaryIncontinence, Urinary Tract Infection, Urinary Tract Obstruction,Vesicointestinal Fistula, Vesicoureteral Reflux, Volatile Anestheticsand Acute Kidney Injury, Von Hippel-Lindau Disease, Waldenstrom'sMacroglobulinemic Glomerulonephritis, Warfarin-Related Nephropathy, WaspStings and Acute Kidney Injury, Wegener's Granulomatosis, Granulomatosiswith Polyangiitis, West Nile Virus and Chronic Kidney Disease, andWunderlich syndrome.

Various cardiovascular diseases may be treated with pharmaceuticalcompositions, AAV particles, of the present invention. As a non-limitingexample, the cardiovascular disease may be Ischemic heart disease alsoknown as coronary artery disease, cerebrovascular disease (Stroke),Peripheral vascular disease, Heart failure, Rheumatic heart disease, andCongenital heart disease.

Various antibody deficiencies may be treated with pharmaceuticalcompositions, AAV particles, of the present invention. As a non-limitingexample, the antibody deficiencies may be X-Linked Agammaglobulinemia(XLA), Autosomal Recessive Agammaglobulinemia (ARA), Common VariableImmune Deficiency (CVID), IgG (IgG1, IgG2, IgG3 and IgG4) SubclassDeficiency, Selective IgA Deficiency, Specific Antibody Deficiency(SAD). Transient Hypogammaglobulinemia of Infancy, Antibody Deficiencywith Normal or Elevated Immunoglobulins, Selective IgM Deficiency,Immunodeficiency with Thymoma (Good's Syndrome), Transcobalamin IIDeficiency, Warts, Hypogammaglobulinemia, Infection, Myelokathexis(WHIM) Syndrome, Drug-Induced Antibody Deficiency, Kappa ChainDeficiency, Heavy Chain Deficiencies, Post-Meiotic Segregation (PMS2)Disorder, and Unspecified Hypogammaglobulinemia.

Various ocular diseases may be treated with pharmaceutical compositions,AAV particles, of the present invention. As a non-limiting example, theocular disease may be thyroid eye disease (TED), Graves' disease (GD)and orbitopathy, Retina Degeneration. Cataract, optic atrophy, maculardegeneration, Leber congenital amaurosis, retinal degeneration, cone-roddystrophy, Usher syndrome, leopard syndrome, photophobia, andphotoaversion.

Various neurological diseases may be treated with pharmaceuticalcompositions, AAV particles, of the present invention. As a non-limitingexample, the neurological disease may be Absence of the SeptumPellucidum, Acid Lipase Disease, Acid Maltase Deficiency, AcquiredEpileptiform Aphasia, Acute Disseminated Encephalomyelitis, AttentionDeficit-Hyperactivity Disorder (ADHD), Adie's Pupil, Adle's Syndrome,Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Agnosia, AicardiSyndrome, Aicardi-Goutieres Syndrome Disorder, AIDS—NeurologicalComplications, Alexander Disease, Alpers' Disease, AlternatingHemiplegia, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS),Anencephaly, Aneurysm, Angelman Syndrome, Angiomatosis, Anoxia,Antiphospholipid Syndrome, Aphasia, Apraxia, Arachnoid Cysts,Arachnoiditis, Amold-Chiari Malformation, Arteriovenous Malformation,Asperger Syndrome, Ataxia, Ataxia Telangiectasia, Ataxias and Cerebellaror Spinocerebellar Degeneration, Atrial Fibrillation and Stroke,Attention Deficit-Hyperactivity Disorder, Autism Spectrum Disorder,Autonomic Dysfunction, Back Pain, Barth Syndrome, Batten Disease,Becker's Myotonia, Behcet's Disease, Bell's Palsy, Benign EssentialBlepharospasm, Benign Focal Amyotrophy, Benign IntracranialHypertension, Bernhardt-Roth Syndrome, Binswanger's Disease,Blepharospasm, Bloch-Sulzberger Syndrome, Brachial Plexus BirthInjuries, Brachial Plexus Injuries, Bradbury-Eggleston Syndrome, Brainand Spinal Tumors, Brain Aneurysm, Brain Injury, Brown-Sequard Syndrome,Bulbospinal Muscular Atrophy, Cerebral Autosomal Dominant Arteriopathywith Sub-cortical Infarcts and Leukoencephalopathy (CADASIL), CanavanDisease, Carpal Tunnel Syndrome, Causalgia, Cavernomas, CavernousAngioma, Cavernous Malformation, Central Cervical Cord Syndrome, CentralCord Syndrome, Central Pain Syndrome, Central Pontine Myelinolysis,Cephalic Disorders, Ceramidase Deficiency, Cerebellar Degeneration,Cerebellar Hypoplasia, Cerebral Aneurysms, Cerebral Arteriosclerosis,Cerebral Atrophy, Cerebral Beriberi, Cerebral Cavernous Malformation,Cerebral Gigantism, Cerebral Hypoxia, Cerebral Palsy,Cerebro-Oculo-Facio-Skeletal Syndrome (COFS), Charcot-Mane-ToothDisease, Chian Malformation, Cholesterol Ester Storage Disease, Chorea,Choreoacanthocytosis, Chronic Inflammatory Demyelinating Polyneuropathy(CIDP), Chronic Orthostatic Intolerance, Chronic Pain, Cockayne SyndromeType II, Coffin Lowry Syndrome, Colpocephaly, Coma, Complex RegionalPain Syndrome, Congenital Facial Diplegia, Congenital Myasthenia,Congenital Myopathy, Congenital Vascular Cavernous Malformations,Corticobasal Degeneration, Cranial Arteritis, Craniosynostosis, Creeencephalitis, Creutzfeldt-Jakob Disease, Cumulative Trauma Disorders,Cushing's Syndrome, Cytomegalic Inclusion Body Disease, CytomegalovirusInfection, Dancing Eyes-Dancing Feet Syndrome, Dandy-Walker Syndrome,Dawson Disease, De Morsier's Syndrome, Dejerine-Klumpke Palsy, Dementia,Dementia—Multi-Infarct, Dementia—Semantic, Dementia—Subcortical,Dementia With Lewy Bodies, Dentate Cerebellar Ataxia, DentatorubralAtrophy, Dermatomyositis, Developmental Dyspraxia, Devic's Syndrome,Diabetic Neuropathy, Diffuse Sclerosis, Dravet Syndrome, Dysautonomia,Dysgraphia, Dyslexia, Dysphagia, Dyspraxia, Dyssynergia CerebellarisMyoclonica, Dyssynergia Cerebellaris Progressiva, Dystonias, EarlyInfantile Epileptic Encephalopathy, Empty Sella Syndrome, Encephalitis,Encephalitis Lethargica, Encephaloceles, Encephalopathy, Encephalopathy(familial infantile), Encephalotrigeminal Anglomatosis, Epilepsy,Epileptic Hermplegia, Erb's Palsy, Erb-Duchenne and Dejerine-KlumpkePalsies, Essential Tremor, Extrapontine Myelinolysis, Fabry Disease,Fahr's Syndrome, Fainting, Familial Dysautonomia, Familial Hemangioma,Familial Idiopathic Basal Ganglia Calcification, Familial PeriodicParalyses, Familial Spastic Paralysis, Farber's Disease, FebrileSeizures, Fibromuscular Dysplasia, Fisher Syndrome, Floppy InfantSyndrome, Foot Drop, Friedreich's Ataxia, Frontotemporal Dementia,Gaucher Disease, Generalized Gangliosidoses, Gerstmann's Syndrome,Gerstmann-Straussler-Scheinker Disease, Giant Axonal Neuropathy, GiantCell Arteritis, Giant Cell Inclusion Disease, Globoid CellLeukodystrophy, Glossopharyngeal Neuralgia, Glycogen Storage Disease,Guillain-Barre Syndrome, Hallervorden-Spatz Disease, Head Injury,Headache, Hemicrania Continua, Hemifacial Spasm, Hemiplegia Alterans,Hereditary Neuropathies, Hereditary Spastic Paraplegia, HeredopathiaAtactica Polyneuritiformis, Herpes Zoster, Herpes Zoster Oticus,Hirayama Syndrome, Holmes-Adie syndrome, Holoprosencephaly, HTLV-1Associated Myelopathy, Hughes Syndrome, Huntington's Disease,Hydranencephaly, Hydrocephalus, Hydrocephalus—Normal Pressure,Hydromyelia, Hypercortisolism, Hypersomnia, Hypertonia, Hypotonia,Hypoxia, Immune-Mediated Encephalomyelitis, Inclusion Body Myositis,Incontinentia Pigmenti, Infantile Hypotonia, Infantile NeuroaxonalDystrophy, Infantile Phytanic Acid Storage Disease, Infantile RefsumDisease, Infantile Spasms, Inflammatory Myopathies, Iniencephaly,Intestinal Lipodystrophy, Intracranial Cysts, Intracranial Hypertension,Isaacs' Syndrome, Joubert Syndrome, Kearns-Savre Syndrome, Kennedy'sDisease, Kinsbourne syndrome, Kleine-Levin Syndrome, Klippel-FeilSyndrome, Klippel-Trenaunay Syndrome (KTS), Klüver-Bucy Syndrome,Korsakoff's Amnesic Syndrome, Krabbe Disease, Kugelberg-WelanderDisease, Kuru, Lambert-Eaton Myasthenic Syndrome, Landau-KleffnerSyndrome, Lateral Femoral Cutaneous Nerve Entrapment, Lateral MedullarySyndrome, Learning Disabilities, Leigh's Disease, Lennox-GastautSyndrome, Lesch-Nyhan Syndrome, Leukodystrophy, Levine-CritchleySyndrome, Lewy Body Dementia, Lipid Storage Diseases, LipoidProteinosis, Lissencephaly, Locked-In Syndrome, Lou Gehrig's Disease,Lupus—Neurological Sequelae, Lyme Disease—Neurological Complications,Machado-Joseph Disease, Macrencephaly, Megalencephaly,Melkersson-Rosenthal Syndrome, Meningitis, Meningitis and Encephalitis,Menkes Disease, Meralgia Paresthetica, Metachromatic Leukodystrophy,Microcephaly, Migraine, Miller Fisher Syndrome, Mini Stroke,Mitochondrial Myopathy, Moebius Syndrome, Monomelic Amyotrophy, MotorNeuron Diseases, Moyamoya Disease, Mucolipidoses, Mucopolysaccharidoses,Multi-Infarct Dementia, Multifocal Motor Neuropathy, Multiple Sclerosis,Multiple System Atrophy, Multiple System Atrophy with OrthostaticHypotension, Muscular Dystrophy, Myasthenia—Congenital, MyastheniaGravis, Myelinoclastic Diffuse Sclerosis, Myoclonic Encephalopathy ofInfants, Myoclonus, Myopathy, Myopathy—Congenital, Myopathy—Thyrotoxic,Myotonia, Myotonia Congenita, Narcolepsy, Neuroacanthocytosis,Neurodegeneration with Brain Iron Accumulation, Neurofibromatosis,Neuroleptic Malignant Syndrome, Neurological Complications of AIDS,Neurological Complications of Lyme Disease, Neurological Consequences ofCytomegalovirus Infection, Neurological Manifestations of Pompe Disease,Neurological Sequelae Of Lupus, Neuromyelitis Optica, Neuromyotonia,Neuronal Ceroid Lipofuscinosis, Neuronal Migration Disorders,Neuropathy—Hereditary, Neurosarcoidosis, Neurosyphilis, Neurotoxicity,Nevus Cavernosus, Niemann-Pick Disease, O'Sullivan-McLeod Syndrome,Occipital Neuralgia, Ohtahara Syndrome, Olivopontocerebellar Atrophy,Opsoclonus Myoclonus, Orthostatic Hypotension, Overuse Syndrome,Pain—Chronic, Pantothenate Kinase-Associated Neurodegeneration,Paraneoplastic Syndromes, Paresthesia, Parkinson's Disease, ParoxysmalChoreoathetosis, Paroxysmal Hemicrania, Parry-Romberg,Pelizaeus-Merzbacher Disease, Pena Shokeir II Syndrome, PerineuralCysts, Periodic Paralyses, Peripheral Neuropathy, PeriventricularLeukomalacia, Persistent Vegetative State, Pervasive DevelopmentalDisorders, Phytanic Acid Storage Disease, Pick's Disease, Pinched Nerve,Piriformis Syndrome, Pituitary Tumors, Polymyositis, Pompe Disease,Porencephaly, Post-Polio Syndrome, Postherpetic Neuralgia,Postinfectious Encephalomyelitis, Postural Hypotension, PosturalOrthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, PrimaryDentatum Atrophy, Primary Lateral Sclerosis, Primary ProgressiveAphasia, Prion Diseases, Progressive Hemifacial Atrophy, ProgressiveLocomotor Ataxia, Progressive Multifocal Leukoencephalopathy,Progressive Sclerosing Poliodystrophy, Progressive Supranuclear Palsy,Prosopagnosia, Pseudo-Torch syndrome, Pseudotoxoplasmosis syndrome,Pseudotumor Cerebri, Psychogenic Movement, Ramsay Hunt Syndrome I,Ramsay Hunt Syndrome II, Rasmussen's Encephalitis, Reflex SympatheticDystrophy Syndrome, Refsum Disease, Refsum Disease—Infantile, RepetitiveMotion Disorders, Repetitive Stress Injuries, Restless Legs Syndrome,Retrovirus-Associated Myelopathy, Rett Syndrome, Reye's Syndrome,Rheumatic Encephalitis, Riley-Day Syndrome, Sacral Nerve Root Cysts,Saint Vitus Dance, Salivary Gland Disease, Sandhoff Disease, Schilder'sDisease, Schizencephaly, Seitelberger Disease, Seizure Disorder,Semantic Dementia, Septo-Optic Dysplasia, Severe Myoclonic Epilepsy ofInfancy (SMEI), Shaken Baby Syndrome, Shingles, Shy-Drager Syndrome,Sjögren's Syndrome, Sleep Apnea, Sleeping Sickness, Sotos Syndrome,Spasticity, Spina Bifida, Spinal Cord Infarction, Spinal Cord Injury,Spinal Cord Tumors, Spinal Muscular Atrophy, Spinocerebellar Atrophy,Spinocerebellar Degeneration, Steele-Richardson-Olszewski Syndrome,Stiff-Person Syndrome, Striatonigral Degeneration, Stroke, Sturge-WeberSyndrome, Subacute Sclerosing Panencephalitis, SubcorticalArteriosclerotic Encephalopathy, Short-lasting, Unilateral, Neuralgiform(SUNCT) Headache, Swallowing Disorders, Sydenham Chorea, Syncope,Syphilitic Spinal Sclerosis, Syringohydromyelia, Syrmgomyella, SystemicLupus Erythematosus, Tabes Dorsalis, Tardive Dyskinesia, Tarlov, Cysts,Tay-Sachs Disease, Temporal Arteritis, Tethered Spinal Cord Syndrome,Thomsen's Myotonia, Thoracic Outlet Syndrome, Thyrotoxic Myopathy, TicDouloureux, Todd's Paralysis, Tourette Syndrome, Transient IschemicAttack, Transmissible Spongiform Encephalopathies, Transverse Myelitis,Traumatic Brain Injury, Tremor, Trigeminal Neuralgia, Tropical SpasticParaparesis, Troyer Syndrome, Tuberous Sclerosis, Vascular ErectileTumor, Vasculitis Syndromes of the Central and Peripheral NervousSystems, Von Economo's Disease, Von Hippel-Lindau Disease (VHL), VonRecklinghausen's Disease, Wallenberg's Syndrome, Werdnig-HoffmanDisease, Wernicke-Korsakoff Syndrome, West Syndrome, Whiplash, Whipple'sDisease, Williams Syndrome. Wilson Disease. Wolman's Disease. X-LinkedSpinal and Bulbar Muscular Atrophy.

Various psychological disorders may be treated with pharmaceuticalcompositions, AAV particles, of the present invention. As a non-limitingexample, the psychological disorders may be Aboulia, Absence epilepsy,Acute stress Disorder, Adjustment Disorders, Adverse effects ofmedication NOS, Age related cognitive decline, Agoraphobia, AlcoholAddiction, Alzheimer's Disease, Amnesia (also known as AmnesticDisorder), Amphetamine Addiction, Anorexia Nervosa, Anterograde amnesia,Antisocial personality disorder (also known as Sociopathy), AnxietyDisorder (Also known as Generalized Anxiety Disorder), Anxiolyticrelated disorders, Asperger's Syndrome (now part of Autism SpectrumDisorder), Attention Deficit Disorder (Also known as ADD), AttentionDeficit Hyperactivity Disorder (Also known as ADHD), Autism SpectrumDisorder (also known as Autism), Autophagia, Avoidant PersonalityDisorder, Barbiturate related disorders, Benzodiazepine relateddisorders, Bereavement, Bibliomania, Binge Eating Disorder, Bipolardisorder (also known as Manic Depression, includes Bipolar I and BipolarII), Body Dysmorphic Disorder, Borderline intellectual functioning,Borderline Personality Disorder, Breathing-Related Sleep Disorder, BriefPsychotic Disorder, Bruxism, Bulimia Nervosa, Caffeine Addiction,Cannabis Addiction, Catatonic disorder, Catatonic schizophrenia,Childhood amnesia, Childhood Disintegrative Disorder (now part of AutismSpectrum Disorder), Childhood Onset Fluency Disorder (formerly known asStuttering), Circadian Rhythm Disorders, Claustrophobia, Cocaine relateddisorders, Communication disorder, Conduct Disorder, ConversionDisorder, Cotard delusion, Cyclothymia (also known as CyclothymicDisorder), Delerium, Delusional Disorder, dementia, DependentPersonality Disorder (also known as Asthenic Personality Disorder),Depersonalization disorder (now known as Depersonalization/DerealizationDisorder), Depression (also known as Major Depressive Disorder),Depressive personality disorder, Derealization disorder (now known asDepersonalization/Derealization Disorder), Dermotillomania,Desynchronosis, Developmental coordination disorder, Diogenes Syndrome,Disorder of written expression, Dispareunia, Dissocial PersonalityDisorder, Dissociative Amnesia, Dissociative Fugue, DissociativeIdentity Disorder (formerly known as Multiple Personality Disorder),Down syndrome, Dyslexia, Dyspareunia, Dysthymia (now known as PersistentDepressive Disorder), Eating disorder NOS, Ekbom's Syndrome (DelusionalParasitosis), Emotionally unstable personality disorder, Encopresis,Enuresis (bedwetting), Erotomania, Exhibitionistic Disorder, Expressivelanguage disorder, Factitious Disorder, Female Sexual Disorders,Fetishistic Disorder, Folie à deux, Fregoli delusion, FrotteuristicDisorder, Fugue State, Ganser syndrome, Gambling Addiction, GenderDysphoria (formerly known as Gender Identity Disorder), GeneralizedAnxiety Disorder, General adaptation syndrome, Grandiose delusions,Hallucinogen Addiction, Haltlose personality disorder, HistrionicPersonality Disorder, Primary hypersomnia, IHuntington's Disease,Hypoactive sexual desire disorder, Hypochondriasis, Hypomania,Hyperkinetic syndrome, Hypersomnia, Hysteria, Impulse control disorder,Impulse control disorder NOS, Inhalant Addiction, Insomnia, IntellectualDevelopment Disorder, Intermittent Explosive Disorder, Joubert syndrome,Kleptomania, Korsakoff's syndrome, Lacunar amnesia, Language Disorder,Learning Disorders, Major Depression (also known as Major DepressiveDisorder), major depressive disorder, Male Sexual Disorders,Malingering, Mathematics disorder, Medication-related disorder,Melancholia, Mental Retardation (now known as Intellectual DevelopmentDisorder), Misophonia, Morbid jealousy, Multiple Personality Disorder(now known as Dissociative Identity Disorder), Munchausen Syndrome,Munchausen by Proxy, Narcissistic Personality Disorder, Narcolepsy,Neglect of child, Neurocognitive Disorder (formerly known as Dementia),Neuroleptic-related disorder, Nightmare Disorder, Non Rapid EyeMovement, Obsessive-Compulsive Disorder, Obsessive-CompulsivePersonality Disorder (also known as Anankastic Personality Disorder),Oneirophrenia, Onychophagia, Opioid Addiction, Oppositional DefiantDisorder, Orthorexia (ON), Pain disorder, Panic attacks, Panic Disorder,Paranoid Personality Disorder, Parkinson's Disease, Partner relationalproblem, Passive-aggressive personality disorder, Pathological gambling,Pedophilic Disorder, Perfectionism, Persecutory delusion, PersistentDepressive Disorder (also known as Dysthymia), Personality change due toa general medical condition, Personality disorder, Pervasivedevelopmental disorder (PDD), Phencyclidine related disorder, Phobicdisorder, Phonological disorder, Physical abuse, Pica, Polysubstancerelated disorder, Postpartum Depression, Post-traumatic embittermentdisorder (PTED), Post Traumatic Stress Disorder, Premature ejaculation,Premenstrual Dysphoric Disorder, Psychogenic amnesia, Psychologicalfactor affecting medical condition, Psychoneurotic personality disorder,Psychotic disorder, not otherwise specified, Pyromania, ReactiveAttachment Disorder, Reading disorder, Recurrent brief depression,Relational disorder, REM Sleep Behavior Disorder, Restless Leg Syndrome,Retrograde amnesia, Retts Disorder (now part of Autism SpectrumDisorder), Rumination syndrome, Sadistic personality disorder,Schizoaffective Disorder, Schizoid Personality Disorder, Schizophrenia,Schizophreniform disorder, Schizotypal Personality Disorder, SeasonalAffective Disorder, Sedative, Hypnotic, or Anxiolytic Addiction,Selective Mutism, Self-defeating personality disorder, SeparationAnxiety Disorder, Sexual Disorders Female, Sexual Disorders Male, SexualAddiction, Sexual Masochism Disorder, Sexual Sadism Disorder, SharedPsychotic Disorder, Sleep Arousal Disorders, Sleep Paralysis, SleepTerror Disorder (now part of Nightmare Disorder, Social AnxietyDisorder, Somatization Disorder, Specific Phobias, Stendhal syndrome,Stereotypic movement disorder, Stimulant Addiction, Stuttering (nowknown as Childhood Onset Fluency Disorder), Substance related disorder,Tardive dyskinesia, Tobacco Addiction, Tourettes Syndrome, Transient ticdisorder, Transient global amnesia, Transvestic Disorder,Trichotillomania, Undifferentiated Somatoform Disorder, Vaginismus, andVoyeunstic Disorder.

Various lung diseases may be treated with pharmaceutical compositions,AAV particles, of the present invention. As a non-limiting example, thelung diseases may be Asbestosis, Asthma, Bronchiectasis, Bronchitis,Chronic Cough, Chronic Obstructive Pulmonary Disease (COPD), Croup,Cystic Fibrosis, Hantavirus, Idiopathic Pulmonary Fibrosis, Pertussis,Pleurisy, Pneumonia, Pulmonary Embolism, Pulmonary Hypertension,Sarcoidosis, Sleep Apnea, Spirometry, Sudden Infant Death Syndrome(SIDS), Tuberculosis, Alagille Syndrome, Autoimmune Hepatitis, BiliaryAtresia, Cirrhosis, ERCP (Endoscopic RetrogradeCholangiopancreatography), and Hemochromatosis, NonalcoholicSteatohepatitis, Porphyria, Primary Biliary Cirrhosis, PrimarySclerosing Cholangitis.

Various bone diseases may be treated with pharmaceutical compositions,AAV particles, of the present invention. As a non-limiting example, thebone diseases may be osteoporosis, neurofibromatosis, osteogenesisimperfecta (OI), rickets, osteosarcoma, achondroplasia, fracture,osteomyelitis, Ewing tumour of bone, osteomalacia, hip dysplasia, Pagetdisease of bone, marble bone disease, osteochondroma, bone cancer, bonedisease, osteochondrosis, osteoma, fibrous dysplasia, cleidocranialdysostosis, osteoclastoma, bone cyst, metabolic bone disease,melorheostosis, callus, Caffey syndrome, and mandibulofacial dysostosis.

Various blood diseases may be treated with pharmaceutical compositions,AAV particles, of the present invention. As a non-limiting example, theblood diseases may be Anemia and CKD (for health care professionals),Aplastic Anemia and Myelodysplastic Syndromes, Deep Vein Thrombosis,Hemochromatosis, Hemophilia, Henoch-Schönlein Purpura, IdiopathicThrombocytopenic Purpura, Iron-Deficiency Anemia, Pernicious Anemia,Pulmonary Embolism, Sickle Cell Anemia, Sickle Cell Trait and OtherHemoglobminopathies, Thalassemia, Thrombotic Thrombocytopenic Purpura,and Von Willebrand Disease.

Various diseases associated with TNF-alpha may be treated with thepharmaceutical compositions, AAV particles, of the present invention. Asa non-limiting example, the disease may be respiratory disorder; asthma;allergic and nonallergic asthma; asthma due to infection; asthma due toinfection with respiratory syncytial virus (RSV); chronic obstructivepulmonary disease (COPD); a condition involving airway inflammation;eosinophilia; fibrosis and excess mucus production; cystic fibrosis;pulmonary fibrosis; an atopic disorder; atopic dermatitis; urticaria,eczema; allergic rhinitis; allergic enterogastritis; an inflammatoryand/or autoimmune condition of the skin; an inflammatory and/orautoimmune condition of gastrointestinal organs, inflammatory boweldiseases (IBD); ulcerative colitis; Crohn's disease; an inflammatoryand/or autoimmune condition of the liver; liver cirrhosis; liverfibrosis; liver fibrosis caused by hepatitis B and/or C virus,scleroderma; tumors or cancers; hepatocellular carcinoma, glioblastoma;lymphoma; Hodgkin's lymphoma; a viral infection; a bacterial infection;a parasitic infection; HTLV-1 infection; suppression of expression ofprotective type 1 immune responses, and suppression of expression of aprotective type 1 immune response during vaccination, rheumatoidarthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis,Lyme arthritis, psoriatic arthritis, reactive arthritis,spondyloarthropathy, systemic lupus erythematosus, Crohn's disease,ulcerative colitis, inflammatory bowel disease, insulin dependentdiabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis,dermatitis scleroderma, graft versus host disease, organ transplantrejection, acute or chronic immune disease associated with organtransplantation, sarcoidosis, atherosclerosis, disseminatedintravascular coagulation, Kawasaki's disease, Grave's disease,nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis,Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys,chronic active hepatitis, uveitis, septic shock, toxic shock syndrome,sepsis syndrome, cachexia, infectious diseases, parasitic diseases,acquired immunodeficiency syndrome, acute transverse myelitis,Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke,primary biliary cirrhosis, hemolytic anemia, malignancies, heartfailure, myocardial infarction, Addison's disease, sporadic,polyglandular deficiency type I and polyglandular deficiency type II,Schmidt's syndrome, adult (acute) respiratory distress syndrome,alopecia, alopecia greata, seronegative arthropathy, arthropathy,Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy,enteropathic synovitis, chlamydia, yersinia and salmonella associatedarthropathy, spondyloarthropathy, atheromatous disease/arteriosclerosis,atopic allergy, autoimmune bullous disease, pemphigus vulgaris,pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmunehaemolytic anaemia, Coombs positive haemolytic anaemia, acquiredpernicious anaemia, juvenile pernicious anaemia, myalgicencephalitis/Royal Free Disease, chronic mucocutaneous candidiasis,giant cell arteritis, primary sclerosing hepatitis, cyptogenicautoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome,Acquired Immunodeficiency Related Diseases, hepatitis B, hepatitis C,common varied immunodeficiency (common variable hypogammaglobulinemia),dilated cardiomyopathy, female infertility, ovarian failure, prematureovarian failure, fibrotic lung disease, cryptogenic fibrosingalveolitis, post-inflammatory interstitial lung disease, interstitialpneumonitis, connective tissue disease associated interstitial lungdisease, mixed connective tissue disease associated lung disease,systemic sclerosis associated interstitial lung disease, rheumatoidarthritis associated interstitial lung disease, systemic lupuserythematosus associated lung disease, dermatomyositis/polymyositisassociated lung disease, Sjögren's disease associated lung disease,ankylosing spondylitis associated lung disease, vasculitic diffuse lungdisease, haemosiderosis associated lung disease, drug-inducedinterstitial lung disease, fibrosis, radiation fibrosis, bronchiolitisobliterans, chronic eosinophilic pneumonia, lymphocytic infiltrativelung disease, postinfectious interstitial lung disease, gouty arthritis,autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmuneor lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibodyhepatitis), autoimmune mediated hypoglycemia, type B insulin resistancewith acanthosis nigricans, hypoparathyroidism, acute immune diseaseassociated with organ transplantation, chronic immune disease associatedwith organ transplantation, osteoarthrosis, primary sclerosingcholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia,autoimmune neutropaenia, renal disease NOS, glomerulonephritides,microscopic vasculitis of the kidneys, Lyme disease, discoid lupuserythematosus, male infertility idiopathic or NOS, sperm autoimmunity,multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonaryhypertension secondary to connective tissue disease, Goodpasture'ssyndrome, pulmonary manifestation of polyarteritis nodosa, acuterheumatic fever, rheumatoid spondylitis, Still's disease, systemicsclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmunethrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroiddisease, hyperthyroidism, goitrous autoimmune hypothyroidism(Hashimoto's disease), atrophic autoimmune hypothyroidism, primarymyxoederma, phacogenic uveitis, primary vasculitis, vitiligo acute liverdisease, chronic liver diseases, alcoholic cirrhosis, alcohol-inducedliver injury, choleostasis, idiosyncratic liver disease, drug-Inducedhepatitis, non-alcoholic steatohepatitis, allergy and asthma, group Bstreptococci (GBS) infection, mental disorders (e.g., depression andschizophrenia), Th2 Type and Th1 Type mediated diseases, acute andchronic pain (different forms of pain), and cancers such as lung,breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectalcancer and hematopoietic malignancies (leukemia and lymphoma)abetalipoproteinemia, acrocyanosis, acute and chronic parasitic orinfectious processes, acute leukemia, acute lymphoblastic leukemia(ALL), acute myeloid leukemia (AML), acute or chronic bacterialinfection, acute pancreatitis, acute renal failure, adenocarcinomas,aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis,allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis,allograft rejection, alpha-1-antitrypsin deficiency, amyotrophic lateralsclerosis, anemia, angina pectoris, anterior horn cell degeneration,anti-CD3 therapy, antiphospholipid syndrome, anti-receptorhypersensitivity reactions, aortic and peripheral aneurysms, aorticdissection, arterial hypertension, arteriosclerosis, arteriovenousfistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrialflutter, atrioventricular block, B cell lymphoma, bone graft rejection,bone marrow transplant (BMT) rejection, bundle branch block, Burkitt'slymphoma, burns, cardiac arrhythmias, cardiac stun syndrome, cardiactumors, cardiomyopathy, cardiopulmonary bypass inflammation response,cartilage transplant rejection, cerebellar cortical degenerations,cerebellar disorders, chaotic or multifocal atrial tachycardia,chemotherapy associated disorders, chronic myelocytic leukemia (CML),chronic alcoholism, chronic inflammatory pathologies, chroniclymphocytic leukemia (CLL), chronic obstructive pulmonary disease(COPD), chronic salicylate intoxication, colorectal carcinoma,congestive heart failure, conjunctivitis, contact dermatitis,corpulmonale, coronary artery disease, Creutzfeldt-Jakob disease,culture negative sepsis, cystic fibrosis, cytokine therapy associateddisorders, dementia pugilistica, demyelinating diseases, denguehemorrhagic fever, dermatitis, dermatologic conditions, diabetes,diabetes mellitus, diabetic arteriosclerotic disease, Diffuse Lewy bodydisease, dilated congestive cardiomyopathy, disorders of the basalganglia, Down's Syndrome in middle age, drug-induced movement disordersinduced by drugs which block CNS dopamine receptors, drug sensitivity,eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis,Epstein-Barr virus infection, erythromelalgia, extrapyramidal andcerebellar disorders, familial hemophagocytic lymphohistiocytosis, fetalthymus implant rejection, Friedreich's ataxia, functional peripheralarterial disorders, fungal sepsis, gas gangrene, gastric ulcer,glomerular nephritis, graft rejection of any organ or tissue, gramnegative sepsis, gram positive sepsis, granulomas due to intracellularorganisms, hairy cell leukemia, Hallervorden-Spatz disease, Hashimoto'sthyroiditis, hay fever, heart transplant rejection, hemochromatosis,hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenicpurpura, hemorrhage, hepatitis (A), His bundle arrhythmias, HIVinfection/HIV neuropathy, Hodgkin's disease, hyperkinetic movementdisorders, hypersensitivity reactions, hypersensitivity pneumonitis,hypertension, hypokinetic movement disorders,hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison'sdisease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity,asthenia, infantile spinal muscular atrophy, inflammation of the aorta,influenza a, ionizing radiation exposure, iridocyclitis/uveitis/opticneuritis, ischemia-reperfusion injury, ischemic stroke, juvenilerheumatoid arthritis (JRA), juvenile spinal muscular atrophy, Kaposi'ssarcoma, kidney transplant rejection, legionella, leishmaniasis,leprosy, lesions of the corticospinal system, lipedema, liver transplantrejection, lymphedema, malaria, malignant lymphoma, malignanthistiocytosis, malignant melanoma, meningitis, meningococcemia,metabolic/idiopathic, migraine headache, mitochondrial multi-systemdisorder, mixed connective tissue disease, monoclonal gammopathy,multiple myeloma, multiple systems degenerations (Menzel,Dejerine-Thomas, Shy-Drager, and Machado-Joseph), myasthenia gravis,Mycobacterium avium intracellulare, nmycobacterium tuberculosis,myelodysplastic syndrome, myocardial infarction, myocardial ischemicdisorders, nasopharyngeal carcinoma, neonatal chronic lung disease,nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscularatrophies, neutropenic fever, non-Hodgkins lymphoma, occlusion of theabdominal aorta and its branches, occlusive arterial disorders, OKT3®therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures,organomegaly, osteoporosis, pancreas transplant rejection, pancreaticcarcinoma, paraneoplastic syndrome/hypercalcemia of malignancy,parathyroid transplant rejection, pelvic inflammatory disease, perennialrhinitis, pericardial disease, peripheral atherosclerotic disease,peripheral vascular disorders, peritonitis, pernicious anemia,Pneumocystis carinii pneumonia, pneumonia, POEMS syndrome(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,and skin changes syndrome), post perfusion syndrome, post pump syndrome,post-MI cardiotomy syndrome, preeclampsia, progressive supranucleopalsy, primary pulmonary hypertension, radiation therapy, Raynaud'sphenomenon and disease, Raynaud's disease, Refsum's disease, regularnarrow QRS tachycardia, renovascular hypertension, reperfusion injury,restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, seniledementia of Lewy body type, seronegative arthropathies, shock, sicklecell anemia, skin allograft rejection, skin changes syndrome, smallbowel transplant rejection, solid tumors, specific arrhythmias, spinalataxia, spinocerebellar degenerations, streptococcal myositis,structural lesions of the cerebellum, subacute sclerosingpanencephalitis, syncope, syphilis of the cardiovascular system,systemic anaphylaxis, systemic inflammatory response syndrome, systemiconset juvenile rheumatoid arthritis, T-cell or FAB ALL, telangiectasia,thromboangitis obliterans, thrombocytopenia, toxicity, transplants,trauma/hemorrhage, type III hypersensitivity reactions, type IVhypersensitivity, unstable angina, uremia urosepsis, urticaria, valvularheart diseases, varicose veins, vasculitis, venous diseases, venousthrombosis, ventricular fibrillation, viral and fungal infections, viralencephalitis/aseptic meningitis, viral-associated hemophagocyticsyndrome, Wemicke-Korsakoff syndrome, Wilson's disease, xenograftrejection of any organ or tissue, acute coronary syndromes, acuteidiopathic polyneuritis, acute inflammatory demyelinatingpolyradiculoneuropathy, acute ischemia, adult Still's disease, alopeciagreata, anaphylaxis, anti-phospholipid antibody syndrome, aplasticanemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmunedermatitis, autoimmune disorder associated with streptococcus infection,autoimmune enteropathy, autoimmune hearing loss, autoimmunelymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmunepremature ovarian failure, blepharitis, bronchiectasis, bullouspemphigoid, cardiovascular disease, catastrophic antiphospholipidsyndrome, celiac disease, cervical spondylosis, chronic ischemia,cicatricial pemphigoid, clinically isolated syndrome (CIS) with risk formultiple sclerosis, conjunctivitis, childhood onset psychiatricdisorder, chronic obstructive pulmonary disease (COPD), dacryocytitis,dermatomyositis, diabetic retinopathy, diabetes mellitus, diskherniation, disk prolapse, drug induced immune hemolytic anemia,endocarditis, endometriosis, endophthalmitis, episcleritis, erythemamultiforme, erythema multiforme major, gestational pemphigoid,Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathicParkinson's disease, idiopathic interstitial pneumonia, IgE-mediatedallergy, immune hemolytic anemia, inclusion body myositis, infectiousocular inflammatory disease, inflammatory demyelinating disease,inflammatory heart disease, inflammatory kidney disease, IPF/UIP,iritis, keratitis, keratojunctivitis sicca, Kussmaul disease orKussmaul-Meier disease, Landry's paralysis, Langerhan's cellhistiocytosis, livedo reticularis, macular degeneration, microscopicpolyangiitis, morbus bechterev, motor neuron disorders, mucous membranepemphigoid, multiple organ failure, myasthenia gravis, myelodysplasticsyndrome, myocarditis, nerve root disorders, neuropathy, non-A non-Bhepatitis, optic neuritis, osteolysis, ovarian cancer, pauciarticularJRA, peripheral artery occlusive disease (PAOD), peripheral vasculardisease (PVD), peripheral artery disease (PAD), phlebitis, polyarteritisnodosa (or periarteritis nodosa), polychondritis, polymyalgiarheumatica, poliosis, polyarticular JRA, polyendocrine deficiencysyndrome, polymyositis, polymyalgia rheumatica (PMR), post-pumpsyndrome, primary Parkinsonism, prostate and rectal cancer andhematopoietic malignancies (leukemia and lymphoma), prostatitis, purered cell aplasia, primary adrenal insufficiency, recurrent neuromyelitisoptica, restenosis, rheumatic heart disease, sapho (synovitis, acne,pustulosis, hyperostosis, and osteitis), scleroderma, secondaryamyloidosis, shock lung, scleritis, sciatica, secondary adrenalinsufficiency, silicone associated connective tissue disease,Sneddon-Wilkinson dermatosis, spondylitis ankylosans, Stevens-Johnsonsyndrome (SJS), systemic inflammatory response syndrome, temporalarteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transversemyelitis, TRAPS (tumor necrosis factor receptor associated periodicsyndrome), type 1 allergic reaction, type II diabetes, urticaria, usualinterstitial pneumonia (UIP), vasculitis, vernal conjunctivitis, viralretinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet maculardegeneration, wound healing, yersinia or salmonella associatedarthropathy.

Various receptor for advanced gly cation endproducts (RAGE) diseases maybe treated with the pharmaceutical compositions, AAV particles, of thepresent invention. As a non-limiting example, the disease may beAmytropic Lateral Sclerosis, Brachial Plexus Injury, Brain Injury,including traumatic brain injury, Cerebral Palsy, Friedrich's Ataxia,Guillain Barre, Leukodystrophies, Multiple Sclerosis, Post Polio, SpinaBifida, Spinal Cord Injury, Spinal Muscle Atrophy, Spinal Tumors,Stroke, Transverse Myelitits, dementia, senile dementia, mild cognitiveimpairment, Alzheimer-related dementia, Huntington's chorea, tardivedyskinesia, hyperkinesias, manias, Morbus Parkinson, steel-Richardsyndrome, Down's syndrome, myasthenia gravis, nerve trauma, vascularamyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation,Friedrich's ataxia, acute confusion disorder, amyotrophic lateralsclerosis, glaucoma, Alzheimer's disease, diabetic nephropathy, sepsis,rheumatoid arthritis and related inflammatory diseases.

Various neurite degenerative diseases may be treated with thepharmaceutical compositions, AAV particles, of the present invention. Asa non-limiting example, the disease may be multiple sclerosis,Parkinson's disease, Alzheimer's disease, Tay-Sachs disease,Niemann-Pick disease, Gaucher's disease, Hurler's syndrome, Huntington'sdisease, amyotrophic lateral sclerosis, idiopathic inflammatorydemyelinating diseases, vitamin B12 deficiency, central pontinemyelinolysis, tabes dorsalis, transverse myelitis, Devic's disease,progressive multifocal leukoencephalopathy, optic neuritis, traumaticinjury to the CNS, an ischemic cerebral stroke, glaucoma, diabeticretinopathy, age-dependent macular degeneration, and a leukodystrophy.

Various neurological diseases may be treated with the pharmaceuticalcompositions, AAV particles, of the present invention. As a non-limitingexample, the disease may be Amyotrophic Lateral Sclerosis, BrachialPlexus Injury, Brain Injury, including traumatic brain injury, CerebralPalsy, Guillain Barre, Leukodystrophies, Multiple Sclerosis, Post Polio,Spina Bifida, Spinal Cord Injury, Spinal Muscle Atrophy, Spinal Tumors,Stroke, Transverse Myelitis; dementia, senile dementia, mild cognitiveimpairment, Alzheimer-related dementia, Huntington's chorea, tardivedyskinesia, hyperkinesias, manias, Morbus Parkinson, steel-Richardsyndrome, Down's syndrome, myasthenia gravis, nerve trauma, vascularamyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation,acute confusion disorder, amyotrophic lateral sclerosis, glaucoma andAlzheimer's disease.

Various cancers may be treated with pharmaceutical compositions, AAVparticles, of the present invention. As used herein, the term “cancer”refers to any of various malignant neoplasms characterized by theproliferation of anaplastic cells that tend to invade surrounding tissueand metastasize to new body sites and also refers to the pathologicalcondition characterized by such malignant neoplastic growths. Cancersmay be tumors or hematological malignancies, and include but are notlimited to, all types of lymphomas/leukemias, carcinomas and sarcomas,such as those cancers or tumors found in the anus, bladder, bile duct,bone, brain, breast, cervix, colon/rectum, endometrium, esophagus, eye,gallbladder, head and neck, liver, kidney, larynx, lung, mediastinum(chest), mouth, ovaries, pancreas, penis, prostate, skin, smallintestine, stomach, spinal marrow, tailbone, testicles, thyroid anduterus.

Types of carcinomas which may be treated with the AAV particles of thepresent invention include, but are not limited to, papilloma/carcinoma,choriocarcinoma, endodermal sinus tumor, teratoma,adenoma/adenocarcinoma, melanoma, fibroma, lipoma, leiomyoma,rhabdomyoma, mesothelioma, angioma, osteoma, chondroma, gliomalymphoma/leukemia, squamous cell carcinoma, small cell carcinoma, largecell undifferentiated carcinomas, basal cell carcinoma and sinonasalundifferentiated carcinoma.

Types of sarcomas which may be treated with the AAV particles of thepresent invention include, but are not limited to, soft tissue sarcomasuch as alveolar soft part sarcoma, angiosarcoma, dermatofibrosarcoma,desmoid tumor, desmoplastic small round cell tumor, extraskeletalchondrosarcoma, extraskeletal osteosarcoma, tibrosarcoma,hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma,liposarcoma, lymphangiosarcoma lymphosarcoma, malignant fibroushistiocytoma, neurofibrosarcoma, rhabdonyosarcoma, synovial sarcoma, andAskin's tumor, Ewing's sarcoma (primitive neuroectodermal tumor),malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, andchondrosarcoma.

As a non-limiting example, the cancer which may be treated may be Acutegranulocytic leukemia Acute lymphocytic leukemia, Acute myelogenousleukemia, Adenocarcinoma, Adenosarcoma, Adrenal cancer, Adrenocorticalcarcinoma, Anal cancer, Anaplastic astrocytoma, Angiosarcoma, Appendixcancer, Astrocytoma, Basal cell carcinoma, B-Cell lymphoma), Bile ductcancer, Bladder cancer, Bone cancer, Bowel cancer, Brain cancer, Brainstem glioma, Brain tumor, Breast cancer, Carcinoid tumors, Cervicalcancer, Cholangiocarcinoma, Chondrosarcoma, Chronic lymphocyticleukemia, Chronic myelogenous leukemia, Colon cancer, Colorectal cancer,Craniopharyngioma, Cutaneous lymphoma, Cutaneous melanoma, Diffuseastrocytoma, Ductal carcinoma in situ, Endometrial cancer, Ependymoma,Epitheloid sarcoma, Esophageal cancer, Ewing sarcoma, Extrahepatic bileduct cancer, Eye cancer, Fallopian tube cancer, Fibrosarcoma,Gallbladder cancer, Gastric cancer, Gastrointestinal cancer,Gastrointestinal carcinoid cancer, Gastrointestinal stromal tumors,General, Germ cell tumor, Glioblastoma multiforme, Glioma, Hairy cellleukemia, Head and neck cancer, Hemangioendothelioma, Hodgkin lymphoma,Hodgkin's disease, Hodgkin's lymphoma, Hypopharyngeal cancer,Infiltrating ductal carcinoma, Infiltrating lobular carcinoma,Inflammatory breast cancer, Intestinal Cancer, Intrahepatic bile ductcancer, Invasive/infiltrating breast cancer, Islet cell cancer, Jawcancer, Kaposi sarcoma, Kidney cancer, Laryngeal cancer, Leiomyosarcoma,Leptomeningeal metastases, Leukemia, Lip cancer, Liposarcoma, Livercancer, Lobular carcinoma in situ, Low-grade astrocytoma, Lung cancer,Lymph node cancer, Lymphoma, Male breast cancer, Medullary carcinoma,Medulloblastoma, Melanoma, Meningioma, Merkel cell carcinoma, Mesenchymal chondrosarcoma, Mesenchymous, Mesothelioma, Metastatic breastcancer, Metastatic melanoma, Metastatic squamous neck cancer, Mixedgliomas, Mouth cancer, Mucinous carcinoma, Mucosal melanoma, Multiplemelanoma, Nasal cavity cancer, Nasopharyngeal cancer, Neck cancer,Neuroblastoma, Neuroendocrine tumors, Non-Hodgkin lymphoma,Non-Hodgkin's lymphoma, Non-small cell lung cancer, Oat cell cancer,Ocular cancer, Ocular melanoma, Oligodendroglioma, Oral cancer, Oralcavity cancer, Oropharyngeal cancer, Osteogenic sarcoma, Osteosarcoma,Ovarian cancer, Ovarian epithelial cancer, Ovarian germ cell tumor,Ovarian primary peritoneal carcinoma, Ovarian sex cord stromal tumor,Paget's disease, Pancreatic cancer, Papillary carcinoma, Paranasal sinuscancer, Parathyroid cancer, Pelvic cancer, Penile cancer, Peripheralnerve cancer, Peritoneal cancer, Pharyngeal cancer, Pheochromocytoma,Pilocytic astrocytoma, Pineal region tumor, Pineoblastoma, Pituitarygland cancer, Primary central nervous system lymphoma, Prostate cancer,Rectal cancer, Renal cell cancer, Renal pelvis cancer, Rhabdomyosarcoma,Salivary gland cancer, Sarcoma, Sarcoma, bone, Sarcoma, soft tissue,Sarcoma, uterine, Sinus cancer, Skin cancer, Small cell lung cancer,Small intestine cancer, Soft tissue sarcoma, Spinal cancer, Spinalcolumn cancer, Spinal cord cancer, Spinal tumor, Squamous cellcarcinoma, Stomach cancer, Synovial sarcoma, T-cell lymphoma),Testicular cancer, Throat cancer, Thymoma/thymic carcinoma, Thyroidcancer, Tongue cancer, Tonsil cancer, Transitional cell cancer,Transitional cell cancer, Transitional cell cancer, Triple-negativebreast cancer, Tubal cancer, Tubular carcinoma, Ureteral cancer,Ureteral cancer, Urethral cancer, Uterine adenocarcinoma, Uterinecancer, Uterine sarcoma, Vaginal cancer, and Vulvar cancer.

The AAV particles or pharmaceutical compositions of the presentinvention useful in preventing or treating HIV and AIDS mayalternatively, or in combination, encode an antibody that targets adifferent infectious agent (e.g., an infectious agent that is not HIV-1or 2). Non-limiting examples of other target antigens include any of thefollowing, including fragments or variants thereof, adenoviruses,Anaplasma phagocytophilium, Ascaris lumbricoides, Bacillus anthracis,Bacillus cereus, Bacteroides sp, Barmah Forest virus, Bartonellabacilliformis, Bartonella henselae, Bartonella quintona, beta-toxin ofClostridium perfringens, Bordetella pertussis, Bordetella parapertussis,Borrelia burgdorferi, Borrelia miyamotoi, Borrelia recurrentis, Borreliasp., Botulinum toxin, Brucella sp., Burkholderia pseudomallei,California encephalitis virus, Campylobacter, Candida albicans,chikungunya virus, Chlamydia psittaci, Chlamydia trachomatis, Clonorchissinensis, Clostridium difficile bacteria, Clostridium tetani, Coloradotick fever virus, Corynebacterium diphtheriae, Corynebacteriumminutissimum, Coxiella burnetii, coxsackie A, coxsackie B, Crimean-Congohemorrhagic fever virus, cytomegalovirus, dengue virus, Eastern Equineencephalitis virus, Ebola viruses, echovirus, Ehrlichia chaffeensis,Ehrlichia equi, Ehrlichia sp. Entamoeba histolytica, Enterobacter sp.,Enterococcus feacalis, Enterovirus 71, Epstein-Barr virus (EBV),Erysipelothrix rhusiopathiae, Escherichia coli, Flavivirus,Fusobacterium necrophorum, Gardnerella vaginalis, Group B streptococcus,Haemophilus aegyptius, Haemophilus ducreyi, Haemophilus influenzae,hantavirus, Helicobacter pylori, Hepatitis A, Hepatitis B, Hepatitis C,Hepatitis D, Hepatitis E, herpes simplex virus 1 and 2, human herpesvirus 6, human herpes Virus 8, human immunodeficiency virus 1 and 2,human T-cell leukemia viruses I and II, influenza viruses (A, B, C),Jamestown Canyon virus, Japanese encephalitis antigenic, Japaneseencephalitis virus, John Cunninham virus, juninvirus, Kaposi'sSarcoma-associated Herpes Virus (KSHV), Klebsiella granulomatis,Klebsiella sp., Kyasanur Forest Disease virus, La Crosse virus,Lassavirus, Legionella pneumophila, Leptospira interrogans, Listeriamonocytogenes, lymphocytic choriomeningitis virus, lyssavirus,Machupovirus, Marburg virus, measles virus, MERS coronavirus (MERS-CoV),Mictococcus sedentarius, Mobiluncus sp., Molluscipoxvirus, Moraxellacatarrhalis, Morbilli-Rubeola virus, Mumpsvirus, Mycobacterium leprae,Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasmagenitalium, Mycoplasma sp, Nairovirus, Neisseria gonorrhoeae, Neisseriameningitidis, Nocardia, Norwalk virus, norovirus, Omsk hemorrhagic fevervirus, papilloma virus, parainfluenza viruses 1-3, parapoxvirus,parvovirus B19, Peptostreptococccus sp., Plasmodium sp., poliovirusestypes I, II, and III, Proteus sp., Pseudomonas aeruginosa, Pseudomonaspseudomallei, Pseudomonas sp., rabies virus, respiratory syncytialvirus, ricin toxin, Rickettsia australis, Rickettsia conori, Rickettsiahonei, Rickettsia prowazekii, Ross River Virus, rotavinrus,rubellavirus, Saint Louis encephalitis, Salmonella typhi, Sarcoptesscabiei, SARS-associated coronavirus (SARS-CoV), Serrana sp., Shigatoxin and Shiga-like toxin, Shigella sp., Sin Nombre Virus, Snowshoehare virus, Staphylococcus aureus, Staphylococcus epidermidis,Streptobacillus moniliformis, Streptococcus pneumoniae, Streptococcusagalactiae, Streptococcus agalactiae, Streptococcus group A-H,Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidumsubsp. Pallidum, Treponema palladium var. carateum, Treponema pallidumvar. endemicum, Tropheryma whippelii, Ureaplasma urealyticum,Varicella-Zoster virus, variola virus, Vibrio cholerae, West Nile virus,yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Zikavirus.

Diagnostic Applications

The AAV particles of the present invention may be used for diagnosticpurposes or as diagnostic tools for any of the aforementioned diseasesor disorders. As a non-limiting example, the AAV particles of thepresent invention or the antibodies encoded within the viral genometherein may be used as a biomarker for disease diagnosis. As a secondnon-limiting example, the AAV particles of the present invention or theantibodies encoded within the viral genome therein may be used fordiagnostic imaging purposes, e.g., MRI. PET, CT or ultrasound.

Preventative Applications

The AAV particles of the present invention or the antibodies encoded bythe viral genome therein may be used to prevent disease or stabilize theprogression of disease. In one embodiment, the AAV particles of thepresent invention are used to as a prophylactic to prevent a disease ordisorder in the future. In one embodiment, the AAV particles of thepresent invention are used to halt further progression of a disease ordisorder. As a non-limiting example, the AAV particles of the inventionmay be used in a manner similar to that of a vaccine.

Research Applications

The AAV particles of the present invention or the antibodies encoded bythe viral genome therein may also be used as research tools. The AAVparticles of the invention may be used as in any research experiment,e.g., in vivo or in vitro experiments. In a non-limiting example, theAAV particles of the invention may be used in cultured cells. Thecultured cells may be derived from any origin known to one with skill inthe art, and may be as non-limiting examples, derived from a stable cellline, an animal model or a human patient or control subject. In anon-limiting example, the AAV particles of the invention may be used inin vivo experiments in animal models (i.e., mouse, rat, rabbit, dog,cat, non-human primate, guinea pig, ferret, c-elegans, drosophila,zebrafish, or any other animal used for research purposes, known in theart). In another non-limiting example, the AAV particles of theinvention may be used in human research experiments or human clinicaltrials.

Combination Applications

The AAV particles of the invention may be used as a combination therapywith any other therapeutic molecule known in the art. The therapeuticmolecule may be approved by the US Food and Drug Administration or maybe in clinical trial or at the preclinical research stage. Thetherapeutic molecule may utilize any therapeutic modality known in theart, with non-limiting examples including gene silencing or interference(i.e., miRNA, siRNA, RNAi, shRNA), gene editing (i.e., TALEN, CRISPRCas9systems, zinc finger nucleases), and gene, protein or enzymereplacement.

Therapeutic Applications: Infectious Diseases

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat infectiousdisease. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Tables 21-42 (SEQ ID NO: 4138-9220).

The methods, components and compositions of the present invention may beused to diagnose, prevent, treat and/or manage infectious diseases.Infectious diseases, also known as transmissible diseases orcommunicable diseases, are caused by invasion and multiplication ofagents in the body. Infection agents are species typically not presentwithin the body and may be, but are not limited to, viruses, bacteria,prions, nematodes, fungus, parasites or arthropods. Additionally, aninfection or symptoms associated with an infection may be caused by oneor more toxins produced by such agents. Humans, and other mammals, reactto infections with an innate immune system response, often involving aninflammation. The illnesses and symptoms involved with infections varyaccording to the infectious agent. Many infections may be subclinicalwithout presenting any definite or observable symptoms, whereas someinfections cause severe symptoms, require hospitalization or may belife-threatening. Some infections are localized, whereas some mayovercome the body through blood circulation or lymphatic vessels Someinfections have long-term effects on wellbeing of infected individuals.

Infectious agents may be transmitted to humans via different routes. Forexample, infection agents may be transmitted by direct contact with aninfected human, an infected animal, or an infected surface Infectionsmay be transmitted by direct contact with bodily fluids of an infectedhuman or an animal, e.g. blood, saliva, sweat, tears, mucus, femaleejaculate, semen, vomit or urine. For example, infection may betransmitted by a fecal-oral route, referring to an infected personshedding the virus in fecal particles which then enters to person'smouth causing infection. The fecal-oral route is especially commontransmission route in environments with poor sanitation and hygiene.Non-limiting examples of agents transmitted by the fecal-oral routeinclude bacteria, e.g. shigella, Salmonella typhii and Vibrio Cholerae,virus, e.g. norovirus, rotavirus, enteroviruses, and hepatitis A, fungi,e.g. Entamadeba histolytica, parasites, tape worms, transmitted bycontaminated food or beverage, leading to food poisoning orgastroenteritis. Infections may be transmitted by a respiratory route,referring to agents that are spread through the air. Typical examplesinclude agents spread as small droplets of liquid or as aerosols, e.g.respiratory droplets expelled from the mouth and nose while coughing andsneezing. Typical examples of respiratory transmitted diseases includethe common cold mostly implicated to rhinoviruses, influenza caused byinfluenza viruses, respiratory tract infections caused by e.g.respiratory syncytial virus (RSV). Infections may be transmitted by asexual transmission route. Examples of common sexually transmittedinfections include e.g. human immunodeficiency virus (HIV) causingacquired immune deficiency syndrome (AIDS), chlamydia caused byNeisseria gonorrhoeae bacteria, fungal infection Candidiasis caused byCandida yeast, and Herpes Simplex disease caused by herpes simplex virusInfections may be transmitted by an oral transmission route, e.g. bykissing or sharing a drinking glass. A common infection transmitted byoral transmission is an infectious mononucleosis caused by Epstein-Barrvirus Infections may be transmitted by a vertical transmission, alsoknown as “mother-to-child transmission.” from mother to an embryo, fetusor infant during pregnancy or childbirth. Examples of infection agentsthat may be transmitted vertically include HIV, chlamydia, rubella,Toxoplasma gondii, and herpes simplex virus. Infections may betransmitted by an iatrogenic route, referring to a transmission bymedical procedures such as injection (contaminated reused needles andsyringes), or transplantation of infected material, blood transfusions,or infection occurring during surgery. For example,methicillin-resistant Staphylococcus aureus (MRSA), which may causeseveral severe infections, may be transmitted via iatrogenic routeduring surgery. Infections may also be transmitted by vector-bornetransmission, where a vector may be an organism transferring theinfection agents from one host to another. Such vectors may betriatomine bugs, e.g. trypanosomes, parasites, animals, arthropodsincluding e.g. mosquitos, flies, lice, flees, tick and mites or humans.Non-limiting examples of mosquito-borne infections include Dengue fever,West Nile virus related infections, Yellow fever and Chikungunya fever.Non-limiting examples of parasite-borne diseases include malaria, HumanAfrican trypanosomiasis and Lyme disease. Non-limiting examples ofdiseases spread by humans or mammals include HIV. Ebola hemorrhagicfever and Marburg fever.

Traditionally infectious diseases are treated with medications and/orgood supportive care. Medical prevention, treatment and/or management ofbacterial infections may include administration of antibiotics.Antibiotics may inhibit the colonization of bacteria or kill thebacteria. Antibiotics include e.g. penicillins, cephalosporins,macrolides, fluoroquinolones, sulfonamides, tetracyclines, andaminoglycosides. Antibiotics may be specific to a certain bacteria oract against broad spectrum of bacteria. Some types of bacteria areespecially susceptible to antibiotics, whereas some bacteria are moreresistant. Development of bacterial strain mutations that are resistantto antibiotics is an increasing concern. Methicillin-resistantStaphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE),multi-drug-resistant Mycobacterium tuberculosis (MDR-TB) and Klebsiellapneumoniae carbapenemase-producing bacteria (KPC) are examples ofbacteria that are resistant to most general antibiotics. Due to theemerging resistance, unnecessary administration and overdosing ofantibiotics should be avoided. Medical prevention, treatment and/ormanagement of viral infections may include administration of antiviralmedications. Antiviral medications may be specific to a certain bacteriaor act against a broad spectrum of viruses. Currently antiviralmedications are available for e.g. HIV, influenza, hepatitis B and CMedical prevention, treatment and/or management of viral infections mayinclude administration of antifungal medication. Antifungal medicationkills or prevents the growth of fungi. Types of antifungal medicationsinclude e.g. imidazoles, triazoles and thiazoles, allylamines, andechinocandins. Development of antifungal medication capable of targetingfungal cells without affecting human cells is a challenge due to thesimilarities of human and fungal cell on the molecular level. Typically,medical treatment is combined with good supportive care, which includesprovision of fluids, bed rest, medication to relieve pain and lowerfever, supportive alternative medicine such as vitamins, antioxidantsand other supplements important for wellbeing of patients.

Antibody therapies for infectious diseases have also been developed.Examples of commercial therapeutic antibodies include raxibacumab(developed by Cambridge Antibody Technology and Human Genome Sciences)which is an antibody for the prophylaxis and treatment of inhaledanthrax. SHIGAMAB™ (developed by Bellus Health Inc.) is a monoclonalantibody for treatment of Shiga toxin induced hemolytic uremic syndrome,and actoxumab and bezlotoxumab (developed by Medarex Inc, and theUniversity of Massachusetts Medical School) are commercial humanmonoclonal antibodies targeting C. difficile toxin A and toxin B,respectively.

Infectious diseases and/or infection related diseases, disorders, and/orconditions that may be treated by methods, components and compositionsof the present invention include, but are not limited to, 14-daymeasles, 5-day fever, acne, acquired immunodeficiency syndrome (AIDS),acrodermatitis chronica atrophicans (ACA), acute hemorrhagicconjunctivitis, acute hemorrhagic cystitis, acute rhinosinusitis, adultT-cell leukemia-lymphoma (ATLL). African sleeping sickness, alveolarhydatid, amebiasis, amebic meningoencephalitis, anaplasmosis, anthrax,arboviral, ascariasis, aseptic meningitis, Athlete's foot, Australiantick typhus, avian Influenza, babesiosis, bacillary angiomatosis,bacterial meningitis, bacterial vaginosis, balanitis, balantidiasis,Bang's disease, Barmah Forest virus, bartonellosis, bat lyssavirus, Baysore, Baylisascaris, beaver fever, beef tapeworm, bejel, biphasicmeningoencephalitis, black bane, black death, black piedra, Blackwaterfever, blastomycosis, blennorrhea of the newborn, blephantis, boils,Bomholm disease, borrelia miyamotoi disease, botulism, boutonneusefever, Brazilian purpuric fever, break bone fever, brill, bronchiolitis,bronchitis, brucellosis, bubonic, bubonic plague, bullous impetigo,Burkholderia mallei, Burkholderia pseudomallei, burly ulcers mycoburuliulcers, Busse-Buschke disease, California group encephalitis,campylobacteriosis, candidiasis, canefield fever, canicola fever,capillariasis, carate, carbapenem-resistant enterobacteriaceae (CRE),Carrion's disease, cat scratch fever, cave disease, central Asianhemorrhagic fever, Central European tick, cervical cancer, Chagasdisease, cancroid, Chicago disease, chickenpox, Chiclero's ulcer,chikungunya fever, chlamydial, cholera, chromoblastomy cosis, ciguatera,clap, clonorchiasis, Clostridium difficile, Clostridium perfringens,coccidioidomycosis fungal, coenurosis, colorado tick fever, condylomaaccuminata, condyloma lata, Congo fever, Congo hemorrhagic fever virus,conjunctivitis, cowpox, crabs, Crimean disease, croup, crypto,cryptococcosis, cryptosporidiosis, cutaneous larval migrans,cyclosporiasis, cystic hydatid, cysticercosis, cystitis, Czechoslovaktick, d68 (EV-d68), dacnrocytitis, dandy fever, darling's disease, deerfly fever, dengue fever types 1, 2, 3, and 4, desert rheumatism, devil'sgrip, diphasic milk fever, diphtheria, disseminated intravascularcoagulation, dog tapeworm, donovanosis, dracontiasis, dracunculosis,duke's disease, dum dum disease, Durand-Nicholas-Favre disease, dwarftapeworm, E. coli, eastern equine encephalitis, Ebola hemorrhagic fever,Ebola virus disease (EVD), ectothrix, ehrlichiosis, encephalitis,endemic relapsing fever, endemic syphilis, endophthalmitis, endothrix,enterobiasis, enterotoxin-B poisoning (staph food poisoning),enterovirus, epidemic keratoconjunctivitis, epidemic relapsing fever,epidemic typhus, epiglottitis, epsilon toxin, erysipelas, erysipeloid,erysipelothricosis, erythema chronicum migrans, erythema infectiosum,erythema marginatum, erythema multiforme, erythema nodosum, erythemanodosum leprosum, erythrasma, espundia, eumycotic mycetoma, Europeanblastomycosis, exanthem subitum, eyeworm, Far-Eastern tick,fascioliasis, fievre boutonneuse, fifth disease, Filatow-Dukes' disease,fish tapeworm, Fitz-Hugh-Curtis syndrome—perihepatitis, flinders islandspotted fever, flu, folliculitis, four corners disease, frambesia,francis disease, furunculosis, gas gangrene, gastroenteritis, genitalherpes, genital warts, German measles, Gerstmann-Straussler-Scheinker(GSS), giardiasis, Gilchrist's disease, gingivitis, gingivostomatitis,glanders, glandular fever, gnathostomiasis, gonococcal, gonorrhea,granuloma inguinale, guinea worm, haemophilus influenza disease,hamburger disease, Hansen's disease, Hantaan disease, Hantaan-Koreanhemorrhagic fever, hantavirus pulmonary syndrome (UPS), hard chancre,hard measles, Haverhill fever, head and body lice, heartland fever,helicobacterosis, hemolytic uremic syndrome (HUS), hepatitis A,hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpangina,herpes—genital, herpes labialis, herpes—neonatal, hidradenitis,histoplasmosis, histoplasmosis, his-werner disease, hiv, hookworms,hordeola, HTLV-associated myelopathy (HAM), human granulocyticehrlichiosis, human monocytic ehrlichiosis, human papillomarivus (HPV),human pulmonary syndrome, human pulmonary syndrome (HPS), human T-celllymphotrophic virus (HTLV), hydatid cyst, hydrophobia, impetigo,including congenital, inclusion conjunctivitis, infantile diarrhea,infectious mononucleosis, infectious myocarditis, infectiouspericarditis, influenza, isosporiasis, Israeli spotted fever, Japaneseencephalitis, jock itch, jorge lobo disease, jungle yellow fever, JuninArgentinian hemorrhagic fever, kala azar, Kaposi's sarcoma, keloidalblastomycosis, keratoconjunctivitis, kuru, Kyasanur forest disease,lacrosse encephalitis, lassa hemorrhagic fever, legionellosis,legionnaires disease, legionnaire's pneumonia, Lemierre's syndrome,lemming fever, leprosy, leptospirosis, listena, listeriosis, liverfluke, lobo's mycosis, lock jaw, lockjaw, loiasis, louping ill, Ludwig'sangina, lung fluke, Lyme disease, lymphogranuloma venereum (LGV),Machupo Bolivian hemorrhagic fever, Madura foot, mal del pinto, malaria,malignant pustule, Malta fever, Marburg hemorrhagic fever, mastersdisease, maternal sepsis, measles, Mediterranean spotted fever,melioidosis, meningitis, meningococcal disease, Middle East RespiratorySyndrome (MERS), methicillin-resistant Staphylococcus aureus (MRSA),milker's nodule, molluscum contagiosum, moniliasis, monkeypox,mononucleosis, mononucleosis-like syndrome, Montezuma's revenge,morbilli, mucormycosis, multiple organ dysfunction syndrome (MODS),multiple-system atrophy (MSA), mumps, murine typhus, Murray Valleyencephalitis (MVE), mycoburuli ulcers, mycotic vulvovagmitis, myositis,Nanukayami fever, necrotizing fasciitis, necrotizing fasciitis—type 1,necrotizing fasciitis—type 2, negishi, new world spotted fever,nocardiosis, nongonococcal urethritis, non-polio enterovirus, norovirus,North American blastomycosis, North Asian tick typhus, Norwalk virus,Norwegian itch, O'hara disease, Omsk hemorrhagic fever, onchoceriasis,onychomycosis, opisthorchiasis, opthalmia neonatorium, oral hairyleukoplakia, orf, oriental sore, oriental spotted fever, omithosis,Oroya fever, otitis externa, otitis media, pannus,paracoccidioidornycosis, paragonimiasis, paramfectious, paralyticshellfish poisoning, paronychia, parotitis, parrot fever, pediculosis,peliosis hepatica, pelvic inflammatory disease, pertussis,phaeohyphomycosis, pharyngoconjunctival fever, piedra, pigbel, pink eyeconjunctivitis, pinta, pinworm, pitted keratolysis, pitvriasisversicolor, plague, pleurodynia, pneumococcal disease, pneumocystispneumonia, pneumocystosis, pneumonia, polio, poliomyelitis, polycystichydatid, Pontiac fever, pork tapeworm, Posada-Wernicke disease,postanginal septicemia, Powassan, progressive multifocalleukencephalopathy (PML), progressive rubella panencephalitis,prostatitis, pseudomembranous colitis, psittacosis, puerperal fever,pustular rash diseases, pyelonephritis, pylephlebitis, q-fever, quinsy,quintana fever, rabbit fever, rabies, racoon roundworm, rat bite fever,rat tapeworm, Reiter syndrome, relapsing fever, respiratory syncytialvirus (RSV), rheumatic fever, rhodotorulosis, ricin poisoning,rickettsialpox, rickettsiosis, Rift valley fever, ringworm, Ritter'sdisease, river blindness, rocky mountain spotted fever, rose handler'sdisease, rose rash of infants, roseola, Ross river fever, rotavirus,roundworm s, rubella, rubeola, Russian spring, salmonellosisgastroenteritis, San Joaquin valley fever, Sao Paulo encephalitis, SaoPaulo fever, scabies infestation, scalded skin syndrome, scalded skinsyndrome, scarlatina, scarlet fever, schistosomiasis, scombroid, scrubtyphus, sennetsu fever, sepsis, septic shock, severe acute respiratorysyndrome, severe acute respiratory syndrome (SARS), shiga toxigenicEscherichia coli, shigella, shigellosis gastroenteritis, shinbone fever,shingles, shipping fever, siberian tick typhus, sinusitis, sixthdisease, slapped cheek disease, sleeping sickness, small pox, smallpox,snail fever, soft chancre, southern tick associated rash illness,sparganosis, Spelunker's disease, sporadic typhus, sporotrichosis,spotted fever, spring, St. Louis encephalitis, staphylococcal foodpoisoning, staphylococcal, strep, throat, streptococcal disease,streptococcal toxic-shock syndrome, strongyloiciasis, stye, subacutesclerosing panencephalitis (SSAPE), sudden acute respiratory syndrome,sudden rash, swimmer's ear, swimmer's itch, swimming poolconjunctivitis, Sylvatic yellow fever, syphilis, systemic inflammatoryresponse syndrome (SIRS), tabes dorsalis, taeniasis, taiga encephalitis,tanner's disease, tapeworm s, temporal lobe encephalitis, tertiarysyphilis, tetani, tetanus, threadworms, thrush, tick, tick typhus, tineabarbae, tinea capitis, tinea corporis, tinea cruris, tinea manuum, tineanigra, Tinea pedis, tinea unguium, tinea versicolor, torulopsosis,torulosis, toxic shock syndrome, toxoplasmosis, transmissiblespongioform, traveler's diarrhea, trench fever 5, trichinellosis,trichomoniasis, trichonycosis axillaris, trichuriasis, tropical spasticparaparesis (TSP), trypanosomiasis, tuberculosis (TB), tularenua,typhoid fever, typhus fever, ulcus molle, undulant fever, urban yellowfever, urethritis, vagmitis, vaginosis, valley fever, vancomycinintermediate (VISA), vancomycin resistant (VRSA), varbuncle, varicella,variola, varrion's disease, venezuelan equine encephalitis, Verrugaperuana, vibrio, Vibrio cholerae, vibriosis, vincent's disease or trenchmouth, viral conjunctivitis, viral meningitis, viralmeningoencephalitis, viral rash, visceral larval migrans, vomito negro,vulvovaginitis, warts, Waterhouse, Weil's disease, West Nile fever,Western equine encephalitis, Whipple's disease, whipworm, white piedra,whitlow, Whitmore's disease, whooping cough, winter diarrhea, wolhyniafever, wool sorters' disease, yaws, yellow fever, yersinosis, zahorsky'sdisease, zika virus disease, zoster, zygomycosis, acute bacterialrhinosinusitis, lobomycosis, and/or any other infectious diseases,disorders or conditions.

John Cunningham Virus (JCV)

John Cunningham Virus is a common human polyomavirus. The transmissionroute of JCV is unknown. The virus is suspected to be spread bycontaminated water and may be obtained through tonsils or by thegastrointestinal tract, 70-90% of humans are estimated to be infected bythe virus, and for normal healthy individuals the infection isasymptomatic. However, for patients with weakened immune system. JCV maylead to Progressive multifocal leukoencephalopathy (PMI). PML is acondition characterized by multifocal progressive damage or inflammationof the white matter of the brain. The symptoms include clumsiness,progressive weakness and changes in visual, speech and personality. PLMhas a mortality rate of 30-50% and patients who survive the disease areleft with severe neurological disabilities. PML occurs in patients witha severe immunodeficiency, most commonly in patients with HIV/AIDS. Asmany as 5% of HIV/AIDS patients are affected by PML. Individuals withother autoimmune conditions such as multiple sclerosis, rheumatoidarthritis, and systemic lupus erythematosus are also at risk, as well asindividuals going through immunosuppressive therapy for cancer, e.glymphoma or Hodgkin's disease, or organ transplant. PML associated withimmunosuppressive therapy is an increasing concern. For example,commercial antibody natalizumab (TYSABR®, developed by Biogen Idec) fortreatment of multiple sclerosis increases susceptibility to PML. Otherdrugs associated with increased risk of PML include Rituximab (RITUXAN®,developed by IDEC Pharmaceuticals), Efalizunab (RAPTIVAR® developed byGenentech and XOMA) and Mycophenolate mofetil (CELLCEPT®, developed byGenentech).

JCV is a nonenveloped, T=7 icosahedral virus with a closed circular,double-stranded DNA genome. The major capsid component is the viralprotein VP1 is made of 72 pentamers formed by VP1 monomers linkedthrough the C terminal end. VP1 starts the infection by binding to thereceptor target cells. After initial infection, typically occurring inchildhood or adolescence, the virus stays quiescent in the kidneys andthe lymphoid organs. In healthy individuals, the virus may replicate inkidney without causing any symptoms. However, in patients with weakenedimmune system, JCV may cross the blood-brain barrier into the centralnervous system causing PML.

As of today, there is no known cure for PML. Current therapies focus onreversing the immune deficiency to slow down or stop the progress of thedisease. There remains a need for therapies neutralizing JVC forprevention, management and treatment of JCV infection and PML Goldmannet al. demonstrated that neutralizing activity with JCV VP1 protein insera of a rabbit (see Goldmann C. et al., 1999, J. Virol.; 73(5):4465-4469). Therapies based on neutralizing JCV antibodies could beapplied for treatment, management and/or prevention of PML. Recently,immunological approaches have been under investigation and neutralizingantibodies binding to JC virus, especially targeting the VP1 protein,have been developed e.g. as described in US Patent PublicationUS2015/0191530. US2015/0056188 and US2015/0050271, the contents of eachof which are incorporated herein by reference in their entirety. Suchantibodies may cause reduction of JCV replication, proliferation orInfectivity. Antibodies may bind to a conformational epitope of JCV VP1protein or to the sialic acid binding pocket of VP1 protein of JCV.

In some embodiments, methods of the present invention may be used toprevent, manage and/or treat JCV infection and/or PML.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat JCV As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 26 (SEQ ID NO: 6802-6865).

Influenza Virus

Influenza viruses cause a common respiratory infection called influenza(flu). Influenza viruses are categorized into three main groups, virusA, B and C Influenza viruses are negative-sense, single-stranded,segmented RNA viruses. Influenza A contains two proteins on the surfaceof the viral envelope; hemagglutinm (H), which is a protein responsiblefor red blood cell agglutination and neuraminidase (N), which is anenzyme cleaving the glycosidic bonds of neuraminic acid. Influenza Amutates at a faster rate than types B and C Several serotypes of H andsubtypes of N have been identified. Influenza Type B, similarly to TypeA, contains H and N protein. Type C influenza virus is a single strandedRNA virus with glycoprotein called hemagglutinin-esterase fusionInfluenza strains vary according to geographical presentation.

Influenza in general is a highly contagious disease and may betransmitted by the respiratory route. Influenza symptoms include e.g.high fever, runny nose, headache, sore throat, muscle pain, cough andoccasionally nausea and vomiting. Influenza may lead to othercomplications such as pneumonia or sinus infections. Influenza may bedangerous to young children, the elderly, pregnant women and individualswith chronic medical conditions or weakened immune system. According toCenters for Disease Control and Prevention (CDC), the estimated annualnumber of flu-associated deaths in the United States ranges between 3000and 49,000, depending on the severity of the seasonal variations.

Influenza may be treated with good supportive care and antiviralmedication. Antiviral medications include neuraminidase inhibitors, e.g.oseltamivir and zanarmvir and M2 protein inhibitors. However, somestrains of influenza appear to be resistant to these antiviralmedications. Seasonal vaccinations to influenza are very efficient inprevention of the disease and are recommended annually.

There remains a need for prevention and treatment therapies forinfluenza, especially for those providing long lasting and broadneutralization Therapeutic antibodies against influenza viruses havebeen developed. In general, antibody responses to different subtypes andserotypes of influenza A. B and C are unique. Some therapeuticantibodies are specific to an antibody type, whereas some have a broadcoverage. Navivumab (developed by Celltrion, Inc.) taught in US Patentapplication US20140234336, firivumab (developed by Celltrion, Inc.)taught in US Patent application US20130004505 and diridavumab (developedby Jansen Biotech, Crucell and Johnson&Johnson) taught in InternationalPatent application WO/2008/028946 are examples of therapeuticallyantibodies against influenza A hemagglutinin HA.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat influenza.As a non-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 21 (SEQ ID NO: 4138-5222).

Hepatitis

Hepatitis is an inflammation of the liver. Hepatitis may be caused by aninfection of hepatitis viruses A, B, C, D or E. In some cases, hepatitismay be asymptotic. A typical symptom of hepatitis is jaundice,characterized by yellowing of the skin, mucous membrane and conjunctiva.Other symptoms include loss of appetite, diarrhea, nausea and fever.Hepatitis may lead to a liver failure. Acute form of hepatitis is healedwithin six months of infection. The inflammation may also progress to achronic hepatitis, which may lead to liver complications such asfibrosis, cirrhosis or hepatocellular carcinoma. There is no specifictreatment for hepatitis. Typically, acute hepatitis is treated with goodsupportive care, including good nutritional balance, fluid and rest.Chronic hepatitis may be treated with antiviral drugs. Hepatitis may beprevented by vaccinations.

Hepatitis A (HAV) virus belongs to the family of Picornaviridae. HAV isencapsidated in an icosahedral structure formed by 60 copies of threeviral structural proteins (VP1, VP2 and VP3), (see e.g. Kim et al. 2004,Virlogy; 318(2):598-607, and references therein). HAV is spread by thefecal-oral-route. Typical transmission is through contaminated food ordrink or in contact with an infected individual. Improperly cookedshellfish is a common source of HAV. Hepatitis A is more abundant indeveloping countries with poor sanitary conditions. According to theWorld Health Organization (WHO), an estimated 1.4 million people areinfected by HAV every year.

Vaccines for prevention of HAV infection exists and are recommended tobe administered to children under 1 year of age by CDC, As of today,there is no specific treatment for HAV infection. The treatment includessupportive therapy and may last for weeks or even months. There remainsa need for treatment therapies for HAV. Antibodies for prevention and/ortreatment of HAV have been developed. For example, U.S. Pat. No.763,476, International Publication WO2011114353 and Kim et al inVirology. 2004 Jan. 20:318(2).598-607, the contents of each of which areincorporated herein by reference in their entirety, teach neutralizingantibodies targeting HAV antigens.

Hepatitis B (HBV) belongs to the family of Orthohepadnaviridae. HBVcomprises a 3.2 kb-partially double-stranded circular DNA genome. HBVvirus may be transmitted via the sexual transmission route, verticaltransmission at birth, iatrogenic route (e.g. blood transfusions,contaminated reused needles and syringes), as well as via exposure tocertain body fluids of an infected individual According to the WHO, anestimated 240 million people are chronically infected with hepatitis Bannually, and more than 780 000 people die to associated complications.

HBV may be prevented by vaccination. The WHO recommends vaccination forall infants, as well as for adults living in increased risk of theinfection. HBV infection may be treated with antiviral medications, e.g.tenofovir and entecavir. The medication does not cure the disease butsuppresses the replication of the virus. Individuals with chronichepatitis B infection are administered antiviral medications for life.There remains a need for therapies providing long lasting managementand/or cure for HBV infection. Antibodies for prevention and/ortreatment of HBV infection are described e.g. in US Patent publicationUS20120308580 and International publication WO2013165972, the contentsof each of which are herein incorporated by their reference in theirentirety.

Hepatitis C (HCV) belongs to the family of Flaviviridae. HCV is apositive-sense single-stranded RNA virus with an open reading frame with9600 nucleotide bases. HCV is most commonly transmitted by the sexualtransmission route or iatrogenic route. Hepatitis C may be transmittedalso via the vertical route, though uncommon. According to WHO, 130-150million people have a chronic HCV infection and approximately half amillion people die from complications associated with HCV annually.

As of today, there is no vaccine for HCV infection. Traditionaltreatment of hepatitis C is based on antiviral medication therapy withe.g. ribavirin and interferon. More recently, direct antiviral agents(DAA) have been developed to treat hepatitis C infections. However,there remains a need for efficient prevention and treatment therapiesfor HCV infection.

Hepatitis D (HDV) is a small spherical enveloped RNA virus belonging tothe genus of deltaviruses. HDV infection may only replicate in thepresence of a HBV virus and therefore HDV infection has a dependency onHBV. HDV virus may be transmitted as coinfection with HBV or besuperimposed on chronic HBV or HBV carrier state. HDV may be transmittedsimilarly to HBV, e.g. via the sexual transmission route, verticaltransmission at birth, iatrogenic route, as well as via exposure tocertain body fluids of an infected individual. Treatment and vaccinationagainst HBV may be applied against HDV, and there remains a need fortherapies to cure both infections.

Hepatitis E (HEV) is a linear, monoparte, single-stranded RNA virusbelonging to the family of Hepeviridae. HEV may be transmitted via thefecal-oral route due to contaminated food or beverage, the iatrogenicroute (e.g. blood transfusions, contaminated reused needles andsyringes) or the vertical transmission route during pregnancy.Contaminated drinking water is the most common source of infection.Improperly cooked shellfish are a common source of HEV. The disease ispresent worldwide but is more abundant in East and South Asia, andespecially in environments with poor sanitation and hygiene. Accordingto WHO, an estimated 20 million HEV infections occur annually leading to56 600 death associated with HEV complications.

There is no specific treatment for HEV. The disease is typically curedwith good supportive care. As of today, vaccinations against 1-HEV arenot globally available, though development in the field has been done.There remains a need for prevention and treatment therapies for HEVinfection. Antibodies for prevention and treatment of HEV have beendeveloped. For example, neutralizing antibodies targeting HEV have beentaught in U.S. Pat. No. 7,148,323, Tang et al. 2011. Proc. Natl. Acad.Sci. U.S.A. 108 (25), 10266-10271 and Gu et al. 2015, Cell Res. 25 (5),604-620, the contents of each of which are incorporated herein byreference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by HAV,HBV, HCV, HDV and/or HEV.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat HAV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 6 (SEQ ID NO: 3197-3237).

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat HBV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 23 (SEQ ID NO: 6311-6627).

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat HDV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 23 (SEQ ID NO: 6311-6627).

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat HEV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 6 (SEQ ID NO: 3197-3237).

Respiratory Syncytial Virus (RSV)

Respiratory syncytial virus (RSV) is a single-stranded RNA virusbelonging to the family of Paramyxoviridae. The RSV RNA is contained ina nucleocapsid made of 11 proteins and covered with a lipid envelope(see, e.g. Piedimonte, 2015, Cleve Clin J Med.; 82(11 Suppl 1):S13-8,and references therein). RSV attaches to the epithelial cells of thehost airway cells with the surface glycoproteins G and F and merges theviral envelope to the membranes of adjacent cells G and F glycoproteinsare the principal antigens exposed to the host immune system.

Respiratory syncytial virus (RSV) causes infections of the respiratorytract including the lungs and breathing passages. RSV is transmittedthrough the respiratory transmission route, in direct contact with nasalor oral secretions of infected individuals, or indirectly e.g. bytouching a contaminated surface. The symptoms include a runny nose,decrease of appetite, coughing, sneezing, fever and wheezing. Theinfection may progress into a pneumonia or bronchiolitis Additionally,RSV infection may have a role in triggering asthma attacks and in theinception of asthma for individuals with a family history of asthma. Inhealthy adults, RSV infection is typically mild and does not requirehospitalization. However, the infection may be dangerous for youngchildren and infants, and for individuals with a weakened immune system.According to the CDC, almost all children under 3 years of age willacquire an RSV infection and up to 2% of cases require hospitalization.RSV infection the most common cause for bronchiolitis and pneumonia inchildren younger than 1-year-old.

As of today, there is no specific medical treatment for RSV infection onthe market and typically the infection is treated with good supportivecare. There remains a need for prevention and treatment therapies forRSV infections and associated complications. Antibodies for treatmentand prevention of RSV infection have been developed. For example,palivizumab (developed by Medimmune) taught in U.S. Pat. No. 8,153,133,the contents of which are incorporated herein by reference in theirentirety, is a nearly human monoclonal antibody targeting the RSV Fglycoprotein. Palivizunumab is used for passive immunity for infants atrisk for severe infection, including children with hemodynamicallysignificant congenital heart defects, profound immunodeficiency andpulmonary or neuromuscular pathologies impairing airway clearance.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by RSV.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat RSV As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 22 (SEQ ID NO: 5223-6310).

Herpes Simplex Virus 1 and 2

Herpes simplex viruses 1 and 2 (HSV1 and HSV2), also known as humanherpesvirus 1 and 2 (HHV-1 and HHV-2), belong to the family ofHerpesviridae. Herpesviruses in general, consist of an icosahedralcapsid surrounded by a membrane envelope. The capsid contains the viraldouble stranded DNA. The capsid is surrounded by an amorphous tegumentof 30 viral proteins. The virion is enveloped by lipids with multipleviral glycoproteins and cellular proteins (see, e.g. McAllister andSchleiss, 2014, Expert Rev Vaccines.; 13(11):1349-1360, and referencestherein).

HSV1 and HSV2 cause an infection known as herpes, which is characterizedby blisters in the skin, or mucous membranes of the mouth, lips, alsoknown as “cold sores”, or genitals. Typically, the symptoms are mild orasymptomatic. However, HSV1 and HSV2 are neurotropic and neuroinvasiveviruses persisting in the body by becoming latent, and sustain in thecell bodies of neurons. The infection is lifelong with outbreaks, orsporadic episodes of viral reactivation, when the virus in the nervecells become active causing new blistering. The infection may bedangerous to individuals with weakened immune system. Neonatal herpes ofinfants may be fatal. Occasionally HSV1 infections may lead toencephalitis or keratitis. HSV1 and HSV2 are transmitted by contact withan infected area during reactivations of the virus. HSV1 is mainlytransmitted by oral-to-oral contact, skin contact or the sexualtransmission route. HSV1 may also be transmitted vertically duringbirth. HSV2 is transmitted via the sexual transmission route and is oneof the most common sexually transmitted infections. According to theWHO, an estimated 67% of world's population aged under 50 years has anHSV-1 infection. An estimated 11% of world's population aged 15-49 yearshas an HSV2 infection.

As of today, there is no vaccination for prevention of HSV1 and HSV2infections on the market. HSV1 and HSV2 infections may be treated withantiviral medications, such as acyclovir, famciclovir and valacyclovir.Antiviral medications do not cure the infection, but reduce the severityand frequency of symptoms. There remains a therapy for prevention andcure for these infections. Antibodies for prevention, treatment andmanagement of HSV1 and HSV2, targeting the viral glycoproteins, havebeen developed, as described e.g. in U.S. Pat. No. 8,431,118, US PatentU.S. Pat. No. 5,646,041. Haynes US Patent Publication US201410302062,the contents of each of which are incorporated herein by reference intheir entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by HSV1and HSV2.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat HSV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 24 (SEQ ID NO: 6628-6736).

Human Cytomegalovirus

Human Cytomegalovirus (HCMV) also known as human herpesvirus 5 (HHV-5)belongs to the family of Herpesviridae, a sub-family ofBetaherpesvirinae. HCMV is a double-stranded DNA enveloped viruscomposed of a nucleocapsid surrounded by structured tegument layer andbounded by a trilaminate membrane envelope.

In most occasions, an initial HCMV infection is asymptomatic, orassociated with mild symptoms e.g. sore throat, fatigue, flu-likesymptoms, and fever. After initial infections, HCMV virus resides inmononuclear cells without detectable symptoms. HCMV infection may bedangerous to individuals with weakened immune system. HCMV may betransmitted by contact with certain body fluids of an infectedindividuals (e.g. saliva, urine, semen). HCMV may be transmittedvertically, especially if acquired during pregnancy, leading to acongenital HCMV infection. According to CDC, about 1 in 150 children areborn with congenital CMV infection. In about 20% of cases, congenitalHCMV infection may lead to premature birth, birth defects ordevelopmental disabilities, e.g. liver, lung, spleen problems, smallhead size, small body size or seizures.

As of today, there is no specific treatment or prevention therapy forHCMV infection. In severe cases of congenital HCMV infection, infantsmay be treated with an antiviral drug, ganciclovir, to prevent hearingloss and developmental outcomes. However, the drug has serious sideeffects. There remains a need for prevention therapy and improvedtherapies for treatment and cure of HCMV infection. Antibodiesneutralizing HCMV have been developed. Such antibodies are taught e.g.in International Patent Publication WO2010007463, U.S. Pat. Nos.9,149,524, 8,492,529 and 8,202,518, the contents of each of which areincorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byHCMV.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat HCMV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 24 (SEQ ID NO: 6628-6736).

Epstein-Barr Virus

Epstein-Barr virus (EBV), also known as human herpesvirus 4 (HHV-4)belongs to the family of Herpesviridae. EBV is a double-stranded DNAvirus composed of a protein nucleocapsid surrounded by a tegument layerand bounded by an envelope containing lipids and surface projection ofglycoproteins. EBV may enter B cells and epithelial cells.

EBV infection causes glandular fever known as infectious mononucleosis,also known as the kissing disease. Typical symptoms include e.g. sorethroat, fever swollen lymph nodes in the neck, enlarged spleen, swollenliver, rash and fatigue. Additionally, EBV infection is associated withcertain cancers, e.g. central nervous system lymphomas. Hodgkin'slymphoma, Burkitt's lymphoma, Guillain-Barre syndrome, multiplesclerosis, and higher susceptibility to certain autoimmune diseases. Thevirus is transmitted via contact with certain bodily fluids of aninfected individual, especially through saliva. The infection affectsmajority of population. According to CDC, 90% of adult population haveantibodies demonstrating current or past EBV infection.

As of today, there is no specific therapy for prevention or treatment ofEBV infection on the market Typically, EBV infection is treated withgood supportive care. Antibodies for prevention, management andtreatment of EBV infection and associated diseases have been developed,e.g. by Wang and Fogg in US Patent publication US20150064174 and Fang etal, in Intervirology 50 (4), 254-263 (2007), the contents of each ofwhich are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by EBV.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat EBV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 31 (SEQ ID NO: 6898-6911).

Varicella Zoster Virus

Varicella zoster virus (VZV), also known as human herpes virus 3 (HHV-3)and chickenpox virus, belongs to the family of Herpesviridae. VZV is alinear duplex DNA molecule containing two segments (L and S) joinedcovalently. At least five clades of the virus have been identified.

VZV causes varicella, also known as chickenpox, which is an infectioncharacterized by blister-like rash, itching, fatigue and fever.Chickenpox may be dangerous for babies, adults and individuals withweakened immune system. After primary phase of the infection, VZVresides in the nerves, including cranial nerve ganglia, dorsal rootganglia and autonomic ganglia, and may eventually lead to shingles,which is a viral disease characterized with a painful skin rash,blistering and occasionally nerve pain. Additionally, VZV has beenassociated with other complications, e.g. neurological conditions,inflammation of arteries, myelitis, Ramsay Hunt syndrome. Mollaret'smeningitis VZV is transmitted by direct contact or by the respiratoryroute. VZV is highly contagious. According to CDC, before VZVvaccination, about 4 million people would be affected by chickenpox inthe US annually, with more than 10,00KK hospitalized.

VZV infection may be prevented by a vaccination, which is recommended byCDC to all children and unvaccinated adults. Chickenpox may be treatedwith antiviral medications, e.g. acyclovir, valacyclovir andfamciclovir, or with other symptom relieving medications and therapies.However, the present antiviral medications may have undesirable sideeffects. There remains a need for improved therapies to treat VZVinfection, and its reactivation stages Antibodies targeting VZV havebeen developed, e.g. as described in U.S. Pat. No. 5,506,132, and USPatent application US20100074906, the contents of which are hereinincorporated by their reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by VZV.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat VZV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 31 (SEQ ID NO: 6898-6911).

Corona Viruses

Coronaviruses are a diverse group of enveloped viruses belonging to thefamily of Coronaviridae. Coronaviruses contain an envelope, a helicalcapsid, and a single-stranded, positive-sense RNA genome. Coronaviruseshave a characteristic structure with viral spike-shaped glycoproteinpopulating the surface of the virus and causing an appearance resemblingthe solar corona. Coronaviruses are a common cause of mammalian andavian infections causing upper respiratory tract, gastrointestinal andcentral nervous system diseases.

Human coronavirus 229E, OC-43, NL63, and HKU1 are a cause a behindtypical, short term ‘common cold’ and affect individuals all over theworld. Typical symptoms of the infections include coughing, sneezing,fatigue and fever. Occasionally the viruses can cause lower-respiratorytract illnesses, such as pneumonia. The viruses are spread by directcontact or by the respiratory route. The infections may be dangerous tothe elderly and individuals with weakened immune system. There is nospecific treatment or prevention therapy for these coronavirusinfections.

Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) causes a viralrespiratory illness. Typical symptoms of the infection include a highfever, headache, body aches, dry coughing and eventually pneumoniaSARS-CoV was identified in 2003 in an outbreak starting from Asia.SARS-CoV is transmitted by direct contact with an infected individual orby the respirator route. According to the WHO, during the 2003 outbreakof SARS-CoV, 8098 people worldwide were infected with symptoms and outof them, 774 died. As of today, there is no specific treatment orprevention therapy for SARS on the market. Antiviral medication andsteroids may be prescribed to certain patients. Antibodies targetingSARS-CoV have been developed, e.g. as described in U.S. Pat. No.7,728,110 and US Patent publication US20110159001, the contents of eachof which are herein incorporated by their reference in their entirety.

Middle East Respiratory syndrome coronavirus (MERS-CoV) causes an acutesevere respiratory infection affecting the lungs and breathing tubes.MERS-CoV was identified in 2012. Typical symptoms include fever, coughand shortness of breath, eventually pneumonia and additionallygastrointestinal symptoms. MERS-CoV is highly dangerous to humans.According to the WHO, 36% of the infections are fatal. MERS-CoV is azoonotic virus transmitted to humans from animals, e.g. bats and camels,or from human to human Camels are suggested to be a reservoir forMERS-CoV. Majority of MERS-CoV infection have occurred in the ArabianPeninsula, and especially in Saudi Arabia. As of today, no specifictreatment of prevention therapy for MERS-CoV infection is available onthe market. Antibodies targeting MERS-CoV have been developed, e.g. asdescribed in International publication WO2015057942, the contents ofwhich are herein incorporated by their reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused bySARS-CoV. MERS-CoV and/or other coronaviruses.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treatcoronaviruses. As a non-limiting example, the AAV particles of thepresent invention comprise a nucleic acid sequence encoding at least oneof the sequences described in Table 25 (SEQ ID NO: 6737-6801).

Poxviruses

Poxviruses affecting humans include orthopoxvirus, parapoxvirus,yatapoxvirus and mollusipoxvirus. Poxviruses are typically brick-shaped,enveloped, single, liner or double-stranded viruses with DNA genome.Typically, poxvirus infections cause lesions, skin nodules, ordisseminated rash Poxviruses may be transmitted by direct contact withcontaminated humans, animals or materials. Diseases caused by poxvirusesinclude e.g. smallpox, monkeypox, molluscum conagiosum, vaccinia virusand orf virus infection.

Smallpox virus infection is highly fatal, and though it does not occurin nature anymore, smallpox virus is considered to be a potentialchemical or biological warfare agent. The threat of terrorism hascreated a need for efficient and improved methods for treatment and/orprevention of smallpox infection. The traditional vaccination forsmallpox, also applicable against monkeypox, has a rare but severe sideeffect due to vaccinia virus, which is the active constituent of thevaccine that eradicated smallpox. Vaccinia Immune Globulin (VIG) is theonly licensed therapeutic treatment for smallpox, but is highly variableand available in limited quantities Antibodies against smallpox havebeen developed, as described e.g. in U.S. Pat. No. 8,623,370 and USPatent publication US20140186370, the contents of each of which areherein incorporated by their reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused bysmallpox virus and/or other poxviruses.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat poxvirus.As a non-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 27 (SEQ ID NO: 6866-6875).

Enterovirus 71

Enterovirus 71 (EV71) belongs to the family of PicornaviridaeEnterovirus 71 is a single-stranded RNA positive sense virus. The virushas approximately 7411 nucleotides. The RNA genome is enclosed in anicosahedral capsid of structural proteins VP1-VP4. (see, e.g. Tan etal., 2014, J. Biomed Sci; 21(1):140, and references therein).

EV71 infections typically cause hand, foot and mouth (HFMD), which ischaracterized by fever, mouth ulcers, and vesicles on the palms of thehands and feet. Additionally, EV7 causes severe neurologicalmanifestations, including poliomyelitis-like acute flaccid paralysis,brainstem encephalitis in infants and children. These neurologicalmanifestations may be fatal, or cause permanent neurologicalconsequences, such as delayed neurodevelopment or reduced cognitivefunction in children. EV71 is transmitted through direct contact withcertain bodily fluids, such as saliva, or the respiratory route, or thefecal-to-mouth route. Outbreaks of EV71 have been reported by WHO in theUS, Europe, and more frequently in Asia-Pacific region in the past 30year.

As of today, no specific treatment or prevention therapy for EV71 is onthe market. Antiviral drugs, e.g. pleconaris and other capsid-functioninhibitors (see, e.g. Tan et al J Biomed Sci. 2014; 21(1): 140), may beprescribed against EV71 infections, though their effectiveness is notwell established. There remains a need for prevention and treatmenttherapies for EV71 infection. Antibodies neutralizing EV71 have beendeveloped. Non-limiting examples include the anti-EV71 antibody MAB979(developed by Merck Millipore) and those taught by Carderosa et al. inInternational Patent Publication WO2015092668, the contents of which areincorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byEV71.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat EV71. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 28 (SEQ ID NO: 6876-6891).

Rubella Virus

Rubella virus belongs to the family of Togaviridae. Rubella virus is apositive sense, single-stranded RNA virus with spike-like, hemagglutinincontaining surface projections. The virus core is enveloped byglycosylated E1 and E2 proteins.

Rubella, also known as German measles or three-day measles, is a viralinfection typically characterized by a rash, low fever, nausea, swollenlymph glands behind the ears and the neck, and mild conjunctivitis. Atlater stage, the infection may develop arthritis and pain in the joints.Typical symptoms of rubella infection are mild and affect children andyoung adults. Rubella virus is transmitted by the respiratory route andthe virus replicates in the nasopharyngeal mucosa and local lymph nodes.However, when an infection is acquired during pregnancy, the virus istransmitted through vertical route with 90% chance and may cause fetaldeath or congenital defects known as congenital rubella syndrome (CRS).Infants with CRS may have hearing impairments, eye and heart defects,diabetes mellitus, thyroid dysfunction and/or autism. According to theWHO, about 10,000 infants with CRS are born every year, majorityoccurring in countries with low vaccine coverage.

As of today, there is no specific treatment for rubella. Rubella may beprevented with vaccination, and rubella has been part of the vaccinationprogram for the past 40 years. However, the infection still persists andan increasing concern related to the life-time of vaccine efficiencyexists. There remains a need for long lasting prevention therapy, aswell as treatment for rubella virus infection. Antibodies againstrubella have been described e.g. in US Patent US20100143376, thecontents of each of which are herein incorporated by reference in theirentirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byrubella.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Rubella.As a non-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 29 (SEQ ID NO: 6892-6895).

Human Papilloma Virus

Human papilloma virus (HPV) is a non-enveloped double-stranded DNA virusbelonging to the family of Papillomaviridae. Over 170 types of HPV havebeen identified.

HPV infections may be asymptomatic, or cause infection related to warts(e.g. plantar, flat or anogenital warts), oral infections such aspapillomas or multifocal epithelial hyperplasia. The infection may beundetected, and clears from the body to low levels within two years.Infections caused by human papillomavirus (HPV) have been associatedwith certain cancers of stratified epithelial tissues, e.g. cervical,anal, vaginal, vulvar and penile cancers, lung and throat cancers.Especially HPV 16 and HPV 18 are known to be carcinogenic. According tothe WHO, persistent genital HPV infection may cause cervical cancerwhich is the second most common cancer in women worldwide. In developingcountries, cervical cancer counts for 13% of all female cancers, andsurvivor rate worldwide is approximately 50%. HPV is very common. CDCestimates that every one in four individuals in the US has an HPVinfection Most commonly HPV is transmitted by the sexual route, but alsothe vertical transmission route, or by direct contact to infected blood,or objects may occur.

Cancers caused by HPV may be prevented by vaccines developed againstcertain HPV types. The vaccines are available worldwide and arerecommended by CDC for all preteen aged children. As of today, there areno specific treatment for HPV infection. There remains a need forprevention and treatment therapy affecting a broad range of HPVinfections Antibodies for HPV have been developed, e.g. as described inInternational publication WO2015096269, the contents of each of whichare herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by HPV

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat HPV. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 30 (SEQ ID NO: 6896 and 6897).

Pseudomonas aeruginosa

Pseudomonas Aeruginosa (P. aeruginosa) is a common Gram-negative,aerobic, rod-shaped bacterium belonging to the family ofPseudomonodaceae. P. aeruginosa is found in soil, water, skin, flora,and in most man-made environments around the world P. aeruginosa isconsidered as an opportunistic pathogen taking advantage of a weakenedimmune system.

P. aeruginosa may cause a variety of mild infections, such as, urinarytract infections, respiratory, system infections, dermatitis, softtissue infections, bacteremia, bone and joint infections,gastrointestinal infections, blood infections, ear infections, skinrash, eye infections and a variety of systemic infections. P. aeruginosais transmitted through water, contaminated hands, materials or objects.In general, P. aeruginosa infections in healthy individuals are verymild or asymptomatic. However, the infections expose a significant riskfor individuals with weakened immunity, such as patients with otherunderlying illnesses or complications, and especially when in a hospitalenvironment. For example, patients with cystic fibrosis have asusceptibility towards loss of lung function due to respiratory tractinfection with the bacterium. Patients attached to breathing machines,patients with catheters, or with surgery wounds or burn wounds arepotentially at risk for serious and life-threatening infections. P.Aeruginosa infection may lead to a fatal sepsis. According to CDC,approximately 51,000 health-care associated infection occur in the USevery year, leading to approximately 400 deaths.

As of today, there are no prevention therapies for P. aeruginosainfection on the market. Some strains of P. aeruginosa may be treatedwith antibiotics, e.g. gentamicin, tobramycin, colistin, and amikacin.However, an increasing number of strains of P. aeruginosa, especiallythose affecting hospitalized patients, are resistant to antibiotics andno specific treatment therapy exists. There remains a need for improvedtreatment and prevention therapies against P. aeruginosa infections.Antibodies against P. aeruginosa have been developed, such as,panobacumab (developed by Kenta Biotech Inc.), which is an antibacterialantibody against P. aeruginosa.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by P.aeruginosa.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat P.aeruginosa. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Table 32 (SEQ ID NO: 6912-7196).

Streptococcus Bacteria

Streptococcus is a genus of gram-positive bacteria belonging to thefamily of Streptoccaceae. Species of Streptococcus are divided intoalpha- and beta-hemolytic species Alpha-hemolytic species causeoxidation of iron in hemoglobin molecules within the red blood cells.Alpha-hemolytic streptococci include e.g. Streptococcus pneumoniae andStreptococcus virilans. Beta-hemolytic species cause complete rupture ofthe red blood cells and include e.g Lancefield groups A and B, alsoknown as ‘group A strep’ and ‘group B strep’. Streptococcus genusincludes overall more than 50 species. Streptococcus bacteria cause avariety of infections in humans, including dental caries, pneumonia,endocarditis, meningitis, respiratory tract infections, urinary tractinfections, neonatal meningitis, pharyngitis and/or sepsis.

Streptococcus pneumoniae is a common bacterium causing, i.e. pneumonia,meningitis, bronchitis, acute sinusitis, conjunctivitis, osteomyelitis,endocarditis and/or septic arthritis. The bacteria is transmitted bydirect contact or via the respiratory route. The bacteria resides in thenasopharynx of healthy carriers and proceeds into an infection undercertain circumstances. The infection may be prevented by vaccines, e.g.conjugate vaccine or polysaccharide vaccines. The infection may betreated with antibiotics, e.g. broad-spectrum cephalosporin, andvancomycin, but there is a concern over increasing resistant towardsantibodies. According to CDC, Streptococcus pneumoniae is currentlyresistant to one or more antibiotics in 30% of infections. Streptococcuspneumoniae is resistant to e.g. penicillins. There remains a need forimproved, non-antibiotic, therapies for treatment of Streptococcuspneumoniae and other Streptococcus infections Antibodies forStreptococcus have been developed, as described e.g. in U.S. Pat. No.5,686,070 and US Patent publication US20070003561, the contents of eachof which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byStreptococcus pneumoniae and other Streptococcus bacteria.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treatStreptococcus pneumoniae. As a non-limiting example, the AAV particlesof the present invention comprise a nucleic acid sequence encoding atleast one of the sequences described in Table 33 (SEQ ID NO: 6900-6902,6905-6907, 6911, 7197-7229).

Staphylococcus Bacteria

Staphylococcus is a genus of gram-positive bacteria belonging to thefamily of Staphylococcacea. The genus includes overall approximately 40species. Most species of the genus are harmless and reside in the skinand mucous membranes of humans. Staphylococcus bacteria may also befound in the soil. The bacteria may cause diseases either through toxinproduction or penetration. Staphylococcal toxins are a common cause offood poisoning. Staphylococcus bacteria may cause a variety of diseases,e.g. localized or diffuse skin infection, gastroenteritis, earinfections, septic arthritis, osteomrnyelitis, sinusitis, infectiveendocarditis and/or toxic shock syndrome.

Staphylococcus aureus (S. aureus) is typically residing in human noseasymptotically. In certain circumstances. S. aureus infections mayaffect many tissues and organs. Individuals with chronic conditions,e.g. diabetes, cancer, vascular disease, eczema and lung disease, havean increased susceptibility towards S. aureus infections. S. aureus maycause skin infections, such as, pimples, impetigo, atopic dermatitis,cellulitis folliculitis. More serious forms of infections includepneumonia, meningitis, osteomyelitis and endocarditis. S. aureus mayalso cause food poisoning. In severe cases, S. aureus infection mayenter the blood stream causing bacteremia and/or sepsis. As of today,there is no medical therapy for prevention of the infection Some strainsof S. aureus may be treated with antibiotics. However, increasingresistance towards antibiotics is a concern. Currently severalantibiotic resistant forms of S aureus exist, including, but not limitedto, Methicillin-resistant Staphylococcus aureus (MRSA).Vanconmycin-intermediate Staphylococcus aureus (VISA) andVancomycin-resistant Staphylococcus aureus (VRSA) The drug resistantforms of S. aureus are more frequent in hospital environments.

Staphylococcus epidermidis (S. epidermidis) resides in the normal humanskin flora and may cause an infection to individuals with weakenedimmune system, and to individuals who have catheters, prostheses orsurgical implants. S. epidermidis has an ability to colonize on plasticmaterials or devices placed within the body. The infection may betreated with some antibiotics, but they do not remove the infection andcan only be used to manage such infections. Many S. epidermis strainsare resistant to antibiotics, such as penicillin, methicillin and/oramoxicillin, and increasing resistance to antibiotics in a concern.

There remains a need for prevention and/or improved treatment therapiesagainst Staphylococcal infections. Antibodies targeting Staphylococcalbacteria have been developed. As an example, pagadaximab (developed byMedimnunune and AstraZeneca) is a monoclonal antibody for prevention ofstaphylococcal sepsis and may be administered to infants with low birthweight.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byStaphylococcus bacteria.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treatStaphylococcal infections. As a non-limiting example, the AAV particlesof the present invention comprise a nucleic acid sequence encoding atleast one of the sequences described in Table 34 (SEQ ID NO: 7230-7478).

Clostridium tetani

Clostridium tetani (C. tetani) is a rod-shaped, anaerobic, Gram-positivebacteria belonging to the family of Clostridiaccae. A matured bacteriumdevelops a terminal spore, which is resistant to heat and commonantiseptics. C. tetani produces tetanospasmin toxin. C. tetani is foundas spores in soil and in the gastrointestinal tract of animals.

C. tetani infection spreads the tetanospamin toxin to the body, causingtetanus, also known as lock jaw. Tetanus is a dangerous diseasecharacterized by painful tightening of the muscles. The disease may leadto locking of the jaw and neck, leading to inability to open mouth orswallow. The tightening may affect the whole body. In severe cases, theinfection may lead to breathing difficulties, pneumonia, or pulmonaryembolism. Even more serious is an infection acquired during pregnancy,leading to almost always fatal neonatal tetanus of an infant. Thebacteria is typically transmitted through broken skin by direct contactwith contaminated soil or objects, or saliva or feces of a contaminatedanimal. Especially susceptible are individuals with burns, puncturewounds, crush injuries or injuries with dead tissue, individuals havinganimal bites or scratches. Tetanus is fairly uncommon in developedcountries. However, the WHO reported an estimated 50, 000 neonataltetanus deaths in year 2008. A program form elimination of tetanus wasstarted in 1989 by the WHO.

Tetanus may be prevented efficiently by a four vaccine combination,DTaP, Tdap, DT, and Td, given to children and adults. For adequateimmunity, the primary vaccine is adrministered during childhood, abooster dose during adolescence and every 10 years thereafter duringadulthood C. tetani infection may be treated with antibiotics, woundcare and with human tetanus immune globulin (an antitoxin) Despite theexisting treatment methods, approximately 10% of tetanus infections leadto death, according to CDC, There remains a need for longer lastingvaccine as well as improved treatment therapies against C. tetaniinfections. Antibodies against C. tetani have been developed, asdescribed e.g. by Larrick. J. W. et al., 1992, Immunol Rev. 130, 69-85,and de Krulf. J. et al., 2009, J. Mol Biol. 387 (3), 548-558, thecontents of each of which are herein incorporated by reference in theirentirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by C.tetani.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat C. tetani.As a non-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 35 (SEQ ID NO: 7479-7535).

Bordetella

Bordetella is a genus of Gram-negative, coccobacilli belonging to thefamily of Alcaliigenaceac. The structure of the bacteria consists of anouter membrane with lipopolysaccharides and phospholipids forming acapsule Bordetelia bacteria affecting humans include, but are notlimited to, B. pertussis, B. parapertussis and B. bronchiseptica, B.pertussis resides in the upper air pathways, mostly the trachea and thebronchii, of humans. B. parapertussis resides in the upper air pathwaysof mammals. The bacteria release toxins that cause damage and swellingof the respiratory pathways.

Pertussis, also known as whooping cough, is a highly contagiousinfection of the respiratory track caused most commonly by B. pertussis,and occasionally by B. parapertussis. Typical symptoms of the infectioninclude severe coughing and difficulty to breathe accompanied by a runnynose, apnea and fever. Additional complications for infants includepneumonia, convulsions, apnea, and encephalopathy. The bacteria aretransmitted through the respiratory tract route. The disease isespecially dangerous for infants According to CDC, about 30,0K00infections were reported in the US in 2014. CDC reports 277 deathsoccurring from 2000 through 2014, out of which 241 where infants lessthan 3 months of age.

Pertussis may be treated with antibiotics, such as, erythromycin,clarithromycin or azithromycin. However, an increasing resistance toantibiotics is a concern. Pertussis caused B. pertussis may be preventedby vaccination, e.g. by DTaP combination vaccine, which is recommendedroutinely for infants by CDC and WHO. Despite the widespreadvaccination, the disease has insisted. The protection provided by thetraditional vaccination is estimated to be 3-6 years. There remains aneed for prevention therapies providing a longer lasting immunity, aswell as for improved, non-antibiotic, treatments. Antibodies forprevention and/or treatment of pertussis have been developed, asdescribed e.g. in International publication WO2014160098, and Hussein,A. H et al, 2007, Infect. Immun. 75 (11), 5476-5482, the contents ofeach of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by B.pertussis, B. parapertussis and/or other Bordetella bacteria.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Bordetellainfection. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Table 36 (SEQ ID NO: 7536-7560).

Mycobacterium

Mycobacterium is a genus of nonmotile and aerobic bacteria, belonging toits own family of Myobacteriaceae. Mycobacteria have an outer membrane,and a hydrophobic and waxy cell wall with mycolic acid/mycolates. Thecell wall is neither truly Gram-positive nor—negative. In general, theinfections are difficult to treat and the bacteria is naturallyresistant to many antibiotics, e.g. penicillin, due to the cell wall.Mycobacteria includes species, such as, but not limited to, M.tuberculosis, Nontuberculous mycobacteria (NTM), M. leprae, M. bovis, M.africanum, and M. micron.

M. tuberculosis is a genetically diverse bacterium and most common anddangerous of the mycobacteria family species. M. tuberculosis causestuberculosis (TB) which is an infection mainly affecting the lungs.Typical early symptoms include cough, fever, night sweat, and weightloss. The disease may be mild for a period of time and therefore earlydiagnosis is difficult. Eventually the symptoms get more severe andcoughing sputum and blood may occur. TB may be transmitted by therespiratory tract. TB affects all ages of the population, but is mostdangerous to children, and individuals with weakened immune systems,e.g. HIV patients. According to the WHO, TB is referred to as a topinfectious disease killer worldwide. WHO reports an estimated 9.6million infections of TB in 2014, out of which 1.5 million cases werefatal. The disease is globally spread, but it is most abundant in theSouth-East Asia and Western Pacific Regions.

TB may be prevented by vaccinations, i.e. Bacille Clamette-Guerinvaccine. The vaccine is provided for children and adults exposed toenvironments with high risk of infection. However, the vaccine is notalways efficient against TB, e.g. due to the diversity of strainsgeographically. TB may be treated with a 6 to 9 month course ofcombinational antimicrobial drug therapy Antimicrobial drugs effectiveagainst TB include e.g. isoniazid, rifampin, ethambutol, andpyrazinamide. However, an increasing resistance towards the medicationis a concern. Certain strains of existing TB are identified asmulti-drug resistant TB strains, which do not respond to therapy withe.g. isoniazid, rifampicin, or other common drugs. WHO reports anestimated 480 000 multidrug-resistant TB infections in 2014. Thereremains a need for prevention therapies protecting against broadspectrum of strains, as well as for improved treatment of M.tuberculosis and/or other mycobacteria. Antibodies against mycobacteriahave been developed, as described e.g. in US Patent publicationsUS20130309237, US20130309237, US20600229438, the contents of each ofwhich are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by M.tuberculosis and/or other mycobacteria.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treatmycobacterium related diseases. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 37 (SEQ ID NO:7561-7576).

Francisella Tularensis

Francisella tularensis (F. tuliarensis) is a facultative intracellularGram-negative, rod-shaped bacterium belonging to the family ofFrancisellaceae. F. tularensis resides in invertebrates, birds,reptiles, fish, and mammals, including humans. It is one of the mostinfectious and pathogenic bacteria known (see, e.g. Pechous et al.,2009, Microbiol Mol Biol Rev.; 73(4): 684-711).

F. yularensis causes infection called Tularemia. Severity of tularemiavaries from mild to fatal. F. Tularensis may be transmitted to a humanby direct skin or eye contact, by the respiratory route or byconsumption of contaminated food or drink. Most commonly, the infectionis acquired while handling infected animals Most common form oftularemia is ulceroglandular tularemia, characterized by skin ulcers onthe site of infection accompanied by swelling or regional lymph glands.Ulceroglandular tularemia is typically acquire by a tick, or deer flybite. Pneumonic tularemia is an infection of the respiratory tractcharacterized by a cough, chest pain, and difficulty of breathing.Pneumonic tularemia is transmitted through the respiratory route and maybe fatal if not treated. Oropharyngeal tularemia is transmitted bycontaminated food or beverage and causes a sore throat, mouth ulcers,tonsillitis and swelling of lymph glands in the neck. Other forms oftularemia include glandular, oculoglandular (affecting the eyes) andtyphoidal (combination of the general symptoms). F. tularensis isconsidered to be a potential biological and chemical warfare agent.

As of today, there is not preventive therapy for tularemia infection onthe market. Some vaccines have been under development (see, e.g. Pechouset al., Microbiol Mol Biol Rev. 2009 December; 73(4): 684-711).Tularemia may be treated with antibiotics, such as, streptomycin,gentamicin, doxycycline, and ciprofloxacin. However, increasingresistance against antibiotics is a concern There remains a need forimproved prevention and treatment therapies for F. tularensisinfections. Antibodies against F. tularensis have been developed, e.g.as described by Rynkiewicz, M. J. et al., 2012, Biochemistry, 51 (28),5684-5694 and Lu. Z., et al., 2013. Immunology, 140 (3), 374-389, thecontents of each of which are herein incorporated by reference in theirentirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by F.tularensis.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat F.tularensis related infections. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 38 (SEQ ID NO:7577-7592).

Toxoplasma gondii

Toxoplasma gondii is a parasitic protozoan infecting warm-bloodedanimals, including humans. Domestic cats and other felines are the mostdesired hosts for Toxoplasma gondii, as they are the only hosts wherethe protozoan is capable of sexual reproduction. According to CDC, morethan 60 million people in the US may be infected by Toxoplasma gondii.

Toxoplasma gondii causes toxoplasmosis, which is typically asymptomaticin healthy individuals and is controlled by the natural immune system.The infection may be obtained from undercooked, contaminated food,especially pork, lamb and venison, from food contaminated by utensils,or contaminated hands, occasionally from contaminated drinking water, orby the fecal-to-oral route from cat feces. Toxoplasma gondii may also betransmitted by vertical route, especially when the protozoan is acquiredduring pregnancy. Children infected during or just prior to pregnancymay have eye problems, or brain damage at birth, or may develop symptomslater in their lives. Toxoplasmosis may be dangerous to individuals witha weakened immune system, such as patients with AIDS, undergoing certainchemotherapies or having organ transplants.

Toxoplasmosis may be treated with certain medications such asantibiotics called sulfadiazine and pyrimethamine, which is ananti-parasite medication used for e.g. malaria. However, resistance toboth of the medications is an increasing concern. There remains a needfor improved treatment methods as well as prevention therapies againstToxoplasma gondii infection. Antibodies targeting Toxoplasma gondii havebeen developed, as described by e.g. Graille, M. et al., 2005, J. Mol.Biol. 354 (2), 447-458, the contents of which are herein incorporated byreference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byToxoplasma gondii.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Toxoplasmagondii related infections. As a non-limiting example, the AAV particlesof the present invention comprise a nucleic acid sequence encoding atleast one of the sequences described in Table 40 (SEQ ID NO: 7617 and7618).

Candida Yeast

Typically, species of yeast are commensals and endosymbionts of humanhosts, but may cause an infection under certain circumstances. C.albicans is a yeast belonging to the family of Saccharomycetaceae C.albicans causes infection of the mouth characterized by white patches onthe tongue, mouth and throat. The infection of the mouth is most typicalwith new born babies, the elderly and individuals with weakened immunesystem, e.g. HIV/AIDS patients. Optionally, the infection may affect thenails, leading o brittle and defected nails. Optionally, the infectionmay cause an infection of the vagina, leading to genital burning oruncomfortable discharge. Typically, Candida albicans infections are mildand localized. However, the infection may be severe or fatal forindividuals with underlying health problems and left untreated. Invasivecandidiasis refers to an infection spreading to many parts of the body,including the heart, brain, eyes, bones and/or joints. Candidemia refersto an infection where candida yeast is present in the blood stream.Severe forms of C. albicans infections affect individuals in health careenvironments, e.g. patients with central venous catheter, patientstreated at an intensive care unit, patients undergoing antibiotictreatments, treatments for kidney failure, recovering from a surgery,and patients with chronic diseases, e.g. diabetes and/or HIV/AIDS. C.albicans is typically transmitted from mother to an infant duringchildbirth and it remains as a species of human's normal microflora. Itmay also be transmitted through the sexual transmission route. Otherspecies of candida yeast family include, e.g., C. glabrata, C.parapsilosis, C. tropicalis, C. krusei and C. lusitaniae.

C. albicans infection may be treated with antifungal drugs, e.g.nystatin, clotrimazole, amphotericin B oral suspension) or systemic oralazoles (e.g. fluconazole, itraconazole, or posaconazole). Despite themedical therapy available, some forms of C. albicans infections aredangerous, or life-threatening. There remains a need for improvedprevention, and/or treatment therapies against C. albicans infections,for example by antibody therapies. Efungumab (developed by NeuTecPharma) is an antibody for treatment of invasive C. albicans infection.

In some embodiment, methods of the present invention may be used toprevent and/or treat C. albicans infections.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat C.albicans related infections. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 41 (SEQ ID NO:7619).

Human Immunodeficiency Virus (HIV)

Human immunodeficiency virus (HIV) is a roughly spherical enveloped RNAvirus belonging to the family of Retroviridae. HIV is composed of twopositive single-stranded RNA copies. The viral core contains a viralcapsule protein, p24, which surrounds the two single stranded RNAs andthe enzymes for HIV replication. The viral envelope consists of twolipid layers, the outer layer glycoprotein 120 (gp 120) and thetransmembrane glycoprotein 41 (gp41). Gp 120 attached to the host cellwhereas gp41 has a role in the cell fusion process. For replication, thevirus needs a host cell and the RNA first transcribes into DNA by enzymereverse transcriptase. HIV infects the CD4 lymphocyte (T cell) leadingto depletion of CD4+ T cells and loss of CD4+ T-cell function, asinfected cell loses its function and converts to a HIV-replicating cell.(see, e.g. Okoye and Picker, 2013, Immunol Rev.; 254(1): 54-64, andreferences therein) Additionally, HIV infection leads to B lymphocyte (Bcell) hyper-activation and dysfunction (see, e.g. Moir and Fauci, 2009,Nat Rev Immunol.; 9(4): 235-245, and references therein). The virus maybe transmitted through sexual transmission route, vertical transmissionroute, iatrogenic (medical procedure) route, or in direct contact withcertain body fluids with high concentration of HIV, including e.g.blood, breast milk, semen, vaginal, and rectal secretions. Two types ofHIV (HIV-1 and HIV-2) have been identified. HIV-1 has higher infectivityand has spread around the globe whereas HIV-2 is more localized to WestAfrica According to CDC, there is about 36.9 million people in the worldwith HIV/AIDS with about 2 million cases arising every year. Theinfection is most abundant in Sub-Saharan Africa.

In acute HIV infection stage, within 2-4 weeks after infection, infectedpatients experience flu-like illness. In the second stage the infectionis asymptomatic and the HIV replication is at low level. The secondstage may last for years or decades, especially when treated with HIVmedication. Eventually, HIV causes acquired immune deficiency syndrome(AIDS), which is a clinical condition characterized by severeimmunosuppression attacking the CD4 cells, making individualssusceptible to life-threatening malignancies and infections.Complications associated with HIV/AIDS include common bacterial andviral infections, parasite infections, certain cancers (e.g. Kaposi'ssarcoma, Non-Hodgkin's lymphoma, and angiosarcoma), progressivemultifocal leukoencephalopathy (PML) and wasting.

As of today, there is no prevention therapy or cure for HIV/AIDS.However, with antiretroviral (ART) therapy, the disease may be managedfor a long period of time. ART therapy comprises of five classes ofdrugs used in different combinations to treat HIV. The drugs target thedifferent phases of the retrovirus life-cycle. However, there remains aneed for improved therapies for prevention, management and/or treatmentof HIV/AIDS.

Antibodies for treatment and prevention of HIV infection have beendeveloped. For example, commercial antibody Ibalizumab (developed byTaimed Biologics Inc.) is a non-immunosuppressive monoclonal antibodybinding to CD4, Anaplasma phagocytophilium inhibiting the viral entryprocess. As another example, suvizumab (developed by Kaktsuden,Chemo-Sero Therapeutic Research Institute) is a humanized antibodytargeting the HIV-1 envelope glycoprotein GP120. As a non-limitingexample, any of the antibodies in Table 42, variants or fragmentsthereof may be used in the treatment and/or prevention of HIV.

Antibodies neutralizing HIV-1 and HIV-1 strains have been identified,but as of today, the researchers have not been able to develop avaccination for HIV. HIV has a capability to evolve with unusually highsomatic mutation and recombination rate. So far, conventional vaccineshave not succeeded in eliciting analogues of the broadly neutralizingantibodies. An alternative approach suggested involves usingadeno-associated vectored gene delivery for expression of antibodiesfrom muscle tissue (e.g. Balasz et al, 2012. Nature Letter, 481, 81-84,Balasz et al. 2014, Nat Med.; 20(3): 296-300, Saunders et al., 2015, JVirol.; 89(16):8334-45, and US Patent publication US20030219733, thecontents of which are herein incorporated by reference in theirentirety). The studies have demonstrated efficient and long lastingprotection from HIV infection by e.g. intravenous or mucosal surfacetransmission.

AAV Particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat I-IVinfection and AIDS. As a non-limiting example, the AAV particles of thepresent invention comprise a nucleic acid sequence encoding at least oneof the sequences described in Table 42 (SEQ ID NO: 7620-9220).

Therapeutic Applications: Toxins

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat infectiousdisease. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Tables 14-17 (SEQ ID NO: 3549-3914).

Toxins are a group of substances that are highly poisonous and dangerousto humans. Toxins are infectious agents in form of bacteria, viruses,fungi, proteins, and other chemical and/or biological substances. Toxinsmay lead to fatal conditions Toxins are produced by nature, and may beproduced synthetically. Exposure to toxins may be unintentional andoccur when in contact with toxic plants, or contaminated food, water,livestock or animals. Due to the life-threatening impact of toxins, theyare considered to be potential biological and/or chemical warfare agentsthat may be applied as weapons of mass destruction in war field. Theyalso impose a threat to be used as means for terrorist attacks.

Ricin

Is a naturally occurring carbohydrate-binding lectin protein produced bycastor oil plant growing in Eastern Africa, India, SoutheasternMediterranean basin area, and in tropical regions. Ricin may also bemanufactured from the waste products when processing castor beans. Ricinhas a globular structure with two toxin chains, chain A and chain B,which both need to be present for the cytotoxic affect. Ricin killscells by inhibiting protein synthesis. Chain B penetrates to the cellwhereas the disulfide bond joining chain A to chain B lectin has anaffinity to bind to cell surface carbohydrates, (see, e.g. Friedman andRasooly, 2013, Toxins (Basel); 5(4): 743-775). Ricin is highly toxic tohumans with median lethal dose (LD₅₀) of 22 micrograms per kilogram ofbody weight. The exposure to Racin may be by inhaling, ingestion or byinjection. The symptoms are dependent of the method of exposure. Wheninhaled, ricing causes severe inflammation of the lungs, causing wouldhas symptoms including coughing, difficulty breathing, muscle ache andnausea. When ingested, ricin induces internal bleeding of the stomachand intestines leading to pain, vomiting and bloody diarrhea, andeventual failure of the kidneys, liver and spleen. When injected, ricininduces failure of the muscles and lymph nodes, and eventually failureof the liver, kidney and spleen. There is no known treatment for Ricinpoisoning.

Unintentional poisoning by Ricin is uncommon. However, Ricin is apotential biological and chemical warfare agent creating a need fortreatment and prevention therapies for ricin poisoning. Antibodiestargeting ricin have been developed, as described e.g. in Internationalpublication WO2015100409, the contents of which are herein incorporatedby reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byricin.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Ricinrelated infections and/or conditions. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 14 (SEQ ID NO:3549-3568).

Bacillus anthracis

Bacillus anthracis is a Gram-positive, rod-shaped bacterium causinganthrax disease (see, e.g. Spencer, 2003, J Clin Pathol.; 56(3):182-187, and references therein). Most animals, especially herbivores,are susceptible to infection of Bacillus anthracis. Anthrax may beinfected via respiratory exposure, skin contact or eating contaminatedfood, in most cases meat. Inhaled anthrax causes flu-like symptoms,pneumonia and severe respiratory collapse. Gastrointestinal anthraxcauses severe diarrhea, acute inflammation of the intestinal tract, andvomiting of blood. Skin exposure to the bacteria will lead to boil-likeskin lesions forming an ulcer with black center. Typically, infection tohumans occurs by eating contaminated meat or while handling infectedanimals or their product, such as skin, wool or meat. Bacillus anthracisis a potential biological warfare agent. In 2001, weeks following theSeptember 11 terrorist attacks, letters containing Bacillus anthraciswere mailed to news media offices and two U.S. Senators resulting indeath of five people and infected many more.

Anthrax may be treated with antibiotics, such as penicillin andamoxicillin, and may be prevented by vaccines, developed both for humansand animals. However, due to increased threat of biological warfare andterrorism, improved methods of treatment are in demand. Anthrax may alsobe treated by antibody therapy. For example. Raxibacumab (developed byCambridge Antibody Technology and Human Genome Sciences) is an antibodyfor the prophylaxis and treatment of inhaled anthrax.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byBacillus anthracis.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Bacillusanthracis related infections and/or conditions. As a non-limitingexample, the AAV particles of the present invention comprise a nucleicacid sequence encoding at least one of the sequences described in Table15 (SEQ ID NO: 3569-3813).

Shiga Toxin and Shiga-Like Toxin

Shiga toxin, including two major types Stx1 and Stx2, is a toxinproduced by Shigella dysenteriae, a rod-shaped bacteria belonging tobacterial genus Shigella. Shiga toxin inhibits protein synthesis withincells. The toxin enters cell via a marcopinosome and inhibits theprotein synthesis by cleaving a specific nucleobase RNA of the 60Ssubunit of ribosome. Shiga-like toxins 1 and 2 are structurally similarto Stx1 and Stx2 and are produced by enterohemorrhagic strains ofEscherichia coli (EHEC) strains. (see, e.g. Friedman and Rasooly, Toxins(Basel). 2013 April; 5(4): 743-775) EHEC type 0157 is the most commonpathogen causing E. Coli outbreaks in the US. Stx2 is considered to beorders of magnitude more toxic that Stx1. The severity of Shiga toxinfoodborne illnesses range from mild diarrhea to a life-threateningcomplication known as hemolytic uremic syndrome (HUS). HUS is a diseaseassociated with hemolytic anemia, acute kidney failure and low plateletcount. Cattle is the major source or infection to humans, but thedisease may be spread by birds or pigs. Shiga infection is typicallyobtained from contaminated food or drink, such as meat, unpasteurizedmilk, or contaminated water, or by contact with cattle Shiga toxin andShiga-like toxins considered to be potential chemical and biologicalwarfare agents.

As of today, there is no prevention therapy or specific treatment forShiga and Shiga-like toxins. Recent developments have been made inantibody therapy of Shiga toxin induced HUS. For example, SHIGAMAB®(developed by Bellus Health Inc.) is a monoclonal antibody for treatmentof Shiga toxin induced HUS.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byShigella dysenteriae.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Shigelladysenteriae related infections and/or conditions. As a non-limitingexample, the AAV particles of the present invention comprise a nucleicacid sequence encoding at least one of the sequences described in Table17 (SEQ ID NO: 3844-3914).

Botulinum Toxins

Botulinum toxins are neurotoxins produced by Clostridium bacteria andthey cause a disease called botulism which is characterized by weakness,problems in vision, tiredness, and problems with speech, followed byweakness of the arms, chest muscles and legs. Botulism may be fatal.There are seven different botulinum neurotoxins with a four-domainstructure varying in antigenic properties and interactions withintracellular targets. L-chain enters the cytosol, cleaves thesynaptosomal protein and blocks neurotransmitter release resulting inperipheral neuromuscular blockade and flaccid paralysis in humans. (see,e.g. Friedman and Rasooly. Toxins (Basel) 2013 April; 5(4): 743-775)Botulinum neurotoxins are highly dangerous to humans, serotype A havinga median lethal dose (LD₅₀) of 0.8 micrograms for a human of 70 kgweight. The bacteria is common in soil and water and may produce thebotulinum toxins when exposed to low oxygen levels and certaintemperatures. Outbreaks of foodborne botulism occur occasionally. Mostsusceptible to contamination by botulinum are baked products, freshmussels, canned fruit and vegetables. Infant botulism occurs when thetoxins are produced and released by bacteria in the infant's intestines.Botulism may also occur in wounds where the bacteria in the absence ofoxygen produces and releases the toxins. Wound botulism is most commonin cases where contaminated needles are used for injection. Botulinumtoxins are potential biological and chemical warfare agents.

As of today, there is no prevention therapy for botulism. Botulism maybe treated with antitoxins that block the circulation of toxins in theblood and prevent worsening of the disease. However, the antitoxins areexpensive and not easily available. In cases of wound botulism, the areainfected may be removed surgically. Additionally, good supportive caretherapy is applied There remains a need for therapies to prevent andtreat botulism. Antibodies targeting botulinum toxins are developed, asdescribed e.g. in US Patent publication US20130058962, and Internationalpublication WO2015100409, the contents of each of which are hereinincorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused bybotulinum toxins.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat botulinumtoxin related infections and/or conditions. As a non-limiting example,the AAV particles of the present invention comprise a nucleic acidsequence encoding at least one of the sequences described in Table 16(SEQ ID NO: 3814-3843).

Therapeutic Applications: Neglected Tropical Diseases (NTDs)

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat infectiousdisease. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Tables 10-13 (SEQ ID NO: 3327-3548).

Neglected Tropical diseases (NTDs) are a diverse category ofcommunicable diseases present in tropical and subtropical environments.NTDs affect more than one billion people in about 150 countries. NTDsare a significant public health problem costing the involved developingeconomies billions of dollars annually. The diseases affect mostly thepopulations with inadequate sanitation, and those in contact withinfectious vectors, domestic animals and livestock. In May 2013, the66^(th) WHO Assembly announced resolution WHA66.12 to integrate measuresand plan investments to improve the wellbeing of populations affected byNTDs. NTDs include Buruli ulcer, Chagas disease, Dengue and Chikungunya,Dracunculiasis (guinea-worm disease). Echinococcosis, Endemictreponematoses (Yaws), Foodborne trematodiases, Human Africantrypanosomiasis (sleeping sickness), Leishmaniasis, Leprosy (Hansendisease), Lymphatic filariasis, Onchocerciasis (river blindness),Rabies, Schistosomiasis. Soil-transmitted helminthiases,Taeniasis/Cysticercosis and Trachoma.

Chikungunya Virus

Chikungunya virus is an arbovirus belonging to the Togoviridae family.The genome is a single-strand RNA molecule encoding four non-structuraland three structural glycoproteins (C, E1, E2) (see, e.g. Caglioti etal., 2013, New Microbiol.; 36(3):211-27, and references therein).Chikungunya fever is a mosquito-borne disease caused by chikungunyavirus. The symptoms include a fever lasting 2-7 days, rash and flu-likesymptoms accompanied by a joint pain that may last for weeks, months oreven years. The disease may be dangerous for the elderly and individualswith chronic medical problems. Chikungunya virus is spread by Aedesalbopictus and Aedes aegypti. Outbreaks of chikungunya fever haveoccurred in Africa, Asia, Europe and Indian and Pacific Oceans, and morerecently in islands in the Caribbean. As an example, according to theWHO, an outbreak of 1.9 million cases in India, Indonesia, Maldives,Myanmar and Thailand since 2005 has been reported. More recently, as ofApril 2015 more than million cases have reported in Caribbean Islands.Latin American countries and the United States.

As of today, there is no specific treatment or vaccination forchikungunya fever. The disease is typically treated with supportive caretherapy, as well as anti-inflammatory drugs and medicines to relieve thesymptoms. Research and development on vaccinations has been done butnone has been approved for commercial use so far Antibodies fordetection and treatment of Chikungunya have been developed. E.g. fullyhuman antibodies binding to an epitope located in an antigenic site ofthe chikungunya virus E1 and E2 envelope proteins were in US PatentPublication US20130189279, the contents of each of which areincorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused bychikungunya virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treatchikungunya virus related infections and/or conditions. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 13 (SEQ ID NO: 3543-3548).

Dengue virus

Dengue virus belongs to the family of Flaviviridae, genus of Flavivirus.It is an enveloped, positive strand RNA virus containing two integralmembrane proteins envelope (E) and premembrane (prM) Dengue virus isclosely related to e.g. Yellow fever. West Nile virus and St. Louis andJapanese encephalitis viruses. There are five serotypes of the virusthat can cause dengue fever, which is a mosquito-borne tropical disease.Neutralizing antibodies target the protein E as it binds to the cellularreceptors and mediates the viral entry into cells Infection with aserotype may produce a lifelong immunity to that serotype but nolong-term immunity against other serotypes, (see e.g., Wahala and deSilva, 2011, Viruses.; 3(12): 2374-2395, and references therein). Infact, an infection by a second serotype may lead to a more severe formof disease, due to the complexity of the antibody respond and possibleantibody dependent enhancement (ADE), which hypothesizes that weaklyneutralizing antibodies from the first infection bind to the secondserotype and enhance the infection. The symptoms of dengue fever aresimilar to flu, including fever, headache, muscle and joint pain andskin rash. The disease may also manifest as a potentially lethalcomplication called severe dengue, also known as dengue hemorrhagicfever. The disease may be dangerous to individuals with chronicdiseases, such as diabetes or asthma, or children and the elderly.Dengue virus is spread by several mosquito species, out of which Aedesaegypti is the most common. Dengue may also be transmitted via infectedblood or organ donation or by the vertical transmission route. Accordingto the WHO, the estimated number of dengue infections annually could beas high as 390 million.

As of today, there is no specific treatment or prevention therapy fordengue fever. Antibodies targeting dengue virus have been developed. Asan example, antibodies neutralizing four serotypes of dengue virus havebeen in US Patent publication US20150225474. US20150218255 and in U.S.Pat. No. 9,073,981, the contents of each of which are incorporatedherein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused bydengue virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Denguevirus related infections and/or conditions. As a non-limiting example,the AAV particles of the present invention comprise a nucleic acidsequence encoding at least one of the sequences described in Table 10(SEQ ID NO: 3327-3449).

Trypanosoma cruzi

Trypanosoma cruzi (T. cruzi) is a species of parasitic euglenoidprotozoan. T. cruzi causes Chagas disease, also known as Americantrypanosomiasis, which is a tropical parasitic disease. The symptoms ofChagas disease at the early stage include fever, swollen lymph nodes,headaches or local swelling at the site of bite. The chronic phase ofChagas starts after 8-12 weeks, which may be symptomless, or includeenlargement of the ventricles of the heart, which may result in heartfailure, or to an enlarged esophagus or enlarged colon. The severity ofChagas disease varies from almost unnoticeable to fatal. Chagas diseaseis spread by an insect vector triatomine bug. These bugs get infectedwith T. cruzi by feeding on the blood of an infected human or animals,and they spread it further by bites and ingestion of blood. Thetriatomine bug is also known as a “kissing bug” referring to itstendency to feed on people's faces T. cruzi may also be transmittedthrough blood transfusions or through breast milk. Chagas disease ispresent mainly in 12 Latin American countries, but has also spread toother continents. According The WHO, over 10 000 people die every yearfrom Chagas disease, and 25 million people are in the risk of infection.

As of today, there is no specific prevention or treatment therapy forChagas disease. The traditional therapies for Chagas have been involvedwith attempts to kill the parasite and treatment of the symptoms. Forexample, azole and nitro-derivative drugs have been used, but have notbeen successful in removal of the parasite fully. Other mechanisms totreat the disease have been under research. After infection in mammals,the parasite incorporates a charged carbohydrate (sialic acid) tosurvive to the chronic phase of the disease. To do so, the parasitescavenged sialic acid it from the host's sialoglycococonjugates, througha transglycosylation reaction catalyzed by an enzyme calledtrans-sialidase. The trans-sialidase has been identified as a potentialtarget for drug development Buschiazzo et al. have reported an antibodyinhibiting the T. cruzi trans-sialidase enzyme providing an antibodytherapy mechanism for Chagas disease (see, Buschiazzo et al., 2012, PLoSPathol. 8 (1), E1002474, and references therein).

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byChagas disease.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Chagasdisease. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Table 12 (SEQ ID NO: 3541 and 3542).

Rabies Virus

Lyssaviruses are a genus of RNA viruses belonging to the family ofRhabdoviridae. Rabies virus is a neurotropic virus with cylindricalmorphology After infection, rabies virus enters the peripheral nervoussystem, and further to central nervous system by retrograde axonaltransport Rabies virus and Australian bat lyssavirus cause rabies Rabiesaffects humans and warm-blooded animals. The early stage symptomsinclude flu-like signs, but later the disease manifests as paralysis,anxiety, insomnia, abnormal behavior, hallucinations. Humans and animalsinfected may also experience hydrophobia, “fear of water”, which isconsidered a characteristic symptom of the disease Eventually thedisease affects the central nervous system and brain, causing death.Humans are typically infected by being bitten, scratched or licked by ananimal with the disease. Most commonly the infection is by dogs. Whereasefficient vaccination programs for animals have been able to reduce oreven eliminate rabies in developing countries, the disease still affectspoor population mainly in Africa and Asia. According to the WHO,post-bite treatment and vaccination is provided for 15 million peopleannually.

Rabies is a vaccine-preventable disease and especially systematicvaccination of dogs has been a cost-effective strategy for prevention ofrabies. Post-exposure prophylaxis (PEP), the treatment of bite victimsimmediately after the exposure, includes local treatment of the wound,rabies vaccination and administration of rabies immunoglobulin. Thoughefficient vaccines for rabies have been developed, there remains a needfor treatment/or management of rabies to prevent death after rabiesvirus has entered the central nervous system (see, e.g., Hicks et al.,2012, Clin Exp Immunol.; 169(3): 199-204, and references therein). Thegenome of rabies virus codes for five viral proteins. Out of the five. Gprotein, which is an external surface glycoprotein, forms protrusionsthat cover the outer surface of the virion envelope and is known toinduce neutralizing antibodies. Also, nucleoprotein (N) molecules andthe phospho-protein (NS) participate in immune responses. G protein hasbeen the target of antibody developments. For example, therapeuticantibodies against rabies virus are taught in U.S. Pat. Nos. 7,071,319,6,890,532, and 9,005,624, the contents of each of which are incorporatedherein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byrabies virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat rabiesvirus related infections and/or conditions. As a non-limiting example,the AAV particles of the present invention comprise a nucleic acidsequence encoding at least one of the sequences described in Table 11(SEQ ID NO: 3450-3540).

Therapeutic Applications: Tropical Diseases (TDs) and Vector-BorneDiseases

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat infectiousdisease. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Tables 10-13 (SEQ ID NO: 3327-3548).

Plasmodium falciparum

Plasmodium falciparum (P. falciparum) is a protozoan parasite belongingto Plasmodium parasite family. P. falciparum is the main cause ofmalaria and responsible for nearly all death cases in malaria. P.falciparum is released to the human bloodstream through mosquito saliva.The parasite has a high rate of replication and capability to alter. P.falciparum, among other Plasmodium parasites, cause malaria, which is amosquito borne tropical disease. The early stage symptoms include fever,headache, chills and vomiting. If not treated at the early stage,malaria can progress to a life-threatening condition involving multipleorgans, resulting in skin yellowing, seizures and coma. In children,malaria may cause severe anemia, respiratory distress in relation tometabolic acidosis, and/or cerebral malaria. The disease is especiallydangerous for young children, pregnant women and individuals withoutimmunity to the disease, such as travelers from non-malaria areas. Aninfection may develop a partial immunity, allowing the followinginfections to be asymptomatic According to the WHO, about half ofworld's population are at risk of malaria. Sub-Saharan Africa carriesthe highest density of malaria. In 2015, 88% of malaria cases and 90% ofmalaria deaths was in Sub-Saharan Africa Malaria is spread by femaleAnopheles mosquitos and caused by 5 different parasite species, out ofwhich Plasmodium falciparum is the most prevalent and responsible forthe severe cases of malaria.

Despite tremendous efforts, there is no commercial vaccination formalaria. Traditional treatment for malaria consists of antimalarialmedicine therapies, such as artemisinin-based combination therapies,which consists of artemisinin combined with antimalarial drugs such asamodiaquine, lumefantrine, mefloquine and sulfadoxine/pyrimethamine.However, drug resistance has been a serious challenge in malariatreatment. Currently resistance is common for all antimalarialmedications apart from artemisinin combination therapy. The cost ofartemisinin treatment is high and there remains a need for preventiontherapies and improved treatment against malaria.

Due to the polymorphic nature and high replication rate of P.falciparum, tolerance to malaria is achieved only after years ofrepeated infections Antibodies for prevention and treatment of malariahave been developed. For example, antibodies against P. falciparum aretaught in U.S. Pat. No. 7,811,569, in US Patent publicationUS20150197562 and in International Patent publication WO2014087007, thecontents of each of which are incorporated herein by reference in theirentirety. A need for mechanism to deliver constant, effectiveconcentration of malaria antibody for a long period is still in needStudies by Deal et al, demonstrate results on vectored immunoprophylaxisdelivery of malaria antibodies to mice (see. Deal et al. PNAS, 2014,111(34), 12528-12532).

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by P.falciparum.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat P.falciparum related infections and/or conditions. As a non-limitingexample, the AAV particles of the present invention comprise a nucleicacid sequence encoding at least one of the sequences described in Table18 (SEQ ID NO: 3915-3971).

Ebola Virus

Genus of Ebola virus includes five viruses. Zaire, Reston, Sudan. TaiForest and Bundibygvo Ebola viruses, is a negative-sense RNA virusbelonging to the family of filoviridae. The West Africa outbreak hasbeen associated with Zaire Ebola virus. The genome of Ebolavirus encodesseven genes. The glycoprotein GP gene encodes two distinct geneproducts: sGP which is a dimeric and secreted glycoprotein and lessabundant GP, which is a trimeric-virion attached, membrane embeddedenvelope glycoprotein and responsible for the virus attachment, fusionand entry during infection. Ebola virus disease is a hemorrhagic feverdisease caused. The early symptoms include fever, sore throat, muscularpain, followed by a diarrhea and rash. Eventually the disease willaffect the liver and kidney function, and cause internal bleeding. Thedisease is highly fatal, as about 50% infected individuals die. TheEbola virus is transmitted by direct contact with the blood and bodyfluids and tissues of an infected person or an animal, most commonly achimpanzee, gorilla, fruit bat, monkey, forest antelope and porcupine.The disease is also transmitted when handling dead bodies of infectedanimals or humans. Also, sexual transmittance of the disease has beensuggested. The WHO has reported more than 28 000 infections and 11 000deaths in Ebola virus disease outbreak in West Africa (2014-present),mainly affecting Guinea, Sierra Leone and Liberia.

As of today, there is no licensed treatment or prevention therapy provento neutralize the virus. Typically. Ebola virus disease is treated witha good supportive care. A variety of blood, immunological and drugtherapies are under investigation, as well as preventive vaccinesundergoing evaluations. However, a demand for effective therapies fortreatment and prevention of Ebola virus disease remain.

Viral surface of GP has been identified as a target for neutralizingantibodies. Antibodies targeting GP of Ebola virus have been taught,e.g. in International Patent publication WO2015127136 and Olal. D., etal., 2012. J. Virol. 86 (5), 2809-2816, the contents of each of whichare incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byEbola virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Ebolarelated infections and/or conditions. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 19 (SEQ ID NO:3972-4024).

Marburg Virus

Marburg virus belongs to the filoviridae family of viruses with coiled,toroid or branched structures with seven proteins. The structure ofMarburg virus is similar to Ebola virus, however, the involved antigensare different. The filoviruses express a single glycoprotein on theirsurface. The glycoprotein is responsible for the infection, as it isinvolved in the attachment and entry of the viruses causing infection.Marburg virus disease is a hemorrhaging fever disease caused by Marburgvirus. It is highly fatal disease and related to Ebola virus diseases.The early symptoms of the disease include severe headache and malaise.Severe hemorrhagic manifestations in later stages include bleeding frommultiple sites. The Marburg virus is transmitted by direct contact withthe blood and body fluids and tissues of infected persons or animals,most commonly fruit bats and monkeys. The disease is also transmittedwhen handling dead the bodies of infected animals or humans. Marburgvirus disease is uncommon, but outbreaks typically have a high rate offatality. According to the WHO, the death rate was as high 80% inoutbreaks of 1998-2000 in Democratic Republic of Congo and 2005 inAngola.

As of today, there is no preventive or treatment therapy for Marburgvirus disease. The current treatment methods include good supportivetreatment. The surface glycoprotein has been a target for development ofantibodies for Marburg disease vaccines and treatments. For example,International Patent publication WO02015127140, and US Patentpublication US20140356354, the contents of which are incorporated hereinby reference in their entirety, teach therapeutic antibodies thatrecognize glycoprotein of filoviruses for different strains of Marburg,as well as Ebola.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byMarburg virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Marburgrelated infections and/or conditions. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Tables 3-42 (SEQ IDNO: 2948-9220).

West Nile Virus

West Nile virus (WNV) is a positive-stranded RNA of the flavivirusgenome and member of the Japanese encephalitis serocomplex offlaviviruses. (see Throsby, M. J. Virol. 80 (14), 6982-6992 (2006)). Twolineages of the virus have been identified. The genome of the virusencodes a single polyprotein producing three structural proteins, capsidC, precursor membrane prM and envelope E as well as seven nonstructuralproteins. WNV causes mosquito-borne infections with a variety ofmanifestations. Tough about 80% of WNV infections are symptomless andnot harmful, in certain cases, the disease may lead to fatalneurological diseases. Infection of MNV may lead to a West Nile fever,which causes flu-like symptoms accompanied by high fever, headache,chills, excessive sweating, fatigue, weakness, swollen lymph nodes, andjoint pains Infection by MNV may also occur as cutaneous manifestations,including rashes that may include punctate erythematous, macular andpopular eruptions. West Nile infections may also affect the centralnervous system resulting in West Nile neuroinvasive diseases, includingmeningitis, encephalitis, meningoencephalitis and poliomyelitis-likesyndrome. These neuroinvasive forms of NWV infections occur in onlyabout 1% of infections, but they may be life-threatening. WNV iscommonly found in Africa. Europe, the Middle East. North America andWest Asia. WNV is typically transmitted to humans and other mammals bymosquitos and is maintained in nature in a cycle involving transmissionbetween birds and mosquitoes WNV is carried by different types ofmosquitos, dependent on geographical distribution. Transmission tohumans may also occur from birds, horses or other humans.

As of today, there is no specific treatment or prevention therapy forMNV infections. Current methods of treatment include good supportivecare. Due to severity of some of the manifestations, there remains aneed for such therapies. Envelope E has been a target of most antibodyrelated studies. Antibodies targeting M and the first non-structuralprotein have also been investigated. As an example. Thorsby et al, 2006,J. Virol. 80 (14), 6982-6992, the contents of which are incorporatedherein by reference in their entirety, teaches antibodies binding to Eand prM proteins. U.S. Pat. Nos. 8,663,950 and 7,527,973, the contentsof each of which are incorporated herein by reference in their entirety,teach antibodies binding to E protein of WNV.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by WestNile virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat West Nilevirus related infections and/or conditions. As a non-limiting example,the AAV particles of the present invention comprise a nucleic acidsequence encoding at least one of the sequences described in Table 20(SEQ ID NO: 3333, 3359, 3393, 3418, 3442, 4025-4137).

Yellow Fever Virus

Yellow fever virus is an enveloped RNA virus belonging to the Flavivirusfamily Yellow fever, also known as Yellow Jack. Yellow Plague or BronzeJohn, is a mosquito-borne viral hemorrhagic disease. In most cases, thesymptoms include fever, headache, chills, loss of appetite, nausea, andmuscle pain. In some occasions, the disease progresses to a second stagewhich includes fever accompanied by abdominal pains, liver damageresulting in jaundice, kidney problems and/or bleeding. The disease isspread primarily by Aedes and Haemogogus type mosquitos. The disease ismost typical in tropical environments. According to the WHO, there are200 000 annual cases of yellow fever resulting in 30 000 deaths mainlyin Africa and Latin America, 90% of cases occur in Africa.

Preventive live-attenuated vaccines for yellow fever are available.However, concern related to post-vaccine adverse events has decreasedthe popularity of the vaccines. The vaccination is not recommended toinfants younger than 9 months, pregnant women and individuals with animmune deficiency. As of today, there is no specific treatment foryellow fever. Current methods for treatment involve with supportive careto treat dehydration, respiratory failure and fever There is a need forimproved prevention and treatment therapies against yellow fever virus.

Envelope E glycoprotein of yellow fever virus has been identified as apotential target for antibody therapies. Neutralizing antibodies foryellow fever virus have been reported by Thibodeaux, B. A. et al, 2012,Antiviral Res. 94 (1), 1-8 and Daffis, S. et al., 2005, Virology, 337(2), 262-272, the contents of each of which are incorporated herein byreference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byyellow fever virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat yellowfever virus related infections and/or conditions. As a non-limitingexample, the AAV particles of the present invention comprise a nucleicacid sequence encoding at least one of the sequences described in Table20 (SEQ ID NO: 3333, 3359, 3393, 3418, 3442, 4025-4137)

Japanese Encephalitis Virus

Japanese encephalitis virus is an enveloped positive sensesingle-stranded RNA virus belonging to Flavivirus family and closelyrelated to St. Louis encephalitis and West Nile virus. The virus causesJapanese encephalitis, also known as Japanese B encephalitis. Inmajority of cases, the disease is symptomless. However, in less than 1%of infections, the disease leads to a life-threatening encephalitis. Theearly stage symptoms include fever, headache and malaise. As the diseaseprogresses into an acute encephalitis, the symptoms include neckrigidity, cachexia, hemiparesis, convulsions and fever, accompanied bylifelong neurological problems such as deafness, and/or mentalretardation. The disease is transmitted to humans via mosquitos of theCulex species. The virus exists in a transmission cycle betweenmosquitos, pigs, and water birds. The disease affects 24 countries inthe South-East Asia and Western Pacific. According to the WHO, anestimated 68 000 clinical cases are reported annually, withcase-fatality rate as high as 30%. Major outbreaks of the disease occurevery 2-15 years.

The disease may be prevented by a vaccination, most common vaccinationbeing a live attenuated vaccine. In general, the vaccines initially showhigh effectiveness, but the protection decreases over time. As of today,there is no specific treatment for the disease. Current treatmenttherapies include good supportive care. There remains a need for longerlasting, improved prevention therapies, and treatment for Japaneseencephalitis virus infections.

Antibodies for treatment of Japanese encephalitis have been developed.For example, Hsieh et al, teach antibodies that target cellularreceptors and interrupts their function in flavivirus infections in USPatent publication US20080292644, the contents of which are incorporatedherein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byJapanese encephalitis virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Japaneseencephalitis virus related infections and/or conditions. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 20 (SEQ ID NO: 3333, 3359, 3393, 3418, 3442,4025-4137).

St. Louis Encephalitis Virus

St. Louis encephalitis virus is a positive-stranded RNA virus and memberof the Flavivirus family and closely related to Japanese encephalitisvirus St Louis encephalitis is a mosquito-borne disease caused by thevirus. In majority of cases, the disease is symptomless. However, inless than 1% of the cases, the disease may lead to encephalitis, whichmay be life-threatening, especially for the elderly. The early stagesymptoms include fever, headache, dizziness, malaise and nausea. If thedisease progresses to the central nervous system, symptoms include stiffneck, confusion, disorientation, dizziness, tremor and unsteadiness, andin severe cases coma or even death. St. Louis encephalitis virus istransmitted to humans through Culex mosquitos. The virus exists in atransmission cycle between mosquitos and birds. The disease mainlyaffects the USA, especially eastern and central states. The disease hasalso spread to Canada and Mexico.

As of today, there is no vaccine or specific treatment for St. Louisencephalitis. Current treatment therapies include good supportive care.There is a demand for preventive and treatment therapies for thedisease. Neutralizing antibodies for St. Louis encephalitis virus havebeen reported in Thibodeaux, B. A. et al, 2012, Antiviral Res 94 (1),1-8 and Daffis, S. et al., 2005, Virology 337 (2), 262-272, the contentsof which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by St.Louis encephalitis virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat St. Louisencephalitis virus related infections and/or conditions. As anon-limiting example, the AAV particles of the present inventioncomprise a nucleic acid sequence encoding at least one of the sequencesdescribed in Table 20 (SEQ ID NO: 3333, 3359, 3393, 3418, 3442,4025-4137).

Therapeutic Application: Foodborne Illness and Gastroenteritis

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat infectiousdisease. As a non-limiting example, the AAV particles of the presentinvention comprise a nucleic acid sequence encoding at least one of thesequences described in Tables 3-9 (SEQ ID NO: 2948-3326).

Foodborne illnesses, also known as food poisoning, are a common andcostly public health problem. The illnesses are typically transmitted bythe fecal-oral-route. The transmission to humans is by consumingcontaminated food or beverage More than 250 different foodbornediseases, mostly infections caused by viruses, bacteria, parasites orfungus, are identified by the CDC, CDC estimates that approximately 48million individuals are affected by foodborne illnesses annually in theUnited States. Gastroenteritis is an inflammation of thegastrointestinal tract involving stomach and small intestine.Gastroenteritis is also caused by an infection caused by viruses,bacteria, parasites or fungus. The transmission to humans is byperson-to-person contact, or by consuming contaminated food or beverage.Foodborne illnesses and gastroenteritis have similar symptoms includingdiarrhea, vomiting, abdominal pain, dehydration. In some cases, thediseases may require hospitalization or be fatal. Both illnesses arebest prevented by proper hand hygiene, proper hygiene while preparingfood, treatments to kill bacteria such as pasteurizing, cooking orheating food, and proper methods to store food.

Rotavirus

Rotavirus is a double-stranded RNA virus belonging to the family ofReoviridae. The rotavirus genome consists of 10 segments coding for asingle protein, and segment 11 coding for two proteins. The virions arenon-enveloped, triple-layered and icosahedral in structure (see, e.g.Aiyegbo et al., 2013, Plos One 8, 61101, and references therein). Thevirus is spread by the fecal-oral-route. Rotavirus is very commonespecially among infants and young children and spreads easily. Almostall children worldwide are infected with rotavirus by the age of 5, andthe disease leads to death of half a million children annually.Rotavirus causes rotavirus gastroenteritis with symptoms includingnausea, vomiting, diarrhea and fever. Rotavirus is associated withdehydration. The disease is milder in adults and more severe in youngchildren, infants and the elderly. Though infection does not providefull immunity to the virus, the first infection is typically the mostsevere in symptoms.

As of today, there is no specific treatment rotavirus infections.Present treatment includes good supportive care including drinking offluids to prevent dehydration. In severe cases, the rotavirusgastroenteritis requires hospital care e.g. treatment with intravenousfluids. Vaccines for prevention of the disease have been developed andCDC recommends rotavirus vaccination for infants as part of the routinevaccinations There remains a need for medical treatment therapies forthe infection. Development has been done in the field of antibodies.E.g. Aiyegbo et al., in Plos One 8, 61101 (2013, teach antibodiestargeting the intermediate capsid layer of VP6 of the triple-layeredparticle and Frenken et al, teach anti-rotavirus antibodies in U.S. Pat.No. 8,105,592, the contents of which are incorporated herein byreference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byrotavirus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat rotavirusrelated infections and/or conditions. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 8 (SEQ ID NO:3286-3310).

Norwalk Virus/Norovirus

Norwalk virus, also known as winter vomiting bug, is the only member ofgenus norovirus belonging to the family of Caliciviridae Norwalk virusis a single-stranded RNA with three open-reading frames that encode apolyprotein precursor to non-structural proteins, and two polypeptidesof different sizes (see e.g. Jiang et al., 1993, Virology; 195(1):51-61,and references therein) Norwalk virus is spread by the fecal-oral-routeNorwalk virus is extremely contagious and can be transmitted throughcontaminated food or drink, touching contaminated surfaces or objects orfrom a contact with an infected individual. The Norwalk virus causes aninflammation of stomach and/or intestines. The symptoms associated withthe infection include stomach pain, nausea, vomiting and diarrhea. Thedisease can be dangerous, especially for your children or young adults.According to CDC, every year 19-21 million infections occur leading to570-800 deaths in the US.

As of today, there is no vaccine or specific treatment for Norwalk virusassociated gastroenteritis. Antibodies for prevention and treatment ofNorwalk virus have been developed. For example, International Patentpublication WO2014126921 and WO2014183052, the contents of each of whichare incorporated herein by reference in their entirety, teachneutralizing antibodies binding to the polypeptides of Norwalk virus.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byNorwalk virus.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat Norwalkvirus related infections and/or conditions. As a non-limiting example,the AAV particles of the present invention comprise a nucleic acidsequence encoding at least one of the sequences described in Table 7(SEQ ID NO. 3238-3285).

Campylobacter jejuni

Campylobacter jejuni (C. jejuni) is an oxidase-positive,catalase-positive, nonfermentative Gram-negative bacteria with a helicalshape. The C. jejuni inhabits in the intestinal tract of animals (e.g.poultry, cattle, pigs, sheep, ostriches and shellfish), and in pets(e.g. cats and dogs). The bacteria may be transmitted to humansfoodborne, e.g, when eating contaminated food or drink, such asunpasteurized milk. According to the WHO, campylobacter is the mostcommon cause of gastroenteritis worldwide C. jejuni causescampylobacteriosis infection. The typical symptoms include diarrhea withblood in the feces, abdominal pain, fever, headache, nausea and/orvomiting. The infection may be dangerous to young children, the elderlyand individuals with immunodeficiency and is most abundant withmalnourished children. C. jejuni infections have been associated withsevere long-term complications such as Guillain-Barre Syndrome,inflammatory bowel disease and reactive arthritis (see, e.g.,Platts-Mills and Kosek, 2014, Curr Opin Infect Dis; 27(5): 444-450, andreferences therein).

Typically, C. jejuni infection does not require specific treatment inaddition to good supportive care. In more severe cases, in humans and inpoultry, the infection has been treated with antibiotics such asfluoroquinoles and macrolides. However, spread of antibiotic-resistantstrains is an increasing concern. The treatment with antibiotics isrecommended in cases where the bacteria has invaded the intestinalmucosa cell and damaged the tissues, or to eliminate the carrier state.There remains a need for prevention therapies, as well as improved,non-antibiotic, therapies for treatment of the infection Antibodiestargeting C. jejuni have been taught e.g. in International Patentpublication WO2014063253, the contents of which are incorporated hereinby reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by C.jejuni.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat C. jejunirelated infections and/or conditions. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 4 (SEQ ID NO:3089-3098).

Clostridium difficile

Clostridium difficile bacteria (C. difficile) is a Gram-positive,anaerobic spore-forming bacteria belonging to the genus of Clostridium.C. difficile inhabits in the soil. C. difficile produces toxins, mostcommonly enterotoxin A and cytotoxin B. Toxins A and B both have aC-terminal receptor-binding domain containing repeating sequences, acentral hydrophobic domain and N-terminal glucosyltranferase domain. Thetoxins bind to the intestinal epithelial cells leading to glucosylationof target Rho GTPases, disruption of the cytoskeleton and cell death. C.difficile toxins A and B are a common cause C. difficile associateddiarrhea and Clostridium difficile colitis, which is an inflammation ofthe large intestine. Typical symptoms of the colitis include flu-likesymptoms, bloating, diarrhea, and/or abdominal pain. The disease maylead to dehydration, kidney failure, bowel perforation, toxic megacolonresulting in colon rupture. The elderly and individuals with a weakenedimmunity are more susceptible to severe and recurring infections whichcan be life-threatening. C. difficile is transmitted by thefecal-oral-route. Due to the ability to form heat-resistant spores, thebacteria is not killed by alcohol-based cleansers or routine surfacecleaning. The bacteria may be cultured on almost any surface andsurvives in clinical environments, such as hospitals. C. difficile isone of the most common and severe healthcare-associated infections.According to CDC, an estimated about half a million infections occur inthe United States annually. In 2011, 29, 000 deaths related to C.difficile were reported.

Currently C. difficile infections are treated with antibiotics such asvanconmycin and metronidazole. However, increasing anantibiotic-resistance to the bacteria is a concern. Especially in casesof recurring infections, antibiotic treatments have an incompleteresponse and they disrupt the normal colonic flora. There remains a needfor prevention and improved treatment therapies for the infection.Antibodies targeting C. difficile have been developed. For example,actoxumab and bezlotoxumab (developed by Medarex Inc and the Universityof Massachusetts Medical School) are human monoclonal antibodiestargeting C. difficile toxin A and toxin B, respectively. The antibodiesmay be administered as a combination for the prevention of recurring C.difficile infection.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by C.difficile.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat C.difficile related infections and/or conditions. As a non-limitingexample, the AAV particles of the present invention comprise a nucleicacid sequence encoding at least one of the sequences described in Table3 (SEQ ID NO: 2948-3088).

Entamoeba histolytica

Entamoeba histolytica (E. histolytica) is an anaerobic one-celledparasite protozoan belonging to the genus of Entamoeba. The active stageof the protozoan exists only in the host and in fresh feces. Cystssurvive outside the host in water, soil and food in moist conditions. E.histolytica causes an infection called amebiasis, also known asameobiasis or entamoebiasis. In majority of cases, amebiasis issymptomless. In 10-20% of individuals infected have symptoms thatinclude loose feces, stomach pain and cramping. The severe more form ofamebiasis called amebic dysentery is associated with stomach pain, bloodstools and fever. In rare cases. E. histolytica invades the liver, formsan abscess and may spread to other parts of the body, such as the lungsor brain. The transmission to humans is mostly via the fecal-oral-route.The disease is typically caused by ingestion of mature cysts incontaminated food, water or via hands. The disease may also betransmitted in close person-to-person contact, e.g. sexual contact. E.histolytica infections are most common in tropical areas and especiallyin poor sanitary conditions. It is estimated that 50 million cases ofamebiasis occur annually, leading to 100, 000 deaths.

As of today, there are no preventive vaccines for E. histolyticainfections, though cellular immunity is important for the prevention ofliver invasive amebiasis. Amebiasis is typically treated withamebicides, which are medicines targeting E. histolytica at specificparts of the body, e.g. the intestine tissue or liver. Optionally, thetreatment may involve one or more antibiotics, as well as steroids.However, increasing antibiotic-resistance of E. histolytica is aconcern. There remains a need for prevention therapy as well as forimproved treatments. Antibodies targeting E. histolytica are taught in,e.g., 2009, Infect. Immun.; 77(1): 549-556, and Tachibana et al., 1999,Clin Diagn Lab Immunol.; 6(3):383-7, the contents of which areincorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by E.histolytica.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat E.histolytica related infections and/or conditions. As a non-limitingexample, the AAV particles of the present invention comprise a nucleicacid sequence encoding at least one of the sequences described in Table9 (SEQ ID NO: 3311-3326).

Helicobacter pylori

Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shapedmicroaerophilic bacterium. H. pylori infection is typically asymptomaticand is suggested to be transmitted through the fecal-oral route ororal-oral route. According to CDC, two-thirds of the world's populationis infected with H. pylori. The infection may cause chronic active,chronic, persistent, and atrophic gastritis, duodenal and gastric ulcersand is associated with cancer. CDC reposts 25 million Americanssuffering from an ulcer during their lifetime. Typical symptomsassociated with ulcer are gnawing or burning pain in the epigastrium,especially between meals. Additional symptoms include nausea, vomiting,loss of appetite, internal bleeding leading to anemia and fatigue.

Typical treatment for H. pylori infection involves antibiotics.Increasing antibiotic resistance and patient noncompliance are majorchallenges associated with the antibiotic treatment. There remains aneed for improved, non-antibiotic, treatment and prevention therapiestargeting H. pylori. Antibodies targeting H. pylori infection have beendeveloped. For example. Boren et al, teach antibodies targeting the BAbAantigen expressed by H. pylori in US patent U.S. Pat. No. 8,025,880, thecontents of which are incorporated herein by reference in theirentirety.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused by H.pylori.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treat H. pylorirelated infections and/or conditions. As a non-limiting example, the AAVparticles of the present invention comprise a nucleic acid sequenceencoding at least one of the sequences described in Table 5 (SEQ ID NO:3099-3196).

Enterotoxin B

Enterotoxin B is a toxin produced by certain strains of Gram-positivebacteria Staphylococcus aureus and is a common cause for food poisoning.Staphylococcus species thrive and produce toxins in unrefrigeratedmeats, dairy, and bakery products. The symptoms associated withenterotoxin B infection are severe diarrhea, nausea and intestinalcramping. The toxin may remain active in the human body after thebacteria has been killed. Enterotoxin B is a so-called superantigen.Superantigens are toxins that may activate T cells by forming a bridgebetween a MHC II on antigen presenting cells (APCs) and the T cellreceptors (TCR). Due to binding of enterotoxin B, the T cells releaselarge amount of cytokines leading to an inflammation andgastroenteritis. Though enterotoxin B infection is typically not lifethreatening, enterotoxin B has been identified as a potential chemicaland biological warfare agent.

As of today, there is no specific prevention or treatment forenterotoxin B infection. Antibodies that neutralize enterotoxin B havebeen investigated, e.g. as described in U.S. Pat. No. 8,895,704.

In some embodiment, methods of the present invention may be used toprevent, manage and/or treat infections and complications caused byenterotoxin B.

AAV particles and methods of using the AAV particles described in thepresent invention may be used to prevent, manage and/or treatenterotoxin B related infections and/or conditions. As a non-limitingexample, the AAV particles of the present invention comprise a nucleicacid sequence encoding at least one of the sequences described in Table5 (SEQ ID NO: 3099-3196).

V. Kits and Devices Kits

In one embodiment, the invention provides a variety of kits forconveniently and/or effectively carrying out methods of the presentinvention. Typically, kits will comprise sufficient amounts and/ornumbers of components to allow a user to perform multiple treatments ofa subject(s) and/or to perform multiple experiments.

Any of the AAV particles of the present invention may be comprised in akit. In some embodiments, kits may further include reagents and/orinstructions for creating and/or synthesizing compounds and/orcompositions of the present invention. In some embodiments, kits mayalso include one or more buffers. In some embodiments, kits of theinvention may include components for making protein or nucleic acidarrays or libraries and thus, may include, for example, solid supports.

In some embodiments, kit components may be packaged either in aqueousmedia or in lyophilized form. The container means of the kits willgenerally include at least one vial, test tube, flask, bottle, syringeor other container means, into which a component may be placed, andpreferably, suitably aliquoted. Where there is more than one kitcomponent. (labeling reagent and label may be packaged together), kitsmay also generally contain second, third or other additional containersinto which additional components may be separately placed. In someembodiments, kits may also comprise second container means forcontaining sterile, pharmaceutically acceptable buffers and/or otherdiluents. In some embodiments, various combinations of components may becomprised in one or more vial. Kits of the present invention may alsotypically include means for containing compounds and/or compositions ofthe present invention, e.g., proteins, nucleic acids, and any otherreagent containers in close confinement for commercial sale. Suchcontainers may include injection or blow-molded plastic containers intowhich desired vials are retained.

In some embodiments, kit components are provided in one and/or moreliquid solutions. In some embodiments, liquid solutions are aqueoussolutions, with sterile aqueous solutions being particularly preferred.In some embodiments, kit components may be provided as dried powder(s).When reagents and/or components are provided as dry powders, suchpowders may be reconstituted by the addition of suitable volumes ofsolvent. In some embodiments, it is envisioned that solvents may also beprovided in another container means. In some embodiments, labeling dyesare provided as dried powders. In some embodiments, it is contemplatedthat 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 120, 130, 140, 150,160, 170, 180, 190, 200, 300, 400, 500, 600, 700, 800, 900, 1000micrograms or at least or at most those amounts of dried dye areprovided in kits of the invention. In such embodiments, dye may then beresuspended in any suitable solvent, such as DMSO.

In some embodiments, kits may include instructions for employing kitcomponents as well the use of any other reagent not included in the kit.Instructions may include variations that may be implemented.

Devices

In one embodiment, the AAV particles may delivered to a subject using adevice to deliver the AAV particles and a head fixation assembly. Thehead fixation assembly may be, but is not limited to, any of the headfixation assemblies sold by MRI interventions. As a non-limitingexample, the head fixation assembly may be any of the assembliesdescribed in U.S. Pat. Nos. 8,099,150, 8,548,569 and 9,031,636 andInternational Patent Publication Nos. WO201108495 and WO2014014585, thecontents of each of which are incorporated by reference in theirentireties. A head fixation assembly may be used in combination with anMRI compatible drill such as, but not limited to, the MRI compatibledrills described in International Patent Publication No. WO2013181008and US Patent Publication No US20130325012, the contents of which areherein incorporated by reference in its entirety.

In one embodiment, the AAV particles may be delivered using a method,system and/or computer program for positioning apparatus to a targetpoint on a subject to deliver the AAV particles. As a non-limitingexample, the method, system and/or computer program may be the methods,systems and/or computer programs described in U.S. Pat. No. 8,340,743,the contents of which are herein incorporated by reference in itsentirety. The method may include: determining a target point in the bodyand a reference point, wherein the target point and the reference pointdefine a planned trajectory line (PTL) extending through each;determining a visualization plane, wherein the PTL intersects thevisualization plane at a sighting point; mounting the guide devicerelative to the body to move with respect to the PTL, wherein the guidedevice does not intersect the visualization plane; determining a pointof intersection (GPP) between the guide axis and the visualizationplane; and aligning the GPP with the sighting point in the visualizationplane.

In one embodiment, the AAV particles may be delivered using anMRI-guided device Non-limiting examples of MRI-guided devices aredescribed in U.S. Pat. Nos. 9,055,884, 9,042,958, 8,886,288, 8,768,433,8,396,532, 8,369,930, 8,374,677 and 8,175,677 and US Patent ApplicationNo. US20140024927 the contents of each of which are herein incorporatedby reference in their entireties. As a non-limiting example, theMRI-guided device may be able to provide data in real time such as thosedescribed in U.S. Pat. Nos. 8,886,288 and 8,768,433, the contents ofeach of which is herein incorporated by reference in its entirety. Asanother non-limiting example, the MRI-guided device or system may beused with a targeting cannula such as the systems described in U.S. Pat.Nos. 8,175,677 and 8,374,677, the contents of each of which are hereinincorporated by reference in their entireties. As yet anothernon-limiting example, the MRI-guided device includes a trajectory guideframe for guiding an interventional device as described, for example, inU.S. Pat. No. 9,055,884 and US Patent Application No. US20140024927, thecontents of each of which are herein incorporated by reference in theirentireties.

In one embodiment, the AAV particles may be delivered using anMRI-compatible tip assembly. Non-limiting examples of MRI-compatible tipassemblies are described in US Patent Publication No. US20140275980, thecontents of which is herein incorporated by reference in its entirety.

In one embodiment, the AAV particles may be delivered using a cannulawhich is MRI-compatible. Non-limiting examples of MRI-compatiblecannulas include those taught in International Patent Publication No.WO2011130107, the contents of which are herein incorporated by referencein its entirety.

In one embodiment, the AAV particles may be delivered using a catheterwhich is MRI-compatible. Non-limiting examples of MRI-compatiblecatheters include those taught in International Patent Publication No.WO02012116265, U.S. Pat. No. 8,825,133 and US Patent Publication No.US20140024909, the contents of each of which are herein incorporated byreference in their entireties.

In one embodiment, the AAV particles may be delivered using a devicewith an elongated tubular body and a diaphragm as described in US PatentPublication Nos US20140276582 and US20140276614, the contents of each ofwhich are herein incorporated by reference in their entireties.

In one embodiment, the AAV particles may be delivered using an MRIcompatible localization and/or guidance system such as, but not limitedto, those described in US Patent Publication Nos. US20150223905 andUS20150230871, the contents of each of which are herein incorporated byreference in their entireties. As a non-limiting example, the MRIcompatible localization and/or guidance systems may comprise a mountadapted for fixation to a patient, a targeting cannula with a lumenconfigured to attach to the mount so as to be able to controllablytranslate in at least three dimensions, and an elongate probe configuredto snugly advance via slide and retract in the targeting cannula lumen,the elongate probe comprising at least one of a stimulation or recordingelectrode.

In one embodiment, the AAV particles may be delivered to a subject usinga trajectory frame as described in US Patent Publication Nos.US20150031982 and US20140066750 and International Patent PublicationNos. WO2015057807 and WO2014039481, the contents of each of which areherein incorporated by reference in their entireties.

In one embodiment, the AAV particles may be delivered to a subject usinga gene gun.

VI. Definitions

At various places in the present specification, substituents ofcompounds of the present disclosure are disclosed in groups or inranges. It is specifically intended that the present disclosure includeeach and every individual subcombination of the members of such groupsand ranges.

About: As used herein, the term “about” means+/−10% of the recitedvalue.

Adeno-associated virus. The term “adeno-associated virus” or “AAV” asused herein refers to members of the dependovirus genus comprising anyparticle, sequence, gene, protein, or component derived therefrom.

AAV Particle: As used herein, an “AAV particle” is a virus whichcomprises a viral genome with at least one payload region and at leastone ITR region, AAV vectors of the present disclosure may be producedrecombinantly and may be based on adeno-associated virus (AAV) parent orreference sequences, AAV particle may be derived from any serotype,described herein or known in the art, including combinations ofserotypes (i.e., “pseudotyped” AAV) or from various genomes (e.g.,single stranded or self-complementary). In addition, the AAV particlemay be replication defective and/or targeted.

Activity: As used herein, the term “activity” refers to the condition inwhich things are happening or being done. Compositions of the inventionmay have activity and this activity may involve one or more biologicalevents.

Administered in combination: As used herein, the term “administered incombination” or “combined administration” means that two or more agentsare administered to a subject at the same time or within an intervalsuch that there may be an overlap of an effect of each agent on thepatient. In some embodiments, they are administered within about 60, 30,15, 10, 5, or 1 minute of one another. In some embodiments, theadministrations of the agents are spaced sufficiently closely togethersuch that a combinatorial (e.g., a synergistic) effect is achieved.

Amelioration: As used herein, the term “amelioration” or “ameliorating”refers to a lessening of severity of at least one indicator of acondition or disease. For example, in the context of neurodegenerationdisorder, amelioration includes the reduction of neuron loss.

Animal: As used herein, the term “animal” refers to any member of theanimal kingdom. In some embodiments. “animal” refers to humans at anystage of development. In some embodiments, “animal” refers to non-humananimals at any stage of development. In certain embodiments, thenon-human animal is a mammal (e.g. a rodent, a mouse, a rat, a rabbit, amonkey, a dog, a cat, a sheep, cattle, a primate, or a pig). In someembodiments, animals include, but are not limited to, mammals, birds,reptiles, amphibians, fish, and worms. In some embodiments, the animalis a transgenic animal, genetically-engineered animal, or a clone.

Antibody: As used herein, the term “antibody” is referred to in thebroadest sense and specifically covers various embodiments including,but not limited to monoclonal antibodies, polyclonal antibodies,multispecific antibodies (e.g. bispecific antibodies formed from atleast two intact antibodies), and antibody fragments (e.g., diabodies)so long as they exhibit a desired biological activity (e.g.,“functional”). Antibodies are primarily amino-acid based molecules butmay also comprise one or more modifications (including, but not limitedto the addition of sugar moieties, fluorescent moieties, chemical tags,etc.). Non-limiting examples of antibodies or fragments thereof includeV_(H) and V_(L) domains, scFvs, Fab, Fab′, F(ab′)₂, Fv fragment,diabodies, linear antibodies, single chain antibody molecules,multispecific antibodies, bispecific antibodies, intrabodies, monoclonalantibodies, polyclonal antibodies, humanized antibodies, codon-optimizedantibodies, tandem scFv antibodies, bispecific T-cell engagers, mAb2antibodies, chimeric antigen receptors (CAR), tetravalent bispecificantibodies, biosynthetic antibodies, native antibodies, miniaturizedantibodies, unibodies, maxibodies, antibodies to senescent cells,antibodies to conformers, antibodies to disease specific epitopes orantibodies to innate defense molecules.

Antibody-based composition: As used herein, “antibody-based” or“antibody-derived” compositions are monomeric or multi-mericpolypeptides which comprise at least one amino-acid region derived froma known or parental antibody sequence and at least one amino acid regionderived from a non-antibody sequence, e.g., mammalian protein.

Approximately: As used herein, the term “approximately” or “about,” asapplied to one or more values of interest, refers to a value that issimilar to a stated reference value. In certain embodiments, the term“approximately” or “about” refers to a range of values that fall within25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%,6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than orless than) of the stated reference value unless otherwise stated orotherwise evident from the context (except where such number wouldexceed 100% of a possible value).

Associated with: As used herein, the terms “associated with.”“conjugated.” “linked.” “attached.” and “tethered.” when used withrespect to two or more moieties, means that the moieties are physicallyassociated or connected with one another, either directly or via one ormore additional moieties that serves as a linking agent, to form astructure that is sufficiently stable so that the moieties remainphysically associated under the conditions in which the structure isused, e.g. physiological conditions. An “association” need not bestrictly through direct covalent chemical bonding. It may also suggestionic or hydrogen bonding or a hybridization based connectivitysufficiently stable such that the “associated” entities remainphysically associated.

Bifunctional. As used herein, the term “bifunctional” refers to anysubstance, molecule or moiety which is capable of or maintains at leasttwo functions. The functions may effect the same outcome or a differentoutcome. The structure that produces the function may be the same ordifferent.

Biocompatible: As used herein, the term “biocompatible” means compatiblewith living cells, tissues, organs or systems posing little to no riskof injury, toxicity or rejection by the immune system.

Biodegradable: As used herein, the term “biodegradable” means capable ofbeing broken down into innocuous products by the action of livingthings.

Biologically active: As used herein, the phrase “biologically active”refers to a characteristic of any substance that has activity in abiological system and/or organism. For instance, a substance that, whenadministered to an organism, has a biological effect on that organism,is considered to be biologically active. In particular embodiments, anAAV particle of the present invention may be considered biologicallyactive if even a portion of the encoded payload is biologically activeor mimics an activity considered biologically relevant.

Capsid: As used herein, the term “capsid” refers to the protein shell ofa virus particle.

Chimeric antigen receptor (C4R). As used herein, the term “chimericantigen receptor” or “CAR” refers to an artificial chimeric proteincomprising at least one antigen specific targeting region (ASTR), atransmembrane domain and an intracellular signaling domain, wherein theantigen specific targeting region comprises a full-length antibody or afragment thereof. As a non-limiting example the ASTR of a CAR may be anyof the antibodies listed in Tables 3-42, antibody-based compositions orfragments thereof. Any molecule that is capable of binding a targetantigen with high affinity can be used in the ASTR of a CAR, The CAR mayoptionally have an extracellular spacer domain and/or a co-stimulatorydomain. A CAR may also be used to generate a cytotoxic cell carrying theCAR.

Complementary and substantially complementary: As used herein, the term“complementary” refers to the ability of polynucleotides to form basepairs with one another. Base pairs are typically formed by hydrogenbonds between nucleotide units in antiparallel polynucleotide strands.Complementary polynucleotide strands can form base pair in theWatson-Crick manner (e.g., A to T, A to U, C to G), or in any othermanner that allows for the formation of duplexes. As persons skilled inthe art are aware, when using RNA as opposed to DNA, uracil rather thanthy mine is the base that is considered to be complementary to adenosineHowever, when a U is denoted in the context of the present invention,the ability to substitute a T is implied, unless otherwise stated.Perfect complementarity or 100% complementarity refers to the situationin which each nucleotide unit of one polynucleotide strand can formhydrogen bond with a nucleotide unit of a second polynucleotide strand.Less than perfect complementarity refers to the situation in which some,but not all, nucleotide units of two strands can form hydrogen bond witheach other. For example, for two 20-mers, if only two base pairs on eachstrand can form hydrogen bond with each other, the polynucleotidestrands exhibit 10% complementarity. In the same example, if 18 basepairs on each strand can form hydrogen bonds with each other, thepolynucleotide strands exhibit 90% complementarity. As used herein, theterm “substantially complementary” means that the siRNA has a sequence(e.g., in the antisense strand) which is sufficient to bind the desiredtarget mRNA, and to trigger the RNA silencing of the target mRNA.

Compound Compounds of the present disclosure include all of the isotopesof the atoms occurring in the intermediate or final compounds.“Isotopes” refers to atoms having the same atomic number but differentmass numbers resulting from a different number of neutrons in thenuclei. For example, isotopes of hydrogen include tritium and deuterium.

The compounds and salts of the present disclosure can be prepared incombination with solvent or water molecules to form solvates andhydrates by routine methods.

Comprehensive Positional Evolution (CPE™): As used herein, the term“comprehensive positional evolution” refers to an antibody evolutiontechnology that allows for mapping of the effects of amino acid changesat every position along an antibody variable domain's sequence. Thiscomprehensive mutagenesis technology can be used to enhance one or moreantibody properties or characteristics.

Comprehensive Protein Synthesis (CPS™): As used herein, the term“comprehensive protein synthesis” refers to a combinatorial proteinsynthesis technology that can be used to optimize antibody properties orcharacteristics by combining the best properties into a new,high-performance antibody.

Conditionally active: As used herein, the term “conditionally active”refers to a mutant or variant of a wild-type polypeptide, wherein themutant or variant is more or less active at physiological conditionsthan the parent polypeptide. Further, the conditionally activepolypeptide may have increased or decreased activity at aberrantconditions as compared to the parent polypeptide. A conditionally activepolypeptide may be reversibly or irreversibly inactivated at normalphysiological conditions or aberrant conditions.

Conserved: As used herein, the term “conserved” refers to nucleotides oramino acid residues of a polynucleotide sequence or polypeptidesequence, respectively, that are those that occur unaltered in the sameposition of two or more sequences being compared. Nucleotides or aminoacids that are relatively conserved are those that are conserved amongstmore related sequences than nucleotides or amino acids appearingelsewhere in the sequences.

In some embodiments, two or more sequences are said to be “completelyconserved” if they are 100% identical to one another. In someembodiments, two or more sequences are said to be “highly conserved” ifthey are at least 70% identical, at least 80% identical, at least 90%identical, or at least 95% identical to one another. In someembodiments, two or more sequences are said to be “highly conserved” ifthey are about 70% identical, about 80% identical, about 90% identical,about 95%, about 98%, or about 99% identical to one another. In someembodiments, two or more sequences are said to be “conserved” if theyare at least 30% identical, at least 40% identical, at least 50%identical, at least 60% identical, at least 70% identical, at least 80%identical, at least 90% identical, or at least 95% identical to oneanother. In some embodiments, two or more sequences are said to be“conserved” if they are about 30% identical, about 40% identical, about50% identical, about 60% identical, about 70% identical, about 80%identical, about 90% identical, about 95% identical, about 98%identical, or about 99% identical to one another. Conservation ofsequence may apply to the entire length of a polynucleotide orpolypeptide or may apply to a portion, region or feature thereof.

Control Elements: As used herein, “control elements”, “regulatorycontrol elements” or “regulatory sequences” refers to promoter regions,polyadenylation signals, transcription termination sequences, upstreamregulatory domains, origins of replication, internal ribosome entrysites (“IRES”), enhancers, and the like, which provide for thereplication, transcription and translation of a coding sequence in arecipient cell. Not all of these control elements need always be presentas long as the selected coding sequence is capable of being replicated,transcribed and/or translated in an appropriate host cell.

Controlled Release: As used herein, the term “controlled release” refersto a pharmaceutical composition or compound release profile thatconforms to a particular pattern of release to effect a therapeuticoutcome.

Cytostatic: As used herein, “cytostatic” refers to inhibiting, reducing,suppressing the growth, division, or multiplication of a cell (e.g., amammalian cell (e.g., a human cell)), bacterium, virus, fungus,protozoan, parasite, prion, or a combination thereof.

Cytotoxic: As used herein, “cytotoxic” refers to killing or causinginjurious, toxic, or deadly effect on a cell (e.g., a mammalian cell(e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite,prion, or a combination thereof.

Delivery: As used herein, “delivery” refers to the act or manner ofdelivering an AAV particle, a compound, substance, entity, moiety, cargoor pay load.

Delivery Agent: As used herein, “delivery agent” refers to any substancewhich facilitates, at least in part, the in vivo delivery of an AAVparticle to targeted cells.

Destabilized: As used herein, the term “destable,” “destabilize,” or“destabilizing region” means a region or molecule that is less stablethan a starting, wild-type or native form of the same region ormolecule.

Detectable label: As used herein. “detectable label” refers to one ormore markers, signals, or moieties which are attached, incorporated orassociated with another entity that is readily detected by methods knownin the art including radiography, fluorescence, chermluminescence,enzymatic activity, absorbance and the like. Detectable labels includeradioisotopes, fluorophores, chromophores, enzymes, dyes, metal ions,ligands such as biotin, avidin, streptavidin and haptens, quantum dots,and the like. Detectable labels may be located at any position in thepeptides or proteins disclosed herein. They may be within the aminoacids, the peptides, or proteins, or located at the N- or C-termini.

Digest: As used herein, the term “digest” means to break apart intosmaller pieces or components. When referring to polypeptides orproteins, digestion results in the production of peptides.

Distal: As used herein, the term “distal” means situated away from thecenter or away from a point or region of interest.

Dosing regimen: As used herein, a “dosing regimen” is a schedule ofadministration or physician determined regimen of treatment,prophylaxis, or palliative care.

Encapsulate: As used herein, the term “encapsulate” means to enclose,surround or encase.

Engineered: As used herein, embodiments of the invention are“engineered” when they are designed to have a feature or property,whether structural or chemical, that varies from a starting point, wildtype or native molecule.

Effective Amount: As used herein, the term “effective amount” of anagent is that amount sufficient to effect beneficial or desired results,for example, clinical results, and, as such, an “effective amount”depends upon the context in which it is being applied. For example, inthe context of administering an agent that treats cancer, an effectiveamount of an agent is, for example, an amount sufficient to achievetreatment, as defined herein, of cancer, as compared to the responseobtained without administration of the agent.

Epitope: As used herein, an “epitope” refers to a surface or region on amolecule that is capable of interacting with a biomolecule. For example,a protein may contain one or more amino acids, e.g., an epitope, whichinteracts with an antibody, e.g., a biomolecule. In some embodiments,when referring to a protein or protein module, an epitope may comprise alinear stretch of amino acids or a three-dimensional structure formed byfolded amino acid chains.

EvoMap™: As used herein, an EvoMap™ refers to a map of a polypeptide,wherein detailed informatics are presented about the effects of singleamino acid mutations within the length of the polypeptide and theirinfluence on the properties and characteristics of that polypeptide.

Expression: As used herein, “expression” of a nucleic acid sequencerefers to one or more of the following events: (1) production of an RNAtemplate from a DNA sequence (e.g., by transcription); (2) processing ofan RNA transcript (e.g. by splicing, editing, 5′ cap formation, and/or3′ end processing), (3) translation of an RNA into a polypeptide orprotein, and (4) post-translational modification of a polypeptide orprotein.

Feature: As used herein, a “feature” refers to a characteristic, aproperty, or a distinctive element.

Formulation: As used herein, a “formulation” includes at least one AAVparticle and a delivery agent.

Fragment: A “fragment,” as used herein, refers to a portion. Forexample, fragments of proteins may comprise polypeptides obtained bydigesting full-length protein isolated from cultured cells.

Functional: As used herein, a “functional” biological molecule is abiological molecule in a form in which it exhibits a property and/oractivity by which it is characterized.

Gene expression: The term “gene expression” refers to the process bywhich a nucleic acid sequence undergoes successful transcription and inmost instances translation to produce a protein or peptide. For clarity,when reference is made to measurement of “gene expression”, this shouldbe understood to mean that measurements may be of the nucleic acidproduct of transcription, e.g. RNA or mRNA or of the amino acid productof translation, e.g., polypeptides or peptides. Methods of measuring theamount or levels of RNA, mRNA, polypeptides and peptides are well knownin the art.

Homology: As used herein, the term “homology” refers to the overallrelatedness between polymeric molecules, e.g. between polynucleotidemolecules (e.g. DNA molecules and/or RNA molecules) and/or betweenpolypeptide molecules. In some embodiments, polymeric molecules areconsidered to be “homologous” to one another if their sequences are atleast 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, or 99% identical or similar. The term “homologous” necessarilyrefers to a comparison between at least two sequences (polynucleotide orpolypeptide sequences). In accordance with the invention, twopolynucleotide sequences are considered to be homologous if thepolypeptides they encode are at least about 50%, 60%, 70%, 80%, 90%,95%, or even 99% for at least one stretch of at least about 20 aminoacids. In some embodiments, homologous polynucleotide sequences arecharacterized by the ability to encode a stretch of at least 4-5uniquely specified amino acids. For polynucleotide sequences less than60 nucleotides in length, homology is determined by the ability toencode a stretch of at least 4-5 uniquely specified amino acids. Inaccordance with the invention, two protein sequences are considered tobe homologous if the proteins are at least about 50%, 60%, 70%, 80%, or90% identical for at least one stretch of at least about 20 amino acids.

Heterologous Region: As used herein the term “heterologous region”refers to a region which would not be considered a homologous region.

Homologous Region: As used herein the term “homologous region” refers toa region which is similar in position, structure, evolution origin,character, form or function.

Identity: As used herein, the term “identity” refers to the overallrelatedness between polymeric molecules, e.g., between polynucleotidemolecules (e.g. DNA molecules and/or RNA molecules) and/or betweenpolypeptide molecules. Calculation of the percent identity of twopolynucleotide sequences, for example, can be performed by aligning thetwo sequences for optimal comparison purposes (e.g., gaps can beintroduced in one or both of a first and a second nucleic acid sequencesfor optimal alignment and non-identical sequences can be disregarded forcomparison purposes). In certain embodiments, the length of a sequencealigned for comparison purposes is at least 30%, at least 40%, at least50%, at least 60%, at least 70%, at least 80%, at least 90%, at least95%, or 100% of the length of the reference sequence. The nucleotides atcorresponding nucleotide positions are then compared. When a position inthe first sequence is occupied by the same nucleotide as thecorresponding position in the second sequence, then the molecules areidentical at that position. The percent identity between the twosequences is a function of the number of identical positions shared bythe sequences, taking into account the number of gaps, and the length ofeach gap, which needs to be introduced for optimal alignment of the twosequences. The comparison of sequences and determination of percentidentity between two sequences can be accomplished using a mathematicalalgorithm. For example, the percent identity between two nucleotidesequences can be determined using methods such as those described inComputational Molecular Biology, Lesk, A. M., ed. Oxford UniversityPress, New York; 1988; Biocomputing: Informatics and Genome Projects,Smith, D. W, ed., Academic Press, New York, 1993; Sequence Analysis inMolecular Biology, von Heinje, G., Academic Press, 1987; ComputerAnalysis of Sequence Data, Part I. Griffin, A. M., and Griffin, H. G.,eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer,Gribskov, M. and Devereux, J., eds., M Stockton Press. New York, 1991;each of which is incorporated herein by reference. For example, thepercent identity between two nucleotide sequences can be determinedusing the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), whichhas been incorporated into the ALIGN program (version 2.0) using aPAM120 weight residue table, a gap length penalty of 12 and a gappenalty of 4. The percent identity between two nucleotide sequences can,alternatively, be determined using the GAP program in the GCG softwarepackage using an NWSgapdna.CMP matrix. Methods commonly employed todetermine percent identity between sequences include, but are notlimited to those disclosed in Carillo, H., and Lipman, D., SIAM JApplied Math., 48:1073 (1988); incorporated herein by reference.Techniques for determining identity are codified in publicly availablecomputer programs. Exemplary computer software to determine homologybetween two sequences include, but are not limited to, GCG programpackage, Devereux, J., et al., Nucleic Acids Research, 12(1), 387(1984)). BLASTP. BLASTN, and FASTA Altschul, S. F. et al., J. Molec.Biol., 215, 403 (1990)).

Inhibit expression of a gene: As used herein, the phrase “inhibitexpression of a gene” means to cause a reduction in the amount of anexpression product of the gene. The expression product can be an RNAtranscribed from the gene (e.g., an mRNA) or a polypeptide translatedfrom an mRNA transcribed from the gene. Typically, a reduction in thelevel of an mRNA results in a reduction in the level of a polypeptidetranslated therefrom. The level of expression may be determined usingstandard techniques for measuring mRNA or protein.

In vitro: As used herein, the term “in vitro” refers to events thatoccur in an artificial environment, e.g., in a test tube or reactionvessel, in cell culture, in a Petri dish, etc., rather than within anorganism (e.g., animal, plant, or microbe).

In vivo: As used herein, the term “in vivo” refers to events that occurwithin an organism (e.g., animal, plant, or microbe or cell or tissuethereof).

Isolated: As used herein, the term “isolated” refers to a substance orentity that has been separated from at least some of the components withwhich it was associated (whether in nature or in an experimentalsetting) Isolated substances may have varying levels of purity inreference to the substances from which they have been associated.Isolated substances and/or entities may be separated from at least about10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%,about 80%, about 90%, or more of the other components with which theywere initially associated. In some embodiments, isolated agents are morethan about 80%, about 85%, about 90%, about 91%, about 92%, about 93%,about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, ormore than about 99% pure. As used herein, a substance is “pure” if it issubstantially free of other components.

Substantially isolated: By “substantially isolated” is meant that asubstance is substantially separated from the environment in which itwas formed or detected. Partial separation can include, for example, acomposition enriched in the substance or AAV particles of the presentdisclosure. Substantial separation can include compositions containingat least about 50%, at least about 60%, at least about 70%, at leastabout 80%, at least about 90%, at least about 95%, at least about 97%,or at least about 99%, by weight of the compound of the presentdisclosure, or salt thereof. Methods for isolating compounds and theirsalts are routine in the art.

Linker: As used herein “linker” refers to a molecule or group ofmolecules which connects two molecules, such as a V_(H) chain and V_(L)chain or an antibody. A linker may be a nucleic acid sequence connectingtwo nucleic acid sequences encoding two different polypeptides. Thelinker may or may not be translated. The linker may be a cleavablelinker.

MicroRNA (miRNA) binding site: As used herein, a microRNA (miRNA)binding site represents a nucleotide location or region of a nucleicacid transcript to which at least the “seed” region of a miRNA binds.

Modified: As used herein “modified” refers to a changed state orstructure of a molecule of the invention. Molecules may be modified inmany ways including chemically, structurally, and functionally.

Naturally Occurring: As used herein. “naturally occurring” or“wild-type” means existing in nature without artificial aid, orinvolvement of the hand of man.

Non-human vertebrate: As used herein, a “non-human vertebrate” includesall vertebrates except Homo sapiens, including wild and domesticatedspecies. Examples of non-human vertebrates include, but are not limitedto, mammals, such as alpaca, banteng, bison, camel, cat, cattle, deer,dog, donkey, gayal, goat, guinea pig, horse, llama, mule, pig, rabbit,reindeer, sheep water buffalo, and yak.

Off-target: As used herein, “off target” refers to any unintended effecton any one or more target, gene, or cellular transcript.

Open reading frame: As used herein, “open reading frame” or “ORF” refersto a sequence which does not contain a stop codon in a given readingframe.

Operably linked: As used herein, the phrase “operably linked” refers toa functional connection between two or more molecules, constructs,transcripts, entities, moieties or the like.

Particle: As used herein, a “particle” is a virus comprised of at leasttwo components, a protein capsid and a polynucleotide sequence enclosedwithin the capsid.

Patient: As used herein. “patient” refers to a subject who may seek orbe in need of treatment, requires treatment, is receiving treatment,will receive treatment, or a subject who is under care by a trainedprofessional for a particular disease or condition.

Payload: As used herein, “payload” or “payload region” refers to one ormore polynucleotides or polynucleotide regions encoded by or within aviral genome or an expression product of such polynucleotide orpolynucleotide region, e.g., a transgene, a polynucleotide encoding apolypeptide or multi-polypeptide or a modulatory nucleic acid orregulatory nucleic acid.

Payload construct: As used herein, “payload construct” is one or morepolynucleotide regions encoding or comprising a payload that is flankedon one or both sides by an inverted terminal repeat (ITR) sequence. Thepayload construct is a template that is replicated in a viral productioncell to produce a viral genome.

Payload construct vector. As used herein, “payload construct vector” isa vector encoding or comprising a payload construct, and regulatoryregions for replication and expression in bacterial cells.

Payload construct expression vector: As used herein, a “payloadconstruct expression vector” is a vector encoding or comprising apayload construct and which further comprises one or more polynucleotideregions encoding or comprising components for viral expression in aviral replication cell.

Peptide: As used herein, “peptide” is less than or equal to 50 aminoacids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 aminoacids long.

Pharmaceutically acceptable: The phrase “pharmaceutically acceptable” isemployed herein to refer to those compounds, materials, compositions,and/or dosage forms which are, within the scope of sound medicaljudgment, suitable for use in contact with the tissues of human beingsand animals without excessive toxicity, irritation, allergic response,or other problem or complication, commensurate with a reasonablebenefit/risk ratio.

Pharmaceutically acceptable excipients: The phrase “pharmaceuticallyacceptable excipient.” as used herein, refers any ingredient other thanthe compounds described herein (for example, a vehicle capable ofsuspending or dissolving the active compound) and having the propertiesof being substantially nontoxic and non-inflammatory in a patient.Excipients may include, for example: antiadherents, antioxidants,binders, coatings, compression aids, disintegrants, dyes (colors),emollients, emulsifiers, fillers (diluents), film formers or coatings,flavors, fragrances, glidants (flow enhancers), lubricants,preservatives, printing inks, sorbents, suspensing or dispersing agents,sweeteners, and waters of hydration. Exemplary excipients include, butare not limited to: butylated hydroxytoluene (BHT), calcium carbonate,calcium phosphate (dibasic), calcium stearate, croscarmellose,crosslinked poly vinyl pyrrolidone, citric acid, crospovidone, cysteine,ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol,methionine, methylcellulose, methyl paraben, microcrystalline cellulose,polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinizedstarch, propyl paraben, retinyl palmitate, shellac, silicon dioxide,sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate,sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide,vitamin A, vitamin E, vitamin C, and xylitol.

Pharmaceutically acceptable salts: The present disclosure also includespharmaceutically acceptable salts of the compounds described herein. Asused herein. “pharmaceutically acceptable salts” refers to derivativesof the disclosed compounds wherein the parent compound is modified byconverting an existing acid or base moiety to its salt form (e.g., byreacting the free base group with a suitable organic acid). Examples ofpharmaceutically acceptable salts include, but are not limited to,mineral or organic acid salts of basic residues such as amines: alkalior organic salts of acidic residues such as carboxylic acids; and thelike. Representative acid addition salts include acetate, acetic acid,adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzenesulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate,camphorsulfonate, citrate, cyclopentanepropionate, digluconate,dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate,glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide,hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate,lactate, laurate, lauryl sulfate, malate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate,oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate,phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate,tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts,and the like. Representative alkali or alkaline earth metal saltsinclude sodium, lithium, potassium, calcium, magnesium, and the like, aswell as nontoxic ammonium, quaternary ammonium, and amine cations,including, but not limited to ammonium, tetramethylammonium,tetraethylammonium, methylamine, dimethylamine, trimethylamine,triethylamine, ethylamine, and the like. The pharmaceutically acceptablesalts of the present disclosure include the conventional non-toxic saltsof the parent compound formed, for example, from non-toxic inorganic ororganic acids. The pharmaceutically acceptable salts of the presentdisclosure can be synthesized from the parent compound which contains abasic or acidic moiety by conventional chemical methods. Generally, suchsalts can be prepared by reacting the free acid or base forms of thesecompounds with a stoichiometric amount of the appropriate base or acidin water or in an organic solvent, or in a mixture of the two:generally, nonaqueous media like ether, ethyl acetate, ethanol,isopropanol, or acetonitrile are preferred. Lists of suitable salts arefound in Remington's Pharmaceutical Sciences. 17^(th) ed., MackPublishing Company, Easton, Pa., 1985, p. 1418. Pharmaceutical Salts:Properties. Selection, and Use, P. H Stahl and C. G. Wermuth (eds.).Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science,66, 1-19 (1977), each of which is incorporated herein by reference inits entirety.

Pharmaceutically acceptable solvate: The term “pharmaceuticallyacceptable solvate,” as used herein, means a compound of the inventionwherein molecules of a suitable solvent are incorporated in the crystallattice. A suitable solvent is physiologically tolerable at the dosageadministered. For example, solvates may be prepared by crystallization,recrystallization, or precipitation from a solution that includesorganic solvents, water, or a mixture thereof. Examples of suitablesolvents are ethanol, water (for example, mono-, di-, and tri-hydrates),N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO),N,N′-dimethylformamide (DMF), N,N′-dimethylacetamide (DMAC),1,3-dimethyl-2-imidazolidinone (DMEU),1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile(ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone,benzyl benzoate, and the like. When water is the solvent, the solvate isreferred to as a “hydrate.”

Pharmacokinetic: As used herein, “pharmacokinetic” refers to any one ormore properties of a molecule or compound as it relates to thedetermination of the fate of substances administered to a livingorganism. Pharmacokinetics is divided into several areas including theextent and rate of absorption, distribution, metabolism and excretion.This is commonly referred to as ADME where: (A) Absorption is theprocess of a substance entering the blood circulation; (D) Distributionis the dispersion or dissemination of substances throughout the fluidsand tissues of the body: (M) Metabolism (or Biotransformation) is theirreversible transformation of parent compounds into daughtermetabolites; and (E) Excretion (or Elimination) refers to theelimination of the substances from the body. In rare cases, some drugsirreversibly accumulate in body tissue.

Physicochemical: As used herein, “physicochemical” means of or relatingto a physical and/or chemical property.

Preventing: As used herein, the term “preventing” refers to partially orcompletely delaying onset of an infection, disease, disorder and/orcondition; partially or completely delaying onset of one or moresymptoms, features, or clinical manifestations of a particularinfection, disease, disorder, and/or condition, partially or completelydelaying onset of one or more symptoms, features, or manifestations of aparticular infection, disease, disorder, and/or condition, partially orcompletely delaying progression from an infection, a particular disease,disorder and/or condition; and/or decreasing the risk of developingpathology associated with the infection, the disease, disorder, and/orcondition.

Proliferate: As used herein, the term “proliferate” means to grow,expand or increase or cause to grow, expand or increase rapidly.“Proliferative” means having the ability to proliferate.“Anti-proliferative” means having properties counter to or inapposite toproliferative properties.

Prophylactic: As used herein, “prophylactic” refers to a therapeutic orcourse of action used to prevent the spread of disease.

Prophylaxis: As used herein, a “prophylaxis” refers to a measure takento maintain health and prevent the spread of disease.

Protein of interest: As used herein, the terms “proteins of interest” or“desired proteins” include those provided herein and fragments, mutants,variants, and alterations thereof.

Proximal: As used herein, the term “proximal” means situated nearer tothe center or to a point or region of interest.

Purified: As used herein, “purify,” “purified,” “purification” means tomake substantially pure or clear from unwanted components, materialdefilement, admixture or imperfection. “Purified” refers to the state ofbeing pure. “Purification” refers to the process of making pure.

Region: As used herein, the term “region” refers to a zone or generalarea. In some embodiments, when referring to a protein or proteinmodule, a region may comprise a linear sequence of amino acids along theprotein or protein module or may comprise a three-dimensional area, anepitope and/or a cluster of epitopes. In some embodiments, regionscomprise terminal regions. As used herein, the term “terminal region”refers to regions located at the ends or termini of a given agent. Whenreferring to proteins, terminal regions may comprise N- and/orC-termini. N-termini refer to the end of a protein comprising an aminoacid with a free amino group. C-termini refer to the end of a proteincomprising an amino acid with a free carboxyl group. N- and/orC-terminal regions may there for comprise the N- and/or C-termini aswell as surrounding amino acids. In some embodiments. N- and/orC-terminal regions comprise from about 3 amino acid to about 30 aminoacids, from about 5 amino acids to about 40 amino acids, from about 10amino acids to about 50 amino acids, from about 20 amino acids to about100 amino acids and/or at least 100 amino acids. In some embodiments,N-terminal regions may comprise any length of amino acids that includesthe N-terminus, but does not include the C-terminus. In someembodiments. C-terminal regions may comprise any length of amino acids,which include the C-terminus, but do not comprise the N-terminus.

In some embodiments, when referring to a polynucleotide, a region maycomprise a linear sequence of nucleic acids along the polynucleotide ormay comprise a three-dimensional area, secondary structure, or tertiarystructure. In some embodiments, regions comprise terminal regions. Asused herein, the term “terminal region” refers to regions located at theends or termini of a given agent. When referring to polynucleotides,terminal regions may comprise 5′ and 3′ termini, 5′ termini refer to theend of a polynucleotide comprising a nucleic acid with a free phosphategroup, 3′ termini refer to the end of a polynucleotide comprising anucleic acid with a free hydroxyl group, 5′ and 3′ regions may there forcomprise the 5′ and 3′ termini as well as surrounding nucleic acids. Insome embodiments, 5′ and 3′ terminal regions comprise from about 9nucleic acids to about 90 nucleic acids, from about 15 nucleic acids toabout 120 nucleic acids, from about 30 nucleic acids to about 150nucleic acids, from about 60 nucleic acids to about 300 nucleic acidsand/or at least 300 nucleic acids. In some embodiments, 5′ regions maycomprise any length of nucleic acids that includes the 5′ terminus, butdoes not include the 3′ terminus. In some embodiments, 3′ regions maycomprise any length of nucleic acids, which include the 3′ terminus, butdoes not comprise the 5′ terminus.

RNA or RN4 molecule: As used herein, the term “RNA” or “RNA molecule” or“ribonucleic acid molecule” refers to a polymer of ribonucleotides; theterm “DNA” or “DNA molecule” or “deoxyribonucleic acid molecule” refersto a polymer of deoxyribonucleotides. DNA and RNA can be synthesizednaturally, e.g., by DNA replication and transcription of DNA,respectively; or be chemically synthesized. DNA and RNA can besingle-stranded (i.e., ssRNA or ssDNA, respectively) or multi-stranded(e.g., double stranded, i.e., dsRNA and dsDNA, respectively). The term“mRNA” or “messenger RNA”, as used herein, refers to a single strandedRNA that encodes the amino acid sequence of one or more polypeptidechains.

Sample: As used herein, the term “sample” or “biological sample” refersto a subset of its tissues, cells or component parts (e.g. body fluids,including but not limited to blood, mucus, lymphatic fluid, synovialfluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood,urine, vaginal fluid and semen). A sample further may include ahomogenate, lysate or extract prepared from a whole organism or a subsetof its tissues, cells or component parts, or a fraction or portionthereof, including but not limited to, for example, plasma, serum,spinal fluid, lymph fluid, the external sections of the skin,respiratory, intestinal, and genitourinary tracts, tears, saliva, milk,blood cells, tumors, organs. A sample further refers to a medium, suchas a nutrient broth or gel, which may contain cellular components, suchas proteins or nucleic acid molecule.

Self-complementary viral particle: As used herein, a “self-complementaryviral particle” is a particle comprised of at least two components, aprotein capsid and a polynucleotide sequence encoding aself-complementary genome enclosed within the capsid.

Signal Sequences: As used herein, the phrase “signal sequences” refersto a sequence which can direct the transport or localization of aprotein.

Single unit dose: As used herein, a “single unit dose” is a dose of anytherapeutic administered in one dose/at one time/single route/singlepoint of contact, i.e., single administration event. In someembodiments, a single unit dose is provided as a discrete dosage form(e.g., a tablet, capsule, patch, loaded syringe, vial, etc.).

Similarity: As used herein, the term “similarity” refers to the overallrelatedness between polymeric molecules, e.g. between polynucleotidemolecules (e.g. DNA molecules and/or RNA molecules) and/or betweenpolypeptide molecules. Calculation of percent similarity of polymericmolecules to one another can be performed in the same manner as acalculation of percent identity, except that calculation of percentsimilarity takes into account conservative substitutions as isunderstood in the art.

Split dose: As used herein, a “split dose” is the division of singleunit dose or total daily dose into two or more doses.

Stable: As used herein “stable” refers to a compound that issufficiently robust to survive isolation to a useful degree of purityfrom a reaction mixture, and preferably capable of formulation into anefficacious therapeutic agent.

Stabilized: As used herein, the term “stabilize”, “stabilized,”“stabilized region” means to make or become stable.

Subject. As used herein, the term “subject” or “patient” refers to anyorganism to which a composition in accordance with the invention may beadministered, e.g., for experimental, diagnostic, prophylactic, and/ortherapeutic purposes. Typical subjects include animals (e.g., mammalssuch as mice, rats, rabbits, non-human primates, and humans) and/orplants.

Substantially: As used herein, the term “substantially” refers to thequalitative condition of exhibiting total or near-total extent or degreeof a characteristic or property of interest. One of ordinary skill inthe biological arts will understand that biological and chemicalphenomena rarely, if ever, go to completion and/or proceed tocompleteness or achieve or avoid an absolute result. The term“substantially” is therefore used herein to capture the potential lackof completeness inherent in many biological and chemical phenomena.

Substantially equal: As used herein as it relates to time differencesbetween doses, the term means plus/minus 2%.

Substantially simultaneously: As used herein and as it relates toplurality of doses, the term means within 2 seconds.

Suffering from: An individual who is “suffering from” a disease,disorder, and/or condition has been diagnosed with or displays one ormore symptoms of a disease, disorder, and/or condition.

Susceptible to: An individual who is “susceptible to” a disease,disorder, and/or condition has not been diagnosed with and/or may notexhibit symptoms of the disease, disorder, and/or condition but harborsa propensity to develop a disease or its symptoms. In some embodiments,an individual who is susceptible to a disease, disorder, and/orcondition (for example, cancer) may be characterized by one or more ofthe following: (1) a genetic mutation associated with development of thedisease, disorder, and/or condition: (2) a genetic polymorphismassociated with development of the disease, disorder, and/or condition:(3) increased and/or decreased expression and/or activity of a proteinand/or nucleic acid associated with the disease, disorder, and/orcondition; (4) habits and/or lifestyles associated with development ofthe disease, disorder, and/or condition: (5) a family history of thedisease, disorder, and/or condition; and (6) exposure to and/orinfection with a microbe associated with development of the disease,disorder, and/or condition. In some embodiments, an individual who issusceptible to a disease, disorder, and/or condition will develop thedisease, disorder, and/or condition. In some embodiments, an individualwho is susceptible to a disease, disorder, and/or condition will notdevelop the disease, disorder, and/or condition.

Sustained release. As used herein, the term “sustained release” refersto a pharmaceutical composition or compound release profile thatconforms to a release rate over a specific period of time.

Synthetic: The term “synthetic” means produced, prepared, and/ormanufactured by the hand of man. Synthesis of polynucleotides orpolypeptides or other molecules of the present invention may be chemicalor enzymatic.

Targeting: As used herein, “targeting” means the process of design andselection of nucleic acid sequence that will hybridize to a targetnucleic acid and induce a desired effect.

Targeted Cells: As used herein. “targeted cells” refers to any one ormore cells of interest. The cells may be found in vitro, in vivo, insitu or in the tissue or organ of an organism. The organism may be ananimal, preferably a mammal, more preferably a human and most preferablya patient.

Therapeutic Agent: The term “therapeutic agent” refers to any agentthat, when administered to a subject, has a therapeutic, diagnostic,and/or prophylactic effect and/or elicits a desired biological and/orpharmacological effect.

Therapeutically effective amount: As used herein, the term“therapeutically effective amount” means an amount of an agent to bedelivered (e.g., nucleic acid, drug, therapeutic agent, diagnosticagent, prophylactic agent, etc.) that is sufficient, when administeredto a subject suffering from or susceptible to an infection, disease,disorder, and/or condition, to treat, improve symptoms of, diagnose,prevent, and/or delay the onset of the infection, disease, disorder,and/or condition. In some embodiments, a therapeutically effectiveamount is provided in a single dose. In some embodiments, atherapeutically effective amount is administered in a dosage regimencomprising a plurality of doses. Those skilled in the art willappreciate that in some embodiments, a unit dosage form may beconsidered to comprise a therapeutically effective amount of aparticular agent or entity if it comprises an amount that is effectivewhen administered as part of such a dosage regimen.

Therapeutically effective outcome: As used herein, the term“therapeutically effective outcome” means an outcome that is sufficientin a subject suffering from or susceptible to an infection, disease,disorder, and/or condition, to treat, improve symptoms of, diagnose,prevent, and/or delay the onset of the infection, disease, disorder,and/or condition.

Total daily dose: As used herein, a “total daily dose” is an amountgiven or prescribed in 24 hr period. It may be administered as a singleunit dose.

Transfection: As used herein, the term “transfection” refers to methodsto introduce exogenous nucleic acids into a cell. Methods oftransfection include, but are not limited to, chemical methods, physicaltreatments and cationic lipids or mixtures.

Treating: As used herein, the term “treating” refers to partially orcompletely alleviating, ameliorating, improving, relieving, delayingonset of, inhibiting progression of, reducing severity of, and/orreducing incidence of one or more symptoms or features of a particularinfection, disease, disorder, and/or condition. For example, “treating”cancer may refer to inhibiting survival, growth, and/or spread of atumor Treatment may be administered to a subject who does not exhibitsigns of a disease, disorder, and/or condition and/or to a subject whoexhibits only early signs of a disease, disorder, and/or condition forthe purpose of decreasing the risk of developing pathology associatedwith the disease, disorder, and/or condition.

Unmodified: As used herein, “unmodified” refers to any substance,compound or molecule prior to being changed in any way Unmodified may,but does not always, refer to the wild type or native form of abiomolecule. Molecules may undergo a series of modifications wherebyeach modified molecule may serve as the “unmodified” starting moleculefor a subsequent modification.

Vector: As used herein, a “vector” is any molecule or moiety whichtransports, transduces or otherwise acts as a carrier of a heterologousmolecule. Vectors of the present invention may be produced recombinantlyand may be based on and/or may comprise adeno-associated virus (AAV)parent or reference sequence Such parent or reference AAV sequences mayserve as an original, second, third or subsequent sequence forengineering vectors. In non-limiting examples, such parent or referenceAAV sequences may comprise any one or more of the following sequences: apolynucleotide sequence encoding a polypeptide or multi-polypeptide,which sequence may be wild-type or modified from wild-type and whichsequence may encode full-length or partial sequence of a protein,protein domain, or one or more subunits of a protein; a polynucleotidecomprising a modulatory or regulatory nucleic acid which sequence may bewild-type or modified from wild-type; and a transgene that may or maynot be modified from wild-type sequence. These AAV sequences may serveas either the “donor” sequence of one or more codons (at the nucleicacid level) or amino acids (at the polypeptide level) or “acceptor”sequences of one or more codons (at the nucleic acid level) or aminoacids (at the polypeptide level).

Viral genome: As used herein, a “viral genome” or “vector genome” is apolynucleotide comprising at least one inverted terminal repeat (ITR)and at least one encoded payload. A viral genome encodes at least onecopy of the payload.

Described herein are compositions, methods, processes, kits and devicesfor the design, preparation, manufacture and/or formulation of AAVparticles. In some embodiments, payloads, such as but not limited to AAVpolynucleotides, may be encoded by payload constructs or containedwithin plasmids or vectors or recombinant adeno-associated viruses(AAVs).

The details of one or more embodiments of the invention are set forth inthe accompanying description below. Although any materials and methodssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, the preferred materialsand methods are now described. Other features, objects and advantages ofthe invention will be apparent from the description. In the description,the singular forms also include the plural unless the context clearlydictates otherwise. Unless defined otherwise, all technical andscientific terms used herein have the same meaning as commonlyunderstood by one of ordinary skill in the art to which this inventionbelongs. In the case of conflict, the present description will control.

The present invention is further illustrated by the followingnon-limiting examples.

VII. EXAMPLES Example 1. Production and Purification of AAV Particles

AAV particles described herein may be produced using methods known inthe art, such as, for example, triple transfection or baculovirusmediated virus production. Any suitable permissive or packaging cellknown in the art may be employed to produce the vectors Mammalian cellsare often preferred. Also preferred are trans-complementing packagingcell lines that provide functions deleted from a replication-defectivehelper virus, e.g., 293 cells or other E1a trans-complementing cells.

The gene cassette may contain some or all of the parvovirus (e.g., AAV)cap and rep genes. Preferably, however, some or all of the cap and repfunctions are provided in trans by introducing a packaging vector(s)encoding the capsid and/or Rep proteins into the cell. Most preferably,the gene cassette does not encode the capsid or Rep proteins.Alternatively, a packaging cell line is used that is stably transformedto express the cap and/or rep genes

Recombinant AAV virus particles are, in some cases, produced andpurified from culture supernatants according to the procedure asdescribed in US20160032254, the contents of which are incorporated byreference Production may also involve methods known in the art includingthose using 293T cell, sf9 insect cells, triple transfection or anysuitable production method.

In some cases, 293 cells are transfected with CaPO4 with plasmidsrequired for production of AAV, i.e., AAV2 rep, an adenoviral helperconstruct and a ITR flanked transgene cassette. The AAV2 rep plasmidalso contains the cap sequence of the particular virus being studied.Twenty-four hours after transfection, which occurs in serum containingDMEM, the medium is replaced with fresh medium with or without serum.Three (3) days after transfection, a sample is taken from the culturemedium of the 293 adherent cells. Subsequently cells are scraped andtransferred into a receptacle. After centrifugation to remove cellularpellet, a second sample is taken from the supernatant after scraping.Next cell lysis is achieved by three consecutive freeze-thaw cycles (−80C. to 37 C.). Cellular debris is removed and sample 3 is taken from themedium. The samples are quantified for AAV particles by DNase resistantgenome titration by Taqman™ PCR, The total production yield from such atransfection is equal to the particle concentration from sample 3.

AAV vector titers are measured according to genome copy number (genomeparticles per milliliter). Genome particle concentrations are based onTaqman® PCR of the vector DNA as previously reported (Clark et al.(1999) Hum. Gene Ther., 10:1031-1039; Veldwijk et al. (2002) Mol. Ther.,6:272-278).

Example 2. Tissue Specific Expression

To evaluate the expression of various encoded antibody payloads intissues, a series of AAV particles carrying the encoded antibodysequences driven by a panel of ubiquitous and tissue-specific promotersare made. These particles are administered to the specific tissue, e.g.,intramuscularly, via an appropriate route, e.g., a single injection inthe gastrocnemius muscle and expression is monitored to determine therelative expression potential of the payload as well as of each promoterin this target tissue. Measurement of antibody production is performedusing standard techniques, for example by ELISA.

In some cases, the cytomegalovirus immediate early promoter (CMV),chimeric chicken-beta-actin (CAG), and ubiquitin C (UBC), CBA, H1promoters provide robust expression.

Example 3. Generation of Antibodies Antibody Production by HybridomaTechnology

Host animals (e.g. mice, rabbits, goats, and llamas) are immunized by aninjection with an antigenic protein to elicit lymphocytes thatspecifically bind to the antigen Lymphocytes are collected and fusedwith immortalized cell lines to generate hybridomas. Hybridomas arecultured in a suitable culture medium that is enriched with appropriateselection agents to promote growth.

Antibodies produced by the cultured hybridomas are subjected to analysisto determine binding specificity of the antibodies for the targetantigen Once antibodies with desirable characteristics are identified,corresponding hybridomas are subcloned through limiting dilutionprocedures and grown by standard methods. Antibodies produced by thesecells are isolated and purified using standard immunoglobulinpurification procedures

Recombinant Antibody Production

Recombinant antibodies are produced using heavy and light chain variableregion cDNA sequences selected from hybridomas or from other sources.Sequences encoding antibody variable domains expressed by hybridomas aredetermined by extracting RNA molecules from antibody-producing hybridomacells and producing cDNA by reverse transcriptase polymerase chainreaction (PCR). PCR is used to amplify cDNA using primers specific forheavy and light chain sequences. PCR products are then subcloned intoplasmids for sequence analysis. Antibodies are produced by insertion ofresulting variable domain sequences into expression vectors.

Recombinant antibodies are also produced using phage display technology.Target antigens are screened, in vitro, using phage display librarieshaving millions to billions of phage particles expressing unique singlechain variable fragments (scFvs) on their viral coat. Precipitated phageparticles are analyzed and sequences encoding expressed scFvs aredetermined. Sequences encoding antibody variable domains and/or CDRs areinserted into expression vectors for antibody production.

Recombinant antibodies are further produced using yeast surface displaytechnology, wherein antibody variable domain sequences are expressed onthe cell surface of Saccharomyces cerevisae. Recombinant antibodies aredeveloped by displaying the antibody fragment of interest as a fusion toe.g. Aga2p protein on the surface of the yeast, where the proteininteracts with proteins and small molecules in a solution, scFvs withaffinity towards desired receptors are isolated from the yeast surfaceusing magnetic separation and flow cytometry. Several cycles of yeastsurface display and isolation will be done to attain scFvs with desiredproperties through directed evolution.

Example 4. Optimization of the Encoded Antibody

To design an optimal framework for the expression of an antibody, theheavy and light chains of several antibodies separated by an F2Aself-processing peptide sequence are cloned into a mammalian expressionvector under the control of the CMV promoter. 293T cells or any suitablecell line transfected with these vectors exhibit secretion of human IgGinto the culture supernatant that is then detected by ELISA.

To increase expression, the antibody chains and/or the processingpeptide are codon optimized for mammalian expression. In some instances,a furin cleavage site at the N-terminus is inserted for betterprocessing.

To improve secretion of the antibody, the endogenous signal sequencesare replaced with a sequence which may or may not be codon optimized,derived from any gene. In some cases, the human growth hormone signalsequence is used. Any of the heavy, light or both chains may be drivenby any signal sequence, whether the same or different. Antibodyexpression is confirmed using standard immunohistochemical techniques,including ELISA

Example 5. Vectored Antibodies

Viral genomes are designed for AAV delivery of antibodies to cells. Theviral genome comprises a payload region and at least one invertedterminal repeat (ITR) region. The payload region may optionally encoderegulatory elements e.g., a promoter region, an intronic region, or apolyadenylation sequence. The payload region comprises a sequenceencoding one or more polypeptides selected from the group consisting ofthose listed in Table 3 An exemplary payload region comprises a sequenceencoding an antibody heavy chain, a region encoding an antibody lightchain and a region encoding a linker connecting the heavy and lightchain sequences or polypeptides before further processing. A promoter isselected to target the desired tissue or for desired regulation ofexpression, or both. The promoter may be selected from human EF1α, CMV,CBA, and its derivative CAG, GUSB, UBC, or any other promoter known toone with skill in the art, or combinations thereof. The 5′ and 3′ ITRsmay or may not be of the same serotype as the capsid of the AAVparticle.

Payload regions may optionally encode a linker between light and heavyantibody chain sequences or polypeptides. Sequence encoding linkers arederived from an internal ribosome entry site (IRES; SEQ ID NO: 899),foot and mouth disease virus 2A (F2A, SEQ ID NO: 900), porcineteschovirus-1 virus 2A (P2A; SEQ ID NO:901), a furin cleavage site (F:SEQ ID NO: 902), or a 5xG4S (SEQ ID NO: 9221 encoded by SEQ ID NO: 903)linker sequence. In various payload regions, the order of heavy andlight chains is alternated with respect to 5′ to 3′ direction. Payloadsare further designed to encode protein signal sequences (to aid inprotein processing, localization, and/or secretion) as well as anuntranslated poly A tail.

Each viral genome is then incorporated into an AAV cloning vector tocreate payload expression vectors.

The payload expression vectors are expressed in e.g. Expi 293 cells. Thesupernatants are collected and expressed antibodies are purified usingprotein A/G beads. Supernatants are diluted with a loading buffer andapplied to a column prepared with A/C beads. Unbound proteins are washedthrough with loading buffer Elution buffer is added to the column,fractions collected, and fractions containing proteins of interest areidentified with absorption spectroscopy technique, pooled together, andneutralized. Western blotting techniques are used to identify payloadregions producing the antibody proteins of interest Purified antibodiesare then tested for their affinity to their specific target by e.g.ELISA essay technique and antibodies with the highest affinity areidentified and selected.

Finally, the rAAVs are produced using, for example, HEK293T cells. Thecells are transfected simultaneously with the viral genome of thepresent invention, a viral genome encoding helper proteins and a viralgenome encoding replication and capsid proteins.

Example 6. In Vivo Expression and Efficacy of Antibody Payloads

To determine the efficacy or comparative expression of encodedantibodies, dose-dependent expression is determined at a series of timepoints. Samples from mice treated with AAV particles encoding antibodiesor luciferase at various levels are examined for expression usingstandard techniques such as nucleic acid analyses for RNA levels,protein analyses for antibody levels and compared to the expression ofthe luciferase control.

Example 7. Treatment of Infectious Disease

AAV particles of the current invention encoding an antibody areadministered to a patient who has been diagnosed with an infectiousdisease, disorder or condition. The purpose of the treatment may beaimed to manage the disease, prevent or slow the progression of thedisease, treat the symptoms associated with the disease and/or cure thedisease.

The AAV particles may be administered through an intramuscular injectionto the skeletal muscle. The administration may include one or moreinjections over a period of time. The level and distribution of AAVparticles and antibody expression is monitored by standard diagnostictechniques known in the art. Such diagnostic techniques include e.g.(e.g. from blood, urine, or saliva), cerebrospinal fluid (CSF) testing,or any other testing useful for monitoring antibody levels in the body.

Additionally, the progression of the disease and the health of thepatient is monitored by standard diagnostic techniques known in the art.Such techniques may include diagnostic imaging (e.g. X-ray, MRA scans,Ultrasound scans, PET scans. Nuclear scans, mammography), biopsy,laboratory tests (e.g. from blood, urine, or saliva), cerebrospinalfluid (CSF) testing, vital signs, clinical tests (cognitive, motor orreflex tests) and other relevant techniques. Treatment with the AAVparticles may results in cure of the non-infectious disease, slowingdown or stabilizing the progression of the disease, or have no effect onthe progression of the disease. Additionally, the treatment may reduceseverity of one or more symptoms associated with the disease, eliminateone or more symptoms associated with the disease or have no effect onthe symptoms.

Example 8. Treatment of HIV or AIDS

AAV particles of the current invention encoding an antibody areadministered to a patient who has been diagnosed with HIV or AIDS. Thepurpose of the treatment may be aimed to manage the disease, prevent orslow the progression of the disease, treat the symptoms associated withthe disease and/or cure the disease.

The AAV particles may be administered through an intramuscular injectionto the skeletal muscle. The administration may include one or moreinjections over a period of time. The level and distribution of AAVparticles and antibody expression is monitored by standard diagnostictechniques known in the art. Such diagnostic techniques include e.g.(e.g. from blood, urine, or saliva), cerebrospinal fluid (CSF) testing,or any other testing useful for monitoring antibody levels in the body.

Additionally, the progression of the disease and the health of thepatient is monitored by standard diagnostic techniques known in the art.Such techniques may include diagnostic imaging (e.g. X-ray, MRA scans,Ultrasound scans, PET scans. Nuclear scans, mammography), biopsy,laboratory tests (e.g. from blood, urine, or saliva), cerebrospinalfluid (CSF) testing, vital signs, clinical tests (cognitive, motor orreflex tests) and other relevant techniques. Treatment with the AAVparticles may results in cure of the non-infectious disease, slowingdown or stabilizing the progression of the disease, or have no effect onthe progression of the disease. Additionally, the treatment may reduceseverity of one or more symptoms associated with the disease, eliminateone or more symptoms associated with the disease or have no effect onthe symptoms.

VIII. Equivalents and Scope

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments in accordance with the invention described herein. The scopeof the present invention is not intended to be limited to the aboveDescription, but rather is as set forth in the appended claims.

In the claims, articles such as “a,” “an,” and “the” may mean one ormore than one unless indicated to the contrary or otherwise evident fromthe context. Claims or descriptions that include “or” between one ormore members of a group are considered satisfied if one, more than one,or all of the group members are present in, employed in, or otherwiserelevant to a given product or process unless indicated to the contraryor otherwise evident from the context. The invention includesembodiments in which exactly one member of the group is present in,employed in, or otherwise relevant to a given product or process. Theinvention includes embodiments in which more than one, or the entiregroup members are present in, employed in, or otherwise relevant to agiven product or process.

It is also noted that the term “comprising” is intended to be open andpermits but does not require the inclusion of additional elements orsteps. When the term “comprising” is used herein, the term “consistingof” is thus also encompassed and disclosed.

Where ranges are given, endpoints are included. Furthermore, it is to beunderstood that unless otherwise indicated or otherwise evident from thecontext and understanding of one of ordinary skill in the art, valuesthat are expressed as ranges can assume any specific value or subrangewithin the stated ranges in different embodiments of the invention, tothe tenth of the unit of the lower limit of the range, unless thecontext clearly dictates otherwise.

In addition, it is to be understood that any particular embodiment ofthe present invention that falls within the prior art may be explicitlyexcluded from any one or more of the claims. Since such embodiments aredeemed to be known to one of ordinary skill in the art, they may beexcluded even if the exclusion is not set forth explicitly herein. Anyparticular embodiment of the compositions of the invention (e.g., anyantibiotic, therapeutic or active ingredient; any method of production;any method of use: etc.) can be excluded from any one or more claims,for any reason, whether or not related to the existence of prior art.

It is to be understood that the words which have been used are words ofdescription rather than limitation, and that changes may be made withinthe purview of the appended claims without departing from the true scopeand spirit of the invention in its broader aspects.

While the present invention has been described at some length and withsome particularity with respect to the several described embodiments, itis not intended that it should be limited to any such particulars orembodiments or any particular embodiment, but it is to be construed withreference to the appended claims so as to provide the broadest possibleinterpretation of such claims in view of the prior art and, therefore,to effectively encompass the intended scope of the invention.

1. An AAV particle comprising a capsid and a viral genome, said viralgenome comprising at least one inverted terminal repeat (ITR) region anda payload region, said payload region comprising a regulatory sequenceoperably linked to at least a first nucleic acid segment, said firstnucleic acid segment encoding one or more polypeptides selected from thegroup consisting of any member given in Tables 3-42 and fragmentsthereof.
 2. The AAV particle of claim 1, wherein the capsid is selectedfrom the group of serotypes consisting of Table
 1. 3. The AAV particleof claim 2, wherein the regulatory sequence comprises a promoter.
 4. TheAAV particle of claim 3, wherein the promoter is selected from the groupconsisting of human elongation factor 1α-subunit (EF1α), cytomegalovirus(CMV) immediate-early enhancer and/or promoter, chicken β-actin (CBA)and its derivative CAG, β glucuronidase (GUSB), or ubiquitin C (UBC).Tissue-specific expression elements can be used to restrict expressionto certain cell types such as, but not limited to, muscle specificpromoters, B cell promoters, monocyte promoters, leukocyte promoters,macrophage promoters, pancreatic acinar cell promoters, endothelialscell promoters, lung tissue promoters, astrocyte promoters, or nervoussystem promoters which can be used to restrict expression to neurons,astrocytes, or oligodendrocytes.
 5. The AAV particle of claim 1, whereinthe viral genome is single stranded.
 6. The AAV particle of claim 1,wherein the viral genome is self-complementary.
 7. The AAV particle ofclaim 1, wherein at least one region of the viral genome iscodon-optimized.
 8. The AAV particle of claim 7, wherein the firstnucleic acid segment is codon-optimized.
 9. The AAV particle of any ofclaims 1-8, wherein the first nucleic acid segment encodes one or morepolypeptides selected from the group consisting of an antibody heavychain, an antibody light chain, a linker, and combinations thereof. 10.The AAV particle of claim 9, wherein any of the polypeptides encoded byfirst nucleic acid segment of the payload region is humanized.
 11. TheAAV particle of claim 9, wherein the linker is selected from one or moreof the members of the group given in Table
 2. 12. The AAV particle ofclaim 9, wherein the first nucleic acid segment encodes from 5′ to 3′,an antibody heavy chain, a linker, and an antibody light chain.
 13. TheAAV particle of claim 9, wherein the first nucleic acid segment encodesfrom 5′ to 3′, an antibody light chain, a linker, and an antibody heavychain.
 14. The AAV particle of claim 9, wherein the first nucleic acidsegment encodes one or more antibody heavy chains.
 15. The AAV particleof claim 14, wherein the first nucleic acid segment encodes one or moreantibody heavy chains selected from those listed in Tables 3-42.
 16. TheAAV particle of claim 9, wherein the first nucleic acid segment encodesone or more antibody light chains.
 17. The AAV particle of claim 16,wherein the first nucleic acid segment encodes one or more antibodylight chains selected from those listed in Tables 3-42.
 18. The AAVparticle of claim 9, wherein the first nucleic acid segment encodes oneor more antibody heavy chains and one or more antibody light chains and,optionally one or more linkers.
 19. The AAV particle of any of claims9-18, wherein said linker is selected from the group consisting of Table2 and combinations thereof.
 20. The AAV particle of claim 1, wherein thefirst nucleic acid segment encodes an antibody, having at least 95%identity to any of the sequences selected from the group consisting ofSEQ ID NO: 2948-9220 (Tables 3-42).
 21. An AAV particle comprising acapsid and a viral genome, said viral genome comprising at least oneinverted terminal repeat (ITR) region and a payload region comprising aregulatory sequence operably linked to at least a first nucleic acidsegment, said first nucleic acid segment encoding a bispecific antibodyderived from any of the sequences listed in Tables 3-42 or portions orfragments thereof.
 22. The AAV particle of claim 21, wherein thebispecific antibody comprises a light and a heavy chain selected fromtwo different starting antibodies selected from the group consisting ofSEQ ID NO: 2948-9220 (Tables 3-42).
 23. A method of producing afunctional antibody in a subject in need thereof, comprisingadministering to said subject the AAV particle of any of claims 1-22.24. The method of claim 23, wherein the level or amount of thefunctional antibody in the target cell or tissue after administration tothe subject is from about 0.001 ug/mL to 100 mg/mL.
 25. The method ofclaim 23, wherein the functional antibody is encoded by a single firstnucleic acid segment of a viral genome within said AAV particle.
 26. Themethod of claim 23, wherein the functional antibody is encoded by twodifferent viral genomes, said two different viral genomes packaged inseparate capsids.
 27. A pharmaceutical composition comprising an AAVparticle of any of the preceding claims in a pharmaceutically acceptableexcipient.
 28. The pharmaceutical composition of claim 27, wherein thepharmaceutically acceptable excipient is saline.
 29. The pharmaceuticalcomposition of claim 27, wherein the pharmaceutically acceptableexcipient is 0.001% pluronic in saline.
 30. A method of expressing anantibody in a cell or tissue comprising administering the AAV particleof any of claims 1-29 via a delivery route selected from the groupconsisting of enteral (into the intestine), gastroenteral, epidural(into the dura mater), oral (by way of the mouth), transdermal,intracerebral (into the cerebrum), intracerebroventricular (into thecerebral ventricles), epicutaneous (application onto the skin),intradermal, (into the skin itself), subcutaneous (under the skin),nasal administration (through the nose), intravenous (into a vein),intravenous bolus, intravenous drip, intra-arterial (into an artery),intramuscular (into a muscle), intracardiac (into the heart),intraosseous infusion (into the bone marrow), intrathecal (into thespinal canal), intraparenchymal (into brain tissue), intraperitoneal,(infusion or injection into the peritoneum), intravesical infusion,intravitreal, (through the eye), intracavernous injection (into apathologic cavity) intracavitary (into the base of the penis),intravaginal administration, intrauterine, extra-amnioticadministration, transdermal (diffusion through the intact skin forsystemic distribution), transmucosal (diffusion through a mucousmembrane), transvaginal, insufflation (snorting), sublingual, sublabial,enema, eye drops (onto the conjunctiva), or in ear drops, auricular (inor by way of the ear), buccal (directed toward the cheek), conjunctival,cutaneous, dental (to a tooth or teeth), electro-osmosis, endocervical,endosinusial, endotracheal, extracorporeal, hemodialysis, infiltration,interstitial, intra-abdominal, intra-amniotic, intra-articular,intrabiliary, intrabronchial, intrabursal, intracartilaginous (within acartilage), intracaudal (within the cauda equine), intracisternal(within the cisterna magna cerebellomedularis), intracorneal (within thecornea), dental intracornal, intracoronary (within the coronaryarteries), intracorporus cavernosum (within the dilatable spaces of thecorporus cavernosa of the penis), intradiscal (within a disc),intraductal (within a duct of a gland), intraduodenal (within theduodenum), intradural (within or beneath the dura), intraepidermal (tothe epidermis), intraesophageal (to the esophagus), intragastric (withinthe stomach), intragingival (within the gingivae), intraileal (withinthe distal portion of the small intestine), intralesional (within orintroduced directly to a localized lesion), intraluminal (within a lumenof a tube), intralymphatic (within the lymph), intramedullary (withinthe marrow cavity of a bone), intrameningeal (within the meninges),intramyocardial (within the myocardium), intraocular (within the eye),intraovarian (within the ovary), intrapericardial (within thepericardium), intrapleural (within the pleura), intraprostatic (withinthe prostate gland), intrapulmonary (within the lungs or its bronchi),intrasinal (within the nasal or periorbital sinuses), intraspinal(within the vertebral column), intrasynovial (within the synovial cavityof a joint), intratendinous (within a tendon), intratesticular (withinthe testicle), intrathecal (within the cerebrospinal fluid at any levelof the cerebrospinal axis), intrathoracic (within the thorax),intratubular (within the tubules of an organ), intratumor (within atumor), intratympanic (within the aurus media), intravascular (within avessel or vessels), intraventricular (within a ventricle), iontophoresis(by means of electric current where ions of soluble salts migrate intothe tissues of the body), irrigation (to bathe or flush open wounds orbody cavities), laryngeal (directly upon the larynx), nasogastric(through the nose and into the stomach), occlusive dressing technique(topical route administration which is then covered by a dressing whichoccludes the area), ophthalmic (to the external eye), oropharyngeal(directly to the mouth and pharynx), parenteral, percutaneous,periarticular, peridural, perineural, periodontal, rectal, respiratory(within the respiratory tract by inhaling orally or nasally for local orsystemic effect), retrobulbar (behind the pons or behind the eyeball),soft tissue, subarachnoid, subconjunctival, submucosal, topical,transplacental (through or across the placenta), transtracheal (throughthe wall of the trachea), transtympanic (across or through the tympaniccavity), ureteral (to the ureter), urethral (to the urethra), vaginal,caudal block, diagnostic, nerve block, biliary perfusion, cardiacperfusion, photopheresis and spinal.
 31. The method of claim 30, whereinthe delivery route is intramuscular.
 32. The method of claim 31, whereinthe intramuscular administration is to at least one limb.
 33. The methodof claim 30, wherein the delivery route is intravascular.
 34. The methodof claim 30, wherein the delivery route is intrathecal.
 35. The methodof claim 30, wherein the delivery route is intracerebroventricular. 36.The method of claim 30, wherein the delivery route is intraparenchymal.37. The method of claim 30, wherein the AAV particle is encapsulated ina nanoparticle.
 38. The method of claim 30, wherein the AAV particle isdelivered by a device.
 39. The method of claim 38, wherein the device isa gene gun.
 40. A method of preventing a disease or disorder in asubject comprising administering to said subject the pharmaceuticalcomposition of any of claims 27-29.
 41. The method of claim 40, whereinthe administration is at a prophylactically effective dose.
 42. Themethod of claim 41, wherein the dose is from about 1 ug/mL to about 500ug/mL of expressed polypeptide or 1=10e4 to 1×10e16 V G/mL from thepharmaceutical composition.
 43. The method of claim 42, wherein thepharmaceutical composition is administered once.
 44. The method of claim42, wherein the pharmaceutical composition is administered more thanonce.
 45. The method of claim 42, wherein the pharmaceutical compositionis administered daily, weekly, monthly or yearly.
 46. The method ofclaim 42, wherein the pharmaceutical composition is co-administered aspart of a combination therapy.
 47. A method of treating a disease ordisorder in a subject in need thereof comprising administering to saidsubject the pharmaceutical composition of any of claims 27-29.
 48. Themethod of claim 47, wherein said disease or disorder is selected fromthe group consisting of diseases caused by John Cunningham Virus (JCV),influenza, hepatitis A, hepatitis B, hepatitis D, hepatitis E,respiratory syncytial virus (RSV), herpes simplex virus 1, herpessimplex virus 2, hyman cytomegalovirus, Epstein-Barr virus, Varicellazoster virus, Coronavirus, Poxvirus, Enterovirus 71, rubella virus,human papilloma virus, Pseudomonas Aeruginosa, Streptococcus bacteria,Staphylococcus bacteria, Clostridium tetani, Bordetella, Mycobacterium,Francisella tularensis, Toxoplasma gondii, Candida yeast, ricin,Bacillus anthracis, shiga toxin, shiga-like toxin, botulinum toxins,chikungunya virus, dengue virus, trypasnosoma cruzi, rabies virus,Plasmodium falciparum, ebola virus, Marburg virus, West Nile virus,Yellow Fever virus, Japanese encephalitis virus, St. Louis encephalitisvirus, rotavirus, Norwalk virus, Campylobacter jejuni, Clostridiumdifficile, Entamoeba histolytica, Helicobacter pyrolii, and EnterotoxinB.
 49. The AAV particle of claim 1, wherein the viral genome comprises 2ITR regions.
 50. The AAV particle of claim 1, wherein the at least oneITR region is derived from the same parental serotype as the capsid. 51.The AAV particle of claim 1, wherein the at least one ITR region isderived from a different serotype as the capsid.
 52. The AAV particle ofclaim 1, wherein the at least one ITR region is derived from AAV2. 53.The AAV particle of claim 1, wherein the at least one ITR region is100-150 nucleotides in length.
 54. The AAV particle of claim 1, whereinthe at least one ITR region is 102 nucleotides in length.
 55. The AAVparticle of claim 1, wherein the at least one ITR region is 140-142nucleotides in length.
 56. The AAV particle of claim 1, wherein the atleast one ITR region is 140 nucleotides in length.
 57. The AAV particleof claim 1, wherein the at least one ITR region is 141 nucleotides inlength.
 58. The AAV particle of claim 1, wherein the at least one ITRregion is 142 nucleotides in length.
 59. The AAV particle of claim 1,wherein the viral genome further comprises an intron or stuffersequence.
 60. A method of producing an antibody in a subject comprisingadministering the AAV particle of claim 1 to said subject, with theproviso that the antibody is not a virus neutralizing antibody.
 61. Amethod of producing an antibody in a subject comprising administeringthe AAV particle of claim 1 to said subject, with the proviso that theantibody is not an HIV or HCV virus neutralizing antibody.
 62. The AAVparticle of claim 1, wherein the payload region of the viral genomecomprises a second nucleic acid segment, said second nucleic acidsegment encoding an aptamer, siRNA, saRNA, ribozyme, microRNA, mRNA orcombination thereof.
 63. The AAV particle of claim 62, wherein thesecond nucleic acid segment encodes an siRNA and said siRNA is designedto target the mRNA that encodes the target of the antibody encoded bythe first nucleic acid segment.
 64. The AAV particle of claim 62,wherein the second nucleic acid segment encodes a microRNA and saidmicroRNA is selected to target the mRNA that encodes the target of theantibody encoded by the first nucleic acid segment.
 65. The AAV particleof claim 62, wherein the second nucleic acid segment encodes an mRNA andsaid mRNA encodes one or more peptides inhibitors of the same target ofthe antibody encoded by the first nucleic acid segment.
 66. The AAVparticle of claim 1 or 62, wherein the payload region of the viralgenome comprises a third nucleic acid segment.
 67. The AAV particle ofclaim 66, wherein the third nucleic acid segment encodes a nuclearexport signal.
 68. The AAV particle of claim 66, wherein the thirdnucleic acid segment encodes a polynucleotide or polypeptide which actsas a regulator of expression of the viral genome in which it is encoded.69. The AAV particle of claim 66, wherein the third nucleic acid segmentencodes a polynucleotide or polypeptide which acts as a regulator ofexpression of the payload region of the viral genome in which it isencoded.
 70. The AAV particle of claim 66, wherein the third nucleicacid segment encodes a polynucleotide or polypeptide which acts as aregulator of expression of the first nucleic acid segment of the payloadregion of the viral genome in which it is encoded.